<SEC-DOCUMENT>0000950170-22-003369.txt : 20220310
<SEC-HEADER>0000950170-22-003369.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310161707
ACCESSION NUMBER:		0000950170-22-003369
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Design Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001807120
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823929248
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40288
		FILM NUMBER:		22729257

	BUSINESS ADDRESS:	
		STREET 1:		6005 HIDDEN VALLEY ROAD
		STREET 2:		SUITE 110
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		858-293-4900

	MAIL ADDRESS:	
		STREET 1:		6005 HIDDEN VALLEY ROAD
		STREET 2:		SUITE 110
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92011
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dsgn-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-10T15:52:57.9564+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dsgn="http://www.designtx.com/20211231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_c8f40f25-3060-43a3-8e57-1cdd36fe0c04" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_8f21a733-a63e-41e6-935a-a3dd426abdc4" unitRef="U_pure" decimals="6" scale="0">0.613497</ix:nonFraction><ix:nonNumeric id="F_0d26d6c4-19b8-4338-bd33-8240f330367d" name="dei:CurrentFiscalYearEndDate" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1">--12-31</ix:nonNumeric><ix:nonFraction id="F_3766fda0-030c-4a24-8af2-30d601782126" name="us-gaap:CommitmentsAndContingencies" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_9410f438-b0a4-468d-8e34-c1e06402216c" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1">http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</ix:nonNumeric><ix:nonNumeric id="F_200bc075-dc2d-4694-a6ce-4841f63dccb6" name="dei:EntityCentralIndexKey" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1">0001807120</ix:nonNumeric><ix:nonNumeric id="F_c34c0616-00d0-4274-a21f-927f363c9ade" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17">http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric id="F_d91553c5-6eee-4258-bcc3-c4d3014546f4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_fa19c920-f2f7-4e75-821f-cf2210cc5a5b" format="ixt-sec:durwordsen">three years</ix:nonNumeric><ix:nonFraction id="F_d29888be-2dc0-4c7f-9efc-f49c43b4b4f3" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_7384e25e-21d9-4449-bdf3-93d8433577e8" name="dei:DocumentFiscalPeriodFocus" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1">FY</ix:nonNumeric><ix:nonNumeric id="F_8eb9aa0e-0c36-40ee-b23e-663ded1df873" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647">http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</ix:nonNumeric><ix:nonNumeric id="F_23401328-9149-4698-9c63-cfb6de561a71" name="dei:AmendmentFlag" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="dsgn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_c09976ce-b915-44ea-8211-24da15127f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f1efe30-75a7-4daa-a934-18cf07b4b011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b235a097-5256-4f3d-babe-7ba3bf8a8a84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96982224-ada7-45f0-9919-ba9faeecebb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f685d75-d65f-4c75-af30-d4d1dc49db36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b433e9b-8bd1-498f-a486-bdee162f0520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4341ac9d-5479-44c1-8530-8d42af2897bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_042f9541-36bc-42b0-97cd-cb54c6a99af9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a36c38a-b117-4fef-bcd2-79b07818ea4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cefbf23-2388-4ecd-bce3-6b76279a6cea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72018646-7064-41a5-8f10-73e8aed069e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd48c120-475c-4c27-9b88-664af08c371a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:July2018NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5f8e035-e6a8-4686-b8f6-c1728d5e5e54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_020e7d21-1fc1-4579-8491-b965545b2a40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad693d79-777f-411a-ab08-35eb238a9099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78c5be72-50bc-4838-96f2-7c678294bfdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da562d4c-497b-43eb-a87c-c6f98abf5d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd90086d-3437-4665-82bf-18b82bd4403a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6936001-b46e-472b-a199-2074ec0ad35f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12ca6ede-1a4e-486f-8641-bc776ecea308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a15b425b-80dd-485a-b5d2-c580a8a02edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adc93247-3f34-454d-be75-6d57971dea64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fd32ca6-5a40-41dd-91d1-a988442615a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_855ff555-2cfb-491d-a8ff-2b1192bb78b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:TwoThousandNineteenConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_becd129a-dfa1-4804-9129-b0961e120502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcd195dc-decb-4c46-97e7-98c2522754a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_657d72a9-16e6-4deb-b551-33c0ee8f5b08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee89e80b-865a-4125-bcb4-76c8de099850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5be4210b-787b-4a2c-b72e-d5904d02b928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5482b53a-c0c0-483d-8704-340e59957e38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36de137c-6361-4ec5-8970-5fc39d50dd4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8bc6058-3ed3-45cd-b9ce-e674b84d8a7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc6ac533-72ba-4dfe-b7e0-cef03f4d60a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:TwoThousandTwentyConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56d217f5-b263-4e46-bd7d-f0d3f3f291ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4729fd04-d690-4b2c-9242-4f8689fbc206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d821d489-20c7-4f0d-9f3e-dd434ad19267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62eaea31-a124-426a-bd6e-5a5adb4841c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fee07a1a-85a2-4821-989e-e63acca8aebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47968354-2359-475e-914a-8809063a760d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe8be1e8-fc44-433d-8028-3795727073cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9aecf3c2-6ec0-470e-aed3-32e15d8ee9b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68c8fb76-ffb2-47b9-87e5-28f51b3c5784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdef21de-d669-4832-a95e-55c903160e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f124e841-56b0-4f7a-af20-08a6724d6ca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:February2019NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49187fc6-8a7a-4911-8230-ce5034a3dd6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18532e58-312b-467e-b271-29e361b67f10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dsgn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09862e22-6777-4916-b800-571e5b594613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_739e698e-899f-4485-a5c7-f66bb6dba318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9488ce8f-cd96-43ae-b83d-da01a404b062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9a6f234-a01b-49c4-8389-6f43a1314b9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86c855a7-1404-41b9-9ec4-470ab3dffc2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e84263eb-baf8-4179-a0c7-153ef77908b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f03e432b-566b-43cb-b18b-e5b052b1516e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb312aa6-c50b-415c-b819-f0af73e2941e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6d2ec7c-c375-4c5a-a4e1-a6f9962559bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3ac15fe-44bb-4b93-b43f-a4b8bb8f3178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4808721b-298d-4f46-a8a8-371b01e8767d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:Jan2020AndDec2019DrawsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69d3f494-4d79-47df-87fd-27a5128beb0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d82638c-fea7-4745-93a8-e904a42ccc5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9851747-c6e0-46a7-ae37-a995db3d6025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02912d63-fe9a-4d28-8b7a-f7b2934ccafb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abbec031-d382-4477-bfc5-49894a1ef5e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5d4f8dd-7c17-4eaa-a38e-dcd85d00e072"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e64fcb9b-97f6-4f5a-8c64-d72962809b07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5088ab17-fa76-49bb-8424-af699c2d83d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03f5fca6-f809-4c6f-a23c-f662104eb076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:May2018NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e20f6e02-a6f1-4121-b27f-17a4335d6c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ab3d3b5-491d-45f2-a868-850168297a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f21a733-a63e-41e6-935a-a3dd426abdc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f8296e2-19aa-4c9e-977c-4e9998334dc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ba72a79-9de9-4033-985b-e7cd791153cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbc31665-46ff-4282-846e-3ddb64f5b097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3d50d4d-9539-4c43-8867-5bbaabbcbf1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:FebruaryAndMarch2019DrawsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9db9070-48ac-46f3-9a8e-aac6cdbfd36d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bd00ed8-2f33-4d98-9fdd-289c66eb1dd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ResearchConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91e891fe-e7f8-423a-b358-a2ff1159c8aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d48e74d-c13f-42ba-9e94-f177898744b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1f43774-a82a-4496-812e-205e05514a80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:ConvertibleNotesIssuedInMayAndJuly2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_131e1c23-bf72-466e-b780-eecada87c188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e79952f3-cdf9-465a-86f5-17818dc1a21a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b4db5f7-9e3b-456b-ab29-20209e77bc6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a91e7f27-4f86-4dc5-b77c-9a9ed9b2d61c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dcbb219-b6bd-4861-9162-652b899dc080"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a9265ec-0c2d-4f31-9eaf-7d31f601c7b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5850416b-5268-46c3-970b-18e7e145562e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8276263-937d-404b-888a-9dfa8d1471b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d411dff-54c7-4585-9301-d3241ffd63f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_395fdd7c-d463-4675-9795-d06cc0e2ea3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49bf2e28-2c6c-4abb-9852-7ee433b3f111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ada34b7-cc0e-46bf-8d53-623a26d0b905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:MayNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_282e8527-291e-424c-a603-4afa6b760575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_737274e3-fa8d-4aae-8a95-66ebe396d35c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a397402b-f716-41a7-8341-71ec3bbe5ef6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_015c050e-1f5a-4b49-8849-0dccea408c5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbf3520d-cad8-496b-89f3-d0074446ef40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59741c86-fa48-4f2f-87fc-b83b830a5544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82824a3c-b613-4fb2-b25d-e5297dacef2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1e0e40d-fa42-4566-b632-bece748465d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_979df7a7-b6e0-451a-8eb9-bb3bdb83d3f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b058460-a53f-45fa-81f1-ff866fb0af2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31bede1d-9fe1-4f2f-8a68-d59a76c82fcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e28222d2-bdab-40c4-91ad-c91e8c333540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac754ff9-5df8-4082-9e89-559e3f5b5c9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7549669b-7c92-4c29-aee8-52f0528f3361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7727e7fe-60e9-46a9-8c20-52528f28b578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ea42364-2fcb-4648-b148-742ec5e08d38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65c3b16a-86a3-451d-ae60-e9601eb9ca53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3f0e0a2-5f92-4f5f-9fe8-1fa2972d3c03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6a447c5-4988-4641-a3e9-2f97b674e8b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf1f9868-ad02-4973-bb86-f39dc0bbe2a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff1ce905-3591-490c-a13f-305cbc1d8d2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa19c920-f2f7-4e75-821f-cf2210cc5a5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33e57430-f87d-45d8-a826-73fae3f00112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ResearchConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b5211fb-3823-4218-9a5e-36b1f275768a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf5d2e5b-41f1-419b-8853-434297531657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_491eb317-efb1-40ae-85f1-8afd062cc647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73cc3eeb-6a6b-45c1-a16b-d0b91237aebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JulyNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d9cb435-50cf-426c-b2e6-da460c39afdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31e5c9e1-0fcc-4298-b3fa-26eb6e19e3b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a94ee29-3474-461c-b2a3-c3b16772709a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b6ab41b-f147-4c0f-b46b-e581e1586d79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_149ca0e1-6a9d-4838-96bf-fc89fbd1fbb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_896a557d-321b-4604-a274-4b73f428a91c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f35bda8e-4477-4e3d-91b7-eb0cd103d909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_769dba12-3ef2-4dad-a5b3-89361f92718a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c915edc-7f15-44b7-bcb1-f158561e7fcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb933540-a365-4b43-a477-40ec4114592f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94255f9d-0677-46bb-9aba-5bed62bc746c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57ffc353-e260-4275-bc08-e6bb76dc5b0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f4f9bba-1873-40dd-acf5-dfd66ac8e7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dsgn:SharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2440876e-d785-4ff7-be3a-fa21b9bbf1e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ceb7f97d-7cb8-4a60-a79b-931a4f103fde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c609f5a0-ad87-42d1-88bd-8814d48c2007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6afdf50d-8689-4ede-8f30-41e7b459c71a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36df1b56-bdb0-4695-b7cf-d0ea73632dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a37bffe0-f723-4a15-9b38-db5ae6d1a171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77d31faf-435b-4663-a7b9-4b732dae06e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4402b367-1f4a-4644-931e-244097e7a86c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1a7a6a9-b9f1-40a5-a2c9-a03c5b0e9341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dsgn:SharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_196bb1dc-ff73-4b87-b41c-495f6b29e794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1ae00c5-b57c-4e18-abdc-e3e4662306cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faf87937-2b9d-462a-a2e3-6532a2a5832f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_499263cc-6cef-4ede-8c9f-5058ea40a149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5eca583-41b5-4449-b248-84c59b8416b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ededf68-d7fc-475f-9e79-3e3146f1d833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b012ef3-2aff-4122-9520-8407c5275290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:InitialClosingOfSeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21b23571-1ef3-47c0-814f-61628e84218b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_820b96e4-02c7-43b6-87e0-576d13934c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7057dd8f-e87d-4239-a296-2ff88e03ec38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_255b9a96-4942-438d-9182-67188791643f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a798c222-0494-49e9-979f-72203726b20d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001807120</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>dsgn:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84123f80-6eb9-46ca-88c3-eb4e5e08b555" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07e7aac0-f1df-4ae7-bac8-2c9d59e4f8c6" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7055526d-4cd9-48d5-82f9-9ec54f36e599" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79dc1658-1f10-49c0-82d8-8b2783d429af" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37404337-7c7e-4677-a8de-6e07e2a5c23a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f122a4be-938f-4c7d-af73-89f0134103c5" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-40288</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e034bf6-e2ae-46ad-a28e-327c58f9a8cd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73121dce-c825-4730-a31c-7cb4446e0fd1" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa0f6ad1-c135-461e-9f78-e0b3e0a29350" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">82-3929248</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_234d7733-5348-4ab6-b458-e7ea3f319d18" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6005 Hidden Valley Road</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cba85c56-3325-4230-9fad-b2f081750596" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 110</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c42134ee-687d-4e38-a82f-e8f4fcf398aa" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Carlsbad</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cada2b5-4fed-4841-8584-8f499d4566b1" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b64a693-23c9-4243-ad36-54f0368380ed" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">92011</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e0614da-af07-431e-9e0c-35543fab2ab5" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">858</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1373472-6915-4214-a036-d309003c3564" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">293-4900</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b37d8dd8-fefc-4ae8-858e-cfc91714d6fa" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92245922-8faa-4d0c-a0e7-a527bef3bed8" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">DSGN</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8f1601a-711b-4b88-aec4-4f42a6c2c97b" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0185a6de-3bbe-44f3-b712-5ca72048e13b" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cf7f6d0-6687-4586-9e83-b3000cf42a3e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ff59133-b93d-4c63-a165-e49a83c93ed8" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ee4d47b-105a-4715-8fc2-95f33c81188d" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.295%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:55.362%;"></td>
    <td style="width:1.178%;"></td>
    <td style="width:20.492%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:2.226%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84c1b9fe-6251-4e83-926c-4d474c5355ab" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_377102cb-b7a9-43e7-bb87-fe905cbeb8fe" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c93f0626-8869-48d6-a819-8a2ab1d47a30" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc3d27cb-8ea9-419e-b7da-701fc51059e0" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ca25d1c-b179-4046-a28d-286490937b30" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes &#9744;     No </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17f68aac-d994-4c1b-b7ce-07ce3a93c4cf" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The aggregate market value of the Common Stock held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 30, 2021, the last business day of the Registrant's most recently completed second quarter was approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f816e037-1a75-4297-af63-14b2f6a76e05" contextRef="C_ff1ce905-3591-490c-a13f-305cbc1d8d2d" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">480,984,316</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">. In determining the market value of non-affiliate common stock, shares of the Registrant's common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 4, 2022 wa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">s </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98caa29a-0f8d-472b-a577-bfa229478ce6" contextRef="C_94255f9d-0677-46bb-9aba-5bed62bc746c" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,156</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91ee4b24-636b-4c6c-a69e-fbc31f7b5639" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant's definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission no later than 120 days after the registrant's fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.003%;"></td>
    <td style="width:80.996%;"></td>
    <td style="width:8.001%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties, many of which are beyond our control. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements as a result of various factors, including those set forth below under the caption &#x201c;Risk Factors.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forward-looking statements include, but are not limited to, statements regarding:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our plans to research, develop and commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, progress, success, cost and timing of our preclinical studies, clinical trials and product development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability and timing to advance our product candidates into, and to successfully initiate, conduct, enroll and complete, clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the reliance on third parties in connection with the development and manufacture of our product candidates, including third parties conducting our preclinical studies and clinical trials as well as third-party suppliers and manufacturers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size and growth of the potential markets for our product candidates and our ability to serve those markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential scope, duration and value of our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rights protecting our platform technologies and product candidates, and our ability to develop and commercialize our product candidates without infringing the proprietary rights of third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to recruit and retain key personnel; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effects of the COVID-19 pandemic on our operations.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions described in the sections of this Annual Report on Form 10-K titled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this report. We discuss many of the risks associated with the forward-looking statements in this Annual Report on Form 10-K in greater detail under the heading &#x201c;Risk Factors.&#x201d; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. You should be aware that the occurrence of any of the events discussed under the caption &#x201c;Risk Factors&#x201d; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline, and you could lose all or a part of the value of your shares of our common stock.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this Annual Report on Form 10-K. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates You should read the following together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Trademarks and Service Marks</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Design Therapeutics,&#x201d; &#x201c;Design,&#x201d; &#x201c;GeneTAC,&#x201d; the Design logo and other trademarks, trade names or service marks of Design Therapeutics, Inc. appearing in this Annual Report on Form 10-K are the property of Design Therapeutics, Inc. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risk Factors Summary</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Below is a summary of the material factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#x201c;Risk Factors&#x201d; under Part I, Item 1A of this Annual Report and should be carefully considered, together with other information in this Annual Report before making investment decisions regarding our common stock.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are early in our development efforts and all of our research programs are still in the preclinical or discovery stage. We have no history of conducting clinical trials to test our product candidates in humans.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical and clinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of earlier studies and trials may not be predictive of future trial results. If development of our programs is unsuccessful or delayed, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, if at all.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue planned clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic could adversely impact our business and affect our operations, as well as the business or operations of our manufacturers or other third parties with whom we conduct business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may rely on third parties to conduct, supervise, and monitor our planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We contract with third parties for the manufacturing and supply of our product candidates for use in preclinical testing and planned clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not realize the benefits of any acquisitions, in-license or strategic alliances that we enter into.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to protect our intellectual property rights throughout the world.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may rely on trade secrets and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The price of our common stock could be subject to volatility related or unrelated to our operations.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 1. Business.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, &#34;Design,&#34; &#34;our company, &#34;we,&#34; &#34;us,&#34; and &#34;our&#34; refer to Design Therapeutics, Inc., a Delaware corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical-stage biopharmaceutical company pioneering GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Certain diseases caused by inherited nucleotide repeat expansion, such as Friedreich ataxia (FA), can result in reduced expression of specific mRNAs and deficiency of vital proteins; in other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington disease, the nucleotide repeat expansions result in the generation of toxic gene products, often associated with pathological nuclear foci and broad splicing disruptions. Our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to selectively target genetic repeat sequences, modulate gene expression either by dialing up or dialing down mRNA transcription, and restore cellular health. As a platform, we believe that GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules have broad potential applicability across monogenic nucleotide repeat expansion diseases affecting millions of individuals worldwide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies for our lead program, we have observed restoration of frataxin (FXN) levels in multiple cell types from FA patients and an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> murine model of FA using our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules. At doses that were observed to be well tolerated in rodents and non-human primates, FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules achieved biodistribution to brain, heart, muscle and other key organs affected by FA, at concentrations that exceeded those observed to restore FXN levels in FA patient cells. Further, and consistent with this favorable target-organ biodistribution, we observed increased endogenous FXN expression in the brain and heart in an animal model of FA after treatment with our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules. Investigational New Drug Application (IND)-enabling studies for our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> development candidate have been completed in alignment with feedback received from the U.S. Food and Drug Administration (FDA) through a pre-IND meeting and from the European Medicines Agency (EMA) through a scientific advice procedure. In late February 2022, the IND for our lead FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> development candidate was cleared by the FDA. We anticipate a first-in-human dosing in FA patients with our lead FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> development candidate in the first half of 2022, with initial topline clinical data expected in the second half of 2022.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our second program in DM1, multiple DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules elicited robust reduction of nuclear foci and correction of splicing defects in DM1 patient muscle cells. Preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> studies demonstrated distribution of DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules to key target tissues including skeletal muscle and heart, achieving tissue concentrations of intact DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule that reduced pathogenic nuclear foci to normal levels in our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> experiments. We expect to complete IND-enabling studies and seek regulatory clearance for a first-in-human clinical trial in 2023.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In an additional research program, we conducted preclinical studies to evaluate the effects of GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules in FECD. When tested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in FECD patient-derived corneal endothelial cells, which contained nuclear foci, our FECD GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules led to robust reductions in toxic nuclear RNA foci and also corrected key mis-spliced transcripts to levels observed in unaffected corneal endothelial cells. We believe this preclinical data support the potential of our novel GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> small molecules to correct the most common underlying genetic cause of FECD, and we plan to advance this research program through additional preclinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have continued to make significant progress in advancing our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> portfolio in preclinical studies to address other serious nucleotide repeat expansion-driven monogenic diseases, and intend to declare additional product candidates as they progress towards the clinic.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe the structure and mechanism of action of our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules may offer the disease-modifying potential of genomic therapeutics, while also offering broad tissue biodistribution, resolution of aberrant gene expression preserving endogenous regulatory control elements, and leveraging established manufacturing, regulatory, and distribution frameworks for small molecules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We utilize our proprietary GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion. Individuals with nucleotide repeat expansion diseases are born with abnormally expanded stretches of specific nucleotide sequences, often with hundreds to thousands of excess repeats present in the mutant gene. Higher number of excess repeats can lead to more severe, and sometimes a more rapidly progressive form of disease. Nucleotide repeat expansion has been identified as the underlying cause of more than 40 debilitating degenerative diseases impacting millions of people. Currently, there are no approved therapeutic options that address the cause of any nucleotide repeat expansion diseases.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.17875;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page108"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specific DNA sequences of a gene can generate RNA through a process called transcription. The RNA is, in turn, used as a template to make the proteins that control cellular functions in a process</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> called translation. Combined, transcription and translation are responsible for gene expression. Individuals who have a nucleotide repeat expansion in the DNA can experience different alterations of transcription. In some diseases such as FA, the transcription machinery stalls at the abnormally expanded repeat sequence leading to insufficient production of a critical protein called FXN. In other cases, such as in DM1, the abnormal RNA transcript arising from the nucleotide repeat expansion mutation is misprocessed, leading to a cascade of downstream toxicity and cellular dysfunction.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules represent a novel class of small molecules designed to act on a diverse array of diseases and selectively target genetic repeat sequences, modulate gene expression either by dialing up or dialing down mRNA transcription, and restore cellular health. We have developed a proprietary framework that combines our understanding of medicinal chemistry and structure-activity relationships that allow us to design DNA-targeting moieties that are connected via a linker to ligand moieties that engage and modulate the transcriptional machinery. GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are heterobifunctional, meaning that they are comprised of two principal moieties that are each designed to have a unique function:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">DNA-Targeting Moiety: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one end of the GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule is a DNA targeting molecule that has been designed to recognize</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and target the molecule to the specific nucleotide repeat sequence of interest (e.g. the repeated GAA sequence seen in the first intron of the FXN gene seen in FA or the CTG repeat in the 3&#x2019; non-coding region of the dystrophy myotonic protein kinase (DMPK) gene seen in DM1).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2985416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ligand Moiety: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the other end of the molecule is designed to interact with the endogenous proteins that can regulate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">transcription to either dial up or dial down the expression of an individual gene.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_0.jpg" alt="img215454963_0.jpg" style="width:592px;height:222px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The structures of the GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to enable them to act specifically at the site of the disease-causing nucleotide repeat expansion by targeting the mutant allele and modulating the transcriptional machinery in a cell. Consequently, the cell can resume gene expression and production of normal protein isoforms that remain under normal physiological control. The versatility of the GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform allows us to design GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules toward a specific nucleotide repeat expansion target, regardless of repeat number, and tailor it to address the underlying disease-specific dysfunction in gene regulation in one of the following ways:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1595833333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restoration of Transcription: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In diseases where the expanded nucleotide repeat structure can cause endogenous</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">transcription machinery to stall, which leads to an insufficient amount of protein production, GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules can be designed to target the desired loci in the genome and engage the endogenous transcriptional machinery with the goal of restoring normal levels of full-length pre-mRNAs. In FA, for example, where the expanded triplet repeat occurs in an intron, a non-coding region of the gene, the abnormally long nucleotide sequence is spliced out of the pre-mRNA thus enabling normal production of natural protein isoforms according to existing physiologic regulatory control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1595833333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page109"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reduction of Toxic Gene Product Levels: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Another type of nucleotide repeat expansion disease occurs when the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">transcription process results in the accumulation of toxic gene products (e.g. DM1, Huntington disease, FECD), and in some cases the formation of nuclear foci, leading to multiple downstream cellular dysfunctions. In these cases, a single copy of expanded repeat containing allele is sufficient to cause the disease. Our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to selectively target the abnormally expanded nucleotide repeat to block the formation of the downstream toxic gene product and restore cellular function without interfering with the gene expression of the normal allele.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our understanding of the properties of the GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules is based on data-driven assessments of compounds we have designed and synthesized, as well as experience with our most advanced compounds for FA and DM1 tested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We continue to develop know-how of diverse configurations of DNA targeting, linker, and ligand moieties that drive the drug properties of molecules which are best suited to be developed for treating the underlying cause of each specific disease. This understanding of GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> chemistry has enabled us to generate multiple candidates designed to have optimal potential therapeutic and drug characteristics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a portfolio of GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> product candidates designed to address genetic diseases driven by inherited nucleotide repeat expansions that have urgent medical need and where no approved disease-modifying treatments are currently available. Because GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to be a novel class of disease-modifying small molecule therapeutic candidates, we have selected disease programs where we believe the underlying cause is amenable to intervention using our technology and prioritized our development efforts where we believe there is a clear and efficient path to advance these candidates through clinical development, with the goal of providing a disease-modifying therapy for patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead candidates and early development programs are summarized in the table below:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 1: GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;font-style:italic;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_1.jpg" alt="img215454963_1.jpg" style="width:624px;height:135px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FA Program Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.17875;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page110"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our FA program is focused on the development of a potentially disease-modifying treatment. FA is a devastating monogenic, autosomal recessive progressive disease where over 95% of cases are</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> caused by homozygous guanine-adenine-adenine (GAA) triplet repeat expansions in the first intron of the FXN gene, which encodes the mitochondrial protein FXN. The disease is characterized by spinocerebellar ataxia, dysarthria, pyramidal weakness, deep sensory loss, hypertrophic cardiomyopathy, skeletal abnormalities, and diabetes mellitus. Clinical onset occurs most often around puberty, leads to severe disability by early adulthood, with substantial functional loss, wheelchair dependence, and loss of quality of life. Affected individuals have reduced life expectancy, with many premature deaths caused by complications of the cardiomyopathy at about the end of the fourth decade of life.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated prevalence of FA is 1 in 40,000-50,000, affecting more than 5,000 individuals living in the United States and more than 20,000 in Europe. Our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> candidate is designed to address the genetic basis of the disease by restoring functional FXN protein levels and we anticipate a first-in -human dosing for our first product candidate in the first half of 2022. The primary cause of mortality (approximately 60% of FA patients) is cardiac arrhythmias or heart failure with the mean life expectancy reduced to approximately 35-40 years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">DM1 Program Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our DM1 program is focused on the development of a potentially disease-modifying treatment for DM1. DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain, and other organs. The cardinal features include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. In addition, affected individuals often experience cardiac arrhythmias, changes in neuropsychological function, and gastrointestinal symptoms. DM1 is caused by a mutation in the DMPK gene and is estimated to have a genetic prevalence of 1 in 2,300-8,000 people, affecting more than 70,000 people in the United States and more than 90,000 people in Europe. Our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to address the genetic basis of the disease by preventing the expression of toxic gene product and consequently of nuclear foci. We expect to complete IND-enabling studies and seek regulatory clearance for a first-in-human trial in 2023.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FECD Program Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD.  FECD is characterized by progressive degeneration of the corneal endothelium and subsequent loss of vision. This genetic eye disease affects more than one million people in the U.S., with approximately 75% of cases caused by a CTG trinucleotide repeat expansion within the transcription factor 4 (TCF4) gene, leading to the formation of toxic RNA foci, global splicing dysregulation, cellular dysfunction, and eventual death of corneal endothelial cells.  Due to the lack of disease-modifying therapies approved for FECD, corneal transplantation is currently the only approved procedure used to restore vision.  Our approach utilizes our FECD GeneTAC&#153; molecules to selectively target the expanded CTG repeats in the TCF4 gene to reduce RNA foci formation and mis-splicing. We believe our preclinical data to date supports the potential of our FECD GeneTAC&#153; small molecules to correct the most common underlying genetic cause of FECD, and we plan to advance this research program through additional preclinical studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research Program Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also advancing our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> product candidate portfolio into development in other serious nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease and spinobulbar muscular atrophy. Many of these monogenic diseases have overlapping triplet repeat expansions, including CTG repeats that cause DM1, allowing for the accumulating knowledge on how to design novel molecules to be applied across multiple diseases also caused by CTG and CAG repeat expansions. Additionally, our medicinal chemistry experiences with GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules allow us to more rapidly design GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules for additional proposed indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We aim to leverage our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform to design, develop and commercialize a pipeline of disease-modifying therapeutic candidates designed to treat a wide range of inherited nucleotide repeat expansion diseases for which there is urgent unmet medical need. In order to achieve our goal, we intend to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2170833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page111"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance our Lead Program in FA Through Clinical Development to Offer Meaningful Patient Benefit. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FA is a serious monogenic degenerative disease for which there are currently no available treatments. Our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are specifically designed to restore levels of FXN, the underlying cause of FA. Restoration of FXN has been shown to improve FA-like symptoms in animal models. We believe that demonstrating clinical proof of concept by restoring FXN expression in FA patients may confirm the therapeutic potential of our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> underscore the broader potential of our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform. We have completed IND-enabling safety studies in both rats and non-human primates, received FDA clearance of our IND in late February 2022 and anticipate beginning a Phase 1 clinical trial in the first half of 2022.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:4.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2170833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance our DM1 Program Through Clinical Development to Offer Meaningful Patient Benefit. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DM1 is a serious</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monogenic degenerative disease for which there are currently no available treatments. Our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are specifically designed to reduce the formation of CUG repeat hairpin structures that trap splicing factors and form toxic nuclear foci that cause DM1. Blocking the formation of CUG foci has demonstrated phenotypic benefit. We believe that demonstrating clinical proof of concept by reducing the repeat hairpin structures in DM1 patients may confirm the therapeutic potential of this candidate. We expect to complete IND-enabling studies and seek regulatory clearance for a first-in-human clinical trial in 2023.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:4.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1595833333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leverage our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;font-style:italic;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Platform to Expand our Pipeline and Address Additional Nucleotide Repeat Expansion Diseases with Significant Unmet Medical Need. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There remains a significant unmet medical need for all nucleotide repeat expansion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diseases. We plan to advance our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> portfolio to address the underlying cause of other serious nucleotide repeat expansion-driven monogenic diseases, which may include FECD, Fragile X syndrome, spinocerebellar ataxias, familial amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease and spinobulbar muscular atrophy, the majority of which have no approved disease-modifying treatments.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:4.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Selectively Enter Into Strategic Collaborations to Realize the Full Potential of Our Platform. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the broad potential of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform, we may explore collaborations in select disease areas or geographic regions that are better served by the resources or specific expertise of a strategic partner to accelerate the development and commercialization of our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> product candidates.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2122916666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Independently Commercialize any Approved Products in Indications and Geographies Where we Believe we can Maximize Value. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to commercialize our product candidates in indications and geographies that we believe we can</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercialize successfully on our own, if any of our candidates receives regulatory approval.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:3.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1691666666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Establish a Leadership Position in Genetic Diseases by Continuing to Build and Leverage our Relationships with the Key Opinion Leaders, Physicians, and Patients. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an established advisory network of pharmaceutical research and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">development experts, scientists, clinicians and patient organizations in areas relevant to our programs. We have continued to grow our network as needed to inform our programs with the most up to date data and practices that might enhance our ability to effectively bring potentially life saving treatments to patients in need.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our History and Team</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our company was created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules) designed to directly address the underlying basis of genetic disease. To achieve this goal, we have assembled a management team with extensive experience in the design, development and commercialization of drugs for serious diseases.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page112"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our company was started by Pratik Shah, Ph.D. and Aseem Z. Ansari, Ph.D. Dr. Shah, our Co-Founder and Executive Chairperson, has more than 30 years of experience founding and leading biopharmaceutical companies and healthcare investment decisions. Dr. Ansari, our Co-Founder, is an internationally recognized pioneer in transcriptional regulation and DNA targeting molecules and the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> chair of the Department of Chemical Biology and Therapeutics at St. Jude Children&#x2019;s Research Hospital. Jo&#xe3;o Siffert, M.D., our President and Chief Executive Officer, has more than 20 years of leadership experience in biopharmaceutical companies and clinical medicine. Prior to Design, Dr. Siffert led a publicly traded biotech company developing gene and cell therapies for devastating degenerative diseases, and previously led research and development organizations in the United States and Europe, including programs that received regulatory approvals followed by commercial launches. Sean Jeffries, Ph.D., our Chief Operating Officer, brings over 20 years of experience in business development, portfolio management, and research and development strategy for both emerging and large biopharmaceuticals companies.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Background on Genomic Medicines</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">What is Genetic Disease?</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Genetic diseases arise when a change to the DNA, called a mutation, disrupts normal cellular functioning. These mutations can range from alteration of a single nucleotide in an individual&#x2019;s DNA to major abnormalities affecting many genes or even entire chromosomes. When a mutation occurs in a single gene, the disease is referred to as a monogenic disease. More than 10,000 monogenic diseases have been identified and many are serious conditions that collectively affect millions of people globally, most of which have no effective therapeutic options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">What is Genomic Medicine?</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Genomic medicines are created based on understanding of genetic causes of disease, targeting specific defects at the genetic level with the potential to address the underlying cause of disease and restore cellular function.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Technical and scientific advances in genomics have identified possible genetic targets for therapeutic interventions. Several approaches have been developed to address diseases caused by genetic mutations, including oligonucleotides, mRNA, gene therapy and gene editing. While these technologies have led to numerous product candidates over the last decade, significant challenges have limited their utility in the clinic as a result of:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immunogenicity that creates safety concerns and limits activity and re-dosing;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unregulated gene expression;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">off-target effects;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations of dose adjustments/silencing;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations and heterogeneity of biodistribution; and</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">challenges with consistency, quality and scalability of manufacturing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Advantages of Our Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are using our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform to develop small molecule genomic medicine candidates that are designed to offer precise modulation of gene transcription. We believe that the GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform may offer several potential mechanistic and development advantages over other genomic medicine modalities, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.852%;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> small molecules may be more tolerable over complex biologics because GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are less likely to cause adverse immune reactions;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:6.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page113"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules may be less likely to be immunogenic and therefore have no limitations with re-dosing;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> treatment is designed to be reversible;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to act on the transcription machinery of the cell and do not alter the genome;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.111%;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules' modulation of transcription is designed to preserve normal physiological post-transcriptional regulation and protein translation controls;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> structure is designed to enable therapeutically active molecules to be deployed directly at the site of disease-causing mutations, which could enhance specificity and potency, and minimize off-target effects;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to enable ongoing dose optimization;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:5.741%;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules can achieve biodistribution across target organs and into the cell without specialized engineering or delivery technologies;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:3.889%;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are synthetically tractable, offering a potentially readily scalable, cost-effective development path that does not require complex customized manufacturing equipment and processes; and</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:0.741%;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules have a modular heterobifunctional structure that is intended to allow us to rationally design novel targeting components for specific DNA sequences, creating a potentially highly efficient discovery engine that could enable us to rapidly expand our portfolio into new disease areas.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By combining the disease-modifying potential of genomic medicines with the drug-like properties, manufacturing and logistics advantages of small molecules, we believe GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules could be developed as novel therapeutic options in genetic diseases where disease-modifying treatments have previously been elusive.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Portfolio</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Friedreich Ataxia</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview, Prevalence and Current Treatment Landscape</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FA is a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems highly dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction. Clinical manifestations include poor coordination of legs and arms, progressive loss of balance and ability to walk, generalized weakness, loss of sensation, scoliosis, hypertrophic cardiomyopathy and cardiac arrythmia, and glucose intolerance, including diabetes. FA patients also report impaired vision, hearing and speech. FA significantly impairs quality of life with loss of independence, physical limitations and reduced participation in social activities and work.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.17875;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary cause of mortality (approximately 60% of FA patients) is cardiac arrhythmias or heart failure with the mean life expectancy reduced to approximately 35-40 years.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page114"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In over 95% of patients, FA is caused by an inherited homozygous increase in the number of GAA triplet repeats found in the first intron of the FXN gene. The number of repeats ranges from up to approximately 30 GAA repeats in healthy individuals to over several hundred to over 1,000 in FA patients. The expanded triplet repeat results in gene silencing and reduction in capacity to produce the FXN protein, which is required for proper functioning of the mitochondria and ultimately the entire cell. Levels of FXN correlate inversely with disease severity, and when levels are reduced to levels of approximately 25% of normal healthy individuals, iron homeostasis and iron-sulfur cluster synthesis are</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impaired, leading to general impairment of normal mitochondrial function. Heterozygote carriers typically have approximately half of the FXN levels of normal individuals, but are asymptomatic and hence on average, the doubling of FXN protein levels in FA patients to achieve carrier levels or higher is expected to restore mitochondrial function and provide therapeutic benefit.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The genetic basis for FA is illustrated in Figure 2 below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 2: Genetic basis for FA</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_2.jpg" alt="img215454963_2.jpg" style="width:523px;height:370px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical course of FA is progressive, with most patients presenting in their adolescent years with gait ataxia and scoliosis. About 10 years after disease onset, most patients lose their ability to walk and require a wheelchair because of progressive loss of balance and muscle weakness in the torso and legs. Eventually, muscle weakness in the tongue and throat makes it difficult to swallow and eat, and almost all patients experience some degree of dysarthria (slowing/slurring of speech), which limits communication. Approximately 50% of FA patients develop glucose intolerance and approximately 30% develop diabetes. More than two thirds of FA patients have cardiac abnormalities at baseline including arrhythmia, conduction abnormalities, or hypertrophic cardiomyopathy. Cardiac abnormalities are responsible for approximately 60% of mortality in FA patients. FA significantly reduces life expectancy and impairs quality of life for patients and their families with loss of independence, physical limitations and reduced participation in social activities and work.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.17875;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page115">&#160;</p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.17875;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated prevalence of FA is 1 in 40,000-50,000, affecting more than 5,000 individuals living in the United States and more than 20,000 in Europe.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.250625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no approved therapies for the treatment of FA, and treatment is focused largely on symptom management. There are several product candidates in clinical development, but none of them have shown the ability to restore the deficiency in FXN protein, which is the underlying cause of the disease. There remains a high unmet medical need for new disease-modifying therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Approach</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our FA program is based on GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> small molecules consisting of a DNA-targeting moiety designed to target the expanded GAA repeat sequence in the first intron of the FXN gene in FA patients, linked to a ligand moiety designed to recruit an endogenous transcriptional elongation complex to unblock the transcriptional machinery, and restore the production of functional natural FXN proteins to therapeutic levels.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The key advantages of our FA program include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:4.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2985416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Designed to Address the Underlying Cause of the Disease. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FA is caused by reduced FXN protein levels. All disease manifestations are downstream effects of FXN deficiency. Our FA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to restore FXN levels, thereby restoring normal physiological activity.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2985416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">High Potency Compounds. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules have shown high potency and prolonged restoration of FXN levels in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical assays in FA patient cells and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> model of FA.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2075;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Designed for Efficient Delivery of Drug to the Target Organs. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have observed good biodistribution and bioavailability for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules in multiple animal species, where they reached therapeutically relevant concentrations in the most affected organs such as heart, brain, muscle and spinal cord.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2218749999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the results of our preclinical studies to date support the hypotheses that FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules may confer a clinical benefit to FA patients. In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> experiments in primary cells from FA patients and in neurons and cardiomyocytes derived from FA patient stem cells, robust and durable increases in FXN mRNA and protein restoration was observed following exposure to FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, even at low nanomolar (nM) concentrations. In preclinical studies, FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules achieved therapeutically relevant concentrations in key organs of disease, including the heart, brain, muscle and spinal cord, at doses that were well tolerated in multiple species.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We assessed the FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> activity in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> models of disease, including multiple types of FA patient cells such as primary white blood cells, lymphoblastoid cells, and cardiomyocytes and neurons derived from stem cells. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> studies were conducted in the Pook800J mouse model, which contains a hemizygous insertion of the human disease allele with approximately 800 GAA repeats onto a genetic background lacking endogenous mouse FXN.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Increase in FXN mRNA and Protein Levels in Patient Blood Cells</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in FA primary patient blood samples that have reduced FXN levels, we observed an increase in both FXN mRNA and protein levels after the administration of FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As illustrated below in Figure 3, after a single 100nM administration of our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we observed increased FXN mRNA levels in all 10 patient samples with GAA repeat lengths ranging from approximately 100 to over 1,000. We also observed an increase in FXN protein levels in all 7 patient samples tested after a single administration of our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As early as sixty hours post this single administration of our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we observed a nearly two-fold increase in FXN protein levels compared to cells with vehicle control. Predictions from studies examining FXN levels in FA patients suggest that a two-fold increase in FXN levels would be highly therapeutic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page116"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 3: FXN mRNA and protein levels in primary patient blood samples</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_3.jpg" alt="img215454963_3.jpg" style="width:604px;height:251px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:1.107%;text-indent:5.164%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in an FA patient lymphoblastoid white blood cell line, we observed that treatment with FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules resulted in a dose dependent increase in FXN mRNA levels with an EC50 of 4nM and an EC90 of 9nM (Figure 4). Following a single dose of an FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we observed increased FXN mRNA levels up to the levels observed in a healthy control with two normal FXN alleles. We also observed a multi-fold increase in FXN protein levels after continuous exposure to 100nM FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for six days.</span></p>
  <p style="margin-left:1.107%;text-indent:5.164%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 4: FXN mRNA and protein levels in patient lymphoblastoid cell line</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_4.jpg" alt="img215454963_4.jpg" style="width:605px;height:359px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Increase in FXN mRNA and Protein in FA Patient Cardiomyocytes and Neurons</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in both cardiomyocytes and neurons derived from an FA patient stem cell line, we observed an increase in FXN mRNA and protein levels following exposure to our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules. As illustrated in Figure 5, in the study of cardiomyocytes derived from an FA patient stem cell line, increased mRNA and protein levels were observed after continuous exposure to 100 nM of our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 5: FXN mRNA and protein levels in patient cardiomyocytes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_5.jpg" alt="img215454963_5.jpg" style="width:624px;height:294px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Figure 5. Cardiomyocytes from an FA patient were incubated in triplicate with 100 nM of an FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule continuously, and cells were harvested for determination of FXN mRNA (left) or protein (right) levels on days 3, 7, and 11. Data are depicted as Mean &#xb1; SD (n=3/group).</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Continuous exposure to low doses of an FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule (10 or 100nM) increased FXN expression in neurons derived from an FA patient stem cell line (Figure 6). Increases in FXN mRNA levels preceded increases in FXN protein, consistent with typical gene expression. Of note, the increase in FXN protein levels after continuous treatment with 10 or 100 nM of the FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule resulted in similar FXN protein levels which were also similar to - and did not exceed - those in a non-FA patient-derived neurons in culture (grey horizontal bar in Figure 6 right panel).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 6: FXN mRNA and protein levels in FA patient neurons</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_6.jpg" alt="img215454963_6.jpg" style="width:624px;height:219px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Figure 6. Neurons from an FA patient were incubated with 10 or 100 nM of an FA GeneTAC molecule continuously, and cells were harvested for determination of FXN mRNA (left) or protein (right) levels on Days 3, 7, 10, and 14.  Data are depicted as Mean &#xb1; SD (n=3/group). Grey horizontal bar (right panel) indicates range of FXN protein levels in non-FA patient derived neurons on Day 14</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in Pook800J mice, we observed an increase in FXN protein levels in both heart and brain tissue after treatment with FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Distribution and Tolerability of FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;font-style:italic;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">molecules</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in Sprague-Dawley rats, after a single intravenous (IV) administration of our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, we observed intact FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules in target tissues (including heart, brain, muscle and spinal cord) at or above concentrations shown to increase FXN mRNA and protein levels in FA patient cells. (Figure 7). In nonhuman primates (NHPs), repeat administration of an FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule resulted in dose-related distribution to key target organs in the context of functional deficits encountered in FA, including the brain, skeletal muscle, and heart (Figure 7). In both species the FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule was well tolerated and resulted in no clinically meaningful changes in hematology, serum biochemistry or histology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 7: FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;font-style:italic;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> concentration in target tissues of NHPs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_7.jpg" alt="img215454963_7.jpg" style="width:624px;height:212px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Figure 7. FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule was administered to male cynomolgus monkeys by IV injection on Days 1, 8, and 15. Plasma and tissues were collected from 2 monkeys at 6, 24, and 168 hours after the Day 15 dose for determination of FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule levels by LC-MS/MS. Data are depicted as the Mean + SE.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page119">&#160;</p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our preclinical studies, we have observed a dose dependent increase in both FXN mRNA and protein levels in primary blood cells collected from FA patients, a dose dependent increase in both FXN mRNA and protein levels in neurons and cardiomyocytes and neurons derived from FA patients, durability of FXN mRNA and protein levels greater than 10 days, and sustained FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> levels after a single dose in heart, brain, muscle and spinal cord in rats.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on these results, we have conducted formal GLP safety studies in both rats and NHPs and anticipate beginning a Phase 1 clinical trial in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Myotonic Dystrophy Type-1 (DM1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview, Prevalence and Current Treatment Landscape</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DM1 is a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. Clinical manifestations include muscle weakness, myotonia (slow muscle relaxation), early cataracts, cardiac arrhythmias and changes in neuropsychological function. DM1 is progressive and may become extremely disabling, leading to poor quality of life and early mortality.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DM1 is caused by an increased number of CTG triplet repeats found in the 3&#x2019; non-coding region of the DMPK gene. The number of repeats ranges from up to approximately 35 in healthy individuals to many thousands in DM1 patients. When transcribed, the higher-than-normal number of triplet repeats in terminal end of the mutant DMPK allele form pre-mRNAs with large CUG hairpin loops that remain entrapped in the nucleus and form clumps also called foci. Specifically, mutant DMPK pre-mRNA sequesters a critical CUG-binding protein, muscle blind-like protein 1 (MBNL1), which leads to the formation of toxic nuclear foci and inhibits the ability of MBNL1 in processing many pre-mRNAs. As a result, multiple pre-mRNAs that encode key proteins are mis-spliced. This mis-splicing in the nucleus results in the translation of atypical proteins, which ultimately cause the clinical presentation of DM1. When levels of mutant DMPK mRNA containing higher numbers of CUG repeats are reduced, nuclear foci are diminished and MBNL1 proteins are freed to function normally. This disease process is illustrated below:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page120">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 8: DM1: Genetic basis and clinical presentation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_8.jpg" alt="img215454963_8.jpg" style="width:363px;height:361px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DM1 is estimated to have a genetic prevalence of 1 in 2,300-8,000 people, affecting more than 70,000 people in the United States and more than 90,000 people in Europe. However, we believe that the patient population is currently underdiagnosed due to lack of available therapies. DM1 is typically categorized into four overlapping phenotypes based on age of onset: late-onset; classical (adult-onset); childhood; and congenital (cDM1).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">Overview of DM1 phenotypes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:0.08333333333333333in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34.016%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:31.891%;"></td>
    <td style="width:0.898%;"></td>
    <td style="width:32.11%;"></td>
   </tr>
   <tr style="height:9.35pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08333333333333333in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">Phenotype</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06944444444444445in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">Age of onset</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">Estimated % of DM1 patients</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="border-top:1.000pt solid;background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:9.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Late-onset</span></p></td>
    <td style="border-top:1.000pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:1.000pt solid;background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:9.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">40+ years</span></p></td>
    <td style="border-top:1.000pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:1.000pt solid;background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:9.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">~10%</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.09722222222222222in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Classical</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06944444444444445in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">10 &#x2013; 40 years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">~65% to 75%</span></p></td>
   </tr>
   <tr style="height:10.8pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08333333333333333in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">(Adult-onset)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08333333333333333in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Childhood</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06944444444444445in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">1 - 10 years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">~15%</span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08333333333333333in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Congenital</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06944444444444445in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Birth</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">~5% to 15%</span></p></td>
   </tr>
   <tr style="height:10.8pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.08333333333333333in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">(cDM1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All DM1 phenotypes, except the late-onset form, are associated with high levels of disease burden and premature mortality. The clinical course of DM1 is progressive, and may become extremely disabling, especially when more generalized limb weakness and respiratory muscle involvement develops. Systemic manifestations such as fatigue, GI complications, cataracts and excessive daytime sleepiness greatly impact a patient&#x2019;s quality of life. As a result, DM1 leads to physical impairment, activity limitations, decreased participation in social activities and work and impairs quality of life for patients and their families. Life expectancy in classical DM1 ranges from 48-55 years. Respiratory failure due to muscle weakness (especially diaphragmatic weakness) causes at least 50% of early mortality, and cardiac abnormalities, including sudden death, account for approximately 30% of early mortality.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page121">&#160;</p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no approved therapies for the treatment of DM1, leaving a high unmet medical need and opportunity for new disease-modifying therapies. There are several product candidates currently in preclinical and clinical development, one of which is in later stage clinical development and does not show disease-modifying potential, while the other product candidates are in preclinical stages and have yet to demonstrate clinical proof-of-concept.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Approach</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our DM1 program is based on GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> small molecule candidates consisting of a DNA-targeting moiety designed to target to the CTG repeats in the 3&#x2019; untranslated region of the DMPK gene, linked to a ligand moiety that is designed to block transcription of the mutant expanded CTG repeat without disrupting the normal DMPK expression. As a result, the DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule is designed to prevent the formation of the CUG hairpin structures that trap splicing proteins and produce nuclear foci. Like our FA program, the DM1 program is designed to address the underlying cause of the disease and benefit from the favorable development advantages of small molecules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently conducting preclinical studies of our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules in DM1 patient cells. We have observed reduced nuclear foci in DM1 cells from multiple patients after administration of our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules. We believe these data support the potential for our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules to be evaluated in clinical trials as a potential therapy for patients with DM1.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in DM1 patient cells that contained toxic nuclear DMPK RNA, we observed reduction of nuclear foci following exposure to our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules. When toxic nuclear DMPK levels are reduced, the nuclear foci are diminished, releasing splicing proteins, allowing restoration of normal mRNA processing, and potentially stopping or reversing disease progression. As illustrated in Figure 9, we observed a reduction in CUG nuclear foci in DM1 patient cells exposed to our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules as determined through a fluorescence in situ hybridization imaging and analysis. This reduction was seen within several days after exposure to our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules. The reduced CUG nuclear foci are indicated by the reduction in green punctate staining.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 9: Decrease in CUG nuclear foci in DM1 patient cells exposed to DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;font-style:italic;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> molecules</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_9.jpg" alt="img215454963_9.jpg" style="width:624px;height:355px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page122"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in cells from multiple DM1 patients, we observed a reduction in the number of observable CUG nuclear foci after exposure to our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule. As seen in Figure 10, after exposing DM1 Patient 1 and 2 cells to our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, we observed an increase in the percentage of cells with no observable CUG nuclear foci to over 92%, similar to healthy cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 10: CUG nuclear foci in cells from multiple DM1 patients</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_10.jpg" alt="img215454963_10.jpg" style="width:608px;height:292px;" />&#160;</p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 11: Percent splicing correction for MBNL1 exon 7 inclusion in DM1 patient fibroblasts</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_11.jpg" alt="img215454963_11.jpg" style="width:515px;height:361px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules corrected splicing defects in MBNL-1 transcript in DM1 myoblasts and restored the splicing levels to &gt;90% of that seen in healthy human skeletal myoblasts. We plan to continue evaluating the properties of our DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules in both </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> preclinical studies. We expect to complete IND-enabling studies and seek regulatory clearance for a first-in-human clinical trial in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Discovery Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also advancing our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> portfolio in other serious nucleotide repeat expansion-driven monogenic diseases, such as FECD, Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease and spinobulbar muscular atrophy as outlined in the table below. Many of these monogenic diseases have overlapping triplet repeat expansions, including CTG repeats that cause DM1, allowing for the accumulating knowledge on how to design novel molecules to be applied across multiple diseases, also caused by CTG and CAG repeat expansions. Additionally, our medicinal chemistry experiences with GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules allow us to more rapidly design GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules for additional indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page123">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 12: Potential broad applicability of GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;font-style:italic;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> molecules across multiple indications</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img215454963_12.jpg" alt="img215454963_12.jpg" style="width:624px;height:199px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2122916666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and biopharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. Any product candidates that we successfully design, develop and commercialize will compete with current therapies and new therapies that may become available in the future. While we believe that our technology, development experience and scientific knowledge in the field of nucleotide repeat expansion diseases and small molecules, and foundational intellectual property provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:8.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Friedreich Ataxia. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no approved therapies for the treatment of FA. Some of the product candidates currently</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in development to treat FA include: omaveloxolone, a Nrf2 activator by Reata Pharmaceuticals; vatiquinone, a 15-lipoxygenase inhibitor by PTC Therapeutics; RT001, a deuterated poly-saturated fatty acid by Retrotope; leriglitazone, a PPAR-gamma agonist by Minoryx Therapeutics; and CTI-1601, an HIV-derived cell penetrating peptide FXN recombinant fusion protein by Larimar Therapeutics. In addition, several companies are in preclinical development for AAV-based gene therapies, including PTC therapeutics, Voyager Therapeutics, Lexeo Therapeutics, Pfizer, Novartis, Lacerta Therapeutics, StrideBio, and AavantiBio. We are not aware of any competing company that has a small molecule program in development that is designed to restore endogenous FXN protein levels, the underlying cause of FA.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2122916666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page124"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Myotonic Dystrophy Type-1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no approved therapies for the treatment of DM1. Some of the candidates currently in clinical-stage development of which we are aware are tideglusib, a GSK3-&#xdf; inhibitor by AMO Pharma for the congenital phenotype of DM1 and AOC 1001, an antibody linked siRNA by Avidity Biosciences. Some of the products</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> currently in preclinical development to treat DM1 include: a histamine 3 receptor inhibitor by Harmony Biosciences for the treatment of excessive daytime sleepiness in DM1; an AAV-antisense candidate by Audentes Therapeutics, an Astellas company; an antibody linked oligonucleotide by Dyne Therapeutics; a peptide conjugated antisense oligonuclieotide by PepGen; gene editing treatments by Vertex Pharmaceuticals; an RNA-targeting AAV-based gene therapy by Locana; an AAV-based RNA degrading gene therapy by Enzerna Biosciences; antisense oligonucleotides by NeuBase Therapeutics; antisense oligonucleotides and siRNA candidates by Triplet Therapeutics; small molecules interacting with RNA by Anima Biotech; anti-miRNA oligonucleotides by Arthex Biotech; small molecule modulators of transcription factors by Syros Pharmaceuticals; and small molecules interacting with RNA by Expansion Therapeutics.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Nucleotide Repeat Expansion Driven Diseases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no approved therapies targeting the underlying</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cause of other inherited nucleotide repeat expansion diseases where we believe GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules could have applicability, including FECD, Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease and spinobulbar muscular atrophy, among others.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will also compete more generally with other companies developing product candidates that utilize alternative scientific and technological approaches to modulate individual genes, including other companies working to develop nuclease-based gene editing technologies, such as Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Precision BioSciences and Sangamo Biosciences.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated within a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of other drugs. The key competitive factors affecting the success of our programs are likely to be their efficacy, safety profile, biodistribution, manufacturability, effectiveness of commercial activities, intellectual property protection and availability of reimbursement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">License Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Wisconsin Alumni Research Foundation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page125"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 20, 2019, we and Wisconsin Alumni Research Foundation (WARF) entered into a human therapeutics exclusive license agreement (the WARF License Agreement), pursuant to which we received (i) an exclusive, worldwide, royalty-bearing, sublicensable license under certain of WARF&#x2019;s patents relating to compounds and methods for treating genetic disease by modulating gene expression, including expression of frataxin, through nucleic acid binding moieties that specifically bind to one or more repeats of a target oligonucleotide sequence as well as a synthetic transcription factor having a nucleic acid binding moiety that specifically binds to a target oligonucleotide sequence and (ii) a non-exclusive, worldwide, sublicensable license under certain of WARF&#x2019;s know-how relating to the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> foregoing patents, in each case (i) and (ii), to research, develop, make, have made, use, have used, sell, offer for sale, have sold, export and import products developed through the use of such licensed patents and know-how in all fields. We are currently using the licensed patents and know-how in our FA program. The licenses granted pursuant to the WARF License Agreement are subject to certain rights retained by (i) the United States government under the Bayh-Dole Act and (ii) WARF to grant the University of Wisconsin, non-profit research institutions collaborating with the University of Wisconsin and governmental agencies non-exclusive licenses to practice and use the licensed patents for non-commercial research purposes. Such rights retained by the United States government and WARF are typical for a license from a U.S. university or research institution, and we believe such rights do not pose a material risk to our business. We further granted to WARF, the University of Wisconsin, the inventors of the licensed patents, and governmental research organizations a covenant not to sue under certain improvements to the licensed patents for non-commercial research purposes. Under the WARF License Agreement, we are required to use commercially reasonable diligence to develop, seek regulatory approval for, manufacture, market and sell licensed products throughout the term of the agreement, including satisfying certain funding and diligence milestones.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the rights granted to us under the WARF License Agreement, we paid WARF an upfront licensing fee of $250,000. We are also required to pay WARF up to an aggregate of $17.6 million upon the achievement of certain development and commercial sales milestones. Each such milestone payment is payable once for each licensed product for which the milestone is achieved, except for the two milestones relating to IND submission and human proof of concept study, which are payable only for the first licensed product for which such milestones are achieved (and not for subsequent licensed products). In addition, we are required to pay WARF, on a licensed product-by-licensed product and country-by-country basis, upon first commercial product sale, a fixed royalty of a low single digit percentage on sales of licensed products by us and/or by our sublicensees, subject to certain reductions and a minimum total annual royalty payment of $100,000. Our royalty obligation will terminate on the date of expiration of the last-to-expire of the licensed patents in the relevant country. We are also obligated to pay WARF sublicense fees in the mid-single digits percentage for funding or royalties earned from the granting of sublicenses to the WARF patents and know-how. We are required to reimburse WARF for all costs associated with filing, prosecuting and maintaining the licensed patents prior to and after the effective date of the WARF License Agreement.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The WARF License Agreement will continue until the earliest of (i) the date of early termination in accordance with the agreement, (ii) expiration of the licensed patents in all countries, or (iii) our cessation, once begun, of royalty payments for more than two years. The WARF License Agreement may be terminated by us upon 90 days&#x2019; written notice, provided we include a statement of reasons for termination. WARF may terminate the WARF License Agreement (a) upon written notice if our cumulative earned royalties paid to WARF does not exceed $100,000 on or before December 31, 2031, (b) if we fail to make timely payments, fail to timely provide development reports or provide any false information with respect thereto, fail to actively pursue the development plan, or commit any breach of any other covenant, representation or warranty under the WARF License Agreement, in each case, without curing such failure or breach within 90 days after written notice thereof, (c) if we commit any act of bankruptcy or become insolvent, or (d) immediately if we or our sublicensee(s) offer any rights to the licensed patents to our or our sublicensees&#x2019; creditors. As of December 31, 2021, the licensed patents include one issued U.S. patent that is projected to expire on or around March 29, 2037, not including any patent term adjustments and extensions. The license also includes eight pending patent applications in the United States, Europe, Canada, and Australia. Any patents that issue from these patent applications have projected expiration dates from 2037 through 2039, not including any patent term adjustments and extensions that may be available.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are synthetically tractable, offering a readily scalable, cost-effective development path that does not require complex customized equipment and processes. We do not own or operate, and currently have no plans to establish, current Good Manufacturing Practice (cGMP) manufacturing facilities and laboratories. We currently rely on third-party manufacturers and suppliers for the raw materials and starting components used to make our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, and we expect to continue to do so to meet our research and development and commercial activities. Our third-party manufacturers are qualified to manufacture our product candidates under cGMP requirements and other applicable laws, guidances and regulations. We believe there are multiple sources for all of the materials and components required for the manufacture of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates and other discoveries, inventions, trade secrets and know-how that are critical to our business operations. Our success also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights. A comprehensive discussion on risks relating to intellectual property is provided under the heading &#x201c;Risk Factors&#x201d; under Part I, Item 1A of this Annual Report.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we own eight pending U.S. patent applications, six pending European patent applications, one pending patent application in Argentina, one pending patent application in Taiwan, and three pending Patent Cooperation Treaty applications, which, if issued (or in case of provisional applications, if issued from future non-provisional applications that we file), are expected to expire between 2039 and 2042, not including any patent term adjustments and extensions that may be available. In addition, we acquired an exclusive license from WARF under one issued U.S. patent, three pending U.S. patent applications, two pending European patent applications, two pending Canadian patent applications and one pending Australian patent application, with the issued patent expected to expire in 2037 and the other patents, if issued, are expected to expire between 2037 and 2039, not including any patent term adjustments and extensions that may be available. These patents cover our proprietary GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Platform technology that is used in our FA program, DM1 program and other therapeutic programs directed to genetic diseases that are further discussed below.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our FA program, as of December 31, 2021, we own or hold an exclusive, worldwide license from WARF. In particular, we have licensed from WARF an issued U.S. patent, a pending U.S. patent application, and two pending patent applications in Europe and Canada directed to compounds and methods for modulating frataxin expression. The U.S. patent and any patents issued from these pending patent applications are projected to expire on or around March 29, 2037, not including any patent term adjustments and extensions. We also license from WARF one pending U.S. patent application and three pending patent applications in Australia, Europe, and Canada directed to methods and compounds for treatment of FA. Any patents that eventually issue from this patent application are projected to expire on or around October 22, 2039. Additionally, we own two pending U.S. patent applications, a pending patent application in Europe, two pending patent applications in Argentina and Taiwan and a pending Patent Cooperation Treaty application directed to compositions of matter and methods for the treatment of FA. Any patents that eventually issue from these patent applications are projected to expire in the 2039-2042 timeframe.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page127"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our DM1 program, as of December 31, 2021, one of our pending U.S. patent applications, one pending patent application in Europe, and one pending Patent Cooperation Treaty application are directed to compositions of matter and methods for the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> treatment of DM1. Any patents issuing from patent applications in these families are projected to expire in the 2039-2041 timeframe, not including any patent term adjustments and extensions that may be available.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, four of our pending U.S. patent applications, four of our pending patent applications in Europe and one of our pending Patent Cooperation Treaty application are directed to our therapeutic programs related to other genetic diseases (including, but not limited to, Amyotrophic Lateral Sclerosis, Fragile X and Spinocerebellar Ataxia). These therapeutic programs utilize our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Platform technology and any patents that issue from these patent applications are projected to expire in the 2039-2041 timeframe not including any patent term adjustments or extensions. We also license from WARF a pending U.S. patent application that, if issued, is projected to expire on or around March 29, 2038, not including any patent term adjustments or extensions. These patent applications cover compositions of matter and methods of treating the related genetic diseases under our therapeutic programs, including the use of transcription modulator molecules that contain a DNA-binding moiety capable of specifically binding to certain nucleotide repeat sequences that are implicated in the applicable genetic disease. In addition to patent protection, we rely on trade secret protection, trademark protection and know-how to expand our proprietary position around our chemistry, technology and other discoveries and inventions that we consider important to our business. We are a party to the WARF License Agreement, described in more detail above, under which we are granted intellectual property rights to know-how that are important to our business.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, six of our pending U.S. patent applications and six of our pending patent applications in Europe are directed to our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Platform. Any patents that are expected to issue from these patent applications are projected to expire in 2039, not including any patent term adjustments and extensions that may be available.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to protect our intellectual property by having confidentiality terms in our agreements with companies with whom we share proprietary and confidential information in the course of business discussions, and by having confidentiality terms in our agreements with our employees, consultants, scientific advisors, clinical investigators and other contractors and also by requiring our employees, commercial contractors, and certain consultants and investigators, to enter into invention assignment agreements that grant us ownership of any discoveries or inventions made by them while in our employ.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a pharmaceutical company that operates in the United States, we are subject to extensive regulation. Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products such as those we are developing. Product candidates that we develop must be approved by the Food and Drug Administration (FDA), before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Drug Development Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page128"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FDCA), and implementing regulations. A new drug must be approved by the FDA through the new</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> drug application (NDA) process before it may be legally marketed in the United States. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.3129166666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#x2019;s Good Laboratory Practice (GLP) regulations and other applicable regulations;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an independent institutional review board (IRB) at each clinical site before each trial may be initiated;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.3129166666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with applicable regulations, including the FDA&#x2019;s good clinical practice (GCP) regulations to establish the safety and efficacy of the proposed drug for its proposed indication;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an NDA after completion of all pivotal trials;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#x2019;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA to assess compliance with GCP regulations;</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA advisory committee review, if applicable; and</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before testing any compounds with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies, to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLP requirements. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:6.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page129"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:4.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">metabolism, distribution and excretion, the side effects associated with increasing doses and if possible, to gain early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <p style="margin-left:4.667%;text-indent:-3.623%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The drug is administered to an expanded patient population to further evaluate dosage and clinical efficacy at</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit/risk ratio of the product and provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase 4 trials. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:6.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page130"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected AEs or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Review and Approval Processes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Pediatric Research Equity Act (PREA) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data need to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. Unless otherwise required by regulation, the Pediatric Research Equity Act does not apply to any drug for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s).</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:6.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page131"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the Prescription Drug User Fee Act (PDUFA) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision after it the application is submitted The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often significantly extended by FDA requests for additional information or clarification.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and typically follows the advisory committee&#x2019;s recommendations.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or (an) additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. For example, the FDA may require Phase 4 testing, which involves clinical trials designed to further assess a drug safety and effectiveness, and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also determine that a REMS is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:15.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page132">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drug Designation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2122916666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has a number of programs intended to expedite the development or review of products that meet certain criteria. For example, the FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it is designed to treat a serious condition, and if approved, would provide a significant improvement in the treatment, diagnosis or prevention of a serious condition compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:6.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page133"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the predicted clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required clinical trials, or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor may seek FDA designation of a product candidate as a &#x201c;breakthrough therapy&#x201d; if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes intensive FDA interaction and guidance. If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug. Breakthrough therapy designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, such designations or shortened review periods may not provide a material commercial advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any drug products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page134"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long term stability of the drug product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters, or untitled letters;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical holds on clinical studies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page135"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA-approved labelling.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketing Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (ANDA) or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of non-patent market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other U.S. Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we currently do not have any products on the market, we are and, upon approval and commercialization, will be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. In the United States, such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting, and physician sunshine laws and regulations.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:16.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page136">&#160;</p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal false claims laws, including the False Claims Act, which prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim under the False Claims Act includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. The federal civil False Claims Act can be enforced through private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers in the name of the government. In addition, manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#x2019; marketing of the product for unapproved, and thus non-covered, uses. In addition, a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) also created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page137"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the federal Physician Payments Sunshine Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> exceptions) annually report information related to certain payments or other transfers of value made or distributed to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, certain ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, applicable manufacturers are also required to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse-midwives.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data Privacy and Security</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and regulations implemented thereunder, imposes obligations on &#x201c;covered entities,&#x201d; including certain health care providers, health plans, and health care clearinghouses, and their respective &#x201c;business associates&#x201d; and covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, as well as their covered subcontractors with respect to the privacy, security and transmission of individually identifiable health information. Entities that are found to be in violation of HIPAA, whether as the result of a breach of unsecured PHI, a complaint about privacy practices, or an audit by HHS, may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page138"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, California recently enacted the California</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Consumer Privacy Act (CCPA), which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling certain personal data of consumers or households. The CCPA requires covered businesses to provide new disclosure to consumers about such business&#x2019; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Additionally, a new privacy law, the California Privacy Rights Act (CPRA), was approved by California voters on November 3, 2020. When it goes into effect on January 1, 2023, the CPRA will modify significantly the CCPA, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. Both the CCPA and CPRA could impact our business activities depending on how they are interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also are or will become subject to applicable privacy laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, if we conduct EU-based clinical trials, we will be subject to Regulation (EU) 2016/679, the General Data Protection Regulation (GDPR) in relation to our collection, control, processing and other use of personal data of European data subjects (i.e. data relating to an identifiable living individual). We process personal data in relation to participants in our clinical trials in the European Economic Area (EEA), including the health and medical data of these participants. The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical data), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing activities and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal data is to be used, imposes limitations on retention of personal data; defines pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EU rules with respect to cross-border transfers of personal data out of the EU and EEA; for example, in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield and imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR, and we maintain an office in Switzerland, which has its own set of stringent privacy and data protection laws and regulations. Fines for certain breaches of the GDPR are significant: up to the greater of &#x20ac;20 million or 4% of total global annual turnover. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, or potential civil claims including class action type litigation.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page139"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the United Kingdom (UK)&#x2019;s withdrawal from the EU and the EEA, referred to as Brexit, has created uncertainty with regard to data protection regulation in the UK. Specifically, while the Data Protection Act of 2018, which &#x201c;implements&#x201d; and complements the GDPR achieved Royal Assent on May 23, 2018 and is now effective in the UK, aspects of data protection in the UK, such as the transfer of data from the EEA to the UK, remain uncertain. Following the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into UK law. Beginning</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2021, the UK is now a &#x201c;third country&#x201d; under the GDPR. Pursuant to the EU-UK Trade and Cooperation Agreement of December 24, 2020, transfers of personal data from the EU to the UK may continue to take place without a need for additional safeguards during a further transition period, to expire on (1) the date on which an adequacy decision with respect to the UK is adopted by the EU Commission; or (2) the expiry of four months, which shall be extended by a further two months unless either the EU or the UK objects. It remains unclear whether the EU Commission will adopt an adequacy decision with respect to the UK. In the absence of such decision after the expiry of the additional transition period, companies may need to put in place additional safeguards for transfers of personal data from the EU to the UK, such as standard contractual clauses approved by the EU Commission.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pharmaceutical Coverage, Pricing and Reimbursement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we or our collaborators obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such drug products.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. We or our collaborators may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our product candidates may not be considered medically necessary or cost-effective. Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, one payor&#x2019;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. For gene therapy and other products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.250625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we elect to participate in certain governmental programs, we may be required to participate in discount and rebate programs, which may result in prices for our future products that will likely be lower than the prices we might otherwise obtain. For example, drug manufacturers participating under the Medicaid Drug Rebate Program must pay rebates on prescription drugs to state Medicaid programs.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page140"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare Reform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding and applying new payment methodologies. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively ACA), was enacted, which affected existing government healthcare programs and resulted in the development of new programs.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among the ACA&#x2019;s provisions of importance to the pharmaceutical industry, in addition to those otherwise described above, are the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.3129166666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and a cap on the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP);</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#x2019; outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extension of manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:5.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.17875;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:16.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page141">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1212499999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been executive judicial and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act (the Tax Act) was enacted, which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The case is currently under review by the U.S. Supreme Court but it is unknown when a decision will be reached. Although the Supreme Court has not yet ruled on the constitutionality of the Affordable Care Act, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA or our business.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have also been proposed and adopted in the United States since the Healthcare Reform Act was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. There has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which has resulted in several Congressional inquiries and proposed federal legislation, additional federal regulations, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page142"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#x2019;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the United States Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that these new laws will result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. In addition, it is possible that there will be further legislation or regulation that could harm our business, financial condition, and results of operations. Further, it is possible that additional governmental action is taken in response to the evolving effects of the novel coronavirus-2019 (COVID-19) pandemic. Additionally, health reform initiatives may arise in the future, particularly in light of the new Biden administration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The U.S. Foreign Corrupt Practices Act</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:14.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Europe / Rest of World Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page143"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we or our potential collaborators obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of an application for a clinical trial authorization (CTA) much like the IND prior to the commencement of human clinical trials. In the EU, for example, a CTA must be submitted to each country&#x2019;s national health authority and an application made to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#x2019;s requirements and a favorable ethics committee opinion has been issued, clinical trial development may proceed.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1308333333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The requirements and process governing the conduct of clinical trials are to a significant extent harmonized at the EU level, but could vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. The way clinical trials are conducted in the EU will undergo a major change when the Clinical Trial Regulation (Regulation (EU No 536/2014) comes into application, expected in 2022.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application either under the so-called centralized or national authorization procedures. The application used to file an NDA in the United States is similar to that required in the European Union, but the exact requirements for authorization may vary.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Centralized Procedure. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The centralized procedure provides for the grant of a single marketing authorization by the European</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commission following a favorable opinion by the European Medicines Agency (EMA) that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases, other immune dysfunctions and viral diseases. The centralized procedure is optional for other products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health or which contain a new active substance for indications other than those specified to be compulsory.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2985416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National Authorization Procedures. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are also two other possible routes to authorize medicinal products in several EU</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.2122916666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Decentralized Procedure. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Using the decentralized procedure, an applicant may apply for simultaneous authorizations in more</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within the mandatory scope of the centralized procedure.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:3.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.1835416666666665;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mutual Recognition Procedure. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the mutual recognition procedure, a medicine is first authorized in one EU Member State,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1356249999999999;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The European Union also provides opportunities for market exclusivity. For example, upon receiving marketing authorization, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#x2019;s data to assess a generic or biosimilar application. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#x2019;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European Union&#x2019;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page144"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The EMA grants orphan drug designation to promote the development of products for the treatment, prevention or diagnosis of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU. In addition, orphan drug designation can be granted if the drug is intended for a life threatening or chronically debilitating condition in the EU and without incentives it is unlikely that sales of the drug in the EU would be sufficient to justify the investment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> required to develop the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation provides opportunities for free or reduced-fee protocol assistance, fee reductions for marketing authorization applications and other post-authorization activities and ten years of market exclusivity following drug approval, which can be extended to 12 years if trials are conducted in accordance with an agreed-upon pediatric investigational plan. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, early access mechanisms for innovative medicines (such as compassionate use programs and named patient supplies), pricing and reimbursement, and promotion and advertising, amongst other things, are subject to national regulations and oversight by national competent authorities and therefore significantly vary from country to country.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sanctions for non-compliance with the aforementioned requirements, which may include administrative and criminal penalties, are generally determined and enforced at national level. However, under the EU financial penalties regime, the EMA can investigate and report on alleged breaches of the EU pharmaceutical rules by holders of a marketing authorization for centrally authorized medicinal products and the European Commission could adopt decisions imposing significant financial penalties on infringing marketing authorization holders.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United Kingdom left the European Union on January 31, 2020. Following the transition period which ended on December 31, 2020, Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom in the coming years.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.15pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:10.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated under the laws of the State of Delaware on December 18, 2017. Our principal executive offices are located at 6005 Hidden Valley Road, Suite 110, Carlsbad, California 92011, and our telephone number is (858) 293-4900. Our corporate website address is www.designtx.com. We make available, free of charge on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after filing such reports with the SEC. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K. We have included our website in this Annual Report on Form 10-K solely as an inactive textual reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 38 employees, 37 of whom were full-time, and 16 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. In addition, we also utilize specialized contract research organizations for additional research and development personnel. Together with our employees, our team comprised approximately 88 full-time equivalents as of December 31, 2021.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 1A. Risk Factors.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risks described below, together with the other information contained in this Annual Report on Form 10-K and in our other public filings with the Securities and Exchange Commission (SEC). If any of the following risks actually occur, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an early-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to business planning, organizing and staffing our company, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies for our lead program and our other development programs, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. We have not yet commenced clinical trials for any of our product candidates, and none of our product candidates have been approved for commercial sale or tested in human subjects. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations, including a net loss of $35.5 million and $8.3 million for the years ended December 31, 2021 and 2020, respectively. We expect that it will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates through clinical development. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page32"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates is capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $384.1 million in cash, cash equivalents and investment securities. Based upon our current operating plan, we estimate that our existing cash, cash equivalents and investment securities will be sufficient to fund our operating expenses and capital expenditure requirements for more than the next 12 months. However, we believe that our existing cash, cash equivalents and investment securities will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for any future product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and scope of clinical programs we decide to pursue;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope and costs of manufacturing our future product candidates and commercial manufacturing activities;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the emergence of competing therapies and other adverse market developments;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost, timing and outcome of seeking FDA, EMA and any other regulatory approvals for any future product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms and timing of establishing and maintaining strategic collaborations, licenses and other similar arrangements and the financial terms of such agreements;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with being a public company;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of any milestone and royalty payments to WARF, or other future licensors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our need and ability to retain key management and hire scientific, technical, medical and business personnel;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our implementation of additional internal systems and infrastructure, including operational, financial and management information systems;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or costs associated with expanding our facilities or building out our laboratory space;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the COVID-19 pandemic; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost associated with commercialization activities for any of our future product candidates, if approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we do not expect to generate revenue from product sales for many years, if at all, we will need to obtain substantial additional funding in connection with our continuing operations and expected increases in expenses. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses or other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The impact of the COVID-19 pandemic on capital markets may affect the availability, amount and type of financing available to us in the future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page33"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial revenue from product sales to support our cost structure, we expect to finance our operations through public or private equity offerings, debt financings or other capital sources, which may include strategic collaborations, licensing arrangements or other similar arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, current stockholders will be or could be diluted, and the terms of these</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise funds through strategic collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are early in our development efforts and all of our research programs are still in the preclinical or discovery stage. We have no history of conducting clinical trials to test our product candidates in humans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are early in our development efforts and most of our operations to date have been limited to developing our platform technologies and conducting drug discovery and preclinical studies. We have completed IND-enabling studies for our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> development candidate. We have not yet begun clinical trials for any of our development programs. As a result, we have limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, and cannot be certain that our planned clinical trials will be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the early stage of development of our products candidates, our ability to eventually generate significant revenues from product sales will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of preclinical studies and clinical trials with favorable results;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance of INDs by the FDA or similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receipt of marketing approvals from applicable regulatory authorities, including new drug applications (NDAs), from the FDA and maintaining such approvals;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market acceptance of any of our approved product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining an acceptable safety profile of our products following approval; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining and growing an organization of scientists and business people who can develop our products and technology.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our FA and DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> candidates, as well as our other product candidates, which may never occur. In the future, we may also become dependent on other product candidates that we may develop or acquire; however, given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical and clinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of earlier studies and trials may not be predictive of future trial results. If development of our programs is unsuccessful or delayed, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page34"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the drug development process, including due to factors outside of our control. Success in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical trials, even after promising results in earlier nonclinical studies or clinical trials. These setbacks have been caused by, among other things, nonclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. The results of preclinical, nonclinical and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and initial clinical trials. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience delays in initiating our clinical trials for our product candidates and we cannot be certain that the trials or any other future clinical trials for our product candidates will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure related to:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our planned clinical trials, or the sufficiency of preclinical data to initiate clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the study population for further analysis of the study&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining regulatory approval to commence a trial;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining institutional review board (IRB), approval at each site;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruiting suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">having patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing patient safety concerns that arise during the course of a trial;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing any conflicts with new or existing laws or regulations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adding a sufficient number of clinical trial sites; or</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing sufficient quantities of product candidate for use in clinical trials.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board (DSMB) for such trial or by the FDA or other regulatory authorities (including foreign regulatory authorities comparable to the FDA). Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, conducting clinical trials in foreign countries, as we plan to do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, principal investigators for our planned clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page35"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenue from any of these product candidates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will be delayed or not realized at all. In addition, any delays in completing our planned clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have concentrated our research and development efforts on product candidates using our platform technologies, and our future success depends on the successful development of this approach. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our planned clinical trials or commercializing any products on a timely or profitable basis, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical trial requirements of the FDA, EMA and other comparable foreign regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and biopharmaceutical industries are also rapidly developing, and our competitors may introduce new technologies improving the treatments in the field of expansion repeat driven diseases and small molecules that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we encounter difficulties or delays enrolling patients in our planned clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to initiate or continue our planned clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, competing clinical trials and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patient eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity of patients to study sites;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the design of the trial;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain patient consents; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page36"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our planned clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We plan to conduct clinical trials for our product candidates outside the United States and the FDA may not accept data from such trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to conduct additional clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the clinical trial must be conducted in accordance with Good Clinical Practices (GCP) requirements and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, such clinical trials would be subject to the applicable local laws of the foreign jurisdictions where the clinical trials are conducted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept any such data, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our development plan. In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign regulatory requirements that could burden or limit our ability to conduct our clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with legal requirements applicable to privacy, data protection, information security and other matters;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign taxes, including value-added tax and withholding of payroll taxes;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">administrative burdens of conducting clinical trials under multiple foreign regulatory schema;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign exchange fluctuations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing, customs, shipment and storage requirements;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impact of the COVID-19 pandemic on our ability to produce our product candidates and conduct clinical trials in foreign countries;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential liability under the Foreign Corrupt Practices Act of 1977, as amended (FCPA), or comparable foreign regulations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cultural differences in medical practice and clinical research; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diminished protection of intellectual property in some countries.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page37"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue planned clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt planned clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our future clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace; regulatory authorities may withdraw or change their approvals of that product;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies; we may be required to change the way the product is administered;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused to subjects or patients; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the product may become less competitive, and our reputation may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, topline and preliminary data from our preclinical studies or planned clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page38"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies or planned clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, such data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim, topline,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, interim or topline data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development, research, testing, manufacturing, labeling, approval, selling, import, export, marketing, promotion and distribution of drug products are subject to extensive and evolving regulation by federal, state and local governmental authorities in the United States, principally the FDA, and by foreign regulatory authorities, which regulations differ from country to country. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining regulatory approval of an NDA can be a lengthy, expensive and uncertain process. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. The number of nonclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all indications. The FDA may also require us to conduct additional studies or trials for our product candidates either prior to or post-approval, such as additional drug-drug interaction studies or safety or efficacy studies or trials, or it may object to elements of our clinical development program such as the number of subjects in our clinical trials from the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical testing or abandon a program for many reasons, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or the applicable foreign regulatory agency&#x2019;s disagreement with the design or implementation of our planned clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page39"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement with the interpretation of data from nonclinical studies or clinical trials; our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s requirement for additional nonclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete our planned clinical testing and receive approval of an NDA or foreign marketing application for our product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or in the case of the FDA, the implementation of a Risk Evaluation and Mitigation Strategy (REMS), which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or a narrower patient population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The COVID-19 pandemic could adversely impact our business and affect our operations, as well as the business or operations of our manufacturers or other third parties with whom we conduct business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we have business operations, and could cause significant disruption in the operations of third parties upon whom we rely. In particular, the ongoing COVID-19 pandemic could materially affect our operations, as well as the business or operations of our suppliers, CROs, other contract service providers or other third parties with whom we conduct business. As a result of measures imposed by governments in affected regions, many commercial activities, businesses and schools have been, were, or may again be suspended as part of measures intended to reduce the spread of COVID-19. As the COVID-19 pandemic continues, we may experience disruptions that could severely impact our business and planned clinical trials, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in enrolling and retaining patients in our planned clinical trials, particularly elderly subjects, who are at a higher risk of severe illness or death from COVID-19;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties interpreting data from our clinical trials due to the possible effects of COVID-19 on patients;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruptions, difficulties or delays arising in our existing operations and company culture as a result of some of our employees working remotely, including those hired during the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of healthcare resources away from the conduct of future clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page40"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations in resources that would otherwise be focused on the conduct of our business, our preclinical studies or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed &#x201c;shelter in place&#x201d; or similar working restrictions;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption in global freight and shipping that may affect the transport of clinical trial materials, such as investigational drug product to be used in our clinical trials;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risks relating to potential disruptions of our contracted manufacturing operations as a result of any potential shut downs or other restrictions in operation due to or impact from the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are to be conducted, or to discontinue the clinical trials altogether, or which may result in unexpected costs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to accept data from clinical trials in affected geographies outside of their respective jurisdictions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and actions taken to reduce its spread continue to rapidly evolve. The extent to which the COVID-19 pandemic may continue to impact the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our planned preclinical studies and clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek orphan drug designation for our product candidates from the FDA and/or from the EMA in the future. However, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek orphan drug designation for our product candidates in the future; however, we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and the European Union (EU), may designate drugs for relatively small patient populations as orphan drugs. Under the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#x2019;s Committee for Orphan Medicinal Products may grant orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, provided that the condition is affecting not more than five in 10,000 persons in the EU or if, without incentives, it is unlikely that marketing of the drug in the EU would generate sufficient returns to justify the investment needed to develop the drug, and no satisfactory method of diagnosis, prevention or treatment of the condition exists (or, if such a method exists, the drug must be of significant benefit to patients). There can be no assurance that the FDA or EMA will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page41"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. If a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of orphan drug exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug or biologic for that time period, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same active moiety in a new drug for the same condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of repeat expansion driven diseases, including FA and DM1. Our competitors include larger and better funded pharmaceutical, specialty pharmaceutical and biotechnology companies. Moreover, we may also compete with universities, governmental agencies and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of a number of companies targeting FA including (i) Reata Pharmaceuticals evaluating omaveloxolone, a Nrf2 activator, (ii) PTC Therapeutics evaluating vatiquinone, a 15-lipoxygenase inhibitor, (iii) Retrotope evaluating RT001, a deuterated poly-saturated fatty acid, (iv) Minoryx Therapeutics evaluating leriglitazone, a PPAR-gamma agonist and (vi) Larimar Therapeutics evaluating CTI-1601, a cell penetrating peptide FXN recombinant fusion protein. In addition, several companies are developing AAV-based gene therapies including PTC Therapeutics, Voyager Therapeutics, Lexeo Therapeutics, Pfizer, Novartis, Lacerta Therapeutics, StrideBio, and AavantiBio.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of a number of programs for DM1 including (i) AMO Pharma evaluating tideglusib, a GSK3-&#xdf; inhibitor, (ii) Harmony Biosciences evaluating a histamine 3 receptor for the treatment of excessive daytime sleepiness in DM1, (iii) Avidity Biosciences evaluating an antibody linked siRNA, (iv) Audentes Therapeutics evaluating an AAV-antisense candidate, (v) Dyne Therapeutics evaluating an antibody linked oligonucleotide, an miR-23b antisense candidate, (vi) PepGen evaluating a peptide conjugated antisense oligonucleotide; (vii) gene editing treatments by Vertex Pharmaceuticals, (viii) an RNA-targeting AAV-based gene therapy by Locana, (ix) an AAV-based RNA degrading gene therapy by Enzerna Biosciences, (x) antisense oligonucleotides by NeuBase Therapeutics, (xi) antisense oligonucleotides and siRNA candidates under evaluation by Triplet Therapeutics, (xii) small molecules interacting with RNA under evaluation by Anima Biotech, (xiii) anti-miRNA oligonucleotides under evaluation by Arthex Biotech, (xiv) small molecule modulators of transcription factors under evaluation by Syros Pharmaceuticals, and (xv) small molecules interacting with RNA under evaluation by Expansion Therapeutics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will also compete more generally with other companies developing alternative scientific and technological approaches to modulate individual genes, including other companies working to develop nuclease-based gene editing technologies, such as Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Precision BioSciences and Sangamo Biosciences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page42"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their collaborators, have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the global COVID-19 pandemic, the FDA and regulatory authorities outside the United States have and may adopt restrictions or other policy measures in response to the COVID-19 pandemic that divert resources and delay their attention to any submissions we may make. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to design such product candidates with the properties that we desire; or</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page43">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Manufacturing, Commercialization and Reliance on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may rely on third parties to conduct, supervise, and monitor our planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our preclinical studies, and any future clinical trials of our product candidates. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and planned clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with Good Laboratory Practice (GLP) and GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under current Good Manufacturing Practice (cGMP) regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities, provide services in a timely manner or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of COVID-19, including quarantines and shelter-in-place orders, which have also adversely impacted the supply chain for many research and clinical supplies, including animals for preclinical testing. In addition, demand for CROs and their resources and services has increased in recent years, which has impacted performance timelines. Furthermore, there are shortages in the supply of materials and animal availability for preclinical testing, which are required to conduct preclinical studies. This has led us to experience increased competition for CRO services, including, without limitation, scheduling preclinical studies and delays in study reporting, which could impact development timelines. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We contract with third parties for the manufacturing and supply of our product candidates for use in preclinical testing and planned clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have any manufacturing facilities. We rely on third parties for the manufacture of our product candidates for preclinical and clinical testing. We will continue to rely on such third parties for commercial product manufacture, if any of our product candidates are approved. We currently have limited manufacturing arrangements and expect that each of our product candidates will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page44"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA&#x2019;s cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contract manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not have direct control of the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the COVID-19 pandemic, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third- party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our or a third-party&#x2019;s failure to execute on our manufacturing requirements, or to so execute on commercially reasonable terms and timelines in compliance with cGMP requirements, could adversely affect our business in a number of ways, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to meet our product specifications and quality requirements consistently;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an inability to initiate or continue preclinical studies or clinical trials of our product candidates under development;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of the cooperation of future collaborators;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to cease development or to recall batches of our product candidates; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in methods of product candidate manufacturing may result in additional costs or delays.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page45"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">efficacy and potential advantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer our products for sale at competitive prices;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of coverage and adequate reimbursement from third-party payor programs, and the willingness of patients to pay out of pocket in the absence of such third-party payor coverage and reimbursement;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of marketing and distribution support; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, a third-party payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page46"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new product&#x2019;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(77,81,86,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centers for Medicare &amp; Medicaid Service</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s (CMS) revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we or collaborators may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are focused initially on the development of treatments for nucleotide expansion repeat diseases. Our projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page47"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Factors that may inhibit our efforts to commercialize future products on our own include:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product portfolios; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of this product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page48"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our In-Licenses and Other Strategic Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not realize the benefits of any acquisitions, in-license or strategic alliances that we enter into.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into in-license agreements with multiple licensors and in the future may seek and form strategic alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our existing technologies and product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#x2019;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in-license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, or if there are materially adverse impacts on our or the counterparty&#x2019;s operations resulting from COVID-19, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may, in the future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of those product candidates, including in territories outside the United States or for certain indications. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page49"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may also require specific technologies to work effectively and efficiently, and rights to those technologies may be held by others. We may be unable to in-license any compositions, methods of use, processes or other third party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impairment of our business reputation;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs due to related litigation;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">distraction of management&#x2019;s attention from our primary business;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize our product candidates; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our product candidates, if approved for commercial sale.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims, or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page50"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability as a result of the planned studies and clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conduct substantially all of our operations at our leased laboratory and office space in Carlsbad, California and remotely. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock awards that vest over time. The value to employees of stock awards and restricted stock awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#x201c;key person&#x201d; insurance policies on the lives of these individuals or the lives of any of our employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 38 employees, 37 of whom were full-time. In addition, we also utilize specialized contract research organizations for additional research and development personnel. Together with our employees, our team comprised approximately 88 full-time equivalents as of December 31, 2021. As we advance our research and development programs, we may be required to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, discovery biology, chemistry, product development, general and administrative matters relating to being a public company, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify, recruit integrate, maintain and motivate additional qualified personnel;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">improve our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page51"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Under current law, U.S. federal net operating losses (NOLs), incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely to offset</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> future taxable income, but the deductibility of such U.S. federal NOLs in taxable years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $40.3 million of U.S. federal NOLs and $10.4 million of state NOLs. U.S. federal NOL carryforwards totaling $0.1 million will begin to expire in 2037 unless previously utilized, and U.S. federal NOL carryforwards of $40.2 million generated after 2017 can be carried forward indefinitely under current law but can only be utilized to offset 80% of future taxable income. State NOL carryforwards totaling $10.4 million will begin to expire in 2037, unless previously utilized. As of December 31, 2021, we also had aggregate U.S. federal and state research and development (R&amp;D) credits of approximately $0.9 million and $0.6 million, respectively. U.S. federal R&amp;D credits carryforwards begin to expire in 2038 unless previously utilized. The state R&amp;D credit carryforwards do not expire. Our NOL carryforwards and R&amp;D credits are subject to review and possible adjustment by the U.S. and state tax authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#x201c;ownership change,&#x201d; which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards, R&amp;D credits and certain other tax attributes to offset its post-change income or taxes may be limited. This could limit the amount of NOLs, R&amp;D credit carryforwards or other applicable tax attributes that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs, R&amp;D credits and other applicable tax attributes carried forward may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state NOL carryforwards to offset taxable income in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows. We have completed a Section 382 study to assess whether an ownership change had occurred from our formation through December 31, 2021. Based upon the study, we determined that we experienced multiple ownership changes during 2020, causing the annual utilization of NOLs, R&amp;D credits, and other applicable tax attributes generated before then to be limited. We do not believe any of the NOLs, R&amp;D credits, and other applicable tax attributes generated through December 31, 2021 will expire solely as a result of the limitations caused by these ownership changes. We may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to further limitations, which could potentially result in increased future tax liability to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not currently have any products on the market, our operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page52"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal false claims, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their covered subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the Affordable Care Act), and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by the physicians described above and their immediate family members.</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page53"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2010, the Affordable Care Act was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers. There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act or our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year, which, due to subsequent legislative amendments, including the Infrastructure Investment and Jobs Act, will stay in effect through 2030. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page54"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#x2019;s proposals. As a result, the FDA concurrently released a final rule and guidance in September 2020, providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the United States Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation (MFN) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinds the MFN Model interim final rule. In July 2021, the Biden administration released an executive order, &#34;Promoting Competition in the American Economy,&#34; with multiple provisions aimed at prescription drugs. In response to Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm and other adverse business impacts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, we and our collaborators and third-party providers may process personal data and other sensitive and confidential data, such as proprietary and confidential business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing and personal data by us and on our behalf. In the United States, numerous federal, state, and local laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), govern the collection, use, disclosure and protection of health-related and other personal data and could apply to our operations or the operations of our collaborators and third-party providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">States are also constantly amending existing laws, requiring attention to frequently changing regulatory requirements. For example, the California Consumer Privacy Act of 2018 (CCPA) imposes obligations on businesses to which it applies. These obligations include, without limitation, providing specific disclosures in privacy notices, affording California residents certain rights related to their personal data, and requiring businesses subject to the CCPA to implement certain measures to effectuate California residents' personal data rights. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). In addition, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), effective January 1, 2023, will expand the CCPA. For example, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CCPA (as amended), which could increase the risk of an enforcement action. At this time, we do not believe we are subject to the CCPA, but should we expand our operations in California, the CCPA (and later, the CPRA) will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions. Other states have enacted data privacy laws. For example, Virginia passed its Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and become effective in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union's General Data Protection Regulation (EU GDPR) and the United Kingdom's GDPR (UK GDPR) impose strict requirements for processing the personal data of individuals located, respectively, within the European Economic Area (EEA) and the United Kingdom (UK). For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines up to 20 million euros or 4% of the annual global revenue, whichever is greater. Further, individuals may initiate litigation related to our processing of their personal data.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At this time, we do not believe we are subject to the EU GDPR or the UK GDPR, but should this change, the EU GDPR and the UK GDPR will increase our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place additional mechanisms or change our business practices to ensure compliance with European and other foreign data protection rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to provide an adequate level of personal data protection. The European Commission released a set of &#x201c;Standard Contractual Clauses&#x201d; that are designed to be a valid mechanism by which entities can transfer personal data out of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection.  Currently, these Standard Contractual clauses are a valid mechanism to transfer personal data outside of the EEA.  The Standard Contractual Clauses, however, require parties that rely upon that legal mechanism to comply with additional obligations such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. Moreover, due to potential legal challenges, there exists some uncertainty regarding whether the Standard Contractual Clauses will remain a valid mechanism for personal data transfers out of the EEA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we cannot implement a valid compliance mechanism for cross-border personal data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or elsewhere. Inability to import personal data to the United States may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these obligations, we may incur significant fines, experience a significant increase in costs, or other consequences.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion. These obligations may be subject to differing applications and interpretations, which may be inconsistent among jurisdictions or in conflict.  Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems, and practices and those of any third parties that process personal data on our behalf.  In addition, these obligations may even require us to change to our business model. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third-parties upon whom we rely may fail to comply such obligations that impacts our compliance posture.  If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.  Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely upon a combination of patents, know-how, trade secrets, and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued or provide assurance that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner, including delays as a result of the COVID-19 pandemic impacting our or our licensors&#x2019; operations. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#x201c;off-label.&#x201d; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page56"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party pre-issuance submissions of prior art to the USPTO or our issued patents may be subject to post-grant review (PGR) proceedings, oppositions, derivations, reexaminations, or inter partes review (IPR) proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if and when patents may issue based on our patent applications;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of protection of any patent issuing based on our patent applications;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether the claims of any patent issuing based on our patent applications will provide protection against competitors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether or not third parties will find ways to invalidate or circumvent our patent rights;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries; and/or</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page57"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether, as the COVID-19 pandemic continues to spread around the globe, we may experience patent office interruption or delays to our ability to timely secure patent coverage to our product candidates.</span></div></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#x201c;prior art,&#x201d; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents are of national or regional effect, and although we currently have an issued patent and pending applications in the United States, filing, prosecuting and defending patents on all of our research programs and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These competitor products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Various companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Various countries outside the United States have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner may have limited remedies in certain circumstances, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies, products and product candidates. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time consuming, expensive and unpredictable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page58"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third -party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensor&#x2019;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse, including due to the effect of the COVID-19 pandemic on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page59"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if enforced, a court may not hold that our patents are valid, enforceable and infringed;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may fail to adequately protect and police our trademarks and trade secrets; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these or similar events occur, they could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our technology licensed from various third parties may be subject to retained rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently party to a license agreement with WARF pursuant to which we acquired an exclusive license to certain patents relating to compounds and methods for modulating gene expression, compounds and methods for modulating FA expression and next generation synthetic transcription factors. WARF retains, and our future licensors may also retain, certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page60"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#x201c;nonexclusive, nontransferable, irrevocable, paid-up license&#x201d; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#x201c;march-in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rights.&#x201d; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#x201c;nonexclusive, partially exclusive, or exclusive license&#x201d; to a &#x201c;responsible applicant or applicants.&#x201d; If the patent owner refuses to do so, the government may grant the license itself. We sometimes collaborate with academic institutions to accelerate our preclinical research or development. While it is our policy to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our future licensors or collaboration partners. If any of our future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce, and defend such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our future product candidates that are subject of such licensed rights could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our future licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page61"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to sublicense patents and other rights to third parties;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to transfer or assign the license;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may be required to license technologies relating to our therapeutic research programs from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities, or the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page62"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our future product candidates or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe existing or future third-party patents. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the U.S. can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our research programs, product candidates, their respective methods of use, manufacture and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page63"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. In the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party&#x2019;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page64"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may choose to challenge the enforceability or validity of claims in a third party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#x2019;s patent in patent opposition proceedings in the European Patent Office (EPO), or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are found to infringe a third-party&#x2019;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop non-infringing technology, which may not be possible on a cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#x2019; fees for willful infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors or other third parties may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#x2019;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page65"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may rely on trade secrets and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our product candidate, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a security incident) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page66"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#x2019;s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page67"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The term of a United States patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent. A patent term extension (PTE) based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous PTEs in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Securities Market and Ownership of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may not be sustained, which may make it difficult for you to sell your shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to our initial public offering in March 2021, there had been no public market for our common stock. The trading market for our common stock on The Nasdaq Global Select Market has been limited and an active trading market for our shares may not be sustained. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares at a price that is attractive to you, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The price of our common stock could be subject to volatility related or unrelated to our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price may be volatile. The stock market in general and the market for biotechnology and pharmaceutical companies, in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares at a price that is attractive to you, or at all. The market price for our common stock may be influenced by numerous factors, many of which are beyond our control, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">overall performance of the equity markets;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our operating performance and the performance of other similar companies;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the published opinions and third-party valuations by banking and market analysts;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results from our future clinical trials with our future product candidates or of our competitors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse results or delays in preclinical studies;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page68"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unanticipated serious safety concerns related to the use of our product candidates;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including without limitation the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses related to future product candidates or clinical development programs;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our failure to achieve product development goals in the timeframe we announce;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the economy as a whole and market conditions in our industry;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trading activity by our principal stockholders;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of our market float;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">political uncertainty and/or instability in the United States;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ongoing and future impact of the COVID-19 pandemic and actions taken to slow its spread; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any other factors discussed in this report.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many biopharmaceutical companies. Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of other biopharmaceutical companies have also been highly volatile as a result of the COVID-19 pandemic. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. As a result of their share ownership, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to our 2021 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 5% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase; or (ii) a lesser number of shares determined by our board of directors prior to the applicable January 1st. In addition, our 2021 Employee Stock Purchase Plan (&#34;ESPP&#34;) authorizes the issuance of 600,000 shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year by the lesser of 1% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year and 1,200,000 shares, subject to the ability of our Board of Directors to take action to reduce the size of the increase in any given year. Increases in the number of shares available for future grant or purchase may result in additional dilution, which could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an &#x201c;emerging growth company&#x201d;, and we intend to take advantage of reduced reporting requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page70"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (i) December 31, 2026 (the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering), (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the date upon which we are deemed to be a &#x201c;large accelerated filer&#x201d;, which means we have been subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), for at least 12 months as of December 31st, and the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company listed on the Nasdaq Global Select Market, we incur significant expenses for director and officer insurance, legal services, accounting services and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and the Nasdaq Global Select Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#x201c;say on pay&#x201d; and proxy access. Recent legislation permits smaller &#x201c;emerging growth companies&#x201d; to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to continue to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costlier. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain our current levels of such coverage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we are subject to requirements of the Sarbanes-Oxley Act, the regulations of the Nasdaq Global Select Market, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly and place significant strain on our personnel, systems and resources. Company responsibilities required by the Sarbanes-Oxley Act include, among other things, that we maintain corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. We are also continuing to improve our internal control over financial reporting. In order to develop, maintain, and improve the effectiveness of our internal controls and procedures, and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting could also adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Select Market. We are not currently required to make a formal assessment of the effectiveness of our internal control over financial reporting under the SEC rules that implement Section 404 of the Sarbanes-Oxley Act. As a public company, we will be required to provide an annual management report on the effectiveness of our internal control over financial reporting commencing with our second annual report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page71"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business, results of operations and financial condition and could cause a decline in the trading price of our common stock.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Recent Accounting Pronouncements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act modified certain provisions of the Tax Act. It is also possible that U.S. tax law will be further modified by the Biden administration and Congress by making tax law changes included in proposed legislation (which has not yet been enacted) that could have an adverse effect on our operations, cash flows and results of operations and contribute to overall market volatility. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our internal information technology systems or sensitive data, or those of our third-party CROs or other contractors or consultants, may fail or suffer security incidents, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates' development programs, compromise sensitive data related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store, transmit or otherwise process proprietary, confidential, and sensitive data (including but not limited to intellectual property, proprietary business information and personal data). We also have outsourced elements of our operations to third parties, and as a result we rely on a number of third-party contractors who have access to our proprietary, confidential, and sensitive data. We may share or receive sensitive data with or from third parties. Our ability to monitor these third parties&#x2019; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase.  These threats are becoming increasingly difficult to detect. These threats come from a variety of sources. In addition to traditional computer &#x201c;hackers,&#x201d; threat actors, personnel misconduct or error (such as theft or misuse), sophisticated nation-state and nation-state supported actors now engage in attacks. We may be subject to a variety of evolving threats, including but not limited to social engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), ransomware attacks, supply-chain attacks, software bugs, server malfunction, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fire, flood, and other similar threats. Ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting payments.  Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us and our services.  The COVID-19 pandemic and our remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the previously identified or similar threats could cause a security incident.  A security incident could result in unauthorized, unlawful or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of or access to data. A security incident could disrupt our (and third parties upon whom we rely) ability to provide our products. We may expend significant resources or modify our business activities (including our clinical trial activities) in an effort to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and data.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have implemented measures designed to protect against security incidents, our security measures may in the future not be sufficient to prevent security incidents. We have no control over the security measures of third parties with whom we share or receive sensitive data. We have not always been able in the past and may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems (including our products), our efforts may not be successful.  Further, we may experience, delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements, could lead to adverse impacts. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our products, deter new customers for using our products, and negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters and research facility are located in the county of San Diego, California, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws), prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page73"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> materials by us or the third parties with whom we share our facilities or contract with, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations may also result in substantial fines, penalties or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law (DGCL) may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement for the affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and</span></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.1404166666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as a Delaware corporation, we are subject to Section 203 of the DGCL. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page74"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; and (iv) any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits against us and our directors, officers, and other employees. While the Delaware courts have determined that such choice of forum provisions are facially valid, and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.  If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, both state and federal court, or other jurisdictions which could seriously harm our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We could be subject to securities class action litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If there are substantial sales of shares of our common stock, the market price of our common stock could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page75"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 2. Properties.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We lease approximately 12,370 square feet of laboratory and office space in Carlsbad, California, pursuant to a lease agreement, with a related party, that commenced in September 2021 and expires in August 2027. We believe that this facility will meet our current and near term needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 3. Legal Proceedings.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has been listed on the Nasdaq Global Market under the symbol &#x201c;DSGN&#x201d; since March 25, 2021. Prior to that date, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Common Stock</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 4, 2022, there were 55,700,156 shares of common stock issued and held by approximately 22 stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 25, 2021, we commenced our initial public offering pursuant to a registration statement on Form S-1 (File No. 333-253954) that was declared effective by the SEC on March 25, 2021, for 12,000,000 shares of our common stock for sale to the public at a price of $20.00 per share. In addition, in March 2021, the underwriters exercised their over-allotment option to purchase 1,800,000 additional shares of our common stock in the initial public offering at the public offering price of $20.00 per share, such that the aggregate offering price of our initial public offering was $276.0 million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were $254.3 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates. The underwriters for our initial public offering were Goldman Sachs &amp; Co. LLC, SVB Leerink LLC, and Piper Sandler &amp; Co.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net proceeds from our initial public offering are being held in cash, cash equivalents and investments securities, primarily in money market funds invested in U.S. government agency securities and U.S. treasury securities. These investments are made pursuant to our investment policy and we may further invest these funds in high-quality marketable debt instruments of corporations and government sponsored enterprises with contractual maturity dates of generally less than two years until needed to fund our operations. There has been no material change in the use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on March 26, 2021. As of December 31, 2021, we had used approximately $16.9 million of the net proceeds received from our initial public offering to support our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 6. [Reserved].</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and notes thereto included in &#x201c;Item 8. Financial Statements and Supplementary Data&#x201d; of this Annual Report on Form 10-K. In addition to historical information, this Annual Report contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the caption &#x201c;Item 1A. Risk Factors.&#34;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a preclinical-stage biopharmaceutical company pioneering GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Certain diseases caused by inherited nucleotide repeat expansion, such as Friedreich ataxia (FA), can result in reduced expression of specific mRNAs and deficiency of vital proteins; in other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington disease, the nucleotide repeat expansions result in the generation of toxic gene products, often associated with pathological nuclear foci and broad splicing disruptions. Our GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules are designed to selectively target genetic repeat sequences, modulate gene expression either by dialing up or dialing down mRNA transcription, and restoring cellular health. As a platform, we believe that GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules have broad potential applicability across monogenic nucleotide repeat expansion diseases affecting millions of individuals worldwide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies for our lead program, we have observed restoration of frataxin (FXN) levels in multiple cell types from FA patients and an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> murine model of FA using our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules. At doses that were observed to be well tolerated in rodents and non-human primates, FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules achieved biodistribution to brain and heart, key organs affected by FA, at concentrations that exceeded those observed to restore FXN levels in FA patient cells. Further, and consistent with this favorable target-organ biodistribution, we observed increased endogenous FXN expression in the brain and heart in an animal model of FA after treatment with our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules. Investigational New Drug Application (IND)-enabling studies for our FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">development candidate have been completed in alignment with feedback received from the U.S. Food and Drug Administration (FDA) through a pre-IND meeting and from the European Medicines Agency (EMA) through a scientific advice procedure. In late February 2022, the IND for our lead FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> development candidate was cleared by the FDA. We anticipate a first-in-human dosing in FA patients with our lead FA GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> development candidate in the first half of 2022, with initial topline clinical data expected in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our second program in DM1, multiple DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules elicited robust reduction of nuclear foci and correction of splicing defects in DM1 patient muscle cells. Preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> studies demonstrated distribution of DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">molecules to key target tissues including skeletal muscle and heart, achieving tissue concentrations of intact DM1 GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecule that reduced pathogenic nuclear foci to normal levels in our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experiments. We expect to complete IND-enabling studies and seek regulatory clearance for a first-in-human clinical trial in 2023.</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In an additional research program, we conducted preclinical studies to evaluate the effects of GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules in FECD. When tested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in FECD patient-derived corneal endothelial cells, which contained nuclear foci, our FECD GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules led to robust reductions in toxic nuclear RNA foci and also corrected key mis-spliced transcripts to levels observed in unaffected corneal endothelial cells. We believe this preclinical data support the potential of our novel GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> small molecules to correct the most common underlying genetic cause of FECD, and we plan to advance this research program through additional preclinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have incurred net losses and negative cash flows from operations since our inception and as of December 31, 2021, had an accumulated deficit of $47.5 million. Our net losses have resulted primarily from costs incurred in connection with organizing and staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies, engaging in manufacturing for our development programs, and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our expenses and operating losses will increase substantially for the foreseeable future as we conduct preclinical studies and clinical trials for our product candidates, nominate additional product candidates from our discovery programs, and as we expand our clinical, regulatory, quality and manufacturing capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution, if we obtain marketing approval for any of our product candidates, and incur additional costs associated with operating as a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page24"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have funded our operations primarily through the sale of our common stock, convertible preferred stock, grant revenue and the issuance of convertible notes and debt. In March 2021, we completed our initial public offering in which we sold 13,800,000 shares of our common stock at $20.00 per share and received net proceeds, after underwriting discount and offering costs, of $254.3 million. In January 2021, we issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net proceeds of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> approximately $124.7 million. Our cash, cash equivalents and investment securities balance as of December 31, 2021, was $384.1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Our Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, our research and development expenses have consisted primarily of direct and indirect costs incurred in connection with our discovery efforts, and the preclinical and formulation development of our product candidates. In the future, we expect a substantial portion of our research and development expenses will relate to the clinical development and manufacturing of our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs include:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">external research and development expenses incurred under agreements with contract research organizations, consultants and other vendors that conduct our preclinical and discovery activities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses related to manufacturing our product candidates for preclinical studies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laboratory supplies; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">license fees.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indirect costs include:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses, consisting of employee salaries, payroll taxes, bonuses, benefits and stock-based compensation charges for those individuals involved in research and development efforts; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">facilities expenses which include allocated expenses for amortization of right-of-use assets, depreciation and other overhead expenses, costs for general laboratory consumables and other indirect expenses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A significant portion of our research and development expenses have been direct costs, which we track by stage of development, preclinical or clinical. However, we do not track our internal research and development expenses on a program specific basis, unless specific to research grants, because these costs are deployed across multiple projects and, as such, are not separately classified.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our research and development expenses will substantially increase for the foreseeable future as we continue the development of our FA program, DM1 program and our other discovery programs, in particular as we advance our product candidates into clinical development. As of the date of this Annual Report, we cannot reasonably determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical programs of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future research and development expenses may vary significantly based on a wide variety of factors such as:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and scope, rate of progress, expense and results of our discovery and preclinical development activities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of trials required for approval;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of sites included in the trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the countries in which the trials are conducted;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the length of time required to enroll eligible patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients that participate in the trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of doses that patients receive;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;" id="page25"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the drop-out or discontinuation rates of patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential additional safety monitoring requested by regulatory agencies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration of patient participation in the trials and follow-up;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the phase of development of the product candidate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and safety profile of the product candidate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, receipt, and terms of any approvals from applicable regulatory authorities including FDA and non-U.S. regulators;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant and changing government regulation and regulatory guidance;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the current COVID-19 pandemic environment; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we establish additional strategic collaborations or other arrangements.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates or any future candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates or any future candidates. Further, a number of factors, including those outside of our control, could adversely impact the timing and duration of our product candidates&#x2019; or any future candidates&#x2019; development, which could increase our research and development expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation charges, for personnel in executive and administrative functions. Other significant general and administrative expenses include insurance costs, legal fees relating to intellectual property and corporate matters and professional fees for accounting, tax and consulting services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that our general and administrative expenses will substantially increase in the foreseeable future as we add general and administrative personnel to support our expanded research and development activities and infrastructure and, if any of our product candidates or any future candidates receive marketing approval, commercialization activities, as well as to support our operations generally, including facility-related expenses and patent-related costs. We also expect to incur increased expenses related to accounting, audit, legal, regulatory and tax-related services, director and officer insurance premiums, board of director fees, investor and public relations, and other costs associated with operating as a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our operating expenses for the years ended December 31, 2021 and 2020 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.514%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:11.069%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:11.037%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:11.069%;"></td>
    <td style="width:0.696%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,778</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,060</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,718</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,053</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,496</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,557</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,831</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,556</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,275</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase of $18.7 million in research and development expenses was due primarily to additional expense</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to support the advancement of our FA program, including chemistry and manufacturing development costs, and costs incurred on our DM1 program during the year ended December 31, 2021 which were not incurred in the same period of 2020. Further, we incurred higher personnel and related costs, including non-cash stock-based compensation, during the year ended December 31, 2021 as compared to the same period in 2020, as we expanded the number of research and development employees to support our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses by direct and indirect costs for the year ended December 31, 2021 and 2020 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.51%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:11.071%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:11.039%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:11.071%;"></td>
    <td style="width:0.696%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,683</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,161</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,522</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indirect costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,095</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,899</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,196</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,778</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,060</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,718</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:5.067%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:9.4pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.87%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.87%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In future periods when clinical trial expenses are incurred, external costs will be broken out between our clinical programs and our preclinical programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page27"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase of $8.6 million in general and administrative expenses was due primarily to additional</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel and related costs, including non-cash stock-based compensation, incurred during the year ended December 31, 2021 as compared to the same period in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2020, as we increased the number of general and administrative personnel to support our organization, including our expanded research and development team and public company operations. Further, we incurred increased insurance expense and professional fees for legal and accounting services during the year ended December 31, 2021 as compared to the same period in 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. Since our inception, we have funded our operations primarily through the sale of our common stock, convertible preferred stock, grant income and the issuance of convertible notes and notes payable. In March 2021, we completed our initial public offering in which we sold 13,800,000 shares of our common stock at $20.00 per share and received net proceeds, after underwriting discount and offering costs, of $254.3 million. In January 2021, we issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net proceeds of approximately $124.7 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $298.6 million of cash and cash equivalents, an increase of $296.2 million from the $2.4 million of cash and cash equivalents at December 31, 2020. In addition, we had $85.5 million of available-for-sale investment securities at December 31, 2021, an increase of $51.8 million from the $33.7 million of available-for-sale investment securities held at December 31, 2020. The increase in our cash and cash equivalents balance at of December 31, 2021 was primarily due to the proceeds received from our initial public offering of common stock completed in March 2021 and Series B convertible preferred stock offering completed in January 2021. Further detail of the change in our cash and cash equivalents for the year ended December 31, 2021 and 2020 is summarized below (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.318%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:10.912%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:10.902%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:10.912%;"></td>
    <td style="width:0.91%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash (used in) provided by:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(29,377</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8,669</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(20,708</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(53,644</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(33,561</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(20,083</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">379,211</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,532</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">334,679</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296,190</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,302</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">293,888</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities was $29.4 million and $8.7 million for the year ended December 31, 2021 and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2020, respectively. The increase in our use of cash was primarily due to the $35.5 million net loss we incurred during the year ended December 31, 2021. The net loss was due primarily to the advancement of our research and development programs and higher personnel costs to support these activities and our preparations to become, and operations as, a public company. Partially offsetting the cash impact of our net loss during the 2021 period was an increase in our accounts payable and accrued expense balances and higher non-cash expenses incurred during the period, including $4.2 million of additional non-cash stock-based compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities was $53.6 million and $33.6 million for the year ended December 31, 2021 and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2020, respectively, due primarily to the purchase of investment securities, partially offset by net proceeds received from the maturity of investment securities during the periods presented. We have classified our investments securities as available-for-sale and all investments are made in accordance with our investment policy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities was $379.2 million for the year ended December 31, 2021, primarily from</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the $254.3 million of net proceeds received from our initial public offering in March 2021 and the $124.7 million of net proceeds received from the closing of our Series B convertible preferred stock financing in January 2021. Net cash provided by financing activities during the year ended December 31, 2020 was $44.5 million, primarily from the $44.7 million of net proceeds received from our Series A convertible preferred stock financing during the period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our planned operating expenses and capital expenditure requirements for more than the next 12 months following the date of this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page28"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future capital requirements will depend on many factors, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, rate of progress and costs of our drug discovery, preclinical development activities and clinical trials for any future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and scope of clinical programs we decide to pursue;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope and costs of manufacturing our future product candidates and commercial manufacturing activities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the emergence of competing therapies and other adverse market developments;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost, timing and outcome of seeking FDA, EMA and any other regulatory approvals for any future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms and timing of establishing and maintaining strategic collaborations, licenses and other similar arrangements and the financial terms of such agreements;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with being a public company;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of any milestone and royalty payments to Wisconsin Alumni Research Foundation (WARF), or other future licensors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our need and ability to retain key management and hire scientific, technical, business, and medical personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our implementation of additional internal systems and infrastructure, including operational, financial and management information systems;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with expanding our facilities or building out our laboratory space;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the COVID-19 pandemic; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost associated with commercialization activities for any of our future product candidates, if approved.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial revenues from product sales to support our cost structure, we expect to finance our cash needs through public or private equity offerings, debt financings, or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through strategic collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations, Commitments and Material Cash Requirements</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, we entered into a lease agreement to rent approximately 12,370 square feet of lab and office space with a related party. The delivery date of the space was September 1, 2021, and the lease commenced at that time. The term of the lease is 72 months after commencement with an option to extend the lease term for a period of three years. Annual rent payments will be approximately $0.8 million per year, subject to annual increases of 3%, plus our share of operating expenses and taxes.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2019, we entered into a Human Therapeutics Exclusive License Agreement (License Agreement) with the Wisconsin Alumni Research Foundation (WARF). Under the License Agreement, we licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, we agreed to pay an upfront fee of $250,000, of which we paid $25,000 upon execution of the agreement and the remaining $225,000 upon the closing of our Series A financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the License Agreement, we are required to pay $125,000 upon the acceptance of an investigation new drug (IND) application in the U.S. and will be required to make further aggregate milestone payments of up to $17.5 million upon achievement of certain other regulatory and commercial milestones. We may also be required to pay royalties based on annual net product sales in the low single digits on our or our sublicensees&#x2019; net product sales on a country-by-country and product-by-product basis, and are subject to a minimum royalty of $0.1 million per calendar year upon first commercial product sale. Further, we may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. We have paid no milestone or royalty payments as of December 31, 2021. Further, we are responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. We may terminate the License Agreement with 90 days written notice or for certain breaches of the agreement. WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we enter into agreements in the normal course of business with third-party vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the contractual obligations above, we also expect to have future material cash requirements related to our planned clinical trials, discovery and preclinical programs, personnel and facilities-related expenses, external research and development and product development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to grant revenue and research and development expenses. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies and estimates are described in more detail in Note 2 to our audited financial statements appearing in Part II, Item 8 of this Annual Report on Form 10-K, we believe the following accounting policies and estimates to be most critical to the preparation of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. Since our inception, we have not experienced any material differences between accrued or prepaid costs and actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense represents the grant date fair value of equity awards recognized in the period using the Black-Scholes option pricing model. We recognize the expense for equity awards on a straight-line basis over the requisite service periods of the awards, which is usually the vesting period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimating the fair value of equity awards pursuant to the Black-Scholes option pricing model requires us to make assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in these assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. We determine these assumptions in the following manner:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair market value of the shares of common stock underlying stock options is determined by our board of directors. Following the closing of our IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which our stock is traded. Prior to our IPO, because there was no public market for our common stock, the board of directors considered, among other things, input from management and valuations of our stock prepared by unrelated third-party valuation firms.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term of stock options represents the period of time that the awards are expected to be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">outstanding. Because we do not have sufficient historical exercise behavior, we determine the expected term assumption using the simplified method for our employees and board members, which calculates the expected term as the average time-to-vesting and the contractual life of the award. The expected term for non-employees is generally the contractual term.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given our limited historical stock price volatility data, the expected</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk-free rate assumption is based on the U.S. Treasury yield in effect at the time of the grant</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with maturities consistent with the expected term of the awards.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend yield assumption is based on our history and expectation of dividend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payouts. We have not paid and do not intend to pay dividends and, therefore, used an expected dividend yield of zero.</span></div></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 10 to our financial statements included in this Annual Report on Form 10-K for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, as amended (JOBS Act), and we may remain an emerging growth company until as late as December 31, 2026 (the fiscal year-end following the fifth anniversary of the completion of our initial public offering). For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have at least $1.07 billion in annual revenue; (ii) the date upon which we are deemed to be a &#x201c;large accelerated filer,&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if we have been subject to the reporting requirements of the Exchange Act for at least 12 months as of December 31st and the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the prior three-year period; and (iv) as December 31, 2026 (the last day of the fiscal year ending after the fifth anniversary of our initial public offering).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable to a &#34;smaller reporting company&#34; as defined under Item 10(f)(1) of Regulation S-K of the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 8. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.917%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(PCAOB ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88a963cc-29b2-4cff-b102-b040b651e481" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets as of December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Comprehensive Loss for the Years Ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_convertible"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Stockholders&#x2019; Equity for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors of Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying balance sheets of Design Therapeutics Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations, comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;financial statements&#x2019;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e7ec4c4-9c23-4b1c-929f-9fad29ddc702" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company's auditor since 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52ef1f5c-92c0-4fad-853e-bba5e10ebb87" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Diego, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and par value data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.174%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.031%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.021%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd506e14-d1e1-4c52-ae0e-e358a9dbd223" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298,569</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70e3283a-d333-4ddd-9097-8781d4e5cb9e" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investment securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f72bc35-6e02-47f9-80d5-f8fb3de1a796" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7326d673-a708-4d26-a707-52be60f51c4f" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_650d658d-fac5-4c30-bdc4-64b81412e1c1" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a36c8e5c-689a-467b-a14a-2bd37094370d" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bb01878-8de9-4425-b8a4-4c5b992cd8f5" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">385,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_163d3deb-4a56-4a7b-84c5-a74b690e78f4" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_937ea65f-927a-47fd-a58c-52bb4230d467" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6d6e701-80a7-4255-b155-5064f7ae1f13" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use asset, related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b5efa71-8ff6-4d12-a3cf-83526fd8d084" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07a8355a-6eee-4e4f-a1bb-4dda0f0d1126" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">212</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c46de8f-d4b8-4e29-b0de-c49d384cd014" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">390,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_895ec1ec-ab8c-4b15-923b-4e8f39b082a6" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities, convertible preferred stock and stockholders' equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable (including related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73c83680-7a97-4c20-9fea-cf66445a0c24" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acb1428b-3bac-4cbc-a6f9-1caf267a799a" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf8f5aa3-e711-4b69-8509-6d17ae840078" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,620</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cae552e1-c9d1-4d44-a321-0d63d15edee3" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,399</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities (including related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53106d7b-a5a2-4c15-b9e5-158e4676bc52" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">504</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53761004-209a-49b4-ba2c-4105739fed6b" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_355875ae-b246-48a6-b988-32f25b38cc3e" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,663</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42b27abf-94c0-45f1-8e4a-ce81f4401f0f" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">931</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78b1b56f-f7b3-4c9c-a53c-2fd76b29f85b" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8985ec5-17a1-4e54-99c6-319785c5ae31" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability, net, related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f378686-62e5-4649-8df5-7089e70d8fc9" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6fb45c2-2971-465f-b576-aa79371edd33" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a65a1b4b-5f50-48f3-8eee-93ad7fbf0b52" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,427</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_382135a5-44e5-412c-a0ed-c98f29981768" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3766fda0-030c-4a24-8af2-30d601782126;"><span style="-sec-ix-hidden:F_d29888be-2dc0-4c7f-9efc-f49c43b4b4f3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencies</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(See Note 12)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible preferred stock; $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a660b466-a3fb-4fa6-865e-f347cd81a449" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_c823fd96-96c6-4e34-996a-1407ca8820a0" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7ddc3f2-0e72-4d22-a91b-91f963b7ace4" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d85f89b0-63df-480c-8c55-3ec590253d5e" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9465f9a8-35c4-46e0-a54e-be052a15acd2" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a8fe7971-9811-4471-9111-932a33548f7b" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,012,499</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding at December 31, 2021 and 2020, respectively; liquidation preference of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74acaa12-1af6-4525-9955-0296dc218f6a" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd805609-00b6-4e26-b6e0-2183bc30542a" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,625</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;as of December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_756115ff-93e6-4836-8f9d-1dda34bfa2d4" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders' equity (deficit):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock: $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8019d51d-ebb6-41d9-8d18-a48541164cc1" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_ad6d109b-3e29-41b4-9299-eb0896eb63a2" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d843203b-4645-40f6-870f-d8459e0db4bc" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_323e90b4-9dd2-4dba-b4fa-945edc958a26" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">60,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bd274af-d892-40ff-9bf8-cf8d8d46646a" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,681,752</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8cf8c16-bddc-4643-9673-5b4d57fd4f53" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,604,774</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05cddede-6215-4841-9e3c-248c223f21c3" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,441,926</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_849b8b3c-d8ac-4666-9bdf-95a19a482273" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,957,821</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares outstanding at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd9f2113-ff46-4c8e-9b19-904eecce9dc8" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bdf58be-44e0-4dba-b0fa-fb650d00e141" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6bde8f4-fcb3-4e3c-b334-257e6ec77887" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">429,824</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2876d85a-a4d6-495c-880d-da1ed541e9ef" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b170ad9-2ff2-41b1-8f4a-28320a02b908" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6299a91e-bd41-435a-a2ae-4ec08d4ef2cf" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated other comprehensive (loss) income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7c81a83-6270-40e2-a54b-a4e70b04ce83" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a2b1f64-0d86-417b-b237-48c3881ce2f0" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders' equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c5b3626-55ab-40cb-8cbb-8e35b90e8f6f" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382,130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04d302c5-b47f-4433-8f30-b8fc537988a5" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed42b555-4a1d-4d2f-a2d6-a5eef00f3456" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">390,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3010bad2-c119-4fad-9b09-b4adc55c1033" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.078%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.074%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.074%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9410f438-b0a4-468d-8e34-c1e06402216c;"><span style="-sec-ix-hidden:F_8eb9aa0e-0c36-40ee-b23e-663ded1df873;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue:</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa1d5ad1-aeab-4fb2-baa3-4ee2184e7822" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development (including related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9a28282-74b5-4439-b3aa-b34b88fb6ae8" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">405</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec4ba9e2-86cb-4c17-b989-5aa917ff852d" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00f9f291-7c4b-406d-866c-0aacc24a1d0f" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,778</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eadb7a30-c145-4d06-905b-ab8949047d7b" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,060</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative (including related party amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e68b9735-7f32-4053-b112-c55fb31edd1e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7f0382b-99b7-459f-85c3-c4f4d290226c" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95a2551c-71d3-47a1-be82-b470508b2895" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,053</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80792fc4-95a0-43be-b2e8-df45afc1a72f" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca0ee62a-f825-469a-921c-c84c85b54633" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,831</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_750576df-5f7e-4846-b9bd-770e9384ffbd" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0bc3152-44f8-49e8-8dd4-02cf33496de3" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,831</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55268e8e-a903-4a57-942f-9c0cbcacc20f" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income, net (including related party expense amounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4dc19f75-154e-4e38-bf19-c626fe73cb49" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:InterestExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3134e1c2-8e8c-4279-9810-b1610c7df4a4" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:InterestExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_378cf409-4d8f-4830-907a-abff848d0bea" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81e3e53a-a644-4efb-a3b2-63a5c6cc1490" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c48a93f-9712-4d9c-af90-a7c2b26e4ade" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e85c061-c60b-4af9-9503-13185ff06450" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69f65237-8a58-4804-b2b8-a74d7937411e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.77</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1628a7c3-afeb-418b-a66b-004ce63b87b9" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.52</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3662ad2-a4a6-42e3-a04c-e92dd1f1e28c" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,936,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18fe71e7-89b4-4a99-886c-8f8d419fc11c" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,796,674</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.171%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.029%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.007%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c5baf8e-2319-43f8-83a5-16dc3b7af607" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c64358bb-58ea-47dd-88ba-63d3abd56f5a" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive gain (loss):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain (loss) on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f05c1c9-a4cc-46df-b2f1-3663847166b6" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a35050f-4817-419a-8275-532a8e459a80" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e916e824-18b8-4470-a75e-a73e79eade82" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_044d0558-793f-4997-bcac-d617f27ddbaa" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_convertible"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands, except share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.235%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:7.919%;"></td>
    <td style="width:0.564%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.842%;"></td>
    <td style="width:7.479%;"></td>
    <td style="width:0.564%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:8.066%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.842%;"></td>
    <td style="width:7.633%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.842%;"></td>
    <td style="width:7.641%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.842%;"></td>
    <td style="width:7.487%;"></td>
    <td style="width:0.564%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.842%;"></td>
    <td style="width:7.479%;"></td>
    <td style="width:0.564%;"></td>
    <td style="width:0.958%;"></td>
    <td style="width:0.842%;"></td>
    <td style="width:7.479%;"></td>
    <td style="width:0.564%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Convertible</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Paid-in</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_810f7e2f-e7c1-4a70-82e7-e58a3979747c" contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,012,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bfb8cda-0f8f-47e6-8606-34fa9e593c5e" contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c3c2d99-f92a-4eef-b98b-9173f0268fe4" contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,957,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b94bf31a-4b3b-4bdd-be5e-df5c523a55da" contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cd1004d-6de4-45d9-8fdd-d7176e4d6e9b" contextRef="C_5be4210b-787b-4a2c-b72e-d5904d02b928" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9240ff5-fecc-46f1-8915-0148c0a6510e" contextRef="C_49bf2e28-2c6c-4abb-9852-7ee433b3f111" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b092964-8b18-4e04-a92f-f59259b879ee" contextRef="C_c09976ce-b915-44ea-8211-24da15127f68" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08b7bd59-121c-409d-9ba7-03a2e68cc78a" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of Series B convertible preferred stock, net of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fdb1d39-043c-4f09-82d3-5068feaea7df" contextRef="C_282e8527-291e-424c-a603-4afa6b760575" name="dsgn:PreferredStockIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2032c2a0-fb48-4ae0-886f-454c649e860f" contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28" name="dsgn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,083,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b77e6ca8-dc9f-413e-a2c2-68187ef98f33" contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Preferred stock converted into shares of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_113a91c1-96cf-4de3-b55b-d52fa7b5f149" contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28" name="dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">41,096,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36620c41-8390-48ab-9d20-76301587cfac" contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28" name="dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">170,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b87f696e-6787-461d-bad8-dc8681c7f874" contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,212,548</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1df743d-17dc-406c-946a-4f258211dc44" contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0865104-de8d-44cb-a661-99949bc703d8" contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d1fe862-db56-4f0e-b8bb-d569789925c8" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Initial public offering of common shares, net of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5eadc46-5eac-4a55-ae38-b44fcb863d80" contextRef="C_739e698e-899f-4485-a5c7-f66bb6dba318" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,728</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de63fc9c-390d-4717-8cdb-efea710d5c11" contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,800,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92d130a3-1184-44fe-8dde-dacf58fcd8d9" contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a2dfa95-5286-4e26-8ae4-34ff682d8254" contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,270</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_543f8085-7866-494e-b87e-aa0bfc4fc7ed" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,271</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercises of stock options and vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a64ec175-7846-40fd-9827-b460f96844c9" contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf" name="dsgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">460,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e250d3f-66f9-4b5b-a50d-2d27945c825e" contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267" name="dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eec41015-ce54-4134-a17d-d6ee91dc2f67" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_457a6f89-cd75-4b99-a6bd-84cd3ae058fb" contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46057354-7820-42ea-91c3-3febb0dfda24" contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9956b55-e8e5-497b-904e-2282450fc06f" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_620046e2-f8f3-4163-8ac7-c3a072ca3344" contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e321593f-0a99-46e9-b395-e02d7255314b" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unrealized loss on investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4db4178d-d600-4735-ba1b-75f1cb8793ff" contextRef="C_a1ae00c5-b57c-4e18-abdc-e3e4662306cd" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e27decf-687c-467b-872d-3f699ca5fbc4" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d2da285-9726-4a9e-94bf-954958b9aa2f" contextRef="C_12ca6ede-1a4e-486f-8641-bc776ecea308" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e9a1a3a-4616-4233-b379-a28e1c2b8972" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95b68278-7982-47fa-926c-e2b9b203e74b" contextRef="C_47968354-2359-475e-914a-8809063a760d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,441,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab628b99-ff01-436e-95f8-c4cc95294ee1" contextRef="C_47968354-2359-475e-914a-8809063a760d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_260b6b09-cf44-413a-ab2a-4ee0ca464fca" contextRef="C_a15b425b-80dd-485a-b5d2-c580a8a02edd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">429,824</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1c59ca5-0791-457a-a0bd-475b9ba203e9" contextRef="C_d3f0e0a2-5f92-4f5f-9fe8-1fa2972d3c03" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7aa80c5-00b4-4283-af46-4c9d6c4b3784" contextRef="C_3a36c38a-b117-4fef-bcd2-79b07818ea4b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_862e347b-1bc7-49f9-bdf5-349470377bba" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382,130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc93e652-b898-40c2-a2d9-a26febe8ffd5" contextRef="C_e5f8e035-e6a8-4686-b8f6-c1728d5e5e54" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,640,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3c76477-8397-4e49-bbc9-cc31e2518330" contextRef="C_e5f8e035-e6a8-4686-b8f6-c1728d5e5e54" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddf216e3-1b69-4eb1-a230-8d75d893c29b" contextRef="C_8d82638c-fea7-4745-93a8-e904a42ccc5f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac3a631c-ada6-489b-ac3c-7b84d115c8a1" contextRef="C_becd129a-dfa1-4804-9129-b0961e120502" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,642</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of Series A convertible preferred stock, net of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6baab98a-10e8-4638-88d6-253359d42202" contextRef="C_a6a447c5-4988-4641-a3e9-2f97b674e8b8" name="dsgn:PreferredStockIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48c4f985-20c0-4302-aff5-4048003470e4" contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36" name="dsgn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,710,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19387536-f95d-49e9-aca0-f8cb44b29366" contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of convertible debt and interest to Series A convertible preferred stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd95612e-ec0e-4468-b260-e52c270b73e6" contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36" name="dsgn:TemporaryEquityConversionOfConvertibleDebtAndInterestShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">301,685</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43583120-7640-4a8b-97d0-fc36e4c21611" contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36" name="dsgn:TemporaryEquityConversionOfConvertibleDebtAndInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Settlement of bifurcated conversion liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f5bd65c-c3e2-4427-843d-5b1cc675a21a" contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36" name="dsgn:TemporaryEquitySettlementOfBifurcatedConversion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c11f9e36-4ceb-4dd1-afbe-1dd764b2ebf4" contextRef="C_d8276263-937d-404b-888a-9dfa8d1471b6" name="dsgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">317,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5ec39cb-343d-4743-a5ad-ab41fe7713a0" contextRef="C_fee07a1a-85a2-4821-989e-e63acca8aebf" name="dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd7667b5-9cc8-4509-93c4-f029baa42dee" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1901503b-003f-4e95-92e1-576ae878ab17" contextRef="C_fee07a1a-85a2-4821-989e-e63acca8aebf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd17e155-1cda-4c8c-bb5f-a3d768861760" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unrealized gain on investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06db0697-a07f-4bef-a632-0973ee0d94cc" contextRef="C_e20f6e02-a6f1-4121-b27f-17a4335d6c9a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42ade89b-0ecb-4d08-a187-6e7c874d21b4" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f896cda-f70d-400c-b03c-b82f8498bdb2" contextRef="C_c1e0e40d-fa42-4566-b632-bece748465d2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_954efa5c-00c3-4c4b-ac96-87f08688f7e5" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4103548e-1ec0-4a5e-bd3d-b84231b8af89" contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,012,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95644428-a3df-4c53-aef9-b14c19983728" contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5202d1e1-e23c-4f40-bf98-0304b360dc88" contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,957,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d158691e-759c-4a42-8ca9-109c9e7d5a48" contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a7be20a-dd99-45f4-b60f-0b88b003996f" contextRef="C_5be4210b-787b-4a2c-b72e-d5904d02b928" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d01df858-d79c-4e7c-9ed7-26a4b41fc2d2" contextRef="C_49bf2e28-2c6c-4abb-9852-7ee433b3f111" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29f993b6-542a-450f-9a9f-7fd7fa7e8bdf" contextRef="C_c09976ce-b915-44ea-8211-24da15127f68" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_771d209f-e18c-4c13-a78c-c19e39a47b03" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.188%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.019%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.019%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b76b2b0-9370-4fd4-a2c1-84b4b401b505" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7097deaf-6cc4-4f77-8f68-f1de3f045405" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reconciliation of net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0795fa8-42c7-48d0-b5b8-a25565e1c502" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eec7c464-ba3e-48f4-b27e-87e808e34c09" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f04a2052-98bf-43ba-af16-235e330c31a3" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c24a907-c018-47f1-bf0e-7080c204bacf" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization of premiums on investment securities, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddec45ff-45e9-49f8-8041-2296863c5d6e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b4390e1-4976-42ea-984a-6792a253a873" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e089d3c-8ac5-4c74-8f2e-18b61aeb1f35" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash interest expense&#x2014;related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3305949b-4e7a-4ab9-9c2a-a193ee30eb8f" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:PaidInKindInterestRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net change in operating lease right-of-use assets and liabilities&#x2014;related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bfacac9-f6a1-4339-80b9-33fcdaf968fb" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expense and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41175b99-0a1e-4168-8f02-a2cc0db79aad" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f81e8ee-9d6c-4ca2-9148-2a839751a7d2" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53cdf55c-67c1-4ebf-84ee-951790afb626" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7975fbf3-1ee6-4a91-a719-0e04ebaf94a4" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb8bf2be-3b7e-4202-a6b9-5ab708bc18c6" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,430</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable and other liabilities&#x2014;related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1be6a4b-a609-4109-a687-0e7d62a5846c" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a58d6ff-dba4-4187-82af-dffce409e367" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,843</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98cfde59-d0cb-4068-b48a-ac7fce2d1a3a" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31b07224-9ac5-443e-a488-3a9c052a1d65" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a810200-8620-4268-87ed-ea71480790f4" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of investment securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1db64dfc-df84-4e57-b605-9c41347ac775" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c40f32b-7a0c-4149-be40-b89c8b2b0ba3" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,589</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from maturities of investment securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3de16cb6-e1f2-4236-bc6d-63b2af1b9f86" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e65e8ce4-bcf4-4f9a-bc79-155f2c8b757e" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ab8c9ca-7ecc-48f3-a87a-9cf0b2390ccf" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0dfe310b-4d19-490a-b48f-a56fc2077472" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9b8bcaf-f7e7-42d6-8d19-7a4a30eaebdd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1715b5ea-d9b2-4f2c-882e-bd42d28ff5c0" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">33,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from initial public offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44e03129-2ec6-46dd-86c3-021064aee87e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,271</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of convertible preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fea1584c-d5ff-4613-9ec8-53c56210e1e4" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f91f9a0-5a5c-4f4e-9a61-e3f1ae813f13" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock through employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edaacb41-a222-4e80-8089-9b5378ae9272" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:IssueOfCommonStockThroughEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from the exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c97894b3-aa02-47b4-b7c9-e7b497e64ec9" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4caee059-ce51-4244-88b2-a21eadd4fd35" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from the issuance of notes payable, net of issuance costs&#x2014;related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_890d5cba-c35c-4e43-9d09-c8fbb59015ce" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:ProceedsFromNotesPayableRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Repayment of notes payable&#x2014;related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cc4a61a-c739-45d0-b36a-c115c40a66bf" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:RepaymentsOfNotesPayableRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21300d07-f51b-49cd-9993-c5d5df6de32e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">379,211</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83f84bd2-64fb-48b1-a2dc-ac18fe9bbded" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8a36d11-7595-40b6-a896-d872fe5dae22" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db39c1fa-4874-4c6d-a891-aa4e7042f9ad" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e15327a-23ca-45b3-92f9-e5e8d4dfee74" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3961cc14-4427-477c-81d2-124e6c11e3eb" contextRef="C_becd129a-dfa1-4804-9129-b0961e120502" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38af2967-172d-44c1-a7f1-6c18eca8a9a7" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298,569</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8843dd3-8274-4871-8551-4651444e8f9a" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosures</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial recognition of operating lease right-of-use asset and operating lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_900b1b29-38ab-4ab5-9a68-aa1108c947dd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,786</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of property and equipment included in accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df61290b-6d1e-4c33-9619-80d75d17eb21" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d9f7594-516c-4569-bb75-9e48f4ad5b10" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a425a15-4ee9-4988-b283-7eb910a6b4ab" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:ConversionOfStockAmountConvertedRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest paid</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a6b8f83-25e3-4bfc-bfa0-6d01b3a20e55" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> to Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b943836-bd61-4bcb-ac24-dc2979cf319d" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_0b943836-bd61-4bcb-ac24-dc2979cf319d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Business</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a preclinical-stage biopharmaceutical company pioneering GeneTAC</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, which are a novel class of small-molecule gene targeted chimera therapeutics that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The Company&#x2019;s lead product candidate is in Friedreich ataxia (&#x201c;FA&#x201d;), its second GeneTAC&#153; program is in myotonic dystrophy type-1 (&#x201c;DM1&#x201d;), and it is also advancing its GeneTAC</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> portfolio to address other serious nucleotide repeat-driven monogenic diseases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Splits</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_beda5436-af98-4afb-ba8a-fc82e28eb71e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockholdersEquityNoteStockSplit"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_746aeccf-2a0f-422e-b7a0-df4f0e2faaad" contextRef="C_042f9541-36bc-42b0-97cd-cb54c6a99af9" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" decimals="0" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2732d54e-a401-44e3-bead-a6e9b337741a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-1.63</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company completed its IPO selling </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9032b882-d44c-4dfa-ab6e-6b117ec5e127" contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,800,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares its common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27e42bd2-e168-41ee-ab9e-ec5e86ba6269" contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">20.00</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Proceeds from the Company&#x2019;s IPO, net of underwriting discounts and commissions and other offering costs, were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a82d8770-3c57-4f58-be61-84303ebd9e44" contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">254.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In connection with the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec2e8d33-608e-4364-8a8b-f852d8ff2018" contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40" name="dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">41,096,478</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding at the time of the IPO converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2353583-5aa7-4065-b79a-8a93899654e1" contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,212,548</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred net operating losses since inception </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9048cb5-19f3-448f-a6fc-73f0093dbbc6" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">47.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021. The Company had cash, cash equivalents and investment securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e8dab43-d056-4d5c-8e00-22dbeff118b9" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">384.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021, and has not generated positive cash flows from operations.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_0b943836-bd61-4bcb-ac24-dc2979cf319d_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management expects</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to incur net losses for the foreseeable future. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the preclinical manufacturing, and clinical development activities as well as the commercialization of the Company&#x2019;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s currently available cash and cash equivalents as of December 31, 2021 are sufficient to meet its anticipated cash requirements for more than the 12 months following the date the financial statements are issued</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bcdbed0-e1be-4d5e-a6fb-4361ce2eb52e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9330000-91f8-4f08-a74b-e009e7d8a543" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Use of Estimates</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company&#x2019;s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the novel coronavirus-2019 (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8910ce59-e251-4a10-9e0f-e47eeef30f26" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bee56cb4-87d2-4335-bc0f-986bf4caaef3" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54e8b798-5629-4557-b76d-504eeb854269" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company&#x2019;s cash reserves are in a readily available checking account.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36c0026e-022a-4d54-971d-cd0cf72046cd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment Securities</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#x2019;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a718f8fe-5a78-4280-b521-07ee2c43eda9" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d91553c5-6eee-4258-bcc3-c4d3014546f4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2e77e6c-be40-4a0c-9285-a4a70f54fae4" contextRef="C_7549669b-7c92-4c29-aee8-52f0528f3361" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c710d499-fd5c-4fe7-bcad-8ef0ad5b13ce" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_641dad0f-921c-4936-b5d8-c840721a477a" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized any impairment losses for the years ended December 31, 2021 and 2020.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5423e391-5beb-42d9-972d-b43822be42af" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_5423e391-5beb-42d9-972d-b43822be42af_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use (&#34;ROU&#34;) lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#34;Short-Term Leases&#34;). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99895f2c-0e15-4328-ac56-9ac214fbed94" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:ShortTermLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_51b6f541-83d5-43a7-9472-e23ef4e251d9" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="dsgn:ShortTermLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Short-Term Leases as of December 31, 2021 or 2020.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_5423e391-5beb-42d9-972d-b43822be42af_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59f6b42e-871d-4ac4-9bd9-20f230981207" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_59f6b42e-871d-4ac4-9bd9-20f230981207_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p></ix:nonNumeric></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_59f6b42e-871d-4ac4-9bd9-20f230981207_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9d5cee9-c450-4759-b85d-f0e0bf21ddce" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:PatentCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8abde2e-9a10-450e-ba70-7f0eb6b55866" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options and restricted stock issued pursuant to the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) and 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), and option features associated with the rights to purchase shares pursuant to the Company&#x2019;s 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) are valued using the Black-Scholes option pricing model on the date of grant or subscription period.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07020100-8d02-4526-9872-38fe55a2ae31" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43f7e26d-2014-4db4-adb8-6dee4957ab17" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Net Loss Per Share</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company&#x2019;s equity incentive plans, employee stock purchase rights under the Company&#x2019;s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1dfb1fa-a523-4676-996b-f7d20e8262f3" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.128%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.243%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.264%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d277da92-1931-462c-8817-d4dcf49da66b" contextRef="C_e64fcb9b-97f6-4f5a-8c64-d72962809b07" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,504,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69fbab04-5347-4b54-b731-494490e71410" contextRef="C_b235a097-5256-4f3d-babe-7ba3bf8a8a84" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,673,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fa8d656-c981-4862-b1c2-63310c225b82" contextRef="C_657d72a9-16e6-4deb-b551-33c0ee8f5b08" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,601,214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares subject to repurchase</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23d63db0-4888-4cc8-9bd2-0c90989897a5" contextRef="C_1f4f9bba-1873-40dd-acf5-dfd66ac8e7ed" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">239,826</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0f59d5f-b2ec-4c4b-bda8-4d0dec08f380" contextRef="C_f1a7a6a9-b9f1-40a5-a2c9-a03c5b0e9341" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">646,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_966eeffe-99b4-4554-b30f-54a4cfbcb951" contextRef="C_1fd32ca6-5a40-41dd-91d1-a988442615a6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,833</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bd28e94-6497-4fd1-ba4c-60111765c753" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,917,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b5c21cd-81e5-491e-a22c-2886b1803834" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,752,765</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88ae6100-0630-437b-b5a0-5cf101ffb1fd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value Measurements</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1:      Observable inputs such as quoted prices in active markets.</span></p><p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2:      Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3:      Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying value of the Company&#x2019;s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company&#x2019;s investment securities, which may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17e097d0-b9c8-43c4-ab42-52111299462f" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the Company&#x2019;s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.909%;"></td>
        <td style="width:1.509%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.437%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.509%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.437%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.509%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.448%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.509%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.512%;"></td>
        <td style="width:0.685%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurement at End of Period Using:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">In Active</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Markets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identical</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Observable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8591deac-b3bc-4899-ba20-23abcc90f02a" contextRef="C_c9a6f234-a01b-49c4-8389-6f43a1314b9a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ad86294-c9d8-47e2-b057-d94ee4aee2dd" contextRef="C_7ba72a79-9de9-4033-985b-e7cd791153cb" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e1ddfda-1523-4ea8-98c7-c676c6600d37" contextRef="C_96982224-ada7-45f0-9919-ba9faeecebb9" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41e3695b-22ce-4e2c-b4d2-d56253cd7e2c" contextRef="C_f03e432b-566b-43cb-b18b-e5b052b1516e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c9a158a-b64a-467c-8dbf-b10eaf32639a" contextRef="C_5088ab17-fa76-49bb-8424-af699c2d83d2" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae84182f-31a6-42fc-ac4d-2c5720bcab09" contextRef="C_9ab3d3b5-491d-45f2-a868-850168297a7c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6042de5e-ef51-4ef3-bdce-a0945a9a3be4" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">383,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fd1e93f-ba55-47d7-b7bf-24bd2f3f6734" contextRef="C_7057dd8f-e87d-4239-a296-2ff88e03ec38" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">383,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1986354b-3278-49ab-94d0-16530a30bd90" contextRef="C_77d31faf-435b-4663-a7b9-4b732dae06e0" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0487b05-d919-4fd8-adc2-52f5aa2fe932" contextRef="C_6dcbb219-b6bd-4861-9162-652b899dc080" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ece7233b-0977-4251-a254-9d192b60b015" contextRef="C_9a94ee29-3474-461c-b2a3-c3b16772709a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62a90721-9cb9-4f02-a746-92cdc47ef6f0" contextRef="C_d8bc6058-3ed3-45cd-b9ce-e674b84d8a7b" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63ab7eb8-eabc-4021-84db-caf36f65cde6" contextRef="C_4b6ab41b-f147-4c0f-b46b-e581e1586d79" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89aa9edd-2697-4c7e-9c5a-ef9022475456" contextRef="C_0cefbf23-2388-4ecd-bce3-6b76279a6cea" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5aed5a97-05af-428a-838f-f67b5be71acc" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_710fd928-9e7e-4589-ad7d-3969fbf70056" contextRef="C_d6936001-b46e-472b-a199-2074ec0ad35f" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:4.667%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.87%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.059454753338299%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in cash and cash equivalents on the accompanying balance sheets.</span></div></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_77a5efc2-b183-4897-9159-a9b4ab48fe17" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Investment Securities</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company&#x2019;s investment policy, it has invested funds in marketable securities. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a8b738b-1980-4cfa-99e1-5d7c8bfe0cdc" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true" continuedAt="F_1a8b738b-1980-4cfa-99e1-5d7c8bfe0cdc_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_1a8b738b-1980-4cfa-99e1-5d7c8bfe0cdc_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:20.987%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:15.486%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:7.149%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:2.119%;"></td>
        <td style="width:7.663%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.092%;"></td>
        <td style="width:0.92%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.274%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.274%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92ac92ec-d1f0-4ec9-9ee9-96d7d481f0c6" contextRef="C_2440876e-d785-4ff7-be3a-fa21b9bbf1e3" name="dsgn:DebtSecuritiesAvailableForSaleMaturity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80ecacf2-2c91-4b15-bafd-bc153f8d5615" contextRef="C_3ededf68-d7fc-475f-9e79-3e3146f1d833" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,896</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02341e97-92be-4579-8a04-bd089291e13f" contextRef="C_3ededf68-d7fc-475f-9e79-3e3146f1d833" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df0b7e93-bd79-4bfc-9558-2edf45146471" contextRef="C_3ededf68-d7fc-475f-9e79-3e3146f1d833" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,893</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_643a213c-26b7-4ac6-ba43-24db53767fc9" contextRef="C_131e1c23-bf72-466e-b780-eecada87c188" name="dsgn:DebtSecuritiesAvailableForSaleMaturity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7370a553-c60b-4d2c-8396-7bd5dfbf84c5" contextRef="C_4d411dff-54c7-4585-9301-d3241ffd63f4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,045</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d33b925b-add4-49c1-950b-9bc7a33ba7bc" contextRef="C_4d411dff-54c7-4585-9301-d3241ffd63f4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b32b92a9-f347-45dd-8cb8-04aa8db02632" contextRef="C_4d411dff-54c7-4585-9301-d3241ffd63f4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7394f639-03d3-4d5b-970e-c5f54b075d99" contextRef="C_abbec031-d382-4477-bfc5-49894a1ef5e2" name="dsgn:DebtSecuritiesAvailableForSaleMaturity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dc3d523-8039-465f-b3d1-9d092507d565" contextRef="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b21a1638-1373-443b-9036-5e9698647db4" contextRef="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_147ea8f0-8b85-480c-993e-e99750ba083e" contextRef="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,878</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc46edf0-2847-4e85-8f68-50206a7a965f" contextRef="C_31e5c9e1-0fcc-4298-b3fa-26eb6e19e3b3" name="dsgn:DebtSecuritiesAvailableForSaleMaturity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b04b6475-348e-4896-853f-bfe9e87e1c04" contextRef="C_820b96e4-02c7-43b6-87e0-576d13934c30" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_825c5edc-6775-4088-b186-bdaf3248f164" contextRef="C_820b96e4-02c7-43b6-87e0-576d13934c30" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_201a470f-232c-4327-96e9-daf3e343b1d7" contextRef="C_820b96e4-02c7-43b6-87e0-576d13934c30" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,702</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7333ba1c-2faa-4ff5-b53a-fb128cceaa19" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,739</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68d1826f-3116-4753-a562-071cdf41130e" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af871fb6-c235-416c-9ccf-ed7c226aacd6" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a48599d-ccec-47c7-a1ad-84c46ad43576" contextRef="C_6b4db5f7-9e3b-456b-ab29-20209e77bc6d" name="dsgn:DebtSecuritiesAvailableForSaleMaturity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be4a8ed4-8e5d-477d-ad4d-4f71140a08f0" contextRef="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_416917ae-c4b6-46a8-918c-72c417334f21" contextRef="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af6544ab-53eb-4761-8745-941535bc3b65" contextRef="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8494452e-b509-4480-899c-43ed0c5c65cb" contextRef="C_3f8296e2-19aa-4c9e-977c-4e9998334dc4" name="dsgn:DebtSecuritiesAvailableForSaleMaturity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a8e9240-5a35-447c-b94d-6f45b4ec9ffe" contextRef="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ad854f8-815e-44c6-b422-792daf58cc2e" contextRef="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1443445-d0f2-42a4-b4cc-ae1d4f6167c2" contextRef="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe8c3fa4-d656-4878-b293-05e9f23722b7" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f101c0e5-767e-4c4f-90e5-b7280e540703" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4280be25-5970-45aa-b760-2afda4432f2c" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,712</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer&#x2019;s industry, any significant deterioration in economic condition and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021 there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d785951-5e48-4c4c-ac34-8c24f6a5e9ce" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:numdotdecimal">38</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities in an unrealized loss position, all of which had been in an unrealized loss position for less than 12 months. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the Company did not record a reserve for credit losses. At December 31, 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ac82719-2da3-4e6c-acc5-bf27a40009d5" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities in an unrealized loss position.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company held </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a99ccc2-b5b6-47d4-8783-884eb0e101bf" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:NumberOfDomesticCertificatesOfDepositHeld" unitRef="U_Security" decimals="INF" format="ixt:numdotdecimal">24</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company&#x2019;s balance sheets, was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd8713c2-b96a-437f-8505-eff73b1fe879" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and less than</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0b5d0ff-4a2e-4e4d-87ce-ae75a2641aa6" contextRef="C_62eaea31-a124-426a-bd6e-5a5adb4841c0" name="dsgn:AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38f89229-8e4f-4ee9-8956-fdb91cde4faa" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Balance Sheet Details</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f11c9ddc-f518-4bd0-bcad-ffe19e73d3a3" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.293%;"></td>
        <td style="width:1.446%;"></td>
        <td style="width:1.403%;"></td>
        <td style="width:17.475%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.446%;"></td>
        <td style="width:1.403%;"></td>
        <td style="width:16.79%;"></td>
        <td style="width:0.717%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d5a8e72-10b8-4dab-a854-d04961c54521" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0deefa58-90a1-4a61-a033-5f125b4d9b0f" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security deposits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d498f2af-e725-4b98-bdee-ba3eecbb162c" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DepositsAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96df9c41-036e-47fd-8749-058e2b3907c7" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8956dc0-48b0-477d-b6b8-5f9e4234751c" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88002a4a-56a0-48eb-bd8b-110240fe2215" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdf7281d-ffb3-4405-9977-ef4fcc3dd9dd" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e627ac03-d904-4e5d-8951-36301fe318f5" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8489ec1a-5b0c-4505-80f3-1aa518254bcc" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17953abe-edba-4a65-92fd-cbd090f5dec4" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:13.029%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:13.029%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_575cbc14-257c-47be-af58-44c6142ad6c0" contextRef="C_ac754ff9-5df8-4082-9e89-559e3f5b5c9e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3c34007-1fd3-4c98-8af5-8fe9b665c271" contextRef="C_da562d4c-497b-43eb-a87c-c6f98abf5d24" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c57db2c-0c96-4178-badd-3b22d01f35c1" contextRef="C_18532e58-312b-467e-b271-29e361b67f10" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e4b1d4e-ba62-4814-8c79-74257a4f7cf7" contextRef="C_21b23571-1ef3-47c0-814f-61628e84218b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26e2c1c3-ba63-4fc4-a558-5d45c1f77b84" contextRef="C_57ffc353-e260-4275-bc08-e6bb76dc5b0c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97491f30-c8b0-4520-b285-0a35a0c6ba6c" contextRef="C_e79952f3-cdf9-465a-86f5-17818dc1a21a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a1a7793-86fd-4400-a751-f8ee2833d77a" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,642</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00b5f768-87f3-45da-891d-4b942bc4d95e" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27f35620-fc2e-4a3f-8d32-dc48d130fc61" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cafd81d2-6655-486a-b9b5-77dcf9c15a18" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4a5c1d0-87d8-4b94-ba48-2a8d54ed28a9" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,508</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ce1ac71-5037-44bb-ac48-fe1343c80f16" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d626aed4-67e5-488e-8c05-d8b69f25108d" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.293%;"></td>
        <td style="width:1.446%;"></td>
        <td style="width:1.403%;"></td>
        <td style="width:17.475%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.446%;"></td>
        <td style="width:1.403%;"></td>
        <td style="width:16.79%;"></td>
        <td style="width:0.717%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued personnel costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5305454-3311-4f99-96c4-7eace5dc9bc1" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d946ec55-2707-4887-92f7-f9286fe743a8" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_afc11dd0-62f2-410c-90f1-78811e108cc5" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">516</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39860c3d-5465-40f9-aae8-e1f0910ed5e0" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="dsgn:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c34c0616-00d0-4274-a21f-927f363c9ade;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of operating lease liability, related party</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da158c5a-1250-44ce-9a71-93599e6cf03c" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">489</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c78e94e-7df4-4e7b-89fc-18ce396c78d3" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31dd61bf-3de4-4fac-b9e3-f47a1dbfeb44" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b221246-592c-4330-8cb1-39556a5eaf10" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de747a2f-2e42-4c2b-a14a-6d6959d51c4b" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">931</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad03aec1-2714-44b8-aa27-79ba57fa670c" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Lease</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company&#x2019;s balance sheets. The Company terminated the agreement in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54c49995-e994-4aae-a92c-6bf4531a4c81" contextRef="C_bf5d2e5b-41f1-419b-8853-434297531657" name="dsgn:LeaseAgreementTerminationDate" format="ixt:datemonthyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2021</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95971a2e-b323-457b-a65f-c0f977a216fb" contextRef="C_2b058460-a53f-45fa-81f1-ff866fb0af2c" name="dsgn:AreaOfLeasedProperty" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">12,370</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of laboratory and office space (the &#x201c;Lease&#x201d;). The Company&#x2019;s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d26c173d-c361-4b09-a153-f2d28db5bd60" contextRef="C_adc93247-3f34-454d-be75-6d57971dea64" name="dsgn:LeaseCommencementDate" format="ixt:datemonthyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2021</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9713b025-71d9-4be8-b5c2-d6c052fc0145" contextRef="C_2b058460-a53f-45fa-81f1-ff866fb0af2c" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months and an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06bac0d0-eab5-4d48-8cff-e04a4af7aaac" contextRef="C_6afdf50d-8689-4ede-8f30-41e7b459c71a" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the lease term for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63c873f2-4a17-426b-976e-c387ca4a1276" contextRef="C_adc93247-3f34-454d-be75-6d57971dea64" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33dafec4-e7e4-4628-b30d-8366fd7f1fa2" contextRef="C_adc93247-3f34-454d-be75-6d57971dea64" name="dsgn:LesseeOperatingLeaseTermOfExpirationYear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and thus, the incremental term was excluded from the calculation of the ROU asset, related party and lease liability, related party. The lease includes variable non-lease components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset, related party and operating lease liability, related party and are reflected as an expense in the period incurred. Lease payments are subject to annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cc4e5fb-e99a-438a-90dd-4057129ac62b" contextRef="C_2b058460-a53f-45fa-81f1-ff866fb0af2c" name="dsgn:PercentageOfAnnualIncreaseInLeasePayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of December 31, 2021, the remaining lease term for the lease was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac8a76df-89d6-4f11-b50e-a7a02d3e01af" contextRef="C_59741c86-fa48-4f2f-87fc-b83b830a5544" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dda8950-7b71-4e13-95c0-6656d62d2685" contextRef="C_59741c86-fa48-4f2f-87fc-b83b830a5544" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.15</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e2c4e26-30a2-426b-815a-08f6c7760175" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.809%;"></td>
        <td style="width:1.934%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:15.972%;"></td>
        <td style="width:0.914%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e8fe042-fcd4-4829-ac7f-782be7716512" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">733</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aee864db-5ea5-45ca-b3bc-b110117a7656" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">755</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_643ba8b5-92bc-4eaa-bf12-490999413da0" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">778</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f74a5f9-d19c-46f6-8fd1-87e40fefbb9c" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e9ad746-9401-4149-bd79-b657772b4894" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1818dd5c-e074-40f0-9fea-b3b7da3664c3" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_718b32cb-8614-4d87-902e-af44da850004" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Present value adjustment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ed04e62-0a12-4fac-b592-cf85e526f236" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, related party</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb217515-89b0-446c-8482-c79b412a2306" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense for the years </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b93a5d42-fc6a-4c1f-b625-b8d2558fed51" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85f190b6-96bc-41fb-821c-57bee94cb3d7" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b622e29-a4e7-40af-bf1d-575476890b8d" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:GrantRevenueTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Grant Revenue</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company&#x2019;s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db8dfb1f-e846-4087-b35d-95064a779ec8" contextRef="C_ceb7f97d-7cb8-4a60-a79b-931a4f103fde" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of grant revenue from awards by the NSF, NIH and FARA, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_431f2cc0-cf60-4fde-8c35-a707b95d281d" contextRef="C_2a9265ec-0c2d-4f31-9eaf-7d31f601c7b3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> grant revenue was recognized for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7eaa4d31-33f4-4bf4-a6f0-bced6247ff80" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Convertible Preferred Stock and Stockholders&#x2019; Deficit</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Authorized Shares</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the completion of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in March 2021, the Company amended its Certificate of Incorporation to authorize </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0224fdc4-96b9-4c32-bc0b-d208dc51c485" contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98ead21e-7d63-42a2-bf95-dbeec58e2d12" contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d31cad9-4959-4a0e-953f-9898ab3d5cac" contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eda19eab-89d9-4656-8928-a24a7a7bafa4" contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Preferred Stock</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February and March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28d4e46e-9fd4-4abb-a141-7be8d4e7d1fd" contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6f35e9eb-2c56-457f-867d-c6f4205eeb8c" contextRef="C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,710,814</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f9b46f5-9200-498c-b585-1d2f14b66981" contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_fab69d2e-4fe4-4809-9d29-a18882921713" contextRef="C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">2.0727</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net cash proceeds of $ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aff6d55d-ceff-49d0-93c5-f84d3ad7cd00" contextRef="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_94379abc-8287-4d2e-b91e-35ede4b621ee" contextRef="C_4402b367-1f4a-4644-931e-244097e7a86c" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">44.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the &#x201c;Series A Financing&#x201d;). In connection with the Series A Financing, the Company issued an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36ae4704-1aca-4f02-bb1e-19c55c24ffec" contextRef="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">301,685</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3960acd8-3864-4109-956f-6cdaa6fc25d6" contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">1.65816</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_608df127-135a-4c1a-bf8e-90f4bdc4cef5" contextRef="C_09862e22-6777-4916-b800-571e5b594613" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,083,979</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_075ca653-62cf-4aac-89d2-f0a44da96446" contextRef="C_09862e22-6777-4916-b800-571e5b594613" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">6.55</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net cash proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f908d42e-78f0-4211-ac70-b4970317b35a" contextRef="C_8b5211fb-3823-4218-9a5e-36b1f275768a" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">124.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All shares of convertible preferred stock outstanding at the Company&#x2019;s IPO were converted into shares of the Company&#x2019;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shares Subject to Repurchase</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6a341b3-1f64-4060-ad8d-0b6878f70803" contextRef="C_86c855a7-1404-41b9-9ec4-470ab3dffc2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient&#x2019;s service is terminated either voluntarily or involuntarily prior to vesting.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65059fc9-634c-47fd-bab7-56c86298570d" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#x2019;s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company&#x2019;s balance sheets, is as follows (in thousands, except share data):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.267%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:13.575%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.029%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bd4c646-6d2a-41c2-ae14-3239af1b3eff" contextRef="C_499263cc-6cef-4ede-8c9f-5058ea40a149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">811,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f131e066-ad6c-4784-9006-34767c81ee20" contextRef="C_becd129a-dfa1-4804-9129-b0961e120502" name="dsgn:UnvestedStockLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares early exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94166f5d-4ffc-40fd-969b-74d51d229626" contextRef="C_7ea42364-2fcb-4648-b148-742ec5e08d38" name="dsgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">153,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bdbc818-a24d-4152-80e5-09a1401940d1" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:SharesEarlyExercisedUnvestedStockLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c58e0ded-2d60-49bc-b92d-817d35313337" contextRef="C_7ea42364-2fcb-4648-b148-742ec5e08d38" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">317,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b410f598-a62b-45aa-af4f-970f36bfe4c7" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:UnvestedStockLiabilityVestedSharesValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8c1dac4-b8a2-4a31-90b9-3be1057ac142" contextRef="C_1f1efe30-75a7-4daa-a934-18cf07b4b011" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">646,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53e08ee7-aece-4041-87d4-ee8d82dc7e88" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="dsgn:UnvestedStockLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a55baa70-1cc1-41fb-8aca-82744fca949c" contextRef="C_d5d4f8dd-7c17-4eaa-a38e-dcd85d00e072" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">407,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e5139a5-0690-4834-8d7e-fdb4f4ecde76" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:UnvestedStockLiabilityVestedSharesValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f438eb9-1921-4882-a031-9d196f9264d4" contextRef="C_cdef21de-d669-4832-a95e-55c903160e95" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">239,826</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac10e98d-35e7-4927-b91c-1f35c22fab69" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:UnvestedStockLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9104a84-241f-4645-a216-db59b984c546" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Incentive Award Plans</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company&#x2019;s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company&#x2019;s IPO. Upon adoption of the 2021 Plan, the Company restricted future grants from its 2018 Plan.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company&#x2019;s affiliates. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe2eb2fc-6659-45b1-9a97-a6ebc81b141b" contextRef="C_b5eca583-41b5-4449-b248-84c59b8416b8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,118,648</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ab9f15e-e527-484b-9943-893f248aeabb" contextRef="C_56d217f5-b263-4e46-bd7d-f0d3f3f291ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">881,352</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fd1832a-78fb-49b9-8b18-50d42285cb56" contextRef="C_8c915edc-7f15-44b7-bcb1-f158561e7fcb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,079,984</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for grant under the 2021 Plan. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7f10cd5-8b9e-43a5-9250-f70ab4e1a34f" contextRef="C_015c050e-1f5a-4b49-8849-0dccea408c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company&#x2019;s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company&#x2019;s board of directors.</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2022, the number of shares available for future issuance was increased by</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81a086e9-9adf-4e6a-8b45-3e6461e1dd09" contextRef="C_bb312aa6-c50b-415c-b819-f0af73e2941e" name="dsgn:CommonStockCapitalSharesReservedForFutureIssuanceIncreased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,784,087</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares so that the total available for future issuance as of January 1, 2022 was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d0ec1f7-2090-4e73-a0d7-337e7d33d9cc" contextRef="C_bb312aa6-c50b-415c-b819-f0af73e2941e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,864,071</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5740885a-664c-4312-b03d-b2653953f9a8" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.77%;"></td>
        <td style="width:1.199%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:9.423%;"></td>
        <td style="width:0.846%;"></td>
        <td style="width:1.199%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:9.562%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:1.199%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:9.594%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:1.199%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:9.573%;"></td>
        <td style="width:0.61%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options and</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9147b20e-d455-49ad-a1ac-230ee97f4010" contextRef="C_becd129a-dfa1-4804-9129-b0961e120502" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77299161-e034-4a90-abcb-79f25c6ca98b" contextRef="C_becd129a-dfa1-4804-9129-b0961e120502" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56c41b5f-19a8-4224-a2b2-8ef9a8e9b1f3" contextRef="C_82824a3c-b613-4fb2-b25d-e5297dacef2a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.95</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a597ca5b-d166-4b01-86b4-0a4f64aa14ec" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,723,913</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bd5e202-ff86-4591-9c34-24ab9695001f" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d626bb79-9186-4d34-858a-82f042125324" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">153,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48d4cfcd-4fcb-4e3c-ab00-27f3913aa428" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Canceled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58e0a0a3-ea48-48fb-bc85-4175b08343af" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,601,214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b223032-ec24-4a82-985b-aabab84371c9" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f2236ad-ca1f-4c21-a26e-59d9a82c2a87" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.71</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb7ff5da-c7bf-45e5-8743-f7c1b8bb5e72" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,468</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c42320c6-8fbc-4b4c-a0fb-8b79b175b40b" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,439,444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2cd9944-9bcd-48ad-ae4c-3bd005593da4" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5e44d93-b0c1-42da-93d5-0a4203720c1f" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">52,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36d1f138-4550-45ad-bebb-8bb84614e58a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Canceled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43c1d302-701d-4cff-9619-13fac04b0fbc" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">313,909</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1381c743-f30a-4d4c-9f95-78cc5cfb6a8f" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8e0581c-c4e4-4370-9c00-1ecb2a4705b9" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,673,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f93731fc-78f9-426b-b703-38e474e0a518" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7d7f91f-a93f-452b-88e2-954427031952" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.12</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_812aaf6c-970a-4218-a6c4-23afb0c2b0ef" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_953a29da-46b8-45c1-b004-e5dcea690270" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,673,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bf13d41-80e1-4993-927d-69f6ae7edbf7" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40cdcf20-447c-4253-ad3d-d3d45cf71d08" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.12</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eae9078d-ca4e-4b6e-a224-9e7bcd3c2698" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65a7bb91-6eed-4705-a541-a31833ea0b58" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">949,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37bc49fd-e4e6-4395-bb4f-78a3375db826" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3b17838-82f5-4bd1-bb0a-e420069ab643" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.78</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7af1467-993f-4211-887d-51e36bf566a2" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,159</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value per share of options granted was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e95ec1bb-566b-4fd6-a719-877557a1dac8" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.39</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edf7fc26-fa19-4773-94b4-1e29e03734d3" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the years ended December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ce698b9-a039-4fb7-b552-b0e4c4e381dd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_883f6cad-abc8-447f-9cf4-9db8dfc077cc" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the years ended December 31, 2021 and 2020, respectively, and the cash received from options exercised was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_625960c4-e763-45bf-ac09-c12cd68c7b5c" contextRef="C_7549669b-7c92-4c29-aee8-52f0528f3361" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91278feb-7da9-41c9-a0b3-84691db1e127" contextRef="C_ee89e80b-865a-4125-bcb4-76c8de099850" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f22e980-6589-4e8e-a06e-0008b34fcedd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.91%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:12.441%;"></td>
        <td style="width:2.313%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:12.441%;"></td>
        <td style="width:2.313%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e164b1c-a002-4db6-8f2d-ba9e8235dca6" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54911982-bb5d-4c72-a598-eb2cec51ce64" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30043019-91a1-4023-98cc-239c1e9cd645" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.07</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04c7fdd8-1ab8-4308-9f95-6efbd748a155" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.32</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2125b465-f817-4ddd-ba73-a457a396c35a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_448208b5-31f5-4e30-ac85-fca054170bfb" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">72.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d14fca6b-295c-4111-b4f7-c464e7328229" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a48d9c91-5e2b-4519-a8b0-3547422cd1fe" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4045241-5f06-4c01-ae6e-3d3319a53516" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81485228-7d21-4996-a9ed-a13642735947" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the assumptions used in the option pricing model in the following manner:</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;The grant date fair market value of the shares of common stock underlying stock options is determined</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> by the Company&#x2019;s board of directors. Following the closing of the Company&#x2019;s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#x2019;s common stock is traded. Prior to the Company&#x2019;s IPO, because there was no public market for the Company&#x2019;s common stock, the board of directors considered, among other things, input from management and valuations of the Company's stock prepared by unrelated third-party valuation firms.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;The expected term of stock options represents the period of time that the awards are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected term assumption using the simplified method for employees and board members, which calculates the expected term as the average time-to-vesting and the contractual life of the award. The expected term for non-employees is generally the contractual term.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Given the Company's limited historical stock price volatility data, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;The risk-free rate assumption is based on the U.S. Treasury yield in effect at the time of the grant with maturities consistent with the expected term of the awards.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;The expected dividend yield assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends and, therefore, used an expected dividend yield of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db76c867-4276-4e52-be6c-c77de6817b0e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company&#x2019;s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company&#x2019;s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e725a736-4708-467f-8c05-269a42ab42db" contextRef="C_cbc31665-46ff-4282-846e-3ddb64f5b097" name="dsgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7db60e20-261e-4e61-a490-4f1b34e7f184" contextRef="C_cbc31665-46ff-4282-846e-3ddb64f5b097" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7dd0eaf9-558f-4241-838b-af1e95a40c0a" contextRef="C_9488ce8f-cd96-43ae-b83d-da01a404b062" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">600,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the ESPP. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_995fdfd4-dde8-4b1a-aec2-1883e85848e1" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company&#x2019;s common stock on the last day of the calendar month before the date of each automatic increase and (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da9d8732-005e-4008-a322-23f80b34c5c9" contextRef="C_9488ce8f-cd96-43ae-b83d-da01a404b062" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2022, the number of shares available for issuance was increased by</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_998b5a1b-8632-4a65-b9a9-42b789254c9e" contextRef="C_68c8fb76-ffb2-47b9-87e5-28f51b3c5784" name="dsgn:CommonStockCapitalSharesReservedForFutureIssuanceIncreased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">556,817</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares so that the total available for future issuance as of January 1, 2022 was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75a8c36a-cdb9-41e9-922a-13612a6ef753" contextRef="C_68c8fb76-ffb2-47b9-87e5-28f51b3c5784" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,145,361</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b653ea41-1bc8-4298-bfdd-be88f281f5b2" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,456</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company's common stock under the ESPP and had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6475dfa4-7760-4a5d-8c0d-bc3f5dd8d263" contextRef="C_769dba12-3ef2-4dad-a5b3-89361f92718a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">588,544</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df7b945a-b0fd-4910-872e-298bbb5661df" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.593%;"></td>
        <td style="width:1.927%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:15.46%;"></td>
        <td style="width:2.313%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a91137ba-6435-49ad-8e22-0ddb2d85f6f8" contextRef="C_769dba12-3ef2-4dad-a5b3-89361f92718a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78cbc5b7-a41f-417f-a348-66107247345c" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.41</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b1adc51-4220-459e-a020-b61746ec0163" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">69.26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd8cafc2-6e00-4459-babc-05225456b2ce" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60b68059-6728-409d-b06b-7aabd76d88f1" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1529cc20-8e5e-48f7-a7eb-197c6506c544" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.256%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.178%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b40722c-22eb-4ab8-840f-ea0fc7650782" contextRef="C_020e7d21-1fc1-4579-8491-b965545b2a40" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62a2e7d7-facd-4c6e-b96e-2deabff5f071" contextRef="C_36df1b56-bdb0-4695-b7cf-d0ea73632dc9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b7e7427-6995-4254-955d-8ff7b1c71b76" contextRef="C_72018646-7064-41a5-8f10-73e8aed069e2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,862</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09bc2d08-7d2e-4bd5-a096-8bd174018ed9" contextRef="C_1d9cb435-50cf-426c-b2e6-da460c39afdd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75755734-2355-424b-8e4a-048550ba7642" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,689</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0e74e62-ee54-443f-8bc2-c95e5bca9bee" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, unrecognized compensation expense related to unvested stock option awards was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1106cfc4-88f5-4f6c-a71c-2b681094694c" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is expected to be recognized in expense over a weighted-average period of</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68e7ac45-a5e6-4038-b11b-91888e27aafd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 3.2 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years. As of December 31, 2021, unrecognized compensation expense related to ESPP rights was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f917ec48-8a27-4ed1-ba55-4743d378ea87" contextRef="C_769dba12-3ef2-4dad-a5b3-89361f92718a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which is expected to be recognized over a remaining period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d6aa96b-738f-4a8a-88d8-b393fe79ef02" contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d695c758-b884-4dda-9156-2b6671bc307e" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Income Taxes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#x2019;s tax years are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters as tax expense. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36f87556-8934-4450-9c1d-1165996b9d87" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_317f1e2f-5fe6-4ff6-ba3f-decf8d5c8ce1" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest or penalties related to income tax matters on its balance sheets at December 31, 2021 or 2020. and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a921876-fb9f-4071-9452-f503010f56f1" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0b08e927-82f7-4bf9-97bb-f0c5c35b4aae" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized interest or penalties in its statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020, respectively. Further, the Company is not currently under examination by any federal, state or local tax authority.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, the Company had federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c8a3409-91dd-45c0-ba58-1aedeab46847" contextRef="C_78c5be72-50bc-4838-96f2-7c678294bfdc" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">d $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ce31981-d83b-40cb-ac39-b4e91c8c3bbb" contextRef="C_5482b53a-c0c0-483d-8704-340e59957e38" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, r</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">espectively. Federal NOL carryforwards totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b69800f-c2bb-42fc-9dcc-27742729f155" contextRef="C_78c5be72-50bc-4838-96f2-7c678294bfdc" name="dsgn:OperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">egin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fad4d07-e571-4ebb-8e33-8d12effde003" contextRef="C_49187fc6-8a7a-4911-8230-ce5034a3dd6a" name="dsgn:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless previously utilized, and federal NOL carryforwards of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e275ad3f-58d3-45b6-9645-3b2bdba7b40a" contextRef="C_78c5be72-50bc-4838-96f2-7c678294bfdc" name="dsgn:OperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enerated after 2017, may be carryforward indefinitely but can only be utilized to offset </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3cbbfc4-d037-4949-93f4-c5873e96568d" contextRef="C_49187fc6-8a7a-4911-8230-ce5034a3dd6a" name="dsgn:NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of future taxable income. State NOL carryforwards totalin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">g $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f01433e4-98c8-4201-ac2d-3388f3580988" contextRef="C_5482b53a-c0c0-483d-8704-340e59957e38" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">gin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3daa9fdc-4a55-45e7-afe6-59c1434ff81e" contextRef="C_896a557d-321b-4604-a274-4b73f428a91c" name="dsgn:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless previously utilized. In addition, the Company also has federal and state research and development (&#x201c;R&amp;D&#x201d;) credit carryforwards totali</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ng $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfb98371-3381-49b3-9589-2ffd57a3a793" contextRef="C_cf1f9868-ad02-4973-bb86-f39dc0bbe2a1" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41efc33b-9c18-4b9c-9f23-4faca5e5ad31" contextRef="C_9aecf3c2-6ec0-470e-aed3-32e15d8ee9b5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> respectively. The federal R&amp;D credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2117049-7d35-4ce4-8494-6e8ee4b71646" contextRef="C_a798c222-0494-49e9-979f-72203726b20d" name="dsgn:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2038</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless previously utilized. The state R&amp;D credit carryforwards do not expire.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the Company&#x2019;s NOL and R&amp;D credit carryforwards may be subject to substantial annual limitations in the event a cumulative ownership change has occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;). In general, an &#x201c;ownership change,&#x201d; as defined by Section 382 of the Code, results from a transaction, or series of transactions over a three-year period, resulting in an ownership change of more than 50% of the outstanding common stock of a company by certain stockholders or public groups. Such an ownership change may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a study to assess whether an ownership change had occurred from the Company's formation through December 31, 2021. Based upon the study, the Company determined that it had experienced multiple ownership</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes during 2020, causing the annual utilization of the NOL and credit carryforwards to be limited. The Company does not believe any of the NOL and credit carryforwards generated through December 31, 2021 would expire solely as a result of annual limitations on the utilization of those attributes. If ownership changes occur in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e38d358-4544-422e-a47b-54abdad61c48" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.174%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.031%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.021%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_380fb8ca-dfbb-454c-8848-536f5ff8d270" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,171</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef21ee63-1f61-4165-b289-bb95ec48177d" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,836</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9027b4c-d960-4e99-b371-9e59d0b7de64" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf841be1-c433-4492-a8a8-0a0476d054c5" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ab4f94e-5f36-4ed1-9135-eb1e1b8381a8" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61fe326c-25e1-4d6b-9383-ab8e650ec15a" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eca4e59b-fa73-40ed-b4f1-91dfae525532" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad0afe23-e46a-45a5-ab74-8180755bbb4e" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c3334aa-0ace-492c-b01f-10c6c0ff5205" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">196</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b784fc6b-eca1-40c5-9a2a-98a9bb8ddef4" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c47d60aa-0049-419b-9ed0-7347834bd0fd" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a481b039-81a4-4621-8d39-615dd27e673b" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7025d946-c89a-46dd-bf61-bc2524aa0368" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89ed6cb8-2f00-445d-b6f4-67f35aa792b6" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_108fc504-b1af-4bf2-8e54-6afaaf7fb5e2" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2a39264-2b52-4fa5-8b38-b9fcc08afa23" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="dsgn:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83071427-d0a5-4952-8880-2a31f76b02c3" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54559ee5-36aa-4f64-89ae-77cf7ff3bb2a" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fbfebfe-eabf-4222-a1df-fa1bf6f40dab" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a3844f6-7c2b-4a94-ae49-1ba79a4f0e43" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.024%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.192%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.01%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8745621d-2719-45a6-bbfc-b82a08537209" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,451</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b553835b-a6a3-42ff-9965-70a6521a733a" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_876eec40-4cd6-4e60-b067-1b9956290e77" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a80eeb3-7706-4b4e-a825-f3ada0394c7c" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">552</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Debt financing</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39682274-c1c6-49ff-973a-fa31a582b4cd" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="dsgn:IncomeTaxReconciliationDebtFinancing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f68b143-9e3f-423e-a709-95c52f6b2661" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">836</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4b4d96c-4fcd-4064-8c74-3098448e29a5" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_215ae69b-ddfe-4a23-a49e-b01f854ab1ca" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22a5045c-cec3-4832-9dd4-34b470a1f899" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a13fd96-2a73-4424-90db-28e856398840" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc07b326-a731-47c5-8941-f84e0afb3825" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next twelve months. Further, due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the effective tax rate.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_198bfa5d-c9c0-444b-ae8f-4b0817c9d37a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.192%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.221%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.221%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at beginning of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cecdffca-874c-4f96-b9a4-6332e255921b" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc60edf2-b665-44cf-8516-9e1215a56dca" contextRef="C_becd129a-dfa1-4804-9129-b0961e120502" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0e87aba-db4f-4d96-9929-a5594f458f3a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7fa4b44-a0cb-4638-9b60-69ec1a7d53c5" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b35b5fa-cc18-404f-af7c-af9c7060168d" contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at end of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96e7119e-54e0-4499-aa90-3cdabd1d65cf" contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">418</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98ae1324-a874-44fd-9cc7-ead3252eea7a" contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b9296f9-cafb-498f-bafb-2ff00b8939b1" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Notes Payable-Related Party</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company issued an unsecured promissory note to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe48586e-1b21-4f84-97c0-bba9a4d060e3" contextRef="C_a397402b-f716-41a7-8341-71ec3bbe5ef6" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to a co-founder (the &#x201c;January Note&#x201d;) for working capital. The January Note bore interest at prime plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f90df369-d7d3-4d8e-9c08-369d2fc239e5" contextRef="C_f35bda8e-4477-4e3d-91b7-eb0cd103d909" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, was scheduled to mature </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c4baff1-3969-4c1d-8465-a1f44201b0b9" contextRef="C_faf87937-2b9d-462a-a2e3-6532a2a5832f" name="us-gaap:DebtInstrumentMaturityDateDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or before January 30, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and included a final payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9910c029-7a68-45c2-abbe-844f4bc7109e" contextRef="C_255b9a96-4942-438d-9182-67188791643f" name="dsgn:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f7462aa-45cc-402e-bc7a-40a42feef362" contextRef="C_a3d50d4d-9539-4c43-8867-5bbaabbcbf1e" name="us-gaap:UnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the January Note with interest payable at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a79cc86-d34e-4cd9-8a28-ab735370c715" contextRef="C_fb933540-a365-4b43-a477-40ec4114592f" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6f557aff-12a0-4eeb-8721-02382387fbd1" contextRef="C_c609f5a0-ad87-42d1-88bd-8814d48c2007" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">10</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.1</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2019, the Company issued an unsecured promissory note to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b854ac9f-6a80-4535-9eaf-4e636692c3e8" contextRef="C_a91e7f27-4f86-4dc5-b77c-9a9ed9b2d61c" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to a co-founder (the &#x201c;November Note&#x201d;) for working capital. The November Note bore interest at prime plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d4c5e43-3fd8-4901-9cb9-492d1b6bdcdc" contextRef="C_d3ac15fe-44bb-4b93-b43f-a4b8bb8f3178" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and matured </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_604c1d7d-8814-4b15-b8fc-6ec35a013cbd" contextRef="C_979df7a7-b6e0-451a-8eb9-bb3bdb83d3f8" name="us-gaap:DebtInstrumentMaturityDateDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or before January 1, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and included a final payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbdaea25-14e7-4fa4-abfd-f5aae5cabfaf" contextRef="C_395fdd7c-d463-4675-9795-d06cc0e2ea3c" name="dsgn:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e2d6e34-2302-4d43-b8c6-3d7f71b2974f" contextRef="C_4808721b-298d-4f46-a8a8-371b01e8767d" name="us-gaap:UnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the November Note with interest payable at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4df026d-d1ea-4e98-8242-865ae4626bf1" contextRef="C_02912d63-fe9a-4d28-8b7a-f7b2934ccafb" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_48a84c9f-224f-4b0e-8179-c8167ed1418c" contextRef="C_a37bffe0-f723-4a15-9b38-db5ae6d1a171" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.25</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Notes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May and July 2018, the Company issued $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95cbd779-0b58-4bb7-8f07-efb2f7ac3245" contextRef="C_c1f43774-a82a-4496-812e-205e05514a80" name="us-gaap:ConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to a co-founder for cash with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4f81749-b9f0-4790-99b6-64cb5b6f1bba" contextRef="C_03f5fca6-f809-4c6f-a23c-f662104eb076" name="us-gaap:DebtInstrumentMaturityDateDescription"><ix:nonNumeric id="F_99161039-2de1-443c-913a-433a7f72179f" contextRef="C_cd48c120-475c-4c27-9b88-664af08c371a" name="us-gaap:DebtInstrumentMaturityDateDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after February 5, 2021, if not converted earlier</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In February 2019, the Company issued an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c16a4c7-5537-4e76-91ef-fe7a1075241c" contextRef="C_ad693d79-777f-411a-ab08-35eb238a9099" name="us-gaap:ConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to consultants for services rendered with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_561ab4fe-b518-4afa-84a6-1bef25759a7a" contextRef="C_f124e841-56b0-4f7a-af20-08a6724d6ca7" name="us-gaap:DebtInstrumentMaturityDateDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after May 16, 2020, if not converted earlier</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The convertible notes bore interest of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7281fd5e-f945-4c95-813c-b46d35f10a11" contextRef="C_ad693d79-777f-411a-ab08-35eb238a9099" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum and were convertible into equity securities sold at the next financing at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_577ceef1-f68b-475d-b6ef-954c1954447f" contextRef="C_ad693d79-777f-411a-ab08-35eb238a9099" name="dsgn:PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bf21f36-4869-4a31-9b9c-4dba3565a3c6" contextRef="C_042f9541-36bc-42b0-97cd-cb54c6a99af9" name="us-gaap:DebtConversionOriginalDebtAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c83dc800-1fef-43d4-8709-f2c3098a5486" contextRef="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">301,685</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24d104da-71ec-4adc-a090-ea6ef499c785" contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5">1.65816</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. See Note 9 for further discussion.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of December 31, 2021 or December 31, 2020.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ff3cc51-211f-4d15-9053-bfd9f5a73294" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="dsgn:DisclosureOfLicenseAgreementTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. License Agreement</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the &#x201c;License Agreement&#x201d;) with the Wisconsin Alumni Research Foundation (&#x201c;WARF&#x201d;). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8284a026-ee21-41d7-98b1-ae7f8e25f128" contextRef="C_36de137c-6361-4ec5-8970-5fc39d50dd4c" name="dsgn:CollaborativeArrangementsUpfrontPayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_045c8c2c-8669-4e74-a57a-c0c758dd944e" contextRef="C_69d3f494-4d79-47df-87fd-27a5128beb0a" name="dsgn:UpfrontPaymentUponExecutionOfAgreement" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the upfront fee upon execution of the agreement and the remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b469174-8489-4292-a88a-643d7777fa4a" contextRef="C_69d3f494-4d79-47df-87fd-27a5128beb0a" name="dsgn:UpfrontPaymentWithinOneYear" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">225,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. In February 2020, the Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f2c0bdb-68c1-40ed-9039-dbb8584b09ec" contextRef="C_9b012ef3-2aff-4122-9520-8407c5275290" name="dsgn:CollaborativeArrangementsUpfrontPayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">225,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> balance upon the initial closing of its Series A preferred stock financing.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the License Agreement, the Company is required to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81a6e7c7-d174-43b5-953b-55a13ea2256a" contextRef="C_fd90086d-3437-4665-82bf-18b82bd4403a" name="dsgn:ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upon the acceptance of an investigation new drug (&#x201c;IND&#x201d;) application in the U.S. and will be required to make further aggregate milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08c2c553-36d8-4814-a1eb-ff53adf01b53" contextRef="C_a9db9070-48ac-46f3-9a8e-aac6cdbfd36d" name="dsgn:ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees&#x2019; net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5628cb67-9e2b-44fc-a42f-475888793e87" contextRef="C_91e891fe-e7f8-423a-b358-a2ff1159c8aa" name="dsgn:ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d330dbc-aeba-47d7-9128-294f618eb2a6" contextRef="C_fd90086d-3437-4665-82bf-18b82bd4403a" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d65781bc-feff-4ce7-911f-a043ffae9ce0" contextRef="C_196bb1dc-ff73-4b87-b41c-495f6b29e794" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestone or royalty payments as of December 31, 2021.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9014a416-a94a-45df-9bb5-931f9ed3f098" contextRef="C_9d48e74d-c13f-42ba-9e94-f177898744b6" name="dsgn:LegalPatentFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the year ended December 31, 2021 and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c25ef688-c2fb-4370-8002-ebeec2b212ad" contextRef="C_5850416b-5268-46c3-970b-18e7e145562e" name="dsgn:LegalPatentFees" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020, which were recorded as general and administrative expenses in the statements of operations.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate the License Agreement with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30858e17-87cc-40d2-a41e-2d0e162d48c0" contextRef="C_d6d2ec7c-c375-4c5a-a4e1-a6f9962559bb" name="dsgn:NoticePeriodForTerminationOfAgreement" format="ixt-sec:durday"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days written notice or for certain breaches of the agreement. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28557f27-b3d5-4f53-8387-ab9a2f28a6f4" contextRef="C_d6d2ec7c-c375-4c5a-a4e1-a6f9962559bb" name="dsgn:NoticePeriodDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8da2eb3-5588-4211-82f7-a41d2c3dfa1a" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Related Party Transactions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreement</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50c43c75-12ef-48b4-a781-f8b79ae41e39" contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.285%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.18%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.169%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12abeeed-3726-40fd-bc7f-c69617299b0f" contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fd5764b-16af-4ee5-b1cc-a690ca19aa01" contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04e5fb46-4cb1-4c89-89a9-26e4b023c0fa" contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Consulting Agreements</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (&#x201c;Marlinspike Group&#x201d;) for research support, management, and business consulting services (the &#x201c;2019 Consulting Agreement&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marlinspike Group provides the use of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0a787da-de66-47eb-89be-71bfbf2e7a8f" contextRef="C_855ff555-2cfb-491d-a8ff-2b1192bb78b8" name="dsgn:AreaOfOffice" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">2,120</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company&#x2019;s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company&#x2019;s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days&#x2019; written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the &#x201c;2020 Consulting Agreement&#x201d;), which provides for the similar services and use of office space for a monthly fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4405abe4-0783-4d80-988b-662be245eb09" contextRef="C_fc6ac533-72ba-4dfe-b7e0-cef03f4d60a7" name="dsgn:MonthlyFeeForConsultancyServices" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days&#x2019; written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_632d47b0-ed1a-4e5c-b1e1-ad5956affa67" contextRef="C_fc6ac533-72ba-4dfe-b7e0-cef03f4d60a7" name="dsgn:TerminationFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b486c88-239a-4f08-8ccd-64c2b0079c23" contextRef="C_e28222d2-bdab-40c4-91ad-c91e8c333540" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.278%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.178%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.178%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9accfdd-02e7-4864-9eb0-348955f3b8f8" contextRef="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec9ec598-b200-4329-8317-f3898f81fdf9" contextRef="C_7727e7fe-60e9-46a9-8c20-52528f28b578" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53d6e4cb-3d6c-443c-9557-8fdf5b211939" contextRef="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a22e205c-c5d7-474d-ba44-668018b9128f" contextRef="C_7727e7fe-60e9-46a9-8c20-52528f28b578" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f14ac80-7b8c-4c55-b2f1-ff2e28c47b89" contextRef="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Asnsari, a co-founder, provides consulting services and advises on certain research and development activities (the &#x201c;Research Consulting Agreement&#x201d;). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6412b44-540c-441c-85bf-a2e9cfebcf80" contextRef="C_149ca0e1-6a9d-4838-96bf-fc89fbd1fbb0" name="dsgn:RelatedPartyTransactionMonthlyFeeForServices" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15b4b7c0-bacc-4570-8f4d-189afe254859" contextRef="C_33e57430-f87d-45d8-a826-73fae3f00112" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" escape="true"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.285%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.18%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.169%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcba0087-2510-4ff6-97be-9693febaf956" contextRef="C_33e57430-f87d-45d8-a826-73fae3f00112" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d666cd6d-da99-433d-8d9b-a5de7fd0def3" contextRef="C_7bd00ed8-2f33-4d98-9fdd-289c66eb1dd5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66d203ac-c6c4-45d1-b3cb-69ca804aa7da" contextRef="C_33e57430-f87d-45d8-a826-73fae3f00112" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a778d9f-a932-4cbc-89a8-ac08bc0e0644" contextRef="C_7bd00ed8-2f33-4d98-9fdd-289c66eb1dd5" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had accrued expenses and other current liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1bc13da-45a1-4b39-b64f-6b71ab39bdaf" contextRef="C_d9851747-c6e0-46a7-ae37-a995db3d6025" name="dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021 and accounts payable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0ffcca1-a1f6-47a3-9f76-62eb266d3c7e" contextRef="C_65c3b16a-86a3-451d-ae60-e9601eb9ca53" name="us-gaap:AccountsPayableCurrentAndNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2020, pursuant to its related party consulting agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Notes and Notes Payable</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May and July 2018, the Company issued a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf5bffdd-b1f0-431d-9d08-bdbf99340aae" contextRef="C_31bede1d-9fe1-4f2f-8a68-d59a76c82fcf" name="us-gaap:ConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_bf5b5af6-70e5-4119-86cf-58a34a604bc9" contextRef="C_4729fd04-d690-4b2c-9242-4f8689fbc206" name="us-gaap:ConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to a co-founder for cash with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f07897e3-a000-4004-90e1-0d3c4e7d90de" contextRef="C_1ada34b7-cc0e-46bf-8d53-623a26d0b905" name="us-gaap:DebtInstrumentMaturityDateDescription"><ix:nonNumeric id="F_982021d8-991a-4070-87fb-7e3f13796ba2" contextRef="C_73cc3eeb-6a6b-45c1-a16b-d0b91237aebe" name="us-gaap:DebtInstrumentMaturityDateDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after February 5, 2021, if not converted earlier</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The notes bore interest of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_046b6b00-82bc-4a92-adc3-57618ea4ea5e" contextRef="C_4729fd04-d690-4b2c-9242-4f8689fbc206" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum and were convertible into equity securities sold at the next financing at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d6315d1-3ac1-4507-a07e-a04e4c8d2db9" contextRef="C_4729fd04-d690-4b2c-9242-4f8689fbc206" name="dsgn:PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the selling price per share of such equity financing. In February 2020, these notes converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be26542e-227b-4ca3-989d-c293ad9318de" contextRef="C_fe8be1e8-fc44-433d-8028-3795727073cf" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">171,025</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 12 for further discussion.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_339eec4d-c929-41f7-a807-5c16324f52bd" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" escape="true" continuedAt="F_339eec4d-c929-41f7-a807-5c16324f52bd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Employee Benefit Plans</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_339eec4d-c929-41f7-a807-5c16324f52bd_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company's U.S. employees. The plan allows eligible employees to defer, at the employee's discretion, pretax compensation up to the IRS annual limits. The Company is not required to make matching contributions under the plan and had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2058c82-fefd-473d-a2cf-f3340186493d" contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t made any such contributions as of December 31, 2021.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tem 9A. Controls and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evaluation of Disclosure Controls and Procedures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term &#x201c;disclosure controls and procedures&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This annual report does not include a report of management&#x2019;s assessment regarding internal control over financial reporting or an attestation report of the company&#x2019;s registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.1404166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 9B. Other Information.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 10. Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item and not set forth below will be set forth in the sections headed</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Election of Directors </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Executive Officers</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contained in our definitive Proxy Statement to be filed with the Commission within 120 days after the conclusion of our year ended December 31, 2021 (the &#x201c;Proxy Statement&#x201d;) pursuant to General Instructions G(3) of Form 10-K and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Business Conduct and Ethics that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. A current copy of the Code of Business Conduct and Ethics is available on the Corporate Governance section of our website at www.designtx.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 11. Executive Compensation.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be set forth in our Proxy Statement in the sections headed</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Executive and Director Compensation</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Director Compensation </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in our Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be set forth in the sections headed</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Security Ownership of Certain Beneficial Owners and Management</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Executive and Director Compensation</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contained in our Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 13. Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be set forth in the sections headed</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Certain Related-Person Transactions</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Information Regarding the Board of Directors and Corporate Governance</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contained in our Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 14. Principal Accounting Fees and Services.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be set forth in the sections headed</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Ratification of Selection of Independent Registered Public Accounting Firm</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contained in our Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 15. Exhibits, Financial Statement Schedules</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following documents are filed as a part of this Annual Report on Form 10-K:</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statements:</span></div></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Financial Statements are listed in &#x201c;Index to Financial Statements&#x201d; under Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statement Schedules:</span></div></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes herein.</span></p>
  <div style="margin-left:4.667%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4961660705107365%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits:</span></div></div>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following exhibits, as required by Item 601 of Regulation S-K are attached or incorporated by reference as stated below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit Index</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.004%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:86.976%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521100253/d108026dex31.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, filed March 30, 2021).</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521100253/d108026dex32.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K, filed March 30, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521088348/d80825dex41.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex42.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Investors&#x2019; Rights Agreement, by and between the Registrant and certain of its stockholders, dated January 25, 2021 (incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="dsgn-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of the Registrant&#x2019;s Common Stock.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnity Agreement, by and between the Registrant and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex102.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. 2018 Equity Incentive Plan, as amended, and Forms of Option Grant notice, Option Agreement, Notice of Exercise, Early Exercise Stock Purchase Agreement, Restricted Stock Grant Notice and Restricted Stock Award Agreement thereunder (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="dsgn-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. 2021 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521088348/d80825dex104.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex105.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement, by and between the Registrant and Pratik Shah, Ph.D., dated March 1, 2020 (incorporated by reference to Exhibit 10.5 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex106.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement, by and between the Registrant and Jo&#xe3;o Siffert, M.D., dated September 21, 2020 (incorporated by reference to Exhibit 10.6 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex107.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement, by and between the Registrant and Sean Jeffries, dated May 21, 2019 (incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521088348/d80825dex108.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.8 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 22, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.004%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:86.976%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9&#134;&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex109.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Human Therapeutics Exclusive License Agreement, by and between the Registrant and Wisconsin Alumni Research Foundation, dated February 20, 2019 (incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10&#165;*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex1010.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consulting Agreement, by and between the Registrant and Marlinspike Group, LLC, dated March 1, 2020 (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521071667/d80825dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease, by and between the Registrant and Crossing Holdings, LLC, dated February 2, 2021 (incorporated by reference to Exhibit 10.11 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1807120/000119312521088348/d80825dex1012.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consulting Agreement, by and between the Registrant and Aseem Z. Ansari, Ph.D., dated December 27, 2017, as amended (incorporated by reference to Exhibit 10.12 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, filed March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="dsgn-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney (see signature page hereto).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="dsgn-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="dsgn-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive and Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*      Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#134;      Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#165;      Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">0-K Summary</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.225%;"></td>
    <td style="width:2.837%;"></td>
    <td style="width:5.696%;"></td>
    <td style="width:46.242%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jo&#xe3;o Siffert, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Jo&#xe3;o Siffert, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xe3;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">o Siffert, M.D., as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.981%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:43.301%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:21.645%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jo&#xe3;o Siffert, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director (Principal Executive and Financial Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Jo&#xe3;o Siffert, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Pratik Shah, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Executive Chairperson and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Pratik Shah, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Julie Burgess</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Accounting Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Julie Burgess</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Simeon George, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Simeon George, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Stella Xu, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stella Xu, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Rodney Lappe, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Rodney Lappe, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ John Schmid</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">John Schmid</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Arsani William, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Arsani William, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Heather Behanna, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Heather Behanna, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Deepa Prasad</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 10, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deepa Prasad</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>dsgn-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF COMMON STOCK</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summary description of the common stock of Design Therapeutics, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our amended and restated certificate of incorporation, amended and restated bylaws, and the Delaware General Corporation Law. Our amended and restated certificate of incorporation and amended and restated bylaws have previously been filed as exhibits with the Securities and Exchange Commission.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of directors, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividends</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose on a non-cumulative basis.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights and Preferences</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Takeover Provisions of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Section 203 of the Delaware General Corporation Law</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 203 defines a &#x201c;business combination&#x201d; to include the following:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any merger or consolidation involving the corporation and the interested stockholder;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, Section 203 defines an &#x201c;interested stockholder&#x201d; as an entity or person who, together with the person&#x2019;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that our board of directors will be classified into three classes of directors;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.958%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.033%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66 2/3% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#x2019;s notice;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or president or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, and not by our stockholders; and</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:93.012%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amendment of any of these provisions would require approval by the holders of at least 66 2/3% of the voting power of all of our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Choice of Forum</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. This provision will not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other claim for which the U.S. federal courts have exclusive jurisdiction.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such Securities Act claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. However, there is uncertainty as to whether a court would enforce such provision, and investors cannot waive compliance with federal securities laws and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing increased consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Listing</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#x201c;DSGN.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Agent and Registrar</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent&#x2019;s address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800) 937-5449.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>dsgn-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">2021 Equity Incentive Plan</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Adopted by the Board of Directors: March </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">18</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">, 2021<br>Approved by the Stockholders: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">March 19</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:1.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.652%;"></td>
    <td style="width:3.348%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;" id="mptableofcontents"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;General.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Shares Subject to the Plan.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Eligibility and Limitations.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Options and Stock Appreciation Rights.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Awards Other Than Options and Stock Appreciation Rights.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Adjustments upon Changes in Common Stock; Other Corporate Events.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Administration.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Tax Withholding</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Miscellaneous.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Covenants of the Company.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Additional Rules for Awards Subject to Section 409A.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Severability.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Termination of the Plan.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#160;Definitions.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.582%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:44.572%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">i</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">General.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Successor to and Continuation of Prior Plan.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Plan is the successor to and continuation of the Prior Plan.  As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan&#x2019;s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan).  All Awards granted under this Plan will be subject to the terms of this Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Plan Purpose.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Available Awards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Plan provides for the grant of the following Awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock Options; (iii) SARs; (iv) Restricted Stock Awards; (v) RSU Awards; (vi) Performance Awards; and (vii) Other Awards.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Adoption Date; Effective Date. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> The Plan will come into existence on the Adoption Date, but no Award may be granted prior to the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Shares Subject to the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ole_link7"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font id="ole_link8"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Share Reserve.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to adjustment in accordance with Section 2(c) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 9,381,505 shares, which is the sum of: (i) 6,118,648 new shares, plus (ii) the number of shares of Common Stock (not to exceed 3,262,857 shares of Common Stock) which represents (A) the Prior Plan&#x2019;s Available Reserve plus (B) the number of Returning Shares, if any, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to five percent (5%) of the total number of shares of Common Stock outstanding on December 31 of the preceding year</font><font id="ole_link11"></font><font id="ole_link12"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">; provided, however that the Board may act prior to January 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Aggregate Incentive Stock Option Limit.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Notwithstanding anything to the contrary in Section 2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 28,144,515 shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Share Reserve Operation.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Limit Applies to Common Stock Issued Pursuant to Awards.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards.  Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued; (2) the settlement of any portion of an Award in cash (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">i.e.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	Reversion of Previously Issued Shares of Common Stock to Share Reserve.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2) any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Eligibility and Limitations.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Eligible Award Recipients.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Specific Award Limitations.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Limitations on Incentive Stock Option Recipients.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Incentive Stock Options may be granted only to Employees of the Company or a &#x201c;parent corporation&#x201d; or &#x201c;subsidiary corporation&#x201d; thereof (as such terms are defined in Sections 424(e) and (f) of the Code).</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Incentive Stock Option $100,000 Limitation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i) the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (ii) the Option is not exercisable after the expiration of five years from the date of grant of such Option.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	Limitations on Nonstatutory Stock Options and SARs.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#x201c;parent&#x201d; of the Company (as such term is defined in Rule 405) unless the stock underlying such Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Aggregate Incentive Stock Option Limit.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section 2(b).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Non-Employee Director Compensation Limit. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $750,000 in total value or (ii) in the event such Non-Employee Director is first appointed or elected to the Board during such Annual Period, $1,000,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations in this Section 3(d) shall apply commencing with the first calendar year that begins following the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Options and Stock Appreciation Rights.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Option and SAR will have such terms and conditions as determined by the Board.  Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for.  Each SAR will be denominated in shares of Common Stock equivalents.  The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Term.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Exercise or Strike Price.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Exercise Procedure and Payment of Exercise Price for Options.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company.  The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.  The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">by cash or check, bank draft or money order payable to the Company;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">pursuant to a &#x201c;cashless exercise&#x201d; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">if the Option is a Nonstatutory Stock Option, by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(v)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Exercise Procedure and Payment of Appreciation Distribution for SARs.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement.  The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR.  Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(e)	Transferability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Options and SARs may not be transferred to third party financial institutions for value.  The Board may impose such additional limitations on the transferability of an Option or SAR as it determines.  In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Restrictions on Transfer.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#x2019;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Domestic Relations Orders.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(f)	Vesting.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#x2019;s Continuous Service.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(g)	Termination of Continuous Service for Cause.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service is terminated for Cause, the Participant&#x2019;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(h)	Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Subject to Section 4(i), if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#x2019;s Disability or death);</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12 months following the date of such termination if such termination is due to the Participant&#x2019;s Disability;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18 months following the date of such termination if such termination is due to the Participant&#x2019;s death; or</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18 months following the date of the Participant&#x2019;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Restrictions on Exercise; Extension of Exercisability.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i) the exercise of the Participant&#x2019;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#x2019;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">as to the maximum permitted number of extensions); provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(j)	Non-Exempt Employees.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award.  Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant&#x2019;s death or Disability, (ii) a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant&#x2019;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#x2019;s then current employment policies and guidelines).  This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(k)	Whole Shares.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Awards Other Than Options and Stock Appreciation Rights.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Restricted Stock Awards and RSU Awards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Form of Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(1)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RSAs: To the extent consistent with the Company&#x2019;s Bylaws, at the Board&#x2019;s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company&#x2019;s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(2)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RSUs: A RSU Award represents a Participant&#x2019;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award.  As a holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company's unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person.  A Participant will not have voting or any other rights as a stockholder of the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Consideration.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(1)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RSA: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future services)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">as the Board may determine and permissible under Applicable Law.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(2)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RSU: Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the Participant&#x2019;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award.  If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#x2019;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	Vesting.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#x2019;s Continuous Service.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	Termination of Continuous Service.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and (ii) any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(v)	Dividends and Dividend Equivalents.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(vi)	Settlement of RSU Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement.  At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ole_link1"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Performance Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board.</font><font id="ole_link2"></font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Other Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5.  Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Adjustments upon Changes in Common Stock; Other Corporate Events.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Capitalization Adjustments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section 2(a); (ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 2(a); and (iii) the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards.  The Board shall make such adjustments, and its determination shall be final, binding and conclusive.  Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment.  The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this Section.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Dissolution or Liquidation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#x2019;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#x2019;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Corporate Transaction.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The following provisions will apply to Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Awards May Be Assumed.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#x2019;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#x2019;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Awards Held by Current Participants.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Current Participants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).  With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement or unless otherwise provided by the Board, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction.  With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	Awards Held by Persons other than Current Participants.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	Payment for Awards in Lieu of Exercise.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection with such exercise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Appointment of Stockholder Representative.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#x2019;s behalf with respect to any escrow, indemnities and any contingent consideration.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(e)	No Restriction on Right to Undertake Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Administration.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Administration by Board.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in subsection (c) below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Powers of Board.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To determine from time to time (1) which of the persons eligible under the Plan will be granted Awards; (2) when and how each Award will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To settle all controversies regarding the Plan and Awards granted under it.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(v)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(vi)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To suspend or terminate the Plan at any time.  Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(vii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To amend the Plan in any respect the Board deems necessary or advisable; provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that stockholder approval will be required for any amendment to the extent required by Applicable Law.  Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(viii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To submit any amendment to the Plan for stockholder approval.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ix)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that, a Participant&#x2019;s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(x)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(xi)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction).</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(xii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1) the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2) the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A) a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B) cash and/or (C) other valuable consideration (as determined by the Board); or (3) any other action that is treated as a repricing under generally accepted accounting principles.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Delegation to Committee.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	General.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  Each Committee may retain the authority to concurrently administer the Plan with Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated.  The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Rule 16b-3 Compliance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Effect of Board&#x2019;s Decision.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(e)	Delegation to an Officer.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself.  Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority.  Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tax Withholding</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Withholding Authorization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agree to make adequate provision for (including), any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable.  Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Satisfaction of Withholding Obligation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a &#x201c;cashless exercise&#x201d; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	No Obligation to Notify or Minimize Taxes; No Liability to Claims.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award.  Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award.  As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so.  Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award.  Additionally, as a condition</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Withholding Indemnification. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#x2019;s and/or its Affiliate&#x2019;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Miscellaneous.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Source of Shares.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Use of Proceeds from Sales of Common Stock.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Corporate Action Constituting Grant of Awards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Stockholder Rights.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(e)	No Employment or Other Service Rights.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#x2019;s agreement with the Company or an Affiliate, or (iii) the service of a Director</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be.  Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(f)	Change in Time Commitment.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  In the event a Participant&#x2019;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(g)	Execution of Additional Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#x2019;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator&#x2019;s request.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(h)	Electronic Delivery and Participation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Any reference herein or in an Award Agreement to a &#x201c;written&#x201d; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#x2019;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).  By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator.  The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Clawback/Recovery.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#x2019;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">policy will be an event giving rise to a Participant&#x2019;s right to voluntary terminate employment upon a &#x201c;resignation for good reason,&#x201d; or for a &#x201c;constructive termination&#x201d; or any similar term under any plan of or agreement with the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(j)	Securities Law Compliance.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(k)	Transfer or Assignment of Awards; Issued Shares.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant.  After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(l)	Effect on Other Employee Benefit Plans. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#x2019;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company's or any Affiliate's employee benefit plans.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(m)	Deferrals.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants.  Deferrals by will be made in accordance with the requirements of Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(n)	Section 409A.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A.  If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#x201c;deferred compensation&#x201d; under Section 409A is a &#x201c;specified employee&#x201d; for purposes of Section 409A, no distribution or payment of any amount that is due because of a &#x201c;separation from service&#x201d; (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#x2019;s &#x201c;separation from service&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or, if earlier, the date of the Participant&#x2019;s death, unless such distribution or payment can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(o)	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Choice of Law.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Covenants of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Compliance with Law.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained.  A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Rules for Awards Subject to Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	Application. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	Non-Exempt Awards Subject to Non-Exempt Severance Arrangements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Non-Exempt Award vests in the ordinary course during the Participant&#x2019;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the calendar year that includes the applicable vesting date, or (ii) the 60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> day that follows the applicable vesting date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#x2019;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> day that follows the date of the Participant&#x2019;s Separation from Service.  However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant&#x2019;s Separation from Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#x2019;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award.  Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	Treatment of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,112,192,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> The provisions of this subsection (c) shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	Vested Non-Exempt Awards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(1)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award.  Upon the Section 409A Change in Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award.  Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(2)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award.  The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred.  In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	Unvested Non-Exempt Awards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to subsection (e) of this Section.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(1)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award.  Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction.  The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred.  In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(2)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award.  Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below.  In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate Transaction.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(3)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section 409A Change in Control.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	Treatment of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  The following provisions of this subsection (d) shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Corporate Transaction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award.  Upon the Section 409A Change in Control the vesting and settlement of any Non-Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award.  Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control pursuant to the preceding provision.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award.  Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction.  The shares to be issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred.  In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section 409A Change in Control.  To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service.  However, if at the time the shares would otherwise be issued to a Participant in connection with a &#x201c;separation from service&#x201d; such Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#x2019;s Separation From Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The provisions in this subsection (e) for delivery of the shares in respect of the settlement of a RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Severability.</font><font style="font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid.  Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Termination of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Board may suspend or terminate the Plan at any time.  No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i) the Adoption Date, or (ii) the date the Plan is approved by the Company&#x2019;s stockholders.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Definitions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As used in the Plan, the following definitions apply to the capitalized terms indicated below:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Acquiring Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Adoption Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the date the Plan is first approved by the Board or Compensation Committee.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act.  The Board may determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Applicable Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means shall mean any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a RSU Award, a SAR, a Performance Award or any Other Award).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(f)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Award Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.  The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided to a Participant along with the Grant Notice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(g)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Board of Directors of the Company (or its designee).  Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(h)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Capitalization Adjustment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">has the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#x2019;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (ii) such Participant&#x2019;s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iii)  such Participant&#x2019;s unauthorized use or disclosure of the Company&#x2019;s confidential information or trade secrets; or (iv) such Participant&#x2019;s gross or willful misconduct.  The determination that a termination of the Participant&#x2019;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#x2019;s Chief Executive Officer with respect to Participants who are not executive officers of the Company.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(j)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal income tax consequences to the Participant in connection with an Award, also constitutes a Section 409A Change in Control:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.  Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#x2019;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Subject Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Incumbent Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(k)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(l)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Compensation Committee and any other committee of Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(m)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the common stock of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(n)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Design Therapeutics, Inc., a Delaware corporation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(o)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Compensation Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Compensation Committee of the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(p)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Consultant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#x201c;Consultant&#x201d; for purposes of the Plan.  Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">25</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Statement under the Securities Act is available to register either the offer or the sale of the Company&#x2019;s securities to such person.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(q)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Continuous Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means that the Participant&#x2019;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#x2019;s service with the Company or an Affiliate, will not terminate a Participant&#x2019;s Continuous Service; provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#x2019;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#x2019;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#x2019;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.  In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#x201c;separation from service&#x201d; as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(r)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Corporate Transaction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a sale</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a sale or other disposition of at least 50% of the outstanding securities of the Company;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(s)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a member of the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(t)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">determine</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">determined</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means as determined by the Board or the Committee (or its designee) in its sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(u)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(v)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means immediately prior to the IPO Date, provided this Plan is approved by the Company&#x2019;s stockholders prior to the IPO Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(w)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#x201c;Employee&#x201d; for purposes of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(x)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Employer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Company or the Affiliate of the Company that employs the Participant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(y)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a corporation, partnership, limited liability company or other entity.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(z)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(aa)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Exchange Act Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#x201c;Exchange Act Person&#x201d; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(bb)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Fair Market Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows:</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">27</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></p>
  <p style="margin-left:0.84%;text-indent:13.446%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(cc)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Governmental</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Body</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(dd)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ee)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Incentive Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an option granted pursuant to Section 4 of the Plan that is intended to be, and qualifies as, an &#x201c;incentive stock option&#x201d; within the meaning of Section 422 of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ff)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">IPO Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(gg)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Materially Impair</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means any amendment to the terms of the Award that materially adversely affects the Participant&#x2019;s rights under the Award.  A Participant's rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant's rights.  For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#x2019;s rights under the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option that may be exercised; (ii) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iii) to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iv) to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section 409A; or (v) to comply with other Applicable Laws.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(hh)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Non-Employee Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Regulation S-K</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a &#x201c;non-employee director&#x201d; for purposes of Rule 16b-3.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Non-Exempt Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, (ii) the terms of any Non-Exempt Severance Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(jj)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Non-Exempt Director Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(kk)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Non-Exempt Severance Arrangement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#x2019;s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Separation from Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ll)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Nonstatutory Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any option granted pursuant to Section 4 of the Plan that does not qualify as an Incentive Stock Option.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(mm)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Officer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(nn)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(oo)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Option Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a written agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant.  The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(pp)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Optionholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(qq)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Other Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 5(c).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">29</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(rr)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Other Award Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means a written agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant.  Each Other Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ss)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Own,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Owned,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Owner,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Ownership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means that a person or Entity will be deemed to &#x201c;Own,&#x201d; to have &#x201c;Owned,&#x201d; to be the &#x201c;Owner&#x201d; of, or to have acquired &#x201c;Ownership&#x201d; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(tt)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(uu)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Performance Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant to such terms as are approved by the Board.  In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards.  Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(vv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Performance Criteria</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any measure of performance selected by the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ww)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Performance Goals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of items that are &#x201c;unusual&#x201d; in nature or occur &#x201c;infrequently&#x201d; as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">compensation and the award of bonuses under the Company&#x2019;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to expense under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles.  In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period.  Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(xx)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Performance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#x2019;s right to vesting or exercise of an Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(yy)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means this Design Therapeutics, Inc. 2021 Equity Incentive Plan, as amended from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(zz)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan Administrator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#x2019;s other equity incentive programs.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(aaa)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Post-Termination Exercise Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the period following termination of a Participant&#x2019;s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(bbb)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Prior Plan&#x2019;s Available Reserve</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the number of shares available for the grant of new awards under the Prior Plan as of the Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ccc)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Prior Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Design Therapeutics, Inc. 2018 Equity Incentive Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ddd)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Prospectus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the document containing the Plan information specified in Section 10(a) of the Securities Act.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(eee)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(fff)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Award Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant Notice.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ole_link10"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ggg)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Returning Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means shares subject to </font><font id="ole_link9"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">outstanding stock awards granted under the Prior Plan and that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> following the Effective Date: (A) are not issued because such stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued; (B) are not issued because such stock award or any portion thereof is settled in cash; (C) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares; (D) are withheld or reacquired to satisfy the exercise, strike or purchase price; or (E) are withheld or reacquired to satisfy a tax withholding obligation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(hhh)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU Award Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means a written agreement between the Company and a holder of a RSU Award evidencing the terms and conditions of a RSU Award grant.  The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided to a Participant along with the Grant Notice.  Each RSU Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(jjj)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rule 16b-3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(kkk)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rule 405</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Rule 405 promulgated under the Securities Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(lll)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Section 409A of the Code and the regulations and other guidance thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(mmm)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Section 409A Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#x2019;s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(nnn)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Securities Act of 1933, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ooo)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Share Reserve</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the number of shares available for issuance under the Plan as set forth in Section 2(a).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ppp)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Stock Appreciation Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">SAR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 4.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(qqq)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">SAR Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a written agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant.  The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided to a Participant along with the Grant Notice.  Each SAR Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(rrr)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Subsidiary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">32</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(sss)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Ten Percent Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(ttt)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Trading Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Company&#x2019;s policy permitting certain individuals to sell Company shares only during certain &#34;window&#34; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(uuu)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Unvested Non-Exempt Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(vvv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vested Non-Exempt Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">33</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.<br>Stock Option Grant Notice<br>(2021 Equity Incentive Plan)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), pursuant to its 2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), has granted to you (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Optionholder&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> an option to purchase the number of shares of the Common Stock set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).  Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:76.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.461%;"></td>
    <td style="width:33.539%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionholder:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date of Grant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vesting Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Number of Shares of Common Stock Subject to Option:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise Price (Per Share):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Exercise Price:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;border-bottom:0.500pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Type of Grant:	[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Incentive Stock Option] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">OR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> [Nonstatutory Stock Option]</font></p>
  <p style="text-indent:-20.0%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exercise and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to the Optionholder&#x2019;s Continuous Service through each applicable vesting date, the Option will vest as follows:</font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[One-fourth (1/4th) of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the Option shall vest and become exercisable each month thereafter on the same day of the month as the Vesting Commencement Date (or if there is no corresponding day, on the last day of the month), subject to Optionholder&#x2019;s Continuous Service through each applicable vesting date.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Optionholder Acknowledgements:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Option Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you) cannot be first </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">exercisable</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for more than $100,000 in value (measured by exercise price) in any calendar year.  Any excess over $100,000 is a Nonstatutory Stock Option.</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You have read and are familiar with the provisions of the Plan, the Stock Option Agreement, the Notice of Exercise and the Prospectus.  In the event of any conflict between the provisions in this Grant Notice, the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">34</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option Agreement, the Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:_________________________________________</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Signature</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:________________________________________</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:________________________________________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Optionholder:</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">____________________________________________</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Signature</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:________________________________________</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-18.805%;padding-left:15.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Attachments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:  Stock Option Agreement, 2021 Equity Incentive Plan, Notice of Exercise</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Attachment I</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Stock Option Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">36</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.<br></font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;">2021 Equity Incentive Plan<br><br></font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Stock Option Agreement</font><font style="font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As reflected by your Stock Option Grant Notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), Design Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) has granted you an option under its 2021 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable.  The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The general terms and conditions applicable to your Option are as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governing Plan Document.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Your Option is subject to all the provisions of the Plan, including but not limited to the provisions in:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">a.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 6 regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">b.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 9(e) regarding the Company&#x2019;s retained rights to terminate your Continuous Service notwithstanding the grant of the Option; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">c.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 8(c) regarding the tax consequences of your Option.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vesting.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to the provisions contained herein, your Option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[[[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Optional Language**** </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event of a Change in Control in which the surviving corporation or acquiring corporation (or its parent company) assumes or continues your Option or substitutes a similar stock award for such option, then the portion of your Option that has not vested as of the effective time of such Change in Control shall continue to vest according to the vesting schedule in your Grant Notice. Notwithstanding the foregoing, if a Change in Control occurs and within three (3) months prior to, or within twelve (12) months after, the effective time of such Change in Control, your Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to your voluntary termination with Good Reason, then, as of the later of (i) the date of your termination of Continuous Service and (ii) immediately prior to the effective time of such Change in Control, the vesting and exercisability of your Option will be accelerated in full.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the occurrence of any of the following events, conditions or actions taken by the Company without your written consent: (i) a material reduction of your annual base salary; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that Good Reason shall not be deemed to have occurred in the event of a reduction in your annual base salary that is pursuant to a salary reduction program affecting substantially all of the similarly situated employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; (ii) a material reduction in your authority, duties or responsibilities; (iii) a relocation of your principal place of employment with the Company to a place that increases your one-way commute by more than fifty (50) miles as compared to your then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary course of business); (iv) in the case of employees reporting to the Board or the Company&#x2019;s Chief Executive Officer, a material adverse change in such reporting level requiring you to report to a corporate officer or executive other than the Board or the Company&#x2019;s Chief Executive Officer, as the case may be; or (v) a material breach by the Company of any material agreement between you and the Company; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that in each case above, in order for your resignation to be deemed to have been for Good Reason, you must first give the Board written notice of the action or omission giving rise to &#x201c;Good Reason&#x201d; within ninety (90) days after the first occurrence thereof, the Company must fail to reasonably cure such action or omission within thirty (30) days after receipt of such notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cure Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and your resignation from all positions you hold with the Company must be effective not later than thirty (30) days after the expiration of such Cure Period.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	If any payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">280G Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then any such 280G Payment (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall be equal to the Reduced Amount.  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Reduced Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that results in the greatest economic benefit for you.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Pro Rata Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows:  (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest  economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Unless you and the Company agree on an alternative accounting firm, at the Company&#x2019;s election, either (i) Ernst &amp; Young LLP or (ii) the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.  The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 2(c) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 2(c) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section 2(c), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.****</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">End of Optional Language</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">]]]]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exercise.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">a.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission.  Please review Sections 4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">b.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To the extent permitted by Applicable Law, you may pay your Option exercise price as follows:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">cash, check, bank draft or money order;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">subject to Company and/or Committee consent at the time of exercise, pursuant to a &#x201c;cashless exercise&#x201d; program as further described in Section 4(c)(ii) of the Plan if at the time of exercise the Common Stock is publicly traded;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">39</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in Section 4(c)(iii) of the Plan; or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">subject to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a &#x201c;net exercise&#x201d; arrangement as further described in Section 4(c)(iv) of the Plan.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">c.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By accepting your Option, you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Lock-Up Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period.  You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.  In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period.  You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 3(c).  The underwriters of the Company&#x2019;s stock are intended third party beneficiaries of this Section 3(c) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Term.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  You may not exercise your Option before the commencement of its term or after its term expires.  The term of your Option commences on the Date of Grant and expires upon the earliest of the following:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">a.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">immediately upon the termination of your Continuous Service for Cause;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">b.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">three months after the termination of your Continuous Service for any reason other than Cause, Disability or death;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">c.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12 months after the termination of your Continuous Service due to your Disability;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">d.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18 months after your death if you die during your Continuous Service;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">e.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">f.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Expiration Date indicated in your Grant Notice; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">g.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the day before the 10th anniversary of the Date of Grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">40</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, if you die during the period provided in Section 4(b) or 4(c) above, the term of your Option shall not expire until the earlier of (i) 18 months after your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant.  Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in Section 4(i) of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option and ending on the day three months before the date of your Option&#x2019;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability.  If the Company provides for the extended exercisability of your Option under certain circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment terminates.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Withholding Obligations.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As further provided in Section 8 of the Plan: (a) you may not exercise your Option unless the applicable tax withholding obligations are satisfied, and (b) at the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#x201c;cashless exercise&#x201d; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with the withholding procedures established by the Company.  Accordingly, you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares of Common Stock subject to your Option, unless and until such obligations are satisfied.  In the event that the amount of the Company&#x2019;s withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Incentive Stock Option Disposition Requirement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  If your Option is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs within two years after the date of your Option grant or within one year after such shares of Common Stock are transferred upon exercise of your Option.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Transferability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Except as otherwise provided in Section 4(e) of the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Corporate Transaction.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No Liability for Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so.  Additionally, you acknowledge that the Option is exempt from Section 409A only if the exercise price is at least equal to the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option.  Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less than the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Other Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.  In addition, you acknowledge receipt of the Company&#x2019;s Trading Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.	</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Questions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">*  *  *  *</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Attachment II</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">2021 Equity Incentive Plan</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Attachment III</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Notice of Exercise</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">(2021 Equity Incentive Plan)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOTICE OF EXERCISE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Design Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6005 Hidden Valley Road, Suite 110</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Carlsbad, CA 92011</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	Date of Exercise: _______________</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This constitutes notice to Design Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that I elect to purchase the below number of shares of Common Stock of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) by exercising my Option for the price set forth below.  Capitalized terms not explicitly defined in this Notice of Exercise but defined in the Grant Notice, Option Agreement or 2021 Equity Incentive Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,112,192,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall have the meanings set forth in the Grant Notice, Option Agreement or Plan, as applicable.  Use of certain payment methods is subject to Company and/or Committee consent and certain additional requirements set forth in the Option Agreement and the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:0.5055555555555555in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.917%;"></td>
    <td style="width:6.185%;"></td>
    <td style="width:28.301%;"></td>
    <td style="width:26.597%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Type of option (check one):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Incentive  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Wingdings;">&#xf0a8;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:26.6pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:26.6pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Nonstatutory  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Wingdings;">&#xf0a8;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Date of Grant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">_______________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Number of Shares as<br>to which Option is<br>exercised:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">_______________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Certificates to be<br>issued in name of:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">_______________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Total exercise price:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$______________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:35.25pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:35.25pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Cash, check, bank draft or money order delivered herewith:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$______________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:35.25pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:35.25pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Value of ________ Shares delivered herewith:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$______________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:35.25pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:35.25pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Regulation T Program (cashless exercise)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$_____________</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:35.25pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:35.25pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Value of _______ Shares pursuant to net exercise:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$_____________</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);text-indent:35.6pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:35.6pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:top;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:22.1pt;word-break:break-word;vertical-align:bottom;text-align:right;"><p style="margin-left:22.1pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Plan, (ii) to satisfy the tax withholding obligations, if any, relating to the exercise of this Option as set forth in the Option Agreement, and (iii) if this exercise relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this Option that occurs within two years after the Date of Grant or within one year after such Shares are issued upon exercise of this Option.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Lock-Up Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.  In order to enforce the foregoing covenant, the Company may impose stop&#x2011;transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:30.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Very truly yours,</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:30.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">______________________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>dsgn-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the following Registration Statement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statement (Form S-8 No. 333-254794) pertaining to the 2018 Equity Incentive Plan (Prior Plan), 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan of Design Therapeutics, Inc. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of our report dated March 10, 2022, with respect to the financial statements of Design Therapeutics, Inc., included in this Annual Report (Form 10-K) of Design Therapeutics, Inc. for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">							</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">							/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">San Diego, California</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>dsgn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Jo&atilde;o Siffert, certify that:</font></p>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Design Therapeutics, Inc.;</font></div></div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.919%;"></td>
    <td style="width:4.081%;"></td>
    <td style="width:4.081%;"></td>
    <td style="width:45.919%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jo&atilde;o Siffert, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Jo&atilde;o Siffert, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive and Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>dsgn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Design Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2021, to which this Certification is attached, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:10.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The undersigned has executed this Certification effective as of March 10, 2022.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.5%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jo&atilde;o Siffert, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Jo&atilde;o Siffert, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive and Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img215454963_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_0.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> E # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"ZO]%L+FX_YZS6ZLQ^I(Y_&M2...&)8HD5(T&U548 'H!3J* "BBB@ HHHH
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MEXK_ .$>\4V<=U'+$9(-3LX6$6<$[7. !T/H<XZY% '?4444 %%%% !1110
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MM+3/$>CZR=NGZA#,^,[ </\ ]\G!_2K=.:5VF9JK3D[*2OZFI1114&@4444
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M!("[91G R5!&<#C&:D#0%E]BA^S17=^[E2R):Q8&[N,G(XP.OK45OK]_HES
M-6$C:?<R"..6<@2H3W8 ],\?YYO3:O:/IGVK2KB*%L$,[(69.,[ I[D]OT-9
M/A#1UU2\.NW?FL8W(@WDG?U!8]NO]?6@#O0<C-<1KFGPQZE>7&L1E].=U:*0
MOT.T<#!SU!XKMZY?Q=;74TEDZ(9K0%EEB*[ADX()_(C/N*PQ$;P?D:4G:1DK
MXQMHM&(00DPW"Q0I$O!3:2/E]1@_I6#K6IWMNTEK+I<BG5%24^9_&.G QP0,
M<=N/6NG\/ZKI&F3QV<-M%!YZDO*IR3(!D@Y_X%C_ .O716FK6VK?:8[1@MS
M, 2+R,CAOI_A6,80J)7EK_D:-N#VT.5TG7)?,BTV"00RH%20R1[71 HVK@YQ
MU]/?O6_I^NVR:HNBS&.*?9F$"0-Y@'7\>_YUY[)HVI6L=SJ4F];^WD+S,\?!
M'U/#=<\]?YZ_A\V6M7YUAR[:DF-OF 84J. %'2IC5E!ZMCE!-:'H5TD/E-++
MD!%)W*2& ^HI]N)!;QB5MTFT;CZFL/PYXE@UXW5ME3<6QQ)M!VL#W&?Q%;)M
M(L87>@]$<J/R!KM3YES(YVK:,GHK/DW6;*MMYT[=6A9R_'KN8\?GBK=M*\\
MDD@>!B3^[<@D<^Q(]Z:8B6BBBF 4444 %%%% !17F/\ PN&+_H"O_P"!(_\
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MW*(V.ZL<$?D37O5>'C:2IU/=V9]!@*\JM.TMT%%%%<AW!1110 4444 %%%%
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M:C_*ON.9_P"%9>&/^?6;_O\ M_C1_P *R\,?\^LW_?\ ;_&NF\^X_P"?-_\
MOM?\://N/^?-_P#OM?\ &CV]7^9A]6H_RK[CF?\ A67AC_GUF_[_ +?XU+:_
M#OPW:745Q':.7B8,H>5F&1Z@]:Z6*21V(>!HQCJ6!S^52T>WJ?S,:P]'^5?<
M5/[*TX=+"U_[\K_A2_V;8#_ERMO^_2_X58D9E0E$+M_=! S^=0?:)_\ GSD_
M[[7_ !K/F?<TY8]@&GV0Z6=O_P!^E_PIWV&T'_+K!_W[%)]HF_Y\Y?\ OI/\
M:/M$W_/E-_WTG_Q5%V.R[#OL=J.EM#_WP*7[+;C_ )81?]\"H_M,W_/E/_WT
MG_Q5'VF7_GQN/^^H_P#XJB["R)1;PCI#'_WR*7R8A_RS3_OD5#]IE_Y\;C_O
MJ/\ ^*H^TR_\^-Q_WU'_ /%4@T.5^)>F-=^%3<0("]G,LY '\/(/\\_A7EZ.
M)$#J<@C->_#%S"RS0,JL"K))@Y'X$C%>2^(_ VH:)<27.DPO=Z<Q+>4G,D/M
MCJ1[_GZUZ>!Q$8KV<CRLPPTI/VL%?N<[15;[= "0Y9&'!5E.15NPM=0UF80:
M592W#DX+[<(OU)X%>FY)*[9Y"BY.R1;\/6+ZKXNTRU096*47$I]%7GGZXQ^(
MKW2N:\'^$XO#5F[RN)M0GP9I1T'^ROM_.NEKP\7656=ULCZ'!4'1I^]NPHHH
MKE.P**** "BBB@ HHHH CFB$T#QL 0PQS6$RW=S.D1CB2XMQQ+DAV Z8^O0C
M/KTKH:H:D;>"![F5]C1C<"#S0!R*S:D]P]OJ&K^1 ['S(\$;0. 3)C(!Q[<]
M?2M1-6L;*V:/2M16Y\H8%NB>;SGU&"3^-98=_/:?48;C9<)E&&">?48SG'''
M:I(;N/1FDEB^SN"_S02 (PY[<8'3/6@![Z9J7BBV,=Q;1V$#$K+,5 FD'0@#
M^$>O/K70ZA#9QZ4UI/#&;.&##F4Y"(!@>I)P/_KUFVWCS1YXD!=Q<L<&!4+-
M^&.M+J&OV4OE^3(9+>="KLHSD \C!'!&?3H:<4V] ,'1-9N-"A%K&HOX%!D,
M<2@3"/. Q ZG^=3WOB*#6M(O_(M&DN)-B1(V/N'!!4^H.3^7I5"ZL;+3I2?#
MDES=S7#@3A7WO&O !QPP'OTK#748]"U@0HN)0Q(C/W4(..?RS6W*F[B(]135
M+F[.F+%)+'A59MF",CG.>G>NRNBM[X8BTBTN)+F>P6+[3# 2'DC (P"1\W;\
MJY/5;^\D\07,MJR3>7$6EFB(93SQ]>]:GAO.FR7.N:I.8)3"452A.4// !QG
M('WNG\JJ:JX&AHDT^C6TEZ=R>8Y1;5FR2H0MGGTRH_.K^DVTS:R+_4K\L&4
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M MRS=2Q]SWJ+3K6SM+*-+&%(H" P"CKGN?6K5:03M[SNR)-7T"BBBJ$%%%%
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MW7O21W%P]NBQ2>6=F7,:*H3MR3GI@U1UN5[FQ33],D\^Y=QOF#*W4'+$#J<
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MG2=TNW"P0M/*SV\B!4498Y*CH*X75-0GU#2_%2K/!>0_8K=TOX+(Q>:?,8$
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MW2!=SZO-<Z5&AM)04,I3;&G0'9Z]!^76N@OO#]O=V[Q(VQ&.[RV4-'GU(/\
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M"FJK)<7S2VDD;80Q9?=DD@;> ._(QR:T5CM/$WAOR+=WCB#*%+KRNT@@$?3
M_&JY]ET$<=X?O+L>)[9[D"TMO*D\UGD7:0>0,=.N.*T-;F>ZT_\ XE,<'GQB
M5I1;@;1\V,Y'? -9'CLW(F%I]DE#KL3SHE^5P<>G-5;:/6M%T^2WAL+N3S\
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M-,\1^(GO#<QK=7,$T)%I*P9/LT0SE5/<$?A0!VU%%% !1110 48SUHHH *
M.@HHH SKC1XKK6K74I[B=_LJGR;<E?*5R"#)C&2VUB.3C!Z=ZT:** "BBB@
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MN?LLRHP<D=E?(/LP/]Z@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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D= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img215454963_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T($IA
M8VMS;VX   60 P "    %   $*:0!  "    %   $+J2D0 "     S0P  "2
MD@ "     S0P  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M1R:/F\QSBI@Z_LHQ3T/HG_A)M!_Z#>G?^!<?^-'_  DV@_\ 0;T[_P "X_\
M&OG:BNW^PZ?\[//_ -8ZO_/M?B?1/_"3:#_T&]._\"X_\:/^$FT'_H-Z=_X%
MQ_XU\[44?V'3_G8?ZQU?^?:_$^B?^$FT'_H-Z=_X%Q_XT?\ "3:#_P!!O3O_
M  +C_P :^=J*/[#I_P [#_6.K_S[7XGT3_PDV@_]!O3O_ N/_&C_ (2;0?\
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M_C7SM11_8=/^=A_K'5_Y]K\3Z)_X2;0?^@WIW_@7'_C1_P )-H/_ $&]._\
M N/_ !KYVHH_L.G_ #L/]8ZO_/M?B?1/_"3:#_T&]._\"X_\:/\ A)M!_P"@
MWIW_ (%Q_P"-?.U%']AT_P"=A_K'5_Y]K\3Z)_X2;0?^@WIW_@7'_C1_PDV@
M_P#0;T[_ ,"X_P#&OG:BC^PZ?\[#_6.K_P ^U^)]$_\ "3:#_P!!O3O_  +C
M_P :/^$FT'_H-Z=_X%Q_XU\[44?V'3_G8?ZQU?\ GVOQ/HG_ (2;0?\ H-Z=
M_P"!<?\ C37\4:!'#)+)KFFI'&NYW:[C 49QDG/ R0/QKYXJKK/_ "*&N_\
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M0_\ Q5?#5%'U==PY#[E_X6!X-_Z&W0O_  90_P#Q5'_"P/!O_0VZ%_X,H?\
MXJOAJBCZNNX<A]R_\+ \&_\ 0VZ%_P"#*'_XJC_A8'@W_H;="_\ !E#_ /%5
M\-44?5UW#D/N7_A8'@W_ *&W0O\ P90__%4?\+ \&_\ 0VZ%_P"#*'_XJOAJ
MBCZNNX<A]R_\+ \&_P#0VZ%_X,H?_BJ/^%@>#?\ H;="_P#!E#_\57PU11]7
M7<.0^Y?^%@>#?^AMT+_P90__ !5'_"P/!O\ T-NA?^#*'_XJOAJBCZNNX<A]
MR_\ "P/!O_0VZ%_X,H?_ (JC_A8'@W_H;="_\&4/_P 57PU11]77<.0^Y?\
MA8'@W_H;="_\&4/_ ,51_P + \&_]#;H7_@RA_\ BJ^&J*/JZ[AR'W+_ ,+
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M-_Z&W0O_  90_P#Q5?#5%'U==Q\A]R_\+ \&_P#0VZ%_X,H?_BJ/^%@>#?\
MH;="_P#!E#_\57PU11]77<.0^Y?^%@>#?^AMT+_P90__ !5'_"P/!O\ T-NA
M?^#*'_XJOAJBCZNNX<A]R_\ "P/!O_0VZ%_X,H?_ (JC_A8'@W_H;="_\&4/
M_P 57PU11]77<.0^Y?\ A8'@W_H;="_\&4/_ ,51_P + \&_]#;H7_@RA_\
MBJ^&J*/JZ[AR'W+_ ,+ \&_]#;H7_@RA_P#BJ/\ A8'@W_H;="_\&4/_ ,57
MPU11]77<.0^Y?^%@>#?^AMT+_P &4/\ \51_PL#P;_T-NA?^#*'_ .*KX:HH
M^KKN'(?<O_"P/!O_ $-NA?\ @RA_^*H_X6!X-_Z&W0O_  90_P#Q5?#5%'U=
M=PY#[E_X6!X-_P"AMT+_ ,&4/_Q5'_"P/!O_ $-NA?\ @RA_^*KX:HH^KKN'
M(?<O_"P/!O\ T-NA?^#*'_XJC_A8'@W_ *&W0O\ P90__%5\-44?5UW#D/N7
M_A8'@W_H;="_\&4/_P 51_PL#P;_ -#;H7_@RA_^*KX:HH^KKN'(?<O_  L#
MP;_T-NA?^#*'_P"*H_X6!X-_Z&W0O_!E#_\ %5\-44?5UW#D/N7_ (6!X-_Z
M&W0O_!E#_P#%4?\ "P/!O_0VZ%_X,H?_ (JOAJBCZNNX<A]R_P#"P/!O_0VZ
M%_X,H?\ XJC_ (6!X-_Z&W0O_!E#_P#%5\-44?5UW#D/N7_A8'@W_H;="_\
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M0_\ Q5?#5%'U==PY#[E_X6!X-_Z&W0O_  90_P#Q5'_"P/!O_0VZ%_X,H?\
MXJOAJBCZNNX<A]R_\+ \&_\ 0VZ%_P"#*'_XJC_A8'@W_H;="_\ !E#_ /%5
M\-44?5UW#D/N7_A8'@W_ *&W0O\ P90__%4?\+ \&_\ 0VZ%_P"#*'_XJOAJ
MBCZNNX<A]R_\+ \&_P#0VZ%_X,H?_BJ/^%@>#?\ H;="_P#!E#_\57PU11]7
M7<.0^Y?^%@>#?^AMT+_P90__ !536OC7PM?7<=K8^)='N;B5ML<,-_$[N?0
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M@*6;D#\1G\:S5:I&?)42U3:MY&KH4IT_:4F]&DT_/9_@8?\ PC.O?] 34?\
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M5U3I\TXSOM?\3BIUN2G.%OBM^#N%%%%:F 4444 %%%% !1110 4444 %%%%
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M..0,]J]E\?6D'Q1TO6KW3XE7Q/X5NIX+F"->;NS61@K@=RH'YAN.5KB_&/\
MR17X<?\ <4_]*%HC-NP7$7X&?$5T#+X=R&&0?MUO_P#'*H:[\)_&OAG19]7U
MO1?LUC;[?-E^U0OMW,%'"N2>6 X%:'P*_P"2U:%_V\?^D\E<9K?_ ",&H_\
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M&JVOCWP2D%]?3W,:R:R P5Y"P! 4C.#ZFO*:*'%WNF%C?\4^%O\ A%YK>/\
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M'X..O4@<KUQ@])X)TS1?A7K$WB;5O'6DZ@((9$BT[1+KSVNRRD!7'&!DYP>
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M#HXV*.&'!KCJ*JVMPZGI7A'7]#\0> )/ 7BZ^_LL1W/VO2]392T<,AR"C@=
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MM=&TO6[:ZCF=]0M#!$8U!"L589;)''(Z9KGJ*].I3C4CRRV/'I5949\\=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P">EO\ ]]T?\*IUS_GI;_\ ?=>R44?VQBO+[@_L#!^?WGC?_"J=<_YZ6_\
MWW1_PJG7/^>EO_WW7LE%']L8KR^X/[ P?G]YXW_PJG7/^>EO_P!]T?\ "J=<
M_P">EO\ ]]U[)11_;&*\ON#^P,'Y_>>-_P#"J=<_YZ6__?='_"J=<_YZ6_\
MWW7LE%']L8KR^X/[ P?G]YXW_P *IUS_ )Z6_P#WW1_PJG7/^>EO_P!]U[)1
M1_;&*\ON#^P,'Y_>>-_\*IUS_GI;_P#?='_"J=<_YZ6__?=>R44?VQBO+[@_
ML#!^?WGC?_"J=<_YZ6__ 'W1_P *IUS_ )Z6_P#WW7LE%']L8KR^X/[ P?G]
MYXW_ ,*IUS_GI;_]]T?\*IUS_GI;_P#?=>R44?VQBO+[@_L#!^?WGC?_  JG
M7/\ GI;_ /?='_"J=<_YZ6__ 'W7LE%']L8KR^X/[ P?G]YXW_PJG7/^>EO_
M -]T?\*IUS_GI;_]]U[)11_;&*\ON#^P,'Y_>>-_\*IUS_GI;_\ ?='_  JG
M7/\ GI;_ /?=>R44?VQBO+[@_L#!^?WGC?\ PJG7/^>EO_WW1_PJG7/^>EO_
M -]U[)11_;&*\ON#^P,'Y_>>-_\ "J=<_P">EO\ ]]U#?_"/7;O0]1LDEME>
M[@$2L7X4[U;)_P"^:]JHJ9YKB)Q<96L_(UI9+A:-15(7NM=SY=_X9I\4_P#0
M0T__ +Z;_"C_ (9I\4_]!#3_ /OIO\*^HJ*X_K$NR/8][^;\O\CY=_X9I\4_
M]!#3_P#OIO\ "C_AFGQ3_P!!#3_^^F_PKZBHH^L2[(/>_F_+_(^7?^&:?%/_
M $$-/_[Z;_"C_AFGQ3_T$-/_ .^F_P *^HJ*/K$NR#WOYOR_R/EW_AFGQ3_T
M$-/_ .^F_P */^&:?%/_ $$-/_[Z;_"OJ*BCZQ+L@][^;\O\CY=_X9I\4_\
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M_OIO\*/^&:?%/_00T_\ [Z;_  KZBHH^L2[(/>_F_+_(^7?^&:?%/_00T_\
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MH_X9I\4_]!#3_P#OIO\ "OJ*BCZQ+L@][^;\O\CY=_X9I\4_]!#3_P#OIO\
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MQ3_T$-/_ .^F_P *^HJ*/K$NR#WOYOR_R/EW_AFGQ3_T$-/_ .^F_P *O_\
M#/'B;_A'_P"S_MMCO^U>?NW'&-FW'2OI.BE]8EV0>]_-^7^1\N_\,T^*?^@A
MI_\ WTW^%'_#-/BG_H(:?_WTW^%?45%/ZQ+L@][^;\O\CY=_X9I\4_\ 00T_
M_OIO\*/^&:?%/_00T_\ [Z;_  KZBHH^L2[(/>_F_+_(^7?^&:?%/_00T_\
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MH_X9I\4_]!#3_P#OIO\ "OJ*BCZQ+L@][^;\O\CY=_X9I\4_]!#3_P#OIO\
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M=\:Z3J]W>V3P65RLKJC'<0/3BOH:BD\1)JU@][O^7^04445SC"BBB@ HHHH
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M67XY^%WACP!\)4EUB</XKDD'DS0SN1*V\;@J' VA.I(SGOR!7?>%_B[X,MO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA1CG.,<UQ^W@\/RPFDK.ZM>[_KKT._ZO-8KFG3<G=6E>R2M_6EM3F=(\/_\
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M^?3_ ,BO_C1_PC&D?\^G_D5_\:+4N[^[_@AS5OY5][_R-:BLG_A&-(_Y]/\
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M^?3_ ,BO_C1_PC&D?\^G_D5_\:+4N[^[_@AS5OY5][_R-:BLG_A&-(_Y]/\
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MHLVK@=7116)XE\7:/X2@MI-:N?*:[E$-O$JEGF<D# 'XC). *$F]@-NBBBD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMKJ)%!#?)&-TAXP-QP3GCW%+X*;XKZ#)I6CCP-H>FZ&EQ&ER\$JETB+ 2/\
M\?!+-MR<X))[&I5[7OJ(]FHHHKG("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUJ*/:R\ON7^0>PAY_>_\S)_L:\_Z&'4O^^+?_P"-4?V->?\ 0PZE_P!\6_\
M\:K6HH]K+R^Y?Y!["'G][_S,G^QKS_H8=2_[XM__ (U1_8UY_P!##J7_ 'Q;
M_P#QJM:BCVLO+[E_D'L(>?WO_,R?[&O/^AAU+_OBW_\ C5']C7G_ $,.I?\
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M_8UY_P!##J7_ 'Q;_P#QJM:BCVLO+[E_D'L(>?WO_,R?[&O/^AAU+_OBW_\
MC5']C7G_ $,.I?\ ?%O_ /&JUJ*/:R\ON7^0>PAY_>_\S)_L:\_Z&'4O^^+?
M_P"-4?V->?\ 0PZE_P!\6_\ \:K6HH]K+R^Y?Y!["'G][_S,G^QKS_H8=2_[
MXM__ (U1_8UY_P!##J7_ 'Q;_P#QJM:BCVLO+[E_D'L(>?WO_,R?[&O/^AAU
M+_OBW_\ C5']C7G_ $,.I?\ ?%O_ /&JUJ*/:R\ON7^0>PAY_>_\S)_L:\_Z
M&'4O^^+?_P"-4?V->?\ 0PZE_P!\6_\ \:K6HH]K+R^Y?Y!["'G][_S,G^QK
MS_H8=2_[XM__ (U1_8UY_P!##J7_ 'Q;_P#QJM221(8GEF=8XT4L[L<!0.I)
M["N)E^,_P^AOC:/XEMS(#C<D4K1_]]A2OZTU4F]E^"_R#V$?/[W_ )G1?V->
M?]##J7_?%O\ _&J/[&O/^AAU+_OBW_\ C5)J/BK1-+\,-XBO-1B_LA55C=P@
MRJ0S!5(V D\D#BJ.J?$/POHWAVPUW4M3\G3=0Q]EG^SRMYF5W#Y0I8<#N!1[
M2;Z?@O\ (/81\_O?^9?_ +&O/^AAU+_OBW_^-4?V->?]##J7_?%O_P#&JUJ*
M7M9>7W+_ "#V$//[W_F9/]C7G_0PZE_WQ;__ !JC^QKS_H8=2_[XM_\ XU45
MEXPT+4/%=YX:L[[S-7LH_-N+;R7&Q?EYW%=I^^O0GK6W3]K-=ON7^0>PAY_>
M_P#,R?[&O/\ H8=2_P"^+?\ ^-4?V->?]##J7_?%O_\ &JUJ*7M9>7W+_(/8
M0\_O?^9D_P!C7G_0PZE_WQ;_ /QJC^QKS_H8=2_[XM__ (U45[XPT+3_ !79
M^&KR^\O5[V/S;>V\ESO7YN=P7:/N-U(Z5MT_:S7;[E_D'L(>?WO_ #,G^QKS
M_H8=2_[XM_\ XU1_8UY_T,.I?]\6_P#\:J/PWXPT+Q='=2>'K[[8MI)Y4Q\E
MX]C>GSJ,_A6U0ZLUO;[E_D'L(>?WO_,R?[&O/^AAU+_OBW_^-4?V->?]##J7
M_?%O_P#&J=XB\2Z3X4TEM3U^[^R6:NJ&7RW?YCT&%!/Z4MUXDT>QT.'6+W4(
M;>PG1'BFE.W>'&5P#R20>F,T>TGV7W+_ "#V$?/[W_F,_L:\_P"AAU+_ +XM
M_P#XU1_8UY_T,.I?]\6__P :J/Q#XPT+PK)8QZ]??9&OY#%;#R7?S&XX^53C
M[PZXK:H]K/R^Y?Y!["'G][_S,G^QKS_H8=2_[XM__C5']C7G_0PZE_WQ;_\
MQJM:J5AK.G:I<W=OIU[#=26;A+@1-N\MB,[21QGV[4O:R\ON7^0>PAY_>_\
M,K?V->?]##J7_?%O_P#&J/[&O/\ H8=2_P"^+?\ ^-5%X8\8:%XRL9KOPW??
M;8(9/*D?R7CVM@'&'4'H16W3=6:WM]R_R#V$//[W_F9/]C7G_0PZE_WQ;_\
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MJ/[&O/\ H8=2_P"^+?\ ^-5K45/M9>7W+_(/80\_O?\ F9/]C7G_ $,.I?\
M?%O_ /&J/[&O/^AAU+_OBW_^-5K$X&3P*I:9K&G:U#-+I-Y#>10S-!))"VY0
MX R,]#C(Z4>UEY?<O\@]A#S^]_YE;^QKS_H8=2_[XM__ (U1_8UY_P!##J7_
M 'Q;_P#QJM:BCVLO+[E_D'L(>?WO_,R?[&O/^AAU+_OBW_\ C5']C7G_ $,.
MI?\ ?%O_ /&JUJ*/:R\ON7^0>PAY_>_\S)_L:\_Z&'4O^^+?_P"-4?V->?\
M0PZE_P!\6_\ \:JPVM::NM)HYO8?[1>(S"U#9?8,98CL.>]4K+QAH6H>*[SP
MU9WWF:O91^;<6WDN-B_+SN*[3]]>A/6G[2?9?<O\@]A'S^]_YDO]C7G_ $,.
MI?\ ?%O_ /&J/[&O/^AAU+_OBW_^-5K44O:R\ON7^0>PAY_>_P#,R?[&O/\
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M/[&O/^AAU+_OBW_^-5K44>UEY?<O\@]A#S^]_P"9D_V->?\ 0PZE_P!\6_\
M\:H_L:\_Z&'4O^^+?_XU6M11[67E]R_R#V$//[W_ )F3_8UY_P!##J7_ 'Q;
M_P#QJC^QKS_H8=2_[XM__C5:U%'M9>7W+_(/80\_O?\ F9/]C7G_ $,.I?\
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M_8UY_P!##J7_ 'Q;_P#QJC^QKS_H8=2_[XM__C5:U%'M9>7W+_(/80\_O?\
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MI?\ ?%O_ /&J/[&O/^AAU+_OBW_^-5K44>UEY?<O\@]A#S^]_P"9D_V->?\
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M,#Q^=:/CK1=4N_V@/!VHVFFWD]C;Q 3W44#-%$=[_>8# ZCKZT>.M%U2[_:
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M&V7Q%JNI>$=56\MX]/U!8I-.M\ M;SLJ%BQV<C)7N>AX%=K\3=%U2_\ V?\
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MFCB=0U$^'['Q1X= <--=K]F4]E<Y/_CH7\Z9HFAQ-\0+C1)U"H;5X'P,X/E
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M04OM5+-_+3\7J7E])O$..\:5U'_M[7\%H<-\6KB0:/I]HIVI/<98_P"Z./\
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M]AMT@\[9LW[1C.W)Q],FM6BG=VL 4444@"BBB@ HHHH **** "BBB@ HHHH
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img215454963_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %R @L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P!M%%=YK>BV
M.F2SK#X7GGMXX]WVD7;A1QDG'/2OHYU5!I/J?+4Z+FG)=/7]$<'177Z)X<LK
MS0P;K(U"^\S[%\Q ^0>GN<UR]I"'U""&53AI51E/'?!%$:L9-I= E1E%1;ZD
M%%>@R>'-+FU2\T\:+<VL,499;_SG*<#/1AC]3TK-T;PY97>A+]IR-1O1(UE\
MQ'"#T]SG\*S6*A:_I^)J\)4O;U_#^M#D**ZKPW!H^H)/;7>DLT]M;/.\OVEA
MO*GIM'3K^E0QVNEZAHFM7\%@;8VRPB)?/9]I+$,<G&<U3K)-IIZ6_'8A4&XI
MIK6_?IOT.;HKT&]\/6EK,B6OA::]C,:MYRWC("2.1BLRQ\.6FJ^%9+FW3R]1
M,TAA3>3O5>=GUQ_*I6*@U?I\O\RWA)I\O7Y_Y'(T5TMU!I6DP:7-/IIN1<V8
M=T\]H_GSUSS^5.\66^D:9=2:?9Z88Y@$87!N&;@C.-I_QJE63:23U_0AT&HM
MMK3UZ_(YBBM"VM(O[*N+R8 YD6"')( 8\ECCT _45;UC0A92SM:S)+# L.]0
M27!=<YZ#C/\ ,5?M(WL1[*7+S?U_6AB45JW'A^^MKNYMI!'OMXUD8@D@[B
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MMU]$4:.LD$L-W<R7B01M [$<JWRX('?'./QJK-HDZ1LT$]O=%'$<BP,248G
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <C\2?\ D46_Z^(O_0JZZN1^)/\ R*+?]?$7_H5==0+J%%%% PIC
M0Q/,DK1H9$!".5Y4'K@]LX%5+Y?-81_V@UL A=DBV^8P'?)!X^@S[U3T2<7#
M.T-[=21* 6BNMC'!&5(9?7T)/T% C:HHHH&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 51:]=-7^RE4\KR?,R&^?.['3T]ZO5CS(?^$DW^
M2N/LH'F[N?O],9_I2;L:4TFW?LS4\Y?0T><OH:@'2LP>(=*-U]F%XIEW^7MV
MG[V<8Z>M+F2W*C2<OA5S;\U?0T>8/>H1TI15$<J)?,'O2[A48ZTZ@EH?N%&X
M4RH+:[ANC)Y+[O+D,;\$88=10%G:Y:S2TVG4""BBB@ HHHH **** .1^)/\
MR*+?]?$7_H5==7(_$C_D4F_Z^(O_ $*NNH%U"BBB@9A:^DL]S:VZ2P*&RRK(
MZJ2P(Y!()P!G[I#>]7;%+:QE:RCND=F.]8CMWJ.Y..H]SSZDT[4[G3H8!'J)
MA9).%A=-YD]@F"6_ &HM#>TFLO-L=.^QVKX:/]VL?F*1D,%'0?7!]J!$EW=W
M,&IV,"QQ_9YV97<D[LA&8 #_ (#U_2LF#7+^8V49^SA[^.*6)A&<1!@S$,-W
MS<+@'CD]*Z&2".62*1U!>)BR'T)!'\B:J+HM@L;HL! 8J<B1@5VDE0ISE0,G
M & ,F@!UA?&?3XYY]JN7,3;0<%@Y3CV)'ZU=JC<01VUG;PPH$C26,*H[?,*O
M4#(OM"^AH^T+Z&JW>B@"VDH<X -/JO;_ 'S]*L4 %%%% !1110 4444 %%%%
M !1110 4444 %%%4+_54T^54:VN9LJ7<PQ[MB@XR>?T&3[4 7Z*Q;B6WUNQ,
ML/VJ6"*0_NX6\O[3@= 21E<GU'*UCV)>]73+"XDN%@>XN?,A,K!U"?=C9LY.
M,^O8=: .RHKCK%6O[VVTNYFG>UB>\Q^]8%Q'(JH"P.3@,?R%:-E/=GPC.T<^
M;B'SXTEERQ(1V4$\Y)P.M '045S=CJ.K7$-E:0O:FY^Q)<S32HQ!W<*  >O!
MR<_AS6E::C+?:"E]&L44S(3ME;Y%8'!R1VR#S0!I45B6&I?V];W%N!-;M&0&
MGMG#(W^Y)CGISQD9IWAR60^&8)'=Y' D^9V+$X9NI/6@#9HKBK226SL]&U*.
M:9[B]AD:XWRLPD/E,XX)P,$#&*-\FE6-A>V\\[37.GRRS>9*SAW$8<-@G .?
M3UH%<[6BN9TV'^S]6TR.*:=UN[-WG$DK/N==A#<G@_,>E4-:N88M;U9[J/4)
M%B@A,;6TK*L1(;DD, .<<GTH'<[6BN*,5W)K"07UM=W\T>G0&06]SY85R7#'
M[RYSC]*DNE@&O75O-;:G,D=K!Y26TDA,9^?.2&Z\#D^E '8T5PZQWSZE:6^H
M6MY>3+IR,\<-SY95M[#+'<H)Q@&K7B*]6W6RT^&\^P/%";K][-R2OW(R2><M
MG//\- CKJ*Y74H[34H=(U&)IQ]MN(@^RX=04*GC .!TIVHZ<8+W+07EUI\<
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M5I(E *DD<GOS70^%II9M#3SI'D9)9$WN<D@.0,GOQ6L(U&.!\O3CI3E55&%
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M=%^Q7Y/G>1YWV8_ZC.<XSZ?+BM71UO=.\07=O-'//!<JLAG6WV1K(!C'4CD
M?B*A3;9DIMM'4U3U:].G:1>7JJ':"%I IZ$@9IDURUQ:M&(+N(RPN=RKAD[?
M@WI7':EX+N?["NKA-<UF9_L[.+>67.XXSM(K0TYK['(M\2?$K,2+J%0>PA7
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MI5G/:I96%O!&6*K,GS-U8EP23[DDFM&@"CWHH[T4 36_WS]*L57M_OGZ58H
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MMF?(M[R,*8$7Y4;!!8?4']*9+X:M[C3M+T^XD,MK8A<QLHQ,57:-WYYK;HH
MY\^%;>#[<NG3M8Q7D*Q.D*# ()^8>A()%21>&;6UFE:S=K>&:T^S20J,JV!A
M6_W@./>MRB@#&L_#T-I-92&5I!:V/V+:RC#KQR?^^?UI^@:!;^'X+F"VD=HI
MIS,%;^ $ !1[#%:U% !1110 4444 %%%% !1110 4444 %%(2!U(&>.:,C=M
MR,XSB@!:*:9$5-[.H7^\3Q2)+'("4=6 ZE3F@!]%-26.0$QNK ?W3FC>F_9N
M7?C.W/- #J*3<-P7(R><4 AAD$$>HH 6BD) Y)Q2T %%%% !5?[%";_[;@^=
MY?E9SQMSGI5BB@:;6PFT>@HP/04M% A,#T%&!Z"EHH ,#THHHH **** "BBB
M@ HHHH **** "BBB@#D?B/\ \BI_V]1?^A5UU<C\1_\ D5/^WJ+_ -"KKJ!=
M0HHHH&8OB,S&T6)+>>>.4A66*(.!\PY;+#C&>.GK3] ,XMI(I83%'&P$:^4D
M7&.RJ3BCQ 89;-;::*616=7*K:O,C!6!*L%'0^]5?"=FEE93+'&(T+* !;-#
MNPH&\A@,DXYQQ0+J=#1110,JW_\ JHO^N\?_ *$*M55O_P#51?\ 7>/_ -"%
M6J ,V>>.WC,DKA4SC)JNNK6+MM6Y4DG&,'K60WC.Q#$?9[G@^B_XU6M_%ME#
M/=.T$Y$L@=< <#:H]?:F([*W^^?I5BL#0_$%MJUY)##%*C+'O)<#&,@=C[UO
MTAA1110 51OGU)77[#%;NF/F,K$'-7J* ,?SO$'_ #[67_?1_P :/.\0?\^U
ME_WT?\:V** ,?SO$'_/M9?\ ?9_QH\[Q!_S[67_?1_QK8HH Q_.\0?\ /M9?
M]]'_ !H\[Q!_S[67_?1_QK8HH Q_.\0?\^UE_P!]'_&CSO$'_/M9?]]'_&MB
MB@#'\[Q!_P ^UE_WT?\ &CSO$'_/M9?]]'_&MBB@#'\[Q!_S[67_ 'T?\:/.
M\0?\^UE_WT?\:V** ,?SO$'_ #[67_?1_P :/.\0?\^UE_WT?\:V** ,?SO$
M'_/M9?\ ?1_QH\[Q!_S[67_?1_QK8HH Q_.\0?\ /M9?]]'_ !J6WDUHW""X
M@M%AS\Q1CG'M6G10!GZK$\@LMB,VV[C9L#. ,Y-4=4M+IM<AO;1&,MO;,5'1
M9/F&4)]QT]P#6]10!E:1;;O#-E!<V_S"W3=%*G(..A![TFD6OV;PS;1"#RI?
MLJAU"8.[;W'K6M10!S/ARPN+2> W$*1G[!&JF*$H#ZA^3\XX_,^](UNWVEX_
MLLAU WXE6?RCCR]X.=^,8V?+C/MBNGHH PM7L[J;6;2ZM WFV\$K(>BL=R?(
M3[C/\^U6] 61-"M!+$\4FTDHXPRY)."*TJ* ,S7+075BI$/FR1S1LF!DCYUR
M1^&:TZ** *%[)JBS 64-N\6WDR,0<U6\[Q!_S[67_?1_QK8HH Q_.\0?\^UE
M_P!]'_&CSO$'_/M9?]]'_&MBB@#'\[Q!_P ^UE_WT?\ &CSO$'_/M9?]]'_&
MMBB@#'\[Q!_S[67_ 'T?\:/.\0?\^UE_WT?\:V** ,?SO$'_ #[67_?1_P :
M/.\0?\^UE_WT?\:V** ,?SO$'_/M9?\ ?1_QH\[Q!_S[67_?1_QK8HH Q_.\
M0?\ /M9?]]'_ !H\[Q!_S[67_?1_QK8HH Q_.\0?\^UE_P!]'_&CSO$'_/M9
M?]]'_&MBB@#'\[Q!_P ^UE_WT?\ &CSO$'_/M9?]]'_&MBB@#'\[Q!_S[67_
M 'T?\:L6<FJM/B\AMDBP>8V.<UH44 <C\1_^14_[>HO_ $*NNKD?B/\ \BK_
M -O47_H5==0+J%%%% S&\17%J+-;6>:-7E97"2(S(ZJP)#[0<)T!)X&>?2J_
MA*(0V,JB6&384B)MPWE$H@4D,0-Q..2..W:K&MZ1=:EO%M=PP"6UDMI/-@,F
M5?'(PRX/'O5^PANH(/+NI+9]N @MX3$JKCI@LU NI:J*XN(;6(RSR+'&"!N8
M]SP!4M4=3@FE%K+"GF-;SB4QY +C:RD#/&?FSSZ4#%NI8Y[6WEB=7C>:)E93
MD$;AR*NUGV-ALTN.WNE&XNTC*K'Y26+8!'IG'X5-_9]OZ2_]_G_QH$>0O_K&
M^IIM>K_\([I/_/E'^9_QH_X1W2?^?&/\S_C3N!R/@/\ Y#-Q_P!>Y_\ 0EKT
M&L^+1-.MV+0VPC8C!*.P./P-6([*&-PZB3<.F96/Z$TAEBBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Y?Q]:W%YX;$5K;RSR?:8FV1(6. W)P*ZBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **\]_X6<W_ $"1_P"!'_V-'_"SF_Z!(_\  C_[&NKZE7_E
M_(X_K^'_ )OP9Z%17GO_  LYO^@2/_ C_P"QH_X6<W_0)'_@1_\ 8T?4J_\
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M!'_V-'_"SF_Z!(_\"/\ [&CZE7_E_(/K^'_F_!GH5%>>_P#"SF_Z!(_\"/\
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M]2.YI&N9WMTMWFD:&,DI&6)52>N!VKU'_A7FB>MU_P!_!_A1_P *\T3UNO\
MOX/\*?UZA_2%_9V(\OO/+I[F>Y*&>:278H1-[$[5'0#/043W,]U)YEQ-)*^
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M2GFGN)8W>'[2!YZ(Y D/<D>YR<>]0M>73[]UQ*?,4(^7/S*,8!]0,#\J]/\
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M X_3TH%U-"BBB@95U#_CV7_KK'_Z&*L2_P"J?_=-5]0_X]U_ZZQ_^ABK$O\
MJG_W30!XO1115".M\!?\A"[_ .N0_G7>UP7@+_D(7?\ UR'\Z[VDQA1112 *
M*** "BBB@ HHHH **** "JEWJEA82)'=WD,+N,JKN <>OT]ZIZV^J((C9*WV
M?GSS H:8?[H;C^9]!6;K$]M_9EQ'!=0P7362F4WD9$DD6&P,G'/WNQP3TH Z
M.XNH+2'SKB9(HL@;W; R3@475W;V4!GNIDAB! +N<#)X%<3XDEN)]-P^FW8L
MK>")H#\I&\[<ELG/ ^4<=2?:M[Q*\DNB6SQILE:ZMBJ2_P )\Q>&Q^N*!&@N
MLZ8]I)=+?VY@B($D@D&$)Z9].HIJZYI3PR3+J%N8HL;WWC"Y.!GZFN4U7[0T
M>M27KP0WR-:1A8U/E^6)5*R<G)Y+ ],;<5I:K-/)H^/M]E>3"\MBGDKL5?WJ
MXW89N] 7-N/6=-EMY;B._MVAAQYCB0$)]?2GVFJ6-^[):7<4S*,L$;.!7-Z_
M87@TW4M2O'MDD-LL*)""5 W@Y8G&?Z<^M7KG4[BTTF\D74+2]NBJI;I;(%.]
MCM7/S'/)'ITH UFU2P2U-RUW"( YC,F\;0P.",^N144&N:5<K(T.H6SK&I=R
M)!A5'4GVK&\.EM-U)],DLIK2*:%981,R$LZ@*Y^4GK\I_.H[5+5_ VR\D:*!
MI6S*JYV'SB03[ XSGC% '1V>HV6H!C:7,4VS[P1LD?6K58&E77F:Y+!,;6YN
M%M@PN[;@%-WW6&3@YY'/K6_0,RM:8J;#$B)F[0?.,[N#P..#5L54UK.;#'E?
M\?:9\S'H>GO5L5'5D?:9BWNDR7NJW3LI1&MT$4PZK(I)!%4;33M0MX[6YN+3
MSI(IY6DA5AD[NC#)Q6O<ZLT.H&SALI[B14#G85  /U/M5R.[B,.^4K$R@;T=
MAE">QJ.6+9ER0;O<P['2+A+VQDFMU$8>>1DR"(MWW1_^J@:1<-#%NMAN&I&9
MLX_U>3S6^MW;&81">/S#QL#C/Y4X7=L2P%Q&2@RP#CCZT^2)2IQL<X^GW\+2
MF*V)0WS2_N]F_85 !7=P.:DTK3;V"736E@91#)<%\L#M#=.GK6_]KM3!Y_VB
M/R?[^\;?SI7O+:.)97N(UC?[K%Q@_C1R1O>X*G&][D].JH+P&],&T;!&)/,W
MC&,^G7\:>E[:R1M(EQ$44X+!Q@?C6ET:W18HJ*&XAN QAE20*<$HP.#4M,84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R/Q(_Y%,_]?,7
M_H5==7(_$C_D4S_U\Q?^A5UU NH4444#.8\16<YG+)<1[+MX1Y!LFG9FB8R#
MHZC''.1^-;>F2W,UDKW?^M).?W)B_P#'2S']:K:YI]Q?I:^0D<GDS>8T;W#P
MAAM8<,@)SS5K38)+>R6.6)8F!/RK</,/^^F )_*@1;HHHH&5=0_X]T_Z[1_^
MABK$O^J?_=-5[_\ U"?]=H__ $,58E_U3_[IH \7HHHJA'6^ O\ D(7?_7(?
MSKO:X+P%_P A"[_ZY#^==[28PHHHI %%%% !1110 445REWI=IJ_C6YAO5D>
M.*QB9%65E )=\]"* .KHK _X0O0O^?:7_P "9/\ XJC_ (0O0_\ GVE_\"9/
M_BJ -6UU&SO99HK>XCDD@<QRH#\R,#@@BI9;:"=E:6&.1D.5+J#CZ5SFB^!]
M.T?5IM25Y9)F=C&"Q"QJ3TZY;CN:ZB@!KHLBE74,IZ@C(H9%< .H8 @X(SR*
M=10!')!#+GS(D?(P=R@Y&<XIB6=K%GR[:%,D$[4 SCD5/10 UT25"DBJZ'JK
M#(-1)96L1S';0H<YRL8%3T4 -**S*Q4%EZ$CD4"-%38$4)_= XIU% $4-O!;
MJ5@ACB!.2$4+G\JEHHH RM:4DV&(T?%VA^9L;>#R.>35L54UI-YL/W#2XNT.
M0?N<'FK8J.K,_M,Y[4+1FUZ2>2TO)83 JJUNQ7D$]<$5%>6D]QJD%Y'8RB"$
M1^;&Y^:7TXSR5KJ*6I]FF2Z29QT4#W4MU%!9NTW]I%Q< #" ,">>OX>]6)-(
MN&TBZ\NW(N&O&D88&Z1-^<<]?7!KIH8(H _E(J;V+MM&,D]34N:2I*VI*HJV
MIR(TV3[,TWV>\)-PLG^K12I"XW!.A'M2R6-U]BM9'L9$E0R@>5&K#D\;HSP,
M^QXKK13@*?LD5[%')3Z9J$\#*MN(G;3TCVH<+N#Y*C\*2YT^XNX[R2VTZ2WB
M>&*+RF4 NP<$G [ =ZZ^EH=),/8IF3IUFUKK=^ZPB.!XXMFT8!(SG^E:]%%:
M)6-8QLK!1113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R/Q(
M_P"13/\ U\Q?^A5UU<C\2/\ D4S_ -?,7_H5==0+J%%%% SF/$6HI;WR6T5Y
M=173H#P^R&-?[S':<GV')]NM:^B8_LJ+_B8/?GG=<.,%CGGCL*HZLNKOJ!_L
M8E)!%^]:X;]R1S@*.3O]^F.N>!5_1QMTY 5NEDR?,^U',F[/.3T/MCC'3B@7
M4OU076;%X7E620HI"Y\E_F). %X^;\,U?KFK?0[VV>&6*."(6YC*VZSNR2%0
MRELL"5X;CKT&30,U[F>.YL8)H7#QO+$58=QO%7)?]4_^Z:S$M7L])@AE*F3[
M0KOM.0"TNX@>PSBM.7_5/_NF@1XO1115 =;X"_Y"%W_UR'\Z[VN"\!?\A"[_
M .N0_G7>TF,****0!1110!2O-8TW3Y1%>7]O!(1N"R2!21Z\USOBOQ1IX\,7
MW]G:M;F[*!4$4P+<L <8]LUNZAX?TG59UGOK"&>4+M#NO./2L/7_  /I<^AW
M4>F:;;Q7I3,3#@Y!!QGWZ4"=SQG[;=G_ )>I_P#OX:3[7<!R_P!HEW$8+;SG
M%;/_  A'B3_H$S?F/\:/^$)\2?\ 0)G_ $_QJB+,QQ?78Z74_P#W\->S>%?%
M&GGPS8_VCJUN+L(1()9@&X) SGVQ7F(\$>)"?^03/^:_XUZ?H7@?2X-$M(]3
MTVWEO0F96(R<DDXS[=/PI,:N;'_"3Z%_T%[+_O\ +_C4EOK^D74Z06^IVDLK
MG"HDH)/T%5/^$-\.?] BV_[YJ6U\+Z'97*7-MIEO'-&<HX7D&D5J9CZQK^IR
MZC)H<%A]FLI7@'VK<6N)$^\!@@*,\9.>15G4=4UBVTO398;:V^W7.Q)+>0GB
M0KD@$=AAORK-OO#&J1_VA:V*V%UI][<-=".ZD>-H)6^\05!W#.3CCJ:GA\+W
M(&DVMS)%-96-L(FQ)(KM)@!GR/<>O<T3VT%.]M#6?5S+X;_M6V,2$P^;^^SM
M7'W@<<\8(^M5=/\ $3_V+?7FK0K;S6*&2XC3G";-X(S[<?4&LX^'=772KC3(
MWLA9R7'F+&7DR$SDIGKR1^IJ:3PJQO;J./RUTV]M&MKE#*[.V0>1G/3)Q]:S
M3E=7(3G=-H=;7_BR;[!=M9:=]DNI$\R!2WFP1-_$6)PQ Z@#\ZFU'7+W3]<$
M!BMWL%"--("=\0=MJD]NN?P%93^%M;O)M,AOVT^6*PDC_P!-221998T.=I3[
MH)QR<U<F\,7-\=4EOUMI)[D_N2LTBJHQ@!@..,9^I-7._0JI>WNFGK^H:A81
M6QTZ*WEEFD\L12YRQQGC'H 2?I5[3;Y-2TVWO(Q@2H&(_NGN/P.16#_8.IWU
MWI[:K);306T11A$\BL7/&_C'.!^IJ_X>TR\TI+JWF,'V9I3) D;,Q0'J"6]^
M?Q-2F[B3ES>1,WB70T8JVK608'!!F7C]:3_A)]"_Z"]E_P!_E_QJ%O!_AYW9
MVTBV+,<GY:3_ (0WPY_T"+;_ +YJR]2EK/B'0Y38XU*WDVW2M^[F7Y>#R?:K
M8\2Z)_T%K/\ [_+6=J_A3P] ;+;IL4>^Y5#L3.[@\'GI5O\ X1#P_P#] FV_
M[YJ=+LC[3)_^$ET/_H+6?_?Y:7_A)=#_ .@M9_\ ?Y:@_P"$/\/?] FV_P"^
M:/\ A#_#W_0)MO\ OFGH5J6/^$ET/_H+6?\ W^6E_P"$ET/_ *"UE_W^7_&J
M_P#PA_A[_H$VW_?-+_PA_A[_ *!-M_WS0!/_ ,)-H?\ T%[+_O\ +_C3AXGT
M+'_(7LO^_P M5_\ A#O#O_0(MO\ ODTO_"&^'?\ H$VW_?-,"Q_PD^A?]!>R
M_P"_RTO_  D^A?\ 07LO^_RU7_X0WP[_ - BV_[YI?\ A#?#O_0(MO\ OF@>
MI/\ \)/H7_07LO\ O\M'_"3Z%_T%[+_O\O\ C4'_  AOAS_H$6W_ 'R:7_A#
M?#G_ $"+;_OF@-2?_A)]"_Z"]E_W^7_&C_A)]"_Z"]E_W^7_ !J#_A#?#O\
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M-M +$9^;!('.!]:T-+^U&T+70D5FD<HLI!=4)^4-CC/],=Z!%VBBB@95O_\
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M-#>LI!NHL$8_U)_^*H$>045W?_"!6_\ S^R?]\?_ %Z/^$"M_P#G]D_[X_\
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M1W\\ "XV1GCZU7_L6Y_Z#%Y^=;%% &/_ &+<_P#08O/SH_L6Y_Z#%Y^=;%%
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M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7Q'_ .15'_7U
G#_Z%76T44"ZA1110,**** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img215454963_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_3.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #[ EP# 2(  A$! Q$!_\0
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M81_"RD]3CTXZ>]4I-#*P06\85YI[SRXIAT>,J"I^G.?;FLU6BS1T)+;^MO\
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MK_C356FE927WDNC5;NXO[C$HK;_X1#7_ /H&R_FO^-'_  B&O_\ 0-E_-?\
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M:=LL6/4]/R%<=HT,VK6NB:7ID,JZAIFBZC!?1^65,4CJ51&R.I;D#\:]VHH
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M+8/:D-:R*,-,VX8&#DYSGFO4:* "BBB@ HHHH **** "BBB@ HHHH *@O?\
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M(005.T@CJ#D>GO7-:=X$NK+4["674UN+:W:">4M&1(\T5NT P<X"D'/KQ^-
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M0!R7A#3M9LIG.IF<'[.B2F1PRRS \N/WC9[\X7((XXP.MHHH **** "BBB@
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M5M_^PKI7]*]NJFK6)C*[?D%%%%24%%%% !1110 4444 %%%% !1110 4444
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MW!QU^]7NM%:PK2@N5?D8SH0G+F=_O9D^%[.?3O">CV5U'Y=Q;V,,4J9!VLJ
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"_%3_ ) .E_\
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M *,:M>N2'B;11\17TLW\?VTVJP"+!SYFXMMSC&<'- '6T444 %%%% !1110
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MWMUCCA6UN(=B3N'*;8Y$(!(0Y?/'%=-XBCNQX G\Z[FM[B*S#3O&L<S,0OS
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MSU[JNG'Q'I3"_M<+'/D^<O'">] '0T4R*6.>,20R))&W1D8$'\13Z "BBB@
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M>_Z[S_\ HEJO_E\O5?H9_P#+A^C_ %.F^'W_ "3W0?\ KRC_ )5YJW_)8/\
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MQ7T0?NGZ5X+X6_Y%C3_^N7]379@DG-W['GYC)QIJSZGI7PL 7X<Z8J@ ![@
M#L//DKL:X_X6_P#).]-_ZZ7'_H^2NPKD>YWK9$-S<1VT)>26*+/"F5MJD]AF
ML?0M=?43.+N;3U99FAC6"?<6*L03SZ\8KFOBS#'<:?H,,T:R1/J:AD89!_=2
M=17$+I6GV6N^'Y;6RMX9/[6MANCC"G&\=Q6L*+E!SOL85,0H5(TVMSWJBBBL
M3H"BO.?&'C+29+R;23IVJW%S8W4/F26\7R ;D=QD,,Y3(Z=ZZ7PKXIT[Q%%<
M06%M>6WV'9&\=U'L8 CY>YSP*?*[7L+F3=KZG0T45S7Q"=X_A]KKHS*PM'P5
M.#2&6K;[<?%=Y ^HS/:Q6\4ZP&.,#,C2KC(7=@;%QSZYS6W7SSJ&@Z=!HUW<
MQPNLR6S,K^<^00I([^M>Z^'V+>&]+9B239Q$D]_D%;5:,J32?4PH8B-9-QZ&
MC7)>+_%NGZ-<P:3=Z3=ZBUU$TIC@5" JL!SN8=R*ZVO+_'W_ "/NF?\ 8-E_
M]&)4TH*<U%]2JTW3IN:Z%WP+XNLR=-\.'1[VSNWM]S2RA-DCHB[VR&)R?<5Z
M'7D/A[_DH^A?]<+K_P!!6O7J=:FJ<W%$X>JZM-3?4*\/BUGQ1JY2]?Q)-$8+
MJ8PHMK"1&0SQ]UY^4D<YZU[A7A.A?\@YO^OFX_\ 1SUKA*<9S:DNACCJLZ=-
M.#L[GI7P[U74=7\-RS:G=&ZN(KV>#S2BH656P,A0!765Q'PL_P"18O?^PI=?
M^AUVLDB0QF25U1!U9C@#\:YY*TFCK@[Q39P_Q4_Y .E_]A:W_P#9JX;5ON67
M_7_;?^C5KM?B;<0W'A[2W@ECE4:O;@LC!AGYO2N*U;[EE_U_VW_HU:[,/_ G
M_70\[%_[S3_KJ>YT445PGIA1110 5E>(KE+;1+@-'-(TJ,B+$)<D[2?O1*67
MH>0.N .2!6K6'XPL!J/A34(/L\MPXB9TBBD=&9@.!\A!/T[]* *?@9[@Z-*E
MQ?W%VR2G;YUE);F($ [1YBAG'^T>M=17'^ +>YM[;4TO+-K>87.UG;SSYA"@
M9#3.S,!T!!VXZ=Z["@ HHHH \\^)'_(R>!O^PPG\UK,^,7_'[H?_ %[7_P#Z
M+2M/XD?\C)X&_P"PPG\UK,^,7_'[H?\ U[7_ /Z+2KI_&C.M_#9WWA+_ )$S
M0O\ L'V__HM:\IT/_DL<7_8;U'_T0U>K>$O^1,T+_L'V_P#Z+6O*=#_Y+'%_
MV&]1_P#1#40Z^G^05-X^O^9Z!\3_ /DFVM_]<5_]#6L[X4_\@_7_ /L+R?\
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M_P#L*Z5_2O7?$'_(M:K_ -><W_H!KR+Q1_R5M_\ L*Z5_2O7?$'_ "+6J_\
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M0_\ 0$KTGP[_ ,BSI7_7G#_Z *\V^,O_ !_:9_V#M0_] 2O2?#O_ "+.E?\
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MRHN(\ GCJ*]7U;[EE_U_VW_HU:[,/_ G_70\_%_[S3_KJ>YT445PGI!1110
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MQ8^D:;X@T;7+&UWQ2+$LL.\JK/\ ,#P0<E:R?%?PYUW3_$NF75_JMG/>ZSJ
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M][WH Z2JUOIUE:75S=6]I!%<7)!GECC"M*1G&XCKC)Z^M9RW&N/8,_V>)9C
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M%% !48N(#G$T9P_EGYA][^[]?:I*XN?PSJ:WCSV3H@N+]YKA"^./F\N5<?Q
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K]_XNE=#I%I-8Z:D$[JT@9V.S[JAG+!1P. " ..U7J* "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img215454963_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_4.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %G ET# 2(  A$! Q$!_\0
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M_P#$T?\ "N-&_P"?B^_[^+_\377T4?6JW\S#ZI0_D1R'_"N-&_Y^+[_OXO\
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M-_S\7W_?Q?\ XFC_ (5QHW_/Q??]_%_^)KKZ*/K5;^9A]4H?R(Y#_A7&C?\
M/Q??]_%_^)H_X5QHW_/Q??\ ?Q?_ (FNOHH^M5OYF'U2A_(CD/\ A7&C?\_%
M]_W\7_XFC_A7&C?\_%]_W\7_ .)KKZ*/K5;^9A]4H?R(Y#_A7&C?\_%]_P!_
M%_\ B:/^%<:-_P _%]_W\7_XFNOHH^M5OYF'U2A_(CD/^%<:-_S\7W_?Q?\
MXFC_ (5QHW_/Q??]_%_^)KKZ*/K5;^9A]4H?R(Y#_A7&C?\ /Q??]_%_^)H_
MX5QHW_/Q??\ ?Q?_ (FNOHH^M5OYF'U2A_(CD/\ A7&C?\_%]_W\7_XFC_A7
M&C?\_%]_W\7_ .)KKZ*/K5;^9A]4H?R(Y#_A7&C?\_%]_P!_%_\ B:/^%<:-
M_P _%]_W\7_XFNOHH^M5OYF'U2A_(CD/^%<:-_S\7W_?Q?\ XFC_ (5QHW_/
MQ??]_%_^)KKZ*/K5;^9A]4H?R(Y#_A7&C?\ /Q??]_%_^)H_X5QHW_/Q??\
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M]X@8)^M &!K/@;P]KD%K%=Z>J_9$\NW>!C$T2?W05(X]NE<;\ Q_Q0MZ>_\
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M2*5V%O;M"B-Y;?*%8#'_ ->OH^@04444 %%%% !1110 4444 %%%% !1110
M4444 >?>-;#4->DA27P==:@EI<2"!X=62WRI5<2?CR,'D8/K6IX"TV;3-/NX
MYM#NM)+R@B.XU 79?CJ&!X^E6/%'B'4]*O=+T[2-+2^O=0,NWS9O*1!& 3DX
MZG/ ]C5[0+K7+JWE;7=.M[&8/B-8)_-#+CJ3@8YH UZ*R]=\1Z1X:M%NM8OH
M[6%VVJ6!8L?90"3^55I/&?AV'P^FNOJT TQVVK.,G+?W0H&<\'C&: -VN(^)
M_P#R!M'_ .PU:?\ H1KJ-'UO3?$&GK?Z5=QW5LQ*[TR,$=00>0?8UR_Q/_Y
MVC_]AJT_]"- ';T444 %%%% !5/5@&T:^4C(-O("/^ FKE5-5_Y ][_U[R?^
M@F@#ROX/^%=!U3P5#J%]I5K<7:W4F)I$RPP1CGVKU^O./@A_R3J/_KZE_F*]
M'H \M^/7_(C67_82C_\ 1<E>I#I7EOQZ_P"1&LO^PE'_ .BY*]2'2@ HHHH
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M)KKG_7 ?^A+7,6W_ "<;=_\ 8-'_ *"E=/\ $_\ Y)KKG_7 ?^A+0!-\.O\
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M_P"@I73_ !/_ .2:ZY_UP'_H2T 3?#K_ ))WH/\ UZ)7+_'C_D08/^PA'_Z
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MO_7O)_Z": .#^"'_ "3J/_KZE_F*]'KSCX(?\DZC_P"OJ7^8KT>@#RWX]?\
M(C67_82C_P#1<E>I#I7EOQZ_Y$:R_P"PE'_Z+DKU(=* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#RGX@Z?9+XIM93X$?6)+MT6:[$C#?A&&Q<, & 4
M<GC'O6AX#TS[)XCN9K;P2?#]I]DV-++*7DD?>#M'S$;<#/3J.M'Q TC1[2X7
M5KR?Q#-=7LJP16>F7)&]@O\ "O;A2357X:7.G3:W-]AM?$47F6(F5]5N=Z/&
MS#:4'?.#S[$4#/4****!!1110 5P_P /O^0IXR_[#DO_ *"M=Q7#_#[_ )"G
MC+_L.2_^@K0!W%%%% !1110 4444 %%%% !1110!Y7XX_P"2R>"O^!?S->J5
MY7XX_P"2R>"O^!?S->J4 >5VW_)QMW_V#1_Z"E=/\3_^2:ZY_P!<!_Z$M<Q;
M?\G&W?\ V#1_Z"E=/\3_ /DFNN?]<!_Z$M $WPZ_Y)WH/_7HE<O\>/\ D08/
M^PA'_P"@/74?#K_DG>@_]>B5R_QX_P"1!@_["$?_ * ] 'I5M_QZP_[B_P J
M\Q^&_P#R4KQ__P!?8_\ 0Y*].MO^/6'_ '%_E7F/PW_Y*5X__P"OL?\ H<E
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M,M>IUY9J/_)QFD?]@QO_ $&6O4Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#@/B3>6VE76B:J=>ATK4+9IA;?:+5YXI0RJ'!" D$#&#[FL[P7IMOXB
MNXM:C\1QZB\.HO>7@AM&A0S&(1QJNX @!223WXK3\4^,;BUU".QLM0M]%ECD
M9))=7LY!%,.-ICD'RXZ]36KX+TN[M(M1U"]U6TU"?4IQ.S62X@7"A?EY/) &
M3WH ZBBBH$O+62&69+F%HHF99'$@*H5^\">Q'?TH GKB/B?_ ,@;1_\ L-6G
M_H1KL;6\M;Z 3VES#<0DX$D+AU)^HKCOB?\ \@;1_P#L-6G_ *$: .WHHHH
M**** "JFJ_\ ('O?^O>3_P!!-6ZJ:K_R![W_ *]Y/_030!P?P0_Y)U'_ -?4
MO\Q7H]><?!#_ ))U'_U]2_S%>CT >6_'K_D1K+_L)1_^BY*]2'2O+?CU_P B
M-9?]A*/_ -%R5ZD.E !1110 4444 %%%% !1110 4444 %%%% !1110!YO\
M$B;Q1J^G:GX<TWPI+<VDZQA-06[0 X*N?D(SP01U]ZZ+PWKWB'5;V6'5_"DF
MCPK'N29KQ9M[9 VX"C'!)S[5E>(?B-+X;\1_V9=>'K^6!I8UBNH%+B96C+,5
M&.6##&W/0$Y&,5L>'O&-KXCO);:#3-6M6CC\PO>VIB4C(& <\GGI0!T=%%%
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M -!-6ZJ:K_R![W_KWD_]!- '!_!#_DG4?_7U+_,5Z/7G'P0_Y)U'_P!?4O\
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M.]!_Z]$KE_CQ_P B#!_V$(__ $!ZZCX=?\D[T'_KT2N7^/'_ "(,'_80C_\
M0'H ]*MO^/6'_<7^5>8_#?\ Y*5X_P#^OL?^AR5Z=;?\>L/^XO\ *O,?AO\
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M6? /_D1+W_L)2?\ HN*@ ^*7_(]?#S_L)G_T9!7J=>6?%+_D>OAY_P!A,_\
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M_P!!- C@_@A_R3J/_KZE_F*]'KSCX(?\DZC_ .OJ7^8KT>@#RWX]?\B-9?\
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MT>Y^+/A"\@U:QEMH-WFS1W",D?)^\P.!^->E?\)AX8_Z&/2/_ Z/_P"*J/\
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M6K8DX+9P#R./>O2?^$P\,?\ 0QZ1_P"!T?\ \54?_"$>%/\ H6M(_P# */\
MPH_X0CPI_P!"UI'_ (!1_P"% &Y'(DL:R1NKQN RLIR&!Z$&G4V.-(8DBB14
MC10JJHP% Z "G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7">/F>]
M\0>%- DFFCL-1NI3="*0QF18T!"%E(."3^E=W6+XB\-6GB.&V$T]S:W%I*)K
M:ZMG"R1-TX)!&#W!% '*>#]4O]+TCQ/9VUM=:L-)U62WM(/-S(8B5PFYO[N2
M>:SO%FJ>*/$5C96\?@C483;WT-T2T\;;@ASC@]Z[_P .^';/PUI\EK:/-*TT
MS7$\\[[I)I&ZLQP.>!V[5KT <1_PFGB3_H0-3_\  F.N2\SQ5_PLW_A+/^$,
MO_)^R?9_L_G1[LXZYS7LE% 'GNI_$?5]&L)+[4/!&HV]K&5#R-<1X&2 .GN0
M*MGQGXD(_P"1!U/_ ,"8ZT/B%HM[XA\$WVF:=&KW4S1%%9@H.V16/)]@:Z>@
M#QOX>2>*O!/AZ;3)_!E_=-)=-/O2:-0 548Y/^S^M=/=^+?$MS93P#P%J:F6
M-D!-Q'QD8KO:* /(? 5UXI\'>&5TF;P5J%RZS/)YB31J/F[8)K<_X6/J_P#:
M_P#9/_"$:C]O\C[3Y'VB//E[MN[TQGBO0JY@:+>_\+1.N^6OV#^QOL>_<,^9
MYV_&.N,=Z ."^(<GBKQKH$&FP>#+^U:*Z6<N\T; @*RXX/\ M?I76_\ "9^)
M/^A U/\ \"8Z[>B@#F=$\1ZSJ>HBVO?"E[IL)4M]HFF1E!'; YYKIJ** "BB
MB@ HHHH **** "BBB@ HHHH **** .!U[X>:CJNMZO?V/BB;3H=5C2*YMTM0
MX=539@DL.Q/IUK3\(^%=6\-L([OQ--J=E';B""V>V6,1 8P0023@#'XUU=%
M!1110 4444 %%%% &;K^KIH/A^_U62)I5M(6E\M3@L0.!GMSWKC&U/XAI =:
M;2?#'D"#S"HF?SO+QNV^9]W^E>@W%O#=VTMO<1)+#*I22-QE64C!!'I7%_\
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MWIWAB1+BTFLH);R::SLYR2]O QRB'/0]3CWH Z^BBB@ HHHH **** "BBB@
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MN?Z4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZD]['
MIMR^G11RWJQDPQRMA6;L">PJU574K>XN]-N;>TNS9W$D96.X5 YB8]&P>N*
M/&]3LM=\0^+I;74/!'AZXU:&W2XD<W#J&0G:N2& 8\8YSQ7KVEQ77]@VT-W!
M#9W/D!'BMON1'&,+[#M7"K\./%":K)J:_$"<7LD0A>7^S4R4!R!]_'4FN_TR
MVN;/3+>WO+PWMS&@62Y9 AD/K@=* /,?#7B*Y\":$OAO4_".L375NSJLUA:B
M6*ZRQ(;=D=01Z_TKJ?AQI-]I?AVY>_M!927U]->)9@_\>R.1M3VQC./>NPHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/0;@?P//-/\ #GB;5]5U^WT+6)AK.F:G;.L[G3)+86[[22A+* RD C/N.G<
M]%_X2+1/^@SI_P#X%)_C5JXOK.T@6>YNX(87("R22!5)(R,$UY+8>#O#LOQF
MU72GTBV:PBTM)4@*_*KEDY^O)_.H?BE/IVK^)['PM<:A!86-C8RW#-)(%7SB
MA6)>?3Y3]&- 'L^1C.1CUJC::WI-_<M;6>J65S.GWHH;A'9?J <UY%JWBNYU
M3X"64T5PR3/+'IUY(#RH7@DG_: 7/^]78:A\/?"&GV^EW$,D>BS64Z&&]CE6
M-Y& X5F;AL_G^M '>50M]<TF[O&L[;5+*:Z7.Z&.X1G&.N5!S7,?%G4+K3OA
MQJ4MF[1R/LB9U."JLX#?F./QJC<_#OP?;>'-.E$L6DR6QBECU2.18Y"^,Y+M
MP<GGG\* /1**\XFUOQ7XD\2:]9^']0L].M=%*Q_OH!(US(0202?NKP1D?KVS
M8_B!X@UVW\&C2FM+2XUDW45SYL1=%:/ W+SGU8#/H#0!ZS17DDGQ!\0:'HOB
MBWU![:_U/2KN&VM[@1>6KF7."RCT"D_I[UMS:EXT\)6&IW^N3V.K6,%D9DFB
MC$+)-V0J.J^_6@#T"BO(O#/CKQ%/KFBK=W7]I6NI?+<11Z9) +-F *XD(PXR
M<$Y/]:I?\)MXV_X0J;Q;_:%A]EL[PPM:?9>9UWA<EL\=0,#TSF@#VJBO*(AJ
M@^-FI7$>H1@+H_G[3;@YBW+B/KU!P=WMC%)HGBOQ?<^ KCQ5?:CI$,#0,ENL
MR%%$@EVF1R 3T# *.N!ZT >L5#<7EM:>7]IN(8?-<1Q^8X7>QZ*,]3[5Y+I7
MBWQ!J>I:GH+ZPEY'+I+W<-[)IC6Y1@<$!&QN7&1G_ BLK1;B[L?AIX*>9K6Z
MBN-=C2&.6W!,"[Y <'/+9!(;C&<4 >ZT5Y?+XC\7:]-XDU#1+^RL;#1)Y($M
MY;?S&N6C&6W,3\N>V/7\:8OC;Q#XAU/PS:Z--:V']KZ?)-*TT/F")U+!BHR,
M_=. ?49H ]3J&2[MHKB&WDN(DGGW>5&S@-)@9.T=3@=<5RGP^U_5-8M]8L]8
MDBFO-+U"2S:>)-@E"]\=N<_I63I][+?_ !!\9ZHQR^C6:6EF&&0F59V./4LO
MY<4 >CU734+*6[>TCNX'N4&6A60%U^JYR.M>2VWC+QE#X?\ #OB>[OK&6RU"
M]2TDLEML,5+,-Y?/7Y3P.!QUYK.@F&E?&?4M:=]L*:K'8S'/&V:)\$_1D% '
MLSZOID;SI)J-HK6ZEY@TZ@QJ.I;G@#(ZU<1UD171@RL,A@<@CUKP[X<VRW_Q
M&O+J\CW?VSHT]W-&_0K+<# ^FW%=S\*+V:?PC-83R-(=*O9K!7;JRI@K^08#
M\* .YHHHH **** "F2H)8GC)P&4J3]:** ,CPIX<@\)^'K?1[>>2>*$N1)(
M&.YBW;ZUG6GP]T--5U34M2M8=5N=0G\TM>P))Y0[(F1P ./P'I110!=\*^%[
M?PG8W-E:7$LEM+<O/''(!^YW8^5<=N*R]4\ ^?KUQK.C:Y>Z-=W8 NQ;@,DV
M.A*GHWO_ (G)10!7B^%NDQZ1J6GM>WT@OIH[G[0\@,L<R#_6!L<DDDG/J:MI
MX'GFT[5+;5/$>IZA)?VYMB\K!4B3U6,?+N]^OZT44 6G\&6KS>&9#=39T",Q
MPC _>@HJ?-^"]JSK'X=_V;<)#9^(M5M]'CN#<)IT3A%!)R5WCYMF?X?_ -=%
M% &UK'AF#6=>T35I;B2.327D>-% P^\ '/\ WS5;4?!.F:SXJCUO5%6]6*V^
MSQ6<\:O$O.=V".3U_P BBB@"&S\ :/8:OJMU;1B*RU.V%M<:?'&J0D 8R ,8
M.,_]]&L>/X4Q>5#IUUXBU2YT&&0.FFR,-IP<A68<E<]N/PHHH [N[LK:^L)K
M&YA62VFC,4D9Z%2,$?E7"1_"F+RH=.NO$6J76@PR!TTV1AM.#D*S#DK[<?A1
M10!IZOX"6\UFYU32]:O='GO(EBNQ:A2LRJ, X(^5@.,C_&I+7P!I=A<>''LY
M9HH]"$WDIP?-,@PQ8^N>>/6BB@"&[^'.F7UMKL,]S<'^UKI;LNI :"1>A0_X
MTD'P[MIK?4UUO5K[5IM0@%N\LQ">6@((V*!@'(!SSR/KDHH FTOP7<V;N;[Q
M+JFH(+9K:&*1@D:*1C)5>'8#N::/A_9CPWH6B_;9_*T>\2[BDP-TC*6(!]OF
M/3THHH 9=_#Z"YO_ !!.NJ74<&N0[+FW"J5#  !@<9XYX]ZGU7P/%J&F:%;P
M:E<6ESHNS[+<HBN?E4+RK#!Z"BB@"D?AI:2:3K^GW&JWMP-:>.6>:0+O5T.[
M(P .2.F/85>@\$0?VO;:E?W\]]-%IK:;()44"9"Q))QWP<<444 9EI\,+>"2
MR@N-<U&[TBPF$]KITI78C DC+ 98#)XK4'@>T%IXEM_M<VW7G9YC@9BW CY?
MS[T44 :T&B6\/AB+069I+9+(698]60)LS]<5QGASPRVJ>'=)TC4YGBNO#&J!
M@T6"LWEDE#[ JP]^*** -S4/ UIJ&H:_=O=SHVLVB6LJJ!B,*,97W^M58OAM
MIL6L6NI"ZG,MOIHL N!AL1F,2'_:VDBBB@#+O_"P1?"?@NUD>6SL9_[0N9I,
M F.-CA<=]S/CCIBO2*** "BBB@ HHHH *P];\,6NN:MHVHSS31RZ5,9HEC(P
MY..&R.GR]J** )?$V@1>)]!N-(N+F>W@G*^8\! 8@$''(/&0*RM9^'7A[5M%
M334LX[$QE#'<VD2)*I7I\V.:** .DN+*&\T^2RO%%Q#+&8I5<??!&#G'K7"I
M\)[1;9M-?Q#K3Z+R5TXSCRQW SCD \XHHH O3_#FTV:9)IVJZAIU]I]HMDMW
M;LNZ6(?PN",'U[?RJR/ 5@(-%C:^OY6TJZ^UI+-+O>:3OO)'3CH,444 .OO
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MP??K^M%% #]$\!)H]]:3/KVKWMO8J5M+6>8".,8P,A0-V!TSTIO_  KG3/\
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E:F^'V@S>'_"<$-V5-]=.UW=%3D>8_)'X# _"BB@#J:*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img215454963_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T($IA
M8VMS;VX   60 P "    %   $*:0!  "    %   $+J2D0 "     SDV  "2
MD@ "     SDV  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M?V;BOY?Q7^8?VO@OY_P?^1WE%<'_ ,+,_P"H3_Y,_P#V%'_"S/\ J$_^3/\
M]A1_9N*_E_%?YA_:^"_G_!_Y'>45P?\ PLS_ *A/_DS_ /84?\+,_P"H3_Y,
M_P#V%']FXK^7\5_F']KX+^?\'_D=Y17!_P#"S/\ J$_^3/\ ]A1_PLS_ *A/
M_DS_ /84?V;BOY?Q7^8?VO@OY_P?^1WE%<'_ ,+,_P"H3_Y,_P#V%'_"S/\
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MNZG!JTMM<HDBW/D*ER6 P[CC<#GN/ITKI_\ A6?_ %%O_);_ .SH_P"%9_\
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M*=XTTMOY>FO<Y72=1BL8-0297)NK5H4V@<$D'GGIQ6;7>?\ "L_^HM_Y+?\
MV='_  K/_J+?^2W_ -G6RS#")MJ6_D_\CGEE>/E%1<-O-?YG!T5WG_"L_P#J
M+?\ DM_]G1_PK/\ ZBW_ )+?_9U7]I87^;\'_D1_9&-_D_%?YG!T5WG_  K/
M_J+?^2W_ -G1_P *S_ZBW_DM_P#9T?VEA?YOP?\ D']D8W^3\5_F<'17>?\
M"L_^HM_Y+?\ V='_  K/_J+?^2W_ -G1_:6%_F_!_P"0?V1C?Y/Q7^9P=;W@
MG_D<+'_MI_Z+:M[_ (5G_P!1;_R6_P#LZOZ)X&_L?6(+_P#M'SO*W?)Y&W.5
M(Z[CZUC7S##3HRC&6K3Z/MZ'1ALKQE.O"<H:)I[KOZG6T445\J?;!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH690<HA'56XSGBM+PIXQT+QOI4FI>&+[[=:13&!Y/)>/#A58C#J#T9><8YH
MVZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'.0#R,XH NR00RO&\L2.T9W(S*"4/J/2@V\+7"W#0QF95VK(5&X#TSUQ4E%
M!7-^ _\ D7;K_L-:K_Z<+BNDKF_ ?_(NW7_8:U7_ -.%Q0!TE%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '-^(_!=OXEFE^UZOJUO:W-O]FN[*WN0(+B/.2"K*=I.<%D*
ML1QFJM_\-M#O]7:\+75O!,;=KNP@=5M[LV^/),@*EOEPOW67(4 Y Q7744 %
M>;?!O_F??^QSU'_VG7I->;?!O_F??^QSU'_VG0!Z31110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"QSU'_ -IUZ37FWP;_ .9]_P"QSU'_ -IT >DT444 %%%% !1110 4444
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MN'[@<<8XQ7TO7S+JOQ$^'7B+Q;I\>L?#B^T_5Y+N)H[@!;:7>7 5FVXWC/\
M>!Z5]-'.#CKVH \G\;?%+6=#\6:EINE2^&;&#28XY)EUZ\>&:^W('_T<+P<9
MVY.?F!%>EZ+J7]L:!I^I_9Y+;[;;1W'D2C#Q;U#;6]QG!KRRZC^)&L:Y>R:K
MX!\*W[6<BBPN+R0-Y0V YC8J21NR3]W!X]Z]6TP7PTFS&KF%K\0)]J-N"(S+
MM&_;GG;NSC/:@"U7%GX8:3_;[7ZWEZEHVJC6GTU3&(&O0,>:3MW]0&V[L9 .
M.H/:44 %<WX#_P"1=NO^PUJO_IPN*Z2N;\!_\B[=?]AK5?\ TX7% '24444
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M<?4JHZ"JNN_#;6[[4M?M8);::P\23Z=/=7C2%)+=K8H9,1X(;?Y8(P< L<\
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M9H^BP&"ISHJH]W?MW\T>J6&K66I^9]AF\WR\;_D9<9SCJ/8U<KC_  %_R_\
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M=AX]_P"7#_MI_P"RUQ]? 9O_ +]/Y?DCZ_+?]UC\_P V=AX"_P"7_P#[9_\
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MTSPE>RR[_#S-&6B F8/#YH&X(2#\OH>>2:]MM[>*TM8K>V01PPH(XT7HJ@8
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MD_\ 035RJ>K_ /(#OO\ KWD_]!-95OX4O1FE+^)'U1Y76QX4_P"1GM/^!_\
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M+06LMO&\,31F,HA4%5*G[I P,=J +=%%5Y[^SM;FVM[J[@AGNF*6\4D@5IF
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M=X+_ 'JG_B7YGV>*_@3]'^1Z11117Z2?$!1110 4444 %%%% !1110 4444
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M):2NJ+>QZ4D0*-@D*Y0#.,G!/OB@#D?C5-HT306%EI;ZKXVUJ+[+I*(S,UH
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MVT_]EKCZ^ S?_?I_+\D?7Y;_ +K'Y_FSO/ __(#F_P"OAO\ T%:Z2N;\#_\
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M,+1B_.;C:8QCS3S\^/O>^: -2BBB@ KF_ ?_ "+MU_V&M5_].%Q725S?@/\
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M3+NMF!'EL"  X1 <CC!(SG@ ZK5?%GAS0;I;77-?TO3;AT$BQ7E['"[*20&
M8@XR",^QKB?@E<P7EKXWNK.:.>WF\87\D4L3ADD4B,AE(X((.017;:KX3\.:
M]=+=:YH&EZE<(@C66\LHYG5020H+ G&23CW-<3\$K:"SM?&]K9PQP6\/C"_C
MBBB0*D:@1@*H'   P * //O$_P#R-VL?]?T__HPUEUJ>)_\ D;M8_P"OZ?\
M]&&LNOT>C_#CZ(_+*_\ %EZL^CO#'_(HZ/\ ]>,'_HL5YG7IGAC_ )%'1_\
MKQ@_]%BO,Z_$^)_XD/67Z'[;P_\ PGZ1_4N:1_R'+'_KXC_]"%>J5Y7I'_(<
ML?\ KXC_ /0A7JE/A_\ A3]2LX_B1] HHJ"\O[33X1+J%U!:QLVT//($!/7&
M3WX/Y5]*DV[(\)M)79/17!W?CN\BU@6EM+H$D4F]HYSJ'RA0>-Y' )!Z?6NP
MT_5++4HS]BO;6Z>,#S1;S+($)]<'V/Y5O5PU6E%2DM&<U'%4JTG&#U1S?CW_
M )</^VG_ ++7'UV'CW_EP_[:?^RUQ]?G&;_[]/Y?DC[G+?\ =8_/\V=YX'_Y
M <W_ %\-_P"@K725S?@?_D!S?]?#?^@K725]?EO^YT_0^<QW^\S]0KP+Q)XA
MUJ/Q-JT$>KWZ0K>3(L:W+A0N\C &<8QVKWVOG'Q/_P C=K'_ %_3_P#HPU]?
MDD8RJ3YE?0^/X@G*-*'*[:C(/$.M6T"0VVKW\42#"1QW+JJCT !XKZ%U?_D!
MWW_7O)_Z":^::^EM7_Y =]_U[R?^@FCB.,8TXV727Z$\,SE*<U)WUC^IY76Q
MX4_Y&>T_X'_Z U8];'A3_D9[3_@?_H#5^+X+_>J?^)?F?KN*_@3]'^1Z1111
M7Z2?$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)IHK>
M"2:XD2**-2[R.P544#)))Z #O3ZJZF+%M(O%UCR/[/,#BZ^TD"+RMIW[R>-N
MW.<\8H Y/6X/AEXDOXKW7I/#6H7,2A$EN)X7;:#D*23R,D\'CDUV4$L,]M'+
M:NDD,B!HWC(*LI&001P1BOG/Q)X?\)KKVIOX5U#X73Z;J42)&NH7D<<E@0FU
MBGEG!!.7SP<G'0"O>_"]K%8^$-'M+:[AO8;>P@BCNH HCG58U =0O&T@9&.,
M'B@#5HHHH *YOP'_ ,B[=?\ 8:U7_P!.%Q725S?@/_D7;K_L-:K_ .G"XH U
MM6U"73;19H;"XOB7VF.W W*,$[N2../UJEX>\1GQ#'YT>F7=K;LF^.:8+MDY
MQ@8)KQ[Q'XBUN'Q1JL,.L7\<27DR*BW3A54.0 !G@5DV^OZS:P)!:ZM?0Q(,
M+''<NJJ/8 \5])3R9RI;J[ZZGRM3/5&ML[+IH?25>/UZ]%&(84C0L510H+L6
M) ]2>2?<\UY#7YEQ#_RZ_P"WOT/TG)OM_+]2YI'_ "'+'_KXC_\ 0A7JE>5Z
M1_R'+'_KXC_]"%>J5KP__"GZD9Q_$CZ!117+_$G_ ))[J7_;+_T:E?4T:?M:
MD:>UVE]Y\]7J>RI2J6O9-_<5?$>G7*^)-,6#6]5@CU*X=)(XK@!8P$)^0;>.
M1WS76VL'V:TB@,LDWEH%\R5LN^!U)[FOF*N]^$'_ "-UU_UXO_Z,CKZ#&98X
M8?F<[\J[;_B?,X'-E4Q/*J=N=]]OP.U\>_\ +A_VT_\ 9:X^NP\>_P#+A_VT
M_P#9:X^OQO-_]^G\OR1^M9;_ +K'Y_FSL/ 7_+__ -L__9J["N/\!?\ +_\
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M_P#18KS.O3/#'_(HZ/\ ]>,'_HL5YG7XGQ/_ !(>LOT/VWA_^$_2/ZES2/\
MD.6/_7Q'_P"A"O5*\KTC_D.6/_7Q'_Z$*]4I\/\ \*?J5G'\2/H%<%\7_P#D
M4;7_ *_D_P#1<E=[7!?%_P#Y%&U_Z_D_]%R5]EE_^]0]3Y+,_P#<ZGH>-5ZC
M\&/^8U_VP_\ :E>75ZC\&/\ F-?]L/\ VI7U>:_[G/Y?FCX[)O\ ?H?/\F=#
MX]_Y</\ MI_[+7'UV'CW_EP_[:?^RUQ]?@^;_P"_3^7Y(_<<M_W6/S_-G>>!
M_P#D!S?]?#?^@K725S?@?_D!S?\ 7PW_ *"M=)7U^6_[G3]#YS'?[S/U"OG'
MQ/\ \C=K'_7]/_Z,-?1U?./B?_D;M8_Z_I__ $8:^QR+^)/T/C.(OX4/4RZ^
MEM7_ .0'??\ 7O)_Z":^::^EM7_Y =]_U[R?^@FCB3^%'TE^@N%_XD_6/ZGE
M=;'A3_D9[3_@?_H#5CUL>%/^1GM/^!_^@-7XK@O]ZI_XE^9^OXK^!/T?Y'I%
M%%%?I)\0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W-
MM!>6LMK>0QSV\R&.6*5 R2*1@JP/!!!P0:DK/U];I_#>IKIUY'8WC6DH@NI<
M;()-AVNV>,*<$_2@#Q/QM=Z!H?BS4M-TKPE\.;&#28XY)EUZWCAFOMR!_P#1
MPJ8.,[<G/S BO:O#ES!>>%M*N;.Q_LZWFLH9(K/8$^SJ4!$>T<#:#C Z8KRN
M%?B3K.H23:YX%\*ZN]F8A:7=U*IQ\BDM&^PDY;)[8/';->M:9=RW%E"M_P#9
MX]16"-KNW@EWB%V'(SUQD, 3UQ0!<KD7^(^EIXD;2S:W?V==172FU+">0+QD
MWB'[V_."!G;C<0,UUU>,+X/UJ+7[C1UL+EDF\=)XC%\RCR!:A5<C=_>#+LV]
M>0>G- 'L]<WX#_Y%VZ_[#6J_^G"XK-\0_#3_ (2#7KC4_P#A-?&&F>?M_P!$
MTW5?)@CVJ%^5-IQG&3SU)-9$'P2@M8S':_$#QY"C.\A6/6@H+.Q9FP(^I9B2
M>Y)/>@#S[Q/_ ,C=K'_7]/\ ^C#677I$O[/&B3S/+-XN\8222,6=WU-"6)Y)
M)\ODTS_AG30/^AK\7?\ @QC_ /C5?40SNG&*CR/0^1J</U9S<N=:L]=KQ^LG
M_A!K[_A='_"(_P#"P?'']G_\(_\ VGYO]M-YOF_:/*QG;C;MYQC.>_:NA_X4
M)IO_ $.WC7_P;+_\;KX#,\OEC>3EE:U_QM_D?H&!QD<+S75[V_472/\ D.6/
M_7Q'_P"A"O5*\L3X#Z?'(KQ^./&ZNIRK+JZ@@^O^KJU_PIO_ *J/\0/_  >?
M_85>6X&6#A*,G>Y..Q4<3)-*UCTFN7^)/_)/=2_[9?\ HU*Y[_A3?_51_B!_
MX//_ +"HKGX(V][;M!>?$#QW<0OC='+K096P<C(,>.HKV:-14ZL9OHT_N/)Q
M%-U:,Z:ZIK[T>5UWOP@_Y&ZZ_P"O%_\ T9'5C_AG30/^AK\7?^#&/_XU5BS^
M 6F:?,9=/\:^-;61EVEX-55"1UQD1].!^5>[B<WIUJ,J:B]3YW"9)4H5XU7-
M.S.E\>_\N'_;3_V6N/K#^&OPZE^(/PUTGQ#K_CGQD;NZ\[<D6KGRTVS.@VAE
M8C(09YZUT_\ PH33?^AV\:_^#9?_ (W7YUC<GJ8G$2JJ25[?E8_0\+F4*%%4
MW&]O\SI? 7_+_P#]L_\ V:NPKS"W^!]M:;OLOC[QU#NQN\O60N?KB.IO^%-_
M]5'^('_@\_\ L*]?!8=X;#QI-WM?\[GFXJLJ]9U$K7_R/2:\%^)/_)0M2_[9
M?^BDKL?^%-_]5'^('_@\_P#L*H7/[/ND7MPT]YXR\97$SXW22ZHC,V!@9)CS
MT%>YE^+CA*KG)7TM^1X>98*6,HJG%VL[_@_\SS6O>OAM_P D]TW_ +:_^C7K
MBO\ AG30/^AK\7?^#&/_ .-5@ZS\/)O#GQ"\%^%]*\=>,XM.UK[=YX&L%6C\
MF(2+Y>U0HRS'.0<^U=>89E#%TE",;:W_ #./+<JG@ZSJ2DG=6_%?Y'3ZO_R'
M+[_KXD_]"-4ZNO\  ?3Y)&>3QQXW9V.69M74DGU_U=-_X4)IO_0[>-?_  ;+
M_P#&Z_.*F0U93<N=:GZ!#-H1BERL]5HKS;_A3?\ U4?X@?\ @\_^PKT#3;/^
MSM*M+'[3<7?V:%(?M%U)OEEVJ!O=OXF.,D]R37UA\\6:*** "BBB@ HHHH *
M*** "BBB@ KD=7^(^EZ/K]SITUK>2PV,EM'J%]&J>39M<'$0?+!CG*YV@X#*
M3UKKJ\:\6^$=:N=:\8Z;::=<SKXGO=+GM;M%!BB6%X_.\QL_+M$9(!Z@C&30
M![+7FWP;_P"9]_['/4?_ &G79:KHU]J-TLMGXEU32D5 IALX[5D8Y)W'S87;
M/..#C@<=<X&C?#9_#_V_^R/&/B"W_M&]DO[KY+%_,GDQO?YK8XS@<# ]!0!Y
M/XG_ .1NUC_K^G_]&&LNO6KKX+V%[>375SXH\0/-/(TDC?Z(-S$Y)P+?'4U%
M_P *.TK_ *&;Q!_WU:?_ "/7UE/.L/&"BT]/3_,^+J9#BI3<E*.K[O\ R.Y\
M,?\ (HZ/_P!>,'_HL5YG5FU@U^R^+D/@>V\9ZPFDP>'%OXV^SV)E5Q/Y(7<;
M?&W:/3.>];?_  JQ/^AN\0?]\V7_ ,C5^>9Q@:F.G&5)I6OOYV\F?HF5XJ&#
M@XU$WHMO(Q](_P"0Y8_]?$?_ *$*]4KAH?ACY$\<T7C#Q LD;!E.RR."#D?\
MNU:O_"+ZO_T/?B#_ +\:?_\ (M&5X*I@X2C4:=WT'C\5#$R3@GIW.DK@OB__
M ,BC:_\ 7\G_ *+DK9_X1?5_^A[\0?\ ?C3_ /Y%JAK'P\GUZS6UU;QGX@N(
M4D$BKY=BN& (SE;8'H37T&%JQHUXU);(\3&495\/*E'=H\0KU'X,?\QK_MA_
M[4J3_A1VE?\ 0S>(/^^K3_Y'INI>"+CP!X+\0ZOX<\7:Y%<6^GS7066.SD1V
MBC=D# V^<9ZX(ZU[6-S6AB,/*E!.[MV[^IX& R?$8;$QJS:LK[7[-=C?\>_\
MN'_;3_V6N/K9T+POJ/C'P7H&KZUXRUQKB[T^&Z98H;%41I(U9@H^S9QGIDFK
M?_"K$_Z&[Q!_WS9?_(U?FN/RBOB<1*K!JSMO?LEV/T;"9C2H48TY)W7IW]38
M\#_\@.;_ *^&_P#05KI*Y*Q\#WNFP&&R\;>((HV;<1Y5@>< =[;V%6?^$7U?
M_H>_$'_?C3__ )%KW<)1E0H1IRW2/)Q%15:LIQV9TE?./B?_ )&[6/\ K^G_
M /1AKVK_ (1?5_\ H>_$'_?C3_\ Y%KF[KX+V%[>375SXH\0/-/(TDC?Z(-S
M$Y)P+?'4U[^6XRGA)RE-/7L>!FN!J8R$8TVE9]?^&9Y+7TMJ_P#R [[_ *]Y
M/_037GW_  H[2O\ H9O$'_?5I_\ (]7TT?6[WQ;JNA7'C?7#:0Z;:S@B"P#L
M9I+E'!/V;IB%<8 /)YZ86;XRGC8*---63W\[>HLFP%7 2DZK3O;;ROY(YVMC
MPI_R,]I_P/\ ] :KG_"K$_Z&[Q!_WS9?_(U36GPWDL;I+BU\8^($E3.UMEB<
M9&.AMO0U^>X?),12K0J2E&R:?7H_0^[K9I1J4I02>J:Z?YG;45S]MX<U2"ZB
MEE\::Y<I&X9H98;$)( <E6VVP;!Z'!!]"*Z"OKCYT**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *;)&DT3Q3(LD;J59&&0P/4$=Q3J* .!
MNO@EX!N;IYTT1K3S&W/%9W<T$;?\ 1PH_ "NI\/^&-$\*V!LO#NF6VG0$@LL
M"8+G&,L>K'W))K5HH **** "BBB@ HHHH XY;K25^)T%]=Z#?6FJ7=O+I5IJ
MDS@1W$<9,S1B,/D<J[!B@R$.#@KGL:XRZTK6M1\>:5J3:9'9_P!GSS++?"\\
MQ)[0I(%C6+L[,T;,2!C80&88SV= !1110 4444 %5-2NKFSM?-LM/EU"3<!Y
M,4B(<>N7('ZU;K-\11:A/X9U*'12%U&2UD2U8G 60J0I_ D&@#'^' TN+P9#
M:^']'GTC3+6>:&WMYYO-W8D;>ZMN;*ER^#GGJ.,5U55].L+?2M,MM/L8Q%;6
ML2PQ(!PJ*, ?D*L4 %%%% !1110 R::.VMY)[B18XHU+N[G 50,DD^F*XZ+5
MO"OB-X_%]Y;7$;^&[J>UM+B=)4<-(J(Q6(<OO#*%!4DY&!DUVE87AG2[K39M
M<:[0*+S5)+F'# Y0H@!]N5/% %OP]K<'B3P]9ZQ:130PWD?F)'.NUU&>C#L:
MTJPO!>EW6B^#--T[4$"7-O$5D4,& .XGJ/K6[0 4444 %%%% !1110 4444
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MO"^HGX+6?A@"+^T8=)M[1AO^3S$1 WS>F5/- ':4444 %%%% !1110 4444
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M>5Y+>U9'+/:J(U$K-C:"7<C;G(&/K7HM !1110 4444 %%%% !1110 4444
M%%%% !117 ?&GQ7JW@OX;7&L:!,D-Y'<1(KO&'&&;!X/% '?T5X'JWB7XW>!
M=)3Q)KXT76M(A*-=06ZA76,D<Y"J1UQD;L9R00#7INL_$WP]HFCZ/?3M=7+Z
MW"LUA:6=NTT\Z% ^0@[ $9H Z^BN$3XP^%Y?!FH^)8OMSVNESK!?6YMBL]LY
M8* R,1W(Y!/?T-;&O^.='\/1:*]TTUP=<N8[:Q2V0.TC.,@\D?+R.?<4 ='1
M7!^(/C#X8\/:U>:7,NHWLVG@-?O8V3S1V8(SF1AP..>_0]QBNRTO4[/6M*MM
M2TNX6YL[J,2PRIT93T/_ -:@"U17)^+/B1H/@_4;?3;_ .V7FIW*&6*PT^V:
M>8H,Y<J.@X/7K@XZ&LG7/BSI?_"J;[Q=X5,FI>6KQ1HMNS&"<*2/.3@HH(!)
M/8@]"#0!Z%17G7P9\2>(/%GA675O$EW).\KIY2/IWV4(-N3L.3YBG<,-QT-4
M+GXQ21?&D>#UT6_-E%&4DECM6>224NJJ^/X80"<OSG(Z=P#U2BN!T[XQ^&]6
M\32Z#I]MJUQ>P7WV*;R[%FCA;<5WNXX5,@\GT/%%]\:/!^GZQ<64UQ>-!:3_
M &:YU&*S=[2"7.-C2@8!R1[4 =]17+^*_B%H?A&2R@OC<WEYJ +6MGI\!GFF
M4#)8*O8#G/U]*QKOXP:(_P .=4\5:';WFH?V:S0S69@:.2*8#.V0$?*HR,L,
M@<^AH ]!HKRG0_CAIT7PST_Q+XMM+ZU::X2TE=+,K&\KJS[H\MS& A^;)K0C
M^.?@Y[V>S/\ :D=VB"2"V?391+>*3P8DQELYR,@<9/0' !Z-17,^&OB#X=\5
M>%[G7].O#'8V9=;MKE?*:W*+N8.#TP#G/2LO0/C!X5\0ZU:Z;:R7UM)?[OL$
MMY9O#%>XZ^6Q&#^./SH [JBN!U?XR^%]&\2:EH-S'J4VI:<%,D%K9M*9 5#$
MKM[!3DDX J#Q#\8M*LOA2WC7P[;3ZM!))Y$2+$R^7)S_ *WNBC')[Y4#J#0!
MZ+17+?#CQ:_C3P/8ZK<6MS;7)BC2X\^W,*R2>6C,\8/6,EN&[UU- !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C
MO[3W_)(5_P"PC#_Z"]>Q53U31],UNS^R:UIUIJ-MN#^3=P+*FX=#M8$9YZT
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img215454963_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'U!98# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"K1117W!^;
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 20?\ 'Q'_ +PKZ%KYZ@_X^(_]X5]"UX6<[P^?Z'TO#^U3
MY?J%%%%>(?1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >1?$3_ )&EO^N2?RKDZZSXB?\ (TM_
MUR3^5<G7V&$_@0]$?!8__>JGJPHHHKH.0**** "BBB@ HHHH **** "BBB@
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M/85GUUQDI14EU."<7"3B^@44451(4444 %%%% !1110 4444 %%%% !1110
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M $$)_P#O@4?VGAN_X,/[&Q?\OXH\QHKT[_A6%E_T$)_^^!1_PK"R_P"@A/\
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MF.(IUYJ5-]#W\IPM7#4I1JJS;"BBBO./5"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHI"0.I H 6BDW+_>'YT;E_O#\Z %HI 0
M>A!I: "BDR,XR,^E!('4@4 +111D9QGF@ HH) ZFB@ HI,@DC/(I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /%4?\)_I7_/"Z_[Y7_XJO-J*V]G$\'^U\3W7W'KNC>(;37&F6VCF4Q %O,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7@/QP_Y*9X.^J?^CA7OU> _'#_DIG@[ZI_Z.% 'OU>>>/(E'Q!\ 3X^?[=,
MGX>77H=>9?%R6^T^Y\+ZM86<MW/:7L@2.,9.]XRJGTQNQUH Y+XMW-WXLEUI
MK.5H]+\*HK.R_P#+6Z9@,=/X0:Z[Q?=2>)#X?\$6TIWZC''=:DRGE+5 "0?]
MX\>M0:]X6;PY\"-6TU5::_EM_.NG5<M+,SJ6/'O_ "K3^&&E7,EE<^*=3A:+
M4-65 D3$DPVZ+M1/T)Z=Z *WQ2T#P[I_@35]3&C:;_:'D+%!-);JSEB0J@$C
M)..GTK;\*^ _#FC:3I4D>BV7VZW@0_:6MU\W?MY8MC.>36;\3X)]5F\+Z'#&
M2MYJJ222[21&L0W<_7I7H% '->/?$[>$/!]YJ\:1R7$>U((Y 2'=B !QSZ_E
M7*W_ (W\::3-I>JZEH6GV^A7MS%;& S,UTADX#''R@9YQR16G\0X9M3UGPEH
MHB9[6XU,7%PRJ24$2[EY[ FD\9PRZOX\\(:0D+26T,TFH709?W>U!A,^X8\"
M@!-:\8Z_>^(;K0_!]CI\LECM%Y?ZC*5@C<C/E@+\Q;U]/2KGAGQG=7NFZPFN
MVD-MJFB@_:TMWW1R+LW!T[X('0UY7?:7X,T?Q9XD7X@Z5?27=Q>/<:?.GG8N
MHFZ*OEMC=GUQUZUT(T)-/^#7B.\T7PK<:'<WT)V6WGR3SO&" "P;E3M)..PH
M [?1_%ES<?#4^*M2CMH':UDND16(0+R4!)[D8S[FL:]^(>JV.E>#Y3HZW%_K
M@)EM(CAE^3("Y/')&2>@S7,>(?%5IX@^']CX:\)Z?=7&GSM;6-U=K;,D=NI(
M!5=V"6X[ @#KUKK8+$7GQCBVQ.(-#T=80\B<,\C<%3[*.: *ESXP\:6MU#X>
M33=)O/%%R&G"02.+>S@R &E).6)YX&.U:?AGQ7KY\42^%_%FGV<&I&W-U;W%
MB[&&>,'!P&Y!!]:QM2URU\"_%;5]6UZ.X@TO5;.!(+U(6DC5XP05;:"03VXJ
MO9:C?Z_K>K_$ V<]AIMAI4EMI:SQ[9+@GYBY7TSC'UH M6/CCQGXH.JCPMHV
MG-!:WDD4-[>R,L<B+QM"@Y9B>_ %==X'\2R>+?"EMJLUJ+:=F>*6('(#HQ5L
M'TR*Y?2(W\*_ AIC;W NSI[SR(H/F>=+DGCM\S?A75>!]);0_!&CZ=(%$L5L
MGF;1U<C+'ZY- '$_&?5--BE\,:7K$Z1:9/?_ &B\)C+D)&,@;0"2"3@\4FE:
MM\&]:U6WT[3]-TN:\N'VQ1C26&X]>I3 K66"XU3XY2SO!BTTG21$'<'#O*V[
M*]N "*[B[N+73K26\N66*&%2[OCH!]* //O'2?\ "%^(M.\=6:%;4;;+5HD_
MCA/"/@#DJ?TP!3?#VBWOCW6HO%WB:';IL#;M&TQONJO::0=V/&,]/RJ"TTN^
M^*NIG5->MIK3PG 66PTV7*/=-R/.D'4#T'_ZSI> +VZ\/QZGX2U82$Z+E[2X
M*8$]J>5(]2!QCKTH X?6_.;QQXF\?6:-GP]?V]LT63EXD7;-@#KPP(^E=C\0
M;A=;U+P/I4$B?9]0U);LOU.V)=XQ]<U+\+M*^U> ;N74[:19=9N+B:Y\P%6E
M5V*@GTRN*YGX?Z7J7_"Q(+"_@?R_#%C-9+,ZD*X:4^6R9Z_)P3[4 >R7-Q':
M6LMQ,VV*)"[GT &37E%IX^\?ZMX4_P"$DT[P[I@L+<R22B>9@]S$I/,0S\N%
M!Y)Y["NQ^)>HR:5\.-<N8=IE-L8E![ER$_/YJX&U\: _#ZU\$:5IEX?%#68L
M'LI;=@L *[6D=NFW!)!![C(H ZO7_B/]B\.^&]2TJQ:YN-<EC$%JX.XJ5R1D
M=#R!D\<YJG>^-/&.FRQZ/-HVGW7B/4',EE:6LC&.WMP.9)W/H<CC ./IF.ST
M&6S\>>$-"9'FL=!TAYEGV_\ +8XCY/3H,@4WQ%J<?@OXJ#Q'K-K,VCWFGK:I
M?1QM(+1PQ)5@ 2 W'3V]\ &EH'BWQ':^*T\->,;"PANKJ)IK&ZL&;RI=OWDP
MQSN')_SFN4\):YKT?C?QAXGUN"RM]-M,VMZR2$F-H%^54!/.=P_&MG1[V;QU
MX]B\50Z?=1Z!H]K)'9/,A5KJ9NKHIYQCCWX^@YG18I/$WP+\1Z9IL<TVM&XE
MENXO**NSF7?MR1AFV@<#V% '1OXV\??8&\1C0-*BT1$\XV$MR?MIA R6S]T'
M'.",]JV]<\266HW_ (-LXK*TOK;6IC<(UPF[R@B;U=1V;G@]J\OM]/\ AMJW
MV*P\/>#+_4]:E*K<6LL]Q MKTW&5R2!CGIFN]MK.&T^*0,-I)#I?AO01$%P7
M +G<-A/)(5<>M #_ /A-_%&MZ_KNC>&=%M7;3KGR/MMZS+ F ,@XY9B<\#&!
M@GK6_P" O$]WXHT&2?4;6.VU"UN'M;E86W1ET."4//'XFL3X>"XT7X87.LW-
MJQO;DW.I2*PP\Q)9ESWR5"BM+X5Z:VF_#O2Q(&$MRK74@88*M(Q?!^F<4 4/
MB0!J.M>#= SM%WJHN6?&<"!2^,>^<5#=^,O%>NZE>0^#;#21864K0M?ZI,P2
MX=>"(U4YP#D;NA]JM202:I\;8Y?*<VVDZ25+NORK-*^05/<[17D^FZ7X#T:R
MN=-\7>'-2G\517$BBVB\_==@N=ACV-MQ@CGCH>M 'J5Q\1;Q/ %WX@73X8;W
M3+L6VHVCR;Q&0X5]K#K]X$5M^+?%,VBV.GPZ; ESJVJ3K!90/G:<\L[8YVJO
M)Q[5SI\(6L/P9U?3H=#&CR75I)<O9)<-<%7 W+EFYS\J\=C2?#F&_P#%%\/&
M>LVCVS1VRV.G6T@YC11^\D[<NP[C@#KB@">^\7^*=8U.ZL_"%GI)@L)#!<WV
MI2LL<DH'S)&JG/!_BZ4R7QY)??##Q+J%]:_8M2TU9K*ZBBDWJD^-H*MW&64U
MYI8:3X$T)+W3/&N@:C-XDBN9-B0^>3?*SDJ8]K!>A YQTKJ]1\/1V?PYTG1K
M#P_)I!UW5X/MFGB=YV$6<L69NGRJN1VH T4UK6O"FC>$?!FAVFG?VU<V(D>6
M^D*0+M W8Q@LQ.>!SWY[=9X/UKQ)?S7^G>)]&6SO;)EQ<VV3;7*MD@QD\Y'<
M?RZ5R7CG6_#?]MSZ!X\T5HM&CB1M.U)8I&RQ W@,@RIZ<#KCGM6Q\)I-3E\/
MWQNY=0ETX7CC2I-1_P!>UM@;2W<C.<9_EB@#OZ*** "BBB@ HHHH **** "B
MBB@ HHHH *SM0T+3M4F6:\M_,=5V@[V'')['W-:-%"=B9PC-<LU=&'_PA^A?
M\^7_ )%?_&C_ (0_0O\ GR_\BO\ XUN44^9]S'ZIA_Y%]R*&G:-8:4TALH/+
M,@ ;YR<XZ=3[U?HHI7N;0A&"Y8JR"J-KI5M:Z5_9P#26^&4B0Y)!))Z?6KU%
M .$6[M&19>';6SNHY_/NIS%GR4FEW+%V^4?2K=GIT5E]J\MG/VF9IGW'H3UQ
M[5<HIW;(A1IP^%&;'HEM&^G,'ES8!A%DCG<,'/%.MM'M;2YO9XMX>[.9,G@=
M>GXDFM"BB[!4::U2_JUOR(+.U2RLXK:,L4B4*I;KBIZ**1HDDK(****!A111
M0 4444 %%%% !1110 4444 %%%% !1110 5YO\:+F['A;3=,M;EK==6U.&QG
M=3@^6P8D9_ ?A7I%<[XR\&:;XXTJ'3]4DN8X89Q.IMW"MN (ZD'^\: ,K_A4
M_@/^S/L']@6GE_\ /3<WFY_W\[OUJE\&[B[/A34-.N;E[A-*U2>Q@=^6\I-N
M 3WZG\.*SO\ A0/A;_H(:U_X%+_\37:>#O!VG>"-(ETW3)+B2&2=IV:X<,VX
M@ \@#^Z* .AHHHH **** /&OVBO^1:T/_L(C_P! :O91TKQK]HK_ )%K0_\
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MB?\ ?/\ ]>D_LJY]%_[ZH_LJY]%_[ZH 4ZK.1@B,_5?_ *]']K3XQA,?[O\
M]>D_LJY]%_[ZH_LJY]%_[ZH 7^UKCT3_ +Y_^O1_:UQZ)_WS_P#7I/[*N?1?
M^^J/[*N?1?\ OJ@!?[6N/1/^^?\ Z]']K7!ZA/\ OG_Z])_95SZ+_P!]4?V5
M<^B_]]4 +_:UQZ)_WS_]>C^UI_1/^^?_ *])_95SZ+_WU1_95SZ+_P!]4 +_
M &M<>B?]\_\ UZ/[6N/1/^^?_KTG]E7/HO\ WU1_95SZ+_WU0!@^+M/F\5:?
M9V;7"0I;WT-VV8]V\(<[<9[UO_VK-N)"QC_@-)_95SZ+_P!]4?V5<^B_]]4
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M^RKGT7_OJ@!?[6N/]C_OG_Z]']K7'^Q_WS_]>D_LJY]%_P"^J/[*N?1?^^J
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M %%%% !1110 445F^(+.[U'PYJ5E83^1>7%K)%!*6*['92%.1R,'N* *>O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[I_QK;T#6+C5'G$R1J(P"-@(ZY]_:N&KJ/!W^LN_]U?ZT9=C*]3$QA*3:_X
M8W#4H492C'7_ ()UE>*7_P#R$+G_ *ZM_,U[77BE_P#\A"Y_ZZM_,U]=2ZGP
M>>?##YE>@=:*!UK<^=/8]!_Y &G_ /7NG\A6A6?H/_( T_\ Z]T_D*T*Y'N?
M=4?X<?1!1112-0HHHH **** "BBB@ HHHH **** "N>\>_\ )/?$?_8-N/\
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M:\<S6KX<_P"1AL?^NR_SK5TU8\6CF]5U$FKW?]=#UZBBBL#Z0**** "BBB@
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MD=P:^?WOX=(2'4_$7P>L;/1)6&9XXU:2!2>KKC/YA:]]M7ADM(7M\>0T:F/
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MOS/7J***Y#[H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#81'_H#5[*.E?.?QD^(/AKQ?HVDVFB7YN9H;X2.IA=,+M(SE@.YKZ,'2@
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MC%J'_7=JS*^@6Q^:U_XLO5_F%>J>"_\ D5[;_>?_ -"->5UZIX+_ .17MO\
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M;24Q7$%A-)%(.JL$)!_.MJL;Q=8W.I^#=:L+./S+FYL9HHDR!N9D( R>!R:
M.&\#^+-8N/@E?>(KNZ^U:E;PW4J23#.2@)4$#MQ74_#GQ!>^*? >FZSJ C%U
M<B3?Y2[5^61E&!] *\8TSP[\8-)\'W'A>VT.W_LZ>.2-PTT)?#@AN=_O5_P[
M:?&KPOH5MH^G:):"TM]VSS)(6;YF+')W^I- 'T#16)X1EUV;PQ9R>)8(X=7.
M_P"T1QE=H^<[?NDC[N.];3+N0KG&1B@#YVUS2_A*OB74Y;OQCK<-^]S(;A8
MQ"ON.Y01$<@'CJ>E>H?"E- 3PQ=+X;O=1OK 7K_Z1?\ WG;8F=O .WH.1US7
M(V7@3Q+X8TNTDLM*T[4KO1M5EDM59PLEY:2J0^YCQO\ F'7IM[\9[/X8Z-J^
MB^'+M-9MH[.6YU":ZALHY ZVL;D$1C'  .3@<<T =K1110 4444 >-?M%?\
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MH>+ZI_R%KS_KL_\ ,U4JWJG_ "%KS_KL_P#,U4KZ9'Y=/XF=_P##S_CUO?\
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M%=;X._U-U]5_K7)5UO@[_4W7U7^M<&5?[W'Y_DSKS#_=Y?+\R;QK_P BS/\
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M+U_0\O-?XD?0\7U3_D+7G_79_P"9JI5O5/\ D+7G_79_YFJE?3(_+I_$SO\
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M /;0?R-<-7<^*O\ D#_]M!_(UPU?!YS_ +S\D?:Y9_ ^85I^'_\ D.6WU/\
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M->I^(-3^(-GHV@MX9T>SU">2U!O_ +4P4H^U,8RZ]26]>E ',_M%?\BUH?\
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MTB9P'F0CD$=I?>MW431X^'RO$0JQG)*R:ZGOU%>/_P#"0_&[_H4-'_[^K_\
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M&_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!7OKN/3]/N;V;/E6\32OMZX49./RKS+1OB
MSJ=QJ6DRZQX=73]#UJ0Q6%W]I#-GMN7T/'I^-=_XHLI=1\*:M9P[O-FM)$0+
MU)VG KP2VU.W\6Z%X \):8)6U;3KM6O8FA<>0L9Y).,8_&@#Z0+J#@L ?<UX
M#\;V4_$SP<001E.__385U/C[X--XW\3OK(U\V0:)(_)%MO\ N]\[Q_*N7/[-
M+$Y/BPD^]C_]LH ]\\Q/[Z_G7*:C\0=*TV^GLY(;EI86*DJ%VDC_ (%7E_\
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M^\/SJK_PS2W_ $-A_P# '_[91_PS2W_0V'_P!_\ ME:>U\CRO[#_ .GGX?\
M!/3_ (?NHTBYRR_Z_P!?]D5UOF)_?7\Z\#'[-3CIXM;_ , ?_ME+_P ,UR?]
M#:W_ (!?_;*RD[NY[.&H^QI1IWO8][\Q/[Z_G1YB?WU_.O!/^&:Y/^AM;_P"
M_P#ME'_#-<G_ $-K?^ 7_P!LI&Y[M<R)]EF^=?N'O[5\]2$>:W(Z^M7_ /AF
MM_\ H;6_\ O_ +93?^&:&_Z&P_\ @#_]LKOP6-^J\WNWOYGFX_+_ *WR^]:U
M^E_U,_(]1^=*",]1^=7_ /AFAO\ H;#_ . /_P!LH_X9H;_H;#_X _\ VRN[
M^V_[GX_\ \_^P/\ IY^'_!/>;>1/LT7SK]P=_:L#Q>Z&SM\.OWSW]J\G_P"&
M:W_Z&UO_  "_^V4G_#-3G_F;6_\  '_[97S>*H^WI2IWM<^GP]3V,U.U['4[
ME_O+^8HW+_>7\Q7 ^)?@&WA[PWJ&K_\ "3&?[)"9?*^R;=V.V=YQ^54? OP3
M;QIX3M=<_P"$A-IY[.OD_9=^W:Q7KO'IZ5XO]A?]//P_X)ZG]K?W/Q_X![5X
M391JS99?]4>_N*[7S$_OK^=>!_\ #-3C_F;3_P" /_VRE_X9KD_Z&UO_  "_
M^V5ZV#POU:E[.]SSL37]O4Y[6-SQ$R_\)#?_ ##_ %S=ZS-P_O#\ZJ_\,TM_
MT-A_\ ?_ +91_P ,TM_T-A_\ ?\ [97H*K;H?-5,EYYN7/OY?\$M;A_>'YUZ
MGX,=!X8MLNOWG[_[1KR+_AFEO^AL/_@#_P#;*/\ AFIQT\6M_P" /_VRE*?,
MK'3@LM^JU'/FOI;;_@GOGF)_?7\Z/,3^^OYUX)_PS7)_T-K?^ 7_ -LH_P"&
M:Y/^AM;_ , O_ME9GJ'O?F)_?7\ZSM?=#X>U+YU_X]I._P#LFO%?^&:Y/^AM
M;_P"_P#ME)_PS4__ $-K?^ /_P!LJHRY9)]B9QYHN/<SR1D\C\Z3(]1^=:'_
M  S0W_0V'_P!_P#ME'_#-#?]#8?_  !_^V5[?]M?W/Q_X!\__8'_ $\_#_@D
M>DD?VQ9<C_CXC[_[0KZ!\Q/[Z_G7@7_#-+?]#8?_  !_^V4[_AFN3_H;6_\
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M+>:A*$CBA )4$XW-D\#- '4T444 %%%% !1110 4444 %%%% !1110 4444
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M." WOT->[T4 87@O3)]%\$Z+IMTH6XMK...50<X8+S^M;M%% !1110 4444
M%%%% !1110 4444 %%%% !UKSSPW;W,?QB\<3F%UCD@LQ'(RD*Q$?8]Z]#HH
M ^>->\)>/M#T_3TN%T2\>Y\00W;7,7G/-)<$MM:4X $8'!P!CBO?M/\ MO\
M9MM_:7D?;O*7[1]GSY>_'S;<\XSTS5FB@ HHHH **** "BBB@ HHHH ****
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MSD8]: %HKQK3O'_CWQ5XSU6Q\/V.DIIVEW1AD^T$[F4,5SG<,GY21@ 5[+G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR2S2C]W&2I;C<#N&.P->ST %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<^NR0<@]<Y)&.*^B/'WA ^-/"\VEQWLMG/N#Q2H3M+#^%@.JFO-=2^&_Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M@O$GPB\-^*?$XUW4FO#*0@DMTE"Q2;?7C/(XX(KO:* ([>"*UMXK>"-8X8D"
M1HHP%4#  _"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#-U_0[/Q)H=UI%^'-M<J%?8VUA@@@@_45F>$? 6
M@>"894T:U9))@!+/(Y=WQTR>P]ABNEHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img215454963_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T($IA
M8VMS;VX   60 P "    %   $*:0!  "    %   $+J2D0 "     S@Q  "2
MD@ "     S@Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<A;?#;1[7XHW?CR.YOCJEW"(7A:1/( $:IPNW=G
M"#^+KFNOHH YSQKX"T#Q_I":?XCM3*L3%X9HVVR0L>I5O?N#D' XX%8O@+X-
M^%/AW>R7VC1W5S?.AC%U>RAW13U"A0JCIUQGWKO:* .'\??"+PM\1I8;C7(;
MB"]A78MY9N$E*9SM.00P^H.,G&,U?\"_#KP]\.]-EM/#MO(&N"IN+F=]\LQ
MXW' &!D\  <GCFNIHH \P\4_L_>"/%?B"36+F*]L;F>3S+A;&942=NY92IP3
MW*XR<GJ<UWOA[P]IGA;0K;1]"M5M;*V!$<8)/4Y))/)))))-:5% !7FW[0?_
M "0GQ#_V[?\ I3%7;^([.^U'PKJMCI%S]DU"YLIH;6X\QD\J5D(1]R\KAB#D
M<C'%?+?Q!^&GQ3\/^!-0U/Q7XU_M/28/*^T6G]JW4WF;I55?D=0IPQ4\GMGK
M0!])?#C_ ))9X4_[ MG_ .B$KI*YOX<?\DL\*?\ 8%L__1"5TE !2,P12QZ
M9.*6B@#G/^$[T;TO?_ *7_XFFKX_T-RP1KQBIVMBSD.#Z'Y:Z6N>\+_\A#Q#
M_P!A1O\ T6E=D?82C*7*]//_ (!PS^L1G&/,M?[OE_B+>E>)+#6;EX++[1O1
M-Y\VW>,8R!U8#UK6HHKEFXM^ZK+[SK@II>^[OTM_F%%%%26%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7Y )0=AG S7N5>)? W_DJ?Q9_P"PT/\ T?=4 >VT444 %%%% !1110 4444
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M4#']Y/J17M?A7Q':>+O"UAKVG1RQVU]'YB), '7D@@X)'4&@#7HHHH ****
M"BBB@ HHHH *\V_:#_Y(3XA_[=O_ $IBKN];EU&#0-0ET.".YU..UD:SAE.$
MDF"DHK<C@M@'D?45\Y?%+7OC)>_#75+?QIX3T?3]$?R?M-S;2JTB8F0K@"=N
MKA1]T\'MUH ]W^''_)+/"G_8%L__ $0E=)7-_#C_ ))9X4_[ MG_ .B$KI*
M"BBB@ KGO"__ "$/$/\ V%&_]%I70USWA?\ Y"'B'_L*-_Z+2NBG_#G\OS.:
MK_%I^K_)G0T445SG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M83JMO#!(%41K%)O#)M&"?0]>*=3#<E%5&UNUNO+_ #%3Q2J5W22>R>J:ZO\
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M.""*UMXX+=!'%$H1$7HJ@8 J2N:I+FFY=SKIQ<(*+Z(****@L**** "BBB@
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MHHHKG.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^+/_ &&A_P"C[J@#VVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***IW*ZF9O\ 0Y+18L=)48MG\"*B<N57M?T*C'F=KV+E
M%8MI=:U=M<!7L%\B8Q',3\D '/WO>M:#SA OVDQF7^(Q@A?PS6=*LJNJ31=2
MFZ>[1)1116YD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MENZU%M2\'7KS*$GB)BE5>@8$=*=:P:V^DPW45\D3+$&CMO)!4KC@$GG)%1W
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M_8:'_H^ZH ]MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIKJ:\_\ A1\/]:\!6>I0Z[X@;6FNY(VC=BY\L*""/F)ZYKT"@ HHHH ****
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M3RI6>X+IM;E<,2,'D8YKW^O$O@;_ ,E3^+/_ &&A_P"C[J@#VVBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S1O]9J
M7_7\_P#Z"M:=9FC?ZS4O^OY__05K3KGPW\)?/\V;5_XC^7Y!111708A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %8EA_R.>K_]<+?_ -GK;K$L
M/^1SU?\ ZX6__L]4MF<];XZ?K^C-NBBBI.@**** "BBB@#GO%7BK_A&?LO\
MH?VG[1O_ .6NS;MV^QS]ZN>_X6G_ -0?_P FO_L*7XI_\PK_ +;?^R5Y[71"
M$7&[/D<QS'%4<5*G3E9*W1=EY'H/_"T_^H/_ .37_P!A1_PM/_J#_P#DU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,YZWQT_7]&;=%%%2= 4444 %%%% '+>-/#-YXC^Q?898(_L_F;O.8C.[;C&
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M'*Z?=:]HMBNG3Z,]\;==D$\,RA74=,YY'I2:W9:WJ/@NYBO(DDO9I%9((/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S-&_UFI?\
M7\__ *"M:=9FC?ZS4O\ K^?_ -!6M.N?#?PE\_S9M7_B/Y?D%%%%=!B%%%%
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M7*]0/*V^7T_A)SV(S7>_M&^%;_Q-\+_,TJ)YY]+NENWAC7<SQA65L#U&[=]
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M10!]14445^:'ZP%%9'B3Q):>%]-CO=0CGDCDE$0$"@G)!/<CCY37,_\ "W]
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MKT6@ HHHH ^1/AMXXU+1?&_B_5M+\(W?BC6[Z=G_ ' /^CQ>8[2$D*Q^9B@
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MOQ!_: T+2[:VM?!IMYKV.^$=]!>Z=(OE1@$,<$+\P( _I71?\+]^%7_00_\
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M""0,XKU+X<^.K/XB>#;?7;*(V[EVAN+<MN,,JXRN>XP00?1ATH U_$?]J?\
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MHXI8IA*&8,=Y+#@G<3GWS6_7GGP(?3G^"^AMI,4T46V02),^YO-$C!SG X+
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M@#Z "MRO./A!X4UWPK9ZM#XB\4Q^(9)9DV,ET\WD;0<J=_0G(XKT>@ HHHH
M**** "BBB@ HHHH S?$>K_\ "/\ A75=9\C[1_9UE-=^3OV>9Y:%]N[!QG&,
MX-?+?Q!_:+_X3OP)J'AS_A%_L'VWRO\ 2/[0\W9LE63[OE+G.S'4=:^MJ\V_
M:#_Y(3XA_P"W;_TIBH Z7X<?\DL\*?\ 8%L__1"5TE<W\./^26>%/^P+9_\
MHA*Z2@#@OB__ ,BC:_\ 7\G_ *+DKQJO9?B__P BC:_]?R?^BY*\:K[3)_\
M=5ZL^"SS_?'Z(****]<\0**** /J*BBBOS0_6#@OB_\ \BC:_P#7\G_HN2O&
MJ]E^+_\ R*-K_P!?R?\ HN2O&J^TR?\ W5>K/@L\_P!\?H@HHHKUSQ HHHH
M^CO#'_(HZ/\ ]>,'_HL5J5E^&/\ D4='_P"O&#_T6*U*_.:W\27JS]2H?PH^
MB"BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBL3QAXHLO!?A&_P!?U(,T%G'N
M\M?O2,2%51]6('MF@#RSXHZ?XL\'?$^U^(WA'2O[:@:Q%E>VHC9V0!LYPOS
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M+>64<SJH)(4%@3C))Q[FO)/@);06?Q)^*EK9PQP6\.K+'%%$@5(U$UR J@<
M #  H ]RHHHH **PKOQIH-C>2VMU>2)-$VUU%M*V#]0N#4"_$'PTZY74)&'J
M+2;_ .(KH6&KM74']S.9XO#IV=1?>CI**9#,EQ;QS0G='(H=201D$9'!I]<^
MQTWOJ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#\<?\AN'_KW
M7_T)JYNND\<?\AN'_KW7_P!":N;K\[S+_?*GJ?9X'_=H>@4445P'8>D>%/\
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M!N/T .3["O3J9-#%<V\D%Q&LL4JE'C=<JZD8((/4$4 <!\.;SP[X[^"^G:7
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M*** "BBB@ HHHH **** "BBB@#@_''_(;A_Z]U_]":N;KI/''_(;A_Z]U_\
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M9(UA0P21^:""2?GZXP.GK7H-<#\(OB)-\0_"LT^I6@LM6T^<VU[ H(&\#(8
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M.:W\27JS]2H?PH^B"BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M[XI_\PK_ +;?^R5I3^)'EYO_ +E/Y?FCSVBBBNL^""O4OAE_R+5Q_P!?;?\
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MZ2N;^''_ "2SPI_V!;/_ -$)724 <%\7_P#D4;7_ *_D_P#1<E>-5[+\7_\
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MH **** "BBB@ HHHH **** "BBB@#@_''_(;A_Z]U_\ 0FKFZZ3QQ_R&X?\
MKW7_ -":N;K\[S+_ 'RIZGV>!_W:'H%%%%<!V'I'A3_D6+3_ ('_ .AM6Q6/
MX4_Y%BT_X'_Z&U;%?I."_P!UI_X5^1\1BOX\_5_F%%%9EPVLQ)+(DECL4%@#
M&^<#_@5;5*G(KV;]#*$.9VO8TZ*Q[2;6KNSAN%DL%$J!P#$_&1G^]6Q2I5?:
M*Z37J.I3Y'9L****U,QD\C10.\<9E91D(IP6]N:R9M<NK<(9M(G4.X1?WB\L
M>@ZULUF:Y_J[+_K]A_\ 0JY,3SJ#G"5K>GZHZ*'(Y*,HWOZDEK?W<]PL<VF3
M0(<YD9U(''L:OT45T0C**M)W^[]#*4E)W2L%%%%60%%%% !7GWQ3_P"85_VV
M_P#9*]!KS[XI_P#,*_[;?^R5I3^)'EYO_N4_E^://:***ZSX(*]2^&7_ "+5
MQ_U]M_Z E>6UZE\,O^1:N/\ K[;_ - 2LJOPGLY+_O:]&=C1117*?<&1=3>(
M5NI!9VE@\ /R-),P8CW %4-/U?Q'J=DMU;V&GB-F91NG8'Y6*GMZBNFK$\(?
M\BS!_P!=9O\ T:]7?38X94Y>V4>=V:;Z=&O+S-B(R&%#,%63:-X4Y /?%/HH
MJ#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KRK]HZ"6X^#EW';Q/*YNH,*BEC][T%>JT4 ?&_B7XI:QXB^
M$]AX(;PI-;QV<%M"+P.[%_)4#.W8,9QZ\5U/AW]HG6_#_A?2]&7P-).NG6<-
MJ)3.Z^9Y:!=V/+.,XSBOI^B@#&\(:Y+XF\'Z9K-Q:?8I;V 2M;EB?+)[9('\
MJV:** /,?CWX1U/Q7\/$;0(WFU#2[M+Z*%%W-*%#*0H[G#9QWVX[UY__ ,-5
M745D+2?P:XUE1Y;)]I*IYO3[FS<.?X>O;/>O4?C!\1)?AMX)&J6=JEU?7-PM
MM;)+G8K%68LV""0 IX!Y)%>4P^,OC]=K'>1>$X1YB[D9]/56 /LS;A^- '<?
ML^^%-9T+PQJFK^)+=K2^UV\^U?9W7:R)@X)7JI)9N/3%>MUY_P#"C5O'VJV>
MI-\1]-6PFCDC%J%B";E(.[H3GG%>@4 %%%% !1110 4444 %%%% !7FW[0?_
M "0GQ#_V[?\ I3%7=ZW8SZIH&H6%G>R6%Q=6LD,5W%G?;LRE1(N"#E2<C!'3
MJ*^<OBE\*?%7AKX:ZIJVJ_$[6-=M+?R?,T^Y$OES;ID49W3,."P;H>5_&@#W
M?X<?\DL\*?\ 8%L__1"5TE<W\./^26>%/^P+9_\ HA*Z2@#@OB__ ,BC:_\
M7\G_ *+DKQJO9?B__P BC:_]?R?^BY*\:K[3)_\ =5ZL^"SS_?'Z(****]<\
M0**** /J*BBBOS0_6#@OB_\ \BC:_P#7\G_HN2O&J]E^+_\ R*-K_P!?R?\
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M)(>%50>Y)_ 9)X%?/W_"ZO%DL?\ ;5O\+=//AY<NTO\ 9TK#8.O^D ;!]=M
M'M?PR^*-A\3K34+C3M/N+);%T1A.RG=N!/&/I7<URGPY\5:#XT\)QZUX<M8[
M1)&,=Q;JBJT,J]5;;UX((/<$?2NKH **** "BBB@ HHHH **** "O-OV@_\
MDA/B'_MV_P#2F*N[UN+49] U"+0YX[;4Y+61;.:492.8J0C-P> V">#]#7SE
M\4M!^,EE\-=4N/&GBS1]0T1/)^TVUM$HD?,R!<$0+T<J?O#@=^E 'N_PX_Y)
M9X4_[ MG_P"B$KI*YOX<?\DL\*?]@6S_ /1"5TE '!?%_P#Y%&U_Z_D_]%R5
MXU7LOQ?_ .11M?\ K^3_ -%R5XU7VF3_ .ZKU9\%GG^^/T04445ZYX@4444
M?45%%%?FA^L'!?%__D4;7_K^3_T7)7C5>R_%_P#Y%&U_Z_D_]%R5XU7VF3_[
MJO5GP6>?[X_1!1117KGB!1110!]'>&/^11T?_KQ@_P#18K4K+\,?\BCH_P#U
MXP?^BQ6I7YS6_B2]6?J5#^%'T04445D;!7/:;_R/VN?]>UK_ .SUT-<]IO\
MR/VN?]>UK_[/712^&?I^J.:M\=/U_P#;6=#1117.=(4444 %%%% !3(IHKB/
M?!(DJ9(W(P(R.".*\]^(FI>-[^]D\->!]/-E');"6\\07#%8[="6!2+^])A>
MW3(Z9#"I^SI_R1'2?^NMQ_Z.>@#TNXNK>TC\R[GC@3.-TKA1^9J1'61 Z,&5
MAD$'(->,>%]!T_XL>/?%7B#Q=;_VGI^DZ@^E:59S,?)A$8_>/@'!+94\],_3
M%SP3#_P@/QHU+P'822#0+[3AJNGVTDA?[*^_:Z*3SM)#'KV'<DT >K7%W;6:
MAKNXB@5C@&5PH)_&I00R@J001D$=Z\4\ >&]+^+-_KWC3QG;#5HI;^6RTJWF
M<F&WM4Q@HH.,DGD^H)&,FM7X:F3PC\3?$GP\2XEETJV@CU+28YG+M!$Y >,$
M\[0S #Z9ZDT >KT$@ DG '4UYQ%\>/ MQIR75K?75R6#,;>WLY))8U4X+.J@
M[!_O8SVKJ='\4Z-XQ\*3:MX<O4O+-D=-ZJ5*L!RK*0"#R.#Z@]#0!N1R)+&'
MB=71AD,IR#^-.KYL_9KNIM U"WL;AV^Q^)[*6YM]QX%Q;S.CHH]XR&/T%>I_
M&*YFN?"UGX7L7=+OQ-?Q:<&CQN2$G=,_/8(I!_WJ .^CECE!,3JX!P2IS@^E
M.KR?]FS_ )(S:?\ 7W/_ .AUZQ0 4444 %%%% !1110 4444 %%%% !1110
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MYA7LOQ?_ .11M?\ K^3_ -%R5XU7VF3_ .ZKU9\%GG^^/T04445ZYX@4444
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M#^%_'MOIFNZO?:O!=2Z;;1LMK<1A,+$H& R-C\#BO/:^CO#'_(HZ/_UXP?\
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M@4444 ?45%%%?FA^L'!?%_\ Y%&U_P"OY/\ T7)7C5>R_%__ )%&U_Z_D_\
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MX)\9ZC+J%[9SV-],<RW%A*(S(?4J05)]\9/>H/"O[/\ X%\*:E#?Q6MUJ5U
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MRJ>K_P#($OO^O>3_ -!-?IU;^%+T9\)2_B1]4>5T445^8GW85L>%/^1GM/\
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M] 2LJOPGLY+_ +VO1G8UX[X[_P"1UO\ _MG_ .BUKV*O'?'?_(ZW_P#VS_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\P^-WQ
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M^ZIQCI7C?_#.GQ0_Z&O3?_!C<_\ QJM*+X+?&N"%(H?B&L<<:A41-;O0% X
M V<"N+'XJ>*PT*2F^:.\K+7Y6L>A@LHK8;F:J6;[+_,]X\+ZUJ.M6DTNJ:/-
MI;1N%19<C>,=0" >*^>:T/\ A3?QO_Z*/_Y7+W_XBLO_ (9T^*'_ $->F_\
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MDCTUM8OU<@:3+@'T)_I76^#)'EUZQDDC,3L')0]OD:O+?^%"?%W_ *':U_\
M!M=__&Z?%\"?C#!*)(/'5O'(O1TU>\!'XB.MJ.25*56-3F6C3Z]#.CBZL%-5
M:LIJ2:2:BK>>B1Z_>>./$EO>S0Q>#;R1(W*JX5VW 'KD)C\JZ_1KVYU'1[>Z
MO;)[&>127MY#DIR1[=>OXU\]?\*;^-__ $4?_P KE[_\11_PIOXW_P#11_\
MRN7O_P 17T%*E4A)N4VUVLOT/'HT:L)N4ZCDNUE^B/6M2\:^(K/4[BWM_"%Y
M/%%(4250[!P#PV0I'/7K73Z%J%UJFCPW=_82:?.^=UO(>5P<9Y //N*^?O\
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M?Y,V-VPX/!!'/U%17&AVEU=Z=<2^9OT[/D8;CD <^O04&N)PM2K4E*.S4/\
MR65W^!Q>KW\GA^^\1:5!GS-3"36:@X):4['Y]<]/I6A?62:=XK\(6<?*P1RQ
M@^N$ S717_A^PU+5;/4+I&,]F<Q$'@\Y&?7!YJ2[T>VO=5LM0FW^?9;O*VM@
M?,,'([T6,?J-6\NW-'E\ES<S_P ODB_1113/:"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN8%NK26WD^Y*C(WT(Q4M%
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M)?#3X?>&/$'Q]\6^&]7TS[1I.G?;/LMO]HE3R_+NDC3YE8,<*2.2??FOK:O
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M !1110 4444 %%%% !1110 4444 %<]XV\$:/X_\.OH^OQ.T6X212Q-MDA<
M@,IYYP2.00<UT-% 'F/@GX%:!X/\11ZY-?W^LW]NFRU>]<%8!C P .H&0,G
M[#O7IU%% !1110 4444 <W\1_P#DEGBO_L"WG_HAZ\V_94_Y)9J7_8:E_P#1
M$%>TW-M!>6LMK>0QSV\R&.6*5 R2*1@JP/!!!P0:JZ5HNE:#:M:Z'IEGIMN[
MF1HK.W6%&8@ L0H S@ 9]A0!>HHHH **** /-OV@O^2$^(?^W;_TIBKI?AQ_
MR2OPI_V!K/\ ]$)6WJ&FV.KV$ECJMG;WUI+CS+>YB62-\$$95@0<$ _45+;6
MT%G:Q6MG#'!;PH(XHHD"I&H& J@<  #  H DHHHH **** /FWXR?\G3> O\
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MI4#)(I&"K \$$'!!JKI6B:5H-JUMH>F6>FV[N9&BL[=849B "Q"@#. !GV%
M%ZBBB@ HHHH \W_:"_Y(5XA_[=O_ $IBKH_AO_R2OPI_V!K3_P!$I6YJ&FV.
MK6$EEJMG;WUI+CS+>YB62-\$$95@0<$ _45+;6T%G:Q6MG#';V\*".**) J1
MJ!@*H'   P * )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"&\O+;3[.6[O[B*UMH5+RS3.$1%'4ECP!6-H?CKPMXEO
M7L]!U^PO[E%+&&"<,^!U('4CW'%>-_M+:O\ :M=\)^$[F^-EIEY.)[^3=M 4
MNJ*Q)XPHWGGCOVJ/POIWP=\1_$;1IO NL76BZGIN#!!$CQ+>[#W:0'<2N01P
MS GT- 'T/1110 4444 %1SSPVMN\]S*D,,:EGDD8*J@=22> *DKA_BOX$U#X
MB>$DT33]832XS.LLY:(N)@H.U#@C W8/?D"@#3TSXB^#M:U-=/TKQ-IEU=N=
MJ0QW*EI#Z+_>_#-=+7R]\>?!7A#P-X7\.VOAFT6T\0_:5"/!(QEEB5#N=N>O
MF;,'KG..]>R>-_'DOP_^%]OJ6I*)M<G@CM[>WQDRW3)SQZ Y)^F.I% '30^*
M]"N/$LOAZ#5;:35X5W26:OF1!@'D?0C\ZUZ^5/@KIVKZ7^T==6_B1R^K-923
MW98Y822(DA!]QOP<<9!Q7U70 4444 %9>J>)M%T74;"PU74K>TN]1D\JTAD;
M#3-D#"CZLH_&D\4:E>:/X4U/4=+M#>WMK:R2P6P4MYKA257"\G)XP.:^5]4L
M/&@^,W@36OB)*%U'5=5MWBLP1_HL2W";4P.%ZDXY/J=Q- 'UX[K'&SR,$102
MS,<  =R:YW3?B'X/UG5ETS2O$NF7=ZQPD,5RK&0]<+S\WX9KS?\ :A\0W.E?
M#NSTRSF:+^U;O9-M."\2+N*_0L4_*N-M=%^"6L7NB>'](U^YTK6+&14&IVRL
MOVN8=_-8%<[QD'@=EX(H ^C-:\0:1X<L?MFO:E:Z=;YVB2YE"!CZ#/4^PJOH
M'C#P[XI\S_A'=:LM1:(9D2WF#,@]2O4#WKQ#]H?2UM_'?A/7O$ZR7WA2$+;W
M5O'*%??O+.0N03N7;]WLAY'!K/\  %OH?B+]HJUUCX6V;:=H&GV9_M ,WEB1
MF1U^6,DG!)08QC*$^F0#Z8HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \2^-GBO7[KQMX=^'?A34I-+GU
M?;)=W<)(=8V<JH# @@ ([$#!. ,XSFUX$\"^,/"'Q!$FE>+!X@\)21[;I+RZ
M+R(^T_=7D!@P4YR,J2.HS7#_ !^T:&3XZ^&9=9O'T[1]3MH[6>\5MFQ!*ZRC
M=T'R2#)/ #<\4EII6F_#O]I#P]I?PYU66>RU.-!?VJSB954EL@D=<*-X!Y'7
MH10!].4444 %>,^-_#'C[QY\5/[)%]J&@>#;> %;JSE ^T.%!)(5LY+-M ;@
M!,@9S7LU>4?%WXJ77AR]MO"/@Y8YO$^I !7D("6:-P');Y=W4C/  R>, @'-
M?"G4]?\ #/QOUSX>7FNW&OZ7;0&:.:X8NT3!8V&"2<</M(Z;AGBIOV@OB1>V
M=G/X0\)2.;Y8/M6JW$#8:T@!7"Y'W2Q9<]\$#^(5N_#3P-:^ ?#FJWMKJEMK
MWC&_MY)IYEG$N^0 L(UYW$;NK'!8\G' 'C%[:^/_  [X \6'Q%X,F:77'$NI
M:W<RC>J[U( 4< ;NP]?0   ]\^ UU<7OP2T&XO)Y;B9_M&Z25RS-BYE R3ST
M%>B5XU^S5JFLW/PY@T^^TC[-I5FKFQO]^?M9::4N,=MK<5[+0!X-\;OB?K7V
M76_"_@[3+Q?[/1?[7U;&U+=&"D*C ]3N R<'K@'J.Q^&FO'3/V>]/U[5)9;C
M['IT]U,SN6=PC.V,GJ<#%6OC<BK\%?$NU0-T"DX'4^8G-<_X.TZ?5_V3ET^S
M4O<7&BW4<2 9+.3)@?B>* /.O#F@>,OBMX:U#QC?>.KK3-3FN'CTFRCN3#"Q
M7!*@!AM!)VC'.1DYS7;?$S7?'W@[]GVT:_NT&OFY2TOM0L6)*PG?B0-@;6.(
MU+>K'&"1CR3P-X*\%^(O@]KVL>(==:#6=-646T1N0OV=57>@$9^\'<MTZDD#
M!R:VM2\>^*(OV6--$MQ*YOM1DTY[N4;F:V520NX]R05SUPA% #KM=6^'UUX.
MU?PQ\0[K7[W6)XEN=/-QYJR[BN1MW'())7D9SR"#T^K*^3_&^A^&?A5'X5\2
M?##7OM>LO( 4,RSBYC*<N4'0$X&/]KC!&:^KHF9X49UV,R@E<]#Z4 .HHHH
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M=HD?VSP!D9.>P-97PD\!6_A_5KKQ)XHU^UUGQ=JH/F,EPKB!3R47!^8\#)'
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M5LCY>A?.,;MGM0!AZ<NJ:S\-=4\?WWQ.OK?7;:=C'8_;"I)!&%V[P1NR< #
M'&,=/ICX::QJ6O\ PST+5-<R;ZZM%>5RNWS/1\=/F&&XXYXKYIT_PEX/UKX)
M:EXVUCQ X\6&2:=O])52LPD.R/RQS\PP<]MW' KZ'^#WB#5/%'PIT?5==P;V
M1'1I FWS0DC*KX[9"CIQW% ';T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?//[3.B"/7?"OB>\LWNM*MY?LU^$&<)O5PI_WA
MO'U_"N?^)VJ>%O%OQ \!Q?"W[+)J F&]K"V,7EKOC,6X;1C;B0XQ\HZXKZ?O
M;&UU*QEL]1MH;JUF7;+#,@=''H0>#63H7@?PQX9NI+G0-!L+">08:6" !\>F
M[J![=* -VBBB@ HHHH *XWXH_$&V^''@N75I(Q/=RMY%E >CRD$C=_L@ D_3
M'4BNRK(\0>$]"\510Q>(M+M]12!BT2SKD(3U(_*@#YW^&TG@^^UU/'GQ3\96
M%]K\CB6VLY9OEM<<JS#IN'91POUZ==\1_!/CCQ9\2-'\5^$FTR]TW3[>.73T
MO9?W8<_,7V8YYVD'_97TKO?^%/\ P^_Z%+3?^_5=A;6\-G:Q6UM&L4,*".-%
MZ*H& !^% 'R5H/\ PL+_ (:0O_*_LW_A*-G^F9_U/E[$SM]]NW\:^N:R(?">
M@V_B67Q#!I=NFKS+MDO O[QA@#!/T 'X5KT %%%% !7@?QL_Y+K\,O\ K_A_
M]*8Z]\K)U/PMH>LZK8ZGJNF6]U>Z>X>UGD7+0L&# KZ<@'\* /*/VHO#]UJG
MP]L=3LX6F_LN[W3[1DI$ZX+?0,$_/ZUYU\5]?\ ^(OA?X7L/ UO;'6%N(U6U
MMK4K-&GELKHV%Y)D*>NXC(SUKZPDC2:)XY462-U*LC#(8'J".XKG]*^'WA#0
M]4_M'2/#>FV=X/NS16RAD_W>/E_#% '@WQ(D.B?&SP+=?$3=/HMOIT(D:13)
M%YJAA(Q4=2'*,V!R-O7BGRZCI/B#]JS0+KX:F)[>.W3^T)K.,I&^-_F$X&"-
MA1<],X'6OHG6-"TKQ#8&RUS3K;4+8G/E7,0< ^HST/N*K:!X1\/>%EE'AW1K
M+3C-CS&MX0K.!T!;J0/0T ;%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &)XJ\'Z%XUT?^S/$M@EY;!PZ
M98JT;#^)64@@_0\]#6/X.^$_@_P)>O>^'],V7CKL^TSRM*ZKZ+DX7\,9[UV=
M% !1110 5YUXC^!G@KQ5XAN]:UFVO);V[8-*ZW;*#@!1@=A@ 5Z+10!P?A'X
M-^$/ ^O#6- MKF.[$;1;I+AG&UNO!^E=5XBT"Q\4>'[O1=71WL[M0DJHY4D
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MEXRO*)9C)DJ"!C/3J:ZBBB@ KF?"G@#0O!=_JMYH4,T<VK2++=&24N&8%R,
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M'/49 H ZVBBB@ HHHH **** "BBHKNZ@L;.:[O)5AMX(VDED<X5% R2?8 4
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M2,G(  ))'2N=T3X]RIXHM="^('A*^\+37S*EM/,Q:-BW W;E4@9P-PR 3S@
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MX5 ZLQ]@2/HHK,D_:)U34FO+SP=\/M2UG1K)RLM[YC+G')X6-@O'/4D Y(%
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M&@#O?AKXT\>:EXFU#P]X_P##+6LEFI*:G:PLL#D8^4L25)(.05/L17B>O?\
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M][;G@M+@I$3_ +O.T>RX% 'F?P7T73/%#?$K[639^%=3;R5ER(E0&21D*EN
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M[X=^&/ 4,J>&=,6VDGP)IW=I)),=BS$D#V&![5G^+?@]X*\:ZDVHZWI/^G.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img215454963_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_8.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %I 6L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** ,'QGK=SX<\(:CJ]I'%)<6R!D64$J26 YP0>_K3?!GB"7Q)X:AOKJ
M)(;U7>&ZA3($<J,01R3['KWK/^*?_),];_ZY+_Z&M<Q?ZN_@J\\000Y!U:PB
MO=/4=[HXA8#U)8HWTS0!K>&_B#<:SXQUFRNDL[?1K2%YK>Y)*ET63RRS,6V[
M<ANPKNI+VTALOMLMU"EKM#^>T@";3T.[ICGK7FN@>'K:P\=S>'I%#P+X8CMY
M1_?S(0Y_$DG\:S;26;5M!T;X?W+%[F#4WM;X?WK6V(?/L&!C - 'J6H:]H^D
MI$^H:I96BS#,9GG5-X]1D\UG^*O%UGX9\,2:T&@NE^3R(A<!//W,!\K<YP"3
MP#P*PO#%E9ZIXU\7SZG;PW%]!=);QI,@;RK?8"@4'H&Y/'6N.UBWMT^'WCJS
MMXD?3K#5E6QX!$),D?F*GH 21QZF@#V&;6M*@TU=1EU*S2Q;[MRTZB,_1LX-
M/L]5T_4+(WMG?6UQ:C.9HI59!CKD@X&*XN]L;*X^+.EZ;=VT/]GVVD//96Y0
M"/SS+AB%Z$A>?;K5*_@@TWQ[X@M-,C2*VN/#KSWD40P@F#$*Q X#%2?KUH [
M@^)="%W#:'6=/^T3A6BB^TIN<-]T@9YSV]:5KN['B=+,3:?]C-F93$7/VGS-
MX&0N<>7COZUYI/H&EP?  7"6,'VDZ?'<^>4'F>82#G=UXZ?3CI6EJMU=0^-V
MN[<EKM/"$TL9ZDN'!'ZT =RWB+1$U,::VKV*WQ;:+8W">9GTVYSGVK3KS32=
M!\*2_"*RN-46&*WEM4N+F_ 'FK*2"S;\$[M_'?TKTB$@P1D,SC:,,W4\=3[T
M >?:)K_CSQ';W=WIP\-QV\-W+;JMQ'/O.QL9.UB*V?#_ (O>YFU+3O$$$&EZ
MGI@5KC][^Y>-ONR*QQ\OUZ<51^%?_(N:A_V%;K_T.J4=K;>)_BGXA"8EL(M%
M&F73KR#([[B,^H&1[$4 =_->VEM9F\GNH8K4 ,9I) J 'H=QXP<BJ=_XBT32
MIHX=0U>QM99!E$GN%0L/7!/3WKS*PN)M>TCPYX'NCNN+2_>'4U[>3:D$ ^S9
MB -:DVEZBOB+Q!J.DV.B^([6YG$=U;W+[+B%U0 Q!B"N,=CZT =1XB\96'AZ
MZTF&:2V8:A<+&6:Y5/*C()\TYZKQCL.>M:MUKFDV2.UUJ=G"J!68R3JNT-]T
MG)[XX]:\QE&C:IHG@&6RTXQVW]JBV\FZQ(Z*OF!HRQSN7<#CMTK:AT73=3^+
MVKF^LX;A+;3K<Q1RH&122PSM/&0. >V30!V6H>(-&TF:.'4=5LK263E$GG5"
M1ZX)Z59FOK2W2)YKJ"-)CMB9Y  YQG SUX!/%<-X&TZPU=_$UWJMI!=:C)JL
M\%Q]HC#E(UP$3GHNWI7')#;7GAK0=/NG\S2(_%KVML7;(>V&\*N>ZG)7Z4 >
MQ:=KNDZN\B:;J=G>-%]\6\ZN5^N#6!H?CFRGM;R37+_3K!X]1N+2%7E$>](V
MP#\S<GU/2J'B&PL],\?>#Y-+MH;:[FFFAE6! GF0"/+;@.H'!'I57P)H&E7F
MG^)KF[L+>XFGU:\C=YHPQV!N%&>@Y)_&@#T#[=:?:(K?[5!Y\R%XH_,&YU'=
M1U(]Q3C=VRWBV9N(A=,GF+"7&\KG&[;UQGO7D-CYEI\,?!GBH%FET6;,K=3]
MF=S'(/P&W\!78>$U&L^+O$/B8D-$)!IEDW4>7%]\@]PSD_E0!L:Z/%1FA_X1
MYM&$6T^;_:"RDY[;=AZ?6N2\/^(O'VO6EU=QGPO#!:W4EM*94G!S&?F(^8C'
MUKTFN&^%X#:'K((!!UF[!!_WA0!V4=[:2V7VV.ZA>TV%_/60%-HZG=TQ[U4F
M\0Z+;P&>;5[".((LF]KA -C?=;.>A['O7ELDDVGZ#JOP[@<K<RZJMG:8Y*VD
M^9=WN HD!K>MM%TE_B_+:S6T,BV>B0BU@D4,J@.5R >X''XT =]97UIJ5JMU
M8W4-S;O]V6%PZG\152V\1Z)>Z@UA:ZO83WBYS!'<(S\=> <\5Y;X@>715^)$
M&A+Y-JEO:LT<(PL4DG$A4#H2F2<5/K.BZE%X5L_(T?PWI*6KP26FH)?-N1@R
M[3GR@6+=#SSG- 'KU<7XP^(5GX:F2PMXWN-3::*,QM$XC17(R2^,=#P >N*T
MKN?Q>NOA+2RTEM'\Q 99)G$VSC>< 8S]['X5E_%3_D4(O^PA;?\ HP4 =M11
M10 4444 %%%% !1110 4444 %%%% !1110!2U;2K/6]+GTW4(C+:3@+(@8KD
M @]1SU JMJ/AK2-5N=-N+VT$LNF/YEHQ9AY;<>AY^Z.N>E:U% &<^E64&KSZ
MZEL[Z@;;R"RL<M&#N"A<XSGO7->%-(FNO%VM>+;S2I=.DO%CM[>&< 2[%4;G
M8 D L0H^BUVU% &!K/@[1];OA?7$<\-X$\LW%K</"[I_=8J1D?6IO^$5T3_A
M&G\/"P1=+==K0*2,\YSG.<YYSG.:V:* ,"[\&Z+?:79V%Q#,RV1)MIOM#^=$
M3U(DSN_7T]*ETOPIH^D65Y:VMNY%Z"+J665GEFR,?,Y.3P3WXK:HH RW\.Z9
M)X;'A]K<G3!"(/)\QL[!T&[.>WK4B:)I\>K1:HL!%Y%:_8T?>>(LAMN,XZ@<
M]:T** .4'PY\-+=B86DODB7SQ9_:'^SB3.=WE9V]>V,>U=7110!Q[_"_PH\L
MLALK@&5VD<+>S*"Q.3P'Q6[I^E:?X;TA[?2=/6*")6<00#YG./4GECC&2:TZ
M* .*\'Z/++XFUWQ7>:9)I\NH%(8()@!(L:* 68 D L0./]D5H:EX%T34M1FO
MW2[M[BXP+@VEU)")L#'SA2 :Z6B@#"O/!VA7NB6FD/9>796;K);I#(T9B89P
M0RD'/)YSSFKMMHMA::I-J4,3"[FA2"20NQW(GW1@G'?K6A10!SFJ^!M#UB_E
MOIX;B*XG4)<-;7+P^>HZ!PI ;^=9/C#PG#>V/AG2;+2U?3+;4HS-!&,*D.QP
M2>_?KUR<UW-% &#HW@_2-#OFOK9+B:[9/+$]U</,Z)_=4L3@?2M#3='L=)@N
M(;*$QQW$[W$@+ELNYRQY/&?2KU% ''>(+!=#\$MX=T+0KF]CN()+6&)&W)%N
M!YD9FR%RQ.>>G:MSPUHL?AWPWI^DQ8(MH0C,/XGZLWXL2?QK5HH *H:3HUCH
MD$T.GPF*.:=[B0%RV7;ECR?TJ_10!PVE:9-K?Q%E\47>CSZ?%9V8M+87(422
MN6;<^ 3P%.T>N[\H]0\(+K?Q(O+V^MKE+5=.B6WNX)6B9)0[9"LI!Z'GM7>T
M4 9.E^&M)TC2YM.M;1?LUP6,XE)D,Q888N6R6)]ZS++X>^';&[MYXX+B1;9_
M,MK>:ZDDAA;L51B0".WI74T4 %4=6T>QURS%IJ$)E@$BRA0Y7YE.0<@CO5ZB
M@ HHHH **** "BBB@ HHHH ***XB\^+'A:QO[NSGFNQ):3-#,5M795920>0/
M4&@#MZ*I:5JUAK>G1:AIMREQ:RC*2)^H(/(/L:NT %%%-=@B,[=%&30 ZBL[
M0];L_$.DQ:E8&0VTI8*9$*'@D'@^XK1H **** "BJ=YJMA87=G:W5U''<7CE
M+>(GYI"!DX'MW/TJY0 4444 %%%% !115/4]5L-&M/M6HW4=O#N"!G/5CT '
M4GV% %RBBB@ HHHH **** "BBB@ HK,U/7K+2;[3K.Z,@EU"4Q0;(RP+<=2.
MG45IT %%%% !1110 45EW'B#3[7Q%9Z%*[B^NXFEB4(2I5<YR>W0U<O[V'3=
M.N;ZX+""VB:63:N3M49.!WX% %BBJFF:C;ZMIEOJ%J6,%P@DC+J5.#Z@]*MT
M %%%% !16%/XNTFWU#5K%Y)?/TJW%S=*(R<(5W<>IP>E:>FZA!JNFV]_:EC!
M<1B2,NNTX/3(/2@"U1110 4444 %%%% !7FWPS*+K?CLR%0@UJ;<6Z8W/UKT
MFO.SX&^&_B#5+NZ1K2]NI9'N+@0ZDS<DY8D*_ R: .$L-<OM"\$>(9=$G^S6
M=YXB-M;7*CY88V!)=?; 49]Z[")-0\&?$/P_I-OKVI:K9ZM'*+B&_G\YD*KD
M2*?X0?Z'\.P.E>%Y/"T.E>58'1+C;'#&L@\N0L?EVMGEB>A!R3[U7\/>"O#7
MAW49I],M\WJH$9Y9VE>)#T4;B=HH \A6^U]?A?\ \)9_PD^L&_MM0\J)#<DQ
M[-V,,I^]R>^>,"NULQJ7A[XH1Z0=<U&_MKS2'N91>3;\2@L-R#HH^7H/7Z5U
MG_"!^'?^$:;P]]B;^S&E\XQ><^=^<YW9SU]ZNW6AZ2^NQ:W<QA;Y+=K5)6E*
MCR^6(QG'=CGK0!Y#;ZWKMS\//!;IK=_'>7NLFWEN?.9G93(P ;)^8#C@Y'%=
M%IUU=>%_'^OZ3-K^H3:9%HQO_-OI#.T+@J"PSUZDX'7BNNMO!/AQ=*TJTM[4
MM9Z?<"\L]L[D*^=P;.?F&3GG(JY<^&M%FU6ZU6ZME:YN[7[#,SR':\3$?)MS
MCDX]Z /)-/U/5;+Q#X4O+74/$<MIJ=V(I)M3N5\NZ5B.4A#':,'@GVQ5LQZO
MK$/Q NY/$FL0+H]U<O9Q6]T452H9@#WV_* %! '-=U9_#/PO8RVDL5I.9+.9
M9K9GNI&\HJ<@+EN!GG'?OFM*T\-:&+35UM8@\&LO(UX4F9A(S95\'/'4CC&*
M /*=2M[GQ)J?PUN[O5=1BN-0MI$DEMYMAC954[TX^5FS\Q[X'I7IOQ!NKBQ\
M ZS<VD\L%Q'!E)8G*LIR.01R*34/ 'AW4]+TW3KBTD\C301:[)W5HP<9&X')
MS@?E6WJ>E6FL:5/IE[&9+6=-DB;B"1]1S0!Y!J\NN:!X*T2[CU[6+J\\12VJ
M7$AG!,"LA8K#G 1CD#)/\/45>L+OQ#IEOXLM"^L1Z='H\UQ;/J=TDES;S!.S
M(Q(!SD>F/S]&OO#&D:GX?CT.\LUET^)$2.-F.4"C"D-G(('?-8TG@33=,\-Z
M];:+;,;_ %&RE@,T\S.[DH54%F)P,D4 >>2W>LZ/X&\.^,HO$^IW=]-/%%);
M37&Z&53D%-G=OEY)R<Y/6GZEJOB#7-?\52PW&O1OI<[062Z?<1Q6\.W.&E#,
M-P;;DGGC/L*[#PI\,-'TZPTBZU+3P=5M(U9U\]FB$H_C"YVYZ<X]^M:^K_#S
MPWK>I2W]Y92>?, )_*G>-9@.F\*0#0!R&L:G?:S)H&GW-WKG]K2:>)[C3=&D
M2'<W3S'FW !<C@<_K7'ZC/J&N?"S3[C4M3OI)K373:*6GR64@$%S_$R\X;W-
M>R:IX$\/:M<VEQ/9O%):0BWB:VF>'$0Z(=I'R]>/>HV^'OAH^'Y]#6P*Z?-<
M?:3$LK_+)P,J<Y'3H.* -8J^B>''"2W%X]G;,5>X??)*54GYCW)Q7B^C:MXJ
MN=-TSQ';3Z[<7UQ>9F\ZYB%C+'N8&-$+9!P/3UQV->VZ5:V=GI<%I8OOMH 8
ME)D\P_*2""Q)R000?<5SD7P[\(V6KP7:V027SC-!;-.WE"0<EEC)QD8STXH
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MR>28'W/YO"[!CY@2",^V3@<T]O%FGINE=W$*(NY?)?S5<R^5M*8Z[N/7\.:
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MKO3%&TJRE%,B A7(Y .,@'WP/RI] 'F'V76;R &Y@U9H,V<\L1:<LLB7*&0
MD@E@FX_(JJ<94<#'3Z]!JD^K%+5KM+9UM%9H'*X'VC]Y@CI\G4CM7444 <A?
M:?>S>"M7L9%O)F6>40 R.TK1B3<N&SN;CIR2>G-4?[-UBU$MWI/VU+J>^NMJ
M2R/Y?EF"0QED8X'[P1_,1G)P37>T4 <MX2345-W]JDO)(3'%L6ZCD4B3YM^#
M([,?X<XPO]W.33-$M#-KLD_V"X@LQ9PQB&X@$8MGC<E8X\ !E&2<\C(&&/0=
M910!RVHO/I^M:O*;&\N$OK*)(#;PF0%U\P%3C[OWEY; YZ\5+9Z;<VM_X;1X
MB1::=+!,Z\JKXA &??:WY5TE% '!1:-JT<%M)</<2V"ZU-/)8I$H=!]J=XY
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M=RH^W:Q&UN ><'&<52TWQQ87ND0WLMO>12S3S0QVR6LLDC^6Q!(4)DC&"3C
M)VDY% '4457L;ZVU*QAO;242V\R[D< C(^AY!]CTJQ0 4444 %%%% !1110
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M*W*!A1110 4444 %<I:>&KWP_<27.DR6U\TAS(-0&+AO;[0H)(] RGZUU=%
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M--2ZMY)6B2>)I%.&17!(/N*\WCM+"ZTWQ!=>'GB75+7[4UHMJ &96B"KC'.
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M^>J?]]"CSHO^>J?]]"@!]%,\Z+_GJG_?0H\Z+_GJG_?0H ?13/.B_P">J?\
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M5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10
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M@9)"#) QG.3TKTY+:WC\K9!$OE*4CVH!L4XR!Z#@<>PJ&?3-/NK86UQ8VTT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)97,,&TR)N\M@P!(R,QD'![B@"5/&*W<5DFFZ;/<W]R)2UHSK&8/*;9)O8G
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M!\-_^16;_K[E_G77U\]IXD\1>'Y9]/@NY;01S,6AVJ=K$\\X-/\ ^$]\4?\
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MT>:( 1R-$I9 .F#VQ4%SX?T*\U)=1N=+L)KU2")WA4OD=#G';MZ59_LG3/\
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M:;=)$D>#NPH/F<[L8R"<<U87QK!=6S_8+*:YN465I(XGC<1B,*2=P;:P^=,
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M1W;NS%F))[<_@!5>WT.QM4TT0HZG3HS% VXYV%=I#'^(' )SW /:@#2HHHH
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M 7<UXMFT#0LMF8T ;S<':$QR#G],YXS5WX6+?)\-]'%_O\SRV*!^OE[CL_\
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M< \<5<@\<1/<:9'-9;8KQYXWN(IA)%&8W2,,&P-R,TBC=Q@]1UQ/%?:?XEU
M6%[ID<@C-R5:0[L>5,83V_BQG].: ,MQ?7V@^$-5*WES<Q6AN)##]YG-J3D\
M8R6P!GNV.]4[2]UC>T,[ZH-.:6!IY42=I%0I+OVLR!OOK$#M P"< "NSM]5C
M.NRZ,EI+%Y%NLHD*A4(SM 7Z8I\FMZ?%J(L'F83E@G^J<H&*[@I?&T,1S@G/
M(]: .,V7T.IRW*OK0M[B"T$TSQ/YODAI@>%'#?ZO./F 9C@'.+$?]N3Q3/\
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-G7U#39:=PHHHI%'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img215454963_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,N!98# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^GZE8ZM:BZTZ\@N[<D@2P2!U)'49'%6JX_X9Z'8>'O!L6GZ;K,&KVZS.PNH
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M5HL8)(2^"@GKQ&U &]\!?^27VW_7S+_,5Z;7F7P%_P"27VW_ %\R_P Q7IM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIC..*[CXL?#R_P#B!9:7!87=M;&SDD9C/NP0P &, ^E>C44 <M\._"]SX/\
M!5GH=Y/#/- TA9XL[3N<MW]C7FOB_P#9_:\UE]3\+:C#8^8_F&WGW*(VZY1E
M!(Y[8XKW.B@#Y^TW]G[6K_6TO/%GB".ZA!!D\J22260#^'<X&![\U[!XD\-+
MJ?@:]\.:8(;19;;R( 1A(P,8X';BNAHH \N^$WPQU+X?WFIS7]]:W(NXXT00
M;OEVDDYR!ZUZ1J%W:V&G7%U?.J6L49:9F&0%QSD>E6:KWUE!J5A<6-TF^WN(
MVBD7.,JPP1^1H ^=+_X4^%_%VL22>!_%NGAI<RFPE8DQCN5Q\V.>A''K6?\
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MTNB>-?'&I1"1I[?!]+<4 >V45YZ-:\3K"&>>$L1GB(5RWB#QWXPTN-I(KFW
M'8P T >UT5\P2?&OQHC$?:K7_P !Q41^.'C4?\O5I_X#B@#ZDHKY9_X7EXV_
MY^K3_P !Q1_PO+QK_P _5I_X#B@#ZFHKY9_X7CXV_P"?JT_\!Q1_PO+QM_S]
M6G_@.* /J:BOEG_A>7C;_GZM/_ <4?\ "\?&V?\ CZM/_ <4 ?4U%?+/_"\?
M&O\ S]6G_@.*/^%Y>-O^?JT_\!Q0!]345\L?\+R\;?\ /U:?^ XH_P"%Y>-O
M^?JT_P# <4 ?4]%?+'_"\O&W_/U:?^ XH_X7EXV_Y^K3_P !Q0!]3T5\L?\
M"\O&W_/U:?\ @.*WO!7Q=\6:WXTTG3+VXMFMKFX$<@6  D'WH ^B:*Y+XCZ]
M?>&_!T^I:<Z)<I+&H+KN&"<'BO&!\9?&'_/S:_\ ?@4 ?2E%?-1^,OC#_GYM
M?_ <4G_"YO&/_/S:_P#@.* /I:BOFH?&;QA_S\VW_?@4[_A<GC#_ )^;7_OP
M* /I.BOFH_&7QA_S\VW_ 'X%)_PN;QC_ ,_-K_X#B@#Z6HKYJ_X7+XP_Y^;7
M_OP*</C)XP/_ "\VO_?@4 ?2=%?-P^,?B\_\O-M_WX% ^,?C#/\ Q\VV/^N
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M 'TQ17S/_P +G\8_\_5K_P" XI/^%T>,L_\ 'S:_^ XH ^F:*^9_^%T>,?\
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MY:_X7CXU_P"?JT_\!Q1_PO#QKG_CZM/_  '% 'U+17RU_P +Q\:_\_5I_P"
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MU,)YIS'O320>U "YP*7.::3CK1NH ,Y/M2\8HS2D<4 -'7B@X!I>G-,(RV:
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MB_\ 0J^:^U "44O2DQF@!0,BFDX-+TIIH 1N<4'VI::,^E #J<N5%-IRY(H
M=G.,4N!U-)@CTI<4 .& .M!X%(%QDT=: #=33F@ YH(P: &^U+GVIPP>*;CK
M0 =J,<4=L4GIB@!.E'2EHH ,9I.0:7.:#TH 0\T8YS2@XZ#FDSGF@ /)I"*,
M]J/YT -SSBC&<B@ 4@^]B@!Z $X/2G<&3:N:10 <FMOPU#IS:F#J4OEP=SB@
M#$()Z=J:<=<UN>)O[-CU%DTIB]OV)K!=>!CN>: $7.2>U2 @$>M(P.  *%QG
MD<T 2E^F*">QXH1D7J.:5@WWB, ]* &.=P [5&0*>0<TW'- #<8%'UH-)TH
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M].'K0 48XI<4G>@!5'84]5H13Z<UI6FG2W(&V,G/M0!G;&S[4X0LS9KM]/\
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MY[44 (,=J7M2T8H 2DS2]J2@!.]%%% "5UGPS_Y*5H'_ %]K_6N4Q75?#/\
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MU% $F<KQ2  =3S2 TN : %(7J#S3MQ;O3 !3EH 6FMTIV>U,H :?I12DTF:
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MDVEODZ8H 9BBBES0 G%'':@GFC)H 2E'2DQ29XH =FDI :6@ HHHQ0 4444
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M$F@=* $_G3@:;WXI0* '<4HXZ4@IPH #UIAZ4_BFGTH ;C/:E9<BC.*0L>]
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M *]7\!60:/S2.E 'H5A<0:?;+'P& J5YA<?,IKFKZ&?SMZ$GFM;36*Q 2=:
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M% #A0:.U!- #2!GFFGK3C29SVH ..U.'6FYYI<T .Q0*3/ I: #M249SQ24
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M"[6S4)[5;NP#R*IXYH 4FCO1BB@ Q129[4>U "&DIU(: %%.--7K3C0 W%'
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M.M.SZT *.M.)SC%)[4HXH L6@)E (KU[P6YBL>*\CLCF<#UKV#PD%731GTH
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M6/BR_L92 \3)U]T4_P!:R+GQG8HF[>,UP7Q:E=/B?K.TD?-%_P"BDKC'N)6
M&\T =OXB\;S7@:*"0JAXKA)I6E<LQ)SZTDA)Y-1,V>U #7.3R:9N%.IN.: #
M/>EZTE+W]J #(ZTX>M)Q3@>,4 .' ZT*:3-.49!YH MV6/.'/>O7_"?[S3\8
M[5XY:-^]!KUOP1>1" 1R' /0F@#:<"-\8Y)Q4H=4D,;C!%-O8,W)P=R]0PK.
MN)&B/!))H GU"'S4(4\&L--*<2,R@[JT_M+*@+ D5);WBNWW: *5I8&W8L5
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M8'04 9%)Y9'S9XH V]+N].31KN*ZMO,N&'[M\_=K#<@/P*5&VHR^M,8X&.]
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M62>],D.%S0!#<R94"J9'-22/O-,SS0 44F#GVH H *6C&** $QFDQ3J3/%
M*.U*IHS0 8XHQ1WI.] !GFBCOBCH:  $T<TH/-'>@!*0GVI:6@!.M%!Z4=:
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M7J*?0 'O33]:#FFCK0 &DIW>B@!G>BG4=: &=Z:>M.:FT .&:ZOX:?\ )2-
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M2"G#I0 4&B@\"@!,TXXIM+0 &BBB@!"*7%(33ATH 3H*C8\T\TQNM "8IV*
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M(/44BG!P:O:M) ][*;<8B+$IGTJ@,GK0 XG'%(>:4\@4T]:  FCI3>].'M0
M8R,TO/2E%&.<B@#Z9^#?_)-[+_KK+_Z&:^>/B+_R47Q!_P!?TG\Z^B/@W_R3
M>R_ZZR_^AFOG?XB_\E%\0?\ 7])_.@#F1Z]J7%(.E*: $YQ10110 4F,TZF]
MZ '"DHHZT +0:*"* %YHQ24N: $H(SB@\&@=:  J>M-Q3J0T )]*6D6G8SF@
M!!1CG-&,&EH ,BBDI: #-'4TE+0 G2D[TII,=Z $-&>*4TGI0 O44O:@=**
M BC/2@\44 *<9I#[444 %(12TAZT !XI#2BFT +S0*!S3A0 AHQ010N68"@"
M6*(RM@5J16*;!D8-.LK8;5' )[FI[F-H)"AD#%>A6@"I=6/E/L==K8S6?-;E
M#QTKH;N:SGMX#&96N<8E+=/PJH\89.E &$3CBD)YJ>YC\N0\57/- !1C)H[4
M4 )U.*7&*/>EXQ0 G)HI>E% 'W;1110 4444 %%%% !7Q_XL\06_A[XK7FK^
M%X9;&[L[V99$EPR%PQ5B/]EOFR/>OL"O&K(?##Q3\0=0T$^&"^K?:)S/-(&"
MNZL=YX;N<T <O'^TKJBH!)X=M'8#DBX89_#!K5\/?M!7VM^)-,TI_#]M$M[=
M1VYD%PQ*AF SC;SUKT3_ (5)X#_Z%NU_[Z?_ .*KCM7_ .%;>"?'VDZ0?"A3
M4))898+F,G;$2^%?ENS#T[4 >RT444 %%%% !1110!\E_%_GXIZV/]J+_P!%
M)7%J#BNU^+W_ "536_\ >B_]%)7&J?:@!O:D/6GMQ49SF@!O>@GGBC/M1CF@
M!,TH//-'>EZT %+24O'6@ )I.:.]*..:  4N>*.M &* #- H%&>: %I#0#Z4
M4 )11U-+B@ I#P:4THZT )$K,U:$&G7-Q_JXRWT%6]!TJ34[D(J'!->Z^&_!
M]M86T;2HK,1DY% '@SZ+?Q@EH'Q]*SY87C/S@@U]47.BV,MNP\E.F.E>)^/_
M  \MA,9XE(4]1B@#SMLTAZ<4ISG%)WH !3J;3J $I!S110 8I:2C/.*  'FB
ME R*,4 !I.U.Q2$8% ##Q12GFDQ0 *<&GYIHIPXQ0!U/A:#?>Q$C@&O<],"I
M8H/:O&/")4W48/%>OVTP6U SQB@"S*JOD9%5'MH@P;(S4%Q?;00HJB+F25P,
M\"@#3F81IQTK@/&2B:!FQTKM&DW1%3Z5QOBC"VK"@#RZ4?.?K41J>8?O#4)Z
MT -QBE[4=:2@!XSBNK^&O_)2- _Z^U_K7)@XKJ_AJ?\ BY&@?]?:_P!: /H#
MXS?\DYN?^N\7_H5?-8KZ5^,W_).KG_KO%_Z%7S4.E !WH_"ES29)H #P*3.!
MS03CM2$D]L4 +FEI!TI>U !2TF.*!SWH 7-)S2DCTI.M "T=*-QZ"@C- !GF
M@G-!HH ":2@FE- ">]%!Z44 **#THHH .U! [T9 X-3V]O\ :21D* .] %<;
M7XS2MMZ TZ2(Q/@8IA (]Z $QBE7WI!TI: $YSSTI:** %I#0:* #%**.*3I
MS0 A.!24XYI.AH *3O2CI010 T^M)2^U)B@ IS'Y:;2]10 G\/2I8HUV$D\U
M'G I2_% %Q&/E8\Y@/3-5W&"1FHBV%X.:%))Y% "8).#2@8.*7J*0#!S0 C#
M%,IS'--H ,4HZT8H H <,YHYI!3LY% 'TS\&O^2;67_767_T,U\\?$7_ )*+
MX@_Z_I/YU]#_  ;_ .2;V7_767_T,U\\?$3_ )*+X@_Z_I/YT <S2=J6B@ %
M)GFEQ29]J  GGB@<T <]:7O0 ?6EI.M'>@!:0FEI,T %+VH'%&2: "C- &**
M "DI<TG:@ %%  %)W- "]\TM)FB@!1UH/%(>.:='&96  ZT  R>@I"C9R0:Z
M*RTV..)6?!)%69+*%XSA10!R9XI,G-6KV#RI3@8%510 K<#B@44=* %I*4TE
M  !F@#!S10>>E "TW/)I03R*.HH *0T9Q1DF@ ]J04I%(10 O:E4XIN<4 T
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M\4D=G.T:R*5;'<5E22&21F/4\F@!%ZGZTZF)T.:=SF@ /2EHH)H ,\<444E
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M!Q0!H6C_ "XJVJ[NM94$GEMS6DDRL,@T 2NH6J=S(%7%32W*[>M9L\OF-[4
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M+=*;3VXI#TXH ;SVJS;SO'WJL*>* ->+6KF!<+(0*CGU>ZN>LC&LWJ*7ITH
M61V<Y8U'VS3CDTE #3TJ,]13R<4W% !F@YHH_"@!/K76?#3_ )*5H'_7VO\
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ME_QKYR\4_!+QEJWBS5]1M8;(V]U>2S1EKD [68D9&/0UD?\ "@?'7_/"Q_\
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M<_A2&B@!:,]J*3O0 M&<T4>U !2=:6D[T  IW:FTM #A4T=S+%]UB*@&!2T
M3/=2R<,Q/XU78LQY-*2!3>#TH <!Q1C% X%&/>@!,^U/C 8G>< 4SVIP&2 :
M .J\)VC7%]&P7@&O;$:*WLXXSP<5XWX-*_VAM:?RE49!]:];BN(IK,,QW%>_
MK0!))(G&#5V&7"#::PI,N^4/%:5H&6$EZ );V["Q$ENU>/\ C75O-E,2'(%=
MCXEU=+6*3,@!P<"O'M1O&NIRQ.>: *V<GFO2/AO#]HO$.W."*\U4Y<^E>O\
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M%CVKN?&'A/0-.T2VO-/U..>5AED!H \Y4X.T=*,8;-&!NP*1E.>M "G -(<
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MZ!_U]K_6@#Z$^,O/PZN?^N\7_H5?-!X(YKZ7^,O_ "3JY_Z[Q?\ H5?,[9;
M H >5.X =Z:P*N<=:<['@ <BF'*G/<T (N1U[TH&!S2GFEQ0 M HHH *0TM)
M0 =Z":7%%  .E%%'>@ H[4=\=Z,4 %%)TH/-  *6DZBG=J $I:2B@ HHIRCC
MF@ ]Q12Y&,4V@!1BE4\GFF]?:G+UH 7H>>E!G=ALYV_6F\DTC<"@!AC.[-!'
M/-(,D=:=@%#0 A)[4@S@YZTX?+P*:W7B@ Z\58L[.74+A((%+,3T%5CUJ[IF
MH/IMXD\9PP- $NI:5/I\IBF0JXZ@U2R0R@UKZIK3:C>--+\Q;UK-NI%<@JFV
M@"/>#(:83D,*!P"U,4C+4 *.!29_6D')-+TH *7I30>:7/K0 ^B@]*;UH 6C
MF@9I: &D\TT]*4\&DR: "@4< =:0G%  :;2@FEQSS0!]-_!G_DFMEC_GK-_Z
M&:\R\:;3XRU09Y^TO_.O3?@SC_A6UEC_ )ZS?^AFO)O&DH7QSJYW=+I_YT 5
M!$B1ELU@7<^UW8FKEYJ!AA8Y&*Y*ZO))Y"<\&@!+J?SY3SP*KB@#O2]: $!Y
MI>])TI:  T4E+0 4=J*,4 (#S3C2 <TN* $HHHQF@ HI*.U !UI>E(.*44 +
M12&CK0 $BBC% % "C% HZ&CF@ I:2B@!QYI$(#C-!XZ4F* -B%P\?!YJ3RSC
M-95L7\P $UJY(3DT 0SW'E+C-9,DAE;)J6Z9FE.3Q4.!B@!.])WH]:!0!OZ#
M!*LZR[#Y8/)KTX$26J\?PUYAHMW)O6#<=N<]>*])2?R[,*%R<=: ,NY(0GBN
M0\0/D'%=/>R_*Q/6N,UF??)MS0!DD';FFYYI<YX[4F.* %SWH'-(3VH)XH 7
M-+2+03S0 &BDZ4O:@ .>]-IQZ4V@ [T4HYZTE !111S0 9%%''>B@#[NHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /G3XB^++[2?B+J]O#(0B-'
M@?6-37#ZIXLU'44VO,VWTS6K\7&Q\4-:_P!Z+_T4E<06H 25MYW$\U%3VQBF
MT )2GD4F:6@!.E+124 *:.*,\\T4 %(:7M2<T +VHSQ110 #I1FCM0* #WI,
M?-FEX-)WH <,"EI*4B@ IO4XIV/EXIO>@!<#O2Y&<4E'4^] #O2@CG- %&>M
M !CFGC(I$-/P* 'Q-\W->@^"IH@V"1FO.\[>M7]/U:2QD#(30![9-<B.%B6&
M*\B\67:SWYVG.":LW?C":>#RP<'%<Q<3-/(78Y)H KGBF]Z5J3M0 #Y6W5Z+
M\.]2^R:A&KL!DBO.QZ5?L+V2UF5HV((H ^SK/4()K&.42 _+ZURGBCQ';:?;
MR2-*.!TS7B5O\1K^UM!"'/ QUKF=8\37VI,WFS,0>V: )/%.NOJVHR/N)3/R
MBN=+93'>ABQY/>F#- !TH/)SBEI#S0  <YJ2HU!'>G#- #^U(<THI: &@4[M
M2"@XH :PR*C(^:I3TJ,@T )1CO1BB@ _"NK^&G_)2O#_ /U]K_6N4.3TKJOA
MF"/B3X?Y_P"7M?ZT ?0GQF&?AU<C_IO%_P"A5\UU]*_&3_DG=S_UWB_]"KYJ
M)H :1C[N??-&0>M+2<4 +BE%)1UH 7O0.:** "@8ZT=C1UH *,T4TYS0 O6@
M9!H7I2T '>BCO1SF@ -(?2E-(: %QQ0*!2T )F@T8I1[T  XI> ,TGUH^M #
MQ@]J3;QB@#WHQCH: #8>E&,"G FE;!H C)S2-UIW0YI N_(H C()Z=*502AH
M!*$@B@'% "<TA]*6D]J $/W>*<JY&.]-Z&GJ* +!2-44YYICLK]!TIF"QZT,
MP P>E #'(QMIN,4XD <4WG.: $Q@TN>"*,T4 )[4X=*3'-+GG% #J;C%*,XY
MI: &]\]J=24M #3SUIGK3B:;@T &*",T8-+^- #<8IW;I1W% ^M 'TU\&?\
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M0!WI32=J %%!YI 32B@!*4'M2FD&!0 $TTTXTP\T +11@XHQ0 8[T?A2TG-
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M.*/J*,4 +2=>*<%S1C H 3MBD(]Z6DZT *"0/>FD]J4FDQS0 "E[<4#CBEH
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M=<THXI!UXHSF@!0>>:?GBF#FG'@9H 8V<]*0#G-.)Q2=J #O1C(S1[T=>]
M**0GFEH ,^]'/K11[F@!>@S0*<#[5+:6QN[I(!(D>\_><\"@"'.*0].E=&/
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M:Z'1->CT/3[F./3KF2[G 5B1\AYZT\?$'Q!C[UC_ . RT'X@^(/[UC_X#+0
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M* .?82#I#+_WP:DM'1+F-[JUG>)3DA%P:W!XZU_NUE_X#"E_X3G7O[UE_P"
MPH UX_'*K/(YTNX*X0Q''.5&.:K>%M:MM)TW5I[U)FFDN%FBA13ECDD_SJC_
M ,)SK^<>99?^ PH/CC7L_?LL_P#7L* -9O'[*"(].N53TY_O!OZ5QVI7;ZAJ
MEU>+:RQK/(7";#QFMK_A.=?_ +]E_P" PH_X3K7O[UE_X#"@#G LA_Y8R_\
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M &G7&I*G"G-8\TS3/DT ([[V)]::#CBBD/6@!#UH-)S1G- !U%''>@^U ]:
M 4II!Q0>: $/!I<4F"*,YH 6D.:!1R: $ZTO2C%+0 !7;A59CZ*,T[R9A_RQ
ME_[X-7-*UB\T2[-S9&(2E=I\Q PQ]*V?^%A>(?[UE_X#+0!S7E3?\\9?^^#1
MY,__ #QE_P"^#73?\+"\0_WK'_P&6C_A87B'^]8_^ RT )HGB&/0M,EAATVY
M>YF93(6'R\$'(_*IM=\3_P!O7>FB.PGMXK>?S6+*3R<9_E4/_"P_$ _BLO\
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M_KT ?.'_  CNN8_Y!&H?^ S_ .%)_P (]K?_ $"-0_\  9_\*^D/^%Z^"_\
MGK??^ W_ ->@_';P6/\ EI?_ /@-_P#7H ^;_P#A'=;'_,(U#_P&?_"E_P"$
M>UOMI&H?^ S_ .%?1_\ PO;P7_STO_\ P&_^O1_PO7P7_P ]+_\ \!O_ *]
M'S@/#VM_] C4/_ 9_P#"E_X1[6^^CZA_X#/_ (5]'?\ "]?!?_/6^_\  ;_Z
M]'_"]?!?_/2^_P# ;_Z] 'SC_P (]K?_ $!]0_\  9_\*/\ A'M;'31]0_\
M 9_\*^CO^%[>"_\ GK??^ W_ ->C_A>W@L?\M;[_ ,!O_KT ?./_  CVM_\
M0'U#_P !G_PH/A[6_P#H#ZA_X#/_ (5]'?\ "]O!?_/6^_\  ;_Z]'_"]?!?
M_/6^_P# ;_Z] 'SD/#VM?] ?4/\ P&?_  IRZ!K2G/\ 8^H?^ S_ .%?1?\
MPO;P7_SUOO\ P&_^O1_PO;P7_P ];[_P&_\ KT >#:;8:_93!TTK4%/_ %[/
M_A7?:7K^MH%2?2K\\=3;O_A7=_\ "]O!?_/6^_\  ;_Z]'_"]O!?_/6^_P#
M;_Z] & =5O)HP3IEX#_UP;_"J%[K6I(A$6E7Q/M;O_A77?\ "]?!?_/6^_\
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M0/#NM_\ 0(U#_P !G_PKZ5/QN\'C_EI??^ __P!>F_\ "\?!O_/2^_\  ?\
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M>@#Y^_L'6/\ H%7W_@,_^%']@ZQ_T"K[_P !G_PKZ!_X77X0_P">E[_X#_\
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M\]+W_P !_P#Z] 'S[_86KCC^R;__ ,!G_P */[!UC_H%7_\ X#/_ (5]!?\
M"ZO"'_/6]_\  ?\ ^O1_PNOP?_SUO?\ P'_^O0!\^_V#K'_0*OO_  &?_"E_
ML+6,?\@F^_\  9_\*^@/^%V>#_\ GI>_^ __ ->E_P"%U^#_ /GI>_\ @/\
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M [_X5[]_PNKPA_STO?\ P'_^O0/C7X//_+6]_P# ?_Z] '@)T+6,?\@J^_\
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M@#Y[_L'6/^@3?_\ @,_^%']@ZSG_ )!-_P#^ S_X5]!M\;/!ZGF2]_\  ?\
M^O0/C;X//26]_P# ?_Z] 'SY_8.L9_Y!-_C_ *]G_P */[!UC_H$W_\ X#/_
M (5]#'XT>$% )EO/^_'_ ->F?\+L\'Y_UE[_ . __P!>@#Y]&@ZQS_Q*;_\
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M_A0?#VM8_P"0/J'_ (#/_A7T;_PO;P7_ ,];[_P&_P#KT?\ "]?!?_/6^_\
M ;_Z] 'SD/#VM?\ 0'U#_P !G_PIO_"/:WG_ ) ^H?\ @,_^%?1__"]O!1_Y
M:WW_ (#?_7H_X7MX+_YZWW_@-_\ 7H ^</\ A'M;_P"@/J'_ (#/_A2#P]K?
M?1]0_P# 9_\ "OI#_A>O@O\ YZWW_@-_]>C_ (7MX+_YZWW_ (#?_7H ^</^
M$>UL_P#,'U#_ ,!G_P *0>'M;SC^Q]0_\!G_ ,*^D/\ A>W@O_GK??\ @-_]
M>D_X7MX+_P">M]_X#?\ UZ /G(>'M;_Z ^H?^ S_ .%(?#VM'_F#ZA_X#/\
MX5]'?\+V\%?\];[_ ,!O_KTO_"]O!?\ SUOO_ ;_ .O0!\X#P]K8_P"8/J'_
M (#/_A2#P]K7_0'U#_P&?_"OI#_A>W@K_GK??^ W_P!>D_X7MX*_YZWW_@-_
M]>@#YQ_X1[6O^@/J'_@,_P#A2#P_K9_Y@^H?^ S_ .%?1_\ PO?P5_SUOO\
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MO'_('U#_ ,!G_P *^D6^.?@Q#AI+X'_KV_\ KTW_ (7MX+_YZW__ (#?_7H
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M8N0TUK>7.YFC[_+SSCZ5[]0 4444 0WBN]E.L>?,,;!<=<XXKY//@GXLY/\
MHFL_^!?_ -E7UM6/XKFNK?PAK,UCG[7'93-#CKO"''ZT ?(5H/&]_K4NCV=Q
MJUQ?Q,5DABG9BI'!R0<#\ZVK[PE\4].M'NKB#61"@W.4N2Y ^@8FNQ_9^\4Z
M#I2ZII^I7,-KJ%U*KQS3L%$J@?=W'N#S^->Z7GBC0-/MGN;K6;".)!N9C.IX
M^@.30!X?\ $U[4=?NM5NM0EN=/C@:%DDN2S)(2I&5)] >:^AJ^:/A9J[7_QY
MU"YT9&32[UKEY$"[1Y7)4D=OFV_3-?2] !1110!\E?%__DJ>M_[T7_HI*X:N
MY^, _P"+J:W_ +T7_HI*X<+0 "EHP*-O% "44NT8HQB@ I*#R* !B@!1]:/Q
MI,"C Z4 +Q1^%)MYIP% #?PI>>E/Q2[: &8XI=OM3B,"C'O0 S'-&,4ZDH /
MPI,4HH- "8P:6DS10 H]Z<!FFCGM3Q0 N/2E'/%&#3E '6@"]I4*MJ$*$\%A
M7T]X958=(@CCP?E%?+,4_DRJZ'Y@:]7\)?$,6JQP73X4#&2: /93'&[98XIU
MO<B&<*@^7UKDI/&^FL R7"'/O33XYTJ!,M.F3[T =I=7@E<*%JO+,L,>YFQ[
M5Q$GQ%TN/+F56Q[US'B+XIQ20E+098]Q0!7^+.J6\J+%&P+]\=J\@8Y%7M5U
M2;4IVEE<DDYY[5F%C0 YNE-W<49I.E !GVHSFCK0.M #AVIY/J*CSS3PI)XY
MH <'V_=.#5B*_N8CD3,OT--AL9IB L;'\*T$\/WS@'[,_P"5 $]KXKU"VQMF
M8_4UJQ?$+4XQ]_\ 6L-_#][&,O;N/PK/N+)XCA@5(]: -S4/&>HWQ(:5@#Z&
MN>GNI)FRS$GWJ/R_>DV>] #201G%%+M-&WF@!-N12[..*<.E(<GI0 W%)]*=
M@TF#0 TDUU?PT_Y*5X?_ .OM?ZURIZ]*ZKX9C_BY6@?]?:_UH ^@_C/_ ,DY
MN?\ KO%_Z%7S.:^F?C/_ ,DYNO\ KO%_Z%7S/B@! .:6E Q1@&@!,TN32[>:
M"* $R:0\&C/-'>@ [YI<9[TAZT>] "XYI*4],B@#F@  S1MQ3N@HYH 0+WS2
MXI0.]*!0 TKGFC;3B.:2@ I-O-'>G4 ,*XHQ2D]J3- "XYI1C'6D!I: # HQ
M1VI>HH 3%( !D]Z48Q3>A)SQ0 '[HYYH;Y5X.6I05.<4F.M !RJ@D9-(X+ ,
M*3ENIQBG=N!0 !"4W'C%,(W*#3V9@.O'I3,Y'I0 [--'!I>W-'I0 A-&:#[4
M'TH 0'GI2Y&.E,SB@8- "\^M*!Z\B@#G%&#TH 4@=N*0GMU/K2$&E'(H  <#
MWI"1W&:7'.!2$'- "44N#Z4;: $&: .:7%)VQ0 I!'6D_"CGO1UH 3FESQ1G
M%(<T ?3OP8_Y)K9?]=9O_0S7SS\1?^2B^(?^OZ3^=?0WP8X^&ME_UUF_]#-?
M//Q%_P"2B^(/^OZ3^= '+TX#%&*6@!*3%.QQ28% "8HQBEZ"D)XH .M+1VHH
M ,44 CI28H 6BER,4W=0 O.<44G)-. YH 3%+BEQQ10 W'-+SZ44"@ Q1B@T
M9H *.M(3S2]J #BCZ"CO1WH 44(,R >])CFEZ<T =E8%1;*!V%3[%9^< 5S-
MAJK0+L?.*T3JD;<AP* -F&Y,4VT#Y?6EN+H29 '%8QU>*->H)J,:U"H)(S0!
ML2.D<0);\*Y?5YDEFPE/N]8,H*HN*RG<LQ)/)H :32'VI<4=Z $[44O I.U
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MY8]ZZKX:#_BY.@?]?:_UH ^@OC-_R3FZ_P"N\7_H5?-!Z5]+_&?_ ))S<_\
M7>+_ -"KYG[T +VI!0>:.E #L\4'IUHH&.: &T=Z4@4>] "&@#-+S1R!0 $>
ME/'2F^]!:@!W&:":86P>M-)/K0 _=2[JCZ49H ?NS2$G%(*#0 9.:=DTPTN<
MB@!<T"FTN,#WH =2YS31QSFG$YZ4 &<=.:-Y]*3C/)I.!DYS0 HD&>E&<_PT
MW(//2E+-U[4 (-N[TI2 3G-*2".1BDQCD=*  A?QI>V*./2B@!#2$4XTT]:
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MWI2><4T\T !/>DXZ4OM2?3K0 8H' -+T[T#-  12=J7%&: #WI,TN?>DQF@
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MHH X/XSR21_"?6S&2"5B4X]#*@/Z9KC?V<-)L1X<U/5_*5K]KHVY<\E8PJD
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M& ZUDZC\1KJ4$6_ KSQF)[TF3VH V[OQ%J%ZS&2=N>V:R9)7+99LYJ+Z]:*
M%R2.:3/%+DBF]Z "@D8HI.O6@!>*3-&>U+D4 &,4GO2$YI.10 ZD-)FB@!>E
M=5\-/^2DZ!_U]K_6N4S75_#3_DI7A_\ Z^U_K0!]!_&;_DG-U_UWB_\ 0J^:
M1S7TM\9O^2<W7_7>+_T*OFC/YT .Q332Y..M)[T !Z4<FDS2_C0 =*=3,TZ@
M!",FD-.)I,$T )C-%%+CO0 F,4O:EQDT =J &]:*?LI0HH 8,&@#FG[1GBEP
M!0 VD-/-( * &>]+C/M3L8!/:F[<KDMCVH  @[M2<=LYI00!QS3=P!]#0 %M
MV..12CUYH*D_-FD)P* '!AC S30X!/!I 3U%/R<<T )Y@(PJT<]6-'>@\T +
M29YH)I/2@ /6@4=Z,4 &,G-'-.Q24 !Y%'2E'2D]: &AO5<T>9S]SFG C%)P
M3SUH 0C^+.*>O ZYII49YZ4HZ<4 *:,@&C'%(>: #.:7.*0>]!- !D&D/M1T
M-'6@ ZCI2'!XHS01GGO0 VDIW%(<4 )1110!]._!G_DFME_UUF_]#-?//Q%_
MY*+X@_Z_9/YU]#?!G_DFME_UUF_]#-?//Q%_Y*+X@_Z_I/YT <Q^% &*!FB@
M!:2C-'6@ Q112&@ %+@T@I>>U "8I<8HZ48S0 8HHI.: %S1BC!HV^E !12D
M TN.* &T4ZDH 3O0:4CGWJ6&!KB0*!QW- $.<< 4H#9!P:VHM.B0#(R:L"V0
MKMVB@#(AO7B^4Y(JY'JZK_!3GTU&SM%9UQ:O"WJ* -*35TD7!R!Z4P7\('O6
M/CFCOB@#4?4ES\JFJ\^H/*-O053S00#0 44#BC.30 'I2=Z.U% "]J"#VHZ4
MG/K0 HI,&@9H/)H DAE:%\J>*OC4OE^Z<UF=Z#UH N2ZA*PP.!58RLY^8FF=
M:4'C%  ,$T<4"DH ,THIN*=VH 4D4AZ48SUI">,4 )F@\44=:  >M%&,44 %
M%%% !11G%% 'W=1110 5D:[X7T3Q-;K#K.FV]VJ_<,B_,OT/4=:UB0 23@#J
M37$^)?BSX1\,;H[C4ENKD''V>T_>-T[GH/SH QI/@%X'=]RP7L8_NK<G'ZUK
M67A;P!\-XOMYALK%U'%S=2;I/P+<_E7CGB;X_P#B'6"UKH-LNFQ2?*&'[R8Y
M]#T!^@KBO#VA>(/B9XH>S^WF:\*&:6:\E)PH(!/N>1Q0!]5>$O'VB^-;O48M
M&::2.PV!YG3:KEMV-O?'R_K745P?PS^&T?P\L[U?[0:\N+TH96V;479NQM'7
M^(UWE !61XJOY-+\(ZQJ$+%9;:REE0CL50D5KU2U?3TU;1K[3G.U+J!X2?0,
MI']: /E7X=_"ZY^(=EJFI3:D;=8&VHQ7>TLI&XY]NGYU!\./AK'X[GU>TEU%
MK&[L0NQ=FX,22#GZ$#\Z[/X20^*?!/Q)?PGJ%L\5C=F0R[T)1RB,5=&]^/PK
M#\07FM?!_P"*^IZA86RFWO=[P^<I,<L;G=C([JW\O>@#H_@7ING:)X[UO2;[
MS5\06@>)&#_NGC# -@>N0#]*^A*^9?@K9:OXG^*4_BNZ5C'#YLL\X3:C22*5
M"#_OHG';%?35 !1110!\E_%__DJFM_[T7_HI*X<5V_Q?Q_PM36_]Z+_T4E</
MQZT *:.U)BC&: %HQ2;:7;S0 E&?:G*M*0.] #:4=:4\49H .]'>BC% !2@G
M%)WI>U "@TN<TE% !FCC\:0T=: #DT]!N;%-'7%.C^_0![%\,K:!;9V*_.>]
M>A.JI$V#N)KS3P%.8K,D&NU@U!BQ)' ]: +]K'(\A$@PM7S $0[3Q6,-;#3B
M(+^(K1NK]8K3>: *5Y;)."LH!'O7G7BWPO"5:>WP,#)&*[O[:+K[IJGJ%MYE
MG*6QC:: /G^1=CNF.AQ46.>:T-7C$5_,HZ;JH4 (0*;@XIV:* &=*6EI,<T
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MIU% #<49IQ%(>* %%%)FEH !UHI!]:7O0 9-+GTI*44 )S2T4&@!:2C&:*
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M85-=%D0HZAE/4,,@U\U_\-)>(?\ H"Z7^<G_ ,51_P -)>(?^@+I?YR?_%4
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M\7)T#_K[7^M<K75_#,9^).@?]?:_UH ^@?C-_P DYNO^N\7_ *%7S1S7TO\
M&?\ Y)S<_P#7>+_T*OF>@!WO0<'O2 \<T<&@!0:*3-&.] "\4N?RI O&*7&*
M %'-/V\9I$'%2=NM #<>E(5]Z4KQ2XXH 9CGK2LH]:,<\T[&: (\4F*EVX'6
MF$T -]J3\*7M24 +0*.:!0 9Q2=:4C-)B@!0,#KFFD#.:6B@!H QWI0-O2@"
MB@ Z4G/:EH]Z $[BEZ4N!BD&* #%)U-+1GGJ* #I1CO29R<4N* $'I13J;Q0
M N0:,9- HZT -Q@TN* .31CF@   H/2@]:04 '4T']*6DSDT ':C%+VI 30
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MBO0/A1IK3^-]+N .(IE<UP1 XYKU/X/W447B6VB.-SN * /5/C/_ ,DYNO\
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M@ P<TM-(]Z=U- !BEQ3<8[TN* '4G6CO10 &DR:"*,4 *#BDZTH'6G*N5^M
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MR'Y7;\Z /5H;F!5"K)Q]:DDO+9?F:5>!ZUYG;_VC+]POBM.WT;4+D?,[\^]
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M %^R?SH YD/(,8<C\:#(Y^\Q--H% !NYHQGI0?:CG'% !THHHH .U HI?PH
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M)'- H %3'/4TA)(R>M.[TAYH ;GBC- 'YT8SQ0 "C%'0T9YH .@HZ\4<FEH
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MZD)PQ%9N0.M+QVH EEN)9CF1R3[U#WYI3S0* $.0:.@H-+0 F<FEI.E!/%
M!1GFBE% "8H[4&E% "5:@LR_+<#TJ*W3S9@OO6V(<8 [4 5Q!%$,!1FE"Y.
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M*<1Q32!0 @H/7FCG/M1GG% !BDQ3L4A]J #&*,YHQZT#ZT +2$GI2CK3@,T
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M=9OTN)L^5$T\89\#)VC;DX%)>? /P1I5N;O4-9O[>V1@&DFGC1>3@ G;QDT
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M+_KK+_Z&:^=_B-_R47Q!_P!?TG\Z^B/@W_R3>R_ZZR_^AFOG?XB_\E%\0?\
M7])_.@#F*6@4$T )]:!UI<T@ZT +BBC-+^- "')I>E'M1B@!IS1@TN*!0 8Y
MH.:6B@!,<8HZ<4O6D/% !F@C-%':@ HH%&.: %I**44 )WI<44"@ Q1WHZ=Z
M.U "4O>C%'2@ Q1VHHH 0<4N?:COG-% "$XHP>U!I: $YI<4G&>M!X- "T'K
M[4E&: %I.] YH!H 6DHI.,T *:!TI,44 *>128VTIZ4'F@!=S=C023WIHZ4M
M "=Z7'>@T'I@4 )R#1WH[BEH .M)Q2YI/QH  **6B@#[LHHHH X?XOV4U_\
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MPK1B\-:C*N5@?'TH Q:,\UKR^'-1B!)@? ]JSVMGB)61"M $-%*RGM3>1UH
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M@#Z#^,W_ "3FZ_Z[Q?\ H5?--?2WQF_Y)S<_]=XO_0J^:,YH 6E&#3:4'\:
M#&6Y^Z*0D#! P#2L<#TS2'*[<G- ";R#VI2VX#<M'5^11R#B@!N-H.TFC<PZ
MBI!C:2>M-^8#![T '09% - &W@\@TN.>.E #ATH ]*04Z@ Z4H&12=O>C)H
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MG%)FC;1CF@!>V* .*.AI.] "T4=328[4 +29R.**.U "CCK13310!]W4444
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M_$^Z\7)-HNM,&U2VC\R.8#'G1C .?]H$CZY]J]<H **** /DKXO@?\+4UO\
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M3GBFEB1M"\>M297GCBF\=!0 W&!@4G;BG'GBDXQ0 9HZTE)CF@!<4"CI2]*
M&TM%)VH ^F_@U_R3:R_ZZS?^AFOG?XBC_BXWB#_K^D_G7T1\&O\ DFUE_P!=
M9?\ T,U\[_$7_DHWB#_K^D_G0!S/.*.E&:*  ^@H%+VI.M !1CFEZ4F:  BE
MXH%% "9.:7/%)1WH 7M2=*4TF*  =:G@A\R3GH.M09YK5T^WC:&1Y793CY !
MU- $\,2 < <5+&/FX6JV& &>#4T<FQ\]J - 2!(\$#-1^5&X+,!69<W;&7T%
M3I=+(H7/- $=S:QMD@8K,D@,63U%:;OR>>*A^5SM- &:#FBIKJ'R7]C4&<B@
M [49Q29/2CK0 IZ<4"BD% #P::>M.'2FF@!5&2!6@J!8QFJ,()D JV[X&* )
M 5ZXI"0PQ2P%6SNH8 <B@",Q]ZJ2KA_2KR')JM=K@B@"OBD[TM)F@!3[4<]J
M :6@!,9I>AR*7'&:0'/% &UI7B&?3OE!^6NGMO$\4R@N^#7GV:4LRG&: /0[
MGQ/:QKLW9SUK'O?$,6QA$Q.17)GYN23FD)/X4 2W%PUQ,7:H.^:7M2=Z #D&
MEH)YH- !BDQ1C\Z!0 IHHSFB@!.M%&:* /NVBBB@!'19$*.H92,$$9!KC]:^
M%G@O71F[T*VCDW%O,MAY+$GU*XS^-6OB'K-[X>\!:MJFG.L=W;Q Q.RA@I+
M9P>#UKY3O_'/BCQ1<&+5O$T\<+C#!G9(L?[L8Q^E 'H?C'X2^!=%$LD7C:/3
MW!_U%P5G(/IA,-^AKRV+7M7\-WL\&B^(KD0AA^]M)9(TDQT.#@_F*Z#2/#W@
M!CYFM^-;@D]8[6Q<'/\ O,#_ "KO=&F^!.DB(LTEY,G66\BE?=[E<;?TH ZC
MX&^-M?\ &$&L)KEX+G['Y A;RU4C=OSD@#/W1UKUVN4\$^)/"6O0W47A0P".
MV*^<D-L8@-V<<$#/0UU= !6)XQMYKKP5KEO;Y\Z2PF1-O7<4.*VZ",C!Z4 ?
M/G[.>N:1:#5-*N)(H-2N)$>(N0#*H!&T'U!YQ[U[W>W]GIMI)=WUS#;V\8R\
MDKA5'XFO#/'WP$N+O5)]5\)S0QB4EWLI6*[6[[&]#Z'IZUQ4'P2^(5],D%S;
MQPQD_P"LGNPRK^ )/Z4 ;'PRE36/V@+[4M(&-/WW4YP,9C;(!Q[LRFOIBN'^
M&WPWLOA_IDJB476HW.#<7&W P.BJ.R_SKN* "BBB@#Y+^, _XNGK7^]%_P"B
MDKA2?;-=U\7_ /DJ>M_[T7_HI*X?% #<TN:6C% #<^U+GVI31B@!"WM1D^E+
MVI* %W>U!;)&.*3-&<T 29XHI@I: )-U/1L,#[U 32AL<4 >O^!?$$2P+:.R
MC [UW;(+Q=R%2*^;(+R:V8-&Y4^HKLM(\>7]E&JLP=1ZF@#UJ6U ^]61J.BI
M<C>&Y]*Q+3XBVEP LPVFMJVUFQOP'CN!@]LT 5;'3FMG//-:7V S#!;%6(S"
M#N\Q3GIS3B4P3YJC\: ,:6Q6TEW!JP/&LR/I );#=!6KKFJ6MJI8S!B/>O./
M$&M/JC; <1CH!0!S[9S[4W-*>%Q3: %!I0:;R*,XH >3Q3:-V10* '@ &NI\
M(H#J ..E<HI^:NR\&@&Z8F@#HKV SW'3@5<L8#$N*<,+.3UJPCC/.!0!'+*R
M\8J.W.9@35LQ[AG%1+'MDSB@#G/&$H^S%>]<"W/-=CXPDP2M<5OSVH 2E6FB
MG*?6@!QXI=^.E-8_+46[GI0 \R')YIC-F@\4G2@ HSFC- Y/- "&C'%&*6@!
MH]*,T[BFGB@ (HHS2B@!O2EZ444 )S75_#3_ )*3H'_7VO\ 6N4[5U?PT_Y*
M3H'_ %]K0!]!_&7_ ))U=?\ 7>+_ -"KYG(KZ8^,W'PZN?\ KO%_Z%7S.1D\
MT )1UIV*3&: $[T"EQ28R>* %S2=NE '-% "@^M2(P4\@'-1=*7- #Z2F@T4
M .%!I.E&: %W;2".M*,\L.2:0'--W')QQ0 XD]Q2;@PQTI"Y!%!96'2@!QX3
M H%"H2.*4X)H -NWG/6D R<4[UXI!['!H !P&%)T%*.*:>M "YH-)[TF<_6@
M!V:7--S3L9H 4 $\T-WI#Q2]5H 0_=%& !TIS !%-,;YJ  ]<TS)8T\#%!XZ
M"@ Z'%"],4 YR: !UH =Q2&CBEH 4"F]*7-)0 9HS2J,C-(?6@ S1G!HS1F@
M!&Z4T9IY QP>:3&* $(P<T$C-+FD/K0 G6DQ0*7J: $HI2?:DH 0\TH% I*
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M2Y+\ ]*@,CMC8<CM2W<Z7*)CJ13(QY:T :@N?+@4.1G%(9T."2,8K%87$[$
MG:#3YY?LUHSY/ YS0!RWB^Y5[O:IKEP:N:G<FYN68GO5&@!V1VH)IM%  232
M=#2TG- !G-!ZTG2EH .:*7%.VT ,I*<0* !0 WH*".:<5I#0 W'YT=N:=2&@
M!.]&*.I]J* #.:ZKX:'_ (N3H _Z>UKE375_#3_DI.@9_P"?M?ZT ?0/QF_Y
M)S=?]=XO_0J^:17TM\9_^2<W7_7>+_T*OFC\: %I/I0*.E "TT=:=FDQSZT
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MHHH 4<="<T[S&Q]XTS-&>: '^8^/O&DR3WIO/2EH 6DX%)DYI:  TAZ4M)0
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M-W?ZG'=0DK)^_NKN0_.YYP, YX_"NI_X9P\3?]!72_\ OI__ (FL#P;\46\
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MC<:;UH ?1C I/QH' YH .U.%(.:7M0 A'--Z&G8SWHQQ0 G7-)2@8^M&":
M&C/6DZ=:* %!-.%-S0&H <:3/:@GFDQ[T !Z449)'I1B@!PHXQ29Z4N: "DS
MUI<TF.>* "@F@\<T=Z  @&E%!'-'- "]*/>DI0: $/!W8I!@]*?VQ2 ;1Q0
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M61/7S9?_ $,U\[_$3_DHWB'_ *_I/YT <S24M)WH 4]*;BG?6B@ H/2DH[T
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M?/\ AGC5/^@Y:?\ ?IJ/^&>-4_Z#EI_WZ:OH.B@#Y\_X9XU3_H.6G_?IJ/\
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M)S@U[?10!\]_\,[:K_T';3_OTU'_  SMJG_0<L_^_35]"44 ?/?_  SMJO\
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,4[<G_<-%>K44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img215454963_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_10.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D F # 2(  A$! Q$!_\0
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M/'1U>&+1[J22S@MI9-0M/-,3QILWQ^H( ^4XY'6MR#PN;8:JD<\8CO+"&SC
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MJ/)C_P">:_E2YB_8+N>AT5YYY,?_ #S7\J/)C_YYK^5','L%W/0Z*\\\F/\
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M_P#08OO_  (;_&LY55%V.JEA95(\R9[U17@O]OZ__P!!B^_\"&_QH_M_7_\
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M_P#$T?\ ".Q?\_\ >_\ ?2?_ !-;%%*R#GEW,?\ X1V+_G_O?^^D_P#B:/\
MA'8O^?\ O?\ OI/_ (FMBBBR#GEW,?\ X1V+_G_O?^^D_P#B:A:Q;2M5TF2"
M]N6\V\$3K(5(*E')Z+["MZLS5?\ C_T3C_F(I_Z ].P<\NYU=%)D_P!TT9/]
MTT"%KQGQXBGQE?$CG$?_ * M>RY/]TUXYX[/_%87O':/_P! 6L:WPG9@?XC]
M#FO+3^[1Y:?W:=17,>L-\M/[M'EI_=IU% #?+3^[1Y:?W:=10!ZU\.0%\*@
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M\([HO_0*L_\ ORO^%'_".Z+_ - JS_[\K_A4\II]8\C*HK5_X1W1?^@59_\
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MP?&/_(N/_P!?5K_Z41U9B34444""BBB@ HHHH Q_%7_(K:E_UP-=A7'^*O\
MD5M2_P"N!KL*!A1110 4444 5%TVT6[-T(CYNXM]]MH8C!8+G ..^,T6FFVE
MD[/;Q;"1MY8MM7KA<GY1[# IW]H6?VS[)]IC^T=/+W<YQG'UQSCTIJ:I82"5
MDO("L7+G>,*,XS],T *^G6DGE;H0?*^[R?7//KSSSGGFK51QW$,H0QRHXD4L
MA4Y# =Q^8J2@ K)\4_\ (HZU_P!>$_\ Z+:M:LGQ3_R*.M?]>$__ *+:@""U
M_P"/2'_KFO\ *I:BM?\ CTA_ZYK_ "J6@04444 %%%% $%[_ ,>-Q_UR;^56
M_#7_ "*NC_\ 7E#_ .@"JE[_ ,>-Q_UR;^56_#7_ "*NC_\ 7E#_ .@"@9J4
M444 </\ $K_D'V/_ %U;^5><5Z/\2O\ D'V/_75OY5YQ7'6^,]S!?P5\PHHH
MK(Z@HHHH *[+X;_\ARZ_Z]C_ .A+7&UV7PW_ .0Y=?\ 7L?_ $):NG\:,,5_
M!D>FT445W'@!7(^&?^0##_UTE_\ 1C5UU<CX9_Y ,/\ UTE_]&-0!K4444""
MBBB@ HHHH A\'_\ (OM_U_7O_I3+6]6#X/\ ^1?;_K^O?_2F6MZ@95U*&6XT
MRZA@V>=)$RIO&1DC S6!%I=W%<+=0VEPL<3PMY-Q.LDDA4.IPQ8X&&& 2!D'
MI74T4 8D6EM)!/<36^VYFG:1$+_<!*@;L'#8VAB.1FI]/@OH+QXY"WV50P7)
M4@\C9MQ\V<9W;N_2M2B@ I,'^\:6B@#G/$X_XF'ASD_\A)O_ $EGJW57Q/\
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M/^6DO_HQJ ->BC ]*,#TH$%%&!Z48'I0 448'I1@>E $/@__ )%]O^OZ]_\
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M=I_UT/\ *N*KM/&Q)M+3Y2/WA_E7%_A6$_B/4PW\)!11^%'X5!T!11^%'X4
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ME)+1@\H,\ ^XZ'WS3HM/AAM1;KO*;_,8L<EVSN))[Y/^<46]A!;3O,F\LV[
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M0[E*G( \O()P>1Z5OT4 80L[^VDC:T5HU<_,H93M^;HY;)(P6)P<[F-;M%%
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M6B@!,_7\JS-5(%]HAY_Y"*=O]AZU*S-5_P"/_1/^PBG_ * ] '4^8O\ M?\
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M3XF/K!\8_P#(N/\ ]?5K_P"E$=;>)/[R_P#?/_UZPO& ?_A'6RRX^U6O\/\
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MHI.?04<^@H$+12<^@HY]!0 M%)SZ"CGT% $7@_\ Y%]O^OZ]_P#2F6MZN?\
M"!?^P&PJX^W7G5O^GF7VK=S)_=7_ +Z_^M0,?14<\AAMY91&TA1"P1!DM@=!
M[UD-K5S%<-:36<7VLF,1JDY9,ONX9MO! 4GH<B@#;HK$/B HZQ26RK*)&CD7
MS>X(&$X^<X8'''%:UO-]HC,@7"%CL.?O+Z_CV]L4 2T444 <[XG_ .0AX<_[
M"3?^DL]6JJ^)_P#D(>'/^PDW_I+/5J@04444 %%%% !69JO_ !_Z)_V$4_\
M0'K3K,U7_C_T3_L(I_Z ] '5T444#"N0US_D+S?\!_\ 0177UR&N?\A>;_@/
M_H(J9;&U#XC.HHHJ#J"BBB@ HHHH ZOP_P#\@S_@9K5K*\/_ /(,_P"!FM6M
M%L<53XF%8/C'_D7'_P"OJU_]*(ZWJP?&/_(N/_U]6O\ Z41TR":BBB@04444
M %%%% &/XJ_Y%;4O^N!KL*X_Q5_R*VI?]<#784#"BBB@ HHHH 3 SG SZT
M9P.M9TFLQ1W/EO;S"'S?)-P=NS?Z=<X[9QC-1IK\#*K-;7">8@D@#!<S*6"C
M;SQRR]<?>% &MTX%%5;:^CNRHC5P2&+!@/D(;;@^^0>GH:M4 %9/BG_D4=:_
MZ\)__1;5K5D^*?\ D4=:_P"O"?\ ]%M0!!:_\>D/_7-?Y5+45K_QZ0_]<U_E
M4M @HHHH **** (+W_CQN/\ KDW\JM^&O^15T?\ Z\H?_0!52]_X\;C_ *Y-
M_*K?AK_D5='_ .O*'_T 4#-2BBB@##\2_P#'O!_OG^5<W72>)?\ CW@_WS_*
MN;K.6YV4?@"BBBD:!1110 5L^&_^/Z7_ *Y?U%8U;/AO_C^E_P"N7]136Y%3
MX&=/1116AQ!7(^&?^0##_P!=)?\ T8U==7(^&?\ D P_]=)?_1C4 :U%%% @
MHHHH **** (?!_\ R+[?]?U[_P"E,M;U8/@__D7V_P"OZ]_]*9:WJ!D5S')-
M:RQPR^3*Z%4DVYV$C@X[XK*CT6XCMTC%Q:J\4JS1NELPRXR"7RY+9!(Z@^];
M5% %"#3WBLYHFGW2SR&2615VYR>0!GC@8'/O3+/21::A)<K(N&# *L>"=Q!^
M8Y^;&,+P,#BM*B@ IGE1_P#/-?RI]% '-^)HT74/#F$4?\3%N@_Z=9ZMX'H*
MK>)_^0AX<_["3?\ I+/5J@0F!Z"C ]!2T4 )@>@HP/04M% "8'H*S-653?:(
M" 1_:*=O]AZU*S-5_P"/_1/^PBG_ * ] '4>5'_SS7\J/*C_ .>:_E3Z*!C/
M*C_YYK^5<CK:J-6F   ^7H/]D5V-<AKG_(7F_P" _P#H(J9;&U#XC.P/2C ]
M***@Z@P/2C ]*** # ]*,#THHH ZG0(T;3,E%)WGJ*U/*C_YYK^59OA__D&?
M\#-:M:+8XJGQ,9Y4?_/-?RK"\81H/#K$(H/VJU[?]/$==!6#XQ_Y%Q_^OJU_
M]*(Z9!+@>@HP/04M% A,#T%&!Z"EHH 3 ]!1@>@I:* ,;Q4!_P (MJ7 _P!0
M:Z[RH_\ GFOY5R7BK_D5M2_ZX&NPH&-$:*<A%!]0*=110 4444 8KZ??7&H2
M27<5O- 6(B/VAAY2$8R$V8+8SR3WX(HL]+N&>W&H1V[16UL;954EA+DKEB"!
MC[@XYZFMJB@#%;2KM9(FMY$A&<LJ.R+'R,8 && 48P<#J>];5%% #2@)R2WX
M,161XHC4>$=:.6_X\)_XC_SS:MFLGQ3_ ,BCK7_7A/\ ^BVH KVH_P!$AZ_Z
MM>_M4N/K^=1VO_'I#_US7^52T"$Q]?SHQ]?SI:* $Q]?SHQ]?SI:* *]Z/\
M0;CK_JF[^U6?#4:GPMI'+?\ 'E#_ !'^X*KWO_'C<?\ 7)OY5;\-?\BKH_\
MUY0_^@"@9H^6OJW_ 'V:/+7U;_OLT^B@#!\2(%MX,%OOGJQ/:N=Q72>)?^/>
M#_?/\JYNLY;G91^ ,48HHI&@8HQ110 8K8\.*&OI<Y_U?8D=Q6/6SX;_ ./Z
M7_KE_44UN14^!G2>6OJW_?9H\M?5O^^S3Z*T.(9Y:^K?]]FN3\,@?V##U_UD
MO?\ Z:-77UR/AG_D P_]=)?_ $8U &KCZ_G1CZ_G2T4"$Q]?SHQ]?SI:* $Q
M]?SHQ]?SI:* *_A! = 8Y;_C^O.C'_GYEK=\M?5O^^S6)X/_ .1?;_K^O?\
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M%1_XI;4N#_J#77;V_P">3_F/\:Y+Q5_R*VI?]<#784#&AB3@HP]SC_&G444
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M0/+3C)[5U_V=O^?F;\Q_A56/1;:&29XWF5II/,D(8?,V ,]/0"@#(_L'1_\
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MIN0RJVX<'&0?0]?QJ:H+.W-K;+$TKRL"6:1SRQ)R3[<GIVJ>@ HHHH ****
M"BBB@ HHHH *SIM6C@343+&RFR 8C/WU*Y!'U.1]16C67?Z4UYJ5M<+(JQ#
MN$(YD"MO3\F_0F@"RFHVQG2V>9$N2!F+=DAL9VY]<=JJVNOVEW8+<1R1^88E
MD:)GQM!P.OL3CZU NB2KJ32$JT!N?M.YIY,@]<>6#MZ]_3M3'T"9K&RMQ+&#
M;V9MV/."2T9R/;Y#^= %ZZUJSMH[DK*LDL",S1J>3MZ@'U'?TJP-0M#=_91<
M)Y^<;,\YQG'UQSBLJ31[U[":P#VP@(F\N0@ER7)(SQQC<<D$Y]J=%HDL>H^8
MQ5H!<M<AC/)G))./+SMX)Z^G:@#<HHHH **** "J]]<FRL9KH1F3RD+E%/)
MZX_"K%(0&!! (/!!H I2:I!'=+$2OE^0;AYBV%1<@#\^?R-1RZY91_9V$JM'
M+(T9<'[C!2V".N?;WJBGAV5=,N;9K@-(SQ^2V2,1Q$%$)'/8Y(]:FM-'EBNX
M;F38KK,9&43/*<>64'S/R3SZ#B@"Y_:MIRYGB\@1I() ^<[B0./J/Q/%-76+
M1I3B5/)$/FF8MP/FVX^N:SDT"YBD29)86DB*LBMD*Q#R-@G''$G7U%.NM$NK
MS,LDD*RD*VV,LHW"3>!D8/08W=<\X[4 ;-O=07<7F02*Z@X)'8^A]#4U4-+L
M7LXYC(%$DTF]@LKR8X &6?DG ]!]*OT %5[ZZ%CI]S=LI<01-(5!QG:,X_2K
M%5=2M6O=+N[1&"M/"\88] 2I']: *4NLR6JL;RR,1,+RQE9 P?:NXKG P<>W
MK22>((DTZQN_)<F[E6+R\\H2<-GZ'BF7.EWVHQD73V\>R&1(EB+'+NI7<20.
M ">,=ZB;P],99#YZ>7NC:%,'Y#O1I/S* CZF@#4@U&.XU&XLECE#P(K,SH5!
MR6'&>OW3R.*CFU"<W<MM96@N&A ,K-+L"D\A1P<G'/IR.:E2T9=7FO-PV/!'
M$%[@JSG/_CPJG<Z=<?:KIX8[6>"[VF6*X) 5E &1@'(P!QQTZT 6CJMK%##)
M<O\ 9FE7=Y<WRLOKGTQZ]*=_:=E]K^R_:8_/W;=F>=V,X^N*PQX:N8HE02QR
MEH# ^9I(E WNP.$/S##XVD]NM7_[&<1-&LBA3>+.,9SM 48^O% %L:E#.)$L
M7BN9TY\OS-N1G!.<=/I4%GJTD]E->W-J+>WB#DMYNX_(2#Q@>AJ#2-%EL)H#
M*486\)A1A/(Y8<<[6.$^Z.!GZ\4\Z/*^D)I[RJ$:=GF*D@E#(7P/?D#\Z 'Q
MZVLFF1W/V:03O+Y MB1N$F2-I/3MG/I5JTN;F662*ZM# Z@,&5]Z,#GHV!R,
M<C'I6<VA2Q2RO:W''FI<Q><S.?- *MDGG!7 ]JT+1+XSR37CQ*"H5(8B65<9
MR22 23GT[4 7**** "BBB@ HHHH *PM;GES?HKL@M]-DE7:<?,P8 _4;?_'J
MW:KS644\ZRN ?W;1.I&0Z-U!'X?S]: ,&^U._LWL[BXMD2.**:3;'<%O,VQD
MX(VCT]ZE&L7Z*\<RQB5A'Y3>0PR6)! 0,2>!P<@?E6ZT$3E"\2,4R%RH.,C!
MQ^%5UTG3U@>%;* 1N064(,$CI^7:@#G+W5+Z:U:59/)GB@NU)52 2C1@';N.
M#C/<XS^%78KO4+>[N6,T+Q&_2 J4;.61!D'=P,G..>_-;"Z98HC(MG J,&4J
M(Q@A@ 1^.!GZ5(MI;(@18(PNX/@*/O#&#]1@?E0!@R:O<W6FW4@"1R65L99B
MN>)U8_*.>GR-D>C"NC!RH.,9%9\>DQK:3022%S<2^;.P4#S.1QCTP /I6C0
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M_DB6.2-RPQO4$9*@'[PZ$C^NP=*LS<F<QMN+;RGF-L+8QNVYQG'?%1)H.GH
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M'*YR<*0!GC!.>]:T=O%%-+,BXDF(+G)YP,#]*JMH]F]QYY23?YHF $K!0_\
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M Q !]:DLM*L["262W@C1Y&+%E0 @'' P.G%49EVBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img215454963_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T($IA
M8VMS;VX   60 P "    %   $*:0!  "    %   $+J2D0 "     SDQ  "2
MD@ "     SDQ  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MQ'_>TT?\ ?\ QH]IY,?LO[R-JBL;;XC_ .>NG#_MD_\ \51L\1'_ );Z>/\
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M*SY9N^?O8_"K_P &=1BUCXHF[\./>2:;_8D2:FTH(C^U*% V_@#0!]"T444
M%%%% !1110 4444 %>4_ +_D6M>_[#ES_P"A5ZM7E/P"_P"1:U[_ +#ES_Z%
M0!ZM1110 UY%C7=(P4>I.*C6ZA8X61"?3<*?+&DL>V5%=?1AFLZPM8/M%T?)
MCRLW!VCC@5+;3*25FV:>ZC--.!^--EFC@C,LSK&B]68X JMB=R3-&ZL5_$'V
MEBFC6LEZW3S?NQC_ ($>OX4T:->Z@=VKWS;#_P L+8E$_$]36?/?1&JIV^-V
M)[OQ!9P2^3 7NKC_ )XVXW'\?2JXAUK5/]=*NG0'^"/#RD?4\#]:U+6PMK&$
M16L*1*.RKC-60/RHY7+X@YXQ^%&9:Z+::<&D@@\V;J9)#N=O^!&H8Q,FIR78
MT]MSQK'G<N>"3_6MFDQS1R(7M'UU$0949&#W%.VT"EK0S$Q1BEHH ,4444 )
MBC%+10 F*,4M% "8HQ2T4 %%%% "8HI:* #%&*** $Q1BEHH **** $Q52\M
MKBX1DCF5$92""F:N44FKC3L[E2T@N85"S3)( ,#"8_K5K%+10E8&[NX4444Q
M!1110 4444 %%%% !1110 4444 %%%% !1110!X-\2O%USX8^,<8U73K[7?#
M\FGKYM@L&Z..3)PXX()KK/AS\2-#\2:L=%T/PU>Z.%A,VZ2V$<9P0,9 Z\US
M'Q \3:_X0^.$6IZ;H>K:[ILFG+'+:6\;F(-DX((4C<._%=;X$^)EQXM\1/IM
MSX+U/0@D)E^TW<;*C8(&WE!Z_I0!Z/1110 4444 %%'2O.O$?QO\+>%]>NM)
MU.WU4SVK;9'BM-R=,YW9Z4 >BT5P4WQC\,0> [3Q=*+U=-N[DVT*^0/-9QN_
MAST^4\YK0\$_$C1?'K7BZ+#?1&SV^;]K@\O[V<8Y/H: .MKRGX!?\BUKW_8<
MN?\ T*O5<^U>5? +_D6]>_[#ES_Z%0!ZM110: ,[7-3;2-)FO5MVN!"-S(IP
M<=S7%Z3\2;:;4C UBZ"XEW%B^=O SP!D].U=QJUQ#;:5<2W.#$L9+ ]QCI7(
M^!/"JZ?->7MW&HE=]L<?7RE(!Q^N/PKAK^V=6*@[(]3#?55AYRK1N^AN'4M2
MU'Y=+LQ;QG_EXNAU'LG7\\?2I(?#L4L@FU2>2^EZ_O#\@^BC@5L*@%. KJY+
MZR.#VEM(*PR.%(U"HH4 8  I^*445H9"8I:** "DQ2T4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYFYS]/2N52YY.*9V2@Z<>=JQJ*,<4N*!2UTG& XHHHI@%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3Q5^@#+_ .$9T+_H#6'_ (#)_A1_PC.A?] :P_\  9/\*U** ,O_ (1G0O\
MH#6'_@,G^%'_  C.A?\ 0&L/_ 9/\*U** ,O_A&="_Z UA_X#)_A1_PC.A?]
M :P_\!D_PK4HH R_^$9T+_H#6'_@,G^%'_",Z%_T!K#_ ,!D_P *U** ,O\
MX1G0O^@-8?\ @,G^%>7_  GT72[GQ?\ $%+C3;258=<=(U>!2$'H..!7LE4+
M#1M.TRXNY]/LXK>6]E,UPT:X,K_WCZF@"+_A&="_Z UA_P" R?X4?\(SH7_0
M&L/_  &3_"M0=** ,O\ X1G0O^@-8?\ @,G^%'_",Z%_T!K#_P !D_PK4HH
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MT:3XEL_"=_X:FAM98M?>YCV17#8PH7^^<XYQT ]*]UH **** "BBB@ HHHH
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M:0DCK8WT5K<KY++ME1(]W;GKUH ]K\6_%7PEX*OUL=<U$B\9=WV>"-I'4>K
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MAZ"6U\-:9!<DF:*TB1R>[!0#6E0 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img215454963_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img215454963_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T($IA
M8VMS;VX   60 P "    %   $*:0!  "    %   $+J2D0 "     S8P  "2
MD@ "     S8P  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M9FH<[M;?I>W>U[V^1Z+_ ,+<T'_GTU'_ +]1_P#Q='_"W-!_Y]-1_P"_4?\
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M@_\ /IJ/_?J/_P"+KQZBC^R,+V?WA_;V-[K[CV'_ (6YH/\ SZ:C_P!^H_\
MXNDF^+_A^WL+J]FM=16WM$$DS^4AV*75 <;\GYG4<>M>/U!K7_(A>)_^O&+_
M -++>L,1EF&I4G-)Z>9V8+-\7B,3"E-JS?8]._X:+\"_W]1_\!?_ *]'_#1?
M@7^_J/\ X"__ %Z^3J*\;V5/^7\_\S[/V#_G?X?Y'UC_ ,-%^!?[^H_^ O\
M]>C_ (:+\"_W]1_\!?\ Z]?//@;P?9^+)-5?5-:_L:STRT-W-<?9#<?*& ^Z
MK ]^V:U)O"/P\2WD>'XG^;(JDI'_ ,(_<+N..!G=QGUJ91I1WC^8E1;=N=_A
M_D>Y?\-%^!?[^H_^ O\ ]>C_ (:+\"_W]1_\!?\ Z]> >&? EKJOAZ3Q!XC\
M0VWA_1UG-M'-)"T\LT@ )"1+R0 >3FK&K_#[3K72[?7-$\56^KZ ;M+6[O$M
M'CELRQ^\T)^8C&<<\T.%).S7YA[%O[;_  _R/=_^&B_ O]_4?_ 7_P"O1_PT
M7X%_OZC_ . O_P!>O'[3X9^";_1]0U2U^)?F66F^7]JE_L&8>7YA*IP7R<D'
MH#[UBQ^!M%U+4]5@\.^*O[3M=-T>74FN?[.>'>Z$ Q;7;(X(.[GKTI<M'7W=
MO7U&J+?VW^'^1[U_PT7X%_OZC_X"_P#UZ/\ AHOP+_?U'_P%_P#KUX+:?#6Z
MOOA7-XTM+^-Q;R.LMD8\-L5@"X;/.-P)&!@55^'?@&Z^(/B"33K>[CL8H8O-
MFN9$W!1D* !D9))X&1WJN2E=JVWK_F+V6G-SNWR_R/H3_AHOP+_?U'_P%_\
MKT?\-%^!?[^H_P#@+_\ 7KYKT7PO/K?CB#PW:R_O);LVYFV9VJI.YR,] H+8
MSVZU8\3^$4\*^-AHE]J2O9,T3IJ*0DJT#@$2A 23@$\ GIUI*%%VLM_7_,;H
M--KG>GI_D?1G_#1?@7^_J/\ X"__ %Z/^&B_ O\ ?U'_ ,!?_KUX_:?#/P3?
MZ/J&J6OQ+\RRTWR_M4O]@S#R_,)5."^3D@] ?>J.E_#WPSK&KZE'8>./,TK3
M=/\ MMQJ/]D2C:=^TIY98,< @Y&>O2ERT?Y?S]1>Q?\ ._P_R/;O^&B_ O\
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M'=.OH9Y=0L(KXSSKY20(R%VW<GA0#SW]*2C1:4DM'Z^O<;HM.SF_P_R/>O\
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M\[_#_(^L?^&B_ O]_4?_  %_^O1_PT7X%_OZC_X"_P#UZ^3J*/94_P"7\_\
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MZ/9^#_#HUC13J1:*;8PNGB\L>:<\+UJ/Q=+%;^';*+P]916^A7K"82HS,[R
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M(/(W5YAXP_Y'G7?^PC<?^C&K1LOB#JEEI>@60MK*9?#]X;NREE1RX);<4)#
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MVZ;(X\G.U5[*.@'I5133V_$:V*]%%%: %%%% !1110 4444 %%%% '0_#_\
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M GG#'TKK:JJL11?+4;3]2*+PN(CS4DFO0S/^$9T'_H":=_X"1_X4?\(SH/\
MT!-._P# 2/\ PK3HK+VU3^9_>;^PI?RK[D9G_",Z#_T!-._\!(_\*/\ A&=!
M_P"@)IW_ ("1_P"%-LO$5I?>(+W1X8YA<6:AI&91L.<=#G/?TK5JI3K0=I-_
M>1"&'G?EBG9VVZHS/^$9T'_H":=_X"1_X4?\(SH/_0$T[_P$C_PK3HJ?;5/Y
MG]Y?L*7\J^Y&9_PC.@_] 33O_ 2/_"C_ (1G0?\ H":=_P" D?\ A6G11[:I
M_,_O#V%+^5?<C,_X1G0?^@)IW_@)'_A1_P (SH/_ $!-._\  2/_  K3HH]M
M4_F?WA["E_*ON1F?\(SH/_0$T[_P$C_PH_X1G0?^@)IW_@)'_A3-&\16FN7F
MH6]I',CV$OE2F50 QR1\N">/E/7%:U5.=:#Y9-I^I%.&'J1YH137IVT,S_A&
M=!_Z FG?^ D?^%'_  C.@_\ 0$T[_P !(_\ "KES>VUFT0NITB::01Q!FP78
MG@ =ZHOXBM$\4)H)CF^U/%YH<*-F.>^<YX]*<95Y;-]_N%*.&A\271;+KL._
MX1G0?^@)IW_@)'_A1_PC.@_] 33O_ 2/_"M.BH]M4_F?WFGL*7\J^Y&9_P (
MSH/_ $!-._\  2/_  H_X1G0?^@)IW_@)'_A3+OQ%:6?B2ST26.8W-VA>-U4
M; !GJ<Y_A/:K&E:I_:L$DOV&]LO+D*;+R'RV;CJ!DY'/6M&ZZCS-NWJ9)89R
MY$E?T^9%_P (SH/_ $!-._\  2/_  H_X1G0?^@)IW_@)'_A6G65I?B*TU;5
M=1L+:.99=/<)*9% 5CDCY<$^AZXJ8SK23:;T\RI4\/%I2BM=M!W_  C.@_\
M0$T[_P !(_\ "C_A&=!_Z FG?^ D?^%:=%3[:I_,_O+]A2_E7W(S/^$9T'_H
M":=_X"1_X4?\(SH/_0$T[_P$C_PK3HH]M4_F?WA["E_*ON1F?\(SH/\ T!-.
M_P# 2/\ PH_X1G0?^@)IW_@)'_A6G11[:I_,_O#V%+^5?<C,_P"$9T'_ * F
MG?\ @)'_ (4?\(SH/_0$T[_P$C_PK3HH]M4_F?WA["E_*ON1F?\ ",Z#_P!
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M9T'_ * FG?\ @)'_ (4?\(SH/_0$T[_P$C_PK3HH]M4_F?WA["E_*ON1F?\
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MT'_H":=_X"1_X4?\(SH/_0$T[_P$C_PK3HH]M4_F?WA["E_*ON1F?\(SH/\
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MT^U:_CC\M+LP*943GY0^,@<GC/>MY5D[Z=_R?ZMB>J_KNG^2L?,C?\D"N?\
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M._\ !?)_\>H^SZ]_T$M._P#!?)_\>K3HH]K+R^Y?Y![&/=_>_P#,S/L^O?\
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MG_QZM.BCVLO+[E_D'L8]W][_ ,S,^SZ]_P!!+3O_  7R?_'J/L^O?]!+3O\
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M?_'J/L^O?]!+3O\ P7R?_'JTZ*/:R\ON7^0>QCW?WO\ S,S[/KW_ $$M._\
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M^SZ]_P!!+3O_  7R?_'J/L^O?]!+3O\ P7R?_'JTZ*/:R\ON7^0>QCW?WO\
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M@Y_\=J;QCH^IG5-/\0Z!&MQ=V(*O 3_K$.>GKU/'7FM,/R1A3OUYM]N;97_
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M/4?9]>_Z"6G?^"^3_P"/4<D?YE^/^0>TE_(_P_S-.BLS[/KW_02T[_P7R?\
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MM._\%\G_ ,>HY(_S+\?\@]I+^1_A_F:=%9GV?7O^@EIW_@OD_P#CU'V?7O\
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MRHQ.TNIRI(Z'!P<'(R >U6JS/L^O?]!+3O\ P7R?_'J/L^O?]!+3O_!?)_\
M'J.2/\R_'_(/:2_D?X?YFG169]GU[_H):=_X+Y/_ (]1]GU[_H):=_X+Y/\
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MM._\%\G_ ,>HY(_S+\?\@]I+^1_A_F:=%9GV?7O^@EIW_@OD_P#CU'V?7O\
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MW_@OD_\ CU'V?7O^@EIW_@OD_P#CU')'^9?C_D'M)?R/\/\ ,TZ*S/L^O?\
M02T[_P %\G_QZC[/KW_02T[_ ,%\G_QZCDC_ #+\?\@]I+^1_A_F:=%9GV?7
MO^@EIW_@OD_^/4?9]>_Z"6G?^"^3_P"/4<D?YE^/^0>TE_(_P_S-.BLS[/KW
M_02T[_P7R?\ QZC[/KW_ $$M._\ !?)_\>HY(_S+\?\ (/:2_D?X?YFG169]
MGU[_ *"6G?\ @OD_^/4?9]>_Z"6G?^"^3_X]1R1_F7X_Y![27\C_  _S-.BL
MZ*#6A,AFU"P>,,-ZI8NI([@'SC@^^#]*T:B22V=RXR<MU;[OT"BBBI+"BBO/
MO&][;Z;X^\/7E[)Y<$(9G?:3@9]!S6^'HNO/D79_@KG-BL0L/2=1K:WENTCT
M&BO,M>\1:7K_ (U\,'2+K[0(;K$G[MEVY=,?> ]#79:;XC_M#Q1J6C_9?+^P
M!3YWF9WYQVQQU]36M3!U(04FNEVMK:V,*>/I5*DH)Z)I)K6[:OT^9MT5RUIX
MU^U:;KEW]@V?V2[+M\[/FXSWV_+T]ZH-\1+E-&M]7?P[<#3I&VR3_:%^4YQ\
MHQDCW.!GBDL'7;M;RW757[E/'X9*_-W>SV3L^G1G<45PGBSQ1K%IKFC6VDVV
MZVNW21")54W?*_)D_<'(Y[Y^M6+'4K5O'UV)=%^S:HNGB6:?[47_ (4)CVXV
M\<#</3WJOJ<^3G?9OITTUU_S)^OTW5=..Z:6M[:]M'^GW'9T5PMO\1;R[T.7
M5+;PW-);V[$3N+I0J#CIQENO/''K6OJ'C2RLO#-IJ\<,L_VW"V]NN S,>Q],
M8QWJ98.O%J+CK>VZW*AC\-.+DI:6OLUIWU6IT=%<B/&UY#K6FZ7J6@RV=Q>O
M@[KA65%)X(('S=\CC'XU1L/$WB"Z^(EUI[Z?N@A4(UNLZ 0J67]Z3_&<'I[X
M]::P55IMV6E]UML3+,:"LE=ZI;/1M7[=CO**Y2;QG<7%]=P>']$FU6.R;;/,
M)EC4$=0N0=U/N/'-JO@UM?LK=IU1Q&]N[[&1B0""<'US4?5:VFF]NW7:_:_F
M:_7:&OO;7>SZ;V[V\KG445QK^/9[>33Y;_0KBUL+\JL5TTRDY/\ LCH.<\D$
MCG%=E45*-2E;G6_S_(NCB*5>_LWMY-;[;]PHKD&\;2WEY?0Z3HEQ?V=F2EQ=
M1RJ,'G.U3][IV-<=I%U86?PK:35-._M&'^U"!#Y[18.P<[EY]>/>NJG@*DE>
M6FJTT;U^:M\SCJYE3A)*.JM+75+W?D[_ "O8]@HKE]0\7RV^N+HNCZ2VH7BP
MB1T-PL*J" < MU."*NVGB53H5SJ.K6%UIGV3/FQSH><?W#QN!Z ^M<[P]514
MK;^E]=M-SJCBZ,I.*>J\G;[[6-NBN0B\<SQBTNM5T.:QTR\8+#>&=7Z_=+(!
ME01S_C6CK?B"]TZ\%MI^B3WS!-[S/(((5'IYC#!/M3>%JJ2BUOYJVGG>PHXR
MA*+DGM;H[Z[:6N[]+&]17*Z9X\L[[P[?ZI/;20?8#MFB5A)DGIM8<')[TW3_
M !AJ5W]DGG\-7*6-V0([FWF$Y /0LJC*CUS3>$K*]UMYKU^?R)6.P[2:E>_D
M^]M=-->YUE%<]JWBB6UUH:1H^FOJE^(_-DC698EC7W8]^G'N*L^'O$,6O03_
M +B2UNK63RKFVD.3&WU[C@\^U9NA44/:-:?UTW-5B:3J>R3U^?W7VOY;FQ17
M(_$2]ECT.WTVV<I+J=PMOD?W3U_/@?C5+Q2;F35=&\(:1=-8PS19EDC."(U!
M ''LI^M;4L*ZD8N]KW^Y;LPK8Q4I2C:_+;[Y.R1W=%<)%\.9='U*VO/#6L7%
MNZO^_%P=P=?3"@9^A_,5:^(]XYTBUT:U/^DZI<+"H_V01G]2H_&A8>$ZD84I
MWOY6M_7J)XJI3I3J5J?+R^=[^GY;'8T5P_@"232=0U7PO=.6:SE\V G^*,__
M *U/_ C5.XM+CQYXPU*QN;Z:VTG3"(_*@;!D?)&3GCL>2#C\35?5+5)1<O=2
MO?R>VGG<GZ\W2C)0]]OEY;]5>^OE;<]$HKS[0]%L=!\50C1?%=NUFWR2V4MR
MCR2/TV[1@9SWQD>]7[:8Z-\4KBP3BVU: 7 3L)1G)'U"G/X4I857:A*^E]K>
MO^?4<,;+E3J1M[RB]4]]G]^G0[*BBBN(]$**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HK \4>.?#G@Q;<^)=32R^TD^4OEO(SXQDX0$XY'-.TK
MQOX8URY@M]'UVQO;BX4ND,$P=P ,DLHY7C^]BG9M7&TUN;M%>&Z[X^U?7OBQ
MX9_L.ZN+?PP-4%DDL4C(NH2*1YAX^^@R%';KZ\;>K/JOCSXMZMX9@\0ZGH>G
M:)9I(/[+F\F2:9P#EF[J-V,>WXU:@VD^]_P&XV;3Z?YV_,]7HK@_A!XFU#Q+
MX,E_MF?[3?:;>RV,MQMP9MF"&/OAA^58FK/JOCSXMZMX9@\0ZGH>G:)9I(/[
M+F\F2:9P#EF[J-V,>WXTN3WN7Y_+<26]]+?YV/5Z*\'_ .%F>(#\&PHOA_;A
MUK^PSJ&SG'7S,=-VWC/X]:Z#2YM3\!?%K3?#-QXBU+6],UBQDESJDOG20RQ@
MDE6[*0IX]^]/V?G_ %:_Y TTOZ[V_,]8HKY]74_$VN^ -8^)</BK4[.ZL[MS
M::;%)BS6%& V/%T8X)Y/XYKW+P_JG]M^&]-U4*$^VVL5QM'\.]0V/UI2@TKO
M^KA)6=O7\-S0HHHJ!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M--O9[34(DB2>WBWJA^098]@-IS6QIW@VQL-4BU":\U#4+F%2L+WUQYGE ^G
M]:Z&G4Q5.*4*:NN5K[W<FE@JLW*=9VES*2V>RMZ=SS_1GU/P3-J5C+HE]J$,
M]PTUM/:)Y@;(QAO[O0?K5&Y\,:I9_#6_BEMGDO[V[6X:V@7>4&X<87/IFO3J
M*CZ])2YN57NF_.VWH;/+H.+@Y.UI)>7-OZ^1P7C'3KVZ\,^'HK:SN)I(98C(
MD<3,4 3!R .*[VBBN:I6=2"BUM?\3IHX=4IRFGNDONO_ )GGFA_VKX1EU32?
M[#O+T3SM+:3VZYC;(P ['A> /UK"&BZK_P *L-J=,O/M/]J>9Y/V=M^W9C=M
MQG'O7L%%=D<PE&7-RJ]TWYV.*661DN7G=DI)+33F.!\5Z?;76I(=3\,7]POE
M*([_ $MB\N0.C)@ 8]3GM4&GZ+X@U7P?K-A=FZ6"4K_9\>H,/. 5LX8]LX Y
M_E7HM%9K&RC34$MK=WL[Z7V-'ET'4<W+>_97NK:M;_/[SR6T\.1W:6%C#X/F
M@OE8+>W5ZTP@ '!92)!DGK@?09ZUK:_I\X\=M<ZQHU]K.F>0%M([=3(L;\=1
MD#J#G/KWKT2BK>83<^9KH^KZ]GT,XY53C3Y$^JZ+IW5M?,\Y\)Z;J%GIOB."
M\\/EGED#K92_NXY%.<JCX*G';'MTK+33;R&Z@;PAI&O:1?/(/-2?BU4=_F;[
MP^OY5ZU10LPESRER[^;MM;;K_6HGE<?9QAS/2^ME?5WT=M'Z:>1YQXD\.[/&
MLFJ:IHMSK&FW42@K9[B\4@ &=JD$]/IS[5M^!-(?3[6[NI-*CTL7,@\J /(7
MV#."^YC@\]@*ZRBLIXRI.C[)^2W?3RV-Z>7TX5W76]V]EN_/<XGXC1^5)H.H
MM_JK2_7S#Z D'/\ X[4WC'1]3.J:?XAT"-;B[L05> G_ %B'/3UZGCKS71ZQ
MI-MK>E3:??!C#,,$J<,I!R"/>K%M!]FM(H [R") @=R"S8&,G'>G#$\D(6WC
M?T:?],*F#]I4J<VTE'7JFOZ1Q">)/&.LW]M!IV@/I2*^9Y;M2RE?Q"\>PYJO
MK6AZMXK\>2>7+=:5;:?"%@O/)8!VSSM.1UR>0>BUZ)13CC%"7-2@HZ6[[^NY
M,L ZD.6M4<DVF^FW32UCS,^&]:\+>+=-U5;N\UQ97,5S((G9D0\<\L2,'/\
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MNM5OUN=SUHI$78BKZ#%+7AGT2O;4****!A1110 4444 %%%% !1110 4444
M8'BCQSX<\&+;GQ+J:67VDGRE\MY&?&,G" G'(YJNOBGPSXOLVTG1_$\37&H0
M.$.FW0%S$-O+#&2A'JP'-:>K>&-#UZ>*;6](L]1>%"D9NX%E" XS@,"!T'-9
MF@?#CPEX7U>75-!T6*TO)%*F42.VT$\A0S$+^ 'I5+DM[VX]%JCRKQ)X:U2+
MXB:3X/\ "OCGQ=+>3H;G4)[K5F=;6 =\*%^8^Y[KZYKVG7M2_L#PKJ&I8,IL
M+.28!SDN40D9^N*XCX;Z3J$GCSQMXBUNRN;:>ZOA;6K7$+1[K>/(4KN RI 7
MD<?+6IJ^KW'B/Q%K_@*72Y+:*72'>+4G<[9=X"8"[>Q?J&/3I53;<%%;VO\
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M*U_OO_X#_P#)?B*5N5VVZ?\ @7^5OD>KT445RDA1110 4444 %%%% !1110
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M6%[*TL=Q8R;XGB(!.>JG(.0:3[/KW_02T[_P7R?_ !ZC[/KW_02T[_P7R?\
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MF:=%9GV?7O\ H):=_P""^3_X]1]GU[_H):=_X+Y/_CU')'^9?C_D'M)?R/\
M#_,TZ*S/L^O?]!+3O_!?)_\ 'J/L^O?]!+3O_!?)_P#'J.2/\R_'_(/:2_D?
MX?YFG56+3+.'4[C48X +RX18Y)B26*KG:HST R3@8&23UJM]GU[_ *"6G?\
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M;U_#<T****@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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I,Z*#6A,AFU"P>,,-ZI8NI([@'SC@^^#]*T:**B4G+<N,%';\V_S/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>dsgn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T15:53:04.6553+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_JanuaryNoteMember" xlink:label="dsgn_JanuaryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PaidInKindInterestRelatedParty" xlink:label="dsgn_PaidInKindInterestRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InvestigationNewDrugMember" xlink:label="dsgn_InvestigationNewDrugMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DebtSecuritiesAvailableForSaleMaturity" xlink:label="dsgn_DebtSecuritiesAvailableForSaleMaturity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PreferredStockIssuanceCost" xlink:label="dsgn_PreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" xlink:label="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LegalPatentFees" xlink:label="dsgn_LegalPatentFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MonthlyFeeForConsultancyServices" xlink:label="dsgn_MonthlyFeeForConsultancyServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" xlink:label="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OneYearToTwoYearsMember" xlink:label="dsgn_OneYearToTwoYearsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_JulyNoteMember" xlink:label="dsgn_JulyNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TaxCreditCarryforwardExpirationYear" xlink:label="dsgn_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LicenseAgreementAbstract" xlink:label="dsgn_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" xlink:label="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfLicenseAgreementTable" xlink:label="dsgn_ScheduleOfLicenseAgreementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" xlink:label="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CollaborativeArrangementsUpfrontPayment" xlink:label="dsgn_CollaborativeArrangementsUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesBConvertiblePreferredStockMember" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfAnnualIncreaseInLeasePayments" xlink:label="dsgn_PercentageOfAnnualIncreaseInLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MayNoteMember" xlink:label="dsgn_MayNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ProceedsFromNotesPayableRelatedParty" xlink:label="dsgn_ProceedsFromNotesPayableRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AreaOfLeasedProperty" xlink:label="dsgn_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_RepaymentsOfNotesPayableRelatedParty" xlink:label="dsgn_RepaymentsOfNotesPayableRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_May2018NoteMember" xlink:label="dsgn_May2018NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" xlink:label="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IncomeTaxReconciliationDebtFinancing" xlink:label="dsgn_IncomeTaxReconciliationDebtFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CrossingHoldingsLLCMember" xlink:label="dsgn_CrossingHoldingsLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent" xlink:label="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiability" xlink:label="dsgn_UnvestedStockLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CoFounderMember" xlink:label="dsgn_CoFounderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NoticePeriodForTerminationOfAgreement" xlink:label="dsgn_NoticePeriodForTerminationOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" xlink:label="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" xlink:label="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PatentCostsPolicyTextBlock" xlink:label="dsgn_PatentCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandNineteenConsultingAgreementMember" xlink:label="dsgn_TwoThousandNineteenConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TerminationFee" xlink:label="dsgn_TerminationFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DeferredTaxAssetsLeaseLiability" xlink:label="dsgn_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:label="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AreaOfOffice" xlink:label="dsgn_AreaOfOffice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LeaseCommencementDate" xlink:label="dsgn_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" xlink:label="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ResearchConsultingAgreementsMember" xlink:label="dsgn_ResearchConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_July2018NoteMember" xlink:label="dsgn_July2018NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PrepaidExpensesRelatedPartyCurrent" xlink:label="dsgn_PrepaidExpensesRelatedPartyCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquitySettlementOfBifurcatedConversion" xlink:label="dsgn_TemporaryEquitySettlementOfBifurcatedConversion"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SharesSubjectToRepurchaseMember" xlink:label="dsgn_SharesSubjectToRepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UpfrontPaymentUponExecutionOfAgreement" xlink:label="dsgn_UpfrontPaymentUponExecutionOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="dsgn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LicenseAgreementMember" xlink:label="dsgn_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" xlink:label="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_Jan2020AndDec2019DrawsMember" xlink:label="dsgn_Jan2020AndDec2019DrawsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_RelatedPartyTransactionMonthlyFeeForServices" xlink:label="dsgn_RelatedPartyTransactionMonthlyFeeForServices"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShortTermLeaseLiability" xlink:label="dsgn_ShortTermLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfLicenseAgreementLineItems" xlink:label="dsgn_ScheduleOfLicenseAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NumberOfDomesticCertificatesOfDepositHeld" xlink:label="dsgn_NumberOfDomesticCertificatesOfDepositHeld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UpfrontPaymentWithinOneYear" xlink:label="dsgn_UpfrontPaymentWithinOneYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dsgn_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_WithinOneYearMember" xlink:label="dsgn_WithinOneYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NovemberNoteMember" xlink:label="dsgn_NovemberNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_FebruaryAndMarch2019DrawsMember" xlink:label="dsgn_FebruaryAndMarch2019DrawsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiabilityVestedSharesValue" xlink:label="dsgn_UnvestedStockLiabilityVestedSharesValue"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SharesEarlyExercisedUnvestedStockLiability" xlink:label="dsgn_SharesEarlyExercisedUnvestedStockLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MarlinspikeGroupLLCMember" xlink:label="dsgn_MarlinspikeGroupLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsExpirationYear" xlink:label="dsgn_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InitialClosingOfSeriesAPreferredStockMember" xlink:label="dsgn_InitialClosingOfSeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NoticePeriodDescription" xlink:label="dsgn_NoticePeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_GrantRevenueTextBlock" xlink:label="dsgn_GrantRevenueTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ComputerEquipmentAndSoftwareMember" xlink:label="dsgn_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_February2019NoteMember" xlink:label="dsgn_February2019NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnsecuredPromissoryNoteMember" xlink:label="dsgn_UnsecuredPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConversionOfStockAmountConvertedRelatedParty" xlink:label="dsgn_ConversionOfStockAmountConvertedRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:label="dsgn_LiabilitiesAndStockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" xlink:label="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DisclosureOfLicenseAgreementTextBlock" xlink:label="dsgn_DisclosureOfLicenseAgreementTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_BalanceSheetComponentAbstract" xlink:label="dsgn_BalanceSheetComponentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyConsultingAgreementMember" xlink:label="dsgn_TwoThousandTwentyConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="dsgn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LiabilitiesAndStockholdersEquityTable" xlink:label="dsgn_LiabilitiesAndStockholdersEquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LeaseAgreementTerminationDate" xlink:label="dsgn_LeaseAgreementTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:label="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LesseeOperatingLeaseTermOfExpirationYear" xlink:label="dsgn_LesseeOperatingLeaseTermOfExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_JanuaryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_JanuaryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_JanuaryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Certificates of Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible debt and interest classified as temporary equity during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Debt And Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt and interest to Series A convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, fair value disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PaidInKindInterestRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paid in kind interest related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PaidInKindInterestRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PaidInKindInterestRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense&#8212;related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InvestigationNewDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investigation new drug.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InvestigationNewDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investigation New Drug [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InvestigationNewDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investigation New Drug (IND)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expense and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock remained available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DebtSecuritiesAvailableForSaleMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities, available-for-sale, maturity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DebtSecuritiesAvailableForSaleMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DebtSecuritiesAvailableForSaleMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,681,752 and 16,604,774 shares issued, 55,441,926 and 15,957,821 shares outstanding at December 31, 2021 and 2020,respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for basis of presentation and use of estimates.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Use Of Estimates Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock issuance cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of issued and outstanding common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain (loss) on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of restricted shares of common stock and unvested stock liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Shares Of Common Stock And Unvested Stock Liability Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Shares of Common Stock and Unvested Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions made under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LegalPatentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal patent fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LegalPatentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Patent Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LegalPatentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal patent fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares early exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award options nonvested exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MonthlyFeeForConsultancyServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly fee for consultancy services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MonthlyFeeForConsultancyServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Fee For Consultancy Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MonthlyFeeForConsultancyServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly fee for consultancy services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity converted into shares of common stock, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Converted Into Shares Of Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 12)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance, description and terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net change in operating lease right-of-use assets and liabilities-related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Change in Operating Lease Right-of-Use Assets and Liabilities-Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net change in operating lease right-of-use assets and liabilities-related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering of common shares, net of $21,728 of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial public offering of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OneYearToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">1 year to 2 years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OneYearToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Year To Two Years [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OneYearToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1 Year to 2 Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument variable interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, material impact</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchases of property and equipment included in accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares that may be issued in accordance with plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative (including related party amounts of $328 and $292, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_JulyNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_JulyNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_JulyNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt securities, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued expenses and other current liabilities Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities, related party amounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of selling price per share that can convertible into equity securities sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of selling price per share that can convertible into equity securities sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Accounts Payable And Other Liabilities Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Other Liabilities Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other liabilities related-party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfLicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfLicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of License Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfLicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of License Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses related party amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes to Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised and vesting of early exercised common stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercises of stock options and vesting of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums on investment securities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes issued in May and July 2018.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Issued In May And July2018 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes Issued in May and July 2018</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CollaborativeArrangementsUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangements upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CollaborativeArrangementsUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CollaborativeArrangementsUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from calculation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net related party expense amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock converted into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity converted into shares of common stock, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Converted Into Shares Of Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted into shares of common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses related party amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PercentageOfAnnualIncreaseInLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual increase in lease payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PercentageOfAnnualIncreaseInLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Increase In Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PercentageOfAnnualIncreaseInLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted into shares of common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split of issued and outstanding common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable (including related party amounts of $0 and $20,respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carlsbad, California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase to current year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, Allowance for Credit Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MayNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MayNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MayNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ProceedsFromNotesPayableRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from notes payable related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ProceedsFromNotesPayableRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Notes Payable Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ProceedsFromNotesPayableRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of notes payable, net of issuance costs&#8212;related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased property.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Leased Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of lease space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_RepaymentsOfNotesPayableRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of notes payable related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_RepaymentsOfNotesPayableRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Notes Payable Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_RepaymentsOfNotesPayableRelatedParty_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of notes payable&#8212;related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_May2018NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May 2018 note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_May2018NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May2018 Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_May2018NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2018 Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities (including related party amounts of $504 and $0, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance Increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares reserved for future issuance increased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IncomeTaxReconciliationDebtFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IncomeTaxReconciliationDebtFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Debt Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IncomeTaxReconciliationDebtFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation debt financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CrossingHoldingsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Crossing Holdings LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CrossingHoldingsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Crossing Holdings L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CrossingHoldingsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Crossing Holdings, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expense and other current assets related party current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Current Assets Related Party Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expense and other current assets, related party amounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested stock liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Unvested stock liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Unvested stock liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CoFounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-founder.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CoFounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Co Founder [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CoFounderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aseem Z. Ansari, Ph.D.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NoticePeriodForTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notice period for termination of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NoticePeriodForTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notice Period For Termination Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NoticePeriodForTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for termination of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options and Awards Outstanding, Canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest receivable on available-for-sale investment securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Receivable On Available For Sale Investment Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable on available-for-sale investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected milestone payment on achieving certain regulatory and commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Milestone Payment On Achieving Certain Regulatory And Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected milestone payment on achieving certain regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt securities, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Operating Lease Liabilities, Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandNineteenConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Consulting Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandNineteenConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandNineteenConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Consulting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A and Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options and Awards Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options and Awards Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards not subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award maximum percentage of eligible earnings withheld to participate in offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Eligible Earnings Withheld To Participate In Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of eligible earnings withheld to participate in offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock; $0.0001 par value; no shares and 22,012,499 shares issued and outstanding at December 31, 2021 and 2020,respectively; liquidation preference of zero and $45,625 as of December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial recognition of operating lease right-of-use asset and operating lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial recognition of operating lease right-of-use asset and operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unsecured Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock and Stockholders' Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Plus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AreaOfOffice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AreaOfOffice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AreaOfOffice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: Present value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock through employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issue of Common Stock Through Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock through employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Shares Issued1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ResearchConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research consulting agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ResearchConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Consulting Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ResearchConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Consulting Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_July2018NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July 2018 note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_July2018NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July2018 Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_July2018NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July 2018 Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of Net Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible debt and interest classified as temporary equity during period, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Debt And Interest Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt and interest to Series A convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PrepaidExpensesRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses related party current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PrepaidExpensesRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses Related Party Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_PrepaidExpensesRelatedPartyCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquitySettlementOfBifurcatedConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity settlement of bifurcated conversion.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquitySettlementOfBifurcatedConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Settlement Of Bifurcated Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TemporaryEquitySettlementOfBifurcatedConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of bifurcated conversion liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SharesSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares subject to repurchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SharesSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares subject to repurchase [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SharesSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UpfrontPaymentUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment upon execution of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UpfrontPaymentUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Upon Execution Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UpfrontPaymentUponExecutionOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment upon execution of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering of common shares, net of $21,728 of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected royalty payments upon first commercial product sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Royalty Payments Upon First Commercial Product Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected royalty payments upon first commercial product sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_Jan2020AndDec2019DrawsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jan 2020 and Dec 2019 Draws</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_Jan2020AndDec2019DrawsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jan 2020 and Dec 2019 draws.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_Jan2020AndDec2019DrawsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jan2020 And Dec2019 Draws [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options and Awards Outstanding, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options and Awards Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares early exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Product and Service [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock and stockholders&#8217; deficit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock And Stockholders Deficit [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock And Stockholders Deficit [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_RelatedPartyTransactionMonthlyFeeForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction monthly fee for services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_RelatedPartyTransactionMonthlyFeeForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Monthly Fee For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_RelatedPartyTransactionMonthlyFeeForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly fee for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShortTermLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShortTermLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ShortTermLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfLicenseAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfLicenseAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ScheduleOfLicenseAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options and Awards Outstanding, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term, option to extend period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NumberOfDomesticCertificatesOfDepositHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of domestic certificates of deposit held.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NumberOfDomesticCertificatesOfDepositHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Domestic Certificates Of Deposit Held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NumberOfDomesticCertificatesOfDepositHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of domestic certificates of deposit held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UpfrontPaymentWithinOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment within one year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UpfrontPaymentWithinOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Within One Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UpfrontPaymentWithinOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment within first anniversary of license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Debt Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_WithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Within 1 year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_WithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Within One Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_WithinOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NovemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">November note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NovemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NovemberNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options and Awards Outstanding, Vested and expected to vest at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_FebruaryAndMarch2019DrawsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February and March 2019 draws.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_FebruaryAndMarch2019DrawsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February And March2019 Draws [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_FebruaryAndMarch2019DrawsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February and March 2019 Draws</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiabilityVestedSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested stock liability vested shares value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiabilityVestedSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Stock Liability Vested Shares Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnvestedStockLiabilityVestedSharesValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested shares, Unvested stock liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SharesEarlyExercisedUnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares early exercised, unvested stock liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SharesEarlyExercisedUnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Early Exercised, Unvested Stock Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SharesEarlyExercisedUnvestedStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares early exercised, unvested stock liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, related party amounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MarlinspikeGroupLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marlinspike Group, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MarlinspikeGroupLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marlinspike Group L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_MarlinspikeGroupLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marlinspike Group, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Available For Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InitialClosingOfSeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial closing of series A preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InitialClosingOfSeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Closing Of Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_InitialClosingOfSeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Closing of Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Including Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized grant revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NoticePeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notice period description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NoticePeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notice Period Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NoticePeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination period Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected tax benefit at federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_GrantRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of grant revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_GrantRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Revenue [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_GrantRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio of forward/reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_February2019NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February 2019 note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_February2019NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February2019 Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_February2019NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2019 Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period in expense expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, adopted date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Debt [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnsecuredPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unsecured promissory note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnsecuredPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_UnsecuredPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured Promissory Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConversionOfStockAmountConvertedRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of stock amount converted related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConversionOfStockAmountConvertedRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConversionOfStockAmountConvertedRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LiabilitiesAndStockholdersEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities and stockholders equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LiabilitiesAndStockholdersEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LiabilitiesAndStockholdersEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities And Stockholders Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Original Debt Amount1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including related party amounts of $405 and $53, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Expenses Recognized under Various Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOL, percent of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforward Taxable Income Threshold Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforward taxable income threshold percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized interest or penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DisclosureOfLicenseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DisclosureOfLicenseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of License Agreement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DisclosureOfLicenseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_BalanceSheetComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Balance sheet component.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_BalanceSheetComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Component [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes and Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Consulting Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_TwoThousandTwentyConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Consulting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised and vesting of early exercised common stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised And Vesting Of Early Exercised Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercises of stock options and vesting of restricted stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock and stockholders&#8217; deficit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock And Stockholders Deficit [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock And Stockholders Deficit [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LiabilitiesAndStockholdersEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities and stockholders equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LiabilitiesAndStockholdersEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LiabilitiesAndStockholdersEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities And Stockholders Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net (including related party expense amounts of $0 and $30, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LeaseAgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement termination date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LeaseAgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Termination Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LeaseAgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement termination date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument periodic payment terms balloon payment to be paid, percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of final payment on advanced at maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LesseeOperatingLeaseTermOfExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, Operating Lease, Term of expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LesseeOperatingLeaseTermOfExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dsgn_LesseeOperatingLeaseTermOfExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to renew lease term ends, year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price of common stock purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_JanuaryNoteMember" xlink:to="dsgn_JanuaryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" xlink:to="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PaidInKindInterestRelatedParty" xlink:to="dsgn_PaidInKindInterestRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_InvestigationNewDrugMember" xlink:to="dsgn_InvestigationNewDrugMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_DebtSecuritiesAvailableForSaleMaturity" xlink:to="dsgn_DebtSecuritiesAvailableForSaleMaturity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:to="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PreferredStockIssuanceCost" xlink:to="dsgn_PreferredStockIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" xlink:to="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LegalPatentFees" xlink:to="dsgn_LegalPatentFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_MonthlyFeeForConsultancyServices" xlink:to="dsgn_MonthlyFeeForConsultancyServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" xlink:to="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_OneYearToTwoYearsMember" xlink:to="dsgn_OneYearToTwoYearsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="dsgn_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_JulyNoteMember" xlink:to="dsgn_JulyNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" xlink:to="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TaxCreditCarryforwardExpirationYear" xlink:to="dsgn_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" xlink:to="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LicenseAgreementAbstract" xlink:to="dsgn_LicenseAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" xlink:to="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="dsgn_ScheduleOfLicenseAgreementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:to="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" xlink:to="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_CollaborativeArrangementsUpfrontPayment" xlink:to="dsgn_CollaborativeArrangementsUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_SeriesBConvertiblePreferredStockMember" xlink:to="dsgn_SeriesBConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PercentageOfAnnualIncreaseInLeasePayments" xlink:to="dsgn_PercentageOfAnnualIncreaseInLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_MayNoteMember" xlink:to="dsgn_MayNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ProceedsFromNotesPayableRelatedParty" xlink:to="dsgn_ProceedsFromNotesPayableRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_AreaOfLeasedProperty" xlink:to="dsgn_AreaOfLeasedProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_RepaymentsOfNotesPayableRelatedParty" xlink:to="dsgn_RepaymentsOfNotesPayableRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_May2018NoteMember" xlink:to="dsgn_May2018NoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" xlink:to="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_IncomeTaxReconciliationDebtFinancing" xlink:to="dsgn_IncomeTaxReconciliationDebtFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_CrossingHoldingsLLCMember" xlink:to="dsgn_CrossingHoldingsLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent" xlink:to="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_UnvestedStockLiability" xlink:to="dsgn_UnvestedStockLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_CoFounderMember" xlink:to="dsgn_CoFounderMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_NoticePeriodForTerminationOfAgreement" xlink:to="dsgn_NoticePeriodForTerminationOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" xlink:to="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" xlink:to="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PatentCostsPolicyTextBlock" xlink:to="dsgn_PatentCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TwoThousandNineteenConsultingAgreementMember" xlink:to="dsgn_TwoThousandNineteenConsultingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TerminationFee" xlink:to="dsgn_TerminationFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_DeferredTaxAssetsLeaseLiability" xlink:to="dsgn_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:to="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="dsgn_TwoThousandEighteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_AreaOfOffice" xlink:to="dsgn_AreaOfOffice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LeaseCommencementDate" xlink:to="dsgn_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" xlink:to="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ResearchConsultingAgreementsMember" xlink:to="dsgn_ResearchConsultingAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="dsgn_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_July2018NoteMember" xlink:to="dsgn_July2018NoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" xlink:to="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_PrepaidExpensesRelatedPartyCurrent" xlink:to="dsgn_PrepaidExpensesRelatedPartyCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TemporaryEquitySettlementOfBifurcatedConversion" xlink:to="dsgn_TemporaryEquitySettlementOfBifurcatedConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_SharesSubjectToRepurchaseMember" xlink:to="dsgn_SharesSubjectToRepurchaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_UpfrontPaymentUponExecutionOfAgreement" xlink:to="dsgn_UpfrontPaymentUponExecutionOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="dsgn_OperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LicenseAgreementMember" xlink:to="dsgn_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" xlink:to="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_Jan2020AndDec2019DrawsMember" xlink:to="dsgn_Jan2020AndDec2019DrawsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_RelatedPartyTransactionMonthlyFeeForServices" xlink:to="dsgn_RelatedPartyTransactionMonthlyFeeForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ShortTermLeaseLiability" xlink:to="dsgn_ShortTermLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_ScheduleOfLicenseAgreementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_NumberOfDomesticCertificatesOfDepositHeld" xlink:to="dsgn_NumberOfDomesticCertificatesOfDepositHeld_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_UpfrontPaymentWithinOneYear" xlink:to="dsgn_UpfrontPaymentWithinOneYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" xlink:to="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="dsgn_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_WithinOneYearMember" xlink:to="dsgn_WithinOneYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_NovemberNoteMember" xlink:to="dsgn_NovemberNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_FebruaryAndMarch2019DrawsMember" xlink:to="dsgn_FebruaryAndMarch2019DrawsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_UnvestedStockLiabilityVestedSharesValue" xlink:to="dsgn_UnvestedStockLiabilityVestedSharesValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_SharesEarlyExercisedUnvestedStockLiability" xlink:to="dsgn_SharesEarlyExercisedUnvestedStockLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_MarlinspikeGroupLLCMember" xlink:to="dsgn_MarlinspikeGroupLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_OperatingLossCarryforwardsExpirationYear" xlink:to="dsgn_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_InitialClosingOfSeriesAPreferredStockMember" xlink:to="dsgn_InitialClosingOfSeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_NoticePeriodDescription" xlink:to="dsgn_NoticePeriodDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_GrantRevenueTextBlock" xlink:to="dsgn_GrantRevenueTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ComputerEquipmentAndSoftwareMember" xlink:to="dsgn_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_February2019NoteMember" xlink:to="dsgn_February2019NoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_SeriesAConvertiblePreferredStockMember" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ConsultingAgreementsMember" xlink:to="dsgn_ConsultingAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_UnsecuredPromissoryNoteMember" xlink:to="dsgn_UnsecuredPromissoryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ConversionOfStockAmountConvertedRelatedParty" xlink:to="dsgn_ConversionOfStockAmountConvertedRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_LiabilitiesAndStockholdersEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" xlink:to="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_DisclosureOfLicenseAgreementTextBlock" xlink:to="dsgn_DisclosureOfLicenseAgreementTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_BalanceSheetComponentAbstract" xlink:to="dsgn_BalanceSheetComponentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_TwoThousandTwentyConsultingAgreementMember" xlink:to="dsgn_TwoThousandTwentyConsultingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:to="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="dsgn_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LiabilitiesAndStockholdersEquityTable" xlink:to="dsgn_LiabilitiesAndStockholdersEquityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LeaseAgreementTerminationDate" xlink:to="dsgn_LeaseAgreementTerminationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:to="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dsgn_LesseeOperatingLeaseTermOfExpirationYear" xlink:to="dsgn_LesseeOperatingLeaseTermOfExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>dsgn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T15:53:02.4206+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.designtx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dsgn="http://www.designtx.com/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dsgn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dsgn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dsgn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dsgn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2" id="DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2">
        <link:definition>100020 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>100040 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical" id="StatementStatementsOfOperationsParenthetical">
        <link:definition>100050 - Statement - Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" id="StatementStatementsOfComprehensiveLoss">
        <link:definition>100060 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100070 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100080 - Statement - Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100090 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1" id="DisclosureOrganizationAndDescriptionOfBusiness1">
        <link:definition>100100 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100120 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities" id="Role_DisclosureInvestmentSecurities">
        <link:definition>100140 - Disclosure - Investment Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100150 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLease" id="DisclosureLease">
        <link:definition>100160 - Disclosure - Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureGrantRevenue" id="Role_DisclosureGrantRevenue">
        <link:definition>100170 - Disclosure - Grant Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100180 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement" id="Role_DisclosureLicenseAgreement">
        <link:definition>100190 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit" id="Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>100200 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>100210 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1" id="DisclosureIncomeTaxes1">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>100240 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>100260 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables" id="Role_DisclosureInvestmentSecuritiesTables">
        <link:definition>100280 - Disclosure - Investment Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100290 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseTables" id="DisclosureLeaseTables">
        <link:definition>100300 - Disclosure - Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables" id="Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables">
        <link:definition>100310 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>100320 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100330 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" id="Role_DisclosureRelatedPartyTransactionsTables">
        <link:definition>100340 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100370 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" id="DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv">
        <link:definition>100390 - Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" id="DisclosureInvestmentSecuritiesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Investment Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100410 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100420 - Disclosure - Balance Sheet Details - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails">
        <link:definition>100430 - Disclosure - Balance Sheet Details - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" id="DisclosureLeaseAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Lease - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails" id="DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails">
        <link:definition>100450 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" id="DisclosureGrantRevenueAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Grant Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" id="DisclosureLicenseAgreementAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" id="Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails">
        <link:definition>100500 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100520 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail" id="DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail">
        <link:definition>100530 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails" id="DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails">
        <link:definition>100540 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails">
        <link:definition>100570 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" id="Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails">
        <link:definition>100600 - Disclosure - Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dsgn_BalanceSheetComponentAbstract" name="BalanceSheetComponentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" name="AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" name="AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_AreaOfLeasedProperty" name="AreaOfLeasedProperty" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_AreaOfOffice" name="AreaOfOffice" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_CollaborativeArrangementsUpfrontPayment" name="CollaborativeArrangementsUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" name="CommonStockCapitalSharesReservedForFutureIssuanceIncreased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_ConversionOfStockAmountConvertedRelatedParty" name="ConversionOfStockAmountConvertedRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_DebtSecuritiesAvailableForSaleMaturity" name="DebtSecuritiesAvailableForSaleMaturity" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" name="ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" name="ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_IncomeTaxReconciliationDebtFinancing" name="IncomeTaxReconciliationDebtFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" name="IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" name="InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" name="IssueOfCommonStockThroughEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_LeaseAgreementTerminationDate" name="LeaseAgreementTerminationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_LegalPatentFees" name="LegalPatentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_LesseeOperatingLeaseTermOfExpirationYear" name="LesseeOperatingLeaseTermOfExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_MonthlyFeeForConsultancyServices" name="MonthlyFeeForConsultancyServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" name="NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" name="NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_NoticePeriodDescription" name="NoticePeriodDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_NoticePeriodForTerminationOfAgreement" name="NoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_NumberOfDomesticCertificatesOfDepositHeld" name="NumberOfDomesticCertificatesOfDepositHeld" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" name="OperatingLossCarryforwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_PaidInKindInterestRelatedParty" name="PaidInKindInterestRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_PercentageOfAnnualIncreaseInLeasePayments" name="PercentageOfAnnualIncreaseInLeasePayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" name="PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_PreferredStockIssuanceCost" name="PreferredStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent" name="PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_PrepaidExpensesRelatedPartyCurrent" name="PrepaidExpensesRelatedPartyCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_ProceedsFromNotesPayableRelatedParty" name="ProceedsFromNotesPayableRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_RelatedPartyTransactionMonthlyFeeForServices" name="RelatedPartyTransactionMonthlyFeeForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_RepaymentsOfNotesPayableRelatedParty" name="RepaymentsOfNotesPayableRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_SharesEarlyExercisedUnvestedStockLiability" name="SharesEarlyExercisedUnvestedStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_ShortTermLeaseLiability" name="ShortTermLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" name="TemporaryEquityConversionOfConvertibleDebtAndInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" name="TemporaryEquityConversionOfConvertibleDebtAndInterestShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" name="TemporaryEquityConvertedIntoSharesOfCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" name="TemporaryEquityConvertedIntoSharesOfCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_TemporaryEquitySettlementOfBifurcatedConversion" name="TemporaryEquitySettlementOfBifurcatedConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_TerminationFee" name="TerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_UnvestedStockLiability" name="UnvestedStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="dsgn_UnvestedStockLiabilityVestedSharesValue" name="UnvestedStockLiabilityVestedSharesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_UpfrontPaymentUponExecutionOfAgreement" name="UpfrontPaymentUponExecutionOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_UpfrontPaymentWithinOneYear" name="UpfrontPaymentWithinOneYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="dsgn_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" name="ConvertiblePreferredStockAndStockholdersDeficitLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_LiabilitiesAndStockholdersEquityLineItems" name="LiabilitiesAndStockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ScheduleOfLicenseAgreementLineItems" name="ScheduleOfLicenseAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_CoFounderMember" name="CoFounderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ConsultingAgreementsMember" name="ConsultingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" name="ConvertibleNotesIssuedInMayAndJuly2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_CrossingHoldingsLLCMember" name="CrossingHoldingsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_February2019NoteMember" name="February2019NoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_FebruaryAndMarch2019DrawsMember" name="FebruaryAndMarch2019DrawsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_InitialClosingOfSeriesAPreferredStockMember" name="InitialClosingOfSeriesAPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_InvestigationNewDrugMember" name="InvestigationNewDrugMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_Jan2020AndDec2019DrawsMember" name="Jan2020AndDec2019DrawsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_JanuaryNoteMember" name="JanuaryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_July2018NoteMember" name="July2018NoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_JulyNoteMember" name="JulyNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_MarlinspikeGroupLLCMember" name="MarlinspikeGroupLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_May2018NoteMember" name="May2018NoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_MayNoteMember" name="MayNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_NovemberNoteMember" name="NovemberNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_OneYearToTwoYearsMember" name="OneYearToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ResearchConsultingAgreementsMember" name="ResearchConsultingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_SharesSubjectToRepurchaseMember" name="SharesSubjectToRepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_TwoThousandNineteenConsultingAgreementMember" name="TwoThousandNineteenConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_TwoThousandTwentyConsultingAgreementMember" name="TwoThousandTwentyConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" name="TwoThousandTwentyOneEquityIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_UnsecuredPromissoryNoteMember" name="UnsecuredPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_WithinOneYearMember" name="WithinOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" name="ConvertiblePreferredStockAndStockholdersDeficitTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_LiabilitiesAndStockholdersEquityTable" name="LiabilitiesAndStockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ScheduleOfLicenseAgreementTable" name="ScheduleOfLicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" name="ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_DisclosureOfLicenseAgreementTextBlock" name="DisclosureOfLicenseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_GrantRevenueTextBlock" name="GrantRevenueTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="dsgn_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>dsgn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T15:53:05.4764+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:href="dsgn-20211231.xsd#StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2" xlink:href="dsgn-20211231.xsd#DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations" xlink:href="dsgn-20211231.xsd#StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="dsgn-20211231.xsd#StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="dsgn-20211231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:href="dsgn-20211231.xsd#DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails" xlink:href="dsgn-20211231.xsd#DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dsgn_PaidInKindInterestRelatedParty" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dsgn_ProceedsFromNotesPayableRelatedParty" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dsgn_RepaymentsOfNotesPayableRelatedParty" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="12" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" xlink:label="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PaidInKindInterestRelatedParty" xlink:label="dsgn_PaidInKindInterestRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ProceedsFromNotesPayableRelatedParty" xlink:label="dsgn_ProceedsFromNotesPayableRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" xlink:label="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_RepaymentsOfNotesPayableRelatedParty" xlink:label="dsgn_RepaymentsOfNotesPayableRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" xlink:label="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dsgn_AccruedResearchAndDevelopmentExpenseCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="dsgn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="dsgn_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="dsgn_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dsgn_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DeferredTaxAssetsLeaseLiability" xlink:label="dsgn_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dsgn_IncomeTaxReconciliationDebtFinancing" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IncomeTaxReconciliationDebtFinancing" xlink:label="dsgn_IncomeTaxReconciliationDebtFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>dsgn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T15:53:05.3243+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="dsgn-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="dsgn-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="dsgn-20211231.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="dsgn-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:href="dsgn-20211231.xsd#DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureInvestmentSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureLeaseAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureGrantRevenueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquitySettlementOfBifurcatedConversion" xlink:label="dsgn_TemporaryEquitySettlementOfBifurcatedConversion"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquitySettlementOfBifurcatedConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesBConvertiblePreferredStockMember" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PreferredStockIssuanceCost" xlink:label="dsgn_PreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_PreferredStockIssuanceCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ResearchConsultingAgreementsMember" xlink:label="dsgn_ResearchConsultingAgreementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ConsultingAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ResearchConsultingAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShortTermLeaseLiability" xlink:label="dsgn_ShortTermLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="dsgn_ShortTermLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SharesSubjectToRepurchaseMember" xlink:label="dsgn_SharesSubjectToRepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dsgn_SharesSubjectToRepurchaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_WithinOneYearMember" xlink:label="dsgn_WithinOneYearMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DebtSecuritiesAvailableForSaleMaturity" xlink:label="dsgn_DebtSecuritiesAvailableForSaleMaturity"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OneYearToTwoYearsMember" xlink:label="dsgn_OneYearToTwoYearsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="dsgn_WithinOneYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="dsgn_DebtSecuritiesAvailableForSaleMaturity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="dsgn_OneYearToTwoYearsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NumberOfDomesticCertificatesOfDepositHeld" xlink:label="dsgn_NumberOfDomesticCertificatesOfDepositHeld"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" xlink:label="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="dsgn_NumberOfDomesticCertificatesOfDepositHeld" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ComputerEquipmentAndSoftwareMember" xlink:label="dsgn_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dsgn_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CrossingHoldingsLLCMember" xlink:label="dsgn_CrossingHoldingsLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LeaseAgreementTerminationDate" xlink:label="dsgn_LeaseAgreementTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AreaOfLeasedProperty" xlink:label="dsgn_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LeaseCommencementDate" xlink:label="dsgn_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LesseeOperatingLeaseTermOfExpirationYear" xlink:label="dsgn_LesseeOperatingLeaseTermOfExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfAnnualIncreaseInLeasePayments" xlink:label="dsgn_PercentageOfAnnualIncreaseInLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dsgn_CrossingHoldingsLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_LeaseAgreementTerminationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_AreaOfLeasedProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_LesseeOperatingLeaseTermOfExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_PercentageOfAnnualIncreaseInLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnsecuredPromissoryNoteMember" xlink:label="dsgn_UnsecuredPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_FebruaryAndMarch2019DrawsMember" xlink:label="dsgn_FebruaryAndMarch2019DrawsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_JanuaryNoteMember" xlink:label="dsgn_JanuaryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" xlink:label="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_Jan2020AndDec2019DrawsMember" xlink:label="dsgn_Jan2020AndDec2019DrawsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NovemberNoteMember" xlink:label="dsgn_NovemberNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_May2018NoteMember" xlink:label="dsgn_May2018NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_July2018NoteMember" xlink:label="dsgn_July2018NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_February2019NoteMember" xlink:label="dsgn_February2019NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:label="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="dsgn_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_UnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dsgn_UnsecuredPromissoryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_FebruaryAndMarch2019DrawsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_JanuaryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_Jan2020AndDec2019DrawsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_NovemberNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_May2018NoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_July2018NoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_February2019NoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfLicenseAgreementLineItems" xlink:label="dsgn_ScheduleOfLicenseAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfLicenseAgreementTable" xlink:label="dsgn_ScheduleOfLicenseAgreementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LicenseAgreementMember" xlink:label="dsgn_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InitialClosingOfSeriesAPreferredStockMember" xlink:label="dsgn_InitialClosingOfSeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InvestigationNewDrugMember" xlink:label="dsgn_InvestigationNewDrugMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CollaborativeArrangementsUpfrontPayment" xlink:label="dsgn_CollaborativeArrangementsUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UpfrontPaymentUponExecutionOfAgreement" xlink:label="dsgn_UpfrontPaymentUponExecutionOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UpfrontPaymentWithinOneYear" xlink:label="dsgn_UpfrontPaymentWithinOneYear"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" xlink:label="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" xlink:label="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LegalPatentFees" xlink:label="dsgn_LegalPatentFees"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NoticePeriodForTerminationOfAgreement" xlink:label="dsgn_NoticePeriodForTerminationOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NoticePeriodDescription" xlink:label="dsgn_NoticePeriodDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_ScheduleOfLicenseAgreementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dsgn_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_InitialClosingOfSeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dsgn_InvestigationNewDrugMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_CollaborativeArrangementsUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_UpfrontPaymentUponExecutionOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_UpfrontPaymentWithinOneYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_LegalPatentFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_NoticePeriodForTerminationOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_NoticePeriodDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesBConvertiblePreferredStockMember" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:label="dsgn_LiabilitiesAndStockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LiabilitiesAndStockholdersEquityTable" xlink:label="dsgn_LiabilitiesAndStockholdersEquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiability" xlink:label="dsgn_UnvestedStockLiability"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SharesEarlyExercisedUnvestedStockLiability" xlink:label="dsgn_SharesEarlyExercisedUnvestedStockLiability"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiabilityVestedSharesValue" xlink:label="dsgn_UnvestedStockLiabilityVestedSharesValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_LiabilitiesAndStockholdersEquityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dsgn_LiabilitiesAndStockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_UnvestedStockLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_SharesEarlyExercisedUnvestedStockLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_UnvestedStockLiabilityVestedSharesValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" xlink:label="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="dsgn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsExpirationYear" xlink:label="dsgn_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" xlink:label="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TaxCreditCarryforwardExpirationYear" xlink:label="dsgn_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_OperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PrepaidExpensesRelatedPartyCurrent" xlink:label="dsgn_PrepaidExpensesRelatedPartyCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MarlinspikeGroupLLCMember" xlink:label="dsgn_MarlinspikeGroupLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandNineteenConsultingAgreementMember" xlink:label="dsgn_TwoThousandNineteenConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyConsultingAgreementMember" xlink:label="dsgn_TwoThousandTwentyConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MayNoteMember" xlink:label="dsgn_MayNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CoFounderMember" xlink:label="dsgn_CoFounderMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AreaOfOffice" xlink:label="dsgn_AreaOfOffice"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_JulyNoteMember" xlink:label="dsgn_JulyNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MonthlyFeeForConsultancyServices" xlink:label="dsgn_MonthlyFeeForConsultancyServices"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TerminationFee" xlink:label="dsgn_TerminationFee"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_RelatedPartyTransactionMonthlyFeeForServices" xlink:label="dsgn_RelatedPartyTransactionMonthlyFeeForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_PrepaidExpensesRelatedPartyCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dsgn_MarlinspikeGroupLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_TwoThousandNineteenConsultingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_TwoThousandTwentyConsultingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_MayNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dsgn_CoFounderMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_AreaOfOffice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_JulyNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ConsultingAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_MonthlyFeeForConsultancyServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_TerminationFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_RelatedPartyTransactionMonthlyFeeForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MarlinspikeGroupLLCMember" xlink:label="dsgn_MarlinspikeGroupLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ResearchConsultingAgreementsMember" xlink:label="dsgn_ResearchConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ConsultingAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dsgn_MarlinspikeGroupLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ResearchConsultingAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>dsgn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T15:53:05.0737+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="dsgn-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:href="dsgn-20211231.xsd#StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="dsgn-20211231.xsd#StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations" xlink:href="dsgn-20211231.xsd#StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical" xlink:href="dsgn-20211231.xsd#StatementStatementsOfOperationsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="dsgn-20211231.xsd#StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="dsgn-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="dsgn-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="dsgn-20211231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1" xlink:href="dsgn-20211231.xsd#DisclosureOrganizationAndDescriptionOfBusiness1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="dsgn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="dsgn-20211231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="dsgn-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities" xlink:href="dsgn-20211231.xsd#Role_DisclosureInvestmentSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLease" xlink:href="dsgn-20211231.xsd#DisclosureLease" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureGrantRevenue" xlink:href="dsgn-20211231.xsd#Role_DisclosureGrantRevenue" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="dsgn-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement" xlink:href="dsgn-20211231.xsd#Role_DisclosureLicenseAgreement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit" xlink:href="dsgn-20211231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxes1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans" xlink:href="dsgn-20211231.xsd#DisclosureEmployeeBenefitPlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dsgn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="dsgn-20211231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="dsgn-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables" xlink:href="dsgn-20211231.xsd#Role_DisclosureInvestmentSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseTables" xlink:href="dsgn-20211231.xsd#DisclosureLeaseTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables" xlink:href="dsgn-20211231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="dsgn-20211231.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="dsgn-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:href="dsgn-20211231.xsd#DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureInvestmentSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureLeaseAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails" xlink:href="dsgn-20211231.xsd#DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureGrantRevenueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="dsgn-20211231.xsd#DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails" xlink:href="dsgn-20211231.xsd#DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:href="dsgn-20211231.xsd#Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="dsgn-20211231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent" xlink:label="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" xlink:label="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquitySettlementOfBifurcatedConversion" xlink:label="dsgn_TemporaryEquitySettlementOfBifurcatedConversion"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:label="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" xlink:label="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_23"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_24"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_25"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_TemporaryEquitySettlementOfBifurcatedConversion" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesBConvertiblePreferredStockMember" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PreferredStockIssuanceCost" xlink:label="dsgn_PreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dsgn_PreferredStockIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:label="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" xlink:label="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConversionOfStockAmountConvertedRelatedParty" xlink:label="dsgn_ConversionOfStockAmountConvertedRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" xlink:label="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PaidInKindInterestRelatedParty" xlink:label="dsgn_PaidInKindInterestRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ProceedsFromNotesPayableRelatedParty" xlink:label="dsgn_ProceedsFromNotesPayableRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" xlink:label="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_RepaymentsOfNotesPayableRelatedParty" xlink:label="dsgn_RepaymentsOfNotesPayableRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dsgn_ConversionOfStockAmountConvertedRelatedParty" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dsgn_PaidInKindInterestRelatedParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dsgn_ProceedsFromNotesPayableRelatedParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dsgn_RepaymentsOfNotesPayableRelatedParty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_BalanceSheetComponentAbstract" xlink:label="dsgn_BalanceSheetComponentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_BalanceSheetComponentAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLease" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureGrantRevenue" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_GrantRevenueTextBlock" xlink:label="dsgn_GrantRevenueTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="dsgn_GrantRevenueTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LicenseAgreementAbstract" xlink:label="dsgn_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DisclosureOfLicenseAgreementTextBlock" xlink:label="dsgn_DisclosureOfLicenseAgreementTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LicenseAgreementAbstract" xlink:to="dsgn_DisclosureOfLicenseAgreementTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PatentCostsPolicyTextBlock" xlink:label="dsgn_PatentCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dsgn_PatentCostsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" xlink:label="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ResearchConsultingAgreementsMember" xlink:label="dsgn_ResearchConsultingAgreementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ConsultingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ResearchConsultingAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" xlink:label="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShortTermLeaseLiability" xlink:label="dsgn_ShortTermLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="dsgn_ShortTermLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SharesSubjectToRepurchaseMember" xlink:label="dsgn_SharesSubjectToRepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dsgn_SharesSubjectToRepurchaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_WithinOneYearMember" xlink:label="dsgn_WithinOneYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DebtSecuritiesAvailableForSaleMaturity" xlink:label="dsgn_DebtSecuritiesAvailableForSaleMaturity"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OneYearToTwoYearsMember" xlink:label="dsgn_OneYearToTwoYearsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="dsgn_WithinOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="dsgn_DebtSecuritiesAvailableForSaleMaturity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="dsgn_OneYearToTwoYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NumberOfDomesticCertificatesOfDepositHeld" xlink:label="dsgn_NumberOfDomesticCertificatesOfDepositHeld"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" xlink:label="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="dsgn_NumberOfDomesticCertificatesOfDepositHeld" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ComputerEquipmentAndSoftwareMember" xlink:label="dsgn_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dsgn_ComputerEquipmentAndSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="dsgn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="dsgn_AccruedResearchAndDevelopmentExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CrossingHoldingsLLCMember" xlink:label="dsgn_CrossingHoldingsLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LeaseAgreementTerminationDate" xlink:label="dsgn_LeaseAgreementTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AreaOfLeasedProperty" xlink:label="dsgn_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LeaseCommencementDate" xlink:label="dsgn_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LesseeOperatingLeaseTermOfExpirationYear" xlink:label="dsgn_LesseeOperatingLeaseTermOfExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfAnnualIncreaseInLeasePayments" xlink:label="dsgn_PercentageOfAnnualIncreaseInLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dsgn_CrossingHoldingsLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_LeaseAgreementTerminationDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_AreaOfLeasedProperty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_LeaseCommencementDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_LesseeOperatingLeaseTermOfExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="dsgn_PercentageOfAnnualIncreaseInLeasePayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="dsgn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnsecuredPromissoryNoteMember" xlink:label="dsgn_UnsecuredPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_FebruaryAndMarch2019DrawsMember" xlink:label="dsgn_FebruaryAndMarch2019DrawsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_JanuaryNoteMember" xlink:label="dsgn_JanuaryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" xlink:label="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_Jan2020AndDec2019DrawsMember" xlink:label="dsgn_Jan2020AndDec2019DrawsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NovemberNoteMember" xlink:label="dsgn_NovemberNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_May2018NoteMember" xlink:label="dsgn_May2018NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_July2018NoteMember" xlink:label="dsgn_July2018NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_February2019NoteMember" xlink:label="dsgn_February2019NoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:label="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dsgn_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_UnsecuredDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dsgn_UnsecuredPromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_FebruaryAndMarch2019DrawsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_JanuaryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_Jan2020AndDec2019DrawsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_NovemberNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_May2018NoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_July2018NoteMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_VariableRateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_February2019NoteMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureTable" xlink:to="dsgn_CommitmentsAndContingenciesDisclosureLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LicenseAgreementAbstract" xlink:label="dsgn_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfLicenseAgreementTable" xlink:label="dsgn_ScheduleOfLicenseAgreementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LicenseAgreementMember" xlink:label="dsgn_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InitialClosingOfSeriesAPreferredStockMember" xlink:label="dsgn_InitialClosingOfSeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_InvestigationNewDrugMember" xlink:label="dsgn_InvestigationNewDrugMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ScheduleOfLicenseAgreementLineItems" xlink:label="dsgn_ScheduleOfLicenseAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CollaborativeArrangementsUpfrontPayment" xlink:label="dsgn_CollaborativeArrangementsUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UpfrontPaymentUponExecutionOfAgreement" xlink:label="dsgn_UpfrontPaymentUponExecutionOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UpfrontPaymentWithinOneYear" xlink:label="dsgn_UpfrontPaymentWithinOneYear"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" xlink:label="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" xlink:label="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LegalPatentFees" xlink:label="dsgn_LegalPatentFees"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NoticePeriodForTerminationOfAgreement" xlink:label="dsgn_NoticePeriodForTerminationOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NoticePeriodDescription" xlink:label="dsgn_NoticePeriodDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LicenseAgreementAbstract" xlink:to="dsgn_ScheduleOfLicenseAgreementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dsgn_LicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_InitialClosingOfSeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dsgn_InvestigationNewDrugMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_CollaborativeArrangementsUpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_UpfrontPaymentUponExecutionOfAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_UpfrontPaymentWithinOneYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementTable" xlink:to="dsgn_ScheduleOfLicenseAgreementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="us-gaap_ContractualObligation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_LegalPatentFees" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_NoticePeriodForTerminationOfAgreement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ScheduleOfLicenseAgreementLineItems" xlink:to="dsgn_NoticePeriodDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:label="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesAConvertiblePreferredStockMember" xlink:label="dsgn_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SeriesBConvertiblePreferredStockMember" xlink:label="dsgn_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dsgn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandEighteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable" xlink:to="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LiabilitiesAndStockholdersEquityTable" xlink:label="dsgn_LiabilitiesAndStockholdersEquityTable"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:label="dsgn_LiabilitiesAndStockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiability" xlink:label="dsgn_UnvestedStockLiability"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_SharesEarlyExercisedUnvestedStockLiability" xlink:label="dsgn_SharesEarlyExercisedUnvestedStockLiability"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiabilityVestedSharesValue" xlink:label="dsgn_UnvestedStockLiabilityVestedSharesValue"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_UnvestedStockLiability" xlink:label="dsgn_UnvestedStockLiability_7"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="dsgn_LiabilitiesAndStockholdersEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityTable" xlink:to="dsgn_LiabilitiesAndStockholdersEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_UnvestedStockLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_SharesEarlyExercisedUnvestedStockLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_UnvestedStockLiabilityVestedSharesValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dsgn_LiabilitiesAndStockholdersEquityLineItems" xlink:to="dsgn_UnvestedStockLiability_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" xlink:label="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="dsgn_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" xlink:label="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" xlink:label="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandEighteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="dsgn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_OperatingLossCarryforwardsExpirationYear" xlink:label="dsgn_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" xlink:label="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TaxCreditCarryforwardExpirationYear" xlink:label="dsgn_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_OperatingLossCarryforwardsSubjectToExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_OperatingLossCarryforwardsNotSubjectToExpiration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="dsgn_TaxCreditCarryforwardExpirationYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dsgn_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_DeferredTaxAssetsLeaseLiability" xlink:label="dsgn_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="dsgn_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="dsgn_DeferredTaxAssetsLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_IncomeTaxReconciliationDebtFinancing" xlink:label="dsgn_IncomeTaxReconciliationDebtFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dsgn_IncomeTaxReconciliationDebtFinancing" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PrepaidExpensesRelatedPartyCurrent" xlink:label="dsgn_PrepaidExpensesRelatedPartyCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MarlinspikeGroupLLCMember" xlink:label="dsgn_MarlinspikeGroupLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA" xlink:label="country_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandNineteenConsultingAgreementMember" xlink:label="dsgn_TwoThousandNineteenConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TwoThousandTwentyConsultingAgreementMember" xlink:label="dsgn_TwoThousandTwentyConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" xlink:label="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MayNoteMember" xlink:label="dsgn_MayNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_CoFounderMember" xlink:label="dsgn_CoFounderMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_AreaOfOffice" xlink:label="dsgn_AreaOfOffice"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_JulyNoteMember" xlink:label="dsgn_JulyNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MonthlyFeeForConsultancyServices" xlink:label="dsgn_MonthlyFeeForConsultancyServices"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_TerminationFee" xlink:label="dsgn_TerminationFee"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_RelatedPartyTransactionMonthlyFeeForServices" xlink:label="dsgn_RelatedPartyTransactionMonthlyFeeForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" xlink:label="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_PrepaidExpensesRelatedPartyCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dsgn_MarlinspikeGroupLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_TwoThousandNineteenConsultingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_TwoThousandTwentyConsultingAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_MayNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dsgn_CoFounderMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_AreaOfOffice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="dsgn_JulyNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ConsultingAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_MonthlyFeeForConsultancyServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_TerminationFee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_RelatedPartyTransactionMonthlyFeeForServices" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertibleDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ConsultingAgreementsMember" xlink:label="dsgn_ConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_MarlinspikeGroupLLCMember" xlink:label="dsgn_MarlinspikeGroupLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="dsgn-20211231.xsd#dsgn_ResearchConsultingAgreementsMember" xlink:label="dsgn_ResearchConsultingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ConsultingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dsgn_MarlinspikeGroupLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dsgn_ResearchConsultingAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628587905800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DSGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Design Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001807120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3929248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6005 Hidden Valley Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">293-4900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,984,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant's definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission no later than 120 days after the registrant's fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584904712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 298,569<span></span>
</td>
<td class="nump">$ 2,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment securities</a></td>
<td class="nump">85,495<span></span>
</td>
<td class="nump">33,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">385,435<span></span>
</td>
<td class="nump">36,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, related party</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">390,557<span></span>
</td>
<td class="nump">36,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable (including related party amounts of $0 and $20,respectively)</a></td>
<td class="nump">1,620<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities (including related party amounts of $504 and $0, respectively)</a></td>
<td class="nump">3,663<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,283<span></span>
</td>
<td class="nump">2,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net, related party</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,427<span></span>
</td>
<td class="nump">2,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock; $0.0001 par value; no shares and 22,012,499 shares issued and outstanding at December 31, 2021 and 2020,respectively; liquidation preference of zero and $45,625 as of December 31, 2021 and 2020, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,681,752 and 16,604,774 shares issued, 55,441,926 and 15,957,821 shares outstanding at December 31, 2021 and 2020,respectively</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">429,824<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(47,456)<span></span>
</td>
<td class="num">(11,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(244)<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">382,130<span></span>
</td>
<td class="num">(11,315)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 390,557<span></span>
</td>
<td class="nump">$ 36,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628587891128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related party amounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent', window );">Accrued expenses and other current liabilities, related party amounts</a></td>
<td class="nump">$ 504<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,012,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,012,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 45,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">55,681,752<span></span>
</td>
<td class="nump">16,604,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">55,441,926<span></span>
</td>
<td class="nump">15,957,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities Related Parties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628580029096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible List]</a></td>
<td class="text">us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned<span></span>
</td>
<td class="text">us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including related party amounts of $405 and $53, respectively)</a></td>
<td class="nump">$ 24,778<span></span>
</td>
<td class="nump">$ 6,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (including related party amounts of $328 and $292, respectively)</a></td>
<td class="nump">11,053<span></span>
</td>
<td class="nump">2,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,831<span></span>
</td>
<td class="nump">8,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(35,831)<span></span>
</td>
<td class="num">(8,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net (including related party expense amounts of $0 and $30, respectively)</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,533)<span></span>
</td>
<td class="num">$ (8,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding, basic and diluted</a></td>
<td class="nump">45,936,235<span></span>
</td>
<td class="nump">15,796,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628587813752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Research and development expenses related party amount</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">General and administrative expenses related party amount</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Other income, net related party expense amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584133816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,533)<span></span>
</td>
<td class="num">$ (8,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(400)<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (35,933)<span></span>
</td>
<td class="num">$ (8,124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582778008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="num">$ (3,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,643)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,640,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A and Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,710,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest', window );">Conversion of convertible debt and interest to Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares', window );">Conversion of convertible debt and interest to Series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquitySettlementOfBifurcatedConversion', window );">Settlement of bifurcated conversion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions', window );">Exercises of stock options and vesting of restricted stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions', window );">Exercises of stock options and vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,280)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="num">$ (11,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="num">(11,923)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">22,012,499<span></span>
</td>
<td class="nump">22,012,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 45,356<span></span>
</td>
<td class="nump">$ 45,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,957,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A and Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,083,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Preferred stock converted into shares of common stock</a></td>
<td class="nump">170,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">170,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares', window );">Preferred stock converted into shares of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,096,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue', window );">Preferred stock converted into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (170,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock converted into shares of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,212,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering of common shares, net of $21,728 of issuance costs</a></td>
<td class="nump">254,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">254,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering of common shares, net of $21,728 of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions', window );">Exercises of stock options and vesting of restricted stock</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions', window );">Exercises of stock options and vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,533)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 382,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 429,824<span></span>
</td>
<td class="num">$ (244)<span></span>
</td>
<td class="num">$ (47,456)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,441,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised and vesting of early exercised common stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options exercised and vesting of early exercised common stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible debt and interest classified as temporary equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible debt and interest classified as temporary equity during period, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity converted into shares of common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity converted into shares of common stock, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquitySettlementOfBifurcatedConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity settlement of bifurcated conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquitySettlementOfBifurcatedConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628587879752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PreferredStockIssuanceCost', window );">Preferred stock issuance costs</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PreferredStockIssuanceCost', window );">Preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 21,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_PreferredStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_PreferredStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dsgn_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582592312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (35,533)<span></span>
</td>
<td class="num">$ (8,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,689<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on investment securities, net</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PaidInKindInterestRelatedParty', window );">Non-cash interest expense&#8212;related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty', window );">Net change in operating lease right-of-use assets and liabilities-related party</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="num">(1,017)<span></span>
</td>
<td class="num">(341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">2,418<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties', window );">Accounts payable and other liabilities related-party</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,377)<span></span>
</td>
<td class="num">(8,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investment securities</a></td>
<td class="num">(86,261)<span></span>
</td>
<td class="num">(55,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of investment securities</a></td>
<td class="nump">34,155<span></span>
</td>
<td class="nump">22,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,538)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(53,644)<span></span>
</td>
<td class="num">(33,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">254,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">124,712<span></span>
</td>
<td class="nump">44,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan', window );">Issuance of common stock through employee stock purchase plan</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ProceedsFromNotesPayableRelatedParty', window );">Proceeds from the issuance of notes payable, net of issuance costs&#8212;related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_RepaymentsOfNotesPayableRelatedParty', window );">Repayment of notes payable&#8212;related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">379,211<span></span>
</td>
<td class="nump">44,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">296,190<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">298,569<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability', window );">Initial recognition of operating lease right-of-use asset and operating lease liability</a></td>
<td class="nump">3,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accrued expenses</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConversionOfStockAmountConvertedRelatedParty', window );">Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ConversionOfStockAmountConvertedRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of stock amount converted related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ConversionOfStockAmountConvertedRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable And Other Liabilities Related Parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of operating lease right-of-use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net change in operating lease right-of-use assets and liabilities-related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_PaidInKindInterestRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid in kind interest related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_PaidInKindInterestRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ProceedsFromNotesPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from notes payable related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ProceedsFromNotesPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_RepaymentsOfNotesPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of notes payable related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_RepaymentsOfNotesPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584054184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Business</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Design Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a preclinical-stage biopharmaceutical company pioneering GeneTAC</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules, which are a novel class of small-molecule gene targeted chimera therapeutics that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The Company&#8217;s lead product candidate is in Friedreich ataxia (&#8220;FA&#8221;), its second GeneTAC&#153; program is in myotonic dystrophy type-1 (&#8220;DM1&#8221;), and it is also advancing its GeneTAC</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> portfolio to address other serious nucleotide repeat-driven monogenic diseases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Splits</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-for-1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-1.63</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company completed its IPO selling </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,800,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares its common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.00</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Proceeds from the Company&#8217;s IPO, net of underwriting discounts and commissions and other offering costs, were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In connection with the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,096,478</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding at the time of the IPO converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,212,548</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred net operating losses since inception </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021. The Company had cash, cash equivalents and investment securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">384.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021, and has not generated positive cash flows from operations.</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management expects</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to incur net losses for the foreseeable future. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the preclinical manufacturing, and clinical development activities as well as the commercialization of the Company&#8217;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s currently available cash and cash equivalents as of December 31, 2021 are sufficient to meet its anticipated cash requirements for more than the 12 months following the date the financial statements are issued</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584082712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Use of Estimates</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the novel coronavirus-2019 (&#8220;COVID-19&#8221;) pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company&#8217;s cash reserves are in a readily available checking account.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment Securities</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d91553c5-6eee-4258-bcc3-c4d3014546f4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized any impairment losses for the years ended December 31, 2021 and 2020.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use ("ROU") lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Short-Term Leases as of December 31, 2021 or 2020.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options and restricted stock issued pursuant to the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) and 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), and option features associated with the rights to purchase shares pursuant to the Company&#8217;s 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) are valued using the Black-Scholes option pricing model on the date of grant or subscription period.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584018456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Net Loss Per Share</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company&#8217;s equity incentive plans, employee stock purchase rights under the Company&#8217;s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.128%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.243%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.264%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,504,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,673,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,601,214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares subject to repurchase</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">239,826</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,833</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,917,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,752,765</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583892200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value Measurements</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1:      Observable inputs such as quoted prices in active markets.</span></p><p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2:      Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</span></p><p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3:      Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying value of the Company&#8217;s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company&#8217;s investment securities, which may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the Company&#8217;s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.909%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.437%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.437%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.448%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.512%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurement at End of Period Using:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">In Active</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Markets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identical</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Observable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,771</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,771</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:4.667%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.87%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.059454753338299%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in cash and cash equivalents on the accompanying balance sheets.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583930824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investment Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Investment Securities</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company&#8217;s investment policy, it has invested funds in marketable securities. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:20.987%;"/>
        <td style="width:1.006%;"/>
        <td style="width:15.486%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:7.149%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:2.119%;"/>
        <td style="width:7.663%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.092%;"/>
        <td style="width:0.92%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.274%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.274%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,896</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,893</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,045</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,878</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,911</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">209</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,702</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,739</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,712</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer&#8217;s industry, any significant deterioration in economic condition and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021 there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities in an unrealized loss position, all of which had been in an unrealized loss position for less than 12 months. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the Company did not record a reserve for credit losses. At December 31, 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> securities in an unrealized loss position.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company held </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company&#8217;s balance sheets, was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and less than</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584104632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_BalanceSheetComponentAbstract', window );"><strong>Balance Sheet Component [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Balance Sheet Details</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.293%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:17.475%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:16.79%;"/>
        <td style="width:0.717%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security deposits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.37%;"/>
        <td style="width:13.029%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.37%;"/>
        <td style="width:13.029%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,148</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,642</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,508</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.293%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:17.475%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:16.79%;"/>
        <td style="width:0.717%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued personnel costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,152</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">565</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">516</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c34c0616-00d0-4274-a21f-927f363c9ade;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of operating lease liability, related party</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">489</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">506</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,663</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">931</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_BalanceSheetComponentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance sheet component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_BalanceSheetComponentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584027928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Lease</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company&#8217;s balance sheets. The Company terminated the agreement in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,370</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of laboratory and office space (the &#8220;Lease&#8221;). The Company&#8217;s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months and an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the lease term for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and thus, the incremental term was excluded from the calculation of the ROU asset, related party and lease liability, related party. The lease includes variable non-lease components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset, related party and operating lease liability, related party and are reflected as an expense in the period incurred. Lease payments are subject to annual increases of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of December 31, 2021, the remaining lease term for the lease was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.15</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.809%;"/>
        <td style="width:1.934%;"/>
        <td style="width:1.371%;"/>
        <td style="width:15.972%;"/>
        <td style="width:0.914%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">733</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">755</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">778</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">561</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Present value adjustment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">820</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, related party</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,633</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rent expense for the years </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584978616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation Of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_GrantRevenueTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Grant Revenue</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company&#8217;s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of grant revenue from awards by the NSF, NIH and FARA, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> grant revenue was recognized for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_GrantRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of grant revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_GrantRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584099672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Notes Payable-Related Party</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company issued an unsecured promissory note to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to a co-founder (the &#8220;January Note&#8221;) for working capital. The January Note bore interest at prime plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, was scheduled to mature </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or before January 30, 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and included a final payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the January Note with interest payable at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.1</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2019, the Company issued an unsecured promissory note to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to a co-founder (the &#8220;November Note&#8221;) for working capital. The November Note bore interest at prime plus </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and matured </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or before January 1, 2022</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and included a final payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the November Note with interest payable at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.25</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Notes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May and July 2018, the Company issued $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to a co-founder for cash with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after February 5, 2021, if not converted earlier</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In February 2019, the Company issued an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to consultants for services rendered with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after May 16, 2020, if not converted earlier</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The convertible notes bore interest of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum and were convertible into equity securities sold at the next financing at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301,685</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.65816</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. See Note 9 for further discussion.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingencies</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of December 31, 2021 or December 31, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583948552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DisclosureOfLicenseAgreementTextBlock', window );">License Agreement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. License Agreement</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the &#8220;License Agreement&#8221;) with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the upfront fee upon execution of the agreement and the remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. In February 2020, the Company paid the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> balance upon the initial closing of its Series A preferred stock financing.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the License Agreement, the Company is required to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> upon the acceptance of an investigation new drug (&#8220;IND&#8221;) application in the U.S. and will be required to make further aggregate milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees&#8217; net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestone or royalty payments as of December 31, 2021.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the year ended December 31, 2021 and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020, which were recorded as general and administrative expenses in the statements of operations.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may terminate the License Agreement with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days written notice or for certain breaches of the agreement. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_DisclosureOfLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_DisclosureOfLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584034376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Deficit</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Convertible Preferred Stock and Stockholders&#8217; Deficit</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Authorized Shares</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the completion of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in March 2021, the Company amended its Certificate of Incorporation to authorize </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Preferred Stock</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February and March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,710,814</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0727</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net cash proceeds of $ </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the &#8220;Series A Financing&#8221;). In connection with the Series A Financing, the Company issued an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">301,685</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series A convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.65816</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,083,979</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.55</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for net cash proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All shares of convertible preferred stock outstanding at the Company&#8217;s IPO were converted into shares of the Company&#8217;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shares Subject to Repurchase</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four-year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient&#8217;s service is terminated either voluntarily or involuntarily prior to vesting.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company&#8217;s balance sheets, is as follows (in thousands, except share data):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.267%;"/>
        <td style="width:1.606%;"/>
        <td style="width:0.696%;"/>
        <td style="width:13.575%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.029%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">811,268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares early exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">317,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646,953</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">239,826</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583948552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Incentive Award Plans</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company&#8217;s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company&#8217;s IPO. Upon adoption of the 2021 Plan, the Company restricted future grants from its 2018 Plan.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company&#8217;s affiliates. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,118,648</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">881,352</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,079,984</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for grant under the 2021 Plan. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company&#8217;s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company&#8217;s board of directors.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2022, the number of shares available for future issuance was increased by</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,784,087</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares so that the total available for future issuance as of January 1, 2022 was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,864,071</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.77%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.06%;"/>
        <td style="width:9.423%;"/>
        <td style="width:0.846%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.242%;"/>
        <td style="width:9.562%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.06%;"/>
        <td style="width:9.594%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.242%;"/>
        <td style="width:9.573%;"/>
        <td style="width:0.61%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options and</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,674</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.95</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,723,913</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.93</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">153,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Canceled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,601,214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.71</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,468</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,439,444</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">15.60</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">52,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Canceled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">313,909</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,673,775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.49</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.12</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,673,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.49</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.12</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35,343</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">949,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.78</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,159</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value per share of options granted was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the years ended December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the years ended December 31, 2021 and 2020, respectively, and the cash received from options exercised was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.91%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.441%;"/>
        <td style="width:2.313%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.441%;"/>
        <td style="width:2.313%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.07</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.32</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the assumptions used in the option pricing model in the following manner:</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;The grant date fair market value of the shares of common stock underlying stock options is determined</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> by the Company&#8217;s board of directors. Following the closing of the Company&#8217;s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#8217;s common stock is traded. Prior to the Company&#8217;s IPO, because there was no public market for the Company&#8217;s common stock, the board of directors considered, among other things, input from management and valuations of the Company's stock prepared by unrelated third-party valuation firms.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;The expected term of stock options represents the period of time that the awards are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected term assumption using the simplified method for employees and board members, which calculates the expected term as the average time-to-vesting and the contractual life of the award. The expected term for non-employees is generally the contractual term.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;Given the Company's limited historical stock price volatility data, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;The risk-free rate assumption is based on the U.S. Treasury yield in effect at the time of the grant with maturities consistent with the expected term of the awards.</span></p><p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;The expected dividend yield assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends and, therefore, used an expected dividend yield of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company&#8217;s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company&#8217;s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were approved to be initially reserved for issuance under the ESPP. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company&#8217;s common stock on the last day of the calendar month before the date of each automatic increase and (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,200,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares; provided that before the date of any such increase, the Company&#8217;s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2022, the number of shares available for issuance was increased by</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">556,817</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares so that the total available for future issuance as of January 1, 2022 was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,145,361</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,456</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company's common stock under the ESPP and had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">588,544</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.593%;"/>
        <td style="width:1.927%;"/>
        <td style="width:0.707%;"/>
        <td style="width:15.46%;"/>
        <td style="width:2.313%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.41</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69.26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.18</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.256%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.2%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.178%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,827</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,862</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,689</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, unrecognized compensation expense related to unvested stock option awards was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is expected to be recognized in expense over a weighted-average period of</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 3.2 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years. As of December 31, 2021, unrecognized compensation expense related to ESPP rights was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which is expected to be recognized over a remaining period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584094200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Income Taxes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#8217;s tax years are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#8217;s policy is to recognize interest and penalties related to income tax matters as tax expense. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest or penalties related to income tax matters on its balance sheets at December 31, 2021 or 2020. and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized interest or penalties in its statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020, respectively. Further, the Company is not currently under examination by any federal, state or local tax authority.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, the Company had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">d $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, r</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">espectively. Federal NOL carryforwards totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">egin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless previously utilized, and federal NOL carryforwards of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enerated after 2017, may be carryforward indefinitely but can only be utilized to offset </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of future taxable income. State NOL carryforwards totalin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">g $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">gin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless previously utilized. In addition, the Company also has federal and state research and development (&#8220;R&amp;D&#8221;) credit carryforwards totali</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ng $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> respectively. The federal R&amp;D credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2038</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless previously utilized. The state R&amp;D credit carryforwards do not expire.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the Company&#8217;s NOL and R&amp;D credit carryforwards may be subject to substantial annual limitations in the event a cumulative ownership change has occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). In general, an &#8220;ownership change,&#8221; as defined by Section 382 of the Code, results from a transaction, or series of transactions over a three-year period, resulting in an ownership change of more than 50% of the outstanding common stock of a company by certain stockholders or public groups. Such an ownership change may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a study to assess whether an ownership change had occurred from the Company's formation through December 31, 2021. Based upon the study, the Company determined that it had experienced multiple ownership</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes during 2020, causing the annual utilization of the NOL and credit carryforwards to be limited. The Company does not believe any of the NOL and credit carryforwards generated through December 31, 2021 would expire solely as a result of annual limitations on the utilization of those attributes. If ownership changes occur in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.174%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.031%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.021%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,171</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,836</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">763</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">515</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">196</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,210</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,235</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.024%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.192%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.01%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,451</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">552</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Debt financing</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">836</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">317</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,181</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next twelve months. Further, due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the effective tax rate.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.192%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.221%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.221%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at beginning of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at end of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">418</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584067528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Related Party Transactions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreement</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.285%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.18%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.169%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">313</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Consulting Agreements</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (&#8220;Marlinspike Group&#8221;) for research support, management, and business consulting services (the &#8220;2019 Consulting Agreement&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marlinspike Group provides the use of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,120</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company&#8217;s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company&#8217;s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days&#8217; written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the &#8220;2020 Consulting Agreement&#8221;), which provides for the similar services and use of office space for a monthly fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days&#8217; written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.278%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.178%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.178%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Asnsari, a co-founder, provides consulting services and advises on certain research and development activities (the &#8220;Research Consulting Agreement&#8221;). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.285%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.18%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.169%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had accrued expenses and other current liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021 and accounts payable of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2020, pursuant to its related party consulting agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Convertible Notes and Notes Payable</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May and July 2018, the Company issued a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of convertible notes to a co-founder for cash with a maturity date </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on or after February 5, 2021, if not converted earlier</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The notes bore interest of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum and were convertible into equity securities sold at the next financing at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the selling price per share of such equity financing. In February 2020, these notes converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,025</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 12 for further discussion.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584987208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Employee Benefit Plans</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company's U.S. employees. The plan allows eligible employees to defer, at the employee's discretion, pretax compensation up to the IRS annual limits. The Company is not required to make matching contributions under the plan and had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t made any such contributions as of December 31, 2021.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582753320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Use of Estimates</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the novel coronavirus-2019 (&#8220;COVID-19&#8221;) pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company&#8217;s cash reserves are in a readily available checking account.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment Securities</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d91553c5-6eee-4258-bcc3-c4d3014546f4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognized any impairment losses for the years ended December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use ("ROU") lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Short-Term Leases as of December 31, 2021 or 2020.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lease </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options and restricted stock issued pursuant to the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) and 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), and option features associated with the rights to purchase shares pursuant to the Company&#8217;s 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) are valued using the Black-Scholes option pricing model on the date of grant or subscription period.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584976744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.128%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.243%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.264%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,504,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,673,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,601,214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares subject to repurchase</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">239,826</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,833</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,917,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,752,765</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583889112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the Company&#8217;s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.909%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.437%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.437%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.448%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.509%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.512%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurement at End of Period Using:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">In Active</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Markets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">For</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identical</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Observable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Inputs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">298,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,771</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,771</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383,609</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,812</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:4.667%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.87%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.059454753338299%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in cash and cash equivalents on the accompanying balance sheets.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583868840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail)</a></td>
<td class="text"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:20.987%;"/>
        <td style="width:1.006%;"/>
        <td style="width:15.486%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:7.149%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:2.119%;"/>
        <td style="width:7.663%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.092%;"/>
        <td style="width:0.92%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.274%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.274%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,896</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,893</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,045</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,878</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 year to 2 years</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,911</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">209</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,702</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,739</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">for Credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Market</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 1 year</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">152</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,712</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628586405272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.293%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:17.475%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:16.79%;"/>
        <td style="width:0.717%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Security deposits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.37%;"/>
        <td style="width:13.029%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.37%;"/>
        <td style="width:13.029%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,148</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,642</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,508</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.293%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:17.475%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.446%;"/>
        <td style="width:1.403%;"/>
        <td style="width:16.79%;"/>
        <td style="width:0.717%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued personnel costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,152</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">565</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">516</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c34c0616-00d0-4274-a21f-927f363c9ade;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of operating lease liability, related party</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">489</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">506</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,663</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">931</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583956584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities, Related Party</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.809%;"/>
        <td style="width:1.934%;"/>
        <td style="width:1.371%;"/>
        <td style="width:15.972%;"/>
        <td style="width:0.914%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">733</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">755</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">778</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">561</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Present value adjustment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">820</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, related party</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,633</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584034376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock', window );">Summary of Restricted Shares of Common Stock and Unvested Stock Liability</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company&#8217;s balance sheets, is as follows (in thousands, except share data):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.267%;"/>
        <td style="width:1.606%;"/>
        <td style="width:0.696%;"/>
        <td style="width:13.575%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.029%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">811,268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares early exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">317,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">646,953</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">407,127</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">239,826</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of restricted shares of common stock and unvested stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584853688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.77%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.06%;"/>
        <td style="width:9.423%;"/>
        <td style="width:0.846%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.242%;"/>
        <td style="width:9.562%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.06%;"/>
        <td style="width:9.594%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.199%;"/>
        <td style="width:1.242%;"/>
        <td style="width:9.573%;"/>
        <td style="width:0.61%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options and</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">30,674</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.95</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,723,913</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.93</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">153,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Canceled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,601,214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.71</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8,468</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,439,444</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">15.60</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">52,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.65</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Canceled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">313,909</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3.82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,673,775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.49</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.12</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35,343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,673,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.49</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9.12</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">35,343</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">949,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.78</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,159</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.91%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.441%;"/>
        <td style="width:2.313%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.441%;"/>
        <td style="width:2.313%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.60</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.07</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.32</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.04</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.256%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.2%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.178%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,827</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,862</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,689</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.593%;"/>
        <td style="width:1.927%;"/>
        <td style="width:0.707%;"/>
        <td style="width:15.46%;"/>
        <td style="width:2.313%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.41</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69.26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.18</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628600562104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.174%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.031%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.021%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,171</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,836</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">763</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">515</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">196</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,210</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,235</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.024%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.192%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.01%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,451</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">552</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Debt financing</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">836</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">317</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,181</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Changes to Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.192%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.221%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.221%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at beginning of period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase to current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at end of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">418</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582723464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember', window );">Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Expenses Recognized under Various Agreements</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.278%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.178%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.178%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ResearchConsultingAgreementsMember', window );">Research Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Expenses Recognized under Various Agreements</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.285%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.18%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.169%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Expenses Recognized under Various Agreements</a></td>
<td class="text"><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.285%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.18%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.169%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">313</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ResearchConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_ResearchConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628580712664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split of issued and outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split of issued and outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio of forward/reverse stock split</a></td>
<td class="nump">0.613497<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,456<span></span>
</td>
<td class="nump">$ 11,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investment securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering of common shares | shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock | $</a></td>
<td class="nump">$ 254,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares', window );">Preferred stock converted into shares of common stock | shares</a></td>
<td class="nump">41,096,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock converted into shares of common stock, Shares | shares</a></td>
<td class="nump">25,212,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity converted into shares of common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628587918408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ShortTermLeaseLiability', window );">Short-term leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ShortTermLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ShortTermLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582660264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,917,434<span></span>
</td>
<td class="nump">15,752,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,504,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,673,775<span></span>
</td>
<td class="nump">1,601,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dsgn_SharesSubjectToRepurchaseMember', window );">Shares Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">239,826<span></span>
</td>
<td class="nump">646,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">3,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dsgn_SharesSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dsgn_SharesSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582689608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">$ 383,609<span></span>
</td>
<td class="nump">$ 35,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">298,114<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">5,771<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">79,724<span></span>
</td>
<td class="nump">31,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">383,609<span></span>
</td>
<td class="nump">35,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">298,114<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">5,771<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">$ 79,724<span></span>
</td>
<td class="nump">$ 31,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628581314952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized Cost</a></td>
<td class="nump">$ 85,739<span></span>
</td>
<td class="nump">$ 33,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized Losses</a></td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">$ 85,495<span></span>
</td>
<td class="nump">$ 33,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Within 1 Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DebtSecuritiesAvailableForSaleMaturity', window );">Debt securities, Maturity</a></td>
<td class="text">Within 1 year<span></span>
</td>
<td class="text">Within 1 year<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized Cost</a></td>
<td class="nump">$ 2,896<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">$ 2,893<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | 1 Year to 2 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DebtSecuritiesAvailableForSaleMaturity', window );">Debt securities, Maturity</a></td>
<td class="text">1 year to 2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized Cost</a></td>
<td class="nump">$ 2,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">$ 2,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | Within 1 Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DebtSecuritiesAvailableForSaleMaturity', window );">Debt securities, Maturity</a></td>
<td class="text">Within 1 year<span></span>
</td>
<td class="text">Within 1 year<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized Cost</a></td>
<td class="nump">$ 15,045<span></span>
</td>
<td class="nump">$ 31,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">$ 15,022<span></span>
</td>
<td class="nump">$ 31,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities | 1 Year to 2 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DebtSecuritiesAvailableForSaleMaturity', window );">Debt securities, Maturity</a></td>
<td class="text">1 year to 2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized Cost</a></td>
<td class="nump">$ 64,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized Losses</a></td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">$ 64,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_DebtSecuritiesAvailableForSaleMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities, available-for-sale, maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_DebtSecuritiesAvailableForSaleMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=dsgn_WithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=dsgn_WithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=dsgn_OneYearToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=dsgn_OneYearToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582725704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment Securities - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months | Security</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_NumberOfDomesticCertificatesOfDepositHeld', window );">Number of domestic certificates of deposit held | Security</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities', window );">Accrued interest receivable on available-for-sale investment securities | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities', window );">Accrued interest receivable on available-for-sale investment securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest receivable on available-for-sale investment securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_NumberOfDomesticCertificatesOfDepositHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of domestic certificates of deposit held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_NumberOfDomesticCertificatesOfDepositHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628585515096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,254<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 1,371<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628579993896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dsgn_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dsgn_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dsgn_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582727496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel costs</a></td>
<td class="nump">$ 2,152<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability, related party</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating Lease, Right-of-Use Asset<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,663<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582533848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LeaseAgreementTerminationDate', window );">Lease agreement termination date</a></td>
<td class="text">2021-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dsgn_CrossingHoldingsLLCMember', window );">Crossing Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AreaOfLeasedProperty', window );">Area of lease space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">72 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LesseeOperatingLeaseTermOfExpirationYear', window );">Option to renew lease term ends, year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PercentageOfAnnualIncreaseInLeasePayments', window );">Percentage of annual increase in lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease right-of-use asset discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_AreaOfLeasedProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_AreaOfLeasedProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_LeaseAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_LeaseAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_LesseeOperatingLeaseTermOfExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Term of expiration year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_LesseeOperatingLeaseTermOfExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_PercentageOfAnnualIncreaseInLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual increase in lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_PercentageOfAnnualIncreaseInLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dsgn_CrossingHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dsgn_CrossingHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582669032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">4,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities, related party</a></td>
<td class="nump">$ 3,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628585087000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Recognized grant revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628586665848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold', window );">Percentage of selling price per share that can convertible into equity securities sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Converted amount</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="nump">301,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 1.65816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=dsgn_May2018NoteMember', window );">May 2018 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or after February 5, 2021, if not converted earlier<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=dsgn_July2018NoteMember', window );">July 2018 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or after February 5, 2021, if not converted earlier<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=dsgn_February2019NoteMember', window );">February 2019 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or after May 16, 2020, if not converted earlier<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | January Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or before January 30, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage', window );">Percentage of final payment on advanced at maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | January Note | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | January Note | Prime Plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | November Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or before January 1, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage', window );">Percentage of final payment on advanced at maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | November Note | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | November Note | Prime Plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | February and March 2019 Draws | January Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember', window );">Unsecured Promissory Note | Jan 2020 and Dec 2019 Draws | November Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member', window );">Convertible Notes Issued in May and July 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument periodic payment terms balloon payment to be paid, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of selling price per share that can convertible into equity securities sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_May2018NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_May2018NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_July2018NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_July2018NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_February2019NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_February2019NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dsgn_UnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_JanuaryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_JanuaryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_NovemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_NovemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_FebruaryAndMarch2019DrawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_FebruaryAndMarch2019DrawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_Jan2020AndDec2019DrawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_Jan2020AndDec2019DrawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628586477000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement - Additional Information (Details) - License Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_UpfrontPaymentUponExecutionOfAgreement', window );">Upfront payment upon execution of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_UpfrontPaymentWithinOneYear', window );">Upfront payment within first anniversary of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_NoticePeriodForTerminationOfAgreement', window );">Written notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_NoticePeriodDescription', window );">Termination period Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">Investigation New Drug (IND)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones', window );">Expected milestone payment on achieving certain regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">Investigation New Drug (IND) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones', window );">Expected milestone payment on achieving certain regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">Investigation New Drug (IND) | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale', window );">Expected royalty payments upon first commercial product sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">Initial Closing of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CollaborativeArrangementsUpfrontPayment', window );">Payment for upfront fee</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CollaborativeArrangementsUpfrontPayment', window );">Payment for upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LegalPatentFees', window );">Legal patent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember', window );">General and Administrative Expenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ScheduleOfLicenseAgreementLineItems', window );"><strong>Schedule Of License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LegalPatentFees', window );">Legal patent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_CollaborativeArrangementsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_CollaborativeArrangementsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected milestone payment on achieving certain regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected royalty payments upon first commercial product sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_LegalPatentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal patent fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_LegalPatentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_NoticePeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_NoticePeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_NoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_NoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ScheduleOfLicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ScheduleOfLicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_UpfrontPaymentUponExecutionOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment upon execution of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_UpfrontPaymentUponExecutionOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_UpfrontPaymentWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment within one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_UpfrontPaymentWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dsgn_InvestigationNewDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dsgn_InvestigationNewDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dsgn_InitialClosingOfSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dsgn_InitialClosingOfSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628511148904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,012,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,712<span></span>
</td>
<td class="nump">$ 44,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">6,118,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,079,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Common stock issuance, description and terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company&#8217;s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remained available for issuance</a></td>
<td class="nump">881,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remained available for issuance</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Common stock issuance, description and terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company&#8217;s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company&#8217;s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering', window );">Maximum percentage of eligible earnings withheld to participate in offering</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of common stock purchased</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,710,814<span></span>
</td>
<td class="nump">21,710,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0727<span></span>
</td>
<td class="nump">$ 2.0727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,083,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2018 Equity Incentive Plan | Restricted Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems', window );"><strong>Convertible Preferred Stock And Stockholders Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and stockholders&#8217; deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum percentage of eligible earnings withheld to participate in offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dsgn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dsgn_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dsgn_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582533352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LiabilitiesAndStockholdersEquityLineItems', window );"><strong>Liabilities And Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_UnvestedStockLiability', window );">Beginning Balance, Unvested stock liability</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_SharesEarlyExercisedUnvestedStockLiability', window );">Shares early exercised, unvested stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_UnvestedStockLiabilityVestedSharesValue', window );">Vested shares, Unvested stock liability</a></td>
<td class="num">(122)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_UnvestedStockLiability', window );">Ending Balance, Unvested stock liability</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_LiabilitiesAndStockholdersEquityLineItems', window );"><strong>Liabilities And Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Beginning Balance</a></td>
<td class="nump">646,953<span></span>
</td>
<td class="nump">811,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice', window );">Shares early exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="num">(407,127)<span></span>
</td>
<td class="num">(317,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Ending Balance</a></td>
<td class="nump">239,826<span></span>
</td>
<td class="nump">646,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_LiabilitiesAndStockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities and stockholders equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_LiabilitiesAndStockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options nonvested exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_SharesEarlyExercisedUnvestedStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares early exercised, unvested stock liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_SharesEarlyExercisedUnvestedStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_UnvestedStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_UnvestedStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_UnvestedStockLiabilityVestedSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested stock liability vested shares value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_UnvestedStockLiabilityVestedSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628511184712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.39<span></span>
</td>
<td class="nump">$ 4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in expense expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">6,118,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,079,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Common stock issuance, description and terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company&#8217;s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,864,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased', window );">Number of shares available for future issuance increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,784,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remained available for issuance</a></td>
<td class="nump">881,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">588,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remained available for issuance</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Common stock issuance, description and terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company&#8217;s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company&#8217;s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering', window );">Maximum percentage of eligible earnings withheld to participate in offering</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of common stock purchased</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in expense expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased', window );">Number of shares available for future issuance increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares reserved for future issuance increased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum percentage of eligible earnings withheld to participate in offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584937704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options and Awards Outstanding, Beginning Balance</a></td>
<td class="nump">1,601,214<span></span>
</td>
<td class="nump">30,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options and Awards Outstanding, Granted</a></td>
<td class="nump">1,439,444<span></span>
</td>
<td class="nump">1,723,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options and Awards Outstanding, Exercised</a></td>
<td class="num">(52,974)<span></span>
</td>
<td class="num">(153,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options and Awards Outstanding, Canceled</a></td>
<td class="num">(313,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options and Awards Outstanding, Ending Balance</a></td>
<td class="nump">2,673,775<span></span>
</td>
<td class="nump">1,601,214<span></span>
</td>
<td class="nump">30,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options and Awards Outstanding, Vested and expected to vest at December 31, 2021</a></td>
<td class="nump">2,673,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options and Awards Outstanding, Exercisable at December 31, 2021</a></td>
<td class="nump">949,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">15.60<span></span>
</td>
<td class="nump">0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.65<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">3.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">8.49<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2021</a></td>
<td class="nump">8.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2021</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">9 years 1 month 13 days<span></span>
</td>
<td class="text">9 years 8 months 15 days<span></span>
</td>
<td class="text">9 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2021</a></td>
<td class="text">9 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2021</a></td>
<td class="text">8 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 35,343<span></span>
</td>
<td class="nump">$ 8,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2021</a></td>
<td class="nump">35,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2021</a></td>
<td class="nump">$ 18,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628581059624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 15.60<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.83%<span></span>
</td>
<td class="nump">72.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 19.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582589752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,689<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,827<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,862<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628586596008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Recognized interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">40,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, subject to expiration</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforward, expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage', window );">NOL, percent of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, expiration year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforward, expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward taxable income threshold percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628580699560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 9,171<span></span>
</td>
<td class="nump">$ 2,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">11,994<span></span>
</td>
<td class="nump">3,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,235)<span></span>
</td>
<td class="num">(3,177)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (759)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584854248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected tax benefit at federal statutory rate</a></td>
<td class="num">$ (7,451)<span></span>
</td>
<td class="num">$ (1,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_IncomeTaxReconciliationDebtFinancing', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(836)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 7,974<span></span>
</td>
<td class="nump">$ 2,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_IncomeTaxReconciliationDebtFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation debt financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_IncomeTaxReconciliationDebtFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628585766712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase to current year tax positions</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628582802552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent', window );">Accrued expenses and other current liabilities, related party amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold', window );">Percentage of selling price per share that can convertible into equity securities sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember', window );">Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent', window );">Accrued expenses and other current liabilities, related party amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember', window );">Marlinspike Group, LLC | 2020 Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_MonthlyFeeForConsultancyServices', window );">Monthly fee for consultancy services</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_TerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember', window );">Marlinspike Group, LLC | Carlsbad, California | 2019 Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_AreaOfOffice', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember', window );">Aseem Z. Ansari, Ph.D. | Convertible Notes and Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold', window );">Percentage of selling price per share that can convertible into equity securities sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember', window );">Aseem Z. Ansari, Ph.D. | Convertible Notes and Notes Payable | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred stock converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember', window );">Aseem Z. Ansari, Ph.D. | May Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or after February 5, 2021, if not converted earlier<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember', window );">Aseem Z. Ansari, Ph.D. | July Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on or after February 5, 2021, if not converted earlier<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember', window );">Aseem Z. Ansari, Ph.D. | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dsgn_RelatedPartyTransactionMonthlyFeeForServices', window );">Monthly fee for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities Related Parties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_AreaOfOffice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_AreaOfOffice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_MonthlyFeeForConsultancyServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly fee for consultancy services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_MonthlyFeeForConsultancyServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of selling price per share that can convertible into equity securities sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_RelatedPartyTransactionMonthlyFeeForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction monthly fee for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_RelatedPartyTransactionMonthlyFeeForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dsgn_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dsgn_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dsgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_TwoThousandTwentyConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_TwoThousandTwentyConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_TwoThousandNineteenConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_TwoThousandNineteenConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_CoFounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_MayNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_MayNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=dsgn_JulyNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=dsgn_JulyNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628584906040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 24,778<span></span>
</td>
<td class="nump">$ 6,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,053<span></span>
</td>
<td class="nump">2,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ResearchConsultingAgreementsMember', window );">Research Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember', window );">Marlinspike Group, LLC | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ResearchConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_ResearchConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dsgn_MarlinspikeGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dsgn_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140628583920312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions made under plan</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>dsgn-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:dsgn="http://www.designtx.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dsgn-20211231.xsd" xlink:type="simple"/>
    <context id="C_c09976ce-b915-44ea-8211-24da15127f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1f1efe30-75a7-4daa-a934-18cf07b4b011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b235a097-5256-4f3d-babe-7ba3bf8a8a84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_96982224-ada7-45f0-9919-ba9faeecebb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_6f685d75-d65f-4c75-af30-d4d1dc49db36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4b433e9b-8bd1-498f-a486-bdee162f0520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4341ac9d-5479-44c1-8530-8d42af2897bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_042f9541-36bc-42b0-97cd-cb54c6a99af9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_3a36c38a-b117-4fef-bcd2-79b07818ea4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0cefbf23-2388-4ecd-bce3-6b76279a6cea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_72018646-7064-41a5-8f10-73e8aed069e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cd48c120-475c-4c27-9b88-664af08c371a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:July2018NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e5f8e035-e6a8-4686-b8f6-c1728d5e5e54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_020e7d21-1fc1-4579-8491-b965545b2a40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ad693d79-777f-411a-ab08-35eb238a9099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_78c5be72-50bc-4838-96f2-7c678294bfdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_da562d4c-497b-43eb-a87c-c6f98abf5d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fd90086d-3437-4665-82bf-18b82bd4403a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d6936001-b46e-472b-a199-2074ec0ad35f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_12ca6ede-1a4e-486f-8641-bc776ecea308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a15b425b-80dd-485a-b5d2-c580a8a02edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_adc93247-3f34-454d-be75-6d57971dea64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1fd32ca6-5a40-41dd-91d1-a988442615a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_855ff555-2cfb-491d-a8ff-2b1192bb78b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:TwoThousandNineteenConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_becd129a-dfa1-4804-9129-b0961e120502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fcd195dc-decb-4c46-97e7-98c2522754a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_657d72a9-16e6-4deb-b551-33c0ee8f5b08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ee89e80b-865a-4125-bcb4-76c8de099850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5be4210b-787b-4a2c-b72e-d5904d02b928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5482b53a-c0c0-483d-8704-340e59957e38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_36de137c-6361-4ec5-8970-5fc39d50dd4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_d8bc6058-3ed3-45cd-b9ce-e674b84d8a7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fc6ac533-72ba-4dfe-b7e0-cef03f4d60a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:TwoThousandTwentyConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_56d217f5-b263-4e46-bd7d-f0d3f3f291ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_4729fd04-d690-4b2c-9242-4f8689fbc206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_d821d489-20c7-4f0d-9f3e-dd434ad19267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_62eaea31-a124-426a-bd6e-5a5adb4841c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fee07a1a-85a2-4821-989e-e63acca8aebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_47968354-2359-475e-914a-8809063a760d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe8be1e8-fc44-433d-8028-3795727073cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_9aecf3c2-6ec0-470e-aed3-32e15d8ee9b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_68c8fb76-ffb2-47b9-87e5-28f51b3c5784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_cdef21de-d669-4832-a95e-55c903160e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f124e841-56b0-4f7a-af20-08a6724d6ca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:February2019NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_49187fc6-8a7a-4911-8230-ce5034a3dd6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18532e58-312b-467e-b271-29e361b67f10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dsgn:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_09862e22-6777-4916-b800-571e5b594613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_739e698e-899f-4485-a5c7-f66bb6dba318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9488ce8f-cd96-43ae-b83d-da01a404b062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_c9a6f234-a01b-49c4-8389-6f43a1314b9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_86c855a7-1404-41b9-9ec4-470ab3dffc2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e84263eb-baf8-4179-a0c7-153ef77908b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f03e432b-566b-43cb-b18b-e5b052b1516e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb312aa6-c50b-415c-b819-f0af73e2941e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_d6d2ec7c-c375-4c5a-a4e1-a6f9962559bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3ac15fe-44bb-4b93-b43f-a4b8bb8f3178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_4808721b-298d-4f46-a8a8-371b01e8767d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:Jan2020AndDec2019DrawsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_69d3f494-4d79-47df-87fd-27a5128beb0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_8d82638c-fea7-4745-93a8-e904a42ccc5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d9851747-c6e0-46a7-ae37-a995db3d6025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02912d63-fe9a-4d28-8b7a-f7b2934ccafb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="C_abbec031-d382-4477-bfc5-49894a1ef5e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d5d4f8dd-7c17-4eaa-a38e-dcd85d00e072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e64fcb9b-97f6-4f5a-8c64-d72962809b07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5088ab17-fa76-49bb-8424-af699c2d83d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_03f5fca6-f809-4c6f-a23c-f662104eb076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:May2018NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e20f6e02-a6f1-4121-b27f-17a4335d6c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9ab3d3b5-491d-45f2-a868-850168297a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8f21a733-a63e-41e6-935a-a3dd426abdc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_3f8296e2-19aa-4c9e-977c-4e9998334dc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7ba72a79-9de9-4033-985b-e7cd791153cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cbc31665-46ff-4282-846e-3ddb64f5b097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="C_a3d50d4d-9539-4c43-8867-5bbaabbcbf1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:FebruaryAndMarch2019DrawsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a9db9070-48ac-46f3-9a8e-aac6cdbfd36d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7bd00ed8-2f33-4d98-9fdd-289c66eb1dd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ResearchConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_91e891fe-e7f8-423a-b358-a2ff1159c8aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9d48e74d-c13f-42ba-9e94-f177898744b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c1f43774-a82a-4496-812e-205e05514a80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:ConvertibleNotesIssuedInMayAndJuly2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_131e1c23-bf72-466e-b780-eecada87c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e79952f3-cdf9-465a-86f5-17818dc1a21a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6b4db5f7-9e3b-456b-ab29-20209e77bc6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a91e7f27-4f86-4dc5-b77c-9a9ed9b2d61c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_6dcbb219-b6bd-4861-9162-652b899dc080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2a9265ec-0c2d-4f31-9eaf-7d31f601c7b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5850416b-5268-46c3-970b-18e7e145562e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d8276263-937d-404b-888a-9dfa8d1471b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4d411dff-54c7-4585-9301-d3241ffd63f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_395fdd7c-d463-4675-9795-d06cc0e2ea3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_49bf2e28-2c6c-4abb-9852-7ee433b3f111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1ada34b7-cc0e-46bf-8d53-623a26d0b905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:MayNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_282e8527-291e-424c-a603-4afa6b760575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_737274e3-fa8d-4aae-8a95-66ebe396d35c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a397402b-f716-41a7-8341-71ec3bbe5ef6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_015c050e-1f5a-4b49-8849-0dccea408c5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cbf3520d-cad8-496b-89f3-d0074446ef40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_59741c86-fa48-4f2f-87fc-b83b830a5544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_82824a3c-b613-4fb2-b25d-e5297dacef2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_c1e0e40d-fa42-4566-b632-bece748465d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_979df7a7-b6e0-451a-8eb9-bb3bdb83d3f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2b058460-a53f-45fa-81f1-ff866fb0af2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_31bede1d-9fe1-4f2f-8a68-d59a76c82fcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="C_e28222d2-bdab-40c4-91ad-c91e8c333540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ac754ff9-5df8-4082-9e89-559e3f5b5c9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7549669b-7c92-4c29-aee8-52f0528f3361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7727e7fe-60e9-46a9-8c20-52528f28b578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:MarlinspikeGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7ea42364-2fcb-4648-b148-742ec5e08d38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_65c3b16a-86a3-451d-ae60-e9601eb9ca53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d3f0e0a2-5f92-4f5f-9fe8-1fa2972d3c03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a6a447c5-4988-4641-a3e9-2f97b674e8b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cf1f9868-ad02-4973-bb86-f39dc0bbe2a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ff1ce905-3591-490c-a13f-305cbc1d8d2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_fa19c920-f2f7-4e75-821f-cf2210cc5a5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_33e57430-f87d-45d8-a826-73fae3f00112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ResearchConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8b5211fb-3823-4218-9a5e-36b1f275768a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_bf5d2e5b-41f1-419b-8853-434297531657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_491eb317-efb1-40ae-85f1-8afd062cc647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_73cc3eeb-6a6b-45c1-a16b-d0b91237aebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JulyNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1d9cb435-50cf-426c-b2e6-da460c39afdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_31e5c9e1-0fcc-4298-b3fa-26eb6e19e3b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9a94ee29-3474-461c-b2a3-c3b16772709a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4b6ab41b-f147-4c0f-b46b-e581e1586d79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_149ca0e1-6a9d-4838-96bf-fc89fbd1fbb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dsgn:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dsgn:CoFounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_896a557d-321b-4604-a274-4b73f428a91c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f35bda8e-4477-4e3d-91b7-eb0cd103d909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_769dba12-3ef2-4dad-a5b3-89361f92718a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8c915edc-7f15-44b7-bcb1-f158561e7fcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fb933540-a365-4b43-a477-40ec4114592f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_94255f9d-0677-46bb-9aba-5bed62bc746c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="C_57ffc353-e260-4275-bc08-e6bb76dc5b0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1f4f9bba-1873-40dd-acf5-dfd66ac8e7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dsgn:SharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_34051789-f2bd-40c0-b83a-1a91b3aabe17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2440876e-d785-4ff7-be3a-fa21b9bbf1e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ceb7f97d-7cb8-4a60-a79b-931a4f103fde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c609f5a0-ad87-42d1-88bd-8814d48c2007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_6afdf50d-8689-4ede-8f30-41e7b459c71a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:CrossingHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_36df1b56-bdb0-4695-b7cf-d0ea73632dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a37bffe0-f723-4a15-9b38-db5ae6d1a171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:NovemberNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_77d31faf-435b-4663-a7b9-4b732dae06e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4402b367-1f4a-4644-931e-244097e7a86c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_f1a7a6a9-b9f1-40a5-a2c9-a03c5b0e9341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dsgn:SharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_196bb1dc-ff73-4b87-b41c-495f6b29e794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dsgn:InvestigationNewDrugMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a1ae00c5-b57c-4e18-abdc-e3e4662306cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_faf87937-2b9d-462a-a2e3-6532a2a5832f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_499263cc-6cef-4ede-8c9f-5058ea40a149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_b5eca583-41b5-4449-b248-84c59b8416b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dsgn:TwoThousandTwentyOneEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_3ededf68-d7fc-475f-9e79-3e3146f1d833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:WithinOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9b012ef3-2aff-4122-9520-8407c5275290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dsgn:InitialClosingOfSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dsgn:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_21b23571-1ef3-47c0-814f-61628e84218b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_820b96e4-02c7-43b6-87e0-576d13934c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">dsgn:OneYearToTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7057dd8f-e87d-4239-a296-2ff88e03ec38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_255b9a96-4942-438d-9182-67188791643f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dsgn:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">dsgn:JanuaryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_a798c222-0494-49e9-979f-72203726b20d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001807120</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_Security">
        <measure>dsgn:Security</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_8f21a733-a63e-41e6-935a-a3dd426abdc4"
      decimals="6"
      id="F_c8f40f25-3060-43a3-8e57-1cdd36fe0c04"
      unitRef="U_pure">0.613497</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_0d26d6c4-19b8-4338-bd33-8240f330367d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      id="F_3766fda0-030c-4a24-8af2-30d601782126"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_9410f438-b0a4-468d-8e34-c1e06402216c">http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</us-gaap:TypeOfRevenueExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_200bc075-dc2d-4694-a6ce-4841f63dccb6">0001807120</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      id="F_c34c0616-00d0-4274-a21f-927f363c9ade">http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_fa19c920-f2f7-4e75-821f-cf2210cc5a5b"
      id="F_d91553c5-6eee-4258-bcc3-c4d3014546f4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      id="F_d29888be-2dc0-4c7f-9efc-f49c43b4b4f3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_7384e25e-21d9-4449-bdf3-93d8433577e8">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      id="F_8eb9aa0e-0c36-40ee-b23e-663ded1df873">http://fasb.org/us-gaap/2021-01-31#ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</us-gaap:TypeOfRevenueExtensibleList>
    <dei:AmendmentFlag
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_23401328-9149-4698-9c63-cfb6de561a71">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_84123f80-6eb9-46ca-88c3-eb4e5e08b555">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_07e7aac0-f1df-4ae7-bac8-2c9d59e4f8c6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_7055526d-4cd9-48d5-82f9-9ec54f36e599">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_79dc1658-1f10-49c0-82d8-8b2783d429af">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_37404337-7c7e-4677-a8de-6e07e2a5c23a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_f122a4be-938f-4c7d-af73-89f0134103c5">001-40288</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2e034bf6-e2ae-46ad-a28e-327c58f9a8cd">Design Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_73121dce-c825-4730-a31c-7cb4446e0fd1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_aa0f6ad1-c135-461e-9f78-e0b3e0a29350">82-3929248</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_234d7733-5348-4ab6-b458-e7ea3f319d18">6005 Hidden Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_cba85c56-3325-4230-9fad-b2f081750596">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_c42134ee-687d-4e38-a82f-e8f4fcf398aa">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_1cada2b5-4fed-4841-8584-8f499d4566b1">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_9b64a693-23c9-4243-ad36-54f0368380ed">92011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_5e0614da-af07-431e-9e0c-35543fab2ab5">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_c1373472-6915-4214-a036-d309003c3564">293-4900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_b37d8dd8-fefc-4ae8-858e-cfc91714d6fa">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_92245922-8faa-4d0c-a0e7-a527bef3bed8">DSGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_a8f1601a-711b-4b88-aec4-4f42a6c2c97b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_0185a6de-3bbe-44f3-b712-5ca72048e13b">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2cf7f6d0-6687-4586-9e83-b3000cf42a3e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_9ff59133-b93d-4c63-a165-e49a83c93ed8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2ee4d47b-105a-4715-8fc2-95f33c81188d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_84c1b9fe-6251-4e83-926c-4d474c5355ab">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_377102cb-b7a9-43e7-bb87-fe905cbeb8fe">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_c93f0626-8869-48d6-a819-8a2ab1d47a30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_fc3d27cb-8ea9-419e-b7da-701fc51059e0">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_3ca25d1c-b179-4046-a28d-286490937b30">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_17f68aac-d994-4c1b-b7ce-07ce3a93c4cf">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_ff1ce905-3591-490c-a13f-305cbc1d8d2d"
      decimals="0"
      id="F_f816e037-1a75-4297-af63-14b2f6a76e05"
      unitRef="U_USD">480984316</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_94255f9d-0677-46bb-9aba-5bed62bc746c"
      decimals="INF"
      id="F_98caa29a-0f8d-472b-a577-bfa229478ce6"
      unitRef="U_shares">55700156</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_91ee4b24-636b-4c6c-a69e-fbc31f7b5639">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Portions of the registrant's definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission no later than 120 days after the registrant's fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_88a963cc-29b2-4cff-b102-b040b651e481">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_8e7ec4c4-9c23-4b1c-929f-9fad29ddc702">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_52ef1f5c-92c0-4fad-853e-bba5e10ebb87">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_dd506e14-d1e1-4c52-ae0e-e358a9dbd223"
      unitRef="U_USD">298569000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_70e3283a-d333-4ddd-9097-8781d4e5cb9e"
      unitRef="U_USD">2379000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_9f72bc35-6e02-47f9-80d5-f8fb3de1a796"
      unitRef="U_USD">85495000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_7326d673-a708-4d26-a707-52be60f51c4f"
      unitRef="U_USD">33712000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_650d658d-fac5-4c30-bdc4-64b81412e1c1"
      unitRef="U_USD">1371000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_a36c8e5c-689a-467b-a14a-2bd37094370d"
      unitRef="U_USD">142000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_3bb01878-8de9-4425-b8a4-4c5b992cd8f5"
      unitRef="U_USD">385435000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_163d3deb-4a56-4a7b-84c5-a74b690e78f4"
      unitRef="U_USD">36233000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_937ea65f-927a-47fd-a58c-52bb4230d467"
      unitRef="U_USD">1508000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_c6d6e701-80a7-4255-b155-5064f7ae1f13"
      unitRef="U_USD">71000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_4b5efa71-8ff6-4d12-a3cf-83526fd8d084"
      unitRef="U_USD">3614000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredCosts
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_07a8355a-6eee-4e4f-a1bb-4dda0f0d1126"
      unitRef="U_USD">212000</us-gaap:DeferredCosts>
    <us-gaap:Assets
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_4c46de8f-d4b8-4e29-b0de-c49d384cd014"
      unitRef="U_USD">390557000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_895ec1ec-ab8c-4b15-923b-4e8f39b082a6"
      unitRef="U_USD">36516000</us-gaap:Assets>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_73c83680-7a97-4c20-9fea-cf66445a0c24"
      unitRef="U_USD">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_acb1428b-3bac-4cbc-a6f9-1caf267a799a"
      unitRef="U_USD">20000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_bf8f5aa3-e711-4b69-8509-6d17ae840078"
      unitRef="U_USD">1620000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_cae552e1-c9d1-4d44-a321-0d63d15edee3"
      unitRef="U_USD">1399000</us-gaap:AccountsPayableCurrent>
    <dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_53106d7b-a5a2-4c15-b9e5-158e4676bc52"
      unitRef="U_USD">504000</dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent>
    <dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_53761004-209a-49b4-ba2c-4105739fed6b"
      unitRef="U_USD">0</dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_355875ae-b246-48a6-b988-32f25b38cc3e"
      unitRef="U_USD">3663000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_42b27abf-94c0-45f1-8e4a-ce81f4401f0f"
      unitRef="U_USD">931000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_78b1b56f-f7b3-4c9c-a53c-2fd76b29f85b"
      unitRef="U_USD">5283000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_b8985ec5-17a1-4e54-99c6-319785c5ae31"
      unitRef="U_USD">2330000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_1f378686-62e5-4649-8df5-7089e70d8fc9"
      unitRef="U_USD">3144000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_e6fb45c2-2971-465f-b576-aa79371edd33"
      unitRef="U_USD">145000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_a65a1b4b-5f50-48f3-8eee-93ad7fbf0b52"
      unitRef="U_USD">8427000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_382135a5-44e5-412c-a0ed-c98f29981768"
      unitRef="U_USD">2475000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_a660b466-a3fb-4fa6-865e-f347cd81a449"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_c823fd96-96c6-4e34-996a-1407ca8820a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_a7ddc3f2-0e72-4d22-a91b-91f963b7ace4"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_d85f89b0-63df-480c-8c55-3ec590253d5e"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_9465f9a8-35c4-46e0-a54e-be052a15acd2"
      unitRef="U_shares">22012499</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_a8fe7971-9811-4471-9111-932a33548f7b"
      unitRef="U_shares">22012499</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_74acaa12-1af6-4525-9955-0296dc218f6a"
      unitRef="U_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_bd805609-00b6-4e26-b6e0-2183bc30542a"
      unitRef="U_USD">45625000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_756115ff-93e6-4836-8f9d-1dda34bfa2d4"
      unitRef="U_USD">45356000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_8019d51d-ebb6-41d9-8d18-a48541164cc1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_ad6d109b-3e29-41b4-9299-eb0896eb63a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_d843203b-4645-40f6-870f-d8459e0db4bc"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_323e90b4-9dd2-4dba-b4fa-945edc958a26"
      unitRef="U_shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_3bd274af-d892-40ff-9bf8-cf8d8d46646a"
      unitRef="U_shares">55681752</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_b8cf8c16-bddc-4643-9673-5b4d57fd4f53"
      unitRef="U_shares">16604774</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_05cddede-6215-4841-9e3c-248c223f21c3"
      unitRef="U_shares">55441926</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_849b8b3c-d8ac-4666-9bdf-95a19a482273"
      unitRef="U_shares">15957821</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_dd9f2113-ff46-4c8e-9b19-904eecce9dc8"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_9bdf58be-44e0-4dba-b0fa-fb650d00e141"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_f6bde8f4-fcb3-4e3c-b334-257e6ec77887"
      unitRef="U_USD">429824000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_2876d85a-a4d6-495c-880d-da1ed541e9ef"
      unitRef="U_USD">451000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_2b170ad9-2ff2-41b1-8f4a-28320a02b908"
      unitRef="U_USD">-47456000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_6299a91e-bd41-435a-a2ae-4ec08d4ef2cf"
      unitRef="U_USD">-11923000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_d7c81a83-6270-40e2-a54b-a4e70b04ce83"
      unitRef="U_USD">-244000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_9a2b1f64-0d86-417b-b237-48c3881ce2f0"
      unitRef="U_USD">156000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_8c5b3626-55ab-40cb-8cbb-8e35b90e8f6f"
      unitRef="U_USD">382130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_04d302c5-b47f-4433-8f30-b8fc537988a5"
      unitRef="U_USD">-11315000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_ed42b555-4a1d-4d2f-a2d6-a5eef00f3456"
      unitRef="U_USD">390557000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_3010bad2-c119-4fad-9b09-b4adc55c1033"
      unitRef="U_USD">36516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_aa1d5ad1-aeab-4fb2-baa3-4ee2184e7822"
      unitRef="U_USD">226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_e9a28282-74b5-4439-b3aa-b34b88fb6ae8"
      unitRef="U_USD">405000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_ec4ba9e2-86cb-4c17-b989-5aa917ff852d"
      unitRef="U_USD">53000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_00f9f291-7c4b-406d-866c-0aacc24a1d0f"
      unitRef="U_USD">24778000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_eadb7a30-c145-4d06-905b-ab8949047d7b"
      unitRef="U_USD">6060000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_e68b9735-7f32-4053-b112-c55fb31edd1e"
      unitRef="U_USD">328000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_f7f0382b-99b7-459f-85c3-c4f4d290226c"
      unitRef="U_USD">292000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_95a2551c-71d3-47a1-be82-b470508b2895"
      unitRef="U_USD">11053000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_80792fc4-95a0-43be-b2e8-df45afc1a72f"
      unitRef="U_USD">2496000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_ca0ee62a-f825-469a-921c-c84c85b54633"
      unitRef="U_USD">35831000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_750576df-5f7e-4846-b9bd-770e9384ffbd"
      unitRef="U_USD">8556000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_c0bc3152-44f8-49e8-8dd4-02cf33496de3"
      unitRef="U_USD">-35831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_55268e8e-a903-4a57-942f-9c0cbcacc20f"
      unitRef="U_USD">-8330000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_4dc19f75-154e-4e38-bf19-c626fe73cb49"
      unitRef="U_USD">0</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_3134e1c2-8e8c-4279-9810-b1610c7df4a4"
      unitRef="U_USD">30000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_378cf409-4d8f-4830-907a-abff848d0bea"
      unitRef="U_USD">298000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_81e3e53a-a644-4efb-a3b2-63a5c6cc1490"
      unitRef="U_USD">50000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_5c48a93f-9712-4d9c-af90-a7c2b26e4ade"
      unitRef="U_USD">-35533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_6e85c061-c60b-4af9-9503-13185ff06450"
      unitRef="U_USD">-8280000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="2"
      id="F_69f65237-8a58-4804-b2b8-a74d7937411e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.77</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="2"
      id="F_1628a7c3-afeb-418b-a66b-004ce63b87b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="0"
      id="F_d3662ad2-a4a6-42e3-a04c-e92dd1f1e28c"
      unitRef="U_shares">45936235</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="0"
      id="F_18fe71e7-89b4-4a99-886c-8f8d419fc11c"
      unitRef="U_shares">15796674</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_0c5baf8e-2319-43f8-83a5-16dc3b7af607"
      unitRef="U_USD">-35533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_c64358bb-58ea-47dd-88ba-63d3abd56f5a"
      unitRef="U_USD">-8280000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_9f05c1c9-a4cc-46df-b2f1-3663847166b6"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_3a35050f-4817-419a-8275-532a8e459a80"
      unitRef="U_USD">156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_e916e824-18b8-4470-a75e-a73e79eade82"
      unitRef="U_USD">-35933000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_044d0558-793f-4997-bcac-d617f27ddbaa"
      unitRef="U_USD">-8124000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c"
      decimals="INF"
      id="F_810f7e2f-e7c1-4a70-82e7-e58a3979747c"
      unitRef="U_shares">22012499</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c"
      decimals="-3"
      id="F_3bfb8cda-0f8f-47e6-8606-34fa9e593c5e"
      unitRef="U_USD">45356000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743"
      decimals="INF"
      id="F_9c3c2d99-f92a-4eef-b98b-9173f0268fe4"
      unitRef="U_shares">15957821</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743"
      decimals="-3"
      id="F_b94bf31a-4b3b-4bdd-be5e-df5c523a55da"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5be4210b-787b-4a2c-b72e-d5904d02b928"
      decimals="-3"
      id="F_0cd1004d-6de4-45d9-8fdd-d7176e4d6e9b"
      unitRef="U_USD">451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_49bf2e28-2c6c-4abb-9852-7ee433b3f111"
      decimals="-3"
      id="F_d9240ff5-fecc-46f1-8915-0148c0a6510e"
      unitRef="U_USD">156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c09976ce-b915-44ea-8211-24da15127f68"
      decimals="-3"
      id="F_1b092964-8b18-4e04-a92f-f59259b879ee"
      unitRef="U_USD">-11923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_08b7bd59-121c-409d-9ba7-03a2e68cc78a"
      unitRef="U_USD">-11315000</us-gaap:StockholdersEquity>
    <dsgn:PreferredStockIssuanceCost
      contextRef="C_282e8527-291e-424c-a603-4afa6b760575"
      decimals="-3"
      id="F_0fdb1d39-043c-4f09-82d3-5068feaea7df"
      unitRef="U_USD">288000</dsgn:PreferredStockIssuanceCost>
    <dsgn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28"
      decimals="INF"
      id="F_2032c2a0-fb48-4ae0-886f-454c649e860f"
      unitRef="U_shares">19083979</dsgn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28"
      decimals="-3"
      id="F_b77e6ca8-dc9f-413e-a2c2-68187ef98f33"
      unitRef="U_USD">124712000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockShares
      contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28"
      decimals="INF"
      id="F_113a91c1-96cf-4de3-b55b-d52fa7b5f149"
      unitRef="U_shares">-41096478</dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockShares>
    <dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockValue
      contextRef="C_ab2ff913-8fd1-4d0c-b7c0-d3e187e02c28"
      decimals="-3"
      id="F_36620c41-8390-48ab-9d20-76301587cfac"
      unitRef="U_USD">-170068000</dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf"
      decimals="INF"
      id="F_b87f696e-6787-461d-bad8-dc8681c7f874"
      unitRef="U_shares">25212548</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf"
      decimals="-3"
      id="F_b1df743d-17dc-406c-946a-4f258211dc44"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267"
      decimals="-3"
      id="F_e0865104-de8d-44cb-a661-99949bc703d8"
      unitRef="U_USD">170064000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_0d1fe862-db56-4f0e-b8bb-d569789925c8"
      unitRef="U_USD">170068000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_739e698e-899f-4485-a5c7-f66bb6dba318"
      decimals="-3"
      id="F_b5eadc46-5eac-4a55-ae38-b44fcb863d80"
      unitRef="U_USD">21728000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf"
      decimals="INF"
      id="F_de63fc9c-390d-4717-8cdb-efea710d5c11"
      unitRef="U_shares">13800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf"
      decimals="-3"
      id="F_92d130a3-1184-44fe-8dde-dacf58fcd8d9"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267"
      decimals="-3"
      id="F_1a2dfa95-5286-4e26-8ae4-34ff682d8254"
      unitRef="U_USD">254270000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_543f8085-7866-494e-b87e-aa0bfc4fc7ed"
      unitRef="U_USD">254271000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <dsgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
      contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf"
      decimals="INF"
      id="F_a64ec175-7846-40fd-9827-b460f96844c9"
      unitRef="U_shares">460101</dsgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions>
    <dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
      contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267"
      decimals="-3"
      id="F_3e250d3f-66f9-4b5b-a50d-2d27945c825e"
      unitRef="U_USD">156000</dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions>
    <dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_eec41015-ce54-4134-a17d-d6ee91dc2f67"
      unitRef="U_USD">156000</dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_4341ac9d-5479-44c1-8530-8d42af2897bf"
      decimals="INF"
      id="F_457a6f89-cd75-4b99-a6bd-84cd3ae058fb"
      unitRef="U_shares">11456</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267"
      decimals="-3"
      id="F_46057354-7820-42ea-91c3-3febb0dfda24"
      unitRef="U_USD">194000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_f9956b55-e8e5-497b-904e-2282450fc06f"
      unitRef="U_USD">194000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d821d489-20c7-4f0d-9f3e-dd434ad19267"
      decimals="-3"
      id="F_620046e2-f8f3-4163-8ac7-c3a072ca3344"
      unitRef="U_USD">4689000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_e321593f-0a99-46e9-b395-e02d7255314b"
      unitRef="U_USD">4689000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a1ae00c5-b57c-4e18-abdc-e3e4662306cd"
      decimals="-3"
      id="F_4db4178d-d600-4735-ba1b-75f1cb8793ff"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_7e27decf-687c-467b-872d-3f699ca5fbc4"
      unitRef="U_USD">-400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_12ca6ede-1a4e-486f-8641-bc776ecea308"
      decimals="-3"
      id="F_8d2da285-9726-4a9e-94bf-954958b9aa2f"
      unitRef="U_USD">-35533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_5e9a1a3a-4616-4233-b379-a28e1c2b8972"
      unitRef="U_USD">-35533000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_47968354-2359-475e-914a-8809063a760d"
      decimals="INF"
      id="F_95b68278-7982-47fa-926c-e2b9b203e74b"
      unitRef="U_shares">55441926</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_47968354-2359-475e-914a-8809063a760d"
      decimals="-3"
      id="F_ab628b99-ff01-436e-95f8-c4cc95294ee1"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a15b425b-80dd-485a-b5d2-c580a8a02edd"
      decimals="-3"
      id="F_260b6b09-cf44-413a-ab2a-4ee0ca464fca"
      unitRef="U_USD">429824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d3f0e0a2-5f92-4f5f-9fe8-1fa2972d3c03"
      decimals="-3"
      id="F_b1c59ca5-0791-457a-a0bd-475b9ba203e9"
      unitRef="U_USD">-244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3a36c38a-b117-4fef-bcd2-79b07818ea4b"
      decimals="-3"
      id="F_f7aa80c5-00b4-4283-af46-4c9d6c4b3784"
      unitRef="U_USD">-47456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_862e347b-1bc7-49f9-bdf5-349470377bba"
      unitRef="U_USD">382130000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_e5f8e035-e6a8-4686-b8f6-c1728d5e5e54"
      decimals="INF"
      id="F_fc93e652-b898-40c2-a2d9-a26febe8ffd5"
      unitRef="U_shares">15640133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e5f8e035-e6a8-4686-b8f6-c1728d5e5e54"
      decimals="-3"
      id="F_f3c76477-8397-4e49-bbc9-cc31e2518330"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d82638c-fea7-4745-93a8-e904a42ccc5f"
      decimals="-3"
      id="F_ddf216e3-1b69-4eb1-a230-8d75d893c29b"
      unitRef="U_USD">-3643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_becd129a-dfa1-4804-9129-b0961e120502"
      decimals="-3"
      id="F_ac3a631c-ada6-489b-ac3c-7b84d115c8a1"
      unitRef="U_USD">-3642000</us-gaap:StockholdersEquity>
    <dsgn:PreferredStockIssuanceCost
      contextRef="C_a6a447c5-4988-4641-a3e9-2f97b674e8b8"
      decimals="-3"
      id="F_6baab98a-10e8-4638-88d6-253359d42202"
      unitRef="U_USD">270000</dsgn:PreferredStockIssuanceCost>
    <dsgn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36"
      decimals="INF"
      id="F_48c4f985-20c0-4302-aff5-4048003470e4"
      unitRef="U_shares">21710814</dsgn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36"
      decimals="-3"
      id="F_19387536-f95d-49e9-aca0-f8cb44b29366"
      unitRef="U_USD">44731000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <dsgn:TemporaryEquityConversionOfConvertibleDebtAndInterestShares
      contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36"
      decimals="INF"
      id="F_cd95612e-ec0e-4468-b260-e52c270b73e6"
      unitRef="U_shares">301685</dsgn:TemporaryEquityConversionOfConvertibleDebtAndInterestShares>
    <dsgn:TemporaryEquityConversionOfConvertibleDebtAndInterest
      contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36"
      decimals="-3"
      id="F_43583120-7640-4a8b-97d0-fc36e4c21611"
      unitRef="U_USD">500000</dsgn:TemporaryEquityConversionOfConvertibleDebtAndInterest>
    <dsgn:TemporaryEquitySettlementOfBifurcatedConversion
      contextRef="C_6f685d75-d65f-4c75-af30-d4d1dc49db36"
      decimals="-3"
      id="F_9f5bd65c-c3e2-4427-843d-5b1cc675a21a"
      unitRef="U_USD">125000</dsgn:TemporaryEquitySettlementOfBifurcatedConversion>
    <dsgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
      contextRef="C_d8276263-937d-404b-888a-9dfa8d1471b6"
      decimals="INF"
      id="F_c11f9e36-4ceb-4dd1-afbe-1dd764b2ebf4"
      unitRef="U_shares">317688</dsgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions>
    <dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
      contextRef="C_fee07a1a-85a2-4821-989e-e63acca8aebf"
      decimals="-3"
      id="F_c5ec39cb-343d-4743-a5ad-ab41fe7713a0"
      unitRef="U_USD">1000</dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions>
    <dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_cd7667b5-9cc8-4509-93c4-f029baa42dee"
      unitRef="U_USD">1000</dsgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fee07a1a-85a2-4821-989e-e63acca8aebf"
      decimals="-3"
      id="F_1901503b-003f-4e95-92e1-576ae878ab17"
      unitRef="U_USD">450000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_dd17e155-1cda-4c8c-bb5f-a3d768861760"
      unitRef="U_USD">450000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e20f6e02-a6f1-4121-b27f-17a4335d6c9a"
      decimals="-3"
      id="F_06db0697-a07f-4bef-a632-0973ee0d94cc"
      unitRef="U_USD">156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_42ade89b-0ecb-4d08-a187-6e7c874d21b4"
      unitRef="U_USD">156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_c1e0e40d-fa42-4566-b632-bece748465d2"
      decimals="-3"
      id="F_5f896cda-f70d-400c-b03c-b82f8498bdb2"
      unitRef="U_USD">-8280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_954efa5c-00c3-4c4b-ac96-87f08688f7e5"
      unitRef="U_USD">-8280000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c"
      decimals="INF"
      id="F_4103548e-1ec0-4a5e-bd3d-b84231b8af89"
      unitRef="U_shares">22012499</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_737274e3-fa8d-4aae-8a95-66ebe396d35c"
      decimals="-3"
      id="F_95644428-a3df-4c53-aef9-b14c19983728"
      unitRef="U_USD">45356000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743"
      decimals="INF"
      id="F_5202d1e1-e23c-4f40-bf98-0304b360dc88"
      unitRef="U_shares">15957821</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1d8e8d81-9d9c-4cff-afb2-daa2763cd743"
      decimals="-3"
      id="F_d158691e-759c-4a42-8ca9-109c9e7d5a48"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5be4210b-787b-4a2c-b72e-d5904d02b928"
      decimals="-3"
      id="F_6a7be20a-dd99-45f4-b60f-0b88b003996f"
      unitRef="U_USD">451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_49bf2e28-2c6c-4abb-9852-7ee433b3f111"
      decimals="-3"
      id="F_d01df858-d79c-4e7c-9ed7-26a4b41fc2d2"
      unitRef="U_USD">156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c09976ce-b915-44ea-8211-24da15127f68"
      decimals="-3"
      id="F_29f993b6-542a-450f-9a9f-7fd7fa7e8bdf"
      unitRef="U_USD">-11923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_771d209f-e18c-4c13-a78c-c19e39a47b03"
      unitRef="U_USD">-11315000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_9b76b2b0-9370-4fd4-a2c1-84b4b401b505"
      unitRef="U_USD">-35533000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_7097deaf-6cc4-4f77-8f68-f1de3f045405"
      unitRef="U_USD">-8280000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_b0795fa8-42c7-48d0-b5b8-a25565e1c502"
      unitRef="U_USD">129000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_eec7c464-ba3e-48f4-b27e-87e808e34c09"
      unitRef="U_USD">5000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_f04a2052-98bf-43ba-af16-235e330c31a3"
      unitRef="U_USD">4689000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_7c24a907-c018-47f1-bf0e-7080c204bacf"
      unitRef="U_USD">450000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_ddec45ff-45e9-49f8-8041-2296863c5d6e"
      unitRef="U_USD">77000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_5b4390e1-4976-42ea-984a-6792a253a873"
      unitRef="U_USD">71000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:PaidInKindInterest
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_0e089d3c-8ac5-4c74-8f2e-18b61aeb1f35"
      unitRef="U_USD">12000</us-gaap:PaidInKindInterest>
    <dsgn:PaidInKindInterestRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_3305949b-4e7a-4ab9-9c2a-a193ee30eb8f"
      unitRef="U_USD">26000</dsgn:PaidInKindInterestRelatedParty>
    <dsgn:NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_9bfacac9-f6a1-4339-80b9-33fcdaf968fb"
      unitRef="U_USD">19000</dsgn:NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_41175b99-0a1e-4168-8f02-a2cc0db79aad"
      unitRef="U_USD">1017000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_5f81e8ee-9d6c-4ca2-9148-2a839751a7d2"
      unitRef="U_USD">341000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_53cdf55c-67c1-4ebf-84ee-951790afb626"
      unitRef="U_USD">-201000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_7975fbf3-1ee6-4a91-a719-0e04ebaf94a4"
      unitRef="U_USD">2418000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_bb8bf2be-3b7e-4202-a6b9-5ab708bc18c6"
      unitRef="U_USD">1430000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <dsgn:IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_b1be6a4b-a609-4109-a687-0e7d62a5846c"
      unitRef="U_USD">-5000</dsgn:IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties>
    <dsgn:IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_2a58d6ff-dba4-4187-82af-dffce409e367"
      unitRef="U_USD">-1843000</dsgn:IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_98cfde59-d0cb-4068-b48a-ac7fce2d1a3a"
      unitRef="U_USD">144000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_31b07224-9ac5-443e-a488-3a9c052a1d65"
      unitRef="U_USD">-29377000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_4a810200-8620-4268-87ed-ea71480790f4"
      unitRef="U_USD">-8669000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_1db64dfc-df84-4e57-b605-9c41347ac775"
      unitRef="U_USD">86261000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_7c40f32b-7a0c-4149-be40-b89c8b2b0ba3"
      unitRef="U_USD">55589000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_3de16cb6-e1f2-4236-bc6d-63b2af1b9f86"
      unitRef="U_USD">34155000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_e65e8ce4-bcf4-4f9a-bc79-155f2c8b757e"
      unitRef="U_USD">22104000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_0ab8c9ca-7ecc-48f3-a87a-9cf0b2390ccf"
      unitRef="U_USD">1538000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_0dfe310b-4d19-490a-b48f-a56fc2077472"
      unitRef="U_USD">76000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_b9b8bcaf-f7e7-42d6-8d19-7a4a30eaebdd"
      unitRef="U_USD">-53644000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_1715b5ea-d9b2-4f2c-882e-bd42d28ff5c0"
      unitRef="U_USD">-33561000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_44e03129-2ec6-46dd-86c3-021064aee87e"
      unitRef="U_USD">254271000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_fea1584c-d5ff-4613-9ec8-53c56210e1e4"
      unitRef="U_USD">124712000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_0f91f9a0-5a5c-4f4e-9a61-e3f1ae813f13"
      unitRef="U_USD">44731000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <dsgn:IssueOfCommonStockThroughEmployeeStockPurchasePlan
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_edaacb41-a222-4e80-8089-9b5378ae9272"
      unitRef="U_USD">194000</dsgn:IssueOfCommonStockThroughEmployeeStockPurchasePlan>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_c97894b3-aa02-47b4-b7c9-e7b497e64ec9"
      unitRef="U_USD">34000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_4caee059-ce51-4244-88b2-a21eadd4fd35"
      unitRef="U_USD">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <dsgn:ProceedsFromNotesPayableRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_890d5cba-c35c-4e43-9d09-c8fbb59015ce"
      unitRef="U_USD">200000</dsgn:ProceedsFromNotesPayableRelatedParty>
    <dsgn:RepaymentsOfNotesPayableRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_1cc4a61a-c739-45d0-b36a-c115c40a66bf"
      unitRef="U_USD">400000</dsgn:RepaymentsOfNotesPayableRelatedParty>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_21300d07-f51b-49cd-9993-c5d5df6de32e"
      unitRef="U_USD">379211000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_83f84bd2-64fb-48b1-a2dc-ac18fe9bbded"
      unitRef="U_USD">44532000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_f8a36d11-7595-40b6-a896-d872fe5dae22"
      unitRef="U_USD">296190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_db39c1fa-4874-4c6d-a891-aa4e7042f9ad"
      unitRef="U_USD">2302000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_2e15327a-23ca-45b3-92f9-e5e8d4dfee74"
      unitRef="U_USD">2379000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_becd129a-dfa1-4804-9129-b0961e120502"
      decimals="-3"
      id="F_3961cc14-4427-477c-81d2-124e6c11e3eb"
      unitRef="U_USD">77000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_38af2967-172d-44c1-a7f1-6c18eca8a9a7"
      unitRef="U_USD">298569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_b8843dd3-8274-4871-8551-4651444e8f9a"
      unitRef="U_USD">2379000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <dsgn:InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_900b1b29-38ab-4ab5-9a68-aa1108c947dd"
      unitRef="U_USD">3786000</dsgn:InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_df61290b-6d1e-4c33-9619-80d75d17eb21"
      unitRef="U_USD">29000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_3d9f7594-516c-4569-bb75-9e48f4ad5b10"
      unitRef="U_USD">271000</us-gaap:ConversionOfStockAmountConverted1>
    <dsgn:ConversionOfStockAmountConvertedRelatedParty
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_4a425a15-4ee9-4988-b283-7eb910a6b4ab"
      unitRef="U_USD">354000</dsgn:ConversionOfStockAmountConvertedRelatedParty>
    <us-gaap:InterestPaidNet
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_0a6b8f83-25e3-4bfc-bfa0-6d01b3a20e55"
      unitRef="U_USD">24000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_0b943836-bd61-4bcb-ac24-dc2979cf319d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. Organization and Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Design Therapeutics, Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a preclinical-stage biopharmaceutical company pioneering GeneTAC&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;TM&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; molecules, which are a novel class of small-molecule gene targeted chimera therapeutics that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The Company&#x2019;s lead product candidate is in Friedreich ataxia (&#x201c;FA&#x201d;), its second GeneTAC&#x99; program is in myotonic dystrophy type-1 (&#x201c;DM1&#x201d;), and it is also advancing its GeneTAC&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;TM&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; portfolio to address other serious nucleotide repeat-driven monogenic diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Splits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2020, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-for-1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1-for-1.63&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Company completed its IPO selling &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,800,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares its common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.00&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. Proceeds from the Company&#x2019;s IPO, net of underwriting discounts and commissions and other offering costs, were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In connection with the IPO, all &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41,096,478&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of convertible preferred stock outstanding at the time of the IPO converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,212,548&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred net operating losses since inception &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021. The Company had cash, cash equivalents and investment securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;384.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021, and has not generated positive cash flows from operations.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management expects&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to incur net losses for the foreseeable future. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the preclinical manufacturing, and clinical development activities as well as the commercialization of the Company&#x2019;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s currently available cash and cash equivalents as of December 31, 2021 are sufficient to meet its anticipated cash requirements for more than the 12 months following the date the financial statements are issued&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_beda5436-af98-4afb-ba8a-fc82e28eb71e">5-for-1</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_042f9541-36bc-42b0-97cd-cb54c6a99af9"
      decimals="0"
      id="F_746aeccf-2a0f-422e-b7a0-df4f0e2faaad"
      unitRef="U_pure">5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2732d54e-a401-44e3-bead-a6e9b337741a">1-for-1.63</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40"
      decimals="INF"
      id="F_9032b882-d44c-4dfa-ab6e-6b117ec5e127"
      unitRef="U_shares">13800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab"
      decimals="INF"
      id="F_27e42bd2-e168-41ee-ab9e-ec5e86ba6269"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40"
      decimals="-5"
      id="F_a82d8770-3c57-4f58-be61-84303ebd9e44"
      unitRef="U_USD">254300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockShares
      contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40"
      decimals="INF"
      id="F_ec2e8d33-608e-4364-8a8b-f852d8ff2018"
      unitRef="U_shares">41096478</dsgn:TemporaryEquityConvertedIntoSharesOfCommonStockShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_cbf3520d-cad8-496b-89f3-d0074446ef40"
      decimals="INF"
      id="F_f2353583-5aa7-4065-b79a-8a93899654e1"
      unitRef="U_shares">25212548</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-5"
      id="F_e9048cb5-19f3-448f-a6fc-73f0093dbbc6"
      unitRef="U_USD">-47500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-5"
      id="F_3e8dab43-d056-4d5c-8e00-22dbeff118b9"
      unitRef="U_USD">384100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2bcdbed0-e1be-4d5e-a6fb-4361ce2eb52e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company&#x2019;s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The full extent to which the novel coronavirus-2019 (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company&#x2019;s cash reserves are in a readily available checking account.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investment Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company&#x2019;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d91553c5-6eee-4258-bcc3-c4d3014546f4;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognized any impairment losses for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use ("ROU") lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Short-Term Leases as of December 31, 2021 or 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;lease &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options and restricted stock issued pursuant to the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) and 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), and option features associated with the rights to purchase shares pursuant to the Company&#x2019;s 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) are valued using the Black-Scholes option pricing model on the date of grant or subscription period.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_d9330000-91f8-4f08-a74b-e009e7d8a543">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company&#x2019;s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The full extent to which the novel coronavirus-2019 (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.&lt;/span&gt;&lt;/p&gt;</dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_8910ce59-e251-4a10-9e0f-e47eeef30f26">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_bee56cb4-87d2-4335-bc0f-986bf4caaef3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_54e8b798-5629-4557-b76d-504eeb854269">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company&#x2019;s cash reserves are in a readily available checking account.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_36c0026e-022a-4d54-971d-cd0cf72046cd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investment Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company&#x2019;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_a718f8fe-5a78-4280-b521-07ee2c43eda9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d91553c5-6eee-4258-bcc3-c4d3014546f4;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognized any impairment losses for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_7549669b-7c92-4c29-aee8-52f0528f3361"
      id="F_c2e77e6c-be40-4a0c-9285-a4a70f54fae4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="INF"
      id="F_c710d499-fd5c-4fe7-bcad-8ef0ad5b13ce"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="INF"
      id="F_641dad0f-921c-4936-b5d8-c840721a477a"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_5423e391-5beb-42d9-972d-b43822be42af">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use ("ROU") lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Short-Term Leases as of December 31, 2021 or 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;lease &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <dsgn:ShortTermLeaseLiability
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_99895f2c-0e15-4328-ac56-9ac214fbed94"
      unitRef="U_USD">0</dsgn:ShortTermLeaseLiability>
    <dsgn:ShortTermLeaseLiability
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_51b6f541-83d5-43a7-9472-e23ef4e251d9"
      unitRef="U_USD">0</dsgn:ShortTermLeaseLiability>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_59f6b42e-871d-4ac4-9bd9-20f230981207">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <dsgn:PatentCostsPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_a9d5cee9-c450-4759-b85d-f0e0bf21ddce">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt;</dsgn:PatentCostsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_f8abde2e-9a10-450e-ba70-7f0eb6b55866">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options and restricted stock issued pursuant to the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) and 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), and option features associated with the rights to purchase shares pursuant to the Company&#x2019;s 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) are valued using the Black-Scholes option pricing model on the date of grant or subscription period.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_07020100-8d02-4526-9872-38fe55a2ae31">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_43f7e26d-2014-4db4-adb8-6dee4957ab17">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company&#x2019;s equity incentive plans, employee stock purchase rights under the Company&#x2019;s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.128%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.264%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,504,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,673,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,601,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares subject to repurchase&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;239,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;646,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,917,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,752,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_d1dfb1fa-a523-4676-996b-f7d20e8262f3">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.128%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.264%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,504,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,673,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,601,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares subject to repurchase&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;239,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;646,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,917,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,752,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e64fcb9b-97f6-4f5a-8c64-d72962809b07"
      decimals="0"
      id="F_d277da92-1931-462c-8817-d4dcf49da66b"
      unitRef="U_shares">13504598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b235a097-5256-4f3d-babe-7ba3bf8a8a84"
      decimals="0"
      id="F_69fbab04-5347-4b54-b731-494490e71410"
      unitRef="U_shares">2673775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_657d72a9-16e6-4deb-b551-33c0ee8f5b08"
      decimals="0"
      id="F_2fa8d656-c981-4862-b1c2-63310c225b82"
      unitRef="U_shares">1601214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1f4f9bba-1873-40dd-acf5-dfd66ac8e7ed"
      decimals="0"
      id="F_23d63db0-4888-4cc8-9bd2-0c90989897a5"
      unitRef="U_shares">239826</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f1a7a6a9-b9f1-40a5-a2c9-a03c5b0e9341"
      decimals="0"
      id="F_c0f59d5f-b2ec-4c4b-bda8-4d0dec08f380"
      unitRef="U_shares">646953</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1fd32ca6-5a40-41dd-91d1-a988442615a6"
      decimals="0"
      id="F_966eeffe-99b4-4554-b30f-54a4cfbcb951"
      unitRef="U_shares">3833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="0"
      id="F_8bd28e94-6497-4fd1-ba4c-60111765c753"
      unitRef="U_shares">2917434</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="0"
      id="F_8b5c21cd-81e5-491e-a22c-2886b1803834"
      unitRef="U_shares">15752765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_88ae6100-0630-437b-b5a0-5cf101ffb1fd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1:      Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2:      Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:-10.17%;padding-left:8.8%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3:      Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying value of the Company&#x2019;s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company&#x2019;s investment securities, which may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the Company&#x2019;s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.909%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.437%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.437%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.448%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.512%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value Measurement at End of Period Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Quoted Prices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;In Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Markets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;For&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;383,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;383,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.667%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.87%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.059454753338299%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Included in cash and cash equivalents on the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_17e097d0-b9c8-43c4-ab42-52111299462f">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the Company&#x2019;s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.909%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.437%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.437%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.448%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.509%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.512%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value Measurement at End of Period Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Quoted Prices&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;In Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Markets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;For&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;298,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;383,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;383,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:5.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.667%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.87%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:10.0pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.059454753338299%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Included in cash and cash equivalents on the accompanying balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c9a6f234-a01b-49c4-8389-6f43a1314b9a"
      decimals="-3"
      id="F_8591deac-b3bc-4899-ba20-23abcc90f02a"
      unitRef="U_USD">298114000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_7ba72a79-9de9-4033-985b-e7cd791153cb"
      decimals="-3"
      id="F_8ad86294-c9d8-47e2-b057-d94ee4aee2dd"
      unitRef="U_USD">298114000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_96982224-ada7-45f0-9919-ba9faeecebb9"
      decimals="-3"
      id="F_5e1ddfda-1523-4ea8-98c7-c676c6600d37"
      unitRef="U_USD">5771000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f03e432b-566b-43cb-b18b-e5b052b1516e"
      decimals="-3"
      id="F_41e3695b-22ce-4e2c-b4d2-d56253cd7e2c"
      unitRef="U_USD">5771000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_5088ab17-fa76-49bb-8424-af699c2d83d2"
      decimals="-3"
      id="F_5c9a158a-b64a-467c-8dbf-b10eaf32639a"
      unitRef="U_USD">79724000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9ab3d3b5-491d-45f2-a868-850168297a7c"
      decimals="-3"
      id="F_ae84182f-31a6-42fc-ac4d-2c5720bcab09"
      unitRef="U_USD">79724000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_6042de5e-ef51-4ef3-bdce-a0945a9a3be4"
      unitRef="U_USD">383609000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_7057dd8f-e87d-4239-a296-2ff88e03ec38"
      decimals="-3"
      id="F_1fd1e93f-ba55-47d7-b7bf-24bd2f3f6734"
      unitRef="U_USD">383609000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_77d31faf-435b-4663-a7b9-4b732dae06e0"
      decimals="-3"
      id="F_1986354b-3278-49ab-94d0-16530a30bd90"
      unitRef="U_USD">2100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_6dcbb219-b6bd-4861-9162-652b899dc080"
      decimals="-3"
      id="F_f0487b05-d919-4fd8-adc2-52f5aa2fe932"
      unitRef="U_USD">2100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9a94ee29-3474-461c-b2a3-c3b16772709a"
      decimals="-3"
      id="F_ece7233b-0977-4251-a254-9d192b60b015"
      unitRef="U_USD">1754000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d8bc6058-3ed3-45cd-b9ce-e674b84d8a7b"
      decimals="-3"
      id="F_62a90721-9cb9-4f02-a746-92cdc47ef6f0"
      unitRef="U_USD">1754000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_4b6ab41b-f147-4c0f-b46b-e581e1586d79"
      decimals="-3"
      id="F_63ab7eb8-eabc-4021-84db-caf36f65cde6"
      unitRef="U_USD">31958000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_0cefbf23-2388-4ecd-bce3-6b76279a6cea"
      decimals="-3"
      id="F_89aa9edd-2697-4c7e-9c5a-ef9022475456"
      unitRef="U_USD">31958000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_5aed5a97-05af-428a-838f-f67b5be71acc"
      unitRef="U_USD">35812000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d6936001-b46e-472b-a199-2074ec0ad35f"
      decimals="-3"
      id="F_710fd928-9e7e-4589-ad7d-3969fbf70056"
      unitRef="U_USD">35812000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_77a5efc2-b183-4897-9159-a9b4ab48fe17">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Investment Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company&#x2019;s investment policy, it has invested funds in marketable securities. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:20.987%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:15.486%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:7.149%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:2.119%;"/&gt;
        &lt;td style="width:7.663%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.092%;"/&gt;
        &lt;td style="width:0.92%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.274%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.274%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;for Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Market&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1 year to 2 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1 year to 2 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;for Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Market&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer&#x2019;s industry, any significant deterioration in economic condition and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021 there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; securities in an unrealized loss position, all of which had been in an unrealized loss position for less than 12 months. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and the Company did not record a reserve for credit losses. At December 31, 2020, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; securities in an unrealized loss position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company&#x2019;s balance sheets, was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and less than&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;at December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_1a8b738b-1980-4cfa-99e1-5d7c8bfe0cdc">&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:20.987%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:15.486%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:7.149%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:2.119%;"/&gt;
        &lt;td style="width:7.663%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.092%;"/&gt;
        &lt;td style="width:0.92%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.274%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.274%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;for Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Market&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1 year to 2 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1 year to 2 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;for Credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Market&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Within 1 year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <dsgn:DebtSecuritiesAvailableForSaleMaturity
      contextRef="C_2440876e-d785-4ff7-be3a-fa21b9bbf1e3"
      id="F_92ac92ec-d1f0-4ec9-9ee9-96d7d481f0c6">Within 1 year</dsgn:DebtSecuritiesAvailableForSaleMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3ededf68-d7fc-475f-9e79-3e3146f1d833"
      decimals="-3"
      id="F_80ecacf2-2c91-4b15-bafd-bc153f8d5615"
      unitRef="U_USD">2896000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3ededf68-d7fc-475f-9e79-3e3146f1d833"
      decimals="-3"
      id="F_02341e97-92be-4579-8a04-bd089291e13f"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_3ededf68-d7fc-475f-9e79-3e3146f1d833"
      decimals="-3"
      id="F_df0b7e93-bd79-4bfc-9558-2edf45146471"
      unitRef="U_USD">2893000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <dsgn:DebtSecuritiesAvailableForSaleMaturity
      contextRef="C_131e1c23-bf72-466e-b780-eecada87c188"
      id="F_643a213c-26b7-4ac6-ba43-24db53767fc9">Within 1 year</dsgn:DebtSecuritiesAvailableForSaleMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4d411dff-54c7-4585-9301-d3241ffd63f4"
      decimals="-3"
      id="F_7370a553-c60b-4d2c-8396-7bd5dfbf84c5"
      unitRef="U_USD">15045000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4d411dff-54c7-4585-9301-d3241ffd63f4"
      decimals="-3"
      id="F_d33b925b-add4-49c1-950b-9bc7a33ba7bc"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4d411dff-54c7-4585-9301-d3241ffd63f4"
      decimals="-3"
      id="F_b32b92a9-f347-45dd-8cb8-04aa8db02632"
      unitRef="U_USD">15022000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <dsgn:DebtSecuritiesAvailableForSaleMaturity
      contextRef="C_abbec031-d382-4477-bfc5-49894a1ef5e2"
      id="F_7394f639-03d3-4d5b-970e-c5f54b075d99">1 year to 2 years</dsgn:DebtSecuritiesAvailableForSaleMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75"
      decimals="-3"
      id="F_1dc3d523-8039-465f-b3d1-9d092507d565"
      unitRef="U_USD">2887000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75"
      decimals="-3"
      id="F_b21a1638-1373-443b-9036-5e9698647db4"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_296a5cae-f07d-4a1a-9a8f-e7f138c54a75"
      decimals="-3"
      id="F_147ea8f0-8b85-480c-993e-e99750ba083e"
      unitRef="U_USD">2878000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <dsgn:DebtSecuritiesAvailableForSaleMaturity
      contextRef="C_31e5c9e1-0fcc-4298-b3fa-26eb6e19e3b3"
      id="F_dc46edf0-2847-4e85-8f68-50206a7a965f">1 year to 2 years</dsgn:DebtSecuritiesAvailableForSaleMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_820b96e4-02c7-43b6-87e0-576d13934c30"
      decimals="-3"
      id="F_b04b6475-348e-4896-853f-bfe9e87e1c04"
      unitRef="U_USD">64911000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_820b96e4-02c7-43b6-87e0-576d13934c30"
      decimals="-3"
      id="F_825c5edc-6775-4088-b186-bdaf3248f164"
      unitRef="U_USD">209000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_820b96e4-02c7-43b6-87e0-576d13934c30"
      decimals="-3"
      id="F_201a470f-232c-4327-96e9-daf3e343b1d7"
      unitRef="U_USD">64702000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_7333ba1c-2faa-4ff5-b53a-fb128cceaa19"
      unitRef="U_USD">85739000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_68d1826f-3116-4753-a562-071cdf41130e"
      unitRef="U_USD">244000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_af871fb6-c235-416c-9ccf-ed7c226aacd6"
      unitRef="U_USD">85495000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <dsgn:DebtSecuritiesAvailableForSaleMaturity
      contextRef="C_6b4db5f7-9e3b-456b-ab29-20209e77bc6d"
      id="F_9a48599d-ccec-47c7-a1ad-84c46ad43576">Within 1 year</dsgn:DebtSecuritiesAvailableForSaleMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f"
      decimals="-3"
      id="F_be4a8ed4-8e5d-477d-ad4d-4f71140a08f0"
      unitRef="U_USD">1750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f"
      decimals="-3"
      id="F_416917ae-c4b6-46a8-918c-72c417334f21"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e09699db-f7e7-4ae2-a7a8-55c6cdd17d8f"
      decimals="-3"
      id="F_af6544ab-53eb-4761-8745-941535bc3b65"
      unitRef="U_USD">1754000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <dsgn:DebtSecuritiesAvailableForSaleMaturity
      contextRef="C_3f8296e2-19aa-4c9e-977c-4e9998334dc4"
      id="F_8494452e-b509-4480-899c-43ed0c5c65cb">Within 1 year</dsgn:DebtSecuritiesAvailableForSaleMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f"
      decimals="-3"
      id="F_6a8e9240-5a35-447c-b94d-6f45b4ec9ffe"
      unitRef="U_USD">31806000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f"
      decimals="-3"
      id="F_7ad854f8-815e-44c6-b422-792daf58cc2e"
      unitRef="U_USD">152000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_3d7565b1-fb9a-47d7-bc8a-67c6b591285f"
      decimals="-3"
      id="F_f1443445-d0f2-42a4-b4cc-ae1d4f6167c2"
      unitRef="U_USD">31958000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_fe8c3fa4-d656-4878-b293-05e9f23722b7"
      unitRef="U_USD">33556000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_f101c0e5-767e-4c4f-90e5-b7280e540703"
      unitRef="U_USD">156000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_4280be25-5970-45aa-b760-2afda4432f2c"
      unitRef="U_USD">33712000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_7d785951-5e48-4c4c-ac34-8c24f6a5e9ce"
      unitRef="U_Security">38</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_1ac82719-2da3-4e6c-acc5-bf27a40009d5"
      unitRef="U_Security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <dsgn:NumberOfDomesticCertificatesOfDepositHeld
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_6a99ccc2-b5b6-47d4-8783-884eb0e101bf"
      unitRef="U_Security">24</dsgn:NumberOfDomesticCertificatesOfDepositHeld>
    <dsgn:AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-5"
      id="F_bd8713c2-b96a-437f-8505-eff73b1fe879"
      unitRef="U_USD">100000</dsgn:AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities>
    <dsgn:AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
      contextRef="C_62eaea31-a124-426a-bd6e-5a5adb4841c0"
      decimals="INF"
      id="F_f0b5d0ff-4a2e-4e4d-87ce-ae75a2641aa6"
      unitRef="U_USD">100000</dsgn:AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_38f89229-8e4f-4ee9-8956-fdb91cde4faa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.293%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:17.475%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:16.79%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Security deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.149%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:13.029%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:13.029%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.293%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:17.475%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:16.79%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued personnel costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c34c0616-00d0-4274-a21f-927f363c9ade;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current portion of operating lease liability, related party&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_f11c9ddc-f518-4bd0-bcad-ffe19e73d3a3">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.293%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:17.475%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:16.79%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Security deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_9d5a8e72-10b8-4dab-a854-d04961c54521"
      unitRef="U_USD">1254000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_0deefa58-90a1-4a61-a033-5f125b4d9b0f"
      unitRef="U_USD">60000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_d498f2af-e725-4b98-bdee-ba3eecbb162c"
      unitRef="U_USD">47000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_96df9c41-036e-47fd-8749-058e2b3907c7"
      unitRef="U_USD">110000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_b8956dc0-48b0-477d-b6b8-5f9e4234751c"
      unitRef="U_USD">10000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_88002a4a-56a0-48eb-bd8b-110240fe2215"
      unitRef="U_USD">7000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_bdf7281d-ffb3-4405-9977-ef4fcc3dd9dd"
      unitRef="U_USD">25000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_e627ac03-d904-4e5d-8951-36301fe318f5"
      unitRef="U_USD">1371000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_8489ec1a-5b0c-4505-80f3-1aa518254bcc"
      unitRef="U_USD">142000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_17953abe-edba-4a65-92fd-cbd090f5dec4">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.149%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:13.029%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:13.029%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ac754ff9-5df8-4082-9e89-559e3f5b5c9e"
      decimals="-3"
      id="F_575cbc14-257c-47be-af58-44c6142ad6c0"
      unitRef="U_USD">1148000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_da562d4c-497b-43eb-a87c-c6f98abf5d24"
      decimals="-3"
      id="F_c3c34007-1fd3-4c98-8af5-8fe9b665c271"
      unitRef="U_USD">76000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_18532e58-312b-467e-b271-29e361b67f10"
      decimals="-3"
      id="F_2c57db2c-0c96-4178-badd-3b22d01f35c1"
      unitRef="U_USD">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_21b23571-1ef3-47c0-814f-61628e84218b"
      decimals="-3"
      id="F_8e4b1d4e-ba62-4814-8c79-74257a4f7cf7"
      unitRef="U_USD">292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_57ffc353-e260-4275-bc08-e6bb76dc5b0c"
      decimals="-3"
      id="F_26e2c1c3-ba63-4fc4-a558-5d45c1f77b84"
      unitRef="U_USD">95000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e79952f3-cdf9-465a-86f5-17818dc1a21a"
      decimals="-3"
      id="F_97491f30-c8b0-4520-b285-0a35a0c6ba6c"
      unitRef="U_USD">11000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_5a1a7793-86fd-4400-a751-f8ee2833d77a"
      unitRef="U_USD">1642000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_00b5f768-87f3-45da-891d-4b942bc4d95e"
      unitRef="U_USD">76000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_27f35620-fc2e-4a3f-8d32-dc48d130fc61"
      unitRef="U_USD">134000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_cafd81d2-6655-486a-b9b5-77dcf9c15a18"
      unitRef="U_USD">5000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_f4a5c1d0-87d8-4b94-ba48-2a8d54ed28a9"
      unitRef="U_USD">1508000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_2ce1ac71-5037-44bb-ac48-fe1343c80f16"
      unitRef="U_USD">71000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_d626aed4-67e5-488e-8c05-d8b69f25108d">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.293%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:17.475%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.446%;"/&gt;
        &lt;td style="width:1.403%;"/&gt;
        &lt;td style="width:16.79%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued personnel costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c34c0616-00d0-4274-a21f-927f363c9ade;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current portion of operating lease liability, related party&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_b5305454-3311-4f99-96c4-7eace5dc9bc1"
      unitRef="U_USD">2152000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_d946ec55-2707-4887-92f7-f9286fe743a8"
      unitRef="U_USD">565000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <dsgn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_afc11dd0-62f2-410c-90f1-78811e108cc5"
      unitRef="U_USD">516000</dsgn:AccruedResearchAndDevelopmentExpenseCurrent>
    <dsgn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_39860c3d-5465-40f9-aae8-e1f0910ed5e0"
      unitRef="U_USD">266000</dsgn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_da158c5a-1250-44ce-9a71-93599e6cf03c"
      unitRef="U_USD">489000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_4c78e94e-7df4-4e7b-89fc-18ce396c78d3"
      unitRef="U_USD">506000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_31dd61bf-3de4-4fac-b9e3-f47a1dbfeb44"
      unitRef="U_USD">100000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_8b221246-592c-4330-8cb1-39556a5eaf10"
      unitRef="U_USD">3663000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_de747a2f-2e42-4c2b-a14a-6d6959d51c4b"
      unitRef="U_USD">931000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_ad03aec1-2714-44b8-aa27-79ba57fa670c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company&#x2019;s balance sheets. The Company terminated the agreement in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,370&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of laboratory and office space (the &#x201c;Lease&#x201d;). The Company&#x2019;s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; with a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; months and an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the lease term for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and thus, the incremental term was excluded from the calculation of the ROU asset, related party and lease liability, related party. The lease includes variable non-lease components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset, related party and operating lease liability, related party and are reflected as an expense in the period incurred. Lease payments are subject to annual increases of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of December 31, 2021, the remaining lease term for the lease was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.15&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.809%;"/&gt;
        &lt;td style="width:1.934%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:15.972%;"/&gt;
        &lt;td style="width:0.914%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Rent expense for the years &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <dsgn:LeaseAgreementTerminationDate
      contextRef="C_bf5d2e5b-41f1-419b-8853-434297531657"
      id="F_54c49995-e994-4aae-a92c-6bf4531a4c81">2021-09</dsgn:LeaseAgreementTerminationDate>
    <dsgn:AreaOfLeasedProperty
      contextRef="C_2b058460-a53f-45fa-81f1-ff866fb0af2c"
      decimals="0"
      id="F_95971a2e-b323-457b-a65f-c0f977a216fb"
      unitRef="U_sqft">12370</dsgn:AreaOfLeasedProperty>
    <dsgn:LeaseCommencementDate
      contextRef="C_adc93247-3f34-454d-be75-6d57971dea64"
      id="F_d26c173d-c361-4b09-a153-f2d28db5bd60">2021-09</dsgn:LeaseCommencementDate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_2b058460-a53f-45fa-81f1-ff866fb0af2c"
      id="F_9713b025-71d9-4be8-b5c2-d6c052fc0145">P72M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_6afdf50d-8689-4ede-8f30-41e7b459c71a"
      id="F_06bac0d0-eab5-4d48-8cff-e04a4af7aaac">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_adc93247-3f34-454d-be75-6d57971dea64"
      id="F_63c873f2-4a17-426b-976e-c387ca4a1276">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <dsgn:LesseeOperatingLeaseTermOfExpirationYear
      contextRef="C_adc93247-3f34-454d-be75-6d57971dea64"
      id="F_33dafec4-e7e4-4628-b30d-8366fd7f1fa2">2027</dsgn:LesseeOperatingLeaseTermOfExpirationYear>
    <dsgn:PercentageOfAnnualIncreaseInLeasePayments
      contextRef="C_2b058460-a53f-45fa-81f1-ff866fb0af2c"
      decimals="2"
      id="F_1cc4e5fb-e99a-438a-90dd-4057129ac62b"
      unitRef="U_pure">0.03</dsgn:PercentageOfAnnualIncreaseInLeasePayments>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_59741c86-fa48-4f2f-87fc-b83b830a5544"
      id="F_ac8a76df-89d6-4f11-b50e-a7a02d3e01af">P5Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_59741c86-fa48-4f2f-87fc-b83b830a5544"
      decimals="4"
      id="F_8dda8950-7b71-4e13-95c0-6656d62d2685"
      unitRef="U_pure">0.0715</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_8e2c4e26-30a2-426b-815a-08f6c7760175">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.809%;"/&gt;
        &lt;td style="width:1.934%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:15.972%;"/&gt;
        &lt;td style="width:0.914%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_9e8fe042-fcd4-4829-ac7f-782be7716512"
      unitRef="U_USD">733000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_aee864db-5ea5-45ca-b3bc-b110117a7656"
      unitRef="U_USD">755000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_643ba8b5-92bc-4eaa-bf12-490999413da0"
      unitRef="U_USD">778000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_9f74a5f9-d19c-46f6-8fd1-87e40fefbb9c"
      unitRef="U_USD">801000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_1e9ad746-9401-4149-bd79-b657772b4894"
      unitRef="U_USD">825000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_1818dd5c-e074-40f0-9fea-b3b7da3664c3"
      unitRef="U_USD">561000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_718b32cb-8614-4d87-902e-af44da850004"
      unitRef="U_USD">4453000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_1ed04e62-0a12-4fac-b592-cf85e526f236"
      unitRef="U_USD">820000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_cb217515-89b0-446c-8482-c79b412a2306"
      unitRef="U_USD">3633000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-5"
      id="F_b93a5d42-fc6a-4c1f-b625-b8d2558fed51"
      unitRef="U_USD">600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-5"
      id="F_85f190b6-96bc-41fb-821c-57bee94cb3d7"
      unitRef="U_USD">100000</us-gaap:OperatingLeaseCost>
    <dsgn:GrantRevenueTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_1b622e29-a4e7-40af-bf1d-575476890b8d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. Grant Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company&#x2019;s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of grant revenue from awards by the NSF, NIH and FARA, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; grant revenue was recognized for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</dsgn:GrantRevenueTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_ceb7f97d-7cb8-4a60-a79b-931a4f103fde"
      decimals="-5"
      id="F_db8dfb1f-e846-4087-b35d-95064a779ec8"
      unitRef="U_USD">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2a9265ec-0c2d-4f31-9eaf-7d31f601c7b3"
      decimals="INF"
      id="F_431f2cc0-cf60-4fde-8c35-a707b95d281d"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_7eaa4d31-33f4-4bf4-a6f0-bced6247ff80">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. Convertible Preferred Stock and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Authorized Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the completion of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in March 2021, the Company amended its Certificate of Incorporation to authorize &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February and March 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,710,814&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series A convertible preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0727&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for net cash proceeds of $ &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the &#x201c;Series A Financing&#x201d;). In connection with the Series A Financing, the Company issued an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;301,685&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its Series A convertible preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.65816&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2021, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,083,979&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B convertible preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.55&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for net cash proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;124.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All shares of convertible preferred stock outstanding at the Company&#x2019;s IPO were converted into shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Shares Subject to Repurchase&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient&#x2019;s service is terminated either voluntarily or involuntarily prior to vesting.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company&#x2019;s balance sheets, is as follows (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.267%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:13.575%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.029%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;811,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares early exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;153,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;317,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;646,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;407,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;239,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab"
      decimals="INF"
      id="F_0224fdc4-96b9-4c32-bc0b-d208dc51c485"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab"
      decimals="INF"
      id="F_98ead21e-7d63-42a2-bf95-dbeec58e2d12"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab"
      decimals="INF"
      id="F_5d31cad9-4959-4a0e-953f-9898ab3d5cac"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_308965b5-68d9-4cca-a1bd-6e9f9a2388ab"
      decimals="INF"
      id="F_eda19eab-89d9-4656-8928-a24a7a7bafa4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5"
      decimals="INF"
      id="F_28d4e46e-9fd4-4abb-a141-7be8d4e7d1fd"
      unitRef="U_shares">21710814</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f"
      decimals="INF"
      id="F_6f35e9eb-2c56-457f-867d-c6f4205eeb8c"
      unitRef="U_shares">21710814</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5"
      decimals="INF"
      id="F_6f9b46f5-9200-498c-b585-1d2f14b66981"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.0727</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f"
      decimals="INF"
      id="F_fab69d2e-4fe4-4809-9d29-a18882921713"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.0727</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72"
      decimals="-5"
      id="F_aff6d55d-ceff-49d0-93c5-f84d3ad7cd00"
      unitRef="U_USD">44700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_4402b367-1f4a-4644-931e-244097e7a86c"
      decimals="-5"
      id="F_94379abc-8287-4d2e-b91e-35ede4b621ee"
      unitRef="U_USD">44700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72"
      decimals="INF"
      id="F_36ae4704-1aca-4f02-bb1e-19c55c24ffec"
      unitRef="U_shares">301685</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SharePrice
      contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5"
      decimals="INF"
      id="F_3960acd8-3864-4109-956f-6cdaa6fc25d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.65816</us-gaap:SharePrice>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_09862e22-6777-4916-b800-571e5b594613"
      decimals="INF"
      id="F_608df127-135a-4c1a-bf8e-90f4bdc4cef5"
      unitRef="U_shares">19083979</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_09862e22-6777-4916-b800-571e5b594613"
      decimals="INF"
      id="F_075ca653-62cf-4aac-89d2-f0a44da96446"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.55</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_8b5211fb-3823-4218-9a5e-36b1f275768a"
      decimals="-5"
      id="F_f908d42e-78f0-4211-ac70-b4970317b35a"
      unitRef="U_USD">124700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_86c855a7-1404-41b9-9ec4-470ab3dffc2f"
      id="F_f6a341b3-1f64-4060-ad8d-0b6878f70803">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_65059fc9-634c-47fd-bab7-56c86298570d">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company&#x2019;s balance sheets, is as follows (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.267%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:13.575%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.029%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;811,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares early exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;153,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;317,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;646,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;407,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;239,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_499263cc-6cef-4ede-8c9f-5058ea40a149"
      decimals="INF"
      id="F_4bd4c646-6d2a-41c2-ae14-3239af1b3eff"
      unitRef="U_shares">811268</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <dsgn:UnvestedStockLiability
      contextRef="C_becd129a-dfa1-4804-9129-b0961e120502"
      decimals="-3"
      id="F_f131e066-ad6c-4784-9006-34767c81ee20"
      unitRef="U_USD">1000</dsgn:UnvestedStockLiability>
    <dsgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice
      contextRef="C_7ea42364-2fcb-4648-b148-742ec5e08d38"
      decimals="INF"
      id="F_94166f5d-4ffc-40fd-969b-74d51d229626"
      unitRef="U_shares">153373</dsgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice>
    <dsgn:SharesEarlyExercisedUnvestedStockLiability
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_6bdbc818-a24d-4152-80e5-09a1401940d1"
      unitRef="U_USD">145000</dsgn:SharesEarlyExercisedUnvestedStockLiability>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_7ea42364-2fcb-4648-b148-742ec5e08d38"
      decimals="INF"
      id="F_c58e0ded-2d60-49bc-b92d-817d35313337"
      unitRef="U_shares">317688</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <dsgn:UnvestedStockLiabilityVestedSharesValue
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_b410f598-a62b-45aa-af4f-970f36bfe4c7"
      unitRef="U_USD">-1000</dsgn:UnvestedStockLiabilityVestedSharesValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_1f1efe30-75a7-4daa-a934-18cf07b4b011"
      decimals="INF"
      id="F_c8c1dac4-b8a2-4a31-90b9-3be1057ac142"
      unitRef="U_shares">646953</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <dsgn:UnvestedStockLiability
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_53e08ee7-aece-4041-87d4-ee8d82dc7e88"
      unitRef="U_USD">145000</dsgn:UnvestedStockLiability>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_d5d4f8dd-7c17-4eaa-a38e-dcd85d00e072"
      decimals="INF"
      id="F_a55baa70-1cc1-41fb-8aca-82744fca949c"
      unitRef="U_shares">407127</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <dsgn:UnvestedStockLiabilityVestedSharesValue
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_6e5139a5-0690-4834-8d7e-fdb4f4ecde76"
      unitRef="U_USD">122000</dsgn:UnvestedStockLiabilityVestedSharesValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_cdef21de-d669-4832-a95e-55c903160e95"
      decimals="INF"
      id="F_1f438eb9-1921-4882-a031-9d196f9264d4"
      unitRef="U_shares">239826</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <dsgn:UnvestedStockLiability
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_ac10e98d-35e7-4927-b91c-1f35c22fab69"
      unitRef="U_USD">23000</dsgn:UnvestedStockLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_f9104a84-241f-4645-a216-db59b984c546">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity Incentive Award Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Company&#x2019;s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company&#x2019;s IPO. Upon adoption of the 2021 Plan, the Company restricted future grants from its 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company&#x2019;s affiliates. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,118,648&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;881,352&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; As of December 31, 2021, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,079,984&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for grant under the 2021 Plan. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company&#x2019;s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Effective January 1, 2022, the number of shares available for future issuance was increased by&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,784,087&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares so that the total available for future issuance as of January 1, 2022 was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,864,071&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.77%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:9.562%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:9.594%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:9.573%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Options and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;30,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.95&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,723,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;153,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,601,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,439,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;15.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;52,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;313,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,673,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;35,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,673,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;35,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;949,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.78&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average grant date fair value per share of options granted was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.39&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for the years ended December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for the years ended December 31, 2021 and 2020, respectively, and the cash received from options exercised was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.91%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.32&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines the assumptions used in the option pricing model in the following manner:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;The grant date fair market value of the shares of common stock underlying stock options is determined&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; by the Company&#x2019;s board of directors. Following the closing of the Company&#x2019;s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#x2019;s common stock is traded. Prior to the Company&#x2019;s IPO, because there was no public market for the Company&#x2019;s common stock, the board of directors considered, among other things, input from management and valuations of the Company's stock prepared by unrelated third-party valuation firms.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;The expected term of stock options represents the period of time that the awards are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected term assumption using the simplified method for employees and board members, which calculates the expected term as the average time-to-vesting and the contractual life of the award. The expected term for non-employees is generally the contractual term.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;Given the Company's limited historical stock price volatility data, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;The risk-free rate assumption is based on the U.S. Treasury yield in effect at the time of the grant with maturities consistent with the expected term of the awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.667%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;The expected dividend yield assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends and, therefore, used an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Company&#x2019;s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company&#x2019;s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;600,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were approved to be initially reserved for issuance under the ESPP. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; addition, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company&#x2019;s common stock on the last day of the calendar month before the date of each automatic increase and (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,200,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Effective January 1, 2022, the number of shares available for issuance was increased by&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;556,817&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares so that the total available for future issuance as of January 1, 2022 was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,145,361&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,456&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company's common stock under the ESPP and had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;588,544&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for future issuance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.593%;"/&gt;
        &lt;td style="width:1.927%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:15.46%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.256%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.2%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.178%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, unrecognized compensation expense related to unvested stock option awards was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which is expected to be recognized in expense over a weighted-average period of&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; 3.2 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years. As of December 31, 2021, unrecognized compensation expense related to ESPP rights was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which is expected to be recognized over a remaining period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b5eca583-41b5-4449-b248-84c59b8416b8"
      decimals="INF"
      id="F_fe2eb2fc-6659-45b1-9a97-a6ebc81b141b"
      unitRef="U_shares">6118648</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_56d217f5-b263-4e46-bd7d-f0d3f3f291ef"
      decimals="INF"
      id="F_3ab9f15e-e527-484b-9943-893f248aeabb"
      unitRef="U_shares">881352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_8c915edc-7f15-44b7-bcb1-f158561e7fcb"
      decimals="INF"
      id="F_2fd1832a-78fb-49b9-8b18-50d42285cb56"
      unitRef="U_shares">6079984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
      contextRef="C_015c050e-1f5a-4b49-8849-0dccea408c5c"
      id="F_c7f10cd5-8b9e-43a5-9250-f70ab4e1a34f">the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company&#x2019;s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company&#x2019;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
    <dsgn:CommonStockCapitalSharesReservedForFutureIssuanceIncreased
      contextRef="C_bb312aa6-c50b-415c-b819-f0af73e2941e"
      decimals="INF"
      id="F_81a086e9-9adf-4e6a-8b45-3e6461e1dd09"
      unitRef="U_shares">2784087</dsgn:CommonStockCapitalSharesReservedForFutureIssuanceIncreased>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bb312aa6-c50b-415c-b819-f0af73e2941e"
      decimals="INF"
      id="F_9d0ec1f7-2090-4e73-a0d7-337e7d33d9cc"
      unitRef="U_shares">8864071</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_5740885a-664c-4312-b03d-b2653953f9a8">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.77%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:9.423%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:9.562%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:9.594%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.199%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:9.573%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Options and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;30,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.95&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,723,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;153,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,601,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,439,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;15.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;52,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;313,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,673,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;35,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,673,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9.12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;35,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;949,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.78&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_becd129a-dfa1-4804-9129-b0961e120502"
      decimals="INF"
      id="F_9147b20e-d455-49ad-a1ac-230ee97f4010"
      unitRef="U_shares">30674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_becd129a-dfa1-4804-9129-b0961e120502"
      decimals="3"
      id="F_77299161-e034-4a90-abcb-79f25c6ca98b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_82824a3c-b613-4fb2-b25d-e5297dacef2a"
      id="F_56c41b5f-19a8-4224-a2b2-8ef9a8e9b1f3">P9Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="INF"
      id="F_a597ca5b-d166-4b01-86b4-0a4f64aa14ec"
      unitRef="U_shares">1723913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="2"
      id="F_8bd5e202-ff86-4591-9c34-24ab9695001f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="INF"
      id="F_d626bb79-9186-4d34-858a-82f042125324"
      unitRef="U_shares">153373</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="2"
      id="F_48d4cfcd-4fcb-4e3c-ab00-27f3913aa428"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_58e0a0a3-ea48-48fb-bc85-4175b08343af"
      unitRef="U_shares">1601214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="2"
      id="F_1b223032-ec24-4a82-985b-aabab84371c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      id="F_0f2236ad-ca1f-4c21-a26e-59d9a82c2a87">P9Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_eb7ff5da-c7bf-45e5-8743-f7c1b8bb5e72"
      unitRef="U_USD">8468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="INF"
      id="F_c42320c6-8fbc-4b4c-a0fb-8b79b175b40b"
      unitRef="U_shares">1439444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="2"
      id="F_a2cd9944-9bcd-48ad-ae4c-3bd005593da4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="INF"
      id="F_e5e44d93-b0c1-42da-93d5-0a4203720c1f"
      unitRef="U_shares">52974</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="2"
      id="F_36d1f138-4550-45ad-bebb-8bb84614e58a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="INF"
      id="F_43c1d302-701d-4cff-9619-13fac04b0fbc"
      unitRef="U_shares">313909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="2"
      id="F_1381c743-f30a-4d4c-9f95-78cc5cfb6a8f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_f8e0581c-c4e4-4370-9c00-1ecb2a4705b9"
      unitRef="U_shares">2673775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="2"
      id="F_f93731fc-78f9-426b-b703-38e474e0a518"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_d7d7f91f-a93f-452b-88e2-954427031952">P9Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_812aaf6c-970a-4218-a6c4-23afb0c2b0ef"
      unitRef="U_USD">35343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_953a29da-46b8-45c1-b004-e5dcea690270"
      unitRef="U_shares">2673775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="2"
      id="F_1bf13d41-80e1-4993-927d-69f6ae7edbf7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_40cdcf20-447c-4253-ad3d-d3d45cf71d08">P9Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_eae9078d-ca4e-4b6e-a224-9e7bcd3c2698"
      unitRef="U_USD">35343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_65a7bb91-6eed-4705-a541-a31833ea0b58"
      unitRef="U_shares">949102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="2"
      id="F_37bc49fd-e4e6-4395-bb4f-78a3375db826"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_f3b17838-82f5-4bd1-bb0a-e420069ab643">P8Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_e7af1467-993f-4211-887d-51e36bf566a2"
      unitRef="U_USD">18159000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="2"
      id="F_e95ec1bb-566b-4fd6-a719-877557a1dac8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="2"
      id="F_edf7fc26-fa19-4773-94b4-1e29e03734d3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-2"
      id="F_7ce698b9-a039-4fb7-b552-b0e4c4e381dd"
      unitRef="U_USD">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_883f6cad-abc8-447f-9cf4-9db8dfc077cc"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7549669b-7c92-4c29-aee8-52f0528f3361"
      decimals="-5"
      id="F_625960c4-e763-45bf-ac09-c12cd68c7b5c"
      unitRef="U_USD">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ee89e80b-865a-4125-bcb4-76c8de099850"
      decimals="-5"
      id="F_91278feb-7da9-41c9-a0b3-84691db1e127"
      unitRef="U_USD">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2f22e980-6589-4e8e-a06e-0008b34fcedd">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.91%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.32&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="2"
      id="F_7e164b1c-a002-4db6-8f2d-ba9e8235dca6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="2"
      id="F_54911982-bb5d-4c72-a598-eb2cec51ce64"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_30043019-91a1-4023-98cc-239c1e9cd645">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      id="F_04c7fdd8-1ab8-4308-9f95-6efbd748a155">P6Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="4"
      id="F_2125b465-f817-4ddd-ba73-a457a396c35a"
      unitRef="U_pure">0.7283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="4"
      id="F_448208b5-31f5-4e30-ac85-fca054170bfb"
      unitRef="U_pure">0.7293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="4"
      id="F_d14fca6b-295c-4111-b4f7-c464e7328229"
      unitRef="U_pure">0.0104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="4"
      id="F_a48d9c91-5e2b-4519-a8b0-3547422cd1fe"
      unitRef="U_pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="3"
      id="F_d4045241-5f06-4c01-ae6e-3d3319a53516"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="3"
      id="F_81485228-7d21-4996-a9ed-a13642735947"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="2"
      id="F_db76c867-4276-4e52-be6c-c77de6817b0e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <dsgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering
      contextRef="C_cbc31665-46ff-4282-846e-3ddb64f5b097"
      decimals="2"
      id="F_e725a736-4708-467f-8c05-269a42ab42db"
      unitRef="U_pure">0.15</dsgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_cbc31665-46ff-4282-846e-3ddb64f5b097"
      decimals="2"
      id="F_7db60e20-261e-4e61-a490-4f1b34e7f184"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9488ce8f-cd96-43ae-b83d-da01a404b062"
      decimals="INF"
      id="F_7dd0eaf9-558f-4241-838b-af1e95a40c0a"
      unitRef="U_shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      id="F_995fdfd4-dde8-4b1a-aec2-1883e85848e1">the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company&#x2019;s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9488ce8f-cd96-43ae-b83d-da01a404b062"
      decimals="INF"
      id="F_da9d8732-005e-4008-a322-23f80b34c5c9"
      unitRef="U_shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <dsgn:CommonStockCapitalSharesReservedForFutureIssuanceIncreased
      contextRef="C_68c8fb76-ffb2-47b9-87e5-28f51b3c5784"
      decimals="INF"
      id="F_998b5a1b-8632-4a65-b9a9-42b789254c9e"
      unitRef="U_shares">556817</dsgn:CommonStockCapitalSharesReservedForFutureIssuanceIncreased>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_68c8fb76-ffb2-47b9-87e5-28f51b3c5784"
      decimals="INF"
      id="F_75a8c36a-cdb9-41e9-922a-13612a6ef753"
      unitRef="U_shares">1145361</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      decimals="INF"
      id="F_b653ea41-1bc8-4298-bfdd-be88f281f5b2"
      unitRef="U_shares">11456</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_769dba12-3ef2-4dad-a5b3-89361f92718a"
      decimals="INF"
      id="F_6475dfa4-7760-4a5d-8c0d-bc3f5dd8d263"
      unitRef="U_shares">588544</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      id="F_df7b945a-b0fd-4910-872e-298bbb5661df">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.593%;"/&gt;
        &lt;td style="width:1.927%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:15.46%;"/&gt;
        &lt;td style="width:2.313%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.41&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_769dba12-3ef2-4dad-a5b3-89361f92718a"
      decimals="2"
      id="F_a91137ba-6435-49ad-8e22-0ddb2d85f6f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      id="F_78cbc5b7-a41f-417f-a348-66107247345c">P1Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      decimals="4"
      id="F_4b1adc51-4220-459e-a020-b61746ec0163"
      unitRef="U_pure">0.6926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      decimals="4"
      id="F_fd8cafc2-6e00-4459-babc-05225456b2ce"
      unitRef="U_pure">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      decimals="3"
      id="F_60b68059-6728-409d-b06b-7aabd76d88f1"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_1529cc20-8e5e-48f7-a7eb-197c6506c544">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.256%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.2%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.178%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_020e7d21-1fc1-4579-8491-b965545b2a40"
      decimals="-3"
      id="F_4b40722c-22eb-4ab8-840f-ea0fc7650782"
      unitRef="U_USD">1827000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_36df1b56-bdb0-4695-b7cf-d0ea73632dc9"
      decimals="-3"
      id="F_62a2e7d7-facd-4c6e-b96e-2deabff5f071"
      unitRef="U_USD">177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_72018646-7064-41a5-8f10-73e8aed069e2"
      decimals="-3"
      id="F_3b7e7427-6995-4254-955d-8ff7b1c71b76"
      unitRef="U_USD">2862000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1d9cb435-50cf-426c-b2e6-da460c39afdd"
      decimals="-3"
      id="F_09bc2d08-7d2e-4bd5-a096-8bd174018ed9"
      unitRef="U_USD">273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_75755734-2355-424b-8e4a-048550ba7642"
      unitRef="U_USD">4689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_e0e74e62-ee54-443f-8bc2-c95e5bca9bee"
      unitRef="U_USD">450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-5"
      id="F_1106cfc4-88f5-4f6c-a71c-2b681094694c"
      unitRef="U_USD">18000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_68e7ac45-a5e6-4038-b11b-91888e27aafd">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_769dba12-3ef2-4dad-a5b3-89361f92718a"
      decimals="-5"
      id="F_f917ec48-8a27-4ed1-ba55-4743d378ea87"
      unitRef="U_USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_fcd195dc-decb-4c46-97e7-98c2522754a3"
      id="F_0d6aa96b-738f-4a8a-88d8-b393fe79ef02">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_d695c758-b884-4dda-9156-2b6671bc307e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#x2019;s tax years are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters as tax expense. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accrued interest or penalties related to income tax matters on its balance sheets at December 31, 2021 or 2020. and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognized interest or penalties in its statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020, respectively. Further, the Company is not currently under examination by any federal, state or local tax authority.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021, the Company had federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;an&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, r&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;espectively. Federal NOL carryforwards totaling &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million b&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;egin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, unless previously utilized, and federal NOL carryforwards of&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million g&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;enerated after 2017, may be carryforward indefinitely but can only be utilized to offset &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of future taxable income. State NOL carryforwards totalin&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;g $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million be&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;gin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, unless previously utilized. In addition, the Company also has federal and state research and development (&#x201c;R&amp;amp;D&#x201d;) credit carryforwards totali&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ng $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; respectively. The federal R&amp;amp;D credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; unless previously utilized. The state R&amp;amp;D credit carryforwards do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Utilization of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be subject to substantial annual limitations in the event a cumulative ownership change has occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;). In general, an &#x201c;ownership change,&#x201d; as defined by Section 382 of the Code, results from a transaction, or series of transactions over a three-year period, resulting in an ownership change of more than 50% of the outstanding common stock of a company by certain stockholders or public groups. Such an ownership change may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a study to assess whether an ownership change had occurred from the Company's formation through December 31, 2021. Based upon the study, the Company determined that it had experienced multiple ownership&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;changes during 2020, causing the annual utilization of the NOL and credit carryforwards to be limited. The Company does not believe any of the NOL and credit carryforwards generated through December 31, 2021 would expire solely as a result of annual limitations on the utilization of those attributes. If ownership changes occur in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.174%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.031%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.021%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.024%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.192%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.01%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Debt financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next twelve months. Further, due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.192%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.221%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.221%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increase to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="INF"
      id="F_36f87556-8934-4450-9c1d-1165996b9d87"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="INF"
      id="F_317f1e2f-5fe6-4ff6-ba3f-decf8d5c8ce1"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="INF"
      id="F_7a921876-fb9f-4071-9452-f503010f56f1"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="INF"
      id="F_0b08e927-82f7-4bf9-97bb-f0c5c35b4aae"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_78c5be72-50bc-4838-96f2-7c678294bfdc"
      decimals="-5"
      id="F_2c8a3409-91dd-45c0-ba58-1aedeab46847"
      unitRef="U_USD">40300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5482b53a-c0c0-483d-8704-340e59957e38"
      decimals="-5"
      id="F_9ce31981-d83b-40cb-ac39-b4e91c8c3bbb"
      unitRef="U_USD">10400000</us-gaap:OperatingLossCarryforwards>
    <dsgn:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_78c5be72-50bc-4838-96f2-7c678294bfdc"
      decimals="-5"
      id="F_6b69800f-c2bb-42fc-9dcc-27742729f155"
      unitRef="U_USD">100000</dsgn:OperatingLossCarryforwardsSubjectToExpiration>
    <dsgn:OperatingLossCarryforwardsExpirationYear
      contextRef="C_49187fc6-8a7a-4911-8230-ce5034a3dd6a"
      id="F_1fad4d07-e571-4ebb-8e33-8d12effde003">2037</dsgn:OperatingLossCarryforwardsExpirationYear>
    <dsgn:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_78c5be72-50bc-4838-96f2-7c678294bfdc"
      decimals="-5"
      id="F_e275ad3f-58d3-45b6-9645-3b2bdba7b40a"
      unitRef="U_USD">40200000</dsgn:OperatingLossCarryforwardsNotSubjectToExpiration>
    <dsgn:NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage
      contextRef="C_49187fc6-8a7a-4911-8230-ce5034a3dd6a"
      decimals="2"
      id="F_a3cbbfc4-d037-4949-93f4-c5873e96568d"
      unitRef="U_pure">0.80</dsgn:NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5482b53a-c0c0-483d-8704-340e59957e38"
      decimals="-5"
      id="F_f01433e4-98c8-4201-ac2d-3388f3580988"
      unitRef="U_USD">10400000</us-gaap:OperatingLossCarryforwards>
    <dsgn:OperatingLossCarryforwardsExpirationYear
      contextRef="C_896a557d-321b-4604-a274-4b73f428a91c"
      id="F_3daa9fdc-4a55-45e7-afe6-59c1434ff81e">2037</dsgn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_cf1f9868-ad02-4973-bb86-f39dc0bbe2a1"
      decimals="-5"
      id="F_bfb98371-3381-49b3-9589-2ffd57a3a793"
      unitRef="U_USD">900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_9aecf3c2-6ec0-470e-aed3-32e15d8ee9b5"
      decimals="-5"
      id="F_41efc33b-9c18-4b9c-9f23-4faca5e5ad31"
      unitRef="U_USD">600000</us-gaap:TaxCreditCarryforwardAmount>
    <dsgn:TaxCreditCarryforwardExpirationYear
      contextRef="C_a798c222-0494-49e9-979f-72203726b20d"
      id="F_a2117049-7d35-4ce4-8494-6e8ee4b71646">2038</dsgn:TaxCreditCarryforwardExpirationYear>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_6e38d358-4544-422e-a47b-54abdad61c48">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.174%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.031%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.021%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_380fb8ca-dfbb-454c-8848-536f5ff8d270"
      unitRef="U_USD">9171000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_ef21ee63-1f61-4165-b289-bb95ec48177d"
      unitRef="U_USD">2836000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_d9027b4c-d960-4e99-b371-9e59d0b7de64"
      unitRef="U_USD">1013000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_cf841be1-c433-4492-a8a8-0a0476d054c5"
      unitRef="U_USD">153000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <dsgn:DeferredTaxAssetsLeaseLiability
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_2ab4f94e-5f36-4ed1-9135-eb1e1b8381a8"
      unitRef="U_USD">763000</dsgn:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_61fe326c-25e1-4d6b-9383-ab8e650ec15a"
      unitRef="U_USD">532000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_eca4e59b-fa73-40ed-b4f1-91dfae525532"
      unitRef="U_USD">25000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_ad0afe23-e46a-45a5-ab74-8180755bbb4e"
      unitRef="U_USD">515000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_1c3334aa-0ace-492c-b01f-10c6c0ff5205"
      unitRef="U_USD">196000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_b784fc6b-eca1-40c5-9a2a-98a9bb8ddef4"
      unitRef="U_USD">11994000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_c47d60aa-0049-419b-9ed0-7347834bd0fd"
      unitRef="U_USD">3210000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_a481b039-81a4-4621-8d39-615dd27e673b"
      unitRef="U_USD">11235000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_7025d946-c89a-46dd-bf61-bc2524aa0368"
      unitRef="U_USD">3177000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_89ed6cb8-2f00-445d-b6f4-67f35aa792b6"
      unitRef="U_USD">759000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_108fc504-b1af-4bf2-8e54-6afaaf7fb5e2"
      unitRef="U_USD">33000</us-gaap:DeferredTaxAssetsNet>
    <dsgn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_c2a39264-2b52-4fa5-8b38-b9fcc08afa23"
      unitRef="U_USD">759000</dsgn:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_83071427-d0a5-4952-8880-2a31f76b02c3"
      unitRef="U_USD">33000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_54559ee5-36aa-4f64-89ae-77cf7ff3bb2a"
      unitRef="U_USD">759000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_0fbfebfe-eabf-4222-a1df-fa1bf6f40dab"
      unitRef="U_USD">33000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_3a3844f6-7c2b-4a94-ae49-1ba79a4f0e43">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.024%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.192%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.01%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Debt financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_8745621d-2719-45a6-bbfc-b82a08537209"
      unitRef="U_USD">-7451000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_b553835b-a6a3-42ff-9965-70a6521a733a"
      unitRef="U_USD">-1738000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_876eec40-4cd6-4e60-b067-1b9956290e77"
      unitRef="U_USD">-4000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_0a80eeb3-7706-4b4e-a825-f3ada0394c7c"
      unitRef="U_USD">-552000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <dsgn:IncomeTaxReconciliationDebtFinancing
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_39682274-c1c6-49ff-973a-fa31a582b4cd"
      unitRef="U_USD">6000</dsgn:IncomeTaxReconciliationDebtFinancing>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_7f68b143-9e3f-423e-a709-95c52f6b2661"
      unitRef="U_USD">-836000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_a4b4d96c-4fcd-4064-8c74-3098448e29a5"
      unitRef="U_USD">-71000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_215ae69b-ddfe-4a23-a49e-b01f854ab1ca"
      unitRef="U_USD">317000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_22a5045c-cec3-4832-9dd4-34b470a1f899"
      unitRef="U_USD">174000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_8a13fd96-2a73-4424-90db-28e856398840"
      unitRef="U_USD">7974000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_cc07b326-a731-47c5-8941-f84e0afb3825"
      unitRef="U_USD">2181000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_198bfa5d-c9c0-444b-ae8f-4b0817c9d37a">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.192%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.221%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.221%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increase to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_cecdffca-874c-4f96-b9a4-6332e255921b"
      unitRef="U_USD">15000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_becd129a-dfa1-4804-9129-b0961e120502"
      decimals="-3"
      id="F_fc60edf2-b665-44cf-8516-9e1215a56dca"
      unitRef="U_USD">9000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_f0e87aba-db4f-4d96-9929-a5594f458f3a"
      unitRef="U_USD">1000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="-3"
      id="F_c7fa4b44-a0cb-4638-9b60-69ec1a7d53c5"
      unitRef="U_USD">402000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_491eb317-efb1-40ae-85f1-8afd062cc647"
      decimals="-3"
      id="F_8b35b5fa-cc18-404f-af7c-af9c7060168d"
      unitRef="U_USD">6000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_34051789-f2bd-40c0-b83a-1a91b3aabe17"
      decimals="-3"
      id="F_96e7119e-54e0-4499-aa90-3cdabd1d65cf"
      unitRef="U_USD">418000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4b433e9b-8bd1-498f-a486-bdee162f0520"
      decimals="-3"
      id="F_98ae1324-a874-44fd-9cc7-ead3252eea7a"
      unitRef="U_USD">15000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_2b9296f9-cafb-498f-bafb-2ff00b8939b1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Notes Payable-Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2019, the Company issued an unsecured promissory note to borrow up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to a co-founder (the &#x201c;January Note&#x201d;) for working capital. The January Note bore interest at prime plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%, was scheduled to mature &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on or before January 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and included a final payment of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the January Note with interest payable at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.1&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2019, the Company issued an unsecured promissory note to borrow up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to a co-founder (the &#x201c;November Note&#x201d;) for working capital. The November Note bore interest at prime plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% and matured &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on or before January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and included a final payment of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the November Note with interest payable at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.25&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Convertible Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May and July 2018, the Company issued $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of convertible notes to a co-founder for cash with a maturity date &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on or after February 5, 2021, if not converted earlier&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In February 2019, the Company issued an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of convertible notes to consultants for services rendered with a maturity date &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on or after May 16, 2020, if not converted earlier&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The convertible notes bore interest of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% per annum and were convertible into equity securities sold at the next financing at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million were converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;301,685&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s Series A convertible preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.65816&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. See Note 9 for further discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of December 31, 2021 or December 31, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_a397402b-f716-41a7-8341-71ec3bbe5ef6"
      decimals="-5"
      id="F_fe48586e-1b21-4f84-97c0-bba9a4d060e3"
      unitRef="U_USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_f35bda8e-4477-4e3d-91b7-eb0cd103d909"
      decimals="3"
      id="F_f90df369-d7d3-4d8e-9c08-369d2fc239e5"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_faf87937-2b9d-462a-a2e3-6532a2a5832f"
      id="F_1c4baff1-3969-4c1d-8465-a1f44201b0b9">on or before January 30, 2021</us-gaap:DebtInstrumentMaturityDateDescription>
    <dsgn:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage
      contextRef="C_255b9a96-4942-438d-9182-67188791643f"
      decimals="2"
      id="F_9910c029-7a68-45c2-abbe-844f4bc7109e"
      unitRef="U_pure">0.03</dsgn:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage>
    <us-gaap:UnsecuredDebt
      contextRef="C_a3d50d4d-9539-4c43-8867-5bbaabbcbf1e"
      decimals="-5"
      id="F_4f7462aa-45cc-402e-bc7a-40a42feef362"
      unitRef="U_USD">200000</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_fb933540-a365-4b43-a477-40ec4114592f"
      decimals="INF"
      id="F_0a79cc86-d34e-4cd9-8a28-ab735370c715"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_c609f5a0-ad87-42d1-88bd-8814d48c2007"
      decimals="INF"
      id="F_6f557aff-12a0-4eeb-8721-02382387fbd1"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_a91e7f27-4f86-4dc5-b77c-9a9ed9b2d61c"
      decimals="-5"
      id="F_b854ac9f-6a80-4535-9eaf-4e636692c3e8"
      unitRef="U_USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_d3ac15fe-44bb-4b93-b43f-a4b8bb8f3178"
      decimals="3"
      id="F_4d4c5e43-3fd8-4901-9cb9-492d1b6bdcdc"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_979df7a7-b6e0-451a-8eb9-bb3bdb83d3f8"
      id="F_604c1d7d-8814-4b15-b8fc-6ec35a013cbd">on or before January 1, 2022</us-gaap:DebtInstrumentMaturityDateDescription>
    <dsgn:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage
      contextRef="C_395fdd7c-d463-4675-9795-d06cc0e2ea3c"
      decimals="2"
      id="F_fbdaea25-14e7-4fa4-abfd-f5aae5cabfaf"
      unitRef="U_pure">0.03</dsgn:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage>
    <us-gaap:UnsecuredDebt
      contextRef="C_4808721b-298d-4f46-a8a8-371b01e8767d"
      decimals="-5"
      id="F_6e2d6e34-2302-4d43-b8c6-3d7f71b2974f"
      unitRef="U_USD">400000</us-gaap:UnsecuredDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_02912d63-fe9a-4d28-8b7a-f7b2934ccafb"
      decimals="INF"
      id="F_a4df026d-d1ea-4e98-8242-865ae4626bf1"
      unitRef="U_pure">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_a37bffe0-f723-4a15-9b38-db5ae6d1a171"
      decimals="INF"
      id="F_48a84c9f-224f-4b0e-8179-c8167ed1418c"
      unitRef="U_pure">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="C_c1f43774-a82a-4496-812e-205e05514a80"
      decimals="-5"
      id="F_95cbd779-0b58-4bb7-8f07-efb2f7ac3245"
      unitRef="U_USD">300000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_03f5fca6-f809-4c6f-a23c-f662104eb076"
      id="F_a4f81749-b9f0-4790-99b6-64cb5b6f1bba">on or after February 5, 2021, if not converted earlier</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_cd48c120-475c-4c27-9b88-664af08c371a"
      id="F_99161039-2de1-443c-913a-433a7f72179f">on or after February 5, 2021, if not converted earlier</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:ConvertibleDebt
      contextRef="C_ad693d79-777f-411a-ab08-35eb238a9099"
      decimals="-5"
      id="F_2c16a4c7-5537-4e76-91ef-fe7a1075241c"
      unitRef="U_USD">200000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_f124e841-56b0-4f7a-af20-08a6724d6ca7"
      id="F_561ab4fe-b518-4afa-84a6-1bef25759a7a">on or after May 16, 2020, if not converted earlier</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_ad693d79-777f-411a-ab08-35eb238a9099"
      decimals="INF"
      id="F_7281fd5e-f945-4c95-813c-b46d35f10a11"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <dsgn:PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold
      contextRef="C_ad693d79-777f-411a-ab08-35eb238a9099"
      decimals="INF"
      id="F_577ceef1-f68b-475d-b6ef-954c1954447f"
      unitRef="U_pure">0.80</dsgn:PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="C_042f9541-36bc-42b0-97cd-cb54c6a99af9"
      decimals="-5"
      id="F_9bf21f36-4869-4a31-9b9c-4dba3565a3c6"
      unitRef="U_USD">500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_5da19a76-eb5c-4b29-ac7a-7f31dd304f72"
      decimals="0"
      id="F_c83dc800-1fef-43d4-8709-f2c3098a5486"
      unitRef="U_shares">301685</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SharePrice
      contextRef="C_a00ae526-34b5-48ac-a0e6-a0ab0d3cc6e5"
      decimals="5"
      id="F_24d104da-71ec-4adc-a090-ea6ef499c785"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.65816</us-gaap:SharePrice>
    <dsgn:DisclosureOfLicenseAgreementTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_9ff3cc51-211f-4d15-9053-bfd9f5a73294">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the &#x201c;License Agreement&#x201d;) with the Wisconsin Alumni Research Foundation (&#x201c;WARF&#x201d;). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the upfront fee upon execution of the agreement and the remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. In February 2020, the Company paid the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; balance upon the initial closing of its Series A preferred stock financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the License Agreement, the Company is required to pay $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; upon the acceptance of an investigation new drug (&#x201c;IND&#x201d;) application in the U.S. and will be required to make further aggregate milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees&#x2019; net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; milestone or royalty payments as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the year ended December 31, 2021 and less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2020, which were recorded as general and administrative expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company may terminate the License Agreement with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days written notice or for certain breaches of the agreement. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/span&gt;&lt;/p&gt;</dsgn:DisclosureOfLicenseAgreementTextBlock>
    <dsgn:CollaborativeArrangementsUpfrontPayment
      contextRef="C_36de137c-6361-4ec5-8970-5fc39d50dd4c"
      decimals="0"
      id="F_8284a026-ee21-41d7-98b1-ae7f8e25f128"
      unitRef="U_USD">250000</dsgn:CollaborativeArrangementsUpfrontPayment>
    <dsgn:UpfrontPaymentUponExecutionOfAgreement
      contextRef="C_69d3f494-4d79-47df-87fd-27a5128beb0a"
      decimals="0"
      id="F_045c8c2c-8669-4e74-a57a-c0c758dd944e"
      unitRef="U_USD">25000</dsgn:UpfrontPaymentUponExecutionOfAgreement>
    <dsgn:UpfrontPaymentWithinOneYear
      contextRef="C_69d3f494-4d79-47df-87fd-27a5128beb0a"
      decimals="0"
      id="F_9b469174-8489-4292-a88a-643d7777fa4a"
      unitRef="U_USD">225000</dsgn:UpfrontPaymentWithinOneYear>
    <dsgn:CollaborativeArrangementsUpfrontPayment
      contextRef="C_9b012ef3-2aff-4122-9520-8407c5275290"
      decimals="0"
      id="F_3f2c0bdb-68c1-40ed-9039-dbb8584b09ec"
      unitRef="U_USD">225000</dsgn:CollaborativeArrangementsUpfrontPayment>
    <dsgn:ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones
      contextRef="C_fd90086d-3437-4665-82bf-18b82bd4403a"
      decimals="0"
      id="F_81a6e7c7-d174-43b5-953b-55a13ea2256a"
      unitRef="U_USD">125000</dsgn:ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones>
    <dsgn:ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones
      contextRef="C_a9db9070-48ac-46f3-9a8e-aac6cdbfd36d"
      decimals="-5"
      id="F_08c2c553-36d8-4814-a1eb-ff53adf01b53"
      unitRef="U_USD">17500000</dsgn:ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones>
    <dsgn:ExpectedRoyaltyPaymentsUponFirstCommercialProductSale
      contextRef="C_91e891fe-e7f8-423a-b358-a2ff1159c8aa"
      decimals="INF"
      id="F_5628cb67-9e2b-44fc-a42f-475888793e87"
      unitRef="U_USD">100000</dsgn:ExpectedRoyaltyPaymentsUponFirstCommercialProductSale>
    <us-gaap:ContractualObligation
      contextRef="C_fd90086d-3437-4665-82bf-18b82bd4403a"
      decimals="INF"
      id="F_7d330dbc-aeba-47d7-9128-294f618eb2a6"
      unitRef="U_USD">0</us-gaap:ContractualObligation>
    <us-gaap:RoyaltyExpense
      contextRef="C_196bb1dc-ff73-4b87-b41c-495f6b29e794"
      decimals="INF"
      id="F_d65781bc-feff-4ce7-911f-a043ffae9ce0"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <dsgn:LegalPatentFees
      contextRef="C_9d48e74d-c13f-42ba-9e94-f177898744b6"
      decimals="-5"
      id="F_9014a416-a94a-45df-9bb5-931f9ed3f098"
      unitRef="U_USD">100000</dsgn:LegalPatentFees>
    <dsgn:LegalPatentFees
      contextRef="C_5850416b-5268-46c3-970b-18e7e145562e"
      decimals="INF"
      id="F_c25ef688-c2fb-4370-8002-ebeec2b212ad"
      unitRef="U_USD">100000</dsgn:LegalPatentFees>
    <dsgn:NoticePeriodForTerminationOfAgreement
      contextRef="C_d6d2ec7c-c375-4c5a-a4e1-a6f9962559bb"
      id="F_30858e17-87cc-40d2-a41e-2d0e162d48c0">P90D</dsgn:NoticePeriodForTerminationOfAgreement>
    <dsgn:NoticePeriodDescription
      contextRef="C_d6d2ec7c-c375-4c5a-a4e1-a6f9962559bb"
      id="F_28557f27-b3d5-4f53-8387-ab9a2f28a6f4">WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.</dsgn:NoticePeriodDescription>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_d8da2eb3-5588-4211-82f7-a41d2c3dfa1a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Lease Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.285%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.18%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.169%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Consulting Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (&#x201c;Marlinspike Group&#x201d;) for research support, management, and business consulting services (the &#x201c;2019 Consulting Agreement&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Further, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marlinspike Group provides the use of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,120&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company&#x2019;s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company&#x2019;s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days&#x2019; written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the &#x201c;2020 Consulting Agreement&#x201d;), which provides for the similar services and use of office space for a monthly fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days&#x2019; written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.278%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.178%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.178%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Asnsari, a co-founder, provides consulting services and advises on certain research and development activities (the &#x201c;Research Consulting Agreement&#x201d;). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.285%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.18%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.169%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company had accrued expenses and other current liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as of December 31, 2021 and accounts payable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as of December 31, 2020, pursuant to its related party consulting agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Convertible Notes and Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May and July 2018, the Company issued a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of convertible notes to a co-founder for cash with a maturity date &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on or after February 5, 2021, if not converted earlier&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The notes bore interest of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% per annum and were convertible into equity securities sold at the next financing at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the selling price per share of such equity financing. In February 2020, these notes converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171,025&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 12 for further discussion.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6"
      id="F_50c43c75-12ef-48b4-a781-f8b79ae41e39">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.285%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.18%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.169%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6"
      decimals="-3"
      id="F_12abeeed-3726-40fd-bc7f-c69617299b0f"
      unitRef="U_USD">225000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6"
      decimals="-3"
      id="F_7fd5764b-16af-4ee5-b1cc-a690ca19aa01"
      unitRef="U_USD">88000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_f57abc00-fea9-40c5-819a-c30ce4cb75f6"
      decimals="-3"
      id="F_04e5fb46-4cb1-4c89-89a9-26e4b023c0fa"
      unitRef="U_USD">313000</us-gaap:CostsAndExpenses>
    <dsgn:AreaOfOffice
      contextRef="C_855ff555-2cfb-491d-a8ff-2b1192bb78b8"
      decimals="INF"
      id="F_a0a787da-de66-47eb-89be-71bfbf2e7a8f"
      unitRef="U_sqft">2120</dsgn:AreaOfOffice>
    <dsgn:MonthlyFeeForConsultancyServices
      contextRef="C_fc6ac533-72ba-4dfe-b7e0-cef03f4d60a7"
      decimals="0"
      id="F_4405abe4-0783-4d80-988b-662be245eb09"
      unitRef="U_USD">20000</dsgn:MonthlyFeeForConsultancyServices>
    <dsgn:TerminationFee
      contextRef="C_fc6ac533-72ba-4dfe-b7e0-cef03f4d60a7"
      decimals="-5"
      id="F_632d47b0-ed1a-4e5c-b1e1-ad5956affa67"
      unitRef="U_USD">200000</dsgn:TerminationFee>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_e28222d2-bdab-40c4-91ad-c91e8c333540"
      id="F_4b486c88-239a-4f08-8ccd-64c2b0079c23">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.278%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.178%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.178%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea"
      decimals="-3"
      id="F_f9accfdd-02e7-4864-9eb0-348955f3b8f8"
      unitRef="U_USD">8000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7727e7fe-60e9-46a9-8c20-52528f28b578"
      decimals="-3"
      id="F_ec9ec598-b200-4329-8317-f3898f81fdf9"
      unitRef="U_USD">240000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea"
      decimals="-3"
      id="F_53d6e4cb-3d6c-443c-9557-8fdf5b211939"
      unitRef="U_USD">292000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_7727e7fe-60e9-46a9-8c20-52528f28b578"
      decimals="-3"
      id="F_a22e205c-c5d7-474d-ba44-668018b9128f"
      unitRef="U_USD">240000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_546668a4-9084-4d34-a2b9-4c9ba146c3ea"
      decimals="-3"
      id="F_9f14ac80-7b8c-4c55-b2f1-ff2e28c47b89"
      unitRef="U_USD">300000</us-gaap:CostsAndExpenses>
    <dsgn:RelatedPartyTransactionMonthlyFeeForServices
      contextRef="C_149ca0e1-6a9d-4838-96bf-fc89fbd1fbb0"
      decimals="0"
      id="F_d6412b44-540c-441c-85bf-a2e9cfebcf80"
      unitRef="U_USD">15000</dsgn:RelatedPartyTransactionMonthlyFeeForServices>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_33e57430-f87d-45d8-a826-73fae3f00112"
      id="F_15b4b7c0-bacc-4570-8f4d-189afe254859">&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.285%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.18%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.169%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_33e57430-f87d-45d8-a826-73fae3f00112"
      decimals="-3"
      id="F_bcba0087-2510-4ff6-97be-9693febaf956"
      unitRef="U_USD">180000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7bd00ed8-2f33-4d98-9fdd-289c66eb1dd5"
      decimals="-3"
      id="F_d666cd6d-da99-433d-8d9b-a5de7fd0def3"
      unitRef="U_USD">45000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_33e57430-f87d-45d8-a826-73fae3f00112"
      decimals="-3"
      id="F_66d203ac-c6c4-45d1-b3cb-69ca804aa7da"
      unitRef="U_USD">180000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_7bd00ed8-2f33-4d98-9fdd-289c66eb1dd5"
      decimals="-3"
      id="F_2a778d9f-a932-4cbc-89a8-ac08bc0e0644"
      unitRef="U_USD">45000</us-gaap:CostsAndExpenses>
    <dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
      contextRef="C_d9851747-c6e0-46a7-ae37-a995db3d6025"
      decimals="0"
      id="F_d1bc13da-45a1-4b39-b64f-6b71ab39bdaf"
      unitRef="U_USD">15000</dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="C_65c3b16a-86a3-451d-ae60-e9601eb9ca53"
      decimals="0"
      id="F_e0ffcca1-a1f6-47a3-9f76-62eb266d3c7e"
      unitRef="U_USD">20000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="C_31bede1d-9fe1-4f2f-8a68-d59a76c82fcf"
      decimals="-5"
      id="F_bf5bffdd-b1f0-431d-9d08-bdbf99340aae"
      unitRef="U_USD">300000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="C_4729fd04-d690-4b2c-9242-4f8689fbc206"
      decimals="-5"
      id="F_bf5b5af6-70e5-4119-86cf-58a34a604bc9"
      unitRef="U_USD">300000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_1ada34b7-cc0e-46bf-8d53-623a26d0b905"
      id="F_f07897e3-a000-4004-90e1-0d3c4e7d90de">on or after February 5, 2021, if not converted earlier</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="C_73cc3eeb-6a6b-45c1-a16b-d0b91237aebe"
      id="F_982021d8-991a-4070-87fb-7e3f13796ba2">on or after February 5, 2021, if not converted earlier</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_4729fd04-d690-4b2c-9242-4f8689fbc206"
      decimals="INF"
      id="F_046b6b00-82bc-4a92-adc3-57618ea4ea5e"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <dsgn:PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold
      contextRef="C_4729fd04-d690-4b2c-9242-4f8689fbc206"
      decimals="INF"
      id="F_3d6315d1-3ac1-4507-a07e-a04e4c8d2db9"
      unitRef="U_pure">0.80</dsgn:PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_fe8be1e8-fc44-433d-8028-3795727073cf"
      decimals="INF"
      id="F_be26542e-227b-4ca3-989d-c293ad9318de"
      unitRef="U_shares">171025</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      id="F_339eec4d-c929-41f7-a807-5c16324f52bd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company's U.S. employees. The plan allows eligible employees to defer, at the employee's discretion, pretax compensation up to the IRS annual limits. The Company is not required to make matching contributions under the plan and had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t made any such contributions as of December 31, 2021.&lt;/span&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_e84263eb-baf8-4179-a0c7-153ef77908b1"
      decimals="INF"
      id="F_b2058c82-fefd-473d-a2cf-f3340186493d"
      unitRef="U_USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP#$+8X"_KP7J>7UC/H;M/WXN_@-02P,$%     @ '8)J5"CG)&Q0 P  ^0H
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M.:Q8+<P/N?L#VH1BJY=)H=T_V36V:>"1K-9&EJTS$I2\:I[LH9V(/8<P.N-
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M!A<?J8ZJF8S-QLC:#9>9-#2JW+*@GPDJZT#?YU*:S<8FZ'Y/Z2M02P,$%
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MD&M-1:Z'OL'TEL3/ZE23*E5T(E48D3LI3*')>Y%#?DC@H^Y&?+03/XG.,MY
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M)I1V@UDOA-"[P";HKKKT-U!+ P04    "  =@FI4;2<<$>0&  "-'   &
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M.@I>'XZ(%57.GQAK/U=M/*(JCZTM#[%PU,:5!GJ.(GZ..MT&8$TH[9A(,FF
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M@W)"M0I^<Y_R/64>1-$AC@[*?$00:/]&X#@L^RAP%B4"%A@(R0USS4T*_UY
MN<,J>Q!4M%L92FAT'IRIT#8^ E&%>YDX_YXM@FT);8A/95)[K)@U<1VX<.*?
M$*@#,("5?" 0K GU6JT*0UJ_W0C.]B5T8]IA5"Y5UN^.%;[FUH1&^?DJ3&:
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M@)W-AHO%64B'LR=.AL@YNF>/M4&L]SQ\/&)(5##)-,=ZQ8"B-#,XSF$')Y<
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M,MZ;(ESF)!%6%L#ZVJ 6FQL^H/OZ=?T/4$L#!!0    ( !V":E1'II_?A@,
M -H'   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*U5VV[C-A!]]U<,
MU*+8 $8D41?;J6T@3KK8!;)HL.GEH>@#+8TM8BE22U)V\O<=4K;JHKM!@>Z+
M*)(S9^8,Y[(\:O/)-H@.GENI["IJG.MNXMA6#;;<7NL.%=WLM&FYHZW9Q[8S
MR.N@U,J8)4D9MURH:+T,9X]FO=2]DT+AHP';MRTW+QN4^KB*TNA\\%'L&^</
MXO6RXWM\0O=K]VAH%X\HM6A16:$5&-RMHMOT9I-[^2#PF\"CO?@'SV2K]2>_
M>5^OHL0[A!(KYQ$X+0>\0RD]$+GQ^809C2:]XN7_&?UMX$Y<MMSBG9:_B]HU
MJV@>08T[WDOW41_?X8E/X?$J+6WXPG&0S8H(JMXZW9Z4R8-6J&'ESZ<X7"C,
MDZ\HL),""WX/AH*7]]SQ]=+H(Q@O36C^)U -VN2<4/Y1GIRA6T%Z;KWADJL*
MX2EDP#TZ+J1=QHZ@O4!<G6 V PS["DS*X(-6KK'PDZJQ_B= 3#Z-CK&S8QOV
M*N(]5M>0I5-@"4M?P<M&HEG R_X3T3O==EJA<O#'[=8Z0\GQYRM&\M%('HSD
M_S>:K\+X0KRQ':]P%5&E630'C-;E-7P1'AX-=ES4@,]4J18M<%6#=@T:2B!C
M/$EN+3H+E:9BL@[I>@<D #LMJ2J%VL,;H>A$]Y:4[=7-A,*/[98@_!-<;B;_
M,O<]I%-6Y+26R>0)R:9P+U09G;:"C/[PW9RE[$?(9Y/WRB'Q<53-%8H#WTJ$
M-$T@328_!W]GP(K)+]IQ&5"S6>K7G!%':D.&8#TW_-R+KO6\O@FA![[5ACMM
M7BZ0O?DTG],Z*R<^6WIR_>+>^V'USAVY05B49Y:3M[U1PO5TZ"5VXMG_6V +
M-HH\('611LL:1-L9?4 /:&%1C!)W1,N9?NA;Q(.D]H1B*5BC3#HM*2[DW(._
MX%75M[WD/A04>8JOX$'[#:19#E>T%G!U$=HB"=Q2N*TJTY.6%'PKI' "OU&>
MG('IW:Q6"B7!6N?3A4W3@M%:E,4HY=.<FZH)8:OQ0-/B_,1>J4A+8"6]Q"FA
M.VT"/?+/)P9Q)=^D#^Q(Y&5*H$-$.NY3)Y\OQNB=S0YE4B0EY6 RAB>;EF5&
MZR)+X4M=(;[HMRV:?9@J/FR]<D/K'4_'P74[].N_Q8>I]X&;O5"6?-^1:G(]
MHSEAADDR;)SN0O?>:D>S(/PV-'S1> &ZWVGMSAMO8!SGZ[\ 4$L#!!0    (
M !V":E1BUL;-CP4  (L,   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;)5736_;.!"]YU<,O.VB 1S9ENTXFR\@25NT0((&:;M[6.R!EBB+K42J)!7;
M_W[?4++L!(FQ>XDE:F;XYLV;(7.^-/:GRZ7TM"H+[2YZN??5Z6#@DER6PD6F
MDAI?,F-+X?%J%P-762G2X%06@W@X/!Z40NG>Y7E8N[>7YZ;VA=+RWI*KRU+8
M];4LS/*B-^IM%A[4(O>\,+@\K\1"?I7^>W5O\3;HHJ2JE-HIH\G*[*)W-3J]
MGK!],/A3R:7;>2;.9&[,3W[YG%[TA@Q(%C+Q'$'@YU'>R*+@0(#QJXW9Z[9D
MQ]WG3?2/(7?D,A=.WICB+Y7Z_*)WTJ-49J(N_(-9?I)M/E..EYC"A;^T;&Q'
M,$YJYTW9.@-!J73S*U8M#SL.)\-7'.+6(0ZXFXT"RO?"B\MS:Y9DV1K1^"&D
M&KP!3FDNRE=O\57!SU_>2J1T/O (Q0N#I'6[;MSB5]Q&,=T9[7-''W0JTZ<!
M!L#0 8DW0*[CO1'?RR2B\:A/\3 >[8DW[A(;AWCC?8DY^OMJ[KQ%[?_9$W/2
MQ9R$F)/_2]9^MUE$P9,^:[H3:V0X^H-\+NG&E)70:Y+:2RM34MH;$I#JPDH)
MY?L^"8=^F3OYJ\9KL2:!91#>)U@6(6@AYL8*;^R:7"42255M72VT9Q.!?1#K
MJ.1B(5H-/0FO$E$@EI5:+I5>-($B>E]+]F%D+C?6'P%525KXVDHR6?@03/ND
M/"T!31L/T$E1 Q)#!7:,"Z#IHI+EMF#O&B_".<P9;>PKQH42<U4HOR8T[ Y#
MO_]V$H]F9PX-6 B=,#X(WD7T;8=%1JN %E#8M2,1".FKK+PLY](&>5'$I?@H
MY[;&( I+_3T%:<%M RZ5S^G&&N<8^B=3I/AU?;J]O6$"+=N(JK)FI<"V!-6C
MN#^>#3%SL*&DC*<M*-DIG= I5C+%N84JOF,\G'<\/ OJ"<^CL\,G27?$?%C)
MI.8!1S>Y4!:\.J/[E)BCS-10C T[E T'V%IYD&F$Y5TI519#TEBDH%Q3?U/(
MC34[W@F-$1T\7\Z[0=40E9@2-"6!O^?,!^I$J!4'F\54-G.$=PF*",,:+,J5
MA]2WHFM\,M8.(3UETD:3* JMI;".SB@W2_DH;="G:N2)DPI,B#F*D$CK<4P]
MJ?12%06VDC91O 6^;!&$_J!E+O5S% #F.#FD-*-^P.[SVC4B0D/8H!-1--;<
M*7+5=DEF31G,T(-)78BP6=M<#U^^-RW2Q]Y%4'(EK&_4\:Q#GIGL\M]VI*-'
M86&.2FJCC[K:5$8#G*-W,EI$_5 M/AY!%/$I#M:YQ?I/7Z1/HD. %)XMGS9^
M2^E>]*]V^DO&O ,.9SZYN[DB5[B'A.3"9JT"@*&VZ-3-A*W$N@S)<0@,SA\(
M$>:@UC7*$4H3S@4P/J:W;>6V<H!HK'1@R"GFC=7&G>)RT8S ;1HMGD:X7JPD
MJK_,59*'K=NO ?P6XU78%R==TQ";TZZ1#30#PK<,=7+?:H^%-(UFK=PWV%/E
M$O0XI X:><RFG'$JFWG8B#I,X2.3'6VG,+LGQC;I<B/OF<:\\2P:3>EMA%&
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M<?;J=) *K/L1;!WO;7,;< N,CR6NW>1X ;XOK W=#S;07^0O_@-02P,$%
M  @ '8)J5+O1R175!0  6 X  !D   !X;"]W;W)K<VAE971S+W-H965T,C N
M>&ULM5=-<]LV$+WG5^RHF=:>4222^K1C>\9VDJD[3:N)V_30Z0$B(1$U!3
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MA83*EQLE@6:T .]715&U-W1 ]UNMF_\"4$L#!!0    ( !V":E1H(;%\=@D
M (,9   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)U977/;MA)]UZ_
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MD6'LM42$6HE+VW;2W E0* =&V@3+'^+VK0ZUN'36>VVNQ8^V*?'K$_'^_:4
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M1)(6^3[1(5<'?Z[6CBS?C+\G HS[ .,08/S?I3S-2<]B>)\%/TN$:U/50K^
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M&ZTWX/V-,718^ #]_\#L'U!+ P04    "  =@FI4<U:T,(P2  !$.0  &0
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M* &X=4\)Q DD+X@*Q#FGI,4B%D(2T57.$$I.#4BC$Q@^\D(1>L2$6KF&(KB
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M*13>&;!]VW+S?(52[U=1&AT//HM=X_Q!LEYV?(<;=%^Z.T.[9$2I18O*"JW
MX'857:875[GW#PY_"-S;DS5X):76#W[S>[V*IIX02JR<1^#T><1KE-(#$8U_
M!\QHO-('GJZ/Z+\&[:2EY!:OM?Q3U*Y918L(:MSR7KK/>O\;#GH*CU=I:<,O
M[ ??:015;YUNAV!BT IU^/*GX1U^)( - 2SP/EP46-YPQ]=+H_=@O#>A^460
M&J*)G% ^*1MGR"HHSJT_4=X_:&OA#@UL&FX0WM[S4J+]99DXNL"[)=4 =G4
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MJ-T$^IXK<EW=<06:?PW3_P!02P,$%     @ '8)J5%>@C$[6 P  L@D  !D
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MM0?#'K5__#:(PNA/ZEU !RY/9JQ/I_5\/;^&)^)&QV/?U.\4,NRV@[A;K[Z
MR,(=P:P]BLX3K&",A,CUM-U^T&\ #AMX9.L/SE/[&:P7MX=AV*07-/'(W ^B
MUI,T3!#90;?=[PQ_D">*XQ\$(K=XV#V3_^!_G?^PW>\&U,8G 3721?;X5W-/
M$0^"'J4XJA$.+9F&W4$M;*?3[G9[KAQZ9W8FES[=4J_]U?W&/9JA6KG7@J:C
M6N2FO%+KV?I!,BWOX:-[^9HA75=61(%+6AI<][L>J/*%4 Z,W+A;>2$-W?&N
MNZ9'%2KK0/:EE.8PL!O4S[3)OU!+ P04    "  =@FI432?=7^@#  !H"0
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M-;@981.KYEYO)D96[B[=2(,WLWLM\%<(E#7 [[F4IIW8 -W/U?Q_4$L#!!0
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MH3IK(L>%O90'H^@M)SLS?R\2F2,\LA?4</G(5AGJSK1G"-H>Z"4US**""=^
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M<J,E[:;DIP<3S)C&&,9,ZA7<2L85L_52\.&633-4QSU7$Y$Q=Z,UZ+ $#?:
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M%P%DF).2F5NY_85U0#W'ETJF_2]L:]LH@+341O(:;!5P*JHG>:X3L0>(^P<
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M',43_WY?CU,[G&1)F*5);W@08M*'F R&.!?\'J2F*[/W%^8\ 2D-]Z46^=U
M M,>/7U)NF8]K>R9=9UGIWI%21 GX]%YO48]]=$@=:<,^EQ;5FH@%>,>;_R2
M%,+![I0.GOO;ZQ@<?'QI%F59<O3QG3'$:8!#')\7$^_=17A83G<CH&6S^FEN
M>:0%NH6ZD7EI[NFA-(:[!<(7I>_NQ,?1L^L;G>H;C4=A>BSOJ5T:I^,D>D+=
MW?6!A^^/FZIFXC= >YZB12<L6C#"AY*X.[QQ\J+4W9W[.'UV==,3U:)1=*R9
MOU<H5B WKGY6*!<-UVVYU(_V-?JEJTR/QJ]L[>X*T!U,6_A_)')#N4(,U@8R
MN,@,)=G6TFU'B]J5HRNA37'KFJ7Y_P!I#<S\6@C]V+$+]'\TLS]02P,$%
M  @ '8)J5"?AGDJ[ P  JQ$  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&ULS5A=;^(X%/TK5]$\M-(LB1W"QPB06JIJ*[6SG3*=?5CM@YL8L)K8K.W
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MT@3H_;40N)^8)M?_T])_4$L#!!0    ( !V":E3MM!1%/0,  %T,   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;+5776^;,!3]*Q;J0RNM!9/O*HG4
M)JU6J9.BIMT>ICTX<!.L J:V:=I_/]L0( EAG92\!-O<CW./[</-<,WXJP@
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M;H&GV\P;63!.)%.7Z:Y^6[?"]HJPO9.?S7Z1JW^DL]G?YQBW=SGN?_EL#@J
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MQVA*UM='W=&BM"5[+31> +:9X94+TDS \50(_=XQMT![B<__ 5!+ P04
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M!A1H>2&/9/:)]L6[3@N%J50\+L!@0<R2_)O\*!QQ   YU0!< / IP#\#\ J
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M3_&PJ.)NJW@Q,G.7-R_2&)FZQP6P&)3=@+_/I#3;%VN@NF$<_@M02P,$%
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MH]YW(LTKJA"#E8$,+@:&E"RFIV*CQ<8-($NAS3CCEIF9.$%: _-\)83>;VR
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MSCF%,E=^TVQW'%"6!"!F-.1I;/(5.'04(9H!>884\VD4;:%8^K"1@E()^H#
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MA*4JG 0Q"W(-'O)0 .P9&"GP?66^C/12Q7(++J94DC@1ETKX\6$*+CY=@D_
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MZ:%<Q[8(2\+AF0@_4:%VA?E,WU:JWJN.9.!5#0,B@4J&U)CJ2,?C\*A+]DA
MNRI_]GEW!IDE]&38Q>2[N$,GA#9J@;U3M6$G[)_F/*,<.7JE7)W/RGT+[G@<
MT1/S:C%)L //[H>P%F:%%,1[8K;=LITAJDB@7R/1D5 +T]#9C7ZW[]6Q-X@I
MBFW0JX(+\:]![\RCA?$:*J^^OYO%PK:8KXHS[*[.1\'G^;,E@1;&]U#A?M 6
MTE69A=UU]KA+CR;.8H8]:$'?">M^=4\(^^F[L5/#OJK%L+L8'R5ZCH198&AW
MQ3[XJ@;#[B)\:N#_OS3I'RP(ZN.6 @6KD@R[:_(!UGNJ;\(ZB";J.L'5G7--
M$O"#\A1<_$4)%Y>-Z+IG"<%6JP((4GU' 1"#.=DVW7(F)UH*<DO*I-MF:GHJ
M*%C:0@VV]AU;E7[87?L_X-@S174WKI.68O^^6!T44/=!X4.</[(9CN ("HYA
MN;#V49+5L0)U'RM&BP6G"R+555!1BC,11^")).O&;%O8\G;K@(L=7,NV#6*!
MXP7-FQM5AP?4?7AHA7J>2"MF=UO)[<.N#@ZH^^#0 ?M#P8(/G L#Z-;3O+7S
M0)12OC /;0)$;)W)_-&D'"T?\T;F":LV/H8WT_Q)KC*3OQ!^(UR=. 5(Z+,R
M:?=]Y3J>/[KE'<E6YAEJQJ1DJ6DN*9E3K@74]V?&Y'M'3U ^?0[_ U!+ P04
M    "  =@FI4XKCC;*P#  #&#   &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6S-5UV/VC@4_2M7:"NUTI(O/@8J0 )FNEMIJT4S:OM0[8-)+L0:)V9M
M \._WVL' DQ#H-(\[ O$CL_Q.?>:Z\M@*]6S3A$-O&0BU\-&:LSJH^_K.,6,
M:4^N,*<W"ZDR9FBHEKY>*62) V7"CX*@ZV>,YXW1P,W-U&@@UT;P'&<*]#K+
MF-I-4,CML!$V#A./?)D:.^&/!BNVQ"<T7U<S12._9$EXAKGF,@>%BV%C''Z<
MAAT+<"N^<=SJDV>P5N92/MO!YV38"*PB%!@;2\'H:X-3%,(RD8Y_]Z2-<D\+
M/'T^L']RYLG,G&F<2O&=)R8=-GH-2'#!UL(\RNV?N#?D!,92:/<)V_W:H 'Q
M6AN9[<&D(.-Y\<U>]H$X 43M"X!H#XA> SH7 *T]H.6,%LJ<K7MFV&B@Y!:4
M74UL]L'%QJ')#<]M&I^,HK><<&;T9&3\W)Q0(!*8RHQ.AV8NODWX[D* 27.\
M044IA;&F9*_L6PU?+8#G,!&,\$]Q*@5J^-N]A9GB,<^7\$4F*,!(N$>#BM0C
M?&)<P3<FU@AR 6[W ^H/Q7*CX3TM9ESH#R3A-_!!ITRA'OB&W%K-?KQW-BF<
M11><A1'MGYM4PT.>8').X%.8REA%AUA-HEK&>XP]:(6_0Q1$886@Z>WPH$9.
MJTQ=R_&U+J7.!J8Y_SEU8T617"+]V S,=W"Z;L9V;GJ\92J!'W_9E'PVF.E_
M:@2U2T%M)ZA]09#+[>:0VUAF&8G1-L55V2NX>H[+%IO-*.QXW8&_.8WHSXLZ
M7M K%YW)[)0R.[4R'UY65$,H&/9,POL=,J4_5"FLI^F"0T+4@83MJ@[H]#:"
M%F3%.:UD.K/8+2UV;[.XD8+.A.!F5V6PGN0N\GJM=U6^KN+ZKW%G+NY*%W>U
M1(]</S<7"I$*#>4*M0'%#%8YJ2<*O:!=::0>%GC=J,Y'K_31NRT;"=_P!/,$
M=AQ%4N6CGBCP@J#2QR_#SGST2Q_]6AY;]N A6PFYHYP4M7NV5G%*I05F@N4U
M>X3!\4(*_A]E+3RY(\,W+&Q[LK/*UO?ZW>JJ%49'%=';U*TK/*&K.] NRT[O
M6MD)CU=2V'J+PG.%I=OWHF[=B0V/5U)8?R?]0@VYPA1X8:]6T_'^"6^\@*[7
M@RM,%W_9_DE'F*%:ND99T]%=YZ9H>,K9LAD?NQ;TU?S$-NFNTSS2%!W^%Z:6
MG#I!@0NB#+P[DJJ*IKD8&+ER?>=<&NIBW6-*?S10V07T?B&E.0SL!N5?E]%_
M4$L#!!0    ( !V":E3*^\00]0(  /((   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;,U6RV[;,!#\%4+((0&:Z.%G MN 'VD;($$-NVD/10^TM+:(
M2*1"TG;\]UE2LJ*XMM!##KE8)+4SG-VAN>IMA7Q2,8 F+VG"5=^)M<YN7%>%
M,:1478D,.+Y9"IE2C5.Y<E4F@486E"9NX'EM-Z6,.X.>79O*04^L=<(X3"51
MZS2E<C>"1&S[CN_L%V9L%6NSX YZ&5W!'/1C-I4X<TN6B*7 %1.<2%CVG:%_
M,_8] [ 1OQAL565,3"H+(9[,Y"[J.YY1! F$VE!0?&Q@#$EBF%#'<T'JE'L:
M8'6\9_]JD\=D%E3!6"2_6:3COM-U2 1+ND[T3&R_0Y%0R_"%(E'VEVR+6,\A
MX5IID19@5) RGC_I2U&("L!OGP $!2 X!#1/ !H%H&$3S979M"94TT%/BBV1
M)AK9S,#6QJ(Q&\:-C7,M\2U#G![,M0B?+D=8B(B,18JG0U%;WTMR\M7MBQD#
MP4-$;I_73._(<$MEI,@,,B$UQC..<*H!#=>*B"7YD8&T:$4HS_DDQ.8X;(#<
M"Z7(^00T98FZP*T?YQ-R?G9!S@S1SUBL%8)4S]68L='MAD5VHSR[X$1V?D >
M!->Q(K<\@N@]@8NE*NL5[.LU"FH9)Q!>D8;_A01>X!\1-/Y_N%<CIU':U[!\
MC5/VQ53"Y>)?CX924KZR]2>+':G&3>G.+EO/R)][I"1W:)7Z6R.H60IJ6D'-
MVO.4;Q16!4%^:(YYF#.V+:.Y=C:#9KM[W7,WU;H>"6IY9<P[K:U2:ZM6ZPP4
M4!G&]D1.8(-W6F8J4U.&=DG=_AR^=$I!G0_W)6=L54KN=X/.@2]'@CJ=X[YT
M2ZW=6JW?@.-ED5A;AA%>>DQI<WELH*80UR7Y]>=PQO?>KF#OP[TI**O_AZ#;
M#@[,.1;5:1RXXU:Z1PIR99NJ0B5KKO.+L5PM&_?0MJN#]9%IZ+8KO='D7P,/
M5*X87OT)+)'2N^K@>9%Y@\TG6F2V1RV$QHYGAS%^E( T ?A^*83>3\P&Y6?.
MX!502P,$%     @ '8)J5"$[)QNR P  # \  !D   !X;"]W;W)K<VAE971S
M+W-H965T-34N>&ULM5=M;]LV$/XKA+ "+9!%(N77PC:0V"L6(%V#I-T^#/M
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MK[WV.[TNC$Q>+VT;20G6$?96S6QW<KGOM]S'47B0F+9,&+L)!S7AH)/PC\E
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M05D!7%]*:3XG]D%3/V"G_P%02P,$%     @ '8)J5,XU!^,? P  ; @  !D
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MI#B3SVF4UI/O#TP]AS\PO>72@, -0?;N4LJ=KF=;O;%JY\?#6ED:-GY9T.\
M:J= WS=*V>/&.6A_,&:_ 5!+ P04    "  =@FI4(YRY&[H"   >!P  &0
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M1PBY!I\LN=1[\DGR6/&T<A7YF<Q\/S#7/"37<=:+IJ;?+$#S(%0_37H:33!
M/2]7=YZI8PWJ*/D@8KU5Y"+VP:^1OVR19Q: 'OI>!( ]!N"<61$_<-DE+CTA
MS&'.Y]L%>?-]G5]S.\HEK+J$C3,4M>425 W(P@YRP^-'4^AXK7_\C@Y'O]3
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MNCU0J4N^\5S%DGQ$Q]%3 S;&70?O/@9_Z@Y:/(/PB'CT/7$=EW8 6AZN[@S
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M?EC1>P#&)=!ZJ36> D<POC#9'U!+ P04    "  =@FI4-J8P>U$#  #^%0
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  =@FI4DXRQ1>$$  ""*
M#P   'AL+W=O<FMB;V]K+GAM;,6:2V_;.!" _PKA4_>0M:V'VP9Q@#R:;H"T
M,>(@>RP8B;:)2*1!4DF37[\C*6Y&L3S8RS@G6Q)-?QJ1_(:DCIZL>[BW]D'\
M+@OCIX-5".O#X=!G*U5*_[==*P-7%M:5,L"A6P[]VBF9^Y52H2R&T6@T&992
MF\'QT::NF1OB QM4%K0U<+(^<:?5DW^[7A^*1^WUO2YT>)X.FN^%&HA2&UWJ
M%Y5/!Z.!\"O[](]U^L6:((MYYFQ13 ?C]L*=<D%G6Z?G->2MO/?-F2#O;R2
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MMS^I=YD^#[E<>[[6>/V?I'HZGYNOE[\LOW;.;L(%YP2_$SW^!5!+ P04
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ '8)J5&.+!R<A!P  .QT  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !V":E2Y=[T;OP4   @5   8
M              " @60/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  =@FI4*.<D;% #  #Y"@  &               @(%9%0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ '8)J5)&QJ;,+!
MS0P  !@              ("!WQ@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( !V":E1.Z_K:H0(  *H&   8              " @2 =
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  =@FI4[%&(
M**D"  #E!@  &               @('W'P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ '8)J5$JY.HE>!@  BAX  !@
M ("!UB(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !V"
M:E3OQ@'SCP(  /8&   8              " @6HI  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  =@FI4;2<<$>0&  "-'   &
M        @($O+   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ '8)J5.$Q8##M!P  ?A(  !D              ("!23,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  =@FI4FZJKGM@1  #L,P
M&0              @(%M.P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( !V":E2WZNZI-P0  -L)   9              " @7Q-  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ '8)J5*@II8Y)
M!@  N@\  !D              ("!ZE$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  =@FI47C^94G$'   )$P  &0
M@(%J6   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !V"
M:E1'II_?A@,  -H'   9              " @1)@  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ '8)J5&+6QLV/!0  BPP  !D
M         ("!SV,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  =@FI4)@M63+H#   _"   &0              @(&5:0  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !V":E3(VZ>>ZP4  #H0
M   9              " @89M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ '8)J5#T_8C5R!@  U \  !D              ("!J',
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  =@FI4N]')
M%=4%  !8#@  &0              @(%1>@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( !V":E1@7-M]?@P  +<E   9
M  " @5V   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M'8)J5&@AL7QV"0  @QD  !D              ("!$HT  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  =@FI4Y;O;T74'  #7$P  &0
M            @(&_E@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( !V":E1'A1@YS (  !,&   9              " @6N>  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ '8)J5'-6M#",$@
M1#D  !D              ("!;J$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  =@FI4QF[FY1X#  !7!@  &0              @($Q
MM   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !V":E29
M]MX9B0,  $$(   9              " @8:W  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ '8)J5%>@C$[6 P  L@D  !D
M     ("!1KL  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V":E2 "J3?L00  +H+   9              "
M@<'/  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ '8)J
M5*\8N#<M P  R H  !D              ("!J=0  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  =@FI4PM&<#AH$   S#0  &0
M        @($-V   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( !V":E2Y1.+6R@(  )T(   9              " @5[<  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ '8)J5!8;1_]2 P  W0P
M !D              ("!7]\  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  =@FI4)^&>2KL#  "K$0  &0              @('HX@
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !V":E1FQA-O
MR00  )X6   9              " @=KF  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ '8)J5"[((L_" @  R@<  !D
M ("!VNL  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  =
M@FI4):E1=XL"  #?!@  &0              @('3[@  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !V":E3MM!1%/0,  %T,   9
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M970T-BYX;6Q02P$"% ,4    "  =@FI4[QF 0C(&   &(0  &0
M    @('< 0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M !V":E1!KB75(P4  &T4   9              " @44( 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ '8)J5+;6 BU@!P  6",  !D
M             ("!GPT! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    "  =@FI4Z7YI=%$#  #/"@  &0              @($V%0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !V":E2>Q894]08
M ,4>   9              " @;X8 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ '8)J5'\8E13A!   !A4  !D              ("!
MZA\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  =@FI4
MXKCC;*P#  #&#   &0              @($")0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( !V":E3*^\00]0(  /((   9
M      " @>4H 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ '8)J5"$[)QNR P  # \  !D              ("!$2P! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  =@FI4Y9,M35$#  #,"@
M&0              @('Z+P$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( !V":E3.-0?C'P,  &P(   9              " @8(S 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ '8)J5".<N1NZ
M @  '@<  !D              ("!V#8! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    "  =@FI4QPU0'9\%  !5&0  &0
M@(').0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !V"
M:E0%=QBA<P,  .D,   9              " @9\_ 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ '8)J5%J#+-D? @  ;00  !D
M         ("!24,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
M    "  =@FI4-J8P>U$#  #^%0  #0              @ &?10$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !V":E27BKL<P    !,"   +
M  "  1M) 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !V":E23C+%%X00  ((H
M   /              "  01* 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  =@FI4]4F2S $"  !>)   &@              @ $23P$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  =@FI4UDS DN !  #C(P
M$P              @ %+40$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..10!% -H2  !<4P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>412</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical</Role>
      <ShortName>Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities</Role>
      <ShortName>Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureLease</Role>
      <ShortName>Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Grant Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureGrantRevenue</Role>
      <ShortName>Grant Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables</Role>
      <ShortName>Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseTables</Role>
      <ShortName>Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/DisclosureLease</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv</Role>
      <ShortName>Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Investment Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Investment Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Balance Sheet Details - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Details - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Balance Sheet Details - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Lease - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails</Role>
      <ShortName>Lease - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails</Role>
      <ShortName>Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Grant Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails</Role>
      <ShortName>Grant Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails</Role>
      <ShortName>Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="dsgn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="dsgn-20211231.htm">dsgn-20211231.htm</File>
    <File>dsgn-20211231.xsd</File>
    <File>dsgn-20211231_cal.xml</File>
    <File>dsgn-20211231_def.xml</File>
    <File>dsgn-20211231_lab.xml</File>
    <File>dsgn-20211231_pre.xml</File>
    <File>dsgn-ex10_3.htm</File>
    <File>dsgn-ex23_1.htm</File>
    <File>dsgn-ex31_1.htm</File>
    <File>dsgn-ex32_1.htm</File>
    <File>dsgn-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img215454963_0.jpg</File>
    <File>img215454963_1.jpg</File>
    <File>img215454963_10.jpg</File>
    <File>img215454963_11.jpg</File>
    <File>img215454963_12.jpg</File>
    <File>img215454963_2.jpg</File>
    <File>img215454963_3.jpg</File>
    <File>img215454963_4.jpg</File>
    <File>img215454963_5.jpg</File>
    <File>img215454963_6.jpg</File>
    <File>img215454963_7.jpg</File>
    <File>img215454963_8.jpg</File>
    <File>img215454963_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="511">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dsgn-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 163,
   "dts": {
    "calculationLink": {
     "local": [
      "dsgn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dsgn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dsgn-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dsgn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dsgn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dsgn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 530,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 11
   },
   "keyCustom": 61,
   "keyStandard": 351,
   "memberCustom": 30,
   "memberStandard": 31,
   "nsprefix": "dsgn",
   "nsuri": "http://www.designtx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Organization and Description of Business",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Net Loss Per Share",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Investment Securities",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities",
     "shortName": "Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Balance Sheet Details",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Lease",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureLease",
     "shortName": "Lease",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:GrantRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Grant Revenue",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureGrantRevenue",
     "shortName": "Grant Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:GrantRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Commitments and Contingencies",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:DisclosureOfLicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - License Agreement",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement",
     "shortName": "License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:DisclosureOfLicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit",
     "shortName": "Convertible Preferred Stock and Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stock-Based Compensation",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Related Party Transactions",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Employee Benefit Plans",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Investment Securities (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables",
     "shortName": "Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Lease (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseTables",
     "shortName": "Lease (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables",
     "shortName": "Convertible Preferred Stock and Stockholders' Deficit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e28222d2-bdab-40c4-91ad-c91e8c333540",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e28222d2-bdab-40c4-91ad-c91e8c333540",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "dsgn:ShortTermLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "dsgn:ShortTermLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv",
     "shortName": "Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_491eb317-efb1-40ae-85f1-8afd062cc647",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_491eb317-efb1-40ae-85f1-8afd062cc647",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Investment Securities - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
     "shortName": "Investment Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Security",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Balance Sheet Details - Summary of Property and Equipment (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails",
     "shortName": "Balance Sheet Details - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Balance Sheet Details - Summary of Accrued Liabilities (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Details - Summary of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_bf5d2e5b-41f1-419b-8853-434297531657",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:LeaseAgreementTerminationDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Lease - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails",
     "shortName": "Lease - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_bf5d2e5b-41f1-419b-8853-434297531657",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dsgn:LeaseAgreementTerminationDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails",
     "shortName": "Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "dsgn:GrantRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_2a9265ec-0c2d-4f31-9eaf-7d31f601c7b3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Grant Revenue - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails",
     "shortName": "Grant Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "dsgn:GrantRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_2a9265ec-0c2d-4f31-9eaf-7d31f601c7b3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_ad693d79-777f-411a-ab08-35eb238a9099",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_042f9541-36bc-42b0-97cd-cb54c6a99af9",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtConversionOriginalDebtAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "dsgn:DisclosureOfLicenseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_69d3f494-4d79-47df-87fd-27a5128beb0a",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dsgn:UpfrontPaymentUponExecutionOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - License Agreement - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
     "shortName": "License Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "dsgn:DisclosureOfLicenseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_69d3f494-4d79-47df-87fd-27a5128beb0a",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dsgn:UpfrontPaymentUponExecutionOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_5414cbe1-62fc-4f3d-8c60-dfc1f7889b2f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Operations (Parenthetical)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical",
     "shortName": "Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_4b433e9b-8bd1-498f-a486-bdee162f0520",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "dsgn:UnvestedStockLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "dsgn:ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_becd129a-dfa1-4804-9129-b0961e120502",
      "decimals": "-3",
      "lang": null,
      "name": "dsgn:UnvestedStockLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_4b433e9b-8bd1-498f-a486-bdee162f0520",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail",
     "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_4b433e9b-8bd1-498f-a486-bdee162f0520",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_becd129a-dfa1-4804-9129-b0961e120502",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_34051789-f2bd-40c0-b83a-1a91b3aabe17",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_d9851747-c6e0-46a7-ae37-a995db3d6025",
      "decimals": "0",
      "lang": null,
      "name": "dsgn:AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Comprehensive Loss",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
     "shortName": "Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_f57abc00-fea9-40c5-819a-c30ce4cb75f6",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_becd129a-dfa1-4804-9129-b0961e120502",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_becd129a-dfa1-4804-9129-b0961e120502",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_282e8527-291e-424c-a603-4afa6b760575",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "dsgn:PreferredStockIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_282e8527-291e-424c-a603-4afa6b760575",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "dsgn:PreferredStockIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100090 - Statement - Statements of Cash Flows",
     "role": "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "dsgn-20211231.htm",
      "contextRef": "C_e84263eb-baf8-4179-a0c7-153ef77908b1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Carlsbad, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "verboseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dsgn_AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities Related Parties, Current",
        "label": "Accrued expenses and other current liabilities Related Parties, Current",
        "terseLabel": "Accrued expenses and other current liabilities, related party amounts"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest receivable on available-for-sale investment securities.",
        "label": "Accrued Interest Receivable On Available For Sale Investment Securities",
        "terseLabel": "Accrued interest receivable on available-for-sale investment securities"
       }
      }
     },
     "localname": "AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_AreaOfLeasedProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased property.",
        "label": "Area Of Leased Property",
        "terseLabel": "Area of lease space"
       }
      }
     },
     "localname": "AreaOfLeasedProperty",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "dsgn_AreaOfOffice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office.",
        "label": "Area Of Office",
        "terseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfOffice",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "dsgn_BalanceSheetComponentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet component.",
        "label": "Balance Sheet Component [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetComponentAbstract",
     "nsuri": "http://www.designtx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dsgn_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of presentation and use of estimates.",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dsgn_CoFounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-founder.",
        "label": "Co Founder [Member]",
        "terseLabel": "Aseem Z. Ansari, Ph.D."
       }
      }
     },
     "localname": "CoFounderMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_CollaborativeArrangementsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements upfront payment.",
        "label": "Collaborative Arrangements Upfront Payment",
        "terseLabel": "Payment for upfront fee"
       }
      }
     },
     "localname": "CollaborativeArrangementsUpfrontPayment",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_CommonStockCapitalSharesReservedForFutureIssuanceIncreased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital shares reserved for future issuance increased.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Increased",
        "terseLabel": "Number of shares available for future issuance increased"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceIncreased",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dsgn_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreements.",
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting Agreements"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_ConversionOfStockAmountConvertedRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of stock amount converted related party.",
        "label": "Conversion Of Stock Amount Converted Related Party",
        "terseLabel": "Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party"
       }
      }
     },
     "localname": "ConversionOfStockAmountConvertedRelatedParty",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_ConvertibleNotesIssuedInMayAndJuly2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes issued in May and July 2018.",
        "label": "Convertible Notes Issued In May And July2018 [Member]",
        "terseLabel": "Convertible Notes Issued in May and July 2018"
       }
      }
     },
     "localname": "ConvertibleNotesIssuedInMayAndJuly2018Member",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_ConvertiblePreferredStockAndStockholdersDeficitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock and stockholders\u2019 deficit.",
        "label": "Convertible Preferred Stock And Stockholders Deficit [Line Items]",
        "terseLabel": "Convertible Preferred Stock And Stockholders Deficit [Line Items]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAndStockholdersDeficitLineItems",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_ConvertiblePreferredStockAndStockholdersDeficitTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock and stockholders\u2019 deficit.",
        "label": "Convertible Preferred Stock And Stockholders Deficit [Table]",
        "terseLabel": "Convertible Preferred Stock And Stockholders Deficit [Table]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAndStockholdersDeficitTable",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_CrossingHoldingsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Crossing Holdings LLC.",
        "label": "Crossing Holdings L L C [Member]",
        "terseLabel": "Crossing Holdings, LLC"
       }
      }
     },
     "localname": "CrossingHoldingsLLCMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument periodic payment terms balloon payment to be paid, percentage.",
        "label": "Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage",
        "terseLabel": "Percentage of final payment on advanced at maturity"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dsgn_DebtSecuritiesAvailableForSaleMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities, available-for-sale, maturity.",
        "label": "Debt Securities Available For Sale Maturity",
        "terseLabel": "Debt securities, Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturity",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_DisclosureOfLicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of license agreement.",
        "label": "Disclosure Of License Agreement [Text Block]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "DisclosureOfLicenseAgreementTextBlock",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected milestone payment on achieving certain regulatory and commercial milestones.",
        "label": "Expected Milestone Payment On Achieving Certain Regulatory And Commercial Milestones",
        "terseLabel": "Expected milestone payment on achieving certain regulatory and commercial milestones"
       }
      }
     },
     "localname": "ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected royalty payments upon first commercial product sale.",
        "label": "Expected Royalty Payments Upon First Commercial Product Sale",
        "terseLabel": "Expected royalty payments upon first commercial product sale"
       }
      }
     },
     "localname": "ExpectedRoyaltyPaymentsUponFirstCommercialProductSale",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_February2019NoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February 2019 note.",
        "label": "February2019 Note [Member]",
        "terseLabel": "February 2019 Note"
       }
      }
     },
     "localname": "February2019NoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_FebruaryAndMarch2019DrawsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February and March 2019 draws.",
        "label": "February And March2019 Draws [Member]",
        "terseLabel": "February and March 2019 Draws"
       }
      }
     },
     "localname": "FebruaryAndMarch2019DrawsMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_GrantRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of grant revenue.",
        "label": "Grant Revenue [Text Block]",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "GrantRevenueTextBlock",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureGrantRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dsgn_IncomeTaxReconciliationDebtFinancing": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation debt financing.",
        "label": "Income Tax Reconciliation Debt Financing",
        "terseLabel": "Debt financing"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDebtFinancing",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accounts Payable And Other Liabilities Related Parties",
        "label": "Increase Decrease In Accounts Payable And Other Liabilities Related Parties",
        "terseLabel": "Accounts payable and other liabilities related-party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_InitialClosingOfSeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial closing of series A preferred stock.",
        "label": "Initial Closing Of Series A Preferred Stock [Member]",
        "terseLabel": "Initial Closing of Series A Preferred Stock"
       }
      }
     },
     "localname": "InitialClosingOfSeriesAPreferredStockMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of operating lease right-of-use asset and operating lease liability.",
        "label": "Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability",
        "terseLabel": "Initial recognition of operating lease right-of-use asset and operating lease liability"
       }
      }
     },
     "localname": "InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_InvestigationNewDrugMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investigation new drug.",
        "label": "Investigation New Drug [Member]",
        "terseLabel": "Investigation New Drug (IND)"
       }
      }
     },
     "localname": "InvestigationNewDrugMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_IssueOfCommonStockThroughEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock through employee stock purchase plan.",
        "label": "Issue of Common Stock Through Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock through employee stock purchase plan"
       }
      }
     },
     "localname": "IssueOfCommonStockThroughEmployeeStockPurchasePlan",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_Jan2020AndDec2019DrawsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jan 2020 and Dec 2019 draws.",
        "label": "Jan2020 And Dec2019 Draws [Member]",
        "terseLabel": "Jan 2020 and Dec 2019 Draws"
       }
      }
     },
     "localname": "Jan2020AndDec2019DrawsMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_JanuaryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January note.",
        "label": "January Note [Member]",
        "terseLabel": "January Note"
       }
      }
     },
     "localname": "JanuaryNoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_July2018NoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2018 note.",
        "label": "July2018 Note [Member]",
        "terseLabel": "July 2018 Note"
       }
      }
     },
     "localname": "July2018NoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_JulyNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July note.",
        "label": "July Note [Member]",
        "terseLabel": "July Note"
       }
      }
     },
     "localname": "JulyNoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_LeaseAgreementTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement termination date.",
        "label": "Lease Agreement Termination Date",
        "terseLabel": "Lease agreement termination date"
       }
      }
     },
     "localname": "LeaseAgreementTerminationDate",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "dsgn_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "dsgn_LegalPatentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal patent fees.",
        "label": "Legal Patent Fees",
        "terseLabel": "Legal patent fees"
       }
      }
     },
     "localname": "LegalPatentFees",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_LesseeOperatingLeaseTermOfExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Term of expiration year",
        "label": "Lessee, Operating Lease, Term of expiration year",
        "terseLabel": "Option to renew lease term ends, year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfExpirationYear",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "dsgn_LiabilitiesAndStockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities and stockholders equity.",
        "label": "Liabilities And Stockholders Equity [Line Items]",
        "terseLabel": "Liabilities And Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityLineItems",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_LiabilitiesAndStockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities and stockholders equity.",
        "label": "Liabilities And Stockholders Equity [Table]",
        "terseLabel": "Liabilities And Stockholders Equity [Table]"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityTable",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.designtx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dsgn_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_MarlinspikeGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marlinspike Group, LLC.",
        "label": "Marlinspike Group L L C [Member]",
        "terseLabel": "Marlinspike Group, LLC"
       }
      }
     },
     "localname": "MarlinspikeGroupLLCMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_May2018NoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2018 note.",
        "label": "May2018 Note [Member]",
        "terseLabel": "May 2018 Note"
       }
      }
     },
     "localname": "May2018NoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_MayNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May note.",
        "label": "May Note [Member]",
        "terseLabel": "May Note"
       }
      }
     },
     "localname": "MayNoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_MonthlyFeeForConsultancyServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly fee for consultancy services.",
        "label": "Monthly Fee For Consultancy Services",
        "terseLabel": "Monthly fee for consultancy services"
       }
      }
     },
     "localname": "MonthlyFeeForConsultancyServices",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net change in operating lease right-of-use assets and liabilities-related party.",
        "label": "Net Change in Operating Lease Right-of-Use Assets and Liabilities-Related Party",
        "terseLabel": "Net change in operating lease right-of-use assets and liabilities-related party"
       }
      }
     },
     "localname": "NetChangeInOperatingLeaseRightOfUseAssetsAndLiabilitiesRelatedParty",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward taxable income threshold percentage.",
        "label": "Net Operating Loss Carryforward Taxable Income Threshold Percentage",
        "terseLabel": "NOL, percent of taxable income"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardTaxableIncomeThresholdPercentage",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dsgn_NoticePeriodDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period description.",
        "label": "Notice Period Description",
        "terseLabel": "Termination period Description"
       }
      }
     },
     "localname": "NoticePeriodDescription",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_NoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period for termination of agreement.",
        "label": "Notice Period For Termination Of Agreement",
        "terseLabel": "Written notice period for termination of agreement"
       }
      }
     },
     "localname": "NoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dsgn_NovemberNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November note.",
        "label": "November Note [Member]",
        "terseLabel": "November Note"
       }
      }
     },
     "localname": "NovemberNoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_NumberOfDomesticCertificatesOfDepositHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of domestic certificates of deposit held.",
        "label": "Number Of Domestic Certificates Of Deposit Held",
        "terseLabel": "Number of domestic certificates of deposit held"
       }
      }
     },
     "localname": "NumberOfDomesticCertificatesOfDepositHeld",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dsgn_OneYearToTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1 year to 2 years.",
        "label": "One Year To Two Years [Member]",
        "terseLabel": "1 Year to 2 Years"
       }
      }
     },
     "localname": "OneYearToTwoYearsMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforward, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "dsgn_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to expiration.",
        "label": "Operating Loss Carryforwards Not Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_PaidInKindInterestRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid in kind interest related party.",
        "label": "Paid In Kind Interest Related Party",
        "terseLabel": "Non-cash interest expense\u2014related party"
       }
      }
     },
     "localname": "PaidInKindInterestRelatedParty",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs.",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dsgn_PercentageOfAnnualIncreaseInLeasePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual increase in lease payments.",
        "label": "Percentage Of Annual Increase In Lease Payments",
        "terseLabel": "Percentage of annual increase in lease payments"
       }
      }
     },
     "localname": "PercentageOfAnnualIncreaseInLeasePayments",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dsgn_PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of selling price per share that can convertible into equity securities sold.",
        "label": "Percentage Of Selling Price Per Share That Can Convertible Into Equity Securities Sold",
        "terseLabel": "Percentage of selling price per share that can convertible into equity securities sold"
       }
      }
     },
     "localname": "PercentageOfSellingPricePerShareThatCanConvertibleIntoEquitySecuritiesSold",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dsgn_PreferredStockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock issuance cost.",
        "label": "Preferred Stock Issuance Cost",
        "terseLabel": "Preferred stock issuance costs"
       }
      }
     },
     "localname": "PreferredStockIssuanceCost",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expense and other current assets related party current.",
        "label": "Prepaid Expense And Other Current Assets Related Party Current",
        "terseLabel": "Prepaid expense and other current assets, related party amounts"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherCurrentAssetsRelatedPartyCurrent",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_PrepaidExpensesRelatedPartyCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses related party current.",
        "label": "Prepaid Expenses Related Party Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpensesRelatedPartyCurrent",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_ProceedsFromNotesPayableRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from notes payable related party.",
        "label": "Proceeds From Notes Payable Related Party",
        "terseLabel": "Proceeds from the issuance of notes payable, net of issuance costs\u2014related party"
       }
      }
     },
     "localname": "ProceedsFromNotesPayableRelatedParty",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_RelatedPartyTransactionMonthlyFeeForServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction monthly fee for services.",
        "label": "Related Party Transaction Monthly Fee For Services",
        "terseLabel": "Monthly fee for services"
       }
      }
     },
     "localname": "RelatedPartyTransactionMonthlyFeeForServices",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_RepaymentsOfNotesPayableRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of notes payable related party.",
        "label": "Repayments Of Notes Payable Related Party",
        "negatedLabel": "Repayment of notes payable\u2014related party"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayableRelatedParty",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_ResearchConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research consulting agreements.",
        "label": "Research Consulting Agreements [Member]",
        "terseLabel": "Research Consulting Agreements"
       }
      }
     },
     "localname": "ResearchConsultingAgreementsMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_ScheduleOfLicenseAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of license agreement.",
        "label": "Schedule Of License Agreement [Line Items]",
        "terseLabel": "Schedule Of License Agreement [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfLicenseAgreementLineItems",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_ScheduleOfLicenseAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of license agreement.",
        "label": "Schedule Of License Agreement [Table]",
        "terseLabel": "Schedule Of License Agreement [Table]"
       }
      }
     },
     "localname": "ScheduleOfLicenseAgreementTable",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dsgn_ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of restricted shares of common stock and unvested stock liability.",
        "label": "Schedule Of Restricted Shares Of Common Stock And Unvested Stock Liability Table [Text Block]",
        "terseLabel": "Summary of Restricted Shares of Common Stock and Unvested Stock Liability"
       }
      }
     },
     "localname": "ScheduleOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityTableTextBlock",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dsgn_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum percentage of eligible earnings withheld to participate in offering.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Eligible Earnings Withheld To Participate In Offering",
        "terseLabel": "Maximum percentage of eligible earnings withheld to participate in offering"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfEligibleEarningsWithheldToParticipateInOffering",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dsgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award options nonvested exercise price.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested Exercise Price",
        "terseLabel": "Shares early exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercisePrice",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dsgn_SharesEarlyExercisedUnvestedStockLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares early exercised, unvested stock liability",
        "label": "Shares Early Exercised, Unvested Stock Liability",
        "terseLabel": "Shares early exercised, unvested stock liability"
       }
      }
     },
     "localname": "SharesEarlyExercisedUnvestedStockLiability",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_SharesSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares subject to repurchase.",
        "label": "Shares subject to repurchase [Member]",
        "terseLabel": "Shares Subject to Repurchase"
       }
      }
     },
     "localname": "SharesSubjectToRepurchaseMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_ShortTermLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term lease liability.",
        "label": "Short Term Lease Liability",
        "terseLabel": "Short-term leases"
       }
      }
     },
     "localname": "ShortTermLeaseLiability",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options exercised and vesting of early exercised common stock options.",
        "label": "Stock Issued During Period Shares Stock Options Exercised And Vesting Of Early Exercised Common Stock Options",
        "terseLabel": "Vesting of restricted stock, Shares",
        "verboseLabel": "Exercises of stock options and vesting of restricted stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "dsgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock options exercised and vesting of early exercised common stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options",
        "terseLabel": "Vesting of restricted stock",
        "verboseLabel": "Exercises of stock options and vesting of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards, expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible debt and interest classified as temporary equity during the period.",
        "label": "Temporary Equity Conversion Of Convertible Debt And Interest",
        "terseLabel": "Conversion of convertible debt and interest to Series A convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfConvertibleDebtAndInterest",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_TemporaryEquityConversionOfConvertibleDebtAndInterestShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible debt and interest classified as temporary equity during period, shares.",
        "label": "Temporary Equity Conversion Of Convertible Debt And Interest Shares",
        "terseLabel": "Conversion of convertible debt and interest to Series A convertible preferred stock, Shares"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfConvertibleDebtAndInterestShares",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity converted into shares of common stock, shares.",
        "label": "Temporary Equity Converted Into Shares Of Common Stock Shares",
        "terseLabel": "Preferred stock converted into shares of common stock, Shares",
        "verboseLabel": "Preferred stock converted into shares of common stock"
       }
      }
     },
     "localname": "TemporaryEquityConvertedIntoSharesOfCommonStockShares",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "dsgn_TemporaryEquityConvertedIntoSharesOfCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity converted into shares of common stock, value.",
        "label": "Temporary Equity Converted Into Shares Of Common Stock Value",
        "terseLabel": "Preferred stock converted into shares of common stock"
       }
      }
     },
     "localname": "TemporaryEquityConvertedIntoSharesOfCommonStockValue",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_TemporaryEquitySettlementOfBifurcatedConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity settlement of bifurcated conversion.",
        "label": "Temporary Equity Settlement Of Bifurcated Conversion",
        "terseLabel": "Settlement of bifurcated conversion liability"
       }
      }
     },
     "localname": "TemporaryEquitySettlementOfBifurcatedConversion",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "dsgn_TerminationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination fee.",
        "label": "Termination Fee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "TerminationFee",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen equity incentive plan.",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_TwoThousandNineteenConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Consulting Agreement.",
        "label": "Two Thousand Nineteen Consulting Agreement [Member]",
        "terseLabel": "2019 Consulting Agreement"
       }
      }
     },
     "localname": "TwoThousandNineteenConsultingAgreementMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_TwoThousandTwentyConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Consulting Agreement.",
        "label": "Two Thousand Twenty Consulting Agreement [Member]",
        "terseLabel": "2020 Consulting Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyConsultingAgreementMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employee stock purchase plan.",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_TwoThousandTwentyOneEquityIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive award plan.",
        "label": "Two Thousand Twenty One Equity Incentive Award Plan [Member]",
        "terseLabel": "2021 Equity Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentiveAwardPlanMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_UnsecuredPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note.",
        "label": "Unsecured Promissory Note [Member]",
        "terseLabel": "Unsecured Promissory Note"
       }
      }
     },
     "localname": "UnsecuredPromissoryNoteMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dsgn_UnvestedStockLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested stock liability.",
        "label": "Unvested Stock Liability",
        "periodEndLabel": "Ending Balance, Unvested stock liability",
        "periodStartLabel": "Beginning Balance, Unvested stock liability"
       }
      }
     },
     "localname": "UnvestedStockLiability",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_UnvestedStockLiabilityVestedSharesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested stock liability vested shares value.",
        "label": "Unvested Stock Liability Vested Shares Value",
        "negatedLabel": "Vested shares, Unvested stock liability"
       }
      }
     },
     "localname": "UnvestedStockLiabilityVestedSharesValue",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_UpfrontPaymentUponExecutionOfAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment upon execution of agreement.",
        "label": "Upfront Payment Upon Execution Of Agreement",
        "terseLabel": "Upfront payment upon execution of agreement"
       }
      }
     },
     "localname": "UpfrontPaymentUponExecutionOfAgreement",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_UpfrontPaymentWithinOneYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment within one year.",
        "label": "Upfront Payment Within One Year",
        "terseLabel": "Upfront payment within first anniversary of license agreement"
       }
      }
     },
     "localname": "UpfrontPaymentWithinOneYear",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dsgn_WithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Within 1 year.",
        "label": "Within One Year [Member]",
        "terseLabel": "Within 1 Year"
       }
      }
     },
     "localname": "WithinOneYearMember",
     "nsuri": "http://www.designtx.com/20211231",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r57",
      "r59",
      "r110",
      "r111",
      "r234",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r233",
      "r255",
      "r297",
      "r298",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r519",
      "r522",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r233",
      "r255",
      "r297",
      "r298",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r519",
      "r522",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r277",
      "r278",
      "r470",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r277",
      "r278",
      "r470",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r233",
      "r255",
      "r287",
      "r297",
      "r298",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r519",
      "r522",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r233",
      "r255",
      "r287",
      "r297",
      "r298",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r519",
      "r522",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r110",
      "r111",
      "r234",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r277",
      "r279",
      "r521",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r277",
      "r279",
      "r521",
      "r552",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities (including related party amounts of $504 and $0, respectively)"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r457"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable (including related party amounts of $0 and $20,respectively)",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable Current And Noncurrent",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r41",
      "r108",
      "r451",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Related Parties Current",
        "terseLabel": "Accounts payable, related party amounts"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of premiums on investment securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r208"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r63",
      "r64",
      "r65",
      "r508",
      "r530",
      "r534"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r72",
      "r73",
      "r74",
      "r114",
      "r115",
      "r116",
      "r389",
      "r525",
      "r526",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r334",
      "r335",
      "r336",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r118",
      "r119",
      "r120",
      "r121",
      "r130",
      "r172",
      "r173",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r218",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r370",
      "r371",
      "r372",
      "r373",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r446",
      "r472",
      "r473",
      "r474",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r300",
      "r302",
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r269",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r302",
      "r325",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from calculation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r105",
      "r150",
      "r159",
      "r165",
      "r183",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r385",
      "r390",
      "r412",
      "r455",
      "r457",
      "r490",
      "r506"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r56",
      "r105",
      "r183",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r385",
      "r390",
      "r412",
      "r455",
      "r457"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Debt securities, Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Debt securities, Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r177",
      "r194"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Debt securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r176",
      "r194"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Debt securities, Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r303",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchases of property and equipment included in accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r36",
      "r95"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and investment securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r89",
      "r95",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r89",
      "r422"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates Of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r114",
      "r115",
      "r117",
      "r172",
      "r173",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r218",
      "r330",
      "r331",
      "r332",
      "r370",
      "r395",
      "r396",
      "r397",
      "r413",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r433",
      "r446",
      "r472",
      "r473",
      "r523",
      "r524",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r114",
      "r115",
      "r124",
      "r172",
      "r173",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r218",
      "r330",
      "r331",
      "r332",
      "r370",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r413",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r433",
      "r446",
      "r472",
      "r473",
      "r523",
      "r524",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, adopted date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r118",
      "r129",
      "r174",
      "r191",
      "r337",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, material impact"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r102",
      "r105",
      "r131",
      "r132",
      "r133",
      "r135",
      "r137",
      "r143",
      "r144",
      "r145",
      "r183",
      "r219",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r253",
      "r254",
      "r258",
      "r262",
      "r412",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r216",
      "r495",
      "r512"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r217",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r457"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock: $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,681,752 and 16,604,774 shares issued, 55,441,926 and 15,957,821 shares outstanding at December 31, 2021 and 2020,respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r285",
      "r286",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r76",
      "r497",
      "r515"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r146",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Milestone payment",
        "totalLabel": "Contractual Obligation, Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Amount Converted1",
        "terseLabel": "Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Shares Converted1",
        "terseLabel": "Convertible preferred stock converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r23",
      "r492",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible notes issued",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r21",
      "r491",
      "r504",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes and Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r253",
      "r254",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r25",
      "r26",
      "r265",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs And Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r98",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion Converted Instrument Shares Issued1",
        "terseLabel": "Converted shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r98",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion Original Debt Amount1",
        "terseLabel": "Converted amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r104",
      "r112",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r431",
      "r491",
      "r492",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Debt instrument variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r230",
      "r247",
      "r248",
      "r430",
      "r431",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Debt instrument interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument Maturity Date Description",
        "terseLabel": "Maturity description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r104",
      "r112",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r178",
      "r194",
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Debt securities, Allowance for Credit Losses",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions",
        "terseLabel": "Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r20",
      "r489",
      "r505"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs",
        "terseLabel": "Deferred offering costs",
        "totalLabel": "Deferred Costs, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r364",
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r347",
      "r361"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions made under plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets Current",
        "terseLabel": "Security deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r93",
      "r206"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued personnel costs",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period in expense expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r74",
      "r114",
      "r115",
      "r116",
      "r119",
      "r126",
      "r128",
      "r142",
      "r190",
      "r269",
      "r272",
      "r334",
      "r335",
      "r336",
      "r372",
      "r373",
      "r404",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r525",
      "r526",
      "r527",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.",
        "label": "Extinguishment Of Debt [Axis]",
        "terseLabel": "Extinguishment of Debt"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of debt extinguished.",
        "label": "Extinguishment Of Debt Type [Domain]",
        "terseLabel": "Extinguishment of Debt, Type"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r239",
      "r247",
      "r248",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r408",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r239",
      "r288",
      "r289",
      "r294",
      "r296",
      "r408",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r239",
      "r247",
      "r248",
      "r288",
      "r289",
      "r294",
      "r296",
      "r408",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r239",
      "r247",
      "r248",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r408",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r239",
      "r247",
      "r248",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r204",
      "r471",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r200",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative (including related party amounts of $328 and $292, respectively)",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "verboseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r93",
      "r205",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r350",
      "r357",
      "r363",
      "r375",
      "r377",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxes1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Recognized interest or penalties",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r127",
      "r128",
      "r149",
      "r348",
      "r376",
      "r378",
      "r517"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r345",
      "r346",
      "r357",
      "r358",
      "r362",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Expected tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expense and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Other income, net related party expense amount"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r90",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r182",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure",
        "terseLabel": "Investments, fair value disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r488",
      "r500",
      "r551",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreement"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease right-of-use asset discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities, Related Party"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lease term, option to extend period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLease"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r105",
      "r160",
      "r183",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r386",
      "r390",
      "r391",
      "r412",
      "r455",
      "r456"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r105",
      "r183",
      "r412",
      "r457",
      "r493",
      "r510"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r105",
      "r183",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r386",
      "r390",
      "r391",
      "r412",
      "r455",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r8",
      "r44"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Investment securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r89",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r66",
      "r68",
      "r74",
      "r75",
      "r94",
      "r105",
      "r118",
      "r122",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r134",
      "r150",
      "r158",
      "r161",
      "r164",
      "r166",
      "r183",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r406",
      "r412",
      "r496",
      "r514"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r442",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities, related party",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLeaseSummaryOfMaturitiesOfOperatingLeaseLiabilitiesRelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability, related party",
        "verboseLabel": "Short-term leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net, related party"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, related party"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r45"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r55",
      "r457"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r63"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "verboseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income, net (including related party expense amounts of $0 and $30, respectively)",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid In Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of investment securities",
        "totalLabel": "Payments to Acquire Investments, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r303",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Plus"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from sale of common stock",
        "verboseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r82",
      "r83",
      "r175"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale And Maturity Of Available For Sale Securities",
        "terseLabel": "Proceeds from maturities of investment securities",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r329"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from options exercised",
        "verboseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r66",
      "r68",
      "r74",
      "r88",
      "r105",
      "r118",
      "r127",
      "r128",
      "r150",
      "r158",
      "r161",
      "r164",
      "r166",
      "r183",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r384",
      "r387",
      "r388",
      "r392",
      "r393",
      "r406",
      "r412",
      "r498"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r207"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r209",
      "r457",
      "r501",
      "r511"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r209",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r295",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r295",
      "r449",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Research and development expenses related party amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "General and administrative expenses related party amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r295",
      "r449",
      "r452",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r343",
      "r469",
      "r567"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development (including related party amounts of $405 and $53, respectively)",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Credit Carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Shares"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r272",
      "r337",
      "r457",
      "r509",
      "r529",
      "r534"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r114",
      "r115",
      "r116",
      "r119",
      "r126",
      "r128",
      "r190",
      "r334",
      "r335",
      "r336",
      "r372",
      "r373",
      "r404",
      "r525",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r170",
      "r276",
      "r277",
      "r470"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Grant revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r170",
      "r276",
      "r277",
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue From Contract With Customer Including Assessed Tax",
        "terseLabel": "Recognized grant revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail)"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r302",
      "r324",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense",
        "verboseLabel": "Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r39",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsSummaryOfExpensesRecognizedUnderConsultingAgreementDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions Table [Text Block]",
        "terseLabel": "Summary of Expenses Recognized under Various Agreements"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r303",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r307",
      "r313",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r356",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Changes to Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseForEquityAwardsReportedInStatementsOfOperationsAndComprehensiveLossDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common stock remained available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options and Awards Outstanding, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options and Awards Outstanding, Canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options and Awards Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r309",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options and Awards Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options and Awards Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options and Awards Outstanding, Vested and expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of number of shares that may be issued in accordance with plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms",
        "terseLabel": "Common stock issuance, description and terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r301",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
        "terseLabel": "Number of common stock purchased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r301",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r319",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationWeightedaverageAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "negatedLabel": "Vested shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitSummaryOfRestrictedSharesOfCommonStockAndUnvestedStockLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Price of common stock purchased"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r102",
      "r105",
      "r131",
      "r132",
      "r133",
      "r135",
      "r137",
      "r143",
      "r144",
      "r145",
      "r183",
      "r219",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r253",
      "r254",
      "r258",
      "r262",
      "r269",
      "r412",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r54",
      "r72",
      "r73",
      "r74",
      "r114",
      "r115",
      "r116",
      "r119",
      "r126",
      "r128",
      "r142",
      "r190",
      "r269",
      "r272",
      "r334",
      "r335",
      "r336",
      "r372",
      "r373",
      "r404",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r525",
      "r526",
      "r527",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r142",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r241",
      "r269",
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Preferred stock converted into shares of common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r269",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r269",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Initial public offering of common shares, net of $21,728 of issuance costs, Shares",
        "verboseLabel": "Initial public offering of common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r269",
      "r272",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options and Awards Outstanding, Exercised",
        "terseLabel": "Shares early exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r269",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Preferred stock converted into shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r269",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r269",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Initial public offering of common shares, net of $21,728 of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r105",
      "r171",
      "r183",
      "r412",
      "r457"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r272",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Stockholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Stock split of issued and outstanding common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Conversion ratio of forward/reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split of issued and outstanding common stock"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r429",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r429",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r429",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r219",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229"
     ],
     "calculation": {
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Convertible preferred stock; $0.0001 par value; no shares and 22,012,499 shares issued and outstanding at December 31, 2021 and 2020,respectively; liquidation preference of zero and $45,625 as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheets",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Convertible preferred stock, authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Convertible preferred stock, issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Convertible preferred stock, outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of Series A and Series B convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r118",
      "r119",
      "r120",
      "r121",
      "r130",
      "r172",
      "r173",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r218",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r370",
      "r371",
      "r372",
      "r373",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r446",
      "r472",
      "r473",
      "r474",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Type Of Revenue [Extensible List]",
        "terseLabel": "Revenue, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r109",
      "r288",
      "r296",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfCostGrossUnrealizedHoldingGainsAndLossesAllowancesForCreditLossesAndFairValueOfAvailableforsaleInv"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r344",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesToUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebt": {
     "auth_ref": [
      "r23",
      "r492",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Unsecured Debt",
        "terseLabel": "Borrowings",
        "totalLabel": "Unsecured Debt, Total"
       }
      }
     },
     "localname": "UnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.designtx.com/20211231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r568": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r569": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r570": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r572": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r573": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r574": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r575": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r577": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r578": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r579": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r580": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0000950170-22-003369-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003369-xbrl.zip
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MH:-BF$0013J>)[+.WFB8/E!Z6JA#^.W&&E8CM,-_K81)L18)YZXFKO1#0&I
M)^&!? R!#6A%E8FC&_O]#4R2)50+GT9$&P'[[7)-XL!0%"G*#3TI0[8:S3P#
MDP1ZI[X7DX0"Z(!)PB<9 HT9$2H=A*!,T'GX[<$LE 5@QL\>!C,#>H:^,;G7
MB]I4J8T&1B9U]<M/:.B\J:PJ#R]RK.'S!E7:GU]5Z<4H0[W>_@9D"/- S9-T
M"N;NUTHA+B^.T;QN_AWV:U6,2_O-&G9OVL79G=H_E6Z21"@_!+ EP'3-D4V
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M&Q3\;XYA'X#H&C])C1K;)ROGRXUQT@5J<]'/N1JUV5N]9!W4%H+N$2@T=</
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M8,3),(J]A FC9%^1H6%N)_SKWK@&M0&FM@B8 [A:U:G<;V(!MP4DB@>AIQA
M(XD$87@BS>-($AF:).;"!,KKK19P:P#+KY.;A#.]N"W6DE&)Z\:A(C[S(]#/
M0HRU$8;06,#?BC'7[YUB797U&TL NAR!;)U\X!?S.G7#V-(SJQ9\T%<'Y?AL
M74RSB4&9B_^8>^_OJ43M8N^LU'KC*+!.X@3%(00 $<%"#0:6!\1)DX1X;L2T
M=+GR@]YZ>+\KSP;U) ^UTH1RAE&3H2%QR !N,HI"+37WW2'@91M4=1H(Y@6"
MQ*X";34..!$@ 8D,8I?'W/6T4EL.QSVE;&@KSS[Q5!WE^WR4UCS;%I:HW21,
M$B6(B31(1:X]PB,>DR"0H52*1BKN+4N\QY[X9UJ?IWEK5;Q,6V*-+)<KF?@>
MBXAO?$98P!01&(\<JB!*(JHT#WNGN-ZC'NV7154!AORUR#!3L?K]]_T7R66I
M43X*3!)PYA)&@=4F5%'"DSAFS MIP'L;@O'TD6\O$@4"L&?"F#.2N#%0K_(Q
MC4,DA,E$<,I"Z??WS/"SSF#9ZA-2\ EF739!_]6OD_DK<W3]GL.+\FJ4?M&_
ME<5X=#]=/W8N\TP%9C;.4/!,S9]-ZV[/$PL4!X$Q01 03QI!&' 4PF-CB"<H
M33PA(K";!Y1:!TJ=7!4GY\6XXKGZ "9!K76^!,L>.Q\4EE.=]C==G)5\= [*
M2FLWMCFW;_;W-H7'Z 9?$8^;6]>#QT)+1;V$$V4X!1O$!28)WXD S9=J0+S
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MW,B7O26R'F@Q]Y<$:<N\?%,YD*W3HGI0HB#A6AI?>B34Z)R-7$TXNG!\3]-
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MO8VP'[QDSW40%25) (HDD<J O8R==>+0!(1&,8V5I-RCO=,^OJE^RMR9/7(
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M52(%\P,2N!*K1X:2" \T;L59Z$H_ 3KK;=6I(6W^UF $C8>1\&8C)0 UB8D
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M.:ZM,_^CZ1+K/^GR^)R7^M?)\@'F#Y7QONIX+/ZM97U2?-:C5@%\D4J%S]R
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MKO@$%ZWS?L+G0,OF:,>G.QL#2:(D#0-L 0<&"TLP9,53,8F%%\6^8E["S;I
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MZ+J!\]=4 ;R=?_ LTQ.XQ-4W1(ST927WA10]'&^DX'$@@Y#X/EJ0'EB0B>%
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M:_1^%%'7DZ"=1SPAS-<1$2*.B-&)&TBA16S6E&Q@*?/7<05[4E4W-7I1%)F
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MPB 4!J'PG0F%H9W8(X2"=UHUI>8FI\55#@KW>3K:2H'05LR;.!^[96"9BWT
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MFQBU!9KJ[@)J!;6/EW:$3N];4/-N4-*M-#L0S$ PO288E$9XM\5OF-(52"C
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MW'(& AW0#78:@)#-I;2<:VY/1>Y,:7'>%Z7&GGH[&$?6*&)V5=R!'R<6IS7
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MXBY>^1G2^DDC^6(O6)M^D8(1Y*Q0?)&*EV_+M030WO+AS%<39LKHZX.F2:&
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MFF\51;Z!J:*58!8AI0.RL<9S_$*,OK"MOF3L5&18@_06\"1DZ:1&W5?)Q/J
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MS"R9!\$H#V/E&)'VN2R?AFAT^FCM:^BFB0D%]"M.QTD5&;V+YPPI?'(8/"K
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M#Y>"%PK39-8$KUE-4?6;\AXV91IM^5@%CW6<*<W0*,]"6'TKVZ7?*YOU)5A
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M4WG0<LT&9(BFG[0BA_X^%=MS902Y&><50AAI0$X5RB11'=&&R26UG4XM'*X
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M9$7UD:HAHM'S?;!?YR+TZ+(Q[C5O)R:=EC.!?H>=S9Y8TUBGI6YBMP\#Q)W
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M[K@QI_S@1O-GZ_=.W^%_PU1JKUB8%)DTM+(C )N\M\<W9,QD>3G)DCB#42%
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M),VGEAO2=C8N8C_O0$CWC"[/UFL7CI&VJZGF&"_NUWH\-5C<ZU\O'S=,QDZ
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M-WZM8+ZBWL;9AL?3QHK)(\:HLN8GC;?;7+#2!6B?\_FE>9."S.&)XX?M*FY
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M&5$K"\!XF:L^G3;..0JJVE(HRV4E-$GIR H<WJ#7C0\ME$2=W]W>&YOB5*T
M<XCMPI9%YKD7R(*)2+<N/!H:FEN&.=0@+P#U'6 4I"[K%0(@<5!B0;NBZ_#8
M&KKJ9=ET[3UVP29WGO[T/R^?W3M]<I?>-ED5<GGZD!^MWFNZP9WB>)=%4R9*
M"V$[[9&KTV<KD1'1D=#>&_(N1B7AD23UTTE2?S9TU0ORDVCXY%0W3;=A6D5-
M*G+]<V1./7IYF&/U)3YL@;&1.WWR]=>3.R^>OCJ[R^?113DKX2COY/?.-:_3
M"1(5[02^Q+V=\J_&?/M_P4=7Q"T?L?H=I4)'#IO_?5FL^-#TR2B^I?S7%.C8
M"J)]>(H:4FI0Q*A7"D<5JE8^7Z/VAQ75%8$'@D55L9&,]8X/IPE$&N>E[Q:S
M&RG'FM>TI!"*Q6!Z2$\_*?SM""C#<6S_D7PE?C$\V9+\J&<K3OZ$UA75KT#H
MV(9Y9Q%2(SHTAS S"-(@EHC*!1.S=9+)<*A028$EO531)?&XYEE=O[5</5.[
M*8*.+M>Q@[,2>MUE438"7X:,&*.=47PH3$['U'@:AI:8/$AJY*4P+8K\,-JE
M7 B]B4*&.9*[Y#-:\DDZ-*__*&(\\DIQL95_8HU66R5S\G=S_LQ(<#Z6N#^J
MQ/UD+'&/3N%-.X7/NX9LU.2OW):(H_G7NJ'PS3&6OX[QW>@:WB8DQ<.CM6PO
M<S)IGP0>ED"^2DD(.KY_4XA$07X<G>+2I]&[B"17<M$]R1/ 91Q"-O05X0 ;
M)G>E)W4C'RQ0F)AUENG)$RN_:I6 W 'N-$E**Y$$I*>YHEI\7D?<=-0M+<92
MHXPZ=K+C<*_:<AN2^+CXR%ZZQ66]RRJZFDDF#VW&2>6<GK52P,J 2EYM2$MU
MI"6_)\A$#*KV$GPGDZ=::DJWJ[LMU[GLQWV%GLO@\F\F,0Z74,NI4FY%I;V-
M$L^5$=O% G;1&WJ,$.0K=Y[^3)''6GH?W@I*Y>6/SZZ?C L4V7M3DBE8+CW4
MHIC03>2=S73$6T5%<)>2Z<FE2E]?A])>W4Z78O:0:_)-)5#AP"!P#9.'2>NN
MG$O'']^-AI$_)%887>WEZ^]RNE*NR2E<AX==MBDSR[XP>)<!?A!W?W_TOBE&
MJ4^33E!_6.07TRRR F$$4:&&U]^%F42"Y$5I283%#58];KR5XE:<3 \>GG[U
M*$W#;?"'/CUGL;=TS?#$$\/Z V'H!NPBY YJF*[S"J \WHM,BK=%)KRN!(>S
M55-A%53N;)1\^247JF&\=6=)A"V2D\C4LT!9T0;%./1'8'9&!SF\;?_Q]%62
MB$E4H.ZXV)L*),QY]PH-334O-[$;#^9:JI9DI\ZE&02MI&&^*II8!OD^K-JR
M>EM*(N**)<\&YB\;N4X33GT B<YK<#[_QBD7T4M##RCLE5WL9YB,Y*].[OA_
MT^5^K">/'C[^*UFLK^Y.A(T#K1W.L$Y5$4Z&P;":FY3,OOU9]T\ULK<BQ/I$
MD^*TE??5$\5?*:M+BK<4@\7G'!?Z.:VWAVM0'!VM7G<U%8=.7J%"#POGGN4>
MC_<=%(N72*C:^A[#>!B^0^^T4=0@>Z\VOOQB"08A6]I?O%/>SF7)D+)J\B-Y
M'(,9Q+*-CAX<KN3C)0N X)0N\DN%K<GF4EK*.).:V:JERP*;A[2#5;W)_7M_
MW+_'O'\_3XKDJ=L3KVSEGTR.&YP*P@4W\+AEK9TO$4^<-T6EM"$ /86#1D2A
MD;8M_Z@9^#RO\<A?V%..C22DC:)960QE(5/O)0C(A0L]D[-SM&+<>?X#!;=&
M_B)$'*4XD'2*9-+S&4#WY3RLT!?\WV68<_<FG3&E8/9^K!MRVY3&8W!5"<W,
MIENU?#YE2O5ZD@FBV6D#E0PYOZC\@<=>-X\J8N<$%(AN@H+3#QOR_>S*#F,W
M-;==?J4Q*L,H"D&@<M5'E,ZXC#;'!6W]IX9:V@-I?(NR#>)O@R.!;O_]R__Y
MZ]G+9V^FVHK+%<1B%C"/5:#WL0B*S.%;TN^U'T*.IKI<K[LJN.M*_LG^O&N7
MBE(5S_NRY#X(^_9[YK[>6$MJ1!;%V="CE4%:_)!YD,)?+3; +-*#SDN0SY5S
MX//Y[:@.' 1*< 9#/YC3/+EI$.SQ+.)<8K<3]_T(QZ6F-:( L0*C#KVHI59E
MYYK5LVQ=87FF]*I,1<#6WXT>^5_HB?_@R3>W3COQ\QP</YH3?):M^%?."3[N
MHT6:\X&#Y/K_]JHV$V&0.AJF%O5M5X<!*^O[YY__,I[^G_$5N;8)%9CEMW59
M4'AD[,']D''@_<#2+T$&IVEV1'=SKO 91F+H!+DI<<X')T]N4X#T^4B$'YP^
M\/*<(Y_PR"?\V2S9LS"_C0'I+ZWET1=AT A-78E+JSW0#I=VVW+=K<@O#'77
MYIXG3B7N1Q_/H\_XMN!FUQ62\#](Q(BT'?1]#AP\* <8LR**>M&9D "TVNU=
M3DH,].-%C9_B\.+P3<,(X;1$RO.]I]A-DU@_//GZBSS,1J&P\3"[*3/X0[?M
M4+.;U^=5F<=5QWZB*?!C+8_0N$?P9UK,@W&:9EDVK.28F<4!*_N'$1]\$6?9
M0"$<35862+FF7APOTL,FA?<7,15+1Y(C^3N0(6\Y,PBX#S-;:!>BQ-KTBA,*
M"EFOE,"[4HTH01G8E\A"S$,#+723_M1%]B\)[)#:=3S%4H2'C'L,$H?'>=-'
MY9.3;V[143EV#G]JA2DOT$IZ*=:7Z@WSX'25@ ^7$3O(C*"KKBTO:>GVZ(FZ
M#0AJN$58Q-$&5^\4">/Y15B+\(F)+4GR?;7:Q2YC/)]P5/(F(5>R\'>/P+K4
M3,K)L?C]H?&^7$K!C,%J>]?3MMWV&@3F?EW;,)O+T&BOD"30510\0>QP.VD*
M @EJE!\7X(!5TUTU_F3R+ KX]I[R'B0"E!!T\%FG!^]PJ#YHQL^PCI&2_^#3
M<)0'WG9Y>/X)%_FK^L"=#12A=XJTGT+,(MB 39F@1Q)#[+_%[^NK *8(:7$N
M6]RR*_!FK<4XWLW QT97GLAY\C?IT9"#[U\*%<7 ^MWU2E@\,1P0J?"#4$CU
MEMO(_3 V%7WD['UU?VPJ^O,T KMNCZ^.=LG!3_CA3$[-6,,'X,VJ^]H(0L9O
M76^#)@D3\!O4D6H7]XKV4SMTE8YB41;G%9T7K7!?+\,])JRFH,H:9.<735TI
M;=4B@"JCL#9..2#I:!7J*OHCVV!AN^11@_*:#O%3FK+[]^GTK#>KD/"J/4J-
M0X^JAY>Z$9-2CBE\K00B-4"E1?H8^!$F'_T(#D,+^J&2Y5 @8\$SQ<P4)JC"
MK0&KG=(QHK^E]N-)4%PK\+<=^J&5-%S3&7K(<X6*7\IQ!X0)9RBMO[S0XB.?
M3'XZ\-IX2;&*4BK+R9N+_H,J:M"W6V:DX\-?F$6S7@J=3W9'=:ER1Y(M8GG!
M6-T>=QY7%-]3\"AV;8BF*"H\,I?[I6?>"Z-;'/+#V/1XXPEY:GOXV:]QZI<<
MF]:1]_X>\_@QG61-;U3[USGPGH+@SU-*UH<=2>?"MHZ\AYZ-#&#^38:-)%(O
MVB/7N>\.6B746HK*M:JK[DP@]Q>R/DX?Z 7Y91] J^^UQU02LB_N(:#9!'K3
MS&.W5\-EQDR3U7%1A#CET3<6\!23 I?OW&!@)9U5,=EL'AZM1I9]Y$Q%V/IF
M^"M9K]C\[05K*44IJ=C(U;H]OMI%4J&59/?=ID>O?*CPX ?"I4,+:E$'D6&B
MB;P,.Z%'8!+!;0'],*QU&F"S593_HHM>O4EUN:Z%J"D4<=:*)KM1'_DV:65_
M>>C?WY75[4// XB:5+!I';@'I6S71OD@\+C+X$"/=PPU"-H+8=YF4:@V<?=A
MP5;%FHM82E^M#('MW6E&=9UQF\5(D9PE(U6DK1,:.G=2=RM#[[+^5C8+KGLV
MI@A]YRQ,+7-6(F]",6[\%C]%0#]3GT=Q:XI[_G19[:[O:!HCUUL18!SK)GU3
M5,Z+J.KJ'LAHRCS#7_"J7$MH +)1+]LF!SZ?L:;MYKG6E+^?SM2U5+KIE%MM
MA3*&5GK*-$8.T(4G_$>K7]P[:/9S.:?4>$-^8&+%B_< ?>E:94TY=)IG'4-!
M30([8A-D75?AG%-2HGX8'7BZ>(^25)3T:%M?U"M3D3K<,B1<P2BTKW:^:#4
M + \7S2;#LXN#8Y0X(K41ZT(HH*&W/FD0Y.!8&;)6<QK4L+V1#=K6+Y4N_(G
M/NY_3GUI_Z15M:#CB@<\E*9WBI\J2'8_+Q"J)(;6@,6)%S,CT817AK4K3"??
M-13!61OPNH /SQO.J2AFKBZ;ACVYD%[*9.IIT:=>D6":/&0A6DWTH#%I[L@L
M$K]9GYO#9JLT\=0U3X+(@8VG^WBZ_XX]^2+VL!SD#6&VC>1@N[+Z\X)I["O=
MN]/)?W,>Q03_.*8\:\O" DC7/_JAK?ZQ-VFR*N>L7BC)FP.N^D>U]8.;?KB[
M_[T9AW]W9_^-"KA]L3O^3WSNOEQ^ "W2LN"B;H]I,JUN(S,ZL,JE.UZ2:"GP
M/2#>R3'[U$N2<IL:W6_1%%?2M3_0S.^L01,X'<^7".6_5)@^=2<J#21$1D31
M(H;;*<1HZA:R'A_(\WPTB^K(JKJW=R=]/!J/VX:%\S308<+LXQ],U/<!R^?T
M]D[E)XLA7 51 +%I7;AH'7((ZH!$-/RS0'\N1/L@>O>GT+0Y_?ID\A-\:9RN
MN50:)]B-9[>6AF0Z>!_?O_]H\GVY8.[W_^' ?D>#*Q;3R9N.>=Y.3UE8J&A6
M[8S_Z#1PGJC4-"?P.N[=787-!4-+JPXC*MO)G6\>?7-W\N#)PWM?/;E_7X86
MGY,>?"94<HM% U[A=G)U=74B.?OMNQ.RP2>37]F@OG6=:5,M_RR9E:<YQRSP
M_>UJ_.^SJA*,+P<AB.=?,$W^Z?U[_YQ._A_%4^2PD74?^/S_T2-V32,LE/FG
MW_"/C:*O+U7-W<&2'Y$.][;F- GG58JVKFC<.Q-2Q#D"N ,3EB =P5ZE_CBE
MDMX\?WKB=Y@U+R.J$PIJI(95H #"9M-L)MH+=O6XXC'C4"VLX<BY=29,1"Q,
M(X61 B33LM[H3]DL9I.(UV+R.Z(FXV\,S^W:"]#\K$"UW HUC;9B\[859+."
MLVZ,POC/?RA]B5"CTQ%J-'H[G]?;>4YQ0+T+6GD2U<NG!;2[F,"8S!X9X='[
M^;0->]:*/Y-G*$\11ET4B\G#;R;!YG\Z>?BU""O6:_&9EMUJ=6^+L@6_F]/'
M\6-E=7UU<?+LA$_*'_A_?V3?1'.-(;U5R" I4XE)9[)<9%<)!T@C^E+R$0>+
MJC XHXE7V0,@+]8"9_DU879QITQ3&(=[?G_!YY[7]:('Y;I2[@1RWB"DI/+,
M*(> _E\(R=H :<B:!E/%EA#@N!+V.GX+/,(.YD8Q(GDG%9>*?J[/A4%X?XQ3
M]>^*-<)BUA92U,.[<BV2"=]\D][&A -B"E4E[3/\AC]7N/G%[1CVH)456(U0
M8T9H4B/A(% [<<O@BJ;TQ70"O<]RN5.]['E#/K[^6S4\IA&Q)]HFHENX#>>:
M3<#*8/R7?>C665PQ C!*08@*E+1Q^]$*@>R(8@-5M-@X3;=8W#8HT<BHMR)_
MU@95?W7+DS<<>K6W1I7-NBJ<SC'!WT@ZIBS2[;:>O[TW@UXS< 95J^ N5I?[
M3,H9-[8X <+ECM?_/2W^E[;CV_\5\%][I&?HRS\,G?DIHPL4DIR=3%[3/$Y>
MR#R.YNF3S)-\.>_4_#5H*C)("^)B5]&/YU*X(!.VH-,#]+J0QZLNRZ86$0AA
MDZM8.8]Q>]TZ-,S$P,M==CE+PH/K?9L1O^M60!I6_0 K<0IFB2)UD>&SS,&U
M>H&'Y0+%Z]C5'8,&N9+*DHI\"NZ2!T!V9WTR.4/I!.JN;%XG@=6@DCE-]Z<S
MGZ)>^ALC$OG*(DP;K^7!I&4[[R(?O<S* CJN,W95Z(B_8EDI?ZBC85,(X ;3
M"A\0MLMI@%$K/E:(UB23X;,73M>)?O/\G5(H.Y#&G3?/G]Y%=QLG5*(PE3V@
MON@Y)P18,(OUF:8?HN]XS<L2*40Z">HK&B>GOS>08Q2DN>+2T>05:^(1ZM8B
M7X&%$Q;&P<_: V4S[]:".%9,M*)21894CSPN>]>5'#SY_1:!:V_A9/(39E3;
M^4R]5%DJYI*4PH"B=BH:$^1KZ7-.]###GZUYL)JP(UGHHH=3.C!%,D/[,WHR
M9+S_K39E<MS'\W$><Z^QGUYS."+0;G8E_[M< UKQ4ZP6?4^N7=V0G7H15\*K
MNDVF,,6^J>PUOH[/P6E@*55NP)&WDFIX%_96+.G*VWTQJ<C*K&KNS64>W;DD
MO_D?FR1UV]=:-F4;MOMEU<'CQ@4S6)Q>U7J?N.[9AB U4!A1S<SO: R7+')L
M^L %1)*A$8Q&VL"D]Q[07[.\+DJQQ?RB#)?I0Y40MCY4;EM5]>&V:W&VE]L/
M],R^OO\%UBF/YK&/Q1\5K7&(<0N:GEEOR F9E74/IFI"D4KC>W #RA;B%8JB
M5+DE/XS+:BSDS2H[XM@I"6(GT'UU *)\)G> 12*JV%K/7U'WY++4O2 %,W="
MVT]A!<!W92/E-)+=@(/I2G5*D16R4)V>G@:K7J<^,OE+!4#\EE"86H;(?L5$
MOVNYB.2!E$%YQS?:LB.9Y14<M&(?T:=(Y&WQ5I$)*2]%;SUBD-IMM[!F+[[G
M*A0+ZV&(!4=Q0+-TEG8Y3">A96-3MA?V$*&Z*(3I0$SD-B"1U\DH:8:Y"8K<
M7?(_RSJV.UR6Z&!2[+7Z@AEDF[LGV$M60]F&3$_<3+I1E)F^TV(/;F7B] >Q
MD#*FRN4P!_"2:5W$]K]EILB.?DMA6C:A5<DF*5K%CSFSZXO,L*L@O=P_290=
M/)R@/@7V!SFFKH*;"N^DIZZQ(OZ>G_<_'SXZ>32A3;XR/^0_OSEY&/]@QY1T
MJ@GT=2_GB)\) #:7H?HUJ *+QIR)?<&H9W%='%L"IY])]\E5/+'WW@47?A?"
MH3 DR3$(A,U&8H<R_7^N(?.4 -3OG7;^FTPP9ZB%8H@L<SYL<>L/GN-"QRZ-
M<.I #"PLRZ/%9>NV740<T#UD.)R16\\04\*@1GT;O:5]"Y/'>7YI&.XY)3*U
MU8&@'8&40O"-!,/RBKA<W;QU5FTL)(^%Y(\H)#\8"\FC.WHC.DT:$$E6D;N9
M76R4Q)6,(@"N"R>$) GFCPQ_[-1.>P$6UX=REHTRMXR+,PRU8GNKX-5)9X5(
M=5J7W4K2M0VR=@*V(H])TK2I ]Z?V(#,!A5DW_?E<.3UQ3T/>SM)8=[U7WFA
M4O&VAGZ:&E'@!+O?LP],CI]@[NOT<_&_I'%&$;RJIS5P<UP%C L[N>A.6 +2
M5STDN!<G8WXC*P-K6F1L E.\;8V/W7?]BX<36\&+ TW(-9-X-1BBFQ=G>BU^
ML? 9#E1=J*1P5@^'Z;UB-9<9.6%-0\NRV7QW9+39WI/OK_Y'!9>@@A,0 ZA2
M'8?$P\"AR(J,J^-C>%LQ@8"D_^7?MC"Y!B 0[\6!,:?Y&,XNU-';ZOT0+8_,
MBZ6X0?CJR)'/"J9]@;]Q.*TB^B*(B Y6XM,38F9H7L$.Z=A"4 65K>Q*KOMO
M7=PQQK%W4DZ]SN)H)GH1]+&5X[%+M,<:&(O#RM_E)K%2PC*;'J:)I" RI! 2
M- V%5@H./C1Y= *8I&>VJ"Y&L8A;="[K+ P^F9Q9TMR:1.*8761K7:"<^YX7
MW 6O%945M&18LJ")@,>=A(7&)C.ZBT?^T,>;QA4;Q%FGKC(+([O#;5L#;T!1
MM"(CSS2$J7=$.[JQ^\D 3I61A1=L6*%Y8YN':D-9D$GL:7-;YQ:]XB_&6XV<
M:@\?'*WG^F:HO&#Y#PAP^F.N6/.)#_]N7K3P(I:=I>WR@J/F.P16)#Z!'IUR
M(KG+<G$S<8LBT[&D(4H#,!!'/0JW_3SO4(]Q&W<CJ(7:\C+0"=,>2H4@=+6R
M<"$*YI(<^4"O=QI]!=[X^;PE"\'SA9E(9^.14YS98TY=QFLJ;**:D\D<<YYU
M<2  W\C<2?%_#[O@'Y MO=I/I7D_=[\+/:Z^)I5(XZVGDN7LQ18*-N/VNMF'
M=]&-YO7/YCC<#/CY/Q]^\]7):<QQ<Q1(MG0J%C7#V *48Z[KI(W0FY/)=T X
M@A(.GK&V-J7\,=>*9+.T6X!Y)2K,4)X?>]N4/L]X&_LG ..];,_!3*H5=@'0
MON!R(L:,9\#I _IKM;UH'=_-%9=!5@@!/]?S:- X\$S76J)X.@R4 :99Y(C3
M(#J+!XX%FR1K40X#Y*4?R;(Q&JVC[W<^'J-EU4&!3DL*RTP'6B6+MNW6&RU7
M6[$<M4C-,*(#L0F2M;3\8[%@@D=9O9Q*$H :?#C+!T0>I[AK)+ZW_@@D)")/
MZCXZGCLR3<TU \R)FZ!I$RE0I5\[\X--N@ALG"80>Z=MKV!3EP;M"QM^FBC2
M(3#4J(,TZB!]LKZ:ZG(RXF-K;!'GZ+R6$Z/=QHR\D*>6+5J?=M,LM,F.&E<)
MB"P:.Z +S#\^A'30K;9_'B73G"O%C#MIW$E','FRDY3C +4@DPF,*SUFX*X@
M/0E5W)J;H-HNC*M[7-U'O[IE26>G0I[X<&C%@9 G#T#Z.9-X9(Q;8=P*1[\5
MR/EOSH/2S0LEM6:@N7LM^-JT =6T2NO\I'&ICTO]^)<ZV_KIA,'>AOSNMH .
M<,-T"(!3OGAV-@5!M!$AR=(?8JH;/?U__XL==\5GV16M1,MA4PBD3(F[M$M
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MMC:=_8&O(GX"Z(2$ZD4($D7ETHZ_W#Y5KC<_GGLBK<8.B(I@;U:[1)!ZZ$E
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M&D&L8&OG16[#!9\=WYV]$K/&4D# \*0;4.6W!-7E?-PH!ZTK2"J)L8'0SPD
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M<3N.<[TO)2963WYIR6# L&NP.M TTNF\']% \]H;7,#9-0H1N'1#Z;V4K3
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MBBL4+CL00S26%3'-V7EGS#OC>G:&DT 3_M:,EB\E,I!R.=(OXX:XS$^D2NV
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MA5J5/? S<A&LN6<7<*#Z,QFAMAQT9C%AK[/#RZ[^7WW)TWV6!+&36?!WT7=
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MD8Q!.@\G6LI&;C=UGZS-H!C,:X:@\>2/LW69>_Y_,NKF\QEU<_T0AZ>+NIG
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M661O58+'@R*_L)9:1K[&LT(G+LPOB58IB^O6*Z'S4:G5.8]]91;\J6Z-' S
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MGI^6LUQ2$[<WYQO5>"GN*N3MAA5Q<O;[(WXK&"4I$-69RLW8J1>T@(A$VTC
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MHH[B4]UHWR:41W%AWYT_$<D<17PE"L'\;#>(7<$>+0?":1M3)GLEVU,&T)&
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M!1[&5G4AA=.@3;7LG".6ROC#98<,VL[<[A&9FR1SD&AU[ZOHZ)8R>D5X* E
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M$X_T.CVL,TJI["*STRU>!RZ>MY*=D1^J=9'I8,?!I&5,O^7US0/#(^RD]01
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MZRD!P'H@(!/K>Z+O\GSQTD,JIHMXW%P>6FWYU\K:2.%3"GV"$^17U9V:U3M
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M)B^;8\HH.FYC^:.!1#@BY0Y@)>FFT<L9SF.%=YU)267?_<#KQM1,:KV-^=
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MS'^-9+*X%M%MH7 7X?L6(H%,2U:/Y#<GO#<V^W?VT8I3NH6,7&6\@T/<GA
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M0KY8?(TX/L^EH/>/P/]T>68WD)(F371?^W0*BB\8QZY9<YZ#$>C-.QD0F?A
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M2\-^6B2)I_'4_=.7. ?%&;,>3."1IM;0K5NQ\?BHT_;)A]=#,  \1=_YXK(
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ME[N751"<P,>M=';C)YJT)A@#YETQ[XI'L2N$%790M$!K>$4^$'6G<[))D#3
MN$"EB'N1AE"@>>7/*_\QK7P!<6')9T0% BU%ZD5H Q3+A;)& Q)JJXI[\.D)
M1/"\->:M\2BVAA7I C>#3\F]4@)T'>>DZ@YMR8R##K>;@UC^DQ5M@Y"(YC4-
MQL*D;NR.:K_92' S*C;/&VC>0(]B QTF2Q)=JA[<U P>>*;P&-%T4\3SB*N
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MG(JJH&=_W=27+<R"?<1YK&* O#CXCO1M>?-L5[X#\V2C<+%1%MYZ=9S\(@;
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M(XZG!]&U9:INLA6FU-U84T%8 ,0),N4P(LF2%M[L*'@ST".)/X_S=W5V<P'
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M![&?;29"-@[R /2;/%F0,@/\N'RAP Q;#&Z#LUOWNR6K5:;V*LH_'\Q,2H,
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M,;*Z:=IWR'F[#@G!IYZ>?$1G^7F"!G3()#/83$1GJ) :+ZX1CI6I.;BACV*
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ME[!L0ESJP]Q4=K;(QI'*X$(Q'#>,W^!DB.WD;!HFTGV#O7$Z_<>6HN\(LW%
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M(75)$8:RC?AA6,^]C(\T+6%R1%\\?[";0)" XU0"@^%3TL"E$\@IVX+"$HF
MQ;:I+VFAUR<R D< #B53OBL9FW#BJW)Q)##*=ELEJ(*K\0+]\/GBR13R8!//
MK[C94.M-;7?\EPW\T9I:X#JJ42M8@=S5<'!9^*JN@)B4_ <P\/$R3PN&)MQV
MW_B$7&Z-<\3=#ZALQUL3$",^< =1BU!SU2HZQ-M E_N/%Q?/OU@LXT2A9!OO
M)3<#:*+?-^ZZ-/=KXE%<<ZN@T[3@!I!RM0I;JC50/;^*_Y4RI'R172BII"9#
M1)?DH Q^(F4D3_PV(2R_?L\,V)2H0DW_RT]_5Z#'DMH?X@">^&_$:824AC[V
MBT\8)M*A0V#CWW0G>2_7_IH5^\;M"%6WN I;Q!1DPQ,.(J[@50CK;O$?7SQ_
MOMCQ),L=&3! @)'_ZNNP^/0Y%DH<=G7M7D S?*T$D8@/E\"E] +U_=$JH!%X
MO.HZ+..BZ5M=D@)2N6I#>(:5P^VA=TI /Q@S]Z"K*?^.&,Y/9PSG7*;[U<MT
M5;WJVT';+$FI#3KM$Q4 _I!5&(YL[,<84.^@KP/<<-_8H)T#^<7<\<4XSWC*
M@Y%8CG=RX.=:WV-SJA^JU7TU7LV+;=6!&(.K G\INW7Y]\6?M\TRKMFWK"[X
M'9R:@@M[PPUD(@L;-&XR]I"W"/?^$MU9W]*:+D1MAP"<U'!#G:N6/M4//5):
M+ZU EG6U%G06C8+W9EM=D]]C7OR(!.5MV2[+.G3/WKS?AJ.4*<FG)(AHW+8]
M]<:DSAF"BNXD%YO2OF^_?IV<O#.3)#[7;M\0NONZ9.74W#.M1R5+C/J_^GCK
MZ/P^YV%_U:S7S[Z)\_9N\3?J%GY[:$D[\@>"O>PPE-<$"H\1RN+[-AH;QGB2
M;_MD\'/R9A<W\5%#71)]"\"V+7OGN2G4!MU+JOS4,$,, )I,)2BG"C+2G9+K
MCF_.KT_F0&<3M#&46O=I;'X7=$L1:7(7[3#@LF-]O?B_&DET%-]0KL)5J&N,
MZOT1 487Y_>'0!X1K;^JX^N2&[L#TUC<2#'RN*7\'=^279YZPW6),#&-BT7]
MFZ;Z6:FA)[O-&%N_9RV_.*/D44OQ6YSM%9!39V,\Q*JIQNZI>*:"Y'@X4=.6
M?_AE#^T3VDR7?0DD]P OQIFG[%1+#SWQL%W3U(!@EW3U]640NAUM+)3-TX;E
M4?9OC&+>[YE02'>Z\/YH5@HDM]V.-X1 W!:)6C'4UU7;U!B1[DW]%G'I)"48
M7M!\4I-C?"TT,FZI4>ZLY<U%R888]:V']#0TB7YA OXVF8JV\-5=R;=-IF->
M_ _J/&2^/(XB05OD0W1V24*.OZ,O1->8_BXO<PH'>+%XDSLKR<(:X[N\\Y"Y
M+V7V]-*H02M*FR"Q"D[X+(OO8L1)TZZ<!:<VM\+R>Q5C X>@%:LFYVI'JQQ
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MVP^T_56 \A4Q?$$ZF>2R*#0UB+(17!68+S&?;Q&-V !>$J4A407.U/I6B2"
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MK3F"4>0W";W(EF".@Y\$!_]V.U8LD0W^IF.W* N-?H,2?@8OCU?:(<360/M
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MA:?7Y.)-IQ;/KXO%JXU(_%H$XW5:O<GOW,=^S4<F*D@E^>Z195).+_\K"SH
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M7[KE[/SJ*\\7IZ>+^?5O>N@D3*JGRA@<&C8J5D%($=+Z(1V>'5R-G*''B <
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MMS@N6CQ?]32W?<KWVS<*%7IG<H+EOE4M!QI,:# A^FCOU&WO2$98I(E"8CR
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MY?/MRJW2:7FG[=->EH&RO:Y#SZ?Y3BOP"WQ-5>MY/O7%PIY<]54Y<^_35A#
MY8+Q,S?[ISMO?WXR^;>J3N(]G)0[(3,:^GG8MO+%D/E1Z%ZDSHZ9%/8I/RVM
MBP713B>OYJ$?%MD=FAM#L1B FQJ[0GWQ]T\,^/LB_QY<>U(IY&^O'K0C\N?E
M02>_S!;_;"M'O$XP?VKF10L7Z];-8_NG2B%\5-[;F)V7O^7BP;H'>.;6J\6E
M/]#]WF)D/",_;UX.,W>^6*^>Y>9CBC__LXFKD_($&Z0NOJ$LZ,R=M>E9FXH)
M4C;PY7O>EKQN?O:3+_M]?6C:QC>SXE8]N_S^K[3]VOXZI9Y28_[8P?0UE^CB
MF9Y**[_[&JZ_]Q)>_!S[G1>1IY;1JI]G3RW6AA'\[(.![N($3BZ.W^59Q*CS
MSJ/.!<#N*W]^HI[L/&)RQ\:MET#4LC![$^V[+.]_);><O"S8Q,_Z#NXM*G:G
M9J"#6^R=GL/]2L_@U@+%:/QBQ%",ABA&C'1M#%!YAJ(\R&/(8U7M]GIX[#&;
M=B./[<Z"OHC]W=6$OL]0A!]ID_\8Z3:/=<]_GQ#S)D*?NPC])"\7IY/%65JZ
M57=%VZ5S?&A636KO=_(>8732OA9O)^'M>RK6 V >8)+:(R"/:(\![9JP10K!
M38UH[P+M_NS,'_,3#M7"O%]NU^NTFLP6[3WMR)U&/$9,_X<':CT[_C&K4@8H
M"O4LU'=J3>[P,^IY+[?,G?!:>>8)6*X)B!P%.!8H&.'+_PCUDMP8LIF,8(HG
M#]YE X)J"XX$#53RE+6VQ/@;;2^.EXO<K/J?L,GE5/*]%K36=)SJIKT:RU-1
MX4<$:CU;'14>%;X2A=?$ZIA<!A6"* JO-9BL#&0:$\]$2'%3X>\S1GM7"M_G
M#&UDO<<7>+SL&\X"_I8*#X1FUK@-@2SR9'X1G)FL%IN/N]JBR;I-<=+,OWH;
M^ QC^1C+K\3,V+>1C6@/!.V:L$4*P4V-: _D.O ZBA<_XUYFZ?5:57H-J\IX
MJ!Y+]44J/RQL[53T!:NA*P2U%E 'R/ZC"KMYHJW,SH!@08,PD8"7WH!C4BJ9
M:)#D1C_Y^URL72?"?CK),XO1MI&1 8**H X#5)2M_<I62D$'H421()Z*;'5C
MR)A.8'0RQ"0N K%]W!;U+EM[[31:TQY]?"K8V0T/>M=[XH9-;^!" =T]3]>6
M,\W;!WC:&)BM,3R(T&+D=:1&3";",2(96.,S".X=N$P5,"X3YR1PZFZT4+^/
M[_WVQ"W37SJ6?'Z-)/N9ISI5IB\_'$FB1I) :!':X4&+TK;G;,[ A+-$0R"T
MR)0N;K;/)($FA@1&1'G^&X/([N.?[U+:9%_IG$@1>_?8\29\WSQQ=+HH@/[/
M5<9F^=&GS?JTG72<,?^0VE77;WW2IK!>;C(TIUTB)P;'JE%C!+464 =HW-3#
M0^.OI(G%A!$R9Q R61 V&S!$4&#,*J-XD%&E/L(*1R$L4_=[KU/[F_RB:4,!
M9]4>S>/Q!<F_NB+X'ZBZ^89MIC5>HPQ!]+&4=N!2@Z"B?M=%*>/7;^D%MR1U
M U*U L&2 VN$ Z4M<TQR9_3-R:KWB)WL4[\IZO=@]1OS*,:VS*\7<]A4S'8S
M3)?EI$_2QRZ8FC#>69F]@=#6""T:= \@GW_]EX^,4($'8D0' J%%:(<'[0!I
M?%2.+TG$V,A#\5J#!!&T )-9 FJ\HBYYFGD_+:!<$U_-_T]9RU<7]FY/%6F8
M+X#Y NB3[M@GO;07EVG6#96?G+GEZARC1]4(,():"Z@#M&?JX9^'N:5X"&HY
M! @J@CH,4 =(UZ-R/SDGT@KK023M0#AOP0;FP%'+4^(D>?.@G/78%AAO^IZ_
M;>W8X\Z,[<4/90HO5X?O@>+=:!U<T8U]"B=N_CY]WDIXEER;)AM6A$6&=?F'
M:]NT:B=N'B>SQOEFMLEC[]%?Q<!0C6%CA!8C\B,UB:S/+KA@(2M7S!O.+1A2
M["+.<X@N6V6R?T@J^<8D*@S[?$.PK^9O+NGUUXY=?^O>SYO\US8=;9CU:!Y_
M_<2KO=M-% O9Q\PE""U".SQH!ZB ]8@:IA8-W G^L0@$#M'YD?5[_A6G]NL>
M[#UGY6#X:,<C+@XERKQO^4:<*\:Y)E21,' C(\[UF9'?N$MA/=VE,+Q+^?Y:
M'R_3F6OB92;?QLY<K$[2\L+P1#^M,B)#:&N$=H!*40\'C;]_@*!42V\M$$<3
M"*H,F$P8.!8"B5Y;YV(?_7]>S<.RNZ9YD;9_OYI?\/N+E--RF>+++<T?S>.;
MCN2WESC]7-5,">VK!="(.:Z>G7K/1D C7IL!ZP]"B])>(\F,7]IE-C29E,!&
M%4 $Q\!288 YPZV6U.EX8UK??2HD]RCM7/35&VC$#%?//MUQAZ"OUF%BS.81
M%_CRQ$^6Z4.:K^_9$@A#^[6$F1%4C-W7Q3!8:3F.0X"@(JC# !7I&KWL;WG9
M/,0L90"E0_&8D\]@1.=T2ZHM<=DKIG;C95\:V[]M;>V[.]1MV3CEHV_7A1+L
MNCL(EVM_77?1LW[,B4AAVV=[<N;.G9]=3X>XEGR+L:_*+ Z$MD9H!VC2C<IF
MTE;+[#,'FI("X2P%IZD%DD@QH%RVPHG=)!U<TNCQED4OKR0^E9)^XM)^VFM,
M!35X13%B+D%H$=KA08L*N%\%]-[XS'P"[G4"P;J,.^4M2.=U4;) 3=A1U."Q
M%9!.!<?9R.,KLL5(0-61 &Q\7+=V(ZBU@#I 4Z@>,AK__8ZG/BDG?+'/B 5!
MRQ].&0TDZ:B8DT:H\."N5G<VT[[>TNJ';+6[W/Y(O/L9@BF $Y,'KCT(*@IZ
M790R?D'O-#NJG"%Z)XHX%RTWS)5_YAR2(#9QI1_<N;LV0:=3(SB*^F!%'1,Z
MQK;,;[81F\7\/12).L4LCHK-D = Z\N7TO+3NY6D/.JD7<R:./E\G^$B5+ (
M:#L.L8/J=]>723F]_*^\$SQMJ":#A!;59%"+,$ U&96K;TW(,4D+D01?W'9E
MP OCP 5=?'T6J>-N-UD6&^O^]6(>ULME6=_>DRJ$V']*!:IN75D8O"?WG:/[
M_OU5WDSZZB9.K]L4O^B+7L[CAP<X\J.,K^U;[^\%*II; X%_@(96/50V_BL?
M3CW1C FP+D@0@B=PPAC@S@8BF:-1R3[J3;KA9$43CI>+#TU,\2_G?RWB<&U0
MV=&5,O1<K&NG7/?5XG(W1W5XMF ]FQK3/ Y&R!!^M"/0CMC_>[FE6;8SE#!"
MP"A&H-@'!HQ.$9+35!A2C()\HV[U/O&D?=D19JI47W--T8RH[7P^;F()#N'[
MQ@+ZQ2S^Z/)UC##)L\4_VTE>+DXGS?Q#:GL)..%=WT/LE3L/U#JL<MU]6XJ(
M]D#0K@E;I!#<U(CV0.X^T<+LW44X7B_#B6O+9Q?YPL \+4A-VA362[S2K(N>
M$-1:0!T@V]?#.>,/&]+HE8@Y0,Q&@$A2@U=$@@V"<J%=T+J7Z\=C=]ZQ=?MN
M<13^L6Z6Z=45@_>3=F;4E"GL"SP(*<=+PX&+"H**2ET7I8Q?J740)'/F01>Q
M+:HK+/@D"'AC@_',$^]X'Q=\.U=J*:?2[/4JKZ9S-4"EQGNYX2S@\7(14HH7
M]W+E2%[$2GH.HF",O<9(+T*+0?216D,\)JJ"5Y!H9B 85^"#BJ"X9RY3;[.Y
MT:3X7G&+"_[\I=#G6[?IC?-_MR1Z_B8??7#-K.N8\\MBV7WQ[16+]C1!>$IE
M7^WND$9JI!&$%J$='K0H?OL5OZ1D,B&)(GE9@,C6E8^*FA6UR"P8KZ5.O80"
M]BA^K.Q*4D$E>4T[>Q1EX>CD[S8UXFS9E7NOSC>]]],_ULU9Y^%C=*T:X<4R
MK3'#/T#;J!XB&_\M#G'>!!L<Z!0""),Y.*,=V)")9]R2$/).\BV.+V3A>.;F
MJV+(O;Q4AIXF*4G>URQ!K,ZJ[5ABOL;!R!?"C]8#6@_[?R^W6 \Q)TZ)!Q&I
M!6&)ZYH&9G!2Y<"(UD*SG>2 [-9ZT I-AT,R'1YE8@"V'-QGRT&L !^ ,8/=
MG@]E$="N1+OR&W:EM][XX#)DG30(%A68SL+43CA.DDL^QATV(7QU*1:[:AXD
M^51A6^J1VR#WC%*A?3%L:<-%J& 1T+Y ^^);5<::2B^3@V@] Y%9 &-8 A^+
MK<%,SC*0'38GW+E]P?E4]E9\C/9%G<=TQZ$L3)!ZK.Z$N9F[><!Q& -H*G8O
M@ =HC.S;2$2<*\:Y)E21,' C(\Y]X8R5],,Q_S^OI&^*]]BXV>1L[6=-F"QR
M3LMB44XG\[3:U-:W[;H8F:DP5[O"F\_:Z NAK1': >K#J,)T0B3"*;/ 4E @
M5(Q@5.! &"5*N)3,S;K"AQ;5O[H@RE=;0CW>\.F;"SKMIY)0BBG3%43G:MK,
M(V,.A!:A'1ZT ]2[>B3L7__E(R-4X($8JLN*%QZ/YJQ>.J/%,2W6VP99/TN3
M\@N+G;5,W4(MPM][=5XQTEE+U U!Q5#FZ%S5G!R51@2(,N?BJE(.-@4#D@>I
MBKN::+HQ[K(O5_5-?OZ)1(\O.?1M1Z']%%,S,=6488?<D7$&@HJ@#@-45+<]
MU_EF2[-U!*23 406":Q3%!+/U"5#RU_]]'K?@[J)(FX<![6,P(''.^==L\.K
MSQSWT]/%?.NI3U8GY?G>GTS2Z=EL<9[2Q:?/+AK!3<YF;HZ!L<JD&*&M$5JT
M=?;<S#8Z%[R@X!AC()(A8(BQ8+WDVKADV<V>)C_BR<>VP-@1Z<:RZ3AT8\N\
MVS+HRPL"W7SNLH]FU^6D'T_>5E!T6M-V'AEW(+0([?"@':#BU2-B>.T\<*\5
MKYT?Z]IY=9(FZ6-:AJ;=>+!;'W5QUIE!>*M<CY0@J+6 .D!E'I4O&JPV5G@.
MSI'BBVHOP.M@(96/K$Y*I&![GRK6L>*;+2F^O&#+V-/\,(RRCXP@$%0$=1B@
MHI3MN98GN)2(M!"2I""8$&",9^ 832Y&D2.7O<\(VYF4X7WQ"#QOO"]^?/_[
M>NKW?+$JKS]SY]W4OEN2O2_#6\LT<ZL4RZN7JW.,=56FR AMC= .T.2IA[HP
MKCZ^ X'0(K3#@W: -#XJS]58$F7P#@+ODI^3X& C*8ZLR=Y+2Z@,#YINO4D(
MNNZVON[LXN.M6?S;UNX][LS>?KI/$((I0&/Q8/'N>'=D\%LZVTX=N^&J]NB3
M8ORGEO@P-O@?"/P#-(?J(;6'>;6[6=GA]8 ?Y E#4%$U#A=^5 T<"/,-'Y^&
M()RBQ<?7W(*0D8#GJOR3%N^^N.]*^?Q@'__*HVC?Y)WZ^*(W'Q\5O[:SB .,
M#V*9KP88GUW,CIKX\QX'Q6#LKL9(/UJ3@UJ$ =J4HS+:&.6$1*(A2^I!V!#!
M6LLAR"AC5C%QUDM[\%NF^/URR<;WF>+WK31Y;:>,5M ??(1VW(!Y":&M@/)Q
M$2I8!-3=/2=$\&R$CPR4R$5WBV*"8S& "]3D9+V/79;]SJ;G[DIWA9A*WE>7
M4Y1=S*>H ?EZN*2+:#3S4-!L4_E@&]UP\[C](/UCW7PH1W:._=TKDG,$M190
MT>;9<W]WX[B*E(*65A;[Q2MPQBJ(1K.<9'2)/:@KW*7-TQD\W7\O/_'A;ZE=
M+9NP2K'[PM$\?OZ):Z\\3LMF42RD+<F^2-N_R[]GZUCLI9<?PXF;OT^_N55Z
MF7,*JWXR2JV:4KO7&Z>:SL)H* =!15"' 2J*XW[%,7IN \T.A-$"1%"Q$T<*
MSHFDB6#9NEX" D,4QRDG.#EE!*$!;!:P:VYY?EM 8.)6$Y_*&YMWJ0^+/#G;
M'&6\@:E,N_$&YE 6 0VN/6<^)"HYTPX8#\7JDIZ#+586))E,%#&GI&],FQ->
M<)ZL!^-C,;BLR>"$4>!C2E2Q3"0CO1I<?=E/VN*=#!(5"G$=&QV%N*9%0"'>
MKQ!SJV@(5( 03(/0.H"AD0%E(JE :>+)?RG$/H5(F740LRM";(@ 6_X-GI0?
MEB@CDK#ZA%AK5.'!L11F1@P^\)'*YQ\8\L"X82T7%>.QKNHY/7^H<OW0,-NS
M869<9E9IH)K%8IT%"DYG"L4H,RDXXZS37QIF7!!)M;&0F2_?0P(!;[@#ZBSU
MW#F?:+]74CVE7YBI5'W%2+#@=\#R@J"B9J-FHV8/5+.],8+'R,&P+HW$: I&
M=L,BE*1"B&2R=7BK@8H][$@*)I+<G5W\8A9_= W?KL_.9JEKL^-FD]BT8;9H
MUTMLE+$/:ZP V7WEST_8DYW!/$#5WK<=C&@/!.V:L$4*P4V-:-=M6^(MW>Y\
MUE?%[6N*2;E,8?&^^[CXK8L\69REI5MUB<FS367S9O_ (L.Z_,.U;5IMKO:^
M?-FL<;Z9-=@WOB).Z\&39D^9[#SIN%C[6<+XX.#B@]]<P $JUZ@"A)803SVS
MP(WS()R78)TRX!REQ 0K=+Q19_8C1=B;+KT7//_;)YI_D]]<LO>O'7G_UKVQ
M-_FO;3KJ^/UH'C__^J^7W-Y/.[BI-JJ>6.'7#@@&"U&_APHJZC?J=QU+6OD0
M@+V/CD'EP6NJ,9'D\7H93HJYV&[R>Y==A&!UO@D6="G 9YO1<\VF/4&*7<,T
M%\)R73Y,'\_2O,4+K>KLC]XJ&] *V:<5\CC+.$!;9%2QA)@5999X4)$F$(%S
ML(I:,"1J&:E.GM%^&KJ=-2LW>]F1=FQ672;"JWE8+Y<I_F6]>KU8_5=:';LF
M]I0+7%N1%AIM>(4\5FA1M%&T:UK840<04)$&&4; C(0=U@TOY@6_]B(1(6S^
MM6JZ3;T=5[]:?/;)\IMSZNS.27OBBADZO8@N=$D)OLGK9=A,LP^??BHF*=1G
MK^ E1RW'#R\YT$;!2X[QD"2"BLJ#RG-8RC.JD#:/-FMI!4BJ @BI+'BO)=@D
M3!8N2D])+VW8KSR$-_GM:A'^?G1:0%EM/UU<"-I/+%OW-0(597E@00/,/1A/
MZ& "DV6:;;Y\YI;W#27@!0A>@!S(T<0+$ PNX 7(F&D3H:V!RFI?A7IX"Q4)
M@PZW!AV$$TPZ*D&D9+L&7 8\,QQT\I82I[QP-SJ@_TC085.3][V(PV];#^.X
M<S#Z*;J3 C/IAJ<MF+<P!#UYU=%T:E>3,]=@2_-Z["Z\X*GEA. %#WK_>(<Q
M'I)$4%%Y4'D.2WE&Y>5WCKS)Q:UG,G$0/@?PV1%0D72C,1A)4O:16G#I&G05
M<:]33R/8^W+E48,?U8DO?[L"TN;#V^#XXP^C08>!QOW?-.O]37]BW.]KUO7-
M3!^5N-Z=I*Y%PN*T/.-YEYBPS61PR_+I0F/E+;Q?NMDF":'+>5B=I#9-<C-W
M\]"U=6Q7;K7I&MX^[649Z'[781_2\0M<(E?G\^DO%O;D*D9XYMZG+:&#RP7C
M9V[V3W?>_OQD\F](/_M^TX^W[>\S;N!%:LM#3@K[E)^6UL4":*>35_/0#XOL
M#LV-8;>AR-]7B]^+Y;89_M'=HOQ^18J50OZZ>^K'HIK[/&"7/O?+E;*\O5*6
M+[9$;#[<RUFX,M)?KT_3L@F7-KJW@AO>S;Y1Q=[VP8,+3$ ,S&H;,J?V0=TQ
M+VWT-\OW;M[\C^LLZ>=7^Z;\XV@>CXOQWDW>V+;-O,+@$P0OK@9RO"M/\9?9
M(OS]R205J_ZL.QK+]?]G[VV;&[>1M>'OSZ]@^>R>.ZD2M 0(\&5FLU7.3&;O
MJ<IN\F0FYWS<PAO'/)%%+RG-C,^OOQL@*5&6/)9MV2+ESM8FMD61X(7&U2]H
M=-MFA,5\:<WY8M_7^A?]ALE\AYY^'I8>BFC2:="?/U]N"BA,5\555]'ZQV4-
M8-0;]:40VSNQ;2YV(WKE"KX4NE$.#T*63^,X&3"VQ[/R;U6WP7=@T0=-D%V_
M?M.X <VOYO7WP1=9NYSELKHJ*Y^,7,Q![F?RB_,/_,_:7BI;!7!]XE=%40=*
MULV5;V0UJY4T$_AI5N1E-2_DU TB:!_DKI8N35K#A/@@ /@3GVR@BO+J0L*+
M:C]6T :M@Q)<@4Q88&]P5/YNY_;C^9O]-=H!X=^QD;V>D7B:W.UV_>,HX[ZO
M1KXL9U8O9RYU'1ZA+QJ_$'S$SQ;F9"9K7X6OAEO/2'=M\ DF)EC HK$^N_T"
M;EM)YSFN9 ]^D0M_+^,%$RX#W:^L:SSE2D'#O4R1>W?4R51S+W>' *"QU<Q_
MHJ7K%0"/+^9PZ\(]:[[4,ULN"F.#REY9UP?\*\#K4^O;6]<; MA(>O:Z=OT%
MC"LG:)9Z ;>>&V_5.0$%07Y7%=94U@.PD%\+&7S7+9EWYZO5,@F*11W4%C2Q
MZ:037 01O78W!C?ZLKW=Y76Y*$'> W-=+RH0]>M@<7UE"5W?]NT_:.^^?F$M
M_&J9U64@S6=G(  &[H&X#IY^'0#]+7*PV$HGI]* +#C)=R(-\UT5Y;+>ECUB
MJN*SA=DNYR4L"3?=G0BBC?!H&\'GLP4?KF;%8OR&P7'2B8)W5E5+65V#]F;A
MQ/-KIYAMGEO7QA/(?M<"/83CI:R1@H.'(O,,G"B9.W<JE237*;,LM2JA]A".
MEY>4"Q Z6]6N(^GBVGG"_J]>?$YY RKAL;1:YX3),"><,4M4(D-B<IZ'EN52
MRBWG-N0LSP2G)(J5AN^HD&2)AA=4@NM89AG,UWTQ7F>B_N8<J,VCKE?@UO8W
MIL)O[DN)6[>EAKG."+P+H2N*VE@) Q^ZFP:P]-W^GB/;VLVD-[C ZBCJVE55
M]DV:E@LPV^?^6"/8Z:#OFB],@W?+RNE(=^XQ^(>LP'P"IJ'/SC0LB9@1W!+)
M0THXMQ%18.X1&=M,15&2<+K5(?DP3/.;=6)_.]D,9ZYI(Z?3.!JGJ%8-T@\6
M5><47,DJ^"QG2]MX'6YG;+FX*"L817>$M]T#V_AR\,56_@0P6(;_LZR]+#N_
M%BY?SGJ[9KVAM5[(KD%O+)7V'FTE\WG[ %_C' S19B [SQO[&_8.%E_!%#8'
ME.$:\-,6WN\NG5T+'[N6OU97OL4:/,C=%UC7^?7.NUN]^,9+-PY;B^WR"OZ^
M?ESS=AO;BKNV##W,JY/3[JD[K_H$9C0,&SPE1_CP<T,9W7?ZL#K& A]I%EPY
MJ]S4#A(76;5FNDM^GU- T>9_M,W?]1+\=:G@#\$O( 8N$C1Z\_]XCNW[V_6R
M6[LS'\%QZ^K]K[^ ISN;N:7\:#4]-!1N:YL6,96FC!C.P0XVN212Q9;$BM+$
M:F$I2VY:#5KED6 AO)<T8#5DL2)IED?$A&'".8]MSL.=5L-[SZ-OETZ>?_7<
M]<'3+@S3?U1O6,P-)?=MYO?_?/=-JYE&DS0$%,/P$>;S$0,PK1)RHKBAA>0B
M^-,+D4>66'#&#".6QLXBM6#/JLP2)XIIK&3,XNRF/$9AFL5""1*G)B-<:Y!A
MJ@P!PS?/)(O2U!TSO"&/#NI?G;VPF4<X=R%6OR59_Y*?>Z-0OBUG,UG5_BLW
MQ?%O#-YUI.)VY0)[[J6FP:]5J:T%4R*ORLL^0ZYCQT".DV!NO:GG ]1?JL(W
MK35%K=V)R\;2<8(+]A* T/S>Q _+5HO!Q_7"Q=F=,3EL8_NI5MQPXB8R929-
MDI!$6B2$YR(%CS&F).51"$ZAR2SGA^#^3KC>@6PYG@?CU_Z2O_$,Y_7"K:F\
M\48JK_AV*J_@TVB<"Q'^/O,.Q7OO7\QM,TM?BL6%7XM^Z3F#_X4H :N934T4
MD3A,+>%1S$DJ4T7R5(#$YCDP4OH8P?3GQC_:2[??6UTW08S5>?'W\T79F"4;
M,OJAM48>9:!P.@FS>,*3=)R"VO>2;_?(^_$'V>QH+N!>753!6=FZ0]LEWY8O
M1:YS%HE(I!$14@+AAK$@*LDD"'<6I1G8,-QN]14ZN+'=KY?P9CV+'ZQ>.H7^
M:!EG@#=E$\%'+^,[S:"-@!J&.QX=[OBY /HU1=O=L.V(%?QFZW)9:8N[G@<Y
M[C"&A;<S*GHA/]M 6>MBN_9*5C[J7"\OW4OY])I^,.<+F%&K#-$F.OVI;)P.
ML#BK>9?>XPGV\LJ5A:G]#2H+L]HF/<*ZEZYS>[T*C]?P09VW1 X?=^4K"UNO
MXLC^C>'&RZK)UE%M-M]TX$Y./TWMHDF#\^WG&D>OZUP?S,K:]2*%=](N=JYM
MD[8X!K%RLW@AC=]7T'IYN6SJC1J;%[K9/7DIH16;A3S52A#J[ ?.TYS(.-<D
MB?(PS"*CE(ZW0BL\%#1),Y(S9<!BT2%1:20)E9D[VRF5I5OG-'^S"PG";WZ2
MU1R$ISY?P_ZV07U_?\_ES<%/WS:JD^ECMLN/[_<YJ@(Y7*691G3B0]6;6:1.
MB+6L+R;^W[X/\&< K8N[%&#)M9MF]<J4>TGB'8'+*!5WEK&("3="D]2&(6',
M*)OGE*9J.W+X /%^ ^B[__^TGH#S.=C69;7X:*O+]ZMYJ \2UHA2/KV]V/F8
MQ;O)^'1:Q^TJNWS:)OOZJJP+OP/JY3R?E5_:L&2KC\KY9F[AUA:^*3[??JQJ
M./;B Z2^-6YD__3]OD=@ABPJ_Y!S^<F;?+Z#N5X\VQ&N!XKVHFQ,)6\GM=:1
MVY7WV_NEVXZW[GQZD"]=5]_[6(%'/21=N44W=RD/\](;VI6+U=YB:;NTCL""
MDO<9'F!RPS*OP,BZ*.!7EW>1@RO7%'J?N$^*O/O03%:W;.\%3ZR7=6,W!(XR
M.CO>5Y&7=5'[X*@TX"F"[#>;N+TC%0&\PM+9Z#[<T3#+ZC,#CYR55UZ\?')%
MHQN!>+Y8>+:L5\DNMG(.2,\5V!D":!/H7:5[>*4K^-6_DG^1RNEE@-$9+@48
M.](]LQTU#*5U<N:?-G7[I;QV$"SG7FA N+P*=YB N[+Z#K@OX C-K37N<2VB
MGV4Q<]^:W+BX7M_4P#PM0#7U3B0LY[G\7%;=X_ISVTJQ]P.<,=%+]X(YV(#$
MY>JOQUS) IR?_LO"H^O-08/%W0ZK!<J?B3!V)D%&X+>EES9X<0UD#Q/@7]/.
M"G#XW$&%_DRVIPU6AS;<?:7QJ48S^*G)GG%;J9TOUFQ'K73(\);D>07"!PMQ
M-'2Q(SK62(V;@$XP&S7N%^26W;K;,/ 26B]SYRNT26"7UC:3">L)_GK5M)1P
M]VOEJ D7. J^!/IU@MYXYI2YHPF+"_?9#$R))G  DN3$Z=9D+'_PR\=/AZV'
MIOTTQKYQL-- /%(BV!,<9V9*@U%O0F*ILL[6M\Z556ZKB&K+K!+L(%GU/SK-
M\TO>/[GL;/TUMX-OZ[:^78B]G#EQK6\[NHP!XKVFFTV##\O+2W=> ZBAAW2P
MACKHL.Y[ 0>6,)-%40C_D(PZ:<G#E,B$*P(>9683D[I#'8^1,+\%N5N\?J_M
M+_E/]0+\OX6M_;M>HU0=>-O!0^]$K ^^UU*_-Q'<U03@#L0#C8,Q&#'[;CH4
M/GI<5L;[0SXQ0Z[YZ J<#C!*9G#S)HPQ<P:0=F'RYKO.T&A2RYJ*'U[RVNRR
MX+N_GY__^GV;G.\?N'(_=@ZO\$DB+F3D=LW\6-P=.DNHWK#0G>TD_[# &JTX
M>QGW>R@^AM_Y!&VRN=\,<?GR;J/ELLGJVMP1Z>]^P.\#LC,<C]NOKO68?3 M
M8F&NH8TOW;0D_3][5N<:3%VE9ZR3>( U\#(/"9A5\:$VO<DQNX\8W<)]B[4?
MV0:*;CW]<QNM=I48:CEKB=E%/^=@@!@?Q^I]T:L9G\4S#<YGBXMR^>FB/7'5
MHW88?%.7I)SO#EW],2^_S*SYU+QD&^)QT;MVI'WWNMEJJ+N8C8\C+9PN:15:
M$]N<N.N6<M8>XFK"3O"#']+,A;9@519>(YK"90&O4HSK;VBE87/2W7D_:!/N
MM@EOV#<[973G,EH9-\5B7YNF@/O>:=-,^HMZLHYD]Q;C>@W?ER.*6U;AK42Q
M7:.T,0LORWJQ$5)>O_J]GM%T6^TBOI75Y:=YT4W&I\K=N47 +6M=P;IN@FK.
M2?)'J-PH^U'8+8S<T=+5_%J?6DL:3G+UE$SS0M]:^ILLUG&4B^W#_%P4]:*L
M?%3?/;DJK+/'W1T^RZ9"27/>P%U>5C58\3._X= >Y'2'/\LF8-V&Q5VDNZCT
M\M)EK&HG @TR#9?!*S3!96=M^T_\7D039Y1_N%GZGZ7YU$Z@*I>-N&E957X*
M_3G;.RSHU514/F$6KFVG8%,&5Z%[MUD*[V$*YV-<.??$P>/W1YM2+4WB'*B)
M;5YN&;C'R1[\5=1\%S4CV3V4[/*EVR7[NFACV(TD->EBOK)468$L?BZJ94W<
MHEW717KSRW^]?TMHMBY1!N]H[&6AFTTF TRH79#=[0'-5[_U"&^+#KI-D$E?
MMM>;(5X.UI3ABCNU&VWK9LZW<D!WIL</S8*\^I7;F ?]"WM"? '0SIQ-H9U-
M46P\Y\:Q\CF@6LR;#(G"VS6R,4B TZI/MDON<]_L<%N?;&]-&&>VS-O&U>YQ
M?I.K<J6SNJ],;FX'N@)7I4.\1=7UK2Z!=QR G_S^UB28RW:GJTG @46U^@L(
M[Q]V4=],X7'YP_.Z .KQB0Y.-!S>S3,<]16U/T>^.H75O=%* -KR<XX%VF/?
M;A7[4G6.9ERMB<:<@U?<8+8&N"_E<F96NY0W(@7+JZ8<&'Q[M?PG/8;SBN"S
MV^7;9KFN#D%+='!IC^?NSM<X=/PVS6BHK<B(98(2+FE(,AOFQ/+$6IM'8<ZV
MDMT>5 W#>FQ^ZXST)ER+0=NG*8?5@!VLT!Z]:CJ>O_O+*KFWMI]ZNYX.-K R
MF_(>SAHMY[:SF.>!#V9=57ZCWYL[C5*K&ZN^L9 KN^C[PGWN=K7]5OO"SHBR
M:W-173>L<E'8O)=Z[!+AW&$5XDS^RA<6; RO[@-GU7Z25:>BO/7C#LL!6:]B
M^HZ4ZKKUH?UP@!''E)M]Z1.DFJ/A?:WM5*5[KUGGXWADVQE=921=+:NKLEX;
MHEM0>)!:7+>AKP]75N0P/! \NSI1UHI8*T[2Q##"HT@0I4&=9&FL<JZE!)5R
M"'7RQADS\T4SO[\5]1]OP% H%NXG5"*'$9X-B/V2:# .',BC5RA'V4+H<7T-
MPMFS]5<F+ABI]5+]C]WT3WRJ6R^LH;?F1C=S QKGC\9T=JUA*S!-*^?_N@ON
MF1)_,_&N\ Y![1P7EW?L RJY->TF'GRR=*9ZOO&*Q6+9AD9!(W[5MBD0O/TM
ME[>VRP=PQOLZ?&&\U=XFD<(=?1Y?N[O8O$@;Q:C;\KCMU\NZB6OT ?0X.47K
M2H@X3)2<-=:_6=KM^E--JO4Z%M>"4%;7_?=T@^J<U[*V:ZB\)V=G+B2]ROJ;
M76]6V''O"[, >JFH+V# GY9@8KBUT=?;71)E;\KJ5B<M>D<9>I_V2S7WRRMW
M$QK4,K?MH<)9=\3P^=T0P6VJDBPE(F89X4(D1"6Q(2+DUJI4\!WE3!ZD-V"N
MS^?FQKD$=$.>1H-T"8W^AQ[>J#T>:>9VP9':5[MH@T3-\MV@!I_TT..&&YMQ
M4L,W^LQ66=NE@;K A"/L)B!\4V]TT>G^PURLJ8E.^9O8ZS:XL^+HR>:??=KS
M)/A]^F$:_!U8K9HWF>>?@.RO>YIH$JQ:#@"%J8US6UTEG28A/;B"55LU>F05
M=>FV,CQW?O7!FB"715?<L<?WM3N;=(-*%^UKKO3U+17CVQS;VE:?VPU&EPJS
M#D"OLWPOK/;^0XO*'ER+^1HGF*^1;>5K8+;&7MD:![8\HEB'(8LM"1F3+D6:
MDRRA(!XFU'G"0A[K@W1\6I]W1&OCB>J!KKR8=8T6M#0>5 =TK=2=A[!6M_>S
M)_HG3'J6A5..O=V=QAIHXW$;WN=A[ NW<^;=OC:=M//*6LOCH]OK7E:;!H<_
M< L(!O]>RN9<7F^4W@;I>_ ^QZ&Q4%9[A)_6!DU]Y1J\N5==1X5O.+O&NG-G
MWMGSVW'.5('K'*R^KTXS_A;6QOGN^7^;I:/ZD^!& L@WP6-7F,*YS-W#VK O
M^,A2KQQ@,(+<$2(WHSOVY-JQM&5@>W$#=_#-'Z:3O<BU+R+N<K8FW6:A^\57
MD5[Z8/A*KFZ>=8-W=R'9LI,U'P I7 E:_[3+]3'8V@5!["<O,JL"\QN5:[LQ
M^Z#P&'*M=P"X.T33WPQN(@XWUZ>RUZ7?9;;!M965GX<N4Z3;@&R"(!O37V]F
MQVWZ%W.Y:!-[_(QNVN+*-HV8%ENK]\:JW]S>6#:EQKNA[3C /DRFW.T+]";K
MRNOZP",-2ZZX7%YVH;J66N#7PF>9M'&<K_Z:E=PWH;%NEOJ PHIPP2#78LA!
MV,9Q?+9DFV4_64=TFMV=?EY/U7)V9>%)\VEPOBUT_;FMNMP;-W>+G@,UV<Y!
M:OEWM64%2_/W>5,[""YLJ2+XY,.)/N[4A/0<&=TYB-8,-,W6OVU+IS2O5_43
MV/R.3[?=MMJ?\]D</OW'_:FR%Q8D\K.OU5,"?7[GAO)]X(XKS()NQ"Z1=%9^
M:<*##NIV MMA;SRV73$;JZDY_CR_Q@2AAX8]7.*,5VU[$J/?/^VZ+_@F )=N
M'WQ]7!W&=UDL+U?)A+ (VD_617H;(;C!<7Y=6G?VSL54^W?=O)-O[=9*JDNC
M\2+7"%E;''C>MBM8Y1QNY!E-@]^Z]7)SG73B-&G:[[D6</=[U(Z,IB8Z[#J4
MF6!9=QG5]975SO)8;7:W-LBE!6W3 -O9$MU7NIFZ 5M=NN#WVW6R]E9'AHFK
MI%!MOK,+035KS)=!7O%/]T*M,;%;!)IN$CYCJ*A6C-D[.K_*QG%60OO%:]_C
MTF=!P1R#R>H:%P7"OVK>6!=>0I:^<//SA\EE0M,\S2T1,@''DZ4A48)1$B;6
M,LTC:^1!PN2_5DY %M>_SMS9W;EQL=LK]%V?S'?M\/92NP)[ M]:H-)X@-+8
MP--V>/8.'79;I*Y,H53.<W-[>7:-O#,/E@M7N&7U;7>ONLP7+H>P<1&!$N:%
MMX:;M-"O[N>^,;(VF#PQ-@FAKAQ+X4^.]*@6W!CWOL3-44>PSH5L<BS;)$/W
M#9LO9V#7?5Z%ISM#_KOUVQVB=5;_NP3HD11?R45A0.1>N5/?5(A("Q);:X&'
M7$5TK2.BN8E"R@6/<SY<Z?#1B-6ZVOC/, <<'*+T\RTJ13.;)#;61%D>$@ZJ
M@60L%41RF82YX+FT6\7M$\&S.,X4273&"-<,5(JU*1$L#P5+\RB*]U<IOWN1
M_KG([49]-R=SK\RR^@)+"$R$P0I3[MP'YURO8XUC:I7V_33XV77Z<EZ9,Y9<
M>L':8=_)8(VQN&8Q7X9JD\":TQ\K_G(;B4W[L.8,ATL^\,P'MN/ZKTW!T9GO
M.U;N3WS.5'8V7I<(X?++Y][[\OGV3>#APC6-]EYA5[D5O;&'B,OYO&=1>^O<
MN3HK,?&>B6E*6?5.2V[FU[N3&+HI*R178:A+-RC?0\[?ONW0MVB:?+<^65?*
MJ"EUN):-9HMZ71C19\BZ<%AWF*BR[5YV5^WHQN9P(U#K;VQ'/D^^QXE.:&AX
MEI'<%03EN4U HTM#4IN'T@A%(WV02D'O5]+S2_YS.?_TL_,YSSWJ_]?.S+NR
M GVP71#T]K+Z7D_,EY=K/;'S_6).C30N$Y51>+_,%8(4)B4ZY6'"J.1)LM7U
MDV?4JH@FQ.:*$AY*2U*14Y+*W(0QTSKF6U5/G_[]YN6.*J>C:H*[Z$Y4_F^;
MTW>#4NRZ1J17K(&=.W+94?\,*,)UJSY&OAJ+;)11(A3(/V<F(UG"#%$\2AD#
M4XK)_!#+Y6>G.:W7T'=DJ:T*NIOSQ;XC]/5.T65_D,O>S D:$0]8_PUT?1\<
M1MDKHN\MP)NYL9U]Z#8"705#J7W%U&EPOFB_X?/ P,)H'/C^]QO[Q.T(-%=V
M)^ZN-_>YVF#D.C+87'TEK]L([<H?][5W5\:J,V,;DV''!UUPUJ4CS[6S@)IM
MK_;>;1P4F&S2F$WRZ@H$K*E4VGVJW9,;P\8CU9SO+)LSLZ8UL7V[WJVRHZL=
MG^N@/4+:?-$ES-6M"=;<<.-DYUU/[G:0[7T?[G*R-P=@V]M.@W>>])T9-FLD
MY(NOM.LN<7N_O@^!W\Y9G>OTVU_FQH:OG.GENF?%79/:Q&"D2][637E,.0M4
M655-#<SJYD;X_ZF_<66SV=#AT3;-:#?:_+E7,%I=<GISNM37SW+;>/*ZJ^4[
M<P.OVBAXXT4YZ]8_Q+=F:.Q5ZS8/N[3%FR_D#^S7!2P^V=:S]8MD?6E_H?B=
M_MM6"_P71GQ5-BVJ*N_?E3EQN[7?_>=_1/SU;[_\[O_[?7MG;SYO+JH;*VYR
M8V/&9?2WG:9=1J%W[V  UF]%-)567-9'T^JW.<'=^G5@,I@U!'4-=UNE#7SC
M7;<+"ONLC*:_5B=WOF[9?/7<SD]=%TGMLF,;&'Q1>^*JVC?.=-V TDBT>TSO
M@N81NQ%O_.!UM8C;76N'#(#? NXWAQJ_60'_=QL[JR((G;&UW2CAY/V:+$LS
MD3--0DL%X1%+B=0B)IG4C/)<69-MA;?NT^W UZ=<-37PL_]S)^NW]C6(-OH:
M1 _Q9P15<2XX.".1<>\E$Y+QA!$+5E_.W6%NL[43Q,'VBVRF2*H,^#.9:VS"
M4U<1WUH:^]A=^'SO-7X_)MA:][=6:@8>V')4T%[<-^CD4J '?@CY+A/TTF<9
MMB>39RMA:8IMUZ^"[XKO=ZG+.PS4S7#J3LNFJ\?D[8;V#$6;;.C#NCO4I%,G
MWQ7M@-9:9F,HS@"2[>F].S7\<MZF2JRNWJ'M)UN7[E3[75BP[97DHN]-M1Y?
MX4C9Q1=7D'1#BWHSHCT%XJV&54TCK,J)ISR>='PTQ+*<#SWHL3N0-^APU0-,
MUAVMBO8.W0U3YAN&'_:ZE)\JZY4=N,8/=T%] MY*7=V]#[HS;O1;7U7U-],>
M=K\Q=+HX>#0^RV/%F26I.[G%I>8D4[!J6)BS*,Q2RL+D$-'XW]K*;N=S\W9=
MKNVG9NZ:\/Q=4?D]1HI1^8='Y7_KU][KS5'03E)]]T[10-VR6Y7%OA(U3"+^
M[<Z"J;UM@H9U5[UWFP+_<]O$17S0;K$1J/5^#Y#E=6!S\$46[<FNUI5:]3WS
MR7LP>N]/P)WZPVC/6W45J#5<6QA?[C.X>^C]U)-%V=OB6%^Q*R'E!3&WS(S0
MUF9$<Q$2GHB,J%08DH<V5#FCQCPN[<"'L7Z5KKC.&R<\F+_\-/G+'N' 0XPA
MK@>L,8]<?X\S+V;-OI1Q5>EJW]_QJD&YW2%<!_G767JKOBIMO6)W,L.?D'1A
MDA7I%-\^>]*OI[R1,M?V-7>/ U+M(E3=<4[_#5,T*="^X6&[Y_?\V1EY*I6Q
MH!,S5\\4F 5\;)F$) %:4;$2(HT/4M34:1I J2E"U\P=LLP3EC5U+3;)CSX,
MV8<>&><!C./!;+?>Z_:@.%!%X?U)W\RT[>S8\(]L:G/OK)GM=SA^\B7L@_>=
M#QVX1._@._>%KERWO\[]>5VON\G@HNE^7X?K-KX^:5N5>JLMM[(]?E'799N:
MO+()_=YU<V9V"2:;\Y9K,,S@ZCW?[O)J5EY;&S2P_=K=9'N4/WWX]=?>^U7M
M0;/^88\?9R %Y(.^*%T[DW;X5P"]N^"R-';61=F[P@I-RP%WRG>I:ET5[5>:
M/B>C.-/^\:*XY56+^>=RYHLF!?.EWS5S#1'69;7[9]S[(8]^)GB](<R[<9K<
M< [Z+5R:[\,X@$]FW7'I5<)&)1<W"S:L]M3KU:A<^,:7ZFTDN>GBL$<0QQ<]
MJ 'UP!6/*O0Z*:A+<V_OU%R^QJ@5X)MYT+>L6B>7/B$AMZV.[DR'+A'3OPKH
M<PW:_OEU=IB$L&;"D*0F9*"S64RR-&$D2G,KA&321O0P=7C<R=B/\BLJZ2<J
MP^-/T@/ )Y =.8BNT>[L2[T^\++1&^5Z=58P[S=:S,ON"'BP<!/A"C T6Y[
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ME,Q3PFD"EX<Z(51$-D^2+$P5_49$_/W\K56+\[GYAT?(:?J?8.TNKC^L*D7
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MH<,[G!7RIV,S]CUST)YCQG8FH=T+U^',;ZLZWE52+XIRWNH.9;E,K>$DM<*
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M"G<+<EE4@;O"!LK.RB\!7!+(+M<)K(MZ$2B7[>3:U,O.4B"@VDD-6K]7N3:
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M,39'CUZI>4BB>U(L@< BL.,"=H1Z;3BJ"C='3\;EQ,W1IT_/G=>+:MD:=?,
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M&QFOB6%.;12-M)%[&K@%-(C #TEBBHK7B-6,:@G?$GR]7D2V7*\7K_-Y_II
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MEG.=LU,,<FO_?YQLIWWEI(XN"PD&"E+JI83.^6&AY^)>:A6,IR0 G18U8M2
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MTDW_IA5NVH!-<&%&+GR(*\QOW0':2R+!CO@6JZ4VUB%%E40L+5&K24" GSZ
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MH/EQI+_06O<4%8?>,/SQ>CD^\G:TQJL(]O"HT/4YZ(Y5?T AV0+MIPWMQA%
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M\DRRJ09S6;:\9]TR]*O/\.LH;[/DA=<^;?G]+5^I0/+C^5H+SV6!U,;J2'A
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M<C;PJ "^= $Z.>SIN' [H_KE<.'SV[.IA2>1U "AG&/XQ\"\!9M2'ZQB@K#
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M)+T>^46?KM?.@1'VFSS\BGV___7=)C<!"IYBX4T8[7Q3(B,)-"(>4Q@C1@$
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MT?WN]"I-]]YM;_5J)P(4=N#T4PN1K\6$C7#5;E6M6\ME0WT=U>(6O%T%KS6
M]FL \3@)M(@X48)1#!*$)&4>(VG"4LX3"5+N:3KO_XI"=#<&$#U)T\#F78Y
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MGL *WOQ!D;I9A*P!8A,@\YF?!(&.2"P\3@*6!H2I("64LSAE@795L%+.I9+
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MO.^DSSM1W>,YGS=&TVR%8.H-G 4X.RR7SA*D[YS#:2&Z^.#UP?A$K[,)/*R
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M)WVN0"OF%Y]!^BGX_'S(2O5UR"9G+%^P'H#:BW<&8^<SA)T#OG9&Z>MJ!OM
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M(?-R!LD;P;PYV=_(?6)F%:!7W.0>U"-U2!)5/6<8Z\"[Y_D4KI:K21L;="K
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M%G?1[G '=]_:#K3CK@B92.8I[I,P3##23"E)/!VCP):>\*5F="5Y>Y^NB%F
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M55HC[]=ZP6P^O<HJM<"(H!SG>U_,"HMZR01NWP/]:S2KD0.74URZN<"/P!V
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MYPS4X[@H$9E5C8BL<IJY/-L2!O_Y)7774<9.\$2?"E%.)O_S!0#Y\AN-OFF
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MSF*OSP5[9?+ *"(SV*O-0E#I,H[-$C^5+\(,FF_34G[E,/JZPP^8!N5CA@R
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M1^]"6H.]GI_U-TW7 MYBQ6(&IF(%8#!E9TL!-9:L ;<8LIB2*5T6&,S8U?I
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M7BJF3IY7=>!U$&\N5OAE#@'M;.5\^S]02P,$%     @ '8)J5#XYA8W]#@
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ML=;Z#GPZX9\1O+SJ!;0_-\W5UXQW@BCVZ&/K]P5D4(A0%M'\;2HWS.7I&9@
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MB]]Y%8I3QU.C_#/[QS,,^Y?_!U!+ P04    "  =@FI40!^\.2NO   HT@<
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M"Z"+;Z4 Y=\;F]QJYUVA]V;5?'9[\?"ZA>SKN;VG<&"SG\M2V]3QK707,3_
MT3X2>M8:E2KU"6-K7E,XZT^,JL<FD >A1@S9CE,A)%IPF7<A<9C(U-VK58RS
M&=27-@^"%)HG@X^WP6VF/3:%8-*.30TFW;6@>U7;?HUTF@A-)"F@P9M?\>"
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M^. 2_XE=>9 /QQ8T)-PO B4.%'DQ^Y7:HD!V8=FW( &S.+3QR-*$?$1$#(G
MF'AA\"+0XF-\7(0/3 "A$"CQ9N<!&]SG/YWJLE,F[ADF[ -4MW])P&U1"I0J
M$;C/?Y)T((/Z:?+RDA][DU)H_J@EN"CMS<#_M(2F?  SO'<%K61&!+=B&A!1
M.!)DB6X^P?30)T'=')+CD2-F0@;O"M4ABB4S0Z?O$@T<U]:,\,:96;NG>[8
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MB= *B!BI66G)STK[P6G>(]8KCE0W>2\TZ$+QHG4PZ/X#UUV^5@,9?3*PKM<
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M'828!!=Y_R"107X7^MYR_PQ\T9L(UIA"6^;6$T[]H$2K[;U4(9^M7+"/#B:
M&$DS!>!. &JUE9W7:ZQB'<$8@8CMK-!>8U47AARPK5S *%Q2ZF)U!\:_Q%'1
MI[*CF-LI6'#W/$?RE9D76KJ%M:Q."S)*]["4#>'9> !1WHJ6JWJLB:9GZZG?
M+GFA&!YU1,&H]BTY@I?(;\,GEM!VZU__Y;O3D],_6>[7@),QCZBS6&'*D\L&
MS@R WFL72&(+2R1*-H*JK95J0@*II,'(H;4C'[FD-N&!:RJ8.N\DWC@V3#
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MR#3O1%J*"G%?;2$*)'YI+Y]UB*GPY>7/IT#>F_,LU)-5?? IT#'RK=U2 \Y
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MAZ/<B_8C5)I +U#'ATZ@D#%P1IE*# 6"^RZ LLU1ZI2FN/%P!"0? L]:X(.
MO(;/99(J_2.E_E>%>;"F'=ZQ000)KFK>8L$(1@>G:FL+&QZX7QXS^873)%;!
M,@S+4:RLXO+@ 6.[HK^'-ZV^*OWR'13^F-XQI7/G5,%B]*]4.2ZI$R0_7"!O
MTO.EQOE:9VS D-U$)\V"&[<9[D#_!/;F^Y8F8&PA+(%+W;/MIQB\=YF),0>@
M31,-8R'U%,TZR8J<;0DP _TPMYYR?H.4+-D7OV3?KOSP3?0 R:TN)^,S2(:J
M4EB#%3?]5!K+L 0FQMV0-JRAJUH6!2+:E-; 3W]T$E *MU9P1P5QV%<8FM.
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M/@$&.53>X'""UN0LJ&Y<6$1%\82,&RZC=-8,GE:>=;'H52"241F@2*SGB+4
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MBFI&[SP(V+7(DY%Z)N\23DMD-@U85 \H)5GVS)NS2QE;I=V4T2..)'@8TG2
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ML!3^K2BP(53RF9'T<Q'6U^1$#EGAE*M\U,):/C@Y2\URQ_ZNIC*^;T,Q9 G
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M7R!(R&I#(0I%Y/YUX-+WO]*>A0B"&$%JA)&;\,BK>B#9'[[2*WY)J1M#.AU
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M<3!9789 $/2.(8F<6C\6MAJE)<5]908Y3<=()DK)05_6AKPGL1\)T_M-3'<
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MVMC[B>K3JS8&:95G]&<N4.^&2QQP0282/;TE3[NDR.AN>7JC6^2H00V:!/V
MRN:?/!UXD"MASQUG8E/2 3PY@L>'T#+H&AG!':,-W4K__1R&M$D<RV2UH7=8
M2L8G>4B2WE/B":+S9'1,R4L-XT4RE&L9<I^P,05??^)\Q>0%;E3)&1UUYX/_
M,=G.G6S4:7?/3(;W1M1E=A/SBGBR.N&*%R>4O]^GX6:4R4/2]03A,B;38Z3/
MYHG17/)J#7!99!T^BW7EI! 3AOIW?,IG7L>G<%4?!N2%FRPK2'!)ST7\PJ?#
MQ7UM(#"5-[_3PT2;KK=7?AH=RU\4U#K1:6QE(*82A&QV7L"F)\MR<FB/>N!W
M%2?-I-=7/DLX_P3FJ?R\X9!XM=[.2@PM:H55&X#'9^7Q:<G:FT++-(1J,SU'
MS XT4S8_Y><:4.+:54#^ A=6O56_5SL/_#7T^.95/KXKH($%KDD]#+:Z]9H9
M&\WC.O.B&8MC-5*G1-6AD]+?M8!5>A-(,R-.6K6$-<LM<I7;5= 8B9OUT%J)
M9&(\A]46Y^+>9 -;R!*(#%-KM/6)B:R-W2]S65-3EH"LN+WAP[G:\@XY%CM=
M<MH5/.\N,]DUH[H<9>-WW8"URVG$1LHK ?)_WL2E%_3"/X14DQWI.I$#>'($
MJBPKGE8QR"S>%'>\ZFN45S%_K(82?[/GJ=4RQ',. 8_C7.=-SWGE./=*:PD=
MC#O.V7 ?F/.&B>Z?70+Y*O+D5+!K MFWIG3,@;SFABE-#625L[-96-- T(O[
MA(\.;TCZ2H+K)+TN\B(EH&U ",,4R/KR A6,RK$\.IC'1_/D<!^8<PTX/Y?\
M4\GOEO(;.F>4F:5&)D7S4M2SI$*/FFY-3"GG[!18S']Y2<$DS9SHHLCD2/FC
M3I7G&/'BE4Z33<K;[G%'H@C,GWY\*GJQN-@8)4^06NJ4-1>RXWG7<(1@E)3L
MJ' >OHI\#DCV@.2/[9/_SDT[33EPY [CV$FUD65^"TN 83DQ6Q:I+.R%;9EX
M#O%W_@6JE:QBJ[2IK=*+3Z7D'R AQF6\497,MWKUPPCL ?0]>O0C\E@ZMFY'
M8ABI.8SE*.P-AG&\:J"9BJ$[Y=F$2[D$QKM0G":L'VK$;YJWGNBD;!JPJLX\
MF_'-;RR$M+Z*]?A!V.(<(%'T NZ:POB\8/BU,5;E7MO9J075"7>#$=><L4AE
MJIO--ET509@GZ2K/2<:WU'7DGZK!WUQ</WB"HJ>0]("F2[D0Q(44$+EA-);*
M?0$ -"G5Z(-3=Z"0$6ND/4;;$\0]H/YAV-+(OS7Z9X*Y)'7,7RV$O.W>9'F@
M5_M#E!P)86UD] \@I8[A6JKXO/"(HJIS) ,BQA1_/(A1O0,=]H.O@I0%C8$"
M9SS]]LR30XH'5 [*D'+=+<*5GP* ?T8GP\PS8V.$)3W@3D"PS!,4/!DC-8@&
MJJ8Q?:WD9GH&LC3_VP.1>[X,Z&0W 4D9JM>=OR<CRYZ49ZH*B%5'\& (AS50
MG#)9-P0VF'+S2JSH[ /@8,2;7=)P^$B/FF?-V.=XLK!![M,D*#;Y.GTDZ6NX
M&8DS#J2\-3VVG)@SN^I4,V]4OV339UH4)SECDE*C_MB4N5?- FMSYEZ-90NG
MEIICV]]=$I<N:6[ZFP!B@]OU.'3-F1<3"UZE#%%1<2L_<=3*GS[-AEHY[5+4
M;, J56D"=HZY,?&G58O9&YGZ05#_@_-L!T.Z'J^&1V?$!.K)DQ!7H@0>L,Q&
M^& ,-LN1&=,3SSR_R>I\);0=LJY6+AO&_(P5M9WPK\U*;983^F@\-4KH]/^:
MCF\G0YB1B NT 2E>O>?@!*,"PVV8+;G*"3:K\H&U8+.(.0C3VEY +.K@):NI
MT$NNV!-NDW-HJ=!6;^7"Z9AO#KYD7HJVAB3HLA;C=(Q$%0^:<K-G0F]PY6\@
M?@W:*97(89<G8/,UG43,E5]"<7EY1=T+?'=5YR?E27J&2-V I%!E:-@?@96:
M&ZCCVS@T5DKS,M?M]:F;=PE+MR4!"[3*V+.E_@Z8!W=)_E>25Y"&4Z5>?8O3
M"B9Q7H3I1:Z--./;2TZ>>>6\ZLFJ9PPF Z".O"/5AJLYN;O9Y')^]=/?2 Z^
MS"KN8EPR1D51#>5P7A-N0D9JKJEY<]JGY$*1@+7?1)&"G")<ULH3<*]6N!''
M Z[KC&I-49+$\D_).0'0O,FPE%F)AK JT7 04_ .XHC"Q9YYSWP6U5\9?-^!
MP?<Y155&6B5Q7)L%+.30Y07&!O?$Z-5?$ZKV,G!#]SC<\Z]-S=A>4@$58<O*
M'\D]0A?$#UY!Y0] E=R+0AD.H[/C/ S"J "39W621SL 5;*U&\*QWZ^SY.KM
MR"!+>]WKVSG""Z?GK>$*PF)02-_MW"DXDNOMU?LAY,HRY$V-UI,,>*NL4!Q@
M3Y2C41'*=U:ZU1&WI0;UN^:RY@-B@B\\LE0"(6]>Q)0M5C"/Q &]>=SPU](B
M0.@?!3#6B,MQC[\ZP=1K$6<H<460%K3>*KK1"&<^2XN"6'*EK('K+*E)YE_W
M&$=T"!;Q1Y]@E14P7*O_S5UL^<Z/O5HG-Z$+C^0%1OV9)"^I?]B%&S\:)6D(
M>IY*T'%@T60LJ-]+I>88M.NYN[3(LQVSBU>JR5.J!(4;YN88%=VP$LEQD+,D
MB)9^P&I $(@OR89=4-Y/G\^\+Y^^.(SG6,Y2:8Q!)Y9?:4*9P>3.FHN^P"4M
M(V(!4FV]55)]A3(U9DD[5O1<K*AF097'#28&;T8M+UI,[A]A0>LJ1*@)O9;!
MF XA"54K\I/_?DX%P6V89S*5$%+!.8XIE,NFLTQ2KOM#TJ'PSXUZ<\N<2AES
M1*71 PS#A$^HL>4=Y#B_KU6(-&9\<*[)P<^J?--R>%Y;G$U )J6R_%3W*_18
M/&=A$/KI$1($9;C>B!+C)3V><5B&'SHO,SX5([5T2F A$2RXF_MU&(<YN:6"
M)I1DHD3 );YB(#5?_5^3]"+RL_&&*#[*CVP8KQK'XP.=>6PHCXTUEVVJK-)6
M%?S)QJ9!*'75%*HSI4),RI"Z$Q6NOM*[@])UC=><)AM"@@QN1IE#5'L=QT$I
M2O+\YLO$.5-?R0_$6M3@"0B7,"]-4>@#\=4PAH[Y8*MT4V/%3S=R)O1?.R8C
M6OQQDU".#OF/?+U%=YB/ BJV/]"3PD.?;I/XA=UV_(;[A42 ?/,M*]<O3P9V
M9 OXQ]F98Y;#/_MQ05\WJ-G#+5,J%_H62-,=7;R3_9_ =.7BT&?=)YN2/O92
M<3O* SDD*9L5JZ?1J*JA78,^'9&9NR1,U,_X:1*.<1TSVH;(D[^ 1))M"%DB
MV7HK9M@^@#V:(S-B++><Z?@PM\:\ Y_('C*WTR-'"E#SC!1$#/!I*]5-6_?D
M2520OUYCSAS/;57DNR0%#5/W"3NZ8'U'2(WD: FWR8:[(-4/U/YY*>=&)-ED
M$LS%>FR:C9&9L&B8Y\=*QP1]6<?6@.[(C"K55S2ZF%;PL_98RN:KL,&LVZYJ
MABW0G"J;\6M*&F5![F9_GE3^,XR!^;)!3-5-_)>P>G!$>;5[R-5L/6'VYIB,
M\.,4<GS'._)VF18O!GW%W!3Q;>(H,5=[DK[0\_1SFKSE.P&6V'RG+$T7<POV
M4"&,C=&9$-7KJ]O8]O1:FN,ST@ ZOT\)!+]>BM1T(2Q0:9,%(/"'U<#C"90^
MZE-P5\!=L-X*R55!3OR9]M5N E=C(2]AJ\B<,?!1MRC]>V,^'*!O5>&Q39S,
MKR+\M_6(].N&Q!@+D9%9D&I82U/0MC;$MH!4!F0F'&O-'HTVZ _X*@CH.<[8
MFJY3NN%?PWA#]"^XOBWF6:#74YBMM_< IR[B=.DQ_9:1]?:*2DQ[L"Y97O93
M:2!O- 4;4K?'E)\_ZHM6*ICT82[V/ +I(<Q^NTX)*05Y^F$F?=KZ#HJJ_M0J
M5DGG%63NM54?8U/L7=%"2P5H^S3CT<2/![IUM=^UNQNJR;597'D=FR$:#8K>
M"32PWSPP9XD@$AX%H7WU6JVPIVVJ <?%6@Z"^>T 2;K2YJU_S0>3P;:3&<#T
M(0K+C\#<_0L]8:"ETX\$YK%UK B-:9C1GU0D4@G KS6V.1H+>0D;)8=K"I%2
MKP?$B@V47X.4-KWCX31*F)=<A<__4!;N%,60U/@)D)]$DCG[[Q+TA %6FT6Q
M:<FC>W.W80Q""(1*/Q<@3L"U+>[S%*PO*8&_^@#97#7BV?9ZM^\8BMBJ.3?
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M95>#'+POTLT.2J)16:/M^!A, MUTHJTNHS>B:)OB&QQU5N +5D:W F(KHQM
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M5M%B$"GL<VNJ+M*1HV;OA&XVY7)Y=TKKXLZ-^=YOMUJ <FBN$,G%W"(I&DA
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MI]N_1P$-4]L%W%;7] [U(QYEM&E["@W-4,VNR2L3!"SE!-I-L(US=/L&852
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MV;M_]?_M'>Z%OAW'((JV[Z[#V(O]T(O>/58?_;_O;F+_QW>S*'KW@'NE[QY
M"N +"'XLQHS0"GZ.JF6\I>'/J;\":^\V\<GT_O)#;3UOSS#Z,8'+#Y\^?OS\
M8=>+V0+_ZWW5[#W^T?NS3^\_G_WXE@8_O$.[$:?DVQ(?J9J_';1__4Q:G_WT
MTT\?R&]W3=.0UA ->_;A?[[>/I)UOD<[E"'4P __^2_OWA5PP"0"#V#Q#O_W
MV\--8Y  I.$RSM[(;B+XS\X^?3[[D'EO29RLMQ]PEP\/Z(_O%454_YW%P56<
MA=GV)EXD<$W 13,E'UQ!L/C+#T&ZC-]70V*(_K?R0-EV _[R0QJN-Q'XX8.^
M%3UFB$CQQ\^]"(/UN (@2T73Y_<:=J[W'D0_6H$L]+VHV\2I0_2^BMU?TOEB
MO@&0[+<\]/SNAF;?;3,4QAIT71?)>@/!"L0INB9ND[3;YC!'&7@M,;H@L_ Y
M O=H]@!"$#QFB?\;XCKDOZLD"M ->O7/''&@2[ (_3#KN-XCOF0_)L>3N+[/
M#HN6EZZNH^2UXREH]^YK[GMQ;@Z77AS^3K@)@O82I#X,-_A?\\5YGH8Q2-,S
MT6(Z#M?_ZA[S]=J#V_GB$74*$8UX2(+P_21'(D2\O$\B1#5 N%==Q^MK?85@
MM)O4'<@PQ[P'\'&%#H"<6"7J/=#<K[T0_N)%.?@*//QO<A 45\ =8Z!UW"!N
ME6;D/ ,_AV$F058*0PRTBKK =PDR+XQ4%\$9H?_3?@L*54GR,#>:#X3P%X@X
MQ@-X 7&N>E!I70>:-9+.UB$AS10Q=70U8VX'8AG>J3[20&NZ#7TD;8+9$@+"
M,107PNH^V([(B4>2,JJ>T0>XS_''L4$DP H#V@ B:"C()X(!^E_!38R:@2?O
M#:B(5;1> U': XB0@!H@T3K;/B$6E'J^E ZN.$S_R%^AH9,M .<@1F2;W:.+
M2D'RX_6V18[M2YX=2JYE"J5/'N)$"LOB=C<IV<HM1'TD@U)NIR6)!S(G\79:
MD'"<@:1?U9-"Z62G!--I5X[ZABEI1G4+94895*Y170"SJV$)IQ/)R0UFAUUO
M%@0A_HD7U9QIDGJ__B_9(D7I047?MP:7MK!K.,@C,%_,T&2#$#O37\#^HKYZ
M\Z,\ ,%-?.%%?AYYQ5Y?XH8@: VF#-R D^D?6:KHMB.-7<3"39QFD+BWT[)A
M,,MV?>?Q UXN1'1S[J5AJ@SI$+,8XH8YE!EWB[A(TNP+1%O]+8; B\+?0?!7
M=+>CR7[QPAC;FC =H ,71<DKEM32ZP1>H!6&6?F+.-@O=3%[06O#'!L=RM2+
M\+=5[C,K)FIF1_1PSZXCF],:=AN,!,V-%P97;U@4(]LUSU8 7J"C@\-7T!9F
MLB>XWZ]:@56R0?+Y%@?U_#,/-R30IP=LA%^Q  LD', <!+>A]QQ&A.#U(R'\
MQD!:JAXF(3W40*O:P?S5RTJ>M0O5B9>D20WYNJ+0;>G:OM<_/G7?E9[-5QW1
MO*?LF'7K_<H YZ'E'=-TX#N,:J<U2RLM:/^RG9CMV-T#$@UAZ"-F1I2Z(GIP
MG<15WV]$>"S'JCB@+(^U:8ZF+)":+""=QS:U[KW-!O]Z3FQ8Y/F#//EH_(0I
M%'X%^*D$"#Q$^-X2(-TA7Y-YIM]2;&<YCSS_M]1'A(_(FOSB'E$ZNH"^)@&(
MGA*T# #780QJ:FIMM>3B+N7.8]$T,%5CM$G]::GO72>PB(.=O7HP0*+>)H$9
M!H >-$YDAE:\M2[Z'G::@_HU=)DVE 8<=(5[8RL&/HF+';G#BF1Q]:%62A8,
MO5\QA,4#\!,D6T=A:5O>-2K)N@P)T0-)MX\-B\S.EKGRD-J1/B78ENDGRQA;
M,U&3<H['$4G'CQCV&6H4[(_YA&$4=IM7V2,?=COW+4;B,I*JTSS"2NM.E].+
MT?$3,!./IN>*Z3HR:\WH"DX10J3++?I!V1ROI__7H>C'^#/M.33G#-XR@/8U
M(,]8JVE'B=]H%.%'O0ELXHBGGZ+YDW>W*?!_7"8O'P(0DOG_\P_XK^^+OQ*0
MT3^_7R1(W)P](P4/45LU6N0]@PAMR\'O/PPQI0K()S0J94:-7P\RH1GZ7( _
M>1UY2\J,FK\?%*-[ ,,$T5N GYYSP&JV&W2*U^@H>]'?@0>OT4]2SB3;+0U,
ML\!);J+UMH-,%5T*V+?ZN%T_)Q%E>LW?#S*E@M,]@&6(.42<W7EK&AE2FPTX
MP0NT:1#?%@%X^V^P9<ZPW6Z0*99^S3WULX\SL^F06!9S*!1>3&[H'J.>%F[S
M 2=\$V< WUXX\X>7>>6$F!-F-!]PPM=AA*0ZM*W+!+)IM=EJP.D]KD 486W7
MB]FS:S0:<G)K+XJJ2#WV[!JM!IS>U1K )8Z/@<EKMA*!2&\]Y'3?B")"A.WB
MNF//];#ID$QI[Y H?11YAI/!X/N0S9IXG0:9?!D0M#W[]/R$50/*5 ^:#,R(
M[O+U,X!<+E0V&12QJS>?V%(8 @>UV:!WCI] =..5=F3$I2]PM"Q$-!>P!21^
MKP&G_^2]W03HUB.QOG@R BI@M1]PRK,@@$5P-OX/TJK!&7.ZM+9&I_I)8:J?
M#$SU OUU#I^2UU@TT5K+X:=)CLP<WL/D)<1YP 1S;3<??L+W";IOHO\7;KAL
M@=IX&-4$?QT"CS&]QJ\'F1#.91?=KY*8?2\=-!G6:+43@@J-AV? :C<==**S
M.,Z]2#C)1K,!#\@O281N/@\6:@Y;DF^W&W"*OR(-Y[]CQ.D>@9<B<@MNTC3G
M7)*L]@-.^3Y_CD+_.DH\MOY;;S.,>34/0C3.=0C7-S3]HOG[(:?$$"[KOQUR
M.E4B3_:4=BT&F=:-OX#EAV=9!M+"H<$PDG,:#\KWTKV0#8+S[0-VTP-T^S^!
MM^P<?>PW#C,4]VTLI>[FF<'FLCSH5Q]"?SWP/C4SIY8M/FQ(2KCW_BJ,=@=E
M 9,US553?2VA>$W>)3  \"\_?/SAW09IZEA1^LL/2 ;-4S2+9%.XUO#ORAB&
MVP(*YOS(Y#+$?@%I:2\*+4]."</9J<' \!Z5<'PZ53@./%4E()]/&Y"&3ZR$
MY \Z(4$S>4ZL!Z7E?2N!^..IT0;=XU>B\>^GB<:!>[&$XT^G!@?;E5DB\N=3
M0X3O,RU1^>DT46$Y9BNQ[.3$4ZK[MT+CY*14FK>Y N/D9%2J=[M"X^0$5*XS
MO4)%JXPZ(E0H/OL*DA.55OG1 14X)R>\'D8?5%"<G.!Z&.]007%R$BL]PJ*"
MXV1%56X\1V4Y.U&)E1DN4N%RHK(K-2:EPN1$15AJ\$N%R8D*LI0HFPJ1$Q5B
M60$]%2PG*LC2PX8J4$Y.@&V&)U4PG)SP>A@454%Q<L(K.PRK@N3D!%AZP%?E
MVM0JL49V(\&(+*N@T"JDC@(*9@1;!8E6&744D#0BY"H8M(JEEL/0BL:K(- J
MAXX#@H;AX[-6B7,< .SC#2L0M$J8EH/ BVZL\- J:EJ.AT( 905/K^+G?WPX
M@.@6_:"?3!^"^N<#IO58>.DS029/WR\];T-F_ %$65K]A$2^OO]X]K[,I5+^
M^'N1AJK*HDU/^<%O>V2@;O>IXUK".(,:^@].NO;B19@09]F%!^$VC)<DW1UC
M*7)]C2WML/ZS8&LX'<SMS][!QMV*=C-C$Z[EDI8[$)P.QA91EF!)[[TMKII
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M=1B3*LFXPBE_3T2][#DCLF?#@BGOHU)%DZZU-)O>Z@X) ,U)\>E&T,G88NY
M)D2_V<;85*L'!)66=^ZEH8]Y8QCE&=.-(^IE;#F_ OP<"02S%T01R[(BS'Q!
M)EF3F.56V7$PTRJ&0-IL/B.1E.P<]_0H2K@*$-*E1\?A%(J630"Y0ISC4!U!
M>5R1T7'OH@*/XQ"CXR I'4.AY#Z!Q9/W77^>VN7 U67@"1Y93<=Q'[P"4BTU
MRO$'3@K ")4VQWWK"E!U50B'<++;Y% 9\:.<T7M7]I&5I' KF@T"NI(LL&90
M^W&*M8-Z%Z:9^[A1;8/C$43H6TN!E*H9+5T?-0;F38QX#D@K;5H""5Z/$;']
MHP^5XV:'XZ'4=B =URL5D.:>UB%"F\T+)(V\*G7OR3A$D5IT3['O)(_%0:H8
M^:?"4J-,?BY)_Z(@:P]2I\(D0#^'.+'=)2C^*PJ+.'Y@ZT#Y%J,)1CB \:])
MA-6C+UX8XP7-XWWVR!D,4_2K2_3/>%FL4%#;I+?/F7P]UEZ,  ->#]-754?N
M)3;9N"I%Z6,J!P;"7DZEX]NA@7YU[*CC JT&E+EL<PA/@0V";OP"8(8=MO?5
M4DAT-S4W4*O.W,B$X3+K%MKT),:KG[V%+&F1W\=<E%1S-I?)&K%>5FP4M:WY
M0LQ/^"VR"/:BD?G)SA<=*L/+]#4G*D8>NJF+J7'IA]+0H'S+X%)? ?:C,&5<
M?B_SY(6X);A!?Q6RH7W#J;)>)Z3KU"S#]P_:VY 91$#M[7:VI  :?TXC1H4/
M[G[P^]A<'I:_+.G^MI#?*933;.?AYVXAH[$Y)BW)'RQB"&U6A;EN\72X;O$@
M[];OP"OY#>O*Z324MNR/<E\OD&>MY(B!S$HS#)@+N3%%O+NA'^^-6SS!I_.8
M?6UI^36 KJ L*8_0XN 9M\262@YD:AUE1=BCEU&,8QMA%A/53)FR@]H&AA1?
M[8N1#K'/'==V/'=5.8H'%',)GG&=Q2I\0/HL"@<RNPY%!BDY7&\W.,BRJ+0_
MG8>+'/I85-]/3>;N%@VA;>Z\,TI^-R>&]O3J#4 _3$& </P%88A:SA=(?(VV
MN]_4.'C9B;;2?C_8-RX%Z0P)C*XOVL9FR89?K3=1L@7%QM\C,E]Y*<#58CO<
M*.RQ;%MZL:7,^7:Z<CBC&;39_"-/BRH^3PG#&$-F_^P5-(N#W8@/ZP$@-IB&
M&1*!X$OH@V*E#\!/EC$9A29J#O;9*4IGK%$Z(PI3.\+8__W3)WOL,IHLS]\_
M?;9F3<.9,[]_^L,(C8+?/_W1GM@47LA!XR4=W;%_*H%2C9B 9HTO+I"G@H],
M& (5MA)8QW%BQS0TH[T$002.H\2..I LZ:@5F$VA/F0>S"R#AQ4JT* E"L4Y
M3C[<V#-&BMCI9'7)J*XU8M>Z<R9-1X*@BU,);Q;+1H<,RW%LY$E(/MCE5$JV
MJ+ HA0+%6G&SCF<I',8:OHZ3E/0I9 4G.9YA2%+>9HH!6G&Q]T@IR4QR\0"G
M4@:)"MTQ85V.YVM2T("[AX:=2EDD:>*3#4 [E9)(VH KW9"G4@ZIRZ&5#IL[
ME?I(G3G?X2WA?FVD[A1'0<M59;PK7Q.'#U;(N:I ]85<ZT(].TT%JUMP9(79
M">L./0=E5@AK53+0_CTGX\=86X!G!;)6+61$(!\9_EG!=YJZR-$!I!5\IZV2
M]!^ 6N%\VEI+[WFJ/FE5=$;(1>G9U#Z=ID;#CWS=@=.#0^PJ#L8$D$Q0[0ZN
M'IP=XX9++CQWAY]6?664^%$#@7?X:-4V:/B,-)7;B.LM.)RD:US)TO+G- Q"
MQ+D>O0A(Y%ABMC>WA/U$[KPU^FLM53PW29I$1W-%%^[GW#0P^]^;I_,1I^<:
M-)\>Z[TPNI! >JZ6)D^EIWD*.;C[^TB5QX"W"0FVB'BQ#RX2>HX#3FO-&S[K
MO.'"GG8_V]T;INKPLDCCJ"&M$7ZG-T#'AFBRY137L1%): V8)&0AU_&2%@<;
M97/V\I;K^$Q/I8YXCZ@DL3F.E(2KE"=\.8Z.-!V)!4''7P1-KZ4&\58RY>Y3
M@="Z]S\6F)V]='4=):_C+9&W6X&\T?BPB\FL0G@V]S!Y"1&@Y]MO*8X8GU=E
MW6=(;'TI?-W\Y748R-BBT2078<;)HU1K8+#J;;,T4PW+DJ&*:T3+#F#1(I$
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M^!)BYP;U6$1D,F&1)MA/EC$Q]9$2U.3>E<=-]_=,B[_Z,T]IE!?Z$)8C*RR
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MG+HZ0F9E&FB4U132K+MS2SISH[BGFU\4G5FLQ]O5"G.RESIZ UY+')UDBZB
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MJPW(.YAN(AVOX(;\#?O%YE=UNZRS-,-D^] OT2G6\)03@UUCX8NB-$4>)0Z
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M\VX[A+[)".0ABM;\%;WU(-#';E>Y*2"YFIF!WRW0-^[1MJ)<,N(G51V0*>Z
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M< IT4>@I#!%XQK%+YP9I0N2O8#N9,395A7H0-5&J,2X'>H1:9'&<#%0%4Y:
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M>O6L&$%2545M!EC9M&#2UEJ&T'A]\J0T>W<_CQHF5DE!"5M!;-6QKH.Q;(-
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M_ ;>IEM0ZT2]:=CGL,&!_KZTS[3A!M,X".O4!SKJV$J;;<>]B;F2''^C#7_
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M2PVDO8RIOI&S&H4-\4X9;'^%2XOY7%(L"TDO"'EYG5SHM,V=4\YW,S^F^;*
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M\+3VOSA]/2%J/AH5<D8=OJ:?OTC$2I7%^33^(J/7UW%4S,]?':''KZ^']TO
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M8<7@7B;\&@7O-*?T(!X2%!S1&4I-4UJA!QF^0^S%(CJVA5@92*%:<%?C&#4
M0B.X/=\?Z;'SZ<KRE^.ITUPEQ+VF)C")E,#+B>N4.*R)MYUHWE2=-KS!MBJV
M #4:,6E[C&.)I_69T 3Q5*2/G+46"R)GN#O-%,=D];#&- GPG&MD;(3AX8O
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MKEGK@-=;A[M\C_4OSEBK$Q=W-Q=G@RLV_'G K@>G-U?GPW,4'GP\_;E_\=.
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M;ARG]_;]STGU]MT/4?T?4$L#!!0    ( !V":E0;Q/#TK 8  &$T   /
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MUO(HA;C%N&&)D*AD9?@(HID65J";/(O9<!&E/)L 0UNFPAC2@']),N86&'H
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M, N18\@;!C7U'DVU7 (<P:P$Z!+>@9"Y:AP%ITQ"7BCTC2*WIJ5RB-,H-&4
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M\K-U!8RV"*QAJ$<H/DG<$%!'/B3;QJ!]&/6H \JHY0QX&Q)=7S@'K>-UAZR
MR996P<9H*KK3UHYHG#DNV]&'E4QP;M)YBZME(W.K&F!]J&3U=,(#IG9D_O9B
M%M.F#(AC<$B"K1X#4%C$Q3%' ;[QZ'CE2<HA1\9,OA$Q<FT4+-QS5X#JA\_(
M=/_85>YN*H&<S4TX!O_ ,)Y[6:?DTVC!]TVPOK]539)PS7<]$SN#TTV'[XSD
ML.WN[><^M/ :^/@2I=L#8^E2C=V1*8<OV#=I O#RA>MR!U3(7VWV6VN5*U2X
MM5-* WHQIW:UR6E>7>6O;>UN&1G>"DD&#AIS-("K^R?_'<")<"]$[N=!CO@P
ME)+*U,GL=?QZ,(2'[!R$8+)IX#;13X"5)BAI8K(J0J!&2WI%7H*<<(A!2CRB
M72>EZ50LJX:9,;NI!XAK<BD+,KRU))^[M> :6L:29 CW7_CI)'N@'M( X6FU
M8/U.<'P?-9A-J1 ?S([E]53.A2Y/X?7P_M:7,-&6)4 N\$JL*APP:NA@!T@O
M5"J 0DK L(H6M4/+8'EC+0&)I!8@/EOST($*YC2T!88;4(_W03)KLY*2[@DM
M_[!A@X-!WVS48@9XR_G0X!V,#B@:R(MOB40Q.(*A21*ZZ'!#/#G=9O[(&@HX
M8_TA?H>!GS2DJXYZO%91L2%<B,45ZX W+2R0!PS*3Y""L42:K&&BN>3J:UQ.
MCVEW 6RR""J^&X_CJF&P!QUG'KG.,B!>)%0Z/,+1">_Z;(E,M3"R,:7<@#:N
M2:<S1$3K%<)KQ'YE*12\4Y@<&$LM\7JAW( LB'.@GI:VAHK)M50Z,QQ5NDCQ
M;HEPOBQ<IR*FC&'&H=]S"<0,MR<8TBOF8L?/GSR9D%J+1<ID_;DWE^%BW+_P
M=/Q"7!$NP4#KA:RLW\S_')X?=IPUL&.Z-O0<<+B-ZPCPNL&SZ7I^ Q31U?Y\
MW!V.,6TPY2!XKR,#')TUW.*XIWB(1L*6[U DAW<1:[VZ.;FR?+2M#O=/*V=D
MKT#12,*6!"+<*(?U'F&7(A3 =[;1X3H3D7@\Z?I-.&)]99#$41% +LP+7!EH
M)3!3F(::T4K04Z1$@VN/:O2XFW#G1W^3.4XZLL_: <0(TH;NRR@W8<8D[Z<K
M4NY)V@V> !S%0=TZ>A_GY_DJ>KOZ=2.L. &406D!EK(+3^L]HR/+=4/].:8/
MT,3@?(=N)IV'=*NA.0]GGZ;)]6?\(+'!;AC6)7WZ3TT77F+G].4KD,HP&=1-
M]$!K%[X:YTE'0L0K,6Q7[<>LGS6X(2_6 (=U<IWQUW49:Z\7P$%N-DI=XT8%
M8<.(K82W V @8NS&>H@W.U;$+HPJ2)>&]W;33CVNXDB,*#?2O<5"SE&)@Z&-
M?#!I']I .IU(8[UT)^JP4YH[4D%0M;-0!-K$"<[4@JV'3FX.?-(!YJ" MJ:4
M%-P(.Q[J"2_GAK4JX1=L$0\]JYQ962+X5),.H1*%9*XA?*Q$C,IO;@W[@Q9)
M[0Y'MA&HZS$=?)$\&E2$=R9&D[?LVT_SU*MH\8Q3'.C;B//@"K=UT-IAEP'0
M!+-1N!&P!2SRP+&B;A+TCC!/4F+FHD:YOQ1(P;1XBO:8-$/Q@+B>[A!E=4SE
MHSPRJ;9O+SM_G9/V=@A3A]*D@\Q%\)<DZN_T,<R,UO3'I0CUK@EA3\8Q(W1$
M:R0VZ)-X,4;1T#FV0Y2*JK4,Y%$KNS*F@HH8.YD-+#/1XKG&'H<JS$!&ED)L
MD#O4!OE3:X/&/LYJW4ZWQD<BV:LX"A[62 Z2AK5&FRPU>TWZ'PJ)6Y^![!6>
M^G5F 5<T0+QN:&&B##RL4J7UKE==5?&HVQX,HA-"A03F1/R6Z"*$%9DR!@BA
M+.7?UY7(,#0=BD\OA_KG-;5X9.-LE62Q/=8[=X B[TPH>)% P1_D'RQ9)QDY
MN GYX8;F@>NV=:J'2=1-#S7T'S,QX.X0'AQ?IT;W*-;D!+F3=,$WUK9^\_(=
MVWL_H\;W/M2A_ASN6._;3FW'=BO %!I/+^HVZ6#]+%PA?L]^U&8*C.^</:-^
M8KM7#T;ATL"94E<5;%[&(8?YZ>OS'W\^Y _%Z9V1QQ]S#$PG^R8F=<P# O S
M>S5#S,OEZ&=X11(V'?<O[KA_X*/*6RJZ+;5Q2SN+^SI/"+?=&B[ ^$U'%M^)
MJCF%CQC3?!:MO._>G9'/PEI7?1RR* J+F!(:_AZ^RHZ? ;YZ13!RDOW=&G.A
M5W YP9'_K[$7V?'QX^/GD\['P@,3:N:FEC%D!MIY\,/1T</L^9._'3Q[^O3Y
M[?1Y+QY-3;%Z^9<7C^:^TB__'U!+ P04    "  =@FI4RO*^;U)2   U6
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MVONS_Z#VG\S^SQ'[_G^+V?]$['_F-0_ 0D)X?7E(>  QP,T]4U[PF_^W37Q
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M[Q#M75/HD9;;PO'"=F]_]I<H[4AO@FYRK_!'KG)OOF[!'VG4A80381FHR*@
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MB-.X] 8O<&%'^Q2%L?C@<]"ZP9!78PI-8;GZAGLDIGXF'T-H'S0B&QJ-C;,
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M9VN88Y!K7V^V,M\\/LT?V#(>>V&B&5AA]I")05R05_/SX%_OR7VW.Q5H$H<
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MMR=\%!21)M*D(Z T >D"@8A($R$"TDND21-"[Q ! 8T4 0&E*D4Z$>E=.HB
M]-Y[3Z@!0C)YWKGSEN?>N=_[?7?FSLPWKOSVC[WWV7NMO<K9^[\.)\&/X>>
M:X^4U92!"Q<N ,\('P _?^U R=ON.0!H: #\  !< 8@OR (7"35*0N-1N!U
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M$RF7F#:*SL*U_RH]M_C\+?0?JOU%LW].L>#_3YK]5;&_Z34!D!-=(#B/B!H
M Z?\.Z>#D%?J< ^*PA>3BCT<]R$F5L=SPV",6AG[*<7Z+(:!'3,JC';#*0E
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MZ_^V_O\&UI? :GU2(8_M*K;+8W&HGBY>O*#L$NOVO8L(C4SC+R[% YQAM7C
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MNW\ILN_)]S2Z !*%P1N69A E2M(=>B'[&I^!<H=D&C>8QY+J$X@#?Q=+9JD
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M#G)FC0<RC/+)'(Z)_1C>-O!YPYOD.<H&/.8]F*>-DX-<6.S[,R*GV),]U4R
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M8+[OH.W5/7;IP5CA@2&%GUX#B4?C ,WGQ09334!Z0:DML),8JVD=.EXK(BC
M77]U!(E(IC5H<R5Y28DMOY"5SG5"8,9:NO: K@];$GQ1"-S=CPZ>X1?>U4<A
M-$K2YD->R9X1?KN^["U1.U$;P2E4C"ZEX<?K\H*]N.9S!^949/-UZ0&#(X?^
MV/@%"U^7N["@88@-BTW&6.)K,]L&FC3M.&B<+JZ*['\HU.1_9<W9FR]B-EGL
MNC041#Z0"75>Z9HDJAT] 0Q<J:@YHB)=8!D7I-?E6F4>&ZCW<<IOO>>H3I\
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M_[^=<$2Y6::IW^KE@BNBY*6"B+R/H]]%:7*)8AW0O)J/VPG>,L/055[RTX3
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ML(C062,00D)"$F(26E)26B%61E:A_]\_3!U 00!AQ[J'#;D(8%% L"D@F$8
M"HX3%_+C!_SQ@V!AX^#BX1,0$A&#%<K. 5@0;&PL'&Q<7!P<\*D_^!S H<"E
M9!64QSNO:89_T95**"CV#0&;POMZ:JW>+7;A^V[!A$0T%VCIZ"]=YN"\PB4B
M>E5,7$)2\9J2LHJJVO4[VCJZ>G?U#<PM+*VL;6SMW!]X>'IY^_B&/ H->_SD
M:7A<?$)BTO,7+Y/3,]YFOLO*SLG]4%):]K&\HK*JX4MC4W-+:UM[7__ X-#P
MR+?1F=FY^87%I>65[]L[NWO[!X='QR=G<D$ ;,B?OW^5BP*4"PL'!QL'_TPN
M");7604*'%Q603Q*>4U\,]?S%X6""*@48M^\KR=D$];:HK[OUDM$PRXR<VG[
M3+0?DOV?"1;\?R797X+]+=<H0((- 2</FP*  8<GG.F!1/_EH..F#AWQ(%(M
MDBD=J%''#RRH,3@9'B,:Y9T_T!IMSEZ)J,KCQ&&TQD]5N;XG<<'/X9,8%O?3
MTJVH*C]1^YF\B5MUMIJ-,3<<U\=O\ICG;O"&CHMS,)$",(UMT3T$Q>:#M@7=
MOLQ(FJ\.P-O/6M?E96XM\/F@%\2^R+(/[D<:-CK02#VS>:1E6TS)ADM\_25_
M<( SCYC$],!);8@3_YAN<A^*UZG0B:6B-.&R7UB4(-W<9ST7#!"D^^[9S$"O
MAU3.M,>I2%+2Q_?7\#E9R21D3UL6Y AG2'4/];]&3J;'MKCQ%5ZTB%BX8Y$?
MB#T%0%+WN[^GLMK4Z.>-3!PUD%(2:S^JIWJ*9^IF&=TMY+.W7YCWY41]N>I!
M4A%7N\EWGT/.%LKKW?@SU51)DA)EVW@%.=)/5OWGUV_6O&OB\CGL BQLF3D'
MK+8.7DJ?*$VL[W=JJ4Y9*SV]RGU/0D@H=)RHV&@)(7^[;4Z-SX-47%]_'&XU
MN>(^R1#Y?C/BC4D3!GC,3A$2IT='U]1#X6TW=W>(MXC*]E! A?B:8QE!Q/L,
M&OQ.'7S<ZGOH^]GZ1_RW2TKZIB]\+#B0XLZ[(&M(NG)%*U]B.C*$+>MR(%_+
M',%0]WG<J#<Y(IZ:QL9J1,KO+GF,$V/5T;"<+W-'?B@W$2N+W,!->@7/OO0I
MWRNNPRF;2F&ZV*&$).7*M+L^)5+Z@8?W_=Z-MW'=Q+86 [S2_>>;7XFU?"?
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M9YG&I4+Y0@1&^1$NYZ9W-)P+W ,<.K+]GUP:+$N)QFK],.YTS["SIY-VSG.
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M*#10D-5;):*F1QB@%[9V$7&"_15?#ZPA4 3=;L>>/>US[X.A(/8CW*U^KAB
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M+[BJEW?9_YR1.E6!P"ZVDZ?@_)*+Q!U$PA:>SS3Y]:%_B9Y:N;=4\;?RHZE
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M<\FM]OI%H@RNEQ+>7TNUN_4HFL.<FZ108MP-AN5^*[5OXUNR(7M"W+Q%S$:
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M(K%/Y?Z=$V+S=FE LR<[#??7)<S]S)YL\!KFU"N@#"^]4WY*+L=D2=6IAEH
M)P%^LG=?8Y,?M0OFMFGFJS'#L'E^,20(W?+40W\]*%0QG$ 57%7E6%B&?:,6
M&AE]W'C[;-$A[3L1YV*4#7!6#I2L)0<G3!B-9Z_[003  -]2A()J]DW1G^S^
M:J> IH5:XVGT/Q.UH4EV] X&F(*A?!NV ^%'*H8\%:<Z15N@ZS0&[+7R:*KU
M9&<@-.5"T^,1FBJRZ8$TX;?\E1A/PH'6WW*Z_+.\/\<--D"_ZLIQ^!Q]C %6
MOPKNW9'SVVE7*08O^K,!,/. " E'1)QH!9.Y^.I=\74$$?C^0S;"3Q=NL"O
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M)^\B7^+K''W=?1WYHHZZ\ST>3^R6>9!%.WSJ^AN2!NIL#V>2M $#>H%?/ZZ
MOFZ\F7\B#ZKCW4VHF\E6/)^P#%65/AE[(*#Q1PNK(.C=QCW.DIQ[IU&15;FL
M9;1TH">S<R;>\_Z:;.M4YRZQ$_&=C=5%,1B@1+1X$&0K/>B51NLI7$CY6BIW
MW,\2OJ""DJKY *OH5EL$4D# /EV"A4T64>V\H0B[&7=,#!=0_!2K7UBXMWCX
MYV>32ULAM$4YB\<!0IQBW5$14W6G]'JHHORG'G<+?3,XNK2WJ&*ZU2Z"!L+9
MW",\S,A4G'NUIF<>%L2J(;JGNX=5;J=8N$0@SR?(Y8ZP$YVP: (8#!&T+Y'L
MN5!8)I<:4I@<6[VK'9M;DD>G_2MN&TQ-NP=*)QK:D./[%/A -157+,(9J%#A
ME!2YC/[LQCTEW>G(?6X(9?MCX]=TZ*^VFDJ8]!)8V:QF2,"CD;MSN>:)XC_D
M8WF*3CVZ_ISA8J6M[J\F6^:A&MNEBX11&BL !;T9 \!U33>L]8/> '$@16I_
M]8'!=T/*[*]1')LJ'!4V;F@7PSZA7NF>L!7]G311I;U4F[8D>RCTZ&!F2F-$
MJ0BZ!+S+)\=L04D3LH3+>CS>;"OY:J=OG6WVU9_+L^W+'VZ0W26BB:6YEZ8E
M>[)$KS?3N@H'^KO--'" +^5C$ O?.>Q*Z )V417H)2&9W?2%4V:FV,Z5Q,]#
M.0KA--U;G#C9TSX/N/W;['CBO5RDLK2\)'[%P1M92.VE2OM1H.0:@P'+F1W[
M=.V89_K%6X67DY,Y;H!\I:?0@*MN4+8@048&>"]\Y:(.D")8COBEB<!]O\Q8
MQ;^];\V?HAQLX1% KWH6?/ASDERK7"7:N(;J7$<X3:_)-O?3V;'+4Z\</#+
M*5H_&'28VN<)@C&W5?";K-A&32'7<0 AY(',Q&[C.\1;%9._@*I>[CL1P#!
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M5%@XD)<)U]Z;6'(+]CON*,UEV(XGJH]7-L9 ^>+TFV]*"LH_7WX4/$P+34]
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M! C)'[YV/KWGGO^>^Y_O_/=YKBO/>C*S]^Q9[UHS>^9=DQ#&"+, C8Z&M@8
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M\[:<98Z4V@?RO6,K9<"I;J>=SK=\'3RE,-/(3 "N<[;>DG0=;;@^53HCW4$
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M!V8$47@L?$R64%3E'D(>.Q-Z<FZ&#3;--7AUB+35TYN_-\]G5 R\D_J828$
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MG;P8 K:NZ*""=P8/%ZXOQDA-'3>K)3$EE[SC==,E8.UZTDP9$)A:Q7>F/R>
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M5,=MT9/C(ET?J;Q=U[WN/"U^\4H^F-,5//#[6ZLVF+&[L$ 6Z]\<TJW685
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M)X:.Y7WK$I4= 8AX?3@"$KG(]ZP=! "4BA,VC@-Z_H[]F\J??VO/4*(U!%I
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M^F[7GTE3"/H*J4\= T\T!T@:'@$EG7;]+V2E_P-4F?#A_P!02P,$%     @
M'8)J5',.DH7/>P  L=$  !,   !I;6<R,34T-30Y-C-?,3(N:G!G[+H'6)/=
MMBX:!$&4(@K20:E*E=Z)B'0!D=Y%:@@A] ZQ 4H5$%"J2B\ATCM1>A&0WGOO
M/00(R8G_VF7]:^_C^L^Y^[EWGWL<//-ASIGQS?=[QQASS#$AN%'<+."JNK*:
M,H" @ #P!/\#P,U=/53R =D! )J: !X  ' )0$0@ [B [U'@!^JA(  1OD^
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M@CS"W#R\/#\7(2"Y=.DRZ67J*U>H>9CHF'C^EP7W%4!UB8"4$$A(P :X0$5
M2$6 :P:P @ $%PG^D'^]&A!<("2Z2$QRB?3R%;Q"^57 !0)"P@M$A!<O$A'A
M/PW$?PX@HKIX[9:0 O%U'2L2-E=JX><QGRZQWR_^1O.X;Y=#Y*G;"]++-VCI
MZ!DXN;AOW^$1%1.7D)225GR@I*RBJJ:NJZ=O8&AD;&)M8VMG[P!R=/?P]/+V
M\?5[^2HX)/3UF[#8N'?Q"8GO/R1]SLC,RL[)S<LO*2TKKZBLJJYI;&IN:6UK
M[^CL'Q@<&AX9'1N?FU]87%I>65U;W]L_.#Q"':-/3G_R(@ 0$ORK_*>\J/"\
M+A 1$1*1_.1%<,'[IP(5T<5;0L37%'1(K%ROLPD_OT1]/^93\3=2=I''NS1/
MW?HNW^ 0G>/<^TGM#V9_C=B+_RUF_T;LWWF- \@("?#.(Z0"  ''VM?0-4V-
M2#OLC[!E[;*=L46>%$BK>P+K-,U+'."*NP(.D*ZI@CU7P0%:ANU;@2<O81.P
M\QP+:TN-YUTN1[M[>3)3,XAD>:!P=[&1DUZ>KF/GE&R<7"CVQC+^>?FDZ//3
M:!P@/.,?Q@@6^!3)O=(AT8F-+0U];$]EJ<-0\N:R><M!% %)N<=@YZ['0C?O
MQ,HIDT=I8:#QOD(!)J%SQS"[[3.L<?(';&5 !P= XMN>QS^,/9M@C7>R+29Z
MSY_/WSZZDFLM?)ZZ97%A74I&@T5+1D_:,%1T T$9:6@PC .46H-#GAMN1@JH
M/H*].COU*FS(>%9^A($>FRSC ./&J?W'G@V5D64SIA-[,C@ VC2)$G/J"#Q>
M!V(%HO\TJEO1[2]C-+V1J+G'.K%-0/#DC"S&F7YQFYM)OZJ.-V?"V+1[GCR(
M65PCM[GX7L*.C)/<%<A9=<X1V65#1TMWY!0X_$Q7V&U)2^XXLN$,#X;\%=;I
M0F.L @)4P;9_!^[)I0/UO319F%6<XMJ^+8(>RL-(S27[O[F9W,IH$QDFC0/8
MJ;LH?&,&R5(0:IC/E,\LAADGV,-/]&NK$/((<QEF)(:_FP0;*,9Z=L2* ]"J
M_'EHH>MN3XLJ+NO?)C]TFKOU[L&C=BW@JWTI23@EM0\((^9+9@DRK5J^W\4C
MT%=UK;!>^SZO]N8DK:@U?'KB PR\+%L26Y[1,)T.C%F=V:T493TY'(3M#,(P
MYJQ_&KE48.GZ:1\4(X?J%%'$]88VX9O:@I=;M'E@C06.#8P5%?VPLL- $[G'
M?394ZHU<;Q:L!W@F9T^'P83/W99&_#W+SR'6*A^6U66GMT?.),H1_A9GX.)5
MV*\0Q=-N5$1KOSAH9O@NK6Y6A&:_6]:/MY9/_B%)<:X8E%P\E3.E8B3&8M2B
M8M1YGHZ^YQ+O:+0ZF  /:(B!'&]R)]DY,FT/SV1M38_4-ZA\Q@'^25@NU2Q_
M.(\L,@=AH:DH[[%ER$1M],,4W:-Z]C,6L!$&!Y#9NA$SN6(W5=OJ=235!G<H
M^4Y=#0GT$DEP?:_4(>-?NUI/J8T#!%=_Q %ZLS-P@"!\FU_]#S,;/8?,%WKU
M!J"(<G[#,^GI[@P#:.D';]H>22*6(3O+RVO'XK0B:)AEM&["L A?Q?+8'.1E
MGGE;BH';UR?6W+2!<I#C\=:WWP_N?-.2K=DJG]&DV>D[_&5 5IG"R$!7/AO-
MK$_?.B.T*"A10G$G!C_-B0?.Z9=;DD^8@H#C?O)PECR'DDM95M<?[!6OQ3N[
M!(+X*"YV)9IO#8\<E8<<R':H)$^-X\,55;X#GH%XR5'^DP121#S06+&6W10X
M3_Z4F4LFIN;2=TV^(N3T:%WP<?YI;TA/JBW+IYSIICQ0B?@W]TL\.L6I13GQ
MHL.$@*5.!'IB9U1;]/N@U%3M87WM^'%E:K3R7['M\]+=PBO9WV"(]=VUNV:1
M/^Z\R8I5.-\*;V<Y(D;,E14/Z#X>$*/SE)/+W/]>G*<<6?R6GI)=E(_X8E>\
M9:6IY? PY99L;URZ)J(?M0.>GF'O@\TY.P /UG)Q@!E\0]< _V$\G[5;%&I+
MCD#EA,EWR;74:"_![&NWR(2E=%\:UZR$#CPLKVCX,L@^Z"2@II=Z]1.9=,&=
M10:=K[-V_88C0X+U!12^:;:7JN7-Q<[XSSLF#V&_RBO[(XUQYC[*@4Y:U,U&
M6=46-I&J9+,K'_G7QN,:I^E@UR?-OM'TF\I2^8:9N]&MT/7X;.SH[6,N1&1.
ME'ESVGU(R:++1/"7F:2]^<=CH^\?)T;>F8(J:4WJ_!P%!#C>*[X<*XT"VYU]
MJ[PQS1MZO[PF;-[8^IKO=W&VB&O:00!F4)? UY:QAL293T+=I7>RYQ,B^6OJ
M8V;^V3G0W#+'SX:"%J\%W:FL1LIR\#OM951^?+L;6 ].2.!^81^FS\OAI/\.
MQ?[B=D[BDWP9? #((+HIBB#O^]4ZA_=+,<ERL']ZB'VNP+8WHF"^O>?UD=L-
M"Z/_S)][Z[?_>, '!K7V1U2A6'_E$+\P8,G=^O1IUHG1Z8WMOW"D?H[>C!"T
M/PY%H21JSJ*M_DI$M^5FG+%?&3N?^S^"P!H7&CEWYG^E8 SN25-9IL#1NW1K
M-&N(H!63_F'0=<,"^ ALN7_+)QU;]Q0'Z._R:Z)*L,I[[*ZVMNSUI#3 @OWZ
M95W';I2<#)9!\"MR9A"V2XL#(%0PHI;/84@\O5E!',"B0>MS'=16^P0&/)#O
M'06NP$)/6(UP@"8E-.W9:33V @YPA+=C2/BNX/$1*^8B#K QTBM/O!N8'LXQ
M9*DWC"PN/.Q2]!9K&R-OZZ2CK"FD#!J#J]6Q[^[Q+_H$<9^4\,3&X \+H$MM
ME"3]5&N@HRV#SC3P??R-J>J9.:Q*->Q70,]\[+\FU"!",_=(7F,4(7/GS/;B
M?=T<_+*EJ@ .#HT. (N68RMB]TRKO'_KJ/MZB\%IPS/G_N'M/7X6*:<NUKH?
MZ>\C[)D.%(,Y-D>665J0%3@ Y;[<S*_,41<T,)?^ GH8J*A7CDY<-@8U6(YG
M8;^]]PVRXDFA[>@@^2A_%,[ZO,Q<0W?HR>Y.&+)LRV.*Q5RM"%::QKS]BO#&
MB%/4)9GJC?Y$?N; J?I Y=Q*U$^B];\D^F(\0*RF 6TH$<DON. *92^L4)85
M;WER):17<I*4CH[&<&[FF7/#3?0+3>GI;1FZ3^'=2<L/)JEM;@-L;&)]Z)G7
MJ^^8%T VL$]1)N[NM0'(]M/KO_0YN"] 4+YRX;6L!%APA[-6?!GR83Q?:X5=
M[L*+T5[G<NMF+)7V9?2H0^)X;'V<J%92V'WU,@J":Z^(XIYI ])20;=UO$IF
M1C"MJZ+C*WY^L)A#^S\#1*,=D'B>,'QF^FJ)K?<YSVD"$LVLGH;D@?<$OY<,
M!"#+-<Y?WMW'-.I+"L;%4MX+7(]*W#UNDFY%Y*E8+42+J ]XX  5DX[ L6N1
M.4']:<9/V@ O8]+J[[CU82U[!RU:\-D+ VQ'[?P9B'6W+^@B%HO?.\^0YWZ[
M8[^(0R EFE*A8?>A//N>8#@.\.53TM86>_29L$;J]WS&?'$5DH%R>1/3?:S5
MIN4!L@D3[?5GE^&3/#GMK.7..A!]!0<809 ,8UE,E.9J(_V_83DJ]P32[3H%
MO4SKZX;GH@CI)N,JV>G/[Y(R>08C)LIYP9IGLB>Q_.B>J6:R!:2):XZZ5B?P
MO30_[Q] ^;"YSY@KYS]/#@+8Z>&?XF9C&7K# ;@;X5.JTR<_@$)\Z7EZ4%>?
MO#?CK 44,3W B-1!Z=>"F <0G]+,[S?R+LAN+'%<:C>O=/-Y1"EW?N=V'TB-
MGQ6!<*WAEY'ZB>7W:U*TE6C[.;C%ZEH: SK4-G>#FXU7S>/D290!L[X=1Y[\
M>Z:15&VBA)%K"M)T2V\ZI5GRO\Y&]P0S:(ZI'% ^P0%2L:R+@:9_7C/C3W%I
MP0G&>_TJVE1E"*.QD+[I*^9@X@#' 4HXJ[X:\@390)UG/?-9V'8O5B1GKYTB
M0^L4B.L_3T\%OIUJ<_Y1=MUS?*^XO7TQ4,;&9C&KNZMK>,J;>PP4Y(V&Q>RD
M_RD4@']OTZ.%FK8F&.$J0TMK8D' PS.YI5*G!,%-^@E0JU_!53^46)SW[K &
ME-DAB<%QU]P(',S0JUNIV;E7W+KU@>YFE#*,02>2WJ0+IE/#;W'P,_QW6'\!
M-E]I08P.M/<6@_>VD,<ILJNP_1&'7E\DV6\5#QJH[FI&HM[,:ZHTG>X.QBGZ
MC-XI<XC\3O[M';%3T4#*"VGW-(?R&XBND^A1F8D_#$KP*X-:2OC(-+'NQH-%
M3+I\48P:IFI0@:(ZA$AGE%B'C)M(W/-!3SAK*)(R>^_H_%!H)CN=O/#>FZ5H
MM[JB">OHW&_6:;YK/X8D'YNV]>;6AZMC=G9Q /95RE]MLI-$Q1\<0W56MA^U
M;Y4E+.]!S#N=A80@F5OM/7+"/$7%.3B S4;BJ7?R\GG4LJIL=ZWWYM/J5BV1
MJ'?^TB8@).(GL?*>PT,\T+KV+W=S^C_?L8_W*$,#F'- E*X?T1MGCKO"P678
M]J09%^ZX^BABN3N2_5J32/S9@TK&YXY3RE^> Y1M2'*$+*5]EB4CHG)T_1'O
MFV'F-+U@;[KVCA6BJSZ]LJYZ8JP7)TW6TNBJBC\@G ,4KXL:=-SHC^ 8I69*
M'3OZ^NE^W!H^(+%O_9D%>U!(S8:%5>2O^.WYRM.CH9JUV*X]RF9-Z283$J>$
MXK$.41W@L87+_3SF@_[2,D2(81Q&-:Y1>FE^K42).DYLT-5WM3W73/J9\NR]
MTS/[,+,R_R"K37-$SQ\GW<HO&2IBK^Z$ @_U<(#]Z2I\M5'PHB;J=M%RU#A4
MGCHF0<J+YH":A9$D)J;G3NYC9[S=SE]B?^ZLHU_G^H!4)<.2' PR_23T"^R/
MUY O_G66B<O-&-/%9W5,TU\K/SH&=3;S< #!%7QN9OTC91;^*F4NKM]&X3DF
M'N  =U&4)S\/XV'@+_;KOB>U/P^LZP0'>.]/\K<=L-'-NS#R4BSR:>_#4C .
M4&;1D[ 'K?@ZO4EML_(\SB+>DCP B /$)LZEGUT9AZTN(:K!"776-ZKU0]OG
MAG$ []6892 =#K!,C@- < !4JF^DG_??_VG)/!X'J&Y:.2D]*-PXQ^9T[2N8
MPX*W^;8"&(NZ\HS.&R8UG!DH)5NJEKYX4_@4W2^:6"^=<#A.<N2P8VR-S'Q*
M,?LH5JA'YM30W,\Y4\K0$RW:0\:OKXR0V1*4F^_'&(^U^.90DEJL!U'V9937
M*MV=?L/M:_-"G#50V(_50B@J7ENS;J 0RW3_M"+Q/(O1T?D&L$Q41CNA;LGO
MG#>YS[,6?OFHB/_&'=GV\3ML'[PY7ON]$.;!?I@?*^L6*@26'';5NHMHY7D3
M)%I?):&'*AP=%TE991<EU.34(K..!SZM*M*3NE6+)FF:QIM:5)27;ZPJ%CCZ
M<2Z]C]; VQ;E,?%-)+!\J7TELE!HK;?<<6K=U>2U* Y [\#K[DIT*<9,T76I
MG:W5,+X3R<PKH[.GC8I\E8 <->%'?(B>,37>C'%Q_]9+PY\3"?U4'-*/ZM4:
M8GONU80ZL[H5&4C0/@_O3PX[]L(>(#NP(:YP3<V&P!'5 C_)B3U1B*@_+_":
M#_AQ/V?J)G3[W6>S9QR1\5]O+KP\HI[2-=WM=#Q^(_&J;NR&-R4WZEU!W;:4
M9!O]8:%_.O6ZA-]2=I[$.XON=]\N9X]F7':COKV%7D8@HRR,&=1D)>96O#A*
MQ:+4N*ME\ID9*A_'0K5BP8AXQ*?/S8_*,H@S\J?OP L/O2MJXGS$K_!&4YMM
M7%-!,4MH&51_XU*@ZJ%R'_KB>R0#5M0I'R@'$DXIYH"!XR,F'EN^M9N]5'KN
M!Q$2.BF5--WFZ*3YY=;]?D897DDHIQJGJ5$8Y;LGM^E;17J'"QS&AUI#O3E0
M'=0-3OQD,=])#977*2Z)+H7F2?EKC!48@P9J9PI,P])X(L4VX1X[WG:5 P^2
M3#C2ID/UQ;#1]K,X $6DM9)TC$/V:./:_'Y;DGOC42[&G,\ RUP2WC2L8[IJ
M6,AU+4-$IIW@(E.LBTJ.G/0(OW^!=F".T9AZ3*$!SP;5/3=%\864=).$&;/J
MRA_.'B%1]'!G)E6B,(T'"^BW+^["I,%7;I?+UW6/;P]##L<WW"R$!032NN)Y
MQRS6[XCYFV<?'IY%0E\33#2[3M[A!\L5\CN-+MCU?<6X&U<D2(>MH0Q+H SN
M%D01(KLV"QR"/ZS9^PM!#8(-7P9B&\%@9N5AD?>?&UYV4^$ M>WYIX@WGN1/
MUZ=-,QA4(-%LTQQCU-8_;I\:O)LSH=(K+*PY\?,6ADO3,.4?R#0D;&R,KF'T
M"WV\**EG6OSG8.4])7,KV!\Q$BD47L^?&UO(^2P.E1V_$.3B&GARY\;\!"T)
M(7>1M-V7<G-UB*5>%;):S]@>\IV=Z+;\&%=JOF/I>O]$AUM,7F6EAN?^-WH]
M.J+%-$>'N50)S8W/(P:G'M79['0%T@4:$MEOY$[+$,>IM,$X0"ERCGP$5A$T
MA-(6G_$>$S_YT&7-6+6A W-">ZL6U[(P50RF;:_?>-8=T$ZD.N-/(!VW8V1P
M6H@:EUM.>D,?LI<!HGM91<T1X1Z%C5='K$\.O,N>2AX_=4*V=VTX4Z^UDIIS
MP\LM#M/2N;QU+5=1092[J\.BNGDWPB 1 FF"?+XYLH(FT2W]+="YB=MU<K8T
M#<%^C58\(B)USZ[J=' 3^;D/P-U&D@J/:R#![_+HHEK,K7DH5.TFW7L1_5F5
M(P*00\;46QDA8-/0:P1LL7V26(Z;$:P])4;&2GE'R\XC7J70[!'3Y$"W_^AQ
M2]:"RM<9J0IG?,-?R@L(]M^C*-*C'/KT,W8I7W-6S4\KOY LD10.Z669U3>7
M:!DY#7PQVGTQ+<,A5.@;C#*I.!WE1Z5_A*":V7AQ>SL@%_()!] '.R>S1:\B
M%_09]'W9E;)L(="Q&>?%FL/ C&:N[8'^*9.*<^1<I#9SY#1GB->DDUU%,'Q,
MVM=4Y0IZ.;-J  -TG9/3.E!(-M)UW-V)VEJXM)0,F%/A(,-ZIF;[X.^4FE]N
M""N"<HWS.DUG[G'JR6=\8DWE@L]WJQB4W'C(O[FIMV@RULP>+=6KE7.0IU?
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MS$.9WFHMK!*V8,H+)!MWW/LF.@.Y!=EJ)11AV@V4]ERNLNW;:6@K,%VW8&Q
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M]*EA1>66OA:ZW,_?:[E[>4EGR$U]8VGC6 YTR8!0PT-7LA;4W/"R2D(B6L>
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M=5ESRC=K;>]TC8&OSL/O _'I.D6V/2*=Z\J;C?L.=-6S:"6%HF)>K+OL,+<
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MB8\PFWPZ;P<UNU[2"X@P1(BR9[/_/!NR(L56M4D">PRPF-S_F7GZ'@/"YH:
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M:;KE%8E@[1]9[_-&RX^*+OOX;--]S@EE?5;[-Y9T3EFVK4TZTN#=-==[C@'
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M#9V#K@"8TN)2X@ ,# # //T Z#P@"B C(B(A(B C(2&AH""CHN$\1WOV#(T
M^P4&#@DA&2D)(3'Q*Q 3]2L*!DIB8AHN6H8W+.SL[&34/ +<K/Q,;.RLOW4"
M@X*"@O8,#?_Y<WQ6<F)RUO_?#[0-P$*&<8)]!@=# <!BP<!AP4"[ +*G<2+
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M#<Y=VAG7_SJH:<#47S>D8TY4I9OBD5";8LGN@XC"\986"F@%XBCJ]"HHBN$
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M";*XF'X3$!;MZQ6=+X18O1)]K\C*K"(ZAEDF:IO5%><S4.R8W Y/VP!C %L
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M%&@Q+DS@EH00EM(QB!_[R3".9NEM/Z9=ALB.6*Z_L<5=_'"4&AN.)4/@#+N
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M\B&=^1O3/A)2/R9,)(_2WU2%YB^@2ZS(NGV)$HPI8YAAT\N[K'K<PB./$/!
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MSMM/45+V,,%'6OC--R"& 9;3=+EU=[7UO!9FNQ)OC-W#RX8!'(.,D,B2L?4
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MO>TE7'A!:FE:6N\-A1)U5%0TV6B1\/7"+,;<4GDPUOMQ>3/+R+E"-[T-,,#
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M21+^+%WI:8GWE!U>RWKA^UK)0J?U.TRLF,2'6ON,W.8@P[Z>TRS6B4JS889
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M<3@KX95;D)!=OB2.3WT-H_AV<:7BGV+&8\UM73:PKD3C9^F)9D9#,18[[^2
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M_!>*;3R%!!P;$U:@V$A@[54HHCD("2B,=?UN1NP0&C]H[)3/WU+K4_65IIN
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MU-'R#>#,L,EYZT(Q,G^B3K:_')K72NQJQ(?;3,G'N+%&O-O[!MO5<<GCIWW
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M*I8RE%WC71U,VKVQ1\KOK/_*MV\:=C58R[_.$+Y_X>%".W2'XLRS/EZ+:KQ
MQVX7;\[ RKDYJ7;0SW ?AQV4X,]!;*3_M/[IU^IG;/?R9<LX"4O-R/\=6A)<
M-K?<-&5BE/$]:YZFR5[326O3_,8"&G-T]OXX8SDSI[$V;]E?UYO#Y_XR6CQ$
M*K5B=C-]<2'72+[W5X9A%F]D5)8'7EJR?;WL>;,/W^?FB2R33.VXP"8YNSB'
M&T!%3^ZBA-:WG_J%N*JTZX>*33%=Z0+%(-R@F.V[3]]&RPPN41.!A:0O&G7E
M3TSK)E\(QR[-Q#/N[]@W^/3X4%%IE$L56?EO*/,*]-H,GBCO9/>L"Q2I!]\
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M^ M\R@6+(UJ7,* 7S'C/*/SND*PIN:_'0BLLF:['WI>8 !I9/'FO*3O2%[5
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MCRP0+;O]O/R_%K7<S/X?4$L#!!0    ( !V":E2B6"95_58  #)K   2
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M]Z4!=S=-&@OC';FA(RM[JK@QI-/6DU=GZ^=:_,_Z/NOVV7Y%X;_?/ABS:#=
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M)GLQX7(@;J#-)O8Q'R8P\FC_$2^NK%76V%9C0^!\:XN0"/T'W2S3@$W.+2;
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MK8PL%@HD61[&Z-%[)C#Q(QSW&SM#>T)D6D?DU$11F>U@H4)>U*VI(7DM%P1
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M"19Y+TT^J.2W(/ZYUM#@]4LQP@I4\\]P+TPI@P4<@O<656_0)NH+"I&7T5[
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M]#VSL)F62(:);5XF/A74DRF\D7AEI[(/1@%^/6K(<SUJ-0YHR@J*_X!7C2U
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M#D.9MC(@DG%GRE7BL;-39M1/ \$O-.$6BY'\^TD6E:FCC)&C?NK^OQQ:&X*
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MFPB>QSO!O]G5_SA34DW;8)LA:TA<AQ&39^9%R#P]'G! [*E,KJP*3NSK8_&
MJ!\E''<$29X%OX>\M=7T^]L\GDW?#+IDWZ"^W4#+F7'44 HE<GO)Q&AF^G1G
M'Z<Q1CWJ=[=^E5YLII6?9)J5)UY<S- ENW^K:H!/&'8WI>GN^6QN38ZQ6,+M
MI':HG[_=QW<.2#=_,:V(+^02L^G3<0XH.U&!D.C!B!8Q/CT&F&/J\,+=]WF*
M+]5D^%&PD6T&L<=7*UZ^J1QR\\HVH6=>S&/1T"U%[AC626[1\4F7+DRVWH!7
M,5Z,#.9Y.^1FS*.%UFE2+BZJ&_A ,%M>RLA(*69)UCF8&\Q3)Z94?I&Z?_9*
MAM7PUZ^?,J0HQ8M]Q)]VM1N.&2_!;'$VNNSD]\D,#+H[Q^\?KJ+41!:ME@_E
MAY[Y.<!/K0_3/R3E_K1/-+-TK[+?^F.__8:EI8 )?*LIH=)>7&*ZNDNSK2[/
M3E)X518%%U(V7PW8W\_"^D1\'LQRG5*GNDM]D%JLYRC1\T*\(.=)VG/J"M_#
MAS4XEI?I]C?8EE4NM_+*>,?;'H/&@DO^C7'7Z\[\MSULG,/:"94['81,9^1M
M]++EWRSK#H>&IAC0"U>NJ=4UDVH3"[JL!;NBF&KT,B=^=.0N7QQ6VY]RR9V8
M0.<WF^O8BK@=(M6W07D1\%*\(^ !RVI \/-O\?3*TPQ[3\E3:Q#\*1-[;_;@
MS!%[G7C IGBK$A*&V :MUD?HD8QG(OH@^6B@'AHON\^%!US">[;-Y*GU,GQ>
M__0Z@;ZL*!Z(DSW"_< #BZU%RXWH"NS3_8F]'CR@P.MFAHBATCE(J^S9M\N<
M0L3-EFG*^S<>5/YD7@ED$K,FH'(P4HUM<?D;7D09N^_'+\8QQ:Y(2L3=%_5'
MSO>\%1C*\_+$*1A+X>HO'@SEX(&PP5V>EY9#.R\&<SQX]M*JM[Q&HNL'VPT*
MHNZ;P&R'%UZ'9]%K+<S->W[<6S0U^:&>.ZX,\Z2/?M1-;T>V.K1ROZYFD(^"
MW/=TXG/;BTJ5@M2LCKOTD!RMB.5>MZK=D2C1K@7?(/C9#^T?J9M.Z2-]-%N^
M#+<;R^Y=;+J#6]U!K:OA 1,;T2=]DF\H2AD)ENT,.Y7MX1SEE8#J10=32B=8
M5L1T]_PXZF'(_?*P>882HF\DVQ1!0<VG>X@0LG9K7662J,B-H64&I3?O%5W4
MUX>T2-I?3#SHV*'.N)X'8^!(/T8@O^8$:X77\'P<K'F8BX,&M>@\*X!^.( T
MA,%%KR;O\]=8(T+KZ#QIANQH/<0D=7JKDYLWNZCE)QTD[85N+M@^V/\ 89Q.
MAUN9B]1QJ=F0-PUS=W&3M'>/Z"?A =_H.EM_9X.]83P0BWNUT>E>5+[K(9["
MDQL\WV/85TZ7JE)6!C-T%1:\E7VSD5$ QU>W\J(XWYUQ'<1(&@.5%#6IM]2:
M\G;FX#_ 2::IF\P\8+R!6,O%/;-K+-H@P@.?IRQ TP+9,=23Y<%<W$'$#8;@
M >]<W-6#C')0@)HSLT]3:][Z1YF1I:7G( PQ CV.KY3<15[TLL%=@'S  SG'
MJ:M'>& NZ7BD9%V@[SUBZB$>&##$ U<;CB0/[U%*4:E2T=W7M3MF<9UU9:RA
M@=)P/Y]Q6QOT,+$AEO?,W"S$ \N\>"!^XCB=Y>>*!\+6#)&ZB9CUQ@,_Z"9F
ML7H':4PTXX@FT,Z^J\"I(O;<?BG_J37+?ZJM[6+U<TG/O?",X@G;#_%CHH!3
M5^3%A/Z(Y5]F _FY\G)F,R&&)WD27-^^#+V87+Y'S5 =G T/[%TK<?C&JK%1
MIPOZP[DSWZC3%C)]] 9>.YSI_LQS$&LD7.@D&NO<GU&K]P /D/7@WDP<@#/^
MT?MS9<#?\[3OMGM]3WG-I>/T%U<=[R>-.?CNK[OXS&%]DJI<?1V9+!)#N)P(
M*8&UG8+DP\&/.32AK4U*(@PNM+:GHDI9I2^XID^$SQ@38WD@A\\0LQ6@-5'\
MJ:RZ\H)'WM5/ZA$X>H3&5SAG!QJ>OQ&PP)FW#+5%$QU&Q<7S]GO')33SYZJ,
M5Z)-,GV]LXU&A[\665K&:T?I4;&;!DLL55KB 8.ZOS^)SHM!\7I)P_9'AB5.
MC?,:+G8L%VL&'=./TF1:MHS&5)T%OL97><AFIPU%U^0U%J@ZN#QE&ST@2[X:
MV%PYXR2Q+IO.DXL'0D'W0Q..!35E=?&7V@H4:;J>TU61 ,(N39+%@!6S&A;U
M'VV[.V)8'SH/XCP]PM("D0 "OY.;GO??'7[O<4XH#@X2@MC_F>8L%'A@GA,/
MV#?L^6SP$#?+@GS@L>L:= EA>Z30<V!5ZCAZE+9;M'Q0ZZZDTZ+BY'E_(F[W
MP)W^6U-;NKPU\N ]2#TB-\BXW@3^GG^Q_7"=L_![N.^]"^^W_3+%X#T5'C<_
M[7S>*7JG?*?,BC<!^K+GZ>-\C33V&K4 XF>:Q@M_1W*@.G\>>1P:\G]<+_^%
MMAZ)'DF2=3D#C1%RW#6G&6.I[**WK"H;*E\2D',43C)7<HJ )O;O2 9DF.Z^
MHZ.#/\O!I>/DF-G9V7Y_4)3>IKZ3M[%XU\Q=!7M']$B;@K"2V7LO;Z=(MX]7
MUD%,-UC9?C96I8B48,9)("Z#BM'5F//OK)GF#6LRO=H*E U.(:YSFV3XVXC:
M4,^\*VJX->5AHUF680=3X0/2L053R\1V0O%)"A^=/#]Y"]J&:Z]MX-)Q)@H=
MWD2S0&-U*'L%TPH41Y-Y+-^P!1JATJR?RH6XTJ"/'S8FD)_[E[WC/36,(<FJ
M'B@<XT(QW$W\QML8Y0_I\VD.@N-K<"[/[\2(@'(K/_E'_(7S6_,C9Y)N?'>@
MYR^+C/9QQ0-#13$87<0N+1[H@..Z?RZGMIJFE*8B$ >G&N>OCPOWC1SXP$;G
MW-(5>.A$B%X:I1;HAHH&-7(P>R^U6J/^ON0/==YLNC:<A%/'1GM;>1W(RS?#
M17#_,13H[25=.F@@QMW]'U)<]Y\Q=/P7J[.,>SH)7_4W)\<#:RQ27\:VO!E<
M$]F+9U;T45]O]F=QM1F4'<J.ARLP\+0]0))^N7PM8Z4A;PAD>5NY(_\,ROY_
M*LN["E24I;B'*7]]U,WVY-26J8W=;%#"-\N(I%+LK93(#/J!?CDK8[7".5K[
M=D#M_2HG[G0$,).#AK3 GM7J>_&H53R3.#<!XUGX<!AW^3WT*TISJLM09V!M
M]O)&^$(OWYN1Y[ G"]'W%IZ[2<\PKI/Y.$,A#"SA$YM/_9][P5LR-S..,Z4>
M7X+:'WE,[&98>^"!P@49@9%R?YJIG0&+S>X7*3,\=C";<[56$F<<0KQ9-F]\
M(]QP3Y>Z7UM:5E\71IYZ0.'QOB:P_R;]%44_LF#UBX]B5SK?=.8;%+_]WIKW
M'-YQ.K ]CZR%,OL4+!"-"\TUP.IL*I335.)Z:P=K\W*M.9XKL=A1;&;E?5J^
MK^9Z.<ZY&%9MN5Y4T#530_[,UPGA\VWZFAYA\;<G$V*WRZLFOQ'7:1JI/T%,
MV>(!N!&BZ3H>($'LJ7?N(=;XRT'Y=',<*YT[&BF)_KYA,$XRZ&YLTU0RYA5Z
MH_]!]/+RT*Q^V+GUL&DEE]0.>Q9^:5PZ%^&K-Q%<P'\IUW9.2WJ%C;2<+?9/
M6I]I&KX?QX'2-( EZ"MSU.Q+$9SO?!Y%2A 14KDET"."Q#1K5E6C]9ZX==T_
MY*J%.&?SI3J65M]%W[<0]"Y9N$![(<.0 Q (Z0#VN7GBT=!6?F(O=IT8-;1L
MR1Y#E=G%;(15RKW7UAHN3Q1U'(4R>%2;,@2^U<)SE/.\S(_6AN+NF7I+)\=0
MTNA'2H;T)J=9I  C_^7Y_54NG#@_;F([3C,(=ZL,Z/5UL!(>VIR1M8QXG#]3
MKW2J+#_ZH_OYJ>-;B^:B ZV%F187COM%^TME1TI2@(-='"LLY>TSX6%$C,TS
MM4U<=(5G==/#:Z"C\J+,B88GZM6Y5 5)TR-?/!!>C(37"N2,+7\[SL#YBEM5
MA=-MS5F>1FUR1!P<'DVSQ-3>:)IHVY>$AILH/[,YNB;UXF7U^E>MA RA+ZAO
MLDQUDLFA.P7SU=&;8P^;!:HBKD5=&PW<T';49IPE_-S-=6HU5HZG;:LENC?]
M\]=7SV6S^D+@Y$:\S7+T+_7L/FL[$O;+.&N!JND:0 @BM,<*KMD B4OCX\DN
MAG]";/&-(;[#=/! ?V@KX/;\3Q[#?S:[!K!O&C<\M4Y>\ZDO@L-<X7NP&A[?
M6-;*& G6@NO#]YT>DI4P6N=/8$6_;>QZU/*ZPXG:QHI76=T-?4OA,1R?R9(.
MG!K<DZ_<DB"D08%#]JYH;#C(1*RZ#B#VTGW4?JD"/FK_W<9+ ^4V,.0G]6XI
MOGNOPQ?&6Z-&WZS 1);$/".1?WDB6EIHJK/2023=KF]XW48[>N3K& ^M. O;
M7$D&IE4?;9+J7N@E9- OO*^_ON%VL#;I8?[:>,9*2VF6(JX+\,,#61B]J8;P
MW2MF65C=Z.%%6:("!\=1/( R?XR8&=QQ3'7<2]')*:M0]^:XR>'@>DWLWIU
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M!TV1E;J&!P+">[9LY'[VF[__=/$L@.K/CL<^8\7Q$ 32E;[PJZ,A]E?6??<
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M6(1HFY@-" IJ4R3O<O<=V;WTU]K:@J'*;6>K#1!'5U>G%? 5OPI9P147(9K
MK^7'H GQ ''F<:B)85 2Y87(]/7[4C2,]Q)4AF2N52% BZKN_IM%S=*JVL \
M0.QJXE@1D]MXX/V[X@"2D?&1LDN9YZ0]G<EGW%Q6;B>^=Q&D\%KF^9&E^:"
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M>"^-8(-#"@$?O^+!%>D?A/:P0S2F[B0P&H_!MZ349&;/#(N?\E)V?2OXLU=
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MT^]T]^E[3Y^__QOZ_N]_O1FSQF#LM=>::<WYS;76WN@9]#)P[X6,O R <0,
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M=B="7[$N]E,D+[V0U@T "0DN])Z07UEJ5[.^N!= G3.)^HFLI"0NE,G95HV
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M(KIF)5_IFI6LYO86#T'4$R_0F^T*@N6!Z>/KY-_DO_A'T. _2N+.6<TB*)+
MQ*N;U^&]!8L65O*D=?,1Z K&M@VJ@BV@ 6Q/@U-^SG,PL5L$R=;27VXSHX%
MP_=H0!(7#1SXRIZF4;4N=UQ0D5VVAHIVAQX?(-1)#8[OI:,0Q.#VKQ77&"4
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M3%;3/]/4/<[M3O]1.[AUGI"KOG@RG:R]MZD>_$;GE8)VBVO*>_;>D,CQNC(
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M<Z\-<^EW9I1=W05'(;%\A('T;^E+O:Z*K1LWU0-=6:-_I,2;O_@TSUBGHG;
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M/)@COL]U0P>V=#J/Q(GB50^3B62P$GFMF?.A'-,5SY_5W59X-6VR');\2M&
M8(FJW@G7<<5U]46<"AK0GYJA4G"A%^H&)S!CMOZ]U9F2/:EGX]7R"98#8*Y)
M9__FX =I/?-3$<1,[TQO#=H/ZI&#8<&;!D<_KZM_@TNSZX@%>H8&TCDO0]'
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M?!LXL5CU9K8XR$+0K&]J_]![9BRW_ZA)KW>4J\,N)FYKT%EMX%)RDM>*OEV
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M?-5DD)(Y*^;KOWN##A-.@!+_T#IOLZ%W8@OZ:^YR1-$/#K8NO#^\'&*M]A1
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M_U)_0I+K=(1?W];JN*(=A&%!4FKLI+$YO;JE+V$K :,^\Z6%X5V&;X&,;NP
M9_ET=+JB5N@X$_&A6)% I9[UQ_H2EZOET('TE(F! <'ZR'FL;(=]EZ^81>[B
MD&4#8OEBMAF[ADBM<<Z5VW2B;-%IR7N_?1"'1QOA>6.*-3.I.$":^YP?X]U2
M"<Z6]'-3 BTTCSLOJ5&#R++<%0V8Z+ +KS\OHH<<\C[PP!R+,=(SM+R_'&<K
MG4A)OY+[0X"ZAJS@Z7&SJY">PT%,+?];W'IMP;!QCE5H]U,U;J$QFEO_-LG]
M>W;XBUQ>.BG1AG^CLNVKB6.#\JW7<#;9)^'/N6;2N0=*Y)*?1=>JB1Z]>V0[
M1@A5I>G@)GKC(7LZ8*>*S([^<:UFGAFFQN^J6TJ$&7S;MF2W@. Y*7YX>L4<
M#\#T7#.[=@'7BMZ>KA04E4&"FOU2].?PZ#%SI:&+Q:N;)RXK2DC>-<A,LEN8
ML.MH S3TX<&<->>?V&/I[C\0B;EBZKKV/(&G0[>0;)YI8#RQOBUCKD<N:OES
MMR8.6M4TCY=$7/JM=G,!BR!&2 )^!=9165RET8C<$$:1"5"YC:$];_-C^'A7
M,J:*;:[!O%*I:(5@3@P21BX'01?.55KX8PCH@D7HQE$@A.8=HX#2PO6>J0R"
MFR WC8%XS;Q0^[LC91!K0&Z<TB;,01+S_,L9#Z8L<#EUI"5_>.\#"B@0?'TG
M"C#U"'/" K*CBJ-R_J>B;[\J\:(W.2PAB0(ZJ106L03;8 4X1AZ*V'XOVQM.
M#$% E@LH($D]H<77>#?R!0\*Z #P^"D1T8M+W!ZTWLM0@KX'Q)BV_JL\46C(
M#+TK>7T[]\_=''%(#2R=&&4#957*W 1@5?4I0EV7% 1/;0PMAR;FJ4Z!B;Z#
MT-+QCO)51O+5_O$UV)S]ZS\3#(@J@&D=YXG84*)1)--KF_=._90ZB#/:3_?\
M7D#.V\W?N >) .OA4ZN43QF<W;WV[ZVBFUEA;]2F"O9*TS*>]%2]<VF)PU>$
M/8#[LQZ_ O,&;%?[2-7ERKJIZ)?38BQV\1Q' EWZDVYW)E0GIV3O?CWU=09+
MY$5X@Z8L2>EB#D1%D:K^<+AY5.57?#T_MV%"IBR9"1^.QH@%$HVG(,P#GM.-
M<A$?GN.+XU.TCDY'OZC<XDK%Y?I  WB88^IR+>1--/WK^.\PZ-7YB(T.K[AN
MYS@=7U12Q#E-T\O?B)]8,CM="?MA^"/^?BE_8'*CY^*N?R'5&DN;YUZ=PQ3L
M>+L5R]*@B?(YDSIY4J^;+&=5-ARAB.O]@:1?BTQP<J*!,2;S\DEE5<Q=BY[Q
MQC9)4=6V*1ABC^7Z2F;C"FJ1%B>S$K?V/GFM!243O\AC!T2\K4-]^?T^>5:8
MH,76IA-6'\K[J/7 1 ^#1:<#-_VA1E@QYG:,GX)D19V$R;7<()AUG"^FJ_C:
MR&SI]_5(V*U=\R.XGNM83<3@5J[N*IKU55JITT5TLB7D$GO+D0"Y\(,5I/^V
MZC(U<X/Y!@T%5!R,YYC,+L,:$ ,IH-4TLDJI'?[V/&E^)N9#*R1P\W@/!H@$
M82+5<#Q'6RZ$$; HE^$EZ.L\.AGLY!)2,@^)^02$9]Y.FX^5TPV$E.V2%X_#
M:5M?I!\OO?<J0$EG@&.ON2EQ )=L=M$B:[/([XD'LSUK_%YE7]D=!EI.6_'D
MZ;QQH]2Q':'/0ARW,^A@$FS:I*/'-]BE_6[=&SQ/:A6]5G>K_JF+? ^R>-N<
M<'24 AJ?HX X>@9Y[G;T;4?#T(DK;PW$)GPJ(JI$)]>L8Q\S/V#GRJ>F[B\/
M;\F6YVD__J-(6D?(9+_ 6_,//3Z8JD@_6#*O2X26HPA+[A/0L7/. #SWM=AJ
MW'V.G!$>WVY!OLL;*H4=2&'X/=8DKVY:HQY#F_"\341E0 BL /DS'2H0TJXW
MWQ"W V^/9DM4!S[QMS?'?=N&OC/XXBE&5O9QVH510->E9]U_!C_6!I;=+= Q
M<#JQ"ZE\2I^F]R#MYX)'0OL!DE0.H"P14^T#!^:<2= JU"R>=_$I> U++@]Q
MYP$HH*''_N<KC6:7_^R]BJ. JNKF\9>:**"*UEE\BM4_[R]&#W<O^?ND^E["
MQRUPVZ2YYZ)2%&.N 2[R"#!RLT5BB(V^_\&B>IYJV>X]:!CX)L!3>._\;:>"
M^6DS$UOR<;28PWEQDVL64J_5Y+(/\X$[BK,Y&_IEY&#![MFT5XBM[]^S?WPI
M<63NT1FZ5)H+ 5><J'$%]TMQY_VFA"H017;ZF-%;L;<E8P/B#C.,&.ABYNO9
MJB]B>-[G+!T2=W?A&Y\5[<,_LCH-OBK4*(5B(#[H]@4[3_HX,(SOR7G.1-5I
M'O.]<K9L?-V *&^+S:XEL!3'P&WB@[K'GZ$DU RK'PN[>!#>7 5?[;J?RI1@
M^KZ.U<4S_NAD7P<%5*C*;IH^+^^_R+LV7>4@L7:]K%%%@'K>P54#=ZOZ?.]L
M!3:ZA'YOI-F1%50OM";_EHFIF28:_LD[K/9M)W,=F\9DQ:@*X;L9D@!HR=BS
M@<3A[_+>#*HF:%ZK">V3.$N-PMC66SU%0E6<>O$:>M:TYV<SOMQ8LVRD@-ZY
M+Y8@V5?(IQ>&JB,F6PO['=(+XN?O)"UQ"LPP%.>7'581_PZ:F7!N!SW[S_12
MW3<3 J95#8ANP83^50M/!/D:+[F<<=GD'06T:TO@/JT]7=<[==%@G3'WO"!I
M<AOQ4BEC*Q="OA:/W&Z O,J6-@8@[RLK!,E9>T:PW6];+$@IK+D7-Z"CS/+H
MH/[2OR'I @IKWZIMM'T1T@?9^UQ9N(U(17G -TF,UA>'H&*]0KF JKY'? '4
M=B;[S_V)'\BQZ4UB(OH==%]MWWBBR<J)@!/0GC<S-OLT;8YGM:: _" I7@Y^
M56+/B:VR%)"G6<3F0\08V&C'3XQ\C=5\NP:RQ61V">GI9S^XA<0?-H2B#P,6
MIRQ8P?LD9AKV401@%B__6$7ZO[=/[$;#MC:>U@R*MB8__J)7I4N^CH9M#U)
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M;8N@4)*(7?<EY 57 &R[@46]Q>K6\8?W2[U0TEL#4Y.8GP\+<(D[AAY[.8J
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MOV4/'2E/G"^"Z7A^<NPW^ZSU7@. <M3>P%:00^C!9#*" N)))Y\$1XUO"=@
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M5A:44(M_+21$QW+VR#46% X^Q1T3*GVOYTC"ER6/4&I7/F\_9.*L<K*CY>O
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M^ ?7/-O+WF[>4?UP:_JWI1MK?"GZEU&\=%H,=K5C0U4QP_%SK(4;Q'&%*X/
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M>*SB]\Z3$%+UK#.7A>JYRN8>8-5Y?7HW= 7V?GP@^0S H;E]D>".F7<R= F
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M-1'ZY#K/")MH-"#PN\8U?99Q*&/4GPKU]S@ID)51%7JRC_GV_J!+)]4>L(_
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MA+Q>//ARQV---V)>^S)YRRZZ16K[,(2MMDDU(7$HUW81?4&%LUMI% R-/['
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MJ6 M0CFP/C)-#/!%%0.T-&=?>&<?""_!AB<0/?&9#O \Q#QM'VB-L! #S''
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MRX-U_ T)HT&.;]G!>V]/8O.@[N=FW<K3VXK33\<*1EV?Y:?)[-T5MC 9#I*
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MK$")^/'O%LHP^@"U-/,0:1<M346NQG#V5W$VG%U>EMHXGPFY-YQG-MN:"3!
MESZR HMIWV& O)WWN)-_1./_/A=/E14^P0#WD_JM.]5TH^WWV'+=EXVJ+HEB
M?-_"K9>IHQV]2BVJOAA] K/94/S4[@(8+W?]1D)[R 4G'CX!+PB%T.QUVZM_
M_E"B2:.74=3PX)6NDJOM/_M&R TMNVZ% 5Q )Z:+FY_V=S7(+APQP.=1%C!.
M!@9 :"^?L6\>S)X:8Z&M&+:]KWV.^0!H21P;JL 46)^BV*37",=BYX3I^,L
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MH\<;"IL?=BY PBK:%4D=4^VB2Z,QQC5O)!DB:@ WP_>Y.9LQCPP2L.9*]8_
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MK^FS)<E_E;GY/3M-\J1,?R[MN6<O88!<>7TY/^=*N2/^\%*'WO>ELF4BX4J
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M=3"&[H(DQ!,-D$1 X\X4(;@CN=6T[3SE[='H+OUEUOZ\'D$?%4X,VDM]O"9
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M3?A!_]M#-L:P&.88_V-XX>8?SJH$2X'_<*C$2'QO$:UF'P;:(K;' +F4]>K
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M2-C#D$_1?_=4*RIX.<SC<0=[:7L,*J%.EX-N,J:#@WJDHGOE,."JP.GK45)
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MDK*U3#57CU1 7S41)\=2?>O) H'#U,,'[E16C7^WJT:R;_NVK")N^]!\J2J
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M[;H2WOCAU,P=[:2S2"YURZH6U++(KNJ0(Y5.Y-?#$.OU4##^<RD@E)@CI0]
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M&JPVG0>_TML'<&@J$XFM:&H5J0FD5]PO_F"1@;_NE6W><PPX7UR,0_T+2JQ
M= 4_(HP#R=V7.O,>T#%\?DO13$@_ZWD?@6,=E/64%/XN;NRK4?W<R=;F;]B[
M1%OR%DA14*=E0W#GDQBPK'WCK:;H?9&7G*W,B7M23=#C5,J;B#G'K92RID^>
MQN8%_XN[]PQHLMW6A(.@* A80*1&!4&ITJ030.D*@DKH$5 ID2:]AB(@74!
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M[;\SC?#H7MOAB<I_!F)>M4RGNX*_C;-H'2;(?A\2^Z6#5!ZKJ+1D$S12C!'
MO(Q+(L]HH5B^A>LF>8F,/H)N4M/H37CV2EU_*AR6;Z &I7^H4]3B6C*RWA=W
MDU+6,35UVN0!GF$NC6E5>)6QRO$GZHDC?\>';R*W]W@4=+QQL;/I6/@ZR<1
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M"4X!ZX=G*4UMIX!]DB'/%D9FC=N GI:.\'&4CA1MK-O<&4RPL[G6Q?PZQKX
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M *=ER*)C4YLGP*U:9(9XF&X=CCM4[-C8HF,J3\[\;FN-G]9=1LHEF<O1S0
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MNM)7  71.&L!45Z:3=5(FUQSMJAIJAB%F\;U+2QE]H!F5G,VN2]XJR)K@U-
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M 7DKN6Q%>1*W6W)PULZ^;>N(O@)UO&<<6-GPT*74T%"Y]!'5Q7FEWP47 ,!
M@%=<.LG\M)X"@CXAMA'E,/2]2>+7M#TYD_8!E'<]C/EHJ>PV-C7 #J/O]>A"
M@FUB0U^51C.BP=3W@=80&5ZW\6]G57,P%M!"'4'X% #'PW9SI YZ>\8(_!EK
M4L61N04K\0?@.L_@RE2E/L66@'--R;XP*L!VU%18VX%!;MLTF^; C:1C@2VG
M8V7UQVO^*/D6$*C8'=GA#6N6NX.'H#WIR VGV4QM.5Y65E7RBEHMEM4]9(QY
M?7^M)CQ\#U[$&<$5,A]W0_67>MF#[E<>_M*AR[OPX-DK0WM:&VP<;1XV*7/'
MY4KO,F)/9N4@;?1D<ZAKG%+<G8/G?GD]_B479I>KR&E%W\.8F/$A_(7S[5Z1
M5^\?[F'2!#*S\ '[14,"3<Q?4F>EG8A#B0/"T4WBAQ_F7D4$,LJ*^$TTA4R(
M\O.V/[S09S1:7$EMYKAHU,Y*OBHR=!Q:G.ZFTC9[0U\EV G*+]$?)52,IAJ@
ME#?,)Q\:NM#Q?ZI.[G_RW$SEP?H$SAL#CT7:JRZYOV.5>A-:\0X4HJ]ZZX1.
MEL8<+XT&!1 N>1PT 4<?FDBM'S_9KB@I_%TK 6ECVC).^5O':G"*6]2<A7_#
M2PQ+(U2_JB%^?R- ?<VEEQ:@[??S%9E)F!+ WN<J7AQ-1[[6IC?$7V)>?[7"
M,*O&@L403KEB#/Y800VD=_/94AH?GAW84%3/6U0#!+2P29ZKR$N_G$:-AVIB
M@X,VG&2OLDNS&!-UNA=_VKY?CD7&BQ63[&\2AO]<5P<[L'[8V<FUO/Y93(&D
MCOPMK(JF?!9VT\\<;4<W95FG**4_=5\U;J84$./.#>><2*$G6S88;(X*/MJL
M%2CTS!0>E/[*I2? &<%I/A;WW"\5WP4W6+,EW$TWP1NYO5]6J_)F5>8PE/VB
M1)XCU'UK)WK O?\=R6]U3_>BQM(%B^55&K*Q9=7YM7]B^3K[,B18D3[YFO3U
MY%=7^SW8_@YW](\V W+<DI32U)#OYAO*:F[&W!<9S*!X?W%=^6(QU3UR?VQ7
M"X3<3<7 &*PVHM88OL0DP.7NE;F:$4EVL"H+;?R/JRN,L=!6.7%DDAZ.@M'1
MN +*KK,8K0B7!ZR@=@J(+'B6.3B56^BHX?"&;<S^<-CC0:<?9#PO%M@;KIN$
M* %>C#M->ULH-XYLQ25.',UJN/M775+1*0Z8]H>*M!!I1F1H,E*XVW!];!EQ
M.=-\@0-+ ':M(=T]>L +\,,55RNQADFA'Q$L<_/^#ZP-[I&G8B'^HA# [Y$5
M']90O>*W->*T=S_7SKY\\=^:^ZZHIKIHW4#H+4KO 4%0>N\DH-)$I"DH("A%
M0*2W(*$(TCL(*"5!BJ TZ;U+EX[TDM ["0H$".'PGSM.'>,^W'O/PWV8;WN/
M.>9<:\SY?7OM]<VC@$03\>A6&AA?C]+@F\;AC\LNB40B4W]D+%V47  H)-R^
M4,745P-@X]AZ8U0F@09,MWW^M/F=+J]6C7"#+7G9WEJ%:G]_F=ST20#.W?%[
MZ=&6L\#T4NT?BSXLD+"MDF"3M&^9K@'@(7I""@!( /9U_Y-\NKGA1,EQ@%P
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MP&?:57 L-SU&H+91/]+%Q;K1P<2MPKPJ+C]1D7O' =B0VXPDL.NCI_&$I2L
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M/.$$GUH;KQ^N-LIK=N]'F*R,)_"RJ"M '(0-2NV][2WK5.2+_HDPKW[_D-P
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M_*;:#T@]5M8R<N)>/4GZK8DXWT_OFM^&RU7YW3=(0Q6IK";S"='!=C1APP[
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MDZ??'/Y'#NW^/S?@U>R_ %!+ P04    "  =@FI48S#R&<9B   =:   $@
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M_@2_D@5[+N*0F&2&X-_X]#G%>@N<1296(D 6X)/&.<2^@4&_:$@2-8?Z)3G
M88 UJ%^%53OQ^:\'M1^AIF%@#6F(:Z*44X%I)],/$0J*#&#EM_?EE6_ZO%X
MJ' ]9,2@<[Q":V,'PT.FZF5R]J_946XDT %RK\I\9Y ^V=DWMY2$_$OMIUJ=
M 0AU4_-HK=-%,$+-!T^; ;$]QOA908'U8]4!?H0X*WYOB%YD6:(-\LRO\3C3
M!@;HX@4&VWX8H-BN<MG"U9=[RJY5RN]&GEU:95Z)>J)1D8-/5(;0EFW&.'[
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MZ2G)\:C!_/B3.#Z#?(![07*E ;_%[4CEZMA&2Z3.8-LTT5=CZ=LJTPM/AF#
MR?&$<+RN<($WZ::\]V$S"%+.A9JJ8Z(S@(R-K$H N-X*V..M-,:;9.YJ?--/
M:Q1$H=P8_?DZ_X+R B+"(!3E.%)G%%V, [-%%)D/Y0?]9)KOY5^-M\N*E/<#
M:Y+7 9:VG/6%]SIOUM04L=SC-@YEP3U6H"HKU/6]2E3N/!MJ#T*G)EQ\YYJW
M_4L!5SMM93U83)^EY5BF9:.D"J=_SR6.3M7J]'XVML(.VB8+FO87W.WF<3*
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M2YMX8B/WA%@',(HD/=Q0WCGITUQ0EK;^H0;LB<4)S>6Q71SD?:YD=^WHE[2
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MGHG1-L4#= EV]CBLZ<$,?0U'(L>V]PZ'?09F2/F__;-,XO]H(+P D!KJVM^
MC]6?W5D09CC&K%%ZA\OFOYK9C.;%!42+!]5F3PB%02;PXM^U@E16/AL[[ R6
ME/7NDM##+>8#U.QP]E M;J6TJA_Y^;-C%/+=L!K1=N.D>(OISLE"K:W19Q[J
M?]DKA$B;<+#0*(F^\]@R_:&HK&L.I7Y(#TE:N\\.NR$_.H1#F-'V[)X>8,SS
M,*1!4&3HC)T8VT\)&4>^8GVSQRZ7;[ T.&G%\5MKPR-GE8G.%8<!UFFX4GXW
M/@QP4N$MEKOP1]S'H1@B92GR4)QBNDCG]^MV<SJ\XXW%#?>D[K*5:ZR8/8\X
MM2P;1;]C>RZ\(V-P>,_#7+J+4?'O:P)JJK-4'T$QFH8"2VB?KC3*IAU\Y4<A
M!FL;1BVPAGR8@) LO43=@K5!K8P]3=S79YT6^B^?W]C[ ]PGX"A(+<\5XK@.
M]2CTNL%+D/J9SS0J94$$ X);V#T+,L?J=<=.LK,0"7 ]L74M'L]/$_0ZLA]1
M Z36/Z:=;=0A/5(AFU(I>BFX<^F<\@Q%V'@?X3[PH70AH<$<\):+($.L8@X!
M(W;>#5@+'K*0-/O[<^'M7HOSBR%_IXQU>T5.&,B_/+?6O3L'_0@5L%NHLI==
M')3TS;;T6^><%-F]4(0BO-9VH5D:/'MEF'?RG)CWT/@7 ,PK8&Y8 WO]L)FO
MFLHRY=5:0T?"O[NOL ,)()J8OOW^S0(0QK<]&>_!4/EOTPL>)>>;HU&?*(H?
MKD0""MSC:-HS9::W)-Q/;'N&(]@)J56VL/9C<L^SW'B**MBAB^Y>JNW\NC+P
MRON.8X)L:!3Q]E@D&'#D:5YSGGIRN>[LFY\B!QM!'&41F.]1H$>^A9Y%MT;[
MHA6>>%+ES/;<#X[HDJB$SAPE$@7[DYU*]SHJZB-L/55;_FWOZ>IGKNXY6XCE
M"%(VY)I.<VNQ?4^6U;B+Z";QT0-6 T1U3_?*6%%[X)O=9\);Y^>I\=F'/ZQW
M=463=^-LV9 _>2YG&?W+BN3?29FK#M.%=.1CB/M4+ WC)4,UO+\/QBPT6.[_
M>#[ZFN#0MKT /@:O/L,/2$%I4FZ?4/#][MZ2PC8!>_SN<5.?V[>?7>;G)RPW
M%+'<?;6N[EBVZ[!&^[(AA=9O)W@Y7P!WBMZOA;J8A]_I]]=ZW14[]@K=^-"7
M!,RU;V,Z,Y47!79BL(,4\HZ?/+59]W6L"YU+/2&\;@#M;Z$,?%"[#;E4#XI4
MM82-!!3^7_IB!-3Y>!@F7F.MS39YJ AUB57=02BQ-47D_B4IP071Q6/P\SR\
M<8!NGI#C' 9BPFT"3Y3[_C F%N.].O 5P5%^G2HP@:-T)'G($HDB<%1A<]*%
ML^:/A:J,%TT([&V^\*3W:0>(X+1SS?EPI=WI'\>B=>@%BXH.G*J=-$WV%Z 4
MC T<^@/W-91DYF.S5J+O7OI&A-^E*V-!?-3@(O($[P']ZC5%[(KH]53IRE?$
M[=HUT3D3BV S[L$H$3 +1Y>^XCTNY[QI:M2K"MW"EI5;EUM#N[!'[MR?*T.F
M9O/(GNG7<(6>1^L^:-!MD+@'&52?;9#.%2%LWP,#_:&A=YE@Q%HN'7F#'GZR
M\H)%2-MS.'-=^Z<,0TP+E/1AI]M?+C@_G)H>70JA3V*O)3D"N6W="R"S2.1T
MK?)W4>%7C^A"WV7+%X"(DM]JE]1BN<CN >;C'>,. WV5$[ER7B@#,')VYHK!
M\?WLFC#^N7"MN5_!?N+M>*+9-DXOKD.(0\;"+FU;DD;*AKRJ(CBGQ8OW1%W#
MPQBU]=?B=Y7.@/3>JW&\-&,W0Z>:IEH)AX<X:[P&.?:[X+PH/G7L\S*OWW4'
MC7:_(K[3%?"1,D1NKY0DS:OCI\Q"X13JHGP@WL@T\X@R-# _Z1U+2K+\@31;
M5T5V*P[\I(PJ:BSU^_/0J(>P#6>OPV,_!4M5@Q3,VH7NJ;$M&E\/BQ["=$V2
M]WQKAO96.GOUX.(^>/Y]]>8H#7\*^=]J\DWWR%N)XQS];&K*CC2W=)@(V@H\
M]2TO@$X!(L9Q\WE65'2539V9\MJ2MAP(9*%L4C*4-X(F\[WA.#]ISRD:&LI2
ME8V44BUHIK_1*,Y22WLA0;!Z"):M_[AS,VVW$F>3N& TK6R:OX3Q>]RA/IAB
MMF*\8#XZ7W1:#J[$)N8IK1UQ%OAD)A E=)"6,KL3ZQK^&DR(N5Z"<_(L=#6*
MM0)&F,G$)?ZXXB01L8.$8Y]8A=!+P5_T;Z<?_+J$R,)VR15G9J&E?MC2&Q)2
M5,IDUWJ;7BSX!4L!,9+R1N%/MD*,"JYSFE(E2STV-R&?5FW]/'4K1T Q1;E\
MV\W.A726CM_?7ZJXL%H['SY+^4EX/">5ZDX4R>0.E!]\*SB2!!MH,ZE^%,SI
M_B#KW_=SD'<0>%Z.KL85SBSLD7..*D-:R\M42IX<9_RG_&(SH#7C1ZR"7"))
M[U1T?4GQ\>Z3E2N.!M#+H62@1"Y_V5KCO,_:\J;>"TE%+MS_DK^H2SPFK#2F
M=+:)M]B9^>-M+[>LJD$&&T*:(\T+P%PZQ56@EC$7+GBP'Q&H;1_-$\M%%%0S
M_W IX,D8T1JMQY-XUE<)O75H\N]_.R+P524/^OWB,;3?G1HWR:]\I7*1BS'2
M2:4.[R%<FP;/U9I3NNB@HXU8SO0RQE'X;$#!2>&XHK_^O:,D^X[";NZ4;EO0
MJD$?1@%D451_+Q=24YB(PV? &MOB!Y>V*U02*%?YI^THSJK<C24==HP3GG9!
M)G1(K1ONMGNSD+"TJ(E()_XC2IDI(V3YX6FU>'%*W\+E\/C#PA*IEW)K8W.U
M5Q!.HJR-7FO;@I0:L1K'X)*7><H!68\J8=1B;S2C/';5Y2>O'^/!Z1_:N$\(
M*"*J"D=.+@D+TF;\R :D))S:\9^G4VB;FV?T#X!H834("'HFIA/#N9'9?B3S
M$LKX+D[:=4]I2ZQ>"+B7CW>W?3!_T/7U,6_?0M^+_!-$EAF/1F=95&:"!]KI
M6;(.+M8R3^CN-"9Q0M*[P^BSOMJH_OGWDX/$,(#\7Y7]%Q[UF!6M"6N&YQ,+
M",\ $-[P!<"?$0;8Z%A7=[=[!/G=/KX RJ6@#!/H+P#7T^=7)+DNK<\)T"+1
M^*=K12^ 8*WUCI/E%\#JZ7.]:YT2GA3N*\#7]O@MOT98Q^J3U6K5V4YJX9Y-
M;IZD'.T2X3N!VL:MN7H<A-C(+'>KD9YBWGJ/+8^PDSBWI3_*P4H.DQ@)^5Z6
MN$^1?6D+%X61.3Z%0+0/#O<S5TH<8?\\&?E9J2#/TV+'X],+8*YB+@S!Q,'@
M[Y=RGW'-0UX +6ZOAG8\S$(F)24Q96$'QZ>N2IG?RH=UCV;2LLN>?LN0H<LL
M+L5/3-3^3B:Q]497(NTH01SMX?+S\R#8;X_\%2M]-:#T?V?>%]HH:1_TVN7N
M8VOW6=-FFLV=DPR\_92O,0]'\L7M ?%'B12:VX-IY+ H=^^[8!W#*T(23*OJ
MI]B"%\"D,/@96GFG_'=&Y="Q*?V770Y5IN34R7<J'^%A,=CO/SEE/]+O 5\%
MO9O-DKD@>B.F%K=8FR;E1(FZSET'; K_TCIZSU(VB<:6 4GUI)Z'_U'*607%
MP2SQ?G$)'FSQP!((+.XL! @)MEAP=\E"<(?@08.[0X*%0-"%722$X O!@RVN
M&]R"!;O?5W4?SL,Y+_<^3-7TRU1US_1T_ZM^,]1_/^UZ[OB2ORL31+[1ZU16
M+'#DF*E@,,A ;-\:FSQJ],(0SH8$>^T=:?UO;RMFNF&RO8@IT6%H'!>B"1X-
MPR('>7QIPO;T5+9P:DZ.@3,+!S@V3-;PE6?0^,7CZ72=,Y$533O?<&@\ $J"
M*^^N+8]+_],H2S.E>::F>>K''JDT<6";)REZ(SGIT:)OE$' $O,K2.<!8/O[
M 6"5U7/S?'C?LP!%D-'.=((RL_K#FLG9%YT,<^'KO3#PZ*'*]A.LI<9*"S3P
M-/]-2MJ;6!Z+)NRX2(+RU=K>'^-Z2LII_I$UGTOW2.99: A<D1\_ +-TKZ@W
MQ$\L>'77?S9PTQ%"7586LBJ+PQR\;T3>)GZS$7JFO8P<L Q,.EQ0:J (0 ?7
MGVT;Z=+NACCLH$L[DI6:D$E+?P8M8!QI>BH'F1]P%PH\9K>ICWQ<PXK!K5D)
M63?RX^>\_GQ'WL.,L5;T4: H(R59NB2"R6+Q#Z5FKW!U83-:3(]:0&^R"3O#
M;,,/C'VSVS@/-DP&/JJ!E(F>WLE@ =DHD1M)A&)43LO,0?KM+LP;<->0\1G6
M=AQ)%)N[[&^-K^_O#LXE."?_M!ZR([.&)K9CL9@2J;+DI:TN^A2\UNZ(SW3,
ME3#0^KQS%7:_*.BFM]2 ZW*FXPV7^G_?BW([W8P\U6_1S+QJ$@\ MQN:.O19
M,638_/I\K.Z;-+.$>DM[$!)\8(-\=Y3)H3V2GIX^FV>YGRAQ'WY1?+D5VIW\
M'_.8VO4/'FU)V8O5CFL'!%KM:8=C:O4(9 K%9!\V+T5@0OAR.6+BSP<%041]
M4ZQFN3T15>)N8.2N[)?_M6#A4@VOLP??GR7A23E^].@,]3)H@<FIU/VW_R&/
M$=^!BQ);$G?TM&4*5M<J>7?I_S[!?#0IFXO%(M-97JQ?0C(<Y/3N>! 72OD/
M /D;K9O3[VO*_VG(TRIGA;9K?8FK@)VTM1DM\%8--7:71%[KM_T_LV,1IVY-
M\QH2J:![$]K34D#3JC?@7&P,5D=Z%%^!;,Z#+AA_#0T\$Z 0=#<06[65LC&L
M&Q+Y%VJ-6_?QL'?TY/"#FLXY9K!G/<':7/7T*+BGL6"<$RNF,38S$LI;GIRQ
M!G]4T1ZU19>DHJY5:Y.:?$9"H<?;1;/HYG53T\@P4U##'VTIKCEMO. GQCY'
M%$(Z.&:]"AQUAU2M;T1'%&1H;$41V=D,_O*N?XYCR_J*7J2T(_<23H5%M.JO
M1E;W]B;>NA[R(9C "(H#Q:L(CW/)VCMC<YQ2? ,@+E,$-\W[Q$F5U VV4FX>
M90]TX2MJDO\6@4T?V<![ :JEG1,S.$4/"7^G1;KLO,W-63JP^VYB=OGKTE4G
MNG][=Q+*B^)W <"R1"W;U-Y;0:VB^<)$BC.;$AC:?=:N^'V ;FF'%\L!J51:
M32/U@F8'@P^ <(;^V7=RGY"%)O<0<[7-K:T\C/-@5';DJ J+T<)O9>93+%=,
M/X5QS[/6QCS@6DX?6&>$R@6"$XGLG$I1 DB-!I-*R]$M0$5#S#,73)H62LT*
MP_5^4@_T[S\ &"+#^V%:T7]:<C<ELO%W94=D'@!O>A-JOQ#:2&,W?*;O%S]9
MKF@9]\XW?5,SJ63O&V'4 \T*Y7#HEI4G;'T [(WCJQ=)JS@B6O-&WXC.U^1M
M<V64P!"J5,J1[<3DN:/[MFP%7@9T_?7FIG)SX(K6UE>994E<B;TV@F6%/UKJ
MKZ< 5)I!5M.9Q[Y9XA&SKVP_H,+5,11LWCY$.\VI*L^[O-?+LWMHO90^'KJI
M(U,M/*2H5.H2A[0^HCL 0DE"\C2;,P*'8&_ZKR;T=6(JO<DB'^T37P;-10VB
M4 "[RS')'Y$&;2>TA67#DK]$M[.()L$?'-R$S%,5K#O>6B-/!B4)$E:=%]\8
M>,T9HW%$+6T6+F V*36I%.V>Y#=ED06114YM.R8OWEQ2?!O(=3V+J^4'%8-/
M>07 RR6?$KP!6'V U\A?/M9^7@YBC_RCWE.B/-S!)HJ\@R-PL'4C-1YP,[UH
MKGIX'2^YA_9O1\/=QS(A)9VIPDE(C;_YC?_BTHFJ'ZS<B:'E=[,XXI=X@/ C
MTY3:W\*^C6=37 1 H"2'&)C!(BV/K[;X4=V<;2X#$[2@406DS2AS._Q7&]_T
MZE(C?M<TP#K50D#(B,C&@8J=S@[-Z,=HY-I/Q!R B_+8,(6*]FT5]M4<; 6\
MU@(Y;Q/A9$(0+A8<[S8CA%8X1):N/&<N9D[V#^VQ#Z6,*=356>QB]5#ALY"F
MG?0"QSR^6S[;BS>+BXO#[K@.D.\0_GP</'2PX-&LU*)7P3B>X\EV7M8,@L4T
MIW)4*Y\"_3):&+!REM)U]_-D3 J8?/_8'C&T/*?*E.CC06(%98@Q*A# *\ >
MD.'>7)W>N>6H7.3%S_L3D%*CD^KNQ6W@J--[EC(Z,%5 H4R]D$RZ8^BP/K>T
MB%>X)?(BFTGR'9U.9R'YYZ4?P!*B\\( 46?DS,LL/?%)==MX0>-X%!4)50\3
M:HKI;X(GJD.1;=SGP]R^?=*1AC'.PM!0B$^"BA0!KHN];*A)<VCISN4EQ5T)
MJ]"3-QO:5Q")_H'DRU2I?[(@\T^^<HQ.7&J\$R@_''D[GV@K^>=:6QN?L_(#
M)QU":&4.2MIF#GHD^:Q%>.9DN+G31G58<)!^Y]!I.7Q]F)5B],3TF1(E>)<D
MM7.3"PBA/Y 5)B/G6*$J? Q%)-H6HLY<=<Q&N(35&FIL]S(5!D*<^G-+37?,
M%,5^QE/:)#ID(!/I/GV^KP2=I/<!;,SV\N >3M)E.FCFYY.7^SNNX^+7^L:O
MCV^0+EM=UUKR/ 7+$DC$5(>B!^@UD(_+NUZ>_(C&KW8;DT*BTS!P_-5UP=]4
M"Y%KA/(15H:8@81'U9TYA#P7 A\CTT0*6)1%>U;OF,ZC7X2,7=BHQV0LF]V#
MFNS^4D'&\2E/GL,GS?NH4V2WJI6)T9P)R1C45JG<*".AA B_UM)"NJ&H'/72
M5:1N$-0^B7LMSS#-F,-Z^T5C(UM"*.43!8??K3BX1=*FSJ8NPNC@F.'$LK1U
M9=_#G\;_=%1R8306*XH-S1JB+Y(J-1/Z<%REY@QA)*&Q3-A>BSCH,-'/__<2
MY>'-SP$?+ ?EZG"GV!>. LJS_*V >7H)@>U8MWO9)^_$+=@F\;YVUMDS30R"
M]&&SSBF$/S#+%9J#0\V:*A+,ELZ)G2<'-70O9L8T.]ISTP-)\W'X15*+/)*\
MXH?S!]"3[WV.S]BE]%]L)4&]F0DLIG/!#P#K(B F7A=$.>"VW=\^_I(&RCR<
MFO(C9N)+WAZ#MQ^O4!85_4+QDM*Z_.N4PMYC)1HD\XE1:R<F49=._YNC6YKX
MIZOD+W3N?]F_9_69\0KRR(,B?_SH3K]BV!9S45OH9Y&=:&8V^?4 L#'J7?:I
M>BK/N T9Q,D<RRZVUD7OT>J8IGL\2]I5YN6E 0E2JL1CF.]]"':*SA4%2F%Y
MB;V-0][;"/09R)-PF!9+89 )<SVIFZWD2.+ OI=E-GNJ?B@3X+%&)(/E)[8^
M#R=]Q)>;"'"3('BC[DD6JHY)F%Z)^O"NF/2/1^CWGZ=S)2&=%AM-#P#F?MD&
M"_OU1#'18G)_-=/6TB#G.R5(%<Y=;[+3^=@-V.L?85%G.WEKOC9BL['?YMI@
M[R&X0^V9V$NNL')<&]LR4_E-23=3[%GU\_XEZM?JX_^U& H<-)LFNOJ:?E7C
MEH/;1!E0Z<M$8F=S).4W2OAR1) Y\X^IS@H<^>#[)K+>/)?$;8N*RT&U.*<(
M0KE'E]Z?CZX&G2WN&A[OF-A/W_4?/5U^FMF=D 88!9S7!!6&ZD^]=>4_9Z;A
M2&03>19Q]/,'[KOD#$;3HH48@J)<P*;+GZ\O%M0[IL'[ K3V4RX'R]/3B!%*
M!%9VBH2T!$>G(OEZM8B)LYN7<TU?Y6.6I*R3WEIS!WNBF[O4?0B"@/>7%_WJ
MK''U59(L^_["MZ:A_D55>B6@'XQ65)Z\6A(C)IY?93$6Q%=XE]E!]86 U,T'
M(V!&X?E%D0QB6P3'BEE'"A@:0=MQ O^)M(.9\N.NA!^6[^S<L8#]&V/FG=,&
MIQB]IA,J11PG%Q(ZH5X++6'Y$_I^T_?SB2.7<7PI@5BFVOZ=?>BC@V?@1Z0_
M4Y1PA=L'.?HOT8^?*,@&X'" '&EL]GK_JC^WL]FR\P!:^7[/T,K>QA/&XR&R
M\"C8*&  ]!_K;VVMFZB[BCV*M9_ZE+9U1)D17+)Q:$=&N%38RNI]B<GY-G&N
M=+S<4%I1[.UR%+5T8_/T9M<>BX#9.&LI[![<'/@>GS>87P17)66 4*B_@%N[
M ^L@'N,]!F0LM;K,NG!7"'*=)3Y>":B@(>K(Q7J%%NKW#.@ZDF?Z.[\4"FL#
MTY$*[T7XA.W4XG#E$87";0%XPSX8>HQD)2Q/L[S"]#=%>6&/\:(%Z.QI3[ZQ
MTD%OTE /P7SX_;DO1Q\#5'&;J&+TA#X6/;S=P%;?&^1'(<_%9@OXR^"0OYXH
MIST5,C=)&*;O:V'J!$^(]4K:(@4X7%FH"+RCJ7R#H/W[7J2GHH=IAQ-^<67_
M"D\QTZS@@J H2&^F81E]*UH?+P<W75:NZ(JQXRQ+C."6XS)+\DI2MB[BE;\J
M53;,)9W'!V]>"\3TO']")O2$9 AI=BJ_Z\1;1PLSF'FZ">4H3!.,57AZTG3D
M9MZ:@"W/&8;#'B8E=\"[ 1*_%-D3Y)H_S*-TY4PM]WG3(OA4\";$ <>_WQ^4
MX/"BDQWAC"IM*71=' $E,DE=WWZP4O.(\ 2A(9D#DK719[VT%P@T[J315K.8
MT/5-M)7!G/S.(+^V[[Y3XFS2#)_:^BBCI!#S+AIT:1BBKOZNU3BGL)+^C3%D
M\Z\V'F^5&+N]M'I>3S>?ZWM=,_F%Z4M3%[21*\>=@P29^Y(\#5^/$ZT)? 8A
M$5@_F08C\>RM Y5W?%8C"8,^W9!H<2=GTA^4\7B\"$L=L6_A'2B20,9;@U[G
M+'&0,.)XBJB4^M'+*IMIT5P4KYO+&UGLI YR2'":*+:SZ/4_7KAJ*)[* PQ[
M! >77"GJ\P9X>=%\1*;T7.:.5$G)V'+6XP>U0*8AT"7;($7(;J0FS JV];*P
M3.\9_UW-(.-1C?P!#J  P-N$F+:5WF\3-H'2I;HVQA%'O1"!X_VU*7Z*J.S[
M_($@]_U61.@7S_#X0V)+1D7*4:(QCIDPR9'L\5W/Q>J]%\OKCQ1$QQY?=ZK
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MI5K!5;YYVM"ZRO*H.+RIM=7A36^11]PQ >K)H]04=TU"4:P&\N@Z6SB\)=W
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MKC!842/K7]*H[/7#_/\!4$L#!!0    ( !V":E3U738?*P\! +@T 0 2
M:6UG,C$U-#4T.38S7SDN:G!G[+L'5%/;]CZZ0H  4D2"%"DB"(FHB 0I4H(>
M6I"NHE05E01$FD@12 !13T20(FA$B$! 5,!"[XB B+2 H("4@!21$FFAOXV>
M<\\Y]_[_[_?>&W>\,=X8+XX]A*R]UUISKCF_[YMK;38^;0R K3@#8P, 8P,
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M&( VH4%'6,\8T?RL"6MZWM)D9V<O-5)+YM8'U_J4+-4/&^#--#-#=^A;UP:
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M+4?N3WNRA6<M6$U#V]2+"C9 )5LXM!KP=4?WRLU8H^?9-.UC/JQ3C.RU\]D
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MIC98@1FW;ORE9<T/6K(CN905"(=-Z'%B5 [X+HH9GQ*.0&6_[*6W0,N(7+:
M9S7>0W9[#Y/!59](JP%?S'U9>B(2#)(T6_V1H5YQAK9 S=H,#T;"#N!A%1W%
M"YF\4NBB"2S"5;E6\J7Q.)2W\5=HJ23>BW%W"3X4 1PXVB0ZBJ$.44?B-$9(
M\(;T79$+:4NM<)]F5)TW"E@)E)-!(# 3P/EQFCZCZ ,)2L],AZ:/ZYEO5DN>
M?NI4WB/<X]T4KR[58H;']T_SVTW1MWL6Y%\X^(M.!5#9[8>3/^[<*3AA5#4
M4/8N,4T YY2!4GC)N'[>,8URDF_Q5I4V"A;E!PX?/\\3@,#T^D 1RB%MRZ>
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M(<!$EH\+9$..R B-,?!/@^!Q4"\MGQT2[V(CE,#V._(^W23^P]8W;2\'T)K
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M272)P(\'\^F+J8F%&!!.\<Q([BA'P6YF[Y18L;ZU]-H(@0%%U0O4T'$#/H5
ML.PST+4:YZ:T/*&T?L.M)L@W)&MHS7<'RT,./IOKS5*%*H7NQO62QI^O7DQL
MOI?AM)78]3VEF:32;ZG7'/!432U7Q9GZ=(T/,X,'54U([\V5,)6:>S0&J?:I
MO&MM%'4J"&QGAIHBR% YW1=SXUI[_'G?QR]K ;Z;K8WG;HX<CX8"S?#<@+R
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MP,K@RD-=F1)MC"4V?"8.:!*J\50V2';:G\0T20"%'+_K+$0%,%W.)*[UMS:
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M6VKN)P-!YD*VF">3UN&1&LI?0)3N.F18,T7@Y%$.'2YC8/=8$AX79N@-6.M
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MF -4O(VY&(0[(A1SN DG/AEA8R4MQI#)5\'U0?-YJ_4X1C5$M->=O8&?I.J
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M0/ZB[[\9^G")HN[F=N4]$"?6.$17%CL+E^;L7#/1NW'ZK/=;HT,GBW;>1,T
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M"MM,*:!4Y4E^!,L95A8&5L#&A.(Q6/!E,T^-*SS*))YP@ ET6;ZA%)-\D'
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MLF3L:6[\]"+,.7JQYPQ@O+&<6J4ZGQX*ZS4BD:%?H_1^!CBO^3'H?:UF?;?
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MGQ*4P,#X3A>#L-89(-Y?&/W]E_VPNXO//O#BW!-Z,$*;9T#J@^9Q:8@K[*G
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MVHK"$7Z)E[R8X;E('+3FGS"K?3_OG<J_ZG3T+J^NW.,; W4B;]A.V/+VTN]
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MFE2N25-6=%<DY/"E[7IB1\LDALA@;U<4FCI+16C29,:4(,*AQDD\LZ9]TH1
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MN<K.]!&B0^2$BZ?/-YI*KPJYHZ*]3"#IJ\[7*:R,S$C=<?&CCQ0>/G^_SN>
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M>P=2<NJO_"5!M6D/I''GWQW^HB 0LD^&14047/R"62OY/$?+H>_D3; CWC%
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MQ_XM=L9#';L??7W73G5P.VXET48$VDP%U">AI#8<OS7J' 4L/H*.-/QQN.M
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M&Y&U>^:-EL,UO!8G,Y<.:ZP 8C'O>?F=LPZGO07,U><_WWD0T;*\YN+P9E)
MZLSC5,-]UOK',A$*Q*[$*(NSD\+/Q/>7/VW72%T,/7%4W"+WVJ9$,E]7@S7P
MR>0+L.I=N^3[I$,Q2Z765TFA/$;BPK5+(&,%J%HN^):W\ ;KU5:M;WOQ86-3
MOC="HP%J9TA6G1D<K??W_YDM4?C;]I"W*\!CU6UXXS,5S8FG^(6^TD[ F1#G
M81-.;(&D$UV3+3;+8 )1VA";%0YA@$5+B#/_7CS,!'(5^+DA[6N&3<<0H9&0
M!UZ2GM>(Q<-;>^+M6#!3'1H^> ('&\,QQBTH $/20;F1-Y5R4L+!W3NC+4EH
M&$G=RKK1@ @CTJ8X1:2S:0&<VT$=B<@.\L84[9S!GA@_G!"R$&U824H?A8S-
M&PH)&U_H2%\[J%O8BM<?$9V[LW4XWI^VIM&^7.Y6VK+&FNZF%7 V;@3O8TF$
MO?Q&R @??7H/(VR#0</>9G_-BF'!XK4A^SCWAWW<46[;\*3X8N87NS"CEJ7*
M_Y&3PS34\>==M'>1/Z^B\0>2RNG:8SBA,<L0>V.F$B=VOC.&$[E&]F.*8>D9
M)-T9R,!CBN4,HCX"),H]@Y@%::^;GS$J)#-+@)0D9NM3A2T!>L)8@H!;0U53
M-2>%XF&F&(,+RD=F@"O%MA"M@UW'!$I$GD0N?T[IS$V%7"=8O P:UQ"A(X66
M3>,9B+ENDZW/@H]@+\;X=*1209"'\4(K=3=.:(F$M-S-3L$"@CG1  WS)5E)
M'+4GF4*XIV96N0TU2Y,J":(A$#TI" F!UNM4[V<\9+G:0'A:^80EJ024TWOB
M_;/(D+LBSS5,^2\^_B@-]1,?Y?[3]Z]\&A@B:@..;Y86P&#*0.A-03.5!W&\
MOJ00PK@I&I:+/<H>B,+QZ-"&DRE@KP]%U\>J(WX*QT.4PQ(ZR?QHSHTR)TM.
M*$2(,P%'0Z""Z+DA>A#&S=%1_M"?@5D48%RO%)XWD=:*X[5!/QLWAJ@SG()*
M<R]$1N/6&(^-6W JXNJQ=&CBG)FTF0!#\\^N1X'<ZQ;72G(92"HXS/R;96$P
MRBGM"_U,$(T5 J&HKZ#DA\^0/(]9U"N1C,0!Y.! (/<  CDAZ8'O26]6P!J-
MIJ.F00?8UG?4O&/O1N).D;^G+9D=?^)PNW_4[<"$8&-GEH/V-.I.?F/^9C.I
MV<\/3!,:6IMN7W_F8*<M,RLR[1)GR'M*5REG(?>\G56!8H/).:VZCI%BZ1[$
M(YVO-.';&E["'Q:^['E2=8L4=G^]ZZ9UR$Y;9W?&T>#!PVS]-7UZ=W=J?I0A
M[AQWA06I<FV_$UN;_[68VE4GC9+QDB^NL(G1[@S[]/K[YO[&N @9#RN_.XI#
MA/6('H^342!D1UCCMU 6\N2B)LE.HZ>LX-XQT3V/=K^]HA?W_L+2V ?+^LG<
MBSOU9?O'/*5M[-_O47O5&V)F<& Q<[G4$P_;%U!H@0T76@'V\2<5%7M\#7;E
M&[&+'2(J(5/A=' HH4T-V3F>?4F!UKT:9/97?V#J0*3DTAX7T9;@JL,WFD*O
MR+LVR2R/;VKSDKRWH[M*+MAAK"%"\$GKW<_TLF13,\$M"84E0XC86S)^+H9A
MAO,70B<+]K67>+KL33@@?G3;9<VW6P+ZKF?PRDT/4F=VK(#.W;MC6V,SZ3U,
MG[@;;B=-6LJYJ*!N7K;8XXGPM>(*X3N6>UU?\HEY/M>ACY4LB' MPZLN%:=6
M\9,6XB@1\B[S+[XJWJ\[Z;<E!D/%F;:.75"8*<XF_KC*FQG#M0*>O_YIHJZU
M#C+:U+ATV."?(#,A;J"E[PH=[*1/=E$XP6V44N[S<PISA&2IYR7')SOHV]\?
M#0M'(S;&3#M]F?<C7%Y_-$S8H^64^^4;U_E97%B[!QGM/69.P E-P\/9KI(8
M(HV'2N#DF^3I8VFC^DV[.?'O% [&HOB!DTV).!HPE<)):!KW<*($2W<@1H(%
ML\))L*,2<7QI=O8O6A]2P#&L:Z5V%'67#@U1N W3TWX4CS#/KM>>I5$ B:F%
M74##*A8(F1XN3KPS-*[FF>RM"_;W0MDLA X]S3\W:-0,"[H'2S?',111 %&/
MQ-KYC^)X!DU0D \*0:3[LM*O&+$6D==AV)$!VS^B?#.7+>I_A80A+1=<_U63
M<!V;O-;;SYQ49W><#,/1HM^4PL@2OD1 UT:UJ(S<R#TC'5<)]"4H>FR!J!9L
M:OD'(JS=SBUED@;PIC:VJ)+'LS2>Z7D[^_M438C8,JW1&:29QTR@XF?5F7(&
MHTH!Z&PL9%79;;"RGL#Q8]YB>V9R&8 32:7>DU(*9/OP&/.!%%$:_)R?F8<J
M#MF16$3RL>@DP\S-L/WUHC2>*%-,-PN)@DD)H@;0?7@$D<'!*/2S7!CGJG:K
M)0]:FY[1#BX5*MEZJ(Z9@&TDOU'S8+H$"SXCP9:VU(&<$K1$ -T@#S%:'>WR
MQ?IN]=C=Z@6QXO3E+2N@V70*^3W2 CI=<7_V91ANB9M__*N\J^](9\P4!8_A
MI8%PM ')+XJYV4(?@KNV.M]U<];8 N7]D':9MK)N84BP$'G9"VP6#-*?S32$
MZ*@YB5@/Y$6Q)>4TKE$3)6@*KFS&5SH*)/5;4#C9\*AZ=OS@<$])6BO'.8\E
MD?38D"+LB1F(G;F$!?Q\,_1XC#<:IL>>S6ZP5BX%HCG7Z_44] D]Y+7\.HQ1
M"\A].I)4D@0(II@0%L):--<N @72\YC*D'?@WD'19>/ATU3GMH@D/)R"4;7*
M@$@'H?/B$XY="'VX:F88T-_HU4_>F"Z%N""_S)!YX72HXM,JA)!UO"0_2,&J
M#WP.<WZTMCDNX>"V+XRC>G!>-X3A;%UP:$TDLC0X8,W8FEO*A26SPKYLYO:M
MEKZ^OIODWAM6[F@)4^UC1@XJW<\?<[J8ISA@]FW87WE:ZO+5ZV3D3%%B7\>Y
MA=Q+RS+$M=T[O70;/1ZJ#0G/%B2@$;W^![ %X5MZ#$04[6VZ;IH4Z3\P,-76
MB*CRF5<H\*@2G[\4VE?P[>JN98^;92?MB-^ZJ^H0LX/LJMC_,VU!V-&6WW&H
MZV9I2(>+F:2O!7E91X+NB:1I%RIN&?OT9M(R1"X:)[U[_E"-INZ9&Q(IZS!!
MSL-/>$MVF'_9*-_(SF+/&N<3'9AKXI[HO1[]3.U\Y]<\@5LKN/Z5XW:6+++S
M08#MQ4Z-!751N%Z0R&O2].T8\]KB0J?'-PZ11.M!L/#EY0T6;C%?+\D$%JNW
MEUPM5#.U&)03F?U,E_"K,Y/<\5>%2_]EY=OQ=Z[5G/#!2?&JF9J@F8?:=W:^
M&AV0NUV_?Z02,EA<J=R*0!Z#\E\@)*!!O:*\&(T;?@Z&LO-'@51M.BEWD'+D
M)HWWJX2=IX8BI@$-EX!<$@]\DY[=9\D+P+2@!;L$B==P/!7L)<2P!]D48)"W
M0*B'/)6<1)[LMZ8]G+OX NT,01CTA1!M]VDXG@%,QLTLDQA:)X&*9",\B3\X
M[GI41QG6EK_GE/WE?KOP*9SH(5\,P^=(R\G)79^MCLE9(ERU[S(/]0OE>V;N
MY*D'9QVZ^8GZ<T4I^R<S<K/C>G?A)*<.",54!Q]E<1W.&[6IUQ+% E@]*BD
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MSG8G(),XR,,&PS<0'\ $VF22$'K<W 1P$2C.TR9 ,SD)LFGYV#$G[$8@3T<
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M=^GY/3,WX4RMVUO]6FC?B8A*: JOR;X5<+,C=P7$0WX(U:@_M4)O!1@7VJX
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M_P]02P$"% ,4    "  =@FI4H4QSUJP$! !XIC( $0              @ $
M    9'-G;BTR,#(Q,3(S,2YH=&U02P$"% ,4    "  =@FI48 5=2"L5  #E
M[   $0              @ ';! 0 9'-G;BTR,#(Q,3(S,2YX<V102P$"% ,4
M    "  =@FI4/CF%C?T.   9S@  %0              @ $U&@0 9'-G;BTR
M,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ '8)J5+A%=J[0,0  J)@# !4
M             ( !92D$ &1S9VXM,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( !V":E1 '[PY*Z\  "C2!P 5              "  6A;! !D<V=N+3(P
M,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  =@FI4\F)4Y*Q-  "F]@4 %0
M            @ '&"@4 9'-G;BTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%
M  @ '8)J5")0 %R)K0  FXP&  \              ( !I5@% &1S9VXM97@Q
M,%\S+FAT;5!+ 0(4 Q0    ( !V":E1^3MJE; ,  (D8   /
M  "  5L&!@!D<V=N+65X,C-?,2YH=&U02P$"% ,4    "  =@FI46MR0YUT(
M  "/2@  #P              @ 'T"08 9'-G;BUE>#,Q7S$N:'1M4$L! A0#
M%     @ '8)J5!O$\/2L!@  830   \              ( !?A(& &1S9VXM
M97@S,E\Q+FAT;5!+ 0(4 Q0    ( !V":E0I99,921@  /_[   .
M      "  5<9!@!D<V=N+65X-%\S+FAT;5!+ 0(4 Q0    ( !V":E3*\KYO
M4E(  #58   2              "  <PQ!@!I;6<R,34T-30Y-C-?,"YJ<&=0
M2P$"% ,4    "  =@FI4:NS\+]V/  !9X0  $@              @ %.A 8
M:6UG,C$U-#4T.38S7S$N:G!G4$L! A0#%     @ '8)J5$ZNGV6U5@  N6
M !,              ( !6Q0' &EM9S(Q-30U-#DV,U\Q,"YJ<&=02P$"% ,4
M    "  =@FI4?[WGG (M  #(4@  $P              @ %!:P< :6UG,C$U
M-#4T.38S7S$Q+FIP9U!+ 0(4 Q0    ( !V":E1S#I*%SWL  +'1   3
M          "  728!P!I;6<R,34T-30Y-C-?,3(N:G!G4$L! A0#%     @
M'8)J5 ,IPB,X40  ]%\  !(              ( !=!0( &EM9S(Q-30U-#DV
M,U\R+FIP9U!+ 0(4 Q0    ( !V":E0O6G>%=%P  !%E   2
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M-#4T.38S7S<N:G!G4$L! A0#%     @ '8)J5&,P\AG&8@  '6@  !(
M         ( !:?8* &EM9S(Q-30U-#DV,U\X+FIP9U!+ 0(4 Q0    ( !V"
M:E3U738?*P\! +@T 0 2              "  5]9"P!I;6<R,34T-30Y-C-?
;.2YJ<&=02P4&     !@ & #]!0  NF@,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
